<SEC-DOCUMENT>0001558370-22-002715.txt : 20220303
<SEC-HEADER>0001558370-22-002715.hdr.sgml : 20220303
<ACCEPTANCE-DATETIME>20220303070107
ACCESSION NUMBER:		0001558370-22-002715
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		76
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220303
DATE AS OF CHANGE:		20220303

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Elevation Oncology, Inc.
		CENTRAL INDEX KEY:			0001783032
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				841771427
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40523
		FILM NUMBER:		22706710

	BUSINESS ADDRESS:	
		STREET 1:		888 SEVENTH AVE
		STREET 2:		12TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10106
		BUSINESS PHONE:		212-651-6380

	MAIL ADDRESS:	
		STREET 1:		888 SEVENTH AVE
		STREET 2:		12TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10106

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	14ner Oncology, Inc.
		DATE OF NAME CHANGE:	20190719
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>elev-20211231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8042.36810 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/2/2022 11:56:09 PM -->
      <!-- iXBRL Library version: 1.0.8042.36816 -->
      <!-- iXBRL Service Job ID: c09ae6e8-ecfb-45af-a44a-a6f1de35b1ed -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:elev="http://www.elevationoncology.com/20211231" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" xs:nil="true" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" name="us-gaap:CommitmentsAndContingencies" id="Hidden_K13RrqlPFE27bIg-y8uIZQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" xs:nil="true" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" name="us-gaap:CommitmentsAndContingencies" id="Hidden_HoXiDjL9KUya9PanvcAhGA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" xs:nil="true" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" name="us-gaap:PreferredStockValue" id="Hidden_IihsC53kEkWt42Ha6e4idQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" xs:nil="true" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" name="us-gaap:PreferredStockValue" id="Hidden_gbc1ZDXcAEe99kedebE1CQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="INF" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_R2buor0_jUO0guY27S8VsA">12132610</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="INF" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_BqZZNrCzsUOWgY-YXUKdWg">791821</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_7_nAdfS6MEueO81duCm77g">2.64</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" sign="-" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_-xHMw6Cns0q3G7uP67l6TA">21.80</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_ufCfvphpqUaFsIu6eQ5ybg" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_ku6MkFaccUqqx_e6Z90U5A">32450000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_9Ab4mylPHU2468ViocO1Kw" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_ZzptvVV4KkGo2T3C4NAYcA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_ufCfvphpqUaFsIu6eQ5ybg" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_HJjRn8vxqEqc62bzyHayHw">32450000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_Nqt-0QbioUOT_-2LYCnQeA" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_MhBVK9CA4ECtG86DjvMagA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_n1P4tSrvdk-YvWRGsiNyRQ" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_n2xdQHC12k-aBNJhOd4IKQ">34043889</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_Nqt-0QbioUOT_-2LYCnQeA" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_qssCogmpFkSc9bE3w614Fw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_n1P4tSrvdk-YvWRGsiNyRQ" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_srDnmenbtUiFZLni5r2PKw">34043889</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:EntityCentralIndexKey" id="Tc_5nGLAUE2rU6TAKy5hXTqOg_2_1">0001783032</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:CurrentFiscalYearEndDate" id="Tc_o3eQF_L8N0OqtIr3RfmLpw_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:DocumentFiscalYearFocus" id="Tc_mlovOEvAMUqbRF8xlg7E2Q_4_1">2021</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:DocumentFiscalPeriodFocus" id="Tc_OCi8xxSZfEOI8bfebf95ew_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:AmendmentFlag" id="Narr_RALZcJuwKE6aiFgL8kS8fQ">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw" contextRef="Duration_6_17_2021_To_6_17_2021_3W9jop6fm0qg9b5Wd2MRJg" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_z6l6dXmz8E6xGt27fFRfuQ">0.2367</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" id="Hidden_TDI7DkXArkaTliVYX6vraA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" id="Hidden_JCM5oP1UqkKdMGQnvJ6z0g">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_wqu_jCGum0WRLQslcXomKg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_UQWf1rcSfkun50qyxX6iDQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_9Ab4mylPHU2468ViocO1Kw" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_jYWxfVIF5k6FxM1xOsAXqg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_lgQGmvAd0kSfoX9eaEYLrw">2.64</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" sign="-" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_qV_WDEPC70Od3Xq9E6kzvw">21.80</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_2IktuLtwpEq_DQqGsb7Oow">12132610</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_ZVTobD-be0Gfz_GRdyN0kw">791821</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_item_P9iWedWUGEOmRWtbpyYLhQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsPayableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_elev_MajorSuppliersMember_ocGPhsn9x0qpuSJ02J9oBA" decimals="INF" name="elev:NumberOfMajorVendors" id="Hidden_oYUMpxFyBEukUJ69xj1Vgw">1</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_5J7V4aHIqEu2qGXL8dmwwg" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Hidden_F-nfSSZM0Euu4OQJHKZe8Q">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_SJCr4vEUZkeX-7Wij1oC_Q" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Hidden_gGMsgb7BgEOGbQEJGMhgkw">P6Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="elev-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="As_Of_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_EpGg59YM3Eu1afDfRYaHEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_Nqt-0QbioUOT_-2LYCnQeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_9Ab4mylPHU2468ViocO1Kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_n1P4tSrvdk-YvWRGsiNyRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_ufCfvphpqUaFsIu6eQ5ybg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_JVADeYQhFU6aWETRRcQX9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gO4tR77IjkWsJVcz9PCcFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kfgfNyUS-k-q6vIaH3KKEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_17_2021_To_6_17_2021_3W9jop6fm0qg9b5Wd2MRJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-17</xbrli:startDate><xbrli:endDate>2021-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_cyhJnqE1F0KJ0iWv1_oxBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pt55LruBbU6mC55DMIg-jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0kC6nscYCki9dpypch09Sg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DkD0JhHZk0y1iDRPpYA5Ew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WHl4WL9Hy0eii7jK-CXu0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__MZL6V0mP0KADzeRWa2ESA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_a4fg8WCqfESmafv_THdDEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_M2mN9gE5X0GijbROI6P7SQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A0J2TcXim0O2TZxlcLKsxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_elev_StockIncentivePlan2019Member_FlHgdUrdDkW1Tb42kpCKvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elev:StockIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_elev_EquityIncentivePlan2021Member_kp3FXbetX02QbQ8--SNfwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elev:EquityIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_elev_EmployeeStockPurchasePlan2021Member_uSn9gG9lvkuJEppuSz4hoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elev:EmployeeStockPurchasePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_elev_StockIncentivePlan2019Member_bUnBFZtU70qdI_31neYSXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elev:StockIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_24_2021_us-gaap_PlanNameAxis_elev_StockIncentivePlan2019Member_g20HiHisykWL0YRlk71tPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elev:StockIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_24_2021_us-gaap_PlanNameAxis_elev_EmployeeStockPurchasePlan2021Member_Mo21NNEVb02WGxkNxv7paw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elev:EmployeeStockPurchasePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_1_31_2021_us-gaap_PlanNameAxis_elev_EquityIncentivePlan2021Member_FexWjG0GeEO3y5ruEl4e1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elev:EquityIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_1_31_2021_us-gaap_PlanNameAxis_elev_EmployeeStockPurchasePlan2021Member_s1Fv3k0-skOD-lgjf_7L1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elev:EmployeeStockPurchasePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2020_To_11_30_2020_us-gaap_PlanNameAxis_elev_StockIncentivePlan2019Member_hYYP-cdGa0eXbji1S01uFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elev:StockIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_elev_StockIncentivePlan2019Member_CdA7QcaLgEakV3EDPTac8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elev:StockIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_5J7V4aHIqEu2qGXL8dmwwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_SJCr4vEUZkeX-7Wij1oC_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_19_2021_srt_CounterpartyNameAxis_elev_UnderwritersOfInitialPublicOfferingMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_nGisd7kOYEq_z_1_7FQduw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">elev:UnderwritersOfInitialPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_elev_ComputerSoftwareMember_g5ZhoAlXpUqrIOpTarHh5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">elev:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_elev_ComputerSoftwareMember_NaXHz8_kV0qUWe08M_6KyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">elev:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_elev_ComputerSoftwareMember_YpEaJOWw7UCqEhZ5InjBgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">elev:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2020_To_11_30_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaAndBConvertiblePreferredStockMember_ge5GjDqHukSVK1DEMyGmNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesaAndBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_7_31_2019_us-gaap_StatementClassOfStockAxis_elev_SeriesaAndBConvertiblePreferredStockMember_SRP5C8kaAkm-e3i0QZ6c-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesaAndBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_19_2021_To_7_19_2021_srt_CounterpartyNameAxis_elev_UnderwritersOfInitialPublicOfferingMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_VUvougWN80i1LCZg4HFYSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">elev:UnderwritersOfInitialPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-19</xbrli:startDate><xbrli:endDate>2021-07-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_29_2021_To_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_k4RdvBD3eEmW3XvTBybGKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-29</xbrli:startDate><xbrli:endDate>2021-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_QVkXeAi9dEuUZNo7SoogXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_RFXCBSdsYE2_Vzi1sOOAOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ArLc6smPckCMtFZLqiXo_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_U4BEo4pY0EeqeBvZSRXIWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OZUmi-gHpkqGwGuZU2171Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_AIfL3vjSZUuRhq97AJyp4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_5rOsdDqIEUeymqVgYG3BtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_K5uh10LQgki3KgNzawcwuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_LOXva3eCSEKs92ak-KtE4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_TTW4gSp3Wk-9JNv7SpMKfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_eDgOSR0ApUCe08Ub8rJKgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_ZJ2eCE9YL0WHbRPPPls1ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2019_To_5_31_2019_us-gaap_AssetAcquisitionAxis_elev_AssetPurchaseAgreementRelatingToSeribantumabMember_uhzmSNBzfkm5eBJiG2sU0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">elev:AssetPurchaseAgreementRelatingToSeribantumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_H_M1d8Hn4ki520t7iGj3Ng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_QSMT7xTslESMy-UsUkueuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_WIKQC4DzRE6vI_AOC5-AMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_XBvq6XI_aEGrm9k0W47ISg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_a5d4Y0z3Nk-SAUzQFRv89w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_eKa9OMO3pEGjRYGCoRthgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JBR44UJY20idUxeLVpC0GQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_deAfjK4lqEmKMKksWWn-jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_X-9TCZuQqkap_YeDihjLvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_O_Q119ip30KfTfvFf993FA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qMQDBx_zA0eapJGtZe8uZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_YAEGuEqxPEKdKNDxES3Gxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_xsmSF0gpPU6amqdGOgrEEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_1KlIt4aZN0KI7qkDnMhwtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_W0whaLuINkuS-MK09HdSLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T74WweuKoEO37FYC4NVKJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TK-bm7aGUEm31cUm-csY2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_10_2020_To_11_10_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_v3BvBhMCkkChJbjcubxA5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-10</xbrli:startDate><xbrli:endDate>2020-11-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_9_2020_To_1_9_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_gs0XV9bVfEqDcewwWOI9VQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-09</xbrli:startDate><xbrli:endDate>2020-01-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_7_2019_To_8_7_2019_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_jTYrUmLmVka6PZ8r-YiTkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-07</xbrli:startDate><xbrli:endDate>2019-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_12_2019_To_7_12_2019_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_CRrBhd5h4UWKceI00MOZ2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-12</xbrli:startDate><xbrli:endDate>2019-07-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_aX2mfIiaaEaEvfSZZi_QiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_VfF2WbD_yE25ScPehNSjmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_10_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_CnPFfpHmG0CJMvYDja99aQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_12_2019_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_2gzfDx_IOkyEVrvBv9B-8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_8x_tfsc7QkmeVVMEESIfJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_FwKWSVbO8EC5cGAemvMKBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_24_2021_To_6_24_2021_us-gaap_PlanNameAxis_elev_EmployeeStockPurchasePlan2021Member_ZFyW0T1vXkWCriwlsXAY-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elev:EmployeeStockPurchasePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-24</xbrli:startDate><xbrli:endDate>2021-06-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_elev_EquityIncentivePlan2021Member_xaj81EG8zUqzxS8PpL1PjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elev:EquityIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_Hc0jKnnQ5EKY8gQMK3Ryuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_4iKy94V-6UeB5pmDG5OepA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_elev_MajorSuppliersMember_Lus3zfRWB02sxkyeP9gCsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">elev:MajorSuppliersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsPayableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_elev_MajorSuppliersMember_Coj20v2H-ESbqbb3ODw3Ng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">elev:MajorSuppliersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_elev_MajorSuppliersMember_NVyNryv-ik-_fhgfb89hIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">elev:MajorSuppliersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsPayableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_elev_MajorSuppliersMember_ocGPhsn9x0qpuSJ02J9oBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">elev:MajorSuppliersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AssetAcquisitionAxis_elev_SelexisAgreementMember_p3VwQWadQ02foloetZBlYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">elev:SelexisAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AssetAcquisitionAxis_elev_DyaxAgreementMember_cqZbVZ2gh06l0lshIvlOdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">elev:DyaxAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AssetAcquisitionAxis_elev_SelexisAgreementMember_-Up5XNit8UCwOaN4IdjeDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">elev:SelexisAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AssetAcquisitionAxis_elev_NIHAgreementMember_I6LRl9X8GkOusRfsCtA2GQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">elev:NIHAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AssetAcquisitionAxis_elev_DyaxAgreementMember_TIOCbS27gU2NoUyO8PZbQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">elev:DyaxAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AssetAcquisitionAxis_elev_AssetPurchaseAgreementRelatingToSeribantumabMember_tQNsHiiyPk60TadASippIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">elev:AssetPurchaseAgreementRelatingToSeribantumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AssetAcquisitionAxis_elev_AssetPurchaseAgreementRelatingToSeribantumabMember_5HWpL8YS1E2KOC6PDwU83A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">elev:AssetPurchaseAgreementRelatingToSeribantumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AssetAcquisitionAxis_elev_AssetPurchaseAgreementRelatingToSeribantumabMember_6okAWYA92EqLCivJwShcTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">elev:AssetPurchaseAgreementRelatingToSeribantumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_sZb_K3th-kWfL5-YVdEe1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_jS2k487EQUu-QYmxTZAUcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2022_0iopzwH18EKRlw9y-_pRlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783032</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_s0fAi-9omkmV061racDAlg"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_EUR_QZ9PiilgBE2N3HwLp8Y6Lg"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Vote_IYKGbYhrlUq08si1HNSWpQ"><xbrli:measure>elev:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_P9iWedWUGEOmRWtbpyYLhQ"><xbrli:measure>elev:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_segment_tfgErmtCo0qqRPYk0GJOUQ"><xbrli:measure>elev:segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:7.2pt;min-height:20.15pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:64.54pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_b67f3d78_81d3_4b09_b0ca_5e2bfe5ea080"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:DocumentType" id="Narr_giofxSKi7E6tj13AimfsUA"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;"><ix:nonNumeric format="ixt:booleantrue" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:DocumentAnnualReport" id="Narr_KjIRybTGPESS95iFaRy_pw"><b style="font-family:'Segoe UI Symbol';font-size:7pt;font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;"><b style="font-size:7pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-size:8pt;font-weight:bold;">For the fiscal&#160;year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:DocumentPeriodEndDate" id="Narr_ORKcESvs2UKL5ipbae1eXA"><b style="font-size:8pt;font-weight:bold;">December&#160;31, 2021</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">OR</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:DocumentTransitionReport" id="Narr_5tBYze1xKkyBIuH9wSc3aQ"><b style="font-family:'Segoe UI Symbol';font-size:7pt;font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:7pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For The Transition Period From</b><span style="display:inline-block;width:10.4pt;"></span><b style="font-weight:bold;">To</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-size:8pt;font-weight:bold;">Commission file number: </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:EntityFileNumber" id="Narr_XMk6MC5fN0qtDvxLeViydQ"><b style="font-size:8pt;font-weight:bold;">001-40523</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="elev-20211231x10k001.jpg" alt="Graphic" style="display:inline-block;height:64.49pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:94.48pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:EntityRegistrantName" id="Narr_ULiShuh5k0ujGkvzUzSaZw"><b style="font-weight:bold;">ELEVATION ONCOLOGY,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_9eee1e0c_107d_4d42_9e62_eefa0cf40ce1"></a><a id="Tc_ODTSnWTZZUmHSxqHxAb1cg_2_0"></a><a id="Tc_YUq_yiNc30eUT9PzN_UsAA_2_1"></a><a id="Tc_q0IgRQqLdU-VwVRE1J2DUQ_3_0"></a><a id="Tc_jNH3M_GCAECHlhpe7siBhA_4_0"></a><a id="Tc_j3dH8fhxr0SEsrO5rJTZkw_4_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:EntityIncorporationStateCountryCode" id="Tc_RWYltIqTz0iKVH1PZh79ng_1_0"><b style="font-size:8pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:EntityTaxIdentificationNumber" id="Tc_mZn7Hnk9EUuTThtmtkDhRw_1_1"><b style="font-size:8pt;font-weight:bold;">84-1771427</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">(State of Other Jurisdiction of incorporation or Organization)</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">(I.R.S. Employer Identification No.)</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:EntityAddressAddressLine1" id="Narr_FhvMK5G9tE25bjjvDgaA0g"><b style="font-size:8pt;font-weight:bold;">888 Seventh Ave, 12th Floor</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:EntityAddressCityOrTown" id="Narr_GIwWapLXCEqpaYxThhMU3w"><b style="font-size:8pt;font-weight:bold;">New York</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:EntityAddressStateOrProvince" id="Narr_4EjsTjn0I0edfxCgqeB61A"><b style="font-size:8pt;font-weight:bold;">New York</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:EntityAddressPostalZipCode" id="Tc_BfpGf5tyikW_F3JMaVo4gg_3_1"><span style="font-size:8pt;">10106</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">(Zip code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-size:8pt;font-weight:bold;">Registrant&#8217;s telephone number, including area code: (</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:CityAreaCode" id="Narr_3CfmxA6PnkqCk94KXiFshw"><b style="font-size:8pt;font-weight:bold;">716</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:LocalPhoneNumber" id="Narr_OrxEkVnm-UyBVOnvcpQcwQ"><b style="font-size:8pt;font-weight:bold;">371-1125</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:35.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:29.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:29.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:35.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:29.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:29.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name Of Each Exchange</b></p></td></tr><tr><td style="vertical-align:top;width:35.72%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of Each Class</b></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:29.22%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:29.22%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">On Which Registered</b></p></td></tr><tr><td style="vertical-align:top;width:35.72%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:Security12bTitle" id="Narr_90yKaRo6ikC4t0c92pLrEg"><b style="font-size:8pt;font-weight:bold;">Common stock</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, par value $0.001 per share</b></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:29.22%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:TradingSymbol" id="Narr_BTYqdpAEU0Ou3gaiQqUqQA"><b style="font-size:8pt;font-weight:bold;">ELEV</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:29.22%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:SecurityExchangeName" id="Narr_k4_AE7s6tUqQhOYEl7lW6w"><b style="font-size:8pt;font-weight:bold;">The Nasdaq Stock Market</b></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 6pt 0pt;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act: <b style="font-weight:bold;"> None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:7pt;">Yes </span><span style="font-size:7pt;">&#9744;</span><span style="font-size:7pt;white-space:pre-wrap;">   </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_jWsKjNLZ40iQGWRhEdf3CA"><span style="font-size:7pt;">No</span></ix:nonNumeric><span style="font-size:7pt;"> </span><span style="font-size:7pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">Yes </span><span style="font-size:7pt;">&#9744;</span><span style="font-size:7pt;white-space:pre-wrap;">   </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:EntityVoluntaryFilers" id="Narr_YtrP4Ed12E-G7aLRfTQiyg"><span style="font-size:7pt;">No</span></ix:nonNumeric><span style="font-size:7pt;"> </span><span style="font-size:7pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:7pt;white-space:pre-wrap;">Indicate by check mark whether the registrant:  (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:EntityCurrentReportingStatus" id="Narr_drpQVD4kUEODFsKqR3q7lA"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;"> </span><span style="font-size:7pt;">&#9746;</span><span style="font-size:7pt;white-space:pre-wrap;">   No </span><span style="font-size:7pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.0405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:EntityInteractiveDataCurrent" id="Narr_tK9UQceJ9EGyp9e_tbTjdw"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;"> </span><span style="font-size:7pt;">&#9746;</span><span style="font-size:7pt;white-space:pre-wrap;">   No </span><span style="font-size:7pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:22.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:17.31%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:17.31%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:21.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:21.64%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:22.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Large accelerated filer&#160;&#9744;</p></td><td style="vertical-align:top;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Accelerated filer&#160;&#9744;</p></td><td style="vertical-align:top;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:EntityFilerCategory" id="Narr_aHaRI5UGSUqWaOSeJoBI9g"><span style="font-size:7pt;">Non-accelerated filer</span></ix:nonNumeric><span style="font-size:7pt;">&#160;</span><span style="font-size:7pt;">&#9746;</span></p></td><td style="vertical-align:top;width:21.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;">Smaller reporting company&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:EntitySmallBusiness" id="Narr_hyfo7n8cN0e0j_Th-Lq4rQ"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:21.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;">Emerging growth company&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:EntityEmergingGrowthCompany" id="Narr_DXsYmlbIO0KfQ2swamYYJw"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:EntityExTransitionPeriod" id="Narr_b3zDsfsLWEOkDNn0q3mI9g"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section&#160;404(b)&#160;of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:IcfrAuditorAttestationFlag" id="Narr_M8XVfPGisECa0_FRFJj7lw"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes </span><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:EntityShellCompany" id="Narr_BsXhi5EFLUSuZb7J139iiw"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric><span style="font-size:7pt;"> No </span><span style="font-size:7pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 4pt 0pt;">The aggregate market value of Common Stock held by non-affiliates of the registrant computed by reference to the price of the registrant&#8217;s Common Stock as of June 30, 2021, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" format="ixt:numdotdecimal" scale="6" contextRef="As_Of_6_30_2021_jS2k487EQUu-QYmxTZAUcw" decimals="-5" name="dei:EntityPublicFloat" id="Narr_TcP3IEUDNUSlJg_hFaCsyw">210.6</ix:nonFraction> million (based on the last reported sale price on the Nasdaq Global Select Market as of such date). As of February 28, 2022, there were <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_2_28_2022_0iopzwH18EKRlw9y-_pRlw" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_dEpiw9I8X0KRMe_Z6GUE7A">23,205,915</ix:nonFraction>. shares of the registrant&#8217;s common stock, par value $.0001 per share, outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Documents Incorporated by Reference</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt;">The registrant intends to file a definitive proxy statement pursuant to Regulation 14A relating to the 2022 Annual Meeting of Stockholders within 120 days of the end of the registrant&#8217;s fiscal year ended December 31, 2021. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-indent:14.4pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ae59672c_00fa_4f6e_87ba_3572178a917d"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">TABLE OF CONTENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:93.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:4.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTI_280680"><b style="font-style:normal;font-weight:bold;">PART I</b></a></p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1Business_938839"><span style="font-style:normal;font-weight:normal;">Item&#160;1. Business</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_90125"><span style="font-style:normal;font-weight:normal;">Item&#160;1A. Risk Factors</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">33</p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_531438"><span style="font-style:normal;font-weight:normal;">Item&#160;1B. Unresolved Staff Comments</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">90</p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2Properties_617916"><span style="font-style:normal;font-weight:normal;">Item&#160;2. Properties</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">90</p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3LegalProceedings_893927"><span style="font-style:normal;font-weight:normal;">Item&#160;3. Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">91</p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_88552"><span style="font-style:normal;font-weight:normal;">Item&#160;4. Mine Safety Disclosures</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">91</p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTII_234035"><b style="font-style:normal;font-weight:bold;">PART II</b></a></p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquity_45"><span style="font-style:normal;font-weight:normal;">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">91</p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6SelectedFinancialData"><span style="font-style:normal;font-weight:normal;">Item&#160;6. [Reserved]</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">91</p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">92</p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">102</p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementalD"><span style="font-style:normal;font-weight:normal;">Item&#160;8. Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">103</p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">123</p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9AControlsandProcedures_825120"><span style="font-style:normal;font-weight:normal;">Item&#160;9A. Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">123</p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9BOtherInformation_23751"><span style="font-style:normal;font-weight:normal;">Item&#160;9B. Other Information</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">123</p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9C_Disclosure_Regarding_Foreign_Jur"><span style="font-style:normal;font-weight:normal;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">123</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTIII_833192"><b style="font-style:normal;font-weight:bold;">PART III</b></a></p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Item&#160;10. Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">124</p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item11ExecutiveCompensation_595598"><span style="font-style:normal;font-weight:normal;">Item&#160;11. Executive Compensation</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">124</p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">124</p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">124</p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14PrincipalAccountantsFeesandService"><span style="font-style:normal;font-weight:normal;">Item&#160;14. Principal Accountant&#8217;s Fees and Services</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">124</p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PartIV_195701"><b style="font-style:normal;font-weight:bold;">PART IV</b></a></p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15ExhibitsandFinancialStatementSched"><span style="font-style:normal;font-weight:normal;">Item&#160;15. Exhibits and Financial Statement Schedules</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">124</p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><a href="#Item16Form10KSummary_301707"><span style="font-style:normal;font-weight:normal;">Item&#160;16. Form10K Summary</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">127</p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;">SIGNATURES</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">128</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d97a7d68_5753_494c_a58f_965a5986ac60"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">References to Elevation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Throughout this Annual Report on Form 10-K, or Annual Report, the &#8220;Company&#8221;, &#8220;Elevation&#8221;, &#8220;Elevation Oncology&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, and &#8220;our&#8221;, except where the context requires otherwise, refer to Elevation Oncology, Inc. and its consolidated subsidiary, and &#8220;our board of directors&#8221; refers to the board of directors of Elevation Oncology, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Special Note Regarding Forward-Looking Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This Annual Report contains forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;potentially,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;project,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; and similar expressions that convey uncertainty of future events or outcomes, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in &#8220;Risk factors&#8221; and elsewhere in this filing. Moreover, we operate in a competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Annual Report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The forward-looking statements in this Annual Report include, among other things, statements about:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5.85pt;margin:0pt;"><span style="font-size:5.85pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to develop, obtain regulatory approval and commercialize seribantumab and our future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of our preclinical studies and clinical trials for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">estimates of our addressable market and market growth;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding demand for, and market acceptance of, our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to maintain and expand access to human genetics data;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to compete effectively with existing competitors and new market entrants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential effects of extensive government regulations relating to our industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain, maintain, and protect and enforce intellectual property and proprietary rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights and proprietary technology of third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and maintain collaborations, including our existing joint ventures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to expand our pipeline of product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to attract and retain key management and technical personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effects of the COVID-19 pandemic on any of the above or any other aspect of our business operations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding expenses, future revenue, capital requirements, and our needs for additional financing.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.95pt;margin:0pt;">The forward-looking statements made in this filing relate only to events or information as of the date on which the statements are made in this Annual Report. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Annual Report to conform these statements to actual results or to changes in our expectations, except as required by law. We intend the forward-looking statements contained in this Annual Report to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2bf718f8_5ccd_4d50_a505_67540a440ea0"></a><a id="PARTI_280680"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;I</p><a id="Item1Business_938839"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1. Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are a precision oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Our vision is to elevate precision medicine to the forefront of every cancer treatment journey, as we believe that each patient living with cancer deserves the opportunity to benefit from a genomically-driven treatment decision. We utilize our deep expertise in developing drugs for rare, genomically defined patient populations and strategic collaborations with our diagnostic collaborators to work towards a future where each tumor&#8217;s unique genomic test result can be matched with a purpose-built precision medicine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are focused on identifying oncogenic drivers that are known to be predominantly mutually exclusive with other driver alterations, and pursuing innovations and efficiencies in the conduct of clinical trials that we believe may enable development of targeted therapeutics against those oncogenic drivers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our lead drug development candidate, seribantumab, is an Anti-HER3 monoclonal antibody and potential novel targeted therapy for solid tumors driven by neuregulin-1, or NRG1 fusions, a type of genomic alteration and oncogenic driver, and other receptor tyrosine-protein kinase erbB-, or HER3, genomically defined cancers. We have designed and initiated our registration-directed Phase 2 CRESTONE clinical trial to investigate the safety and efficacy of seribantumab in advanced solid tumors harboring an NRG1 fusion. We expect to complete enrollment of the first 20 patients in Cohort 1 of the CRESTONE study in mid-2022, and to present initial clinical data from approximately 10 patients from Cohort 1 of the CRESTONE study treated with seribantumab at 3 grams weekly at a major medical meeting in mid-2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We also plan to expand our drug development pipeline beyond seribantumab into additional genomically defined cancers by leveraging our value-driving partnerships with Caris Life Sciences and others, as well as by exploring further opportunities to selectively partner on additional precision oncology assets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are managed by a team with significant experience and track records for clinical and commercial execution in the oncology space and backed by a group of renowned scientific advisors and partners that bring diagnostic, clinical, and operational expertise to help optimize execution. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;">Our strategy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our goal is to deliver safe and effective therapies for genomically defined patient populations with significant unmet clinical needs. Key elements of our strategy include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Implement an innovative operational model tailored to the efficient development and potential regulatory approval of precision therapeutics for rare, genomically defined cancers, beginning with the investigation of seribantumab for any solid tumor driven by an NRG1 fusion.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> We have designed our business model around genomically defined cancers with smaller trial size requirements and the potential for accelerated approval. Rather than follow the traditional drug discovery path, we have focused on external development to identify potential assets that we can acquire at attractive economic terms and that will enable us to move efficiently through clinical development. We acquired seribantumab in July 2019 as a Phase 2-ready asset, enabling us to move rapidly into a potentially registration-directed Phase 2 trial. We have also employed innovative models to enhance traditional patient enrollment into our clinical trials, with opportunity for enrollment not only at core sites, but also through referrals through our diagnostic partnerships, and a &#8220;just-in-time&#8221; site initiation model. This enables us to reduce overhead costs for a trial and increase the availability of eligible patients, addressing two key risks in the development of therapies for rare, genomically defined patient populations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Prioritize oncogenic drivers that are predominantly mutually exclusive oncogenic alterations to maximize the probability of clinical success.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> We focus on oncogenic driver events that are most often mutually exclusive within a tumor, meaning that co-expression with other known driver alterations is not observed. We believe that </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to identify and specifically target a mutually exclusive oncogenic driver alteration increases the likelihood of developing a therapy that achieves a clinical benefit for patients as a monotherapy. Our lead program focuses on NRG1 gene fusions in solid tumors, which are oncogenic drivers that are predominantly mutually exclusive with other known genomic alterations. The identification of NRG1 fusions in more than ten solid tumor types may enable a tumor-agnostic development approach.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Rapidly advance our lead product candidate seribantumab, a monoclonal antibody, through late-stage clinical development for solid tumors harboring NRG1 gene fusions.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> In July 2020, we initiated the CRESTONE trial a Phase 2 clinical trial at sites across the United States, Canada, and Australia to assess the safety, tolerability, and anti-tumor activity of seribantumab in patients with tumors harboring an NRG1 fusion. We are conducting the CRESTONE trial with the intent to seek regulatory approval through the accelerated approval pathway, pending continued discussions with the U.S. Food and Drug Administration, or FDA. Given its mechanism of action and broad therapeutic window, we believe that seribantumab has the potential to effect robust and durable responses at a dosing regimen optimized for patients with solid tumors driven by an NRG1 fusion. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Collaborate with diagnostic providers and next-generation sequencing, or NGS, centers of excellence to accelerate enrollment in clinical trials by identifying patients with rare, genomically defined cancers, starting with solid tumors harboring an NRG1 fusion.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> We have entered into agreements with multiple partners selected for their ability to identify NRG1 gene fusions with high sensitivity, particularly through the use of RNA-based next generation sequencing. Through these collaborations, we are able to expand identification of patients who may be eligible for enrollment in our Phase 2 CRESTONE trial beyond those patients who may be identified through traditional clinical trial site enrollment processes. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Expand our pipeline of drug candidates targeted against oncogenic driver alterations through strategic collaborations and/or external development.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> We intend to continue expanding our pipeline by leveraging our partnerships with next-generation sequencing, or NGS diagnostic providers, as well as our own internal expertise and capabilities, to potentially accelerate the identification of additional actionable oncogenic targets. We then expect to in-license, acquire or discover assets with potential against those identified oncogenic driver targets. Through our collaboration with Caris Life Sciences, we continually assess oncogenic fusions and driver mutations identified through our partner&#8217;s screening capabilities to identify potential targets and then elect to initiate a novel drug discovery program for those targets or evaluate existing therapeutics for potential in-licensing or product acquisition, while retaining exclusive access to all targets selected by the parties.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Evaluate strategic opportunities to potentially accelerate development timelines and enhance the commercial potential of our product candidates globally</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> We intend to build an integrated biopharmaceutical company focused on precision oncology with a broad portfolio of targeted therapies. We currently retain full global development and commercialization rights for seribantumab. We plan to commercialize our product candidates in key markets, either alone or with strategic partners, as well as invest in shaping the genomic testing landscape in order to maximize the worldwide commercial potential of our programs.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Actively advocate for and participate in industry-wide initiatives to improve access, awareness, and clarity around precision medicines for rare, genomically defined cancers.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> We envision a future where every patient with cancer has the option of a precision therapy matched to their tumor&#8217;s unique genomic driver. This begins with ensuring the wide availability of genomic testing to identify the increasing number of biomarkers that can be paired with an investigational clinical trial or a commercially available targeted therapy. We aim to increase awareness on the importance of applying the appropriate diagnostic testing method for each actionable driver alteration by collaborating with academic institutions, patient advocacy groups, medical education providers and associations, diagnostic companies, and community oncology practices to advocate for broad genomic testing of tumors, at all lines of therapy, and regardless of the stage of cancer. By comprehensively identifying all actionable genomic driver alterations present at each treatment decision timepoint, patients may dynamically benefit from the prognostic and therapeutically predictive value of diagnostic tests as both their tumor and the treatment landscape evolve. Finally, we advocate for industry-wide initiatives that remove the burden of </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">responsibility from the patient to educate themselves, and move towards presenting a clear, united message that prioritizes patient benefit and well-being.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Background</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The rise of precision cancer therapeutics</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cancer is a heterogeneous group of diseases caused by alterations in cells that give rise to abnormal cell growth and proliferation. Many cancer therapeutics rely on the rapid growth dynamics of cancer cells to elicit a therapeutic effect; notably, most chemotherapeutics inhibit the replication of all cells in the body, but act preferentially to destroy cancer cells as they proliferate faster than non-cancer cells, resulting in significant toxicity. By contrast, targeted therapies are designed to interfere with, or target, the specific pathways within a cancer cell that contribute to the growth and survival of a tumor, while minimizing systemic adverse events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cancer has also historically been diagnosed, classified, and in large part, treated based on a tumor&#8217;s organ site or tissue of origin, thus giving rise to therapeutics for lung cancer, breast cancer or other tissue-based designations. With advances in genomic testing, there has been widespread recognition that cancers may be defined by their unique genomic signatures, instead of tissue of origin, due to shared genomic alterations irrespective of their location in the body. This understanding has both been a result of, and driven by, an increased use of genomic sequencing to better understand the driving factors of each individual cancer. Over the last several&#160;years, the ability to conduct genomic profiling of an individual patient&#8217;s tumor has become more readily accessible and affordable. Our collective understanding of the genomic makeup of tumors has facilitated the development of precision therapeutics designed to specifically inhibit the underlying causes of tumor growth and proliferation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The precision oncology movement strives to improve patient outcomes by identifying the underlying oncogenic driver of each tumor through genomic testing and by matching it to a purpose-built targeted therapeutic. By precisely matching a therapeutic to a tumor&#8217;s genomic driver of disease, the hope is to achieve a deeper and more durable response with fewer off-target side effects for every cancer&#8201;&#8212;&#8201;no matter how rare.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Genomic alterations fall on a spectrum of oncogenic potential</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cancer arises through a process whereby cells acquire a series of alterations that eventually precipitate unrestrained cell growth and division. The changes that accumulate in a cancer cell may encompass many distinct classes of genomic alterations, including overexpression or amplification of individual genes, specific point mutations in a single gene, and chromosomal translocations or fusions of genetic material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">These genomic alterations can be further characterized as driver or passenger alterations that fall on a spectrum of oncogenic potential. Oncogenic driver alterations confer growth and survival advantages to the cancer cells that may lead to oncogenesis and continued growth of a tumor. Passenger mutations, also known as bystander mutations, are those that arise within the cancer cell but are not the primary or underlying cause of oncogenesis and/or continued growth of a tumor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Advances in genomic testing, including increases in the specificity and sensitivity of testing methods, have enabled improved identification of a wider range of genomic alterations. In particular, advancements in and wider availability of RNA-based NGS whole transcriptome sequencing has improved our ability to identify novel gene fusions. These &#8220;chimeric&#8221; genes arise from the re-combination of portions of two normally unrelated genes and are transcribed into corresponding fusion proteins which may retain functionalities related to either or both component proteins. If a tumor suppressor gene or oncogene is involved, the resulting fusion proteins frequently lead to unregulated cell growth and proliferation and are often the primary cause of tumor growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">While gene fusions are generally rare, they have high oncogenic potential. Most importantly, they can appear in tumors as oncogenic drivers, predominantly mutually exclusive with any other known genomic driver alteration. Accordingly, these fusions represent important genomic alterations to identify and subsequently target with a precision therapy.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:255pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">NRG1 fusions and HER3 inhibition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The ERBB family of proteins contains four members including epidermal growth factor receptor (EGFR; ERBB1; HER1), ERBB2 (HER2), ERBB3 (HER3), and ERBB4 (HER4). While EGFR, HER2, and HER4 are tyrosine kinases, HER3 is a pseudo-kinase meaning that HER3 does not have meaningful catalytic activity of its own.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">When HER3 is activated by its ligand, NRG1, it undergoes an obligate pairing through homo- or heterodimerization with HER2 or other ERBB family members. The formation of these HER3-HER2 dimers and other ERBB family complexes leads to the downstream activation of PI3-Kinase and AKT, or PI3K/AKT as well as MAP-Kinase, or MAPK, key pathways that regulate cell growth and proliferation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Alterations that disrupt signaling of ERBB and downstream signaling pathways through PI3K/AKT and MAPK are often identified in tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Tumorigenesis driven by NRG1 fusions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">NRG1 gene fusions are rare genomic alterations that arise when portions of the NRG1 gene are combined with portions of a second gene, known as its fusion partner. NRG1 gene fusions are transcribed by a cell into NRG1 fusion proteins. As long as the NRG1 portion of the fusion protein retains its active component, known as the EGF-like domain, the fusion protein can act like a normal NRG1 protein, and can induce signaling through the HER3 receptor. Based on current literature, it appears that nearly all NRG1 fusions contain the genomic region that encodes the EGF-like domain of the protein and therefore are able to bind to HER3 and activate downstream signaling pathways.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Production of the wild-type NRG1 protein is normally tightly regulated by a cell to prevent uncontrolled cell growth and proliferation. Cells may not be able to regulate the aberrant NRG1 fusion proteins in the same way, and their production may lead to over-activation of HER3 and downstream PI3K/AKT and MAPK pathways leading to tumor growth and proliferation (Figure 1).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Figure 1. NRG1 fusions drive tumor growth&#160;&amp; proliferation through HER3.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="elev-20211231x10k002.jpg" alt="Diagram&#10;&#10;Description automatically generated" style="display:inline-block;height:255pt;width:468pt;" /></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 1. </b>[<b style="font-weight:bold;">Left</b>] The NRG1 gene encodes the NRG1 protein, which is a ligand for HER3. Ligand-induced activation of HER3 by NRG1 enables preferential dimerization with HER2 and activation of downstream PI3K/AKT and MAPK signaling pathways. Production of the NRG1 protein is tightly regulated by the cell to avoid overactivation of downstream pathways. [<b style="font-weight:bold;">Right</b>] Portions of the NRG1 gene may be aberrantly combined with portions of an unrelated gene, resulting in an NRG1 gene fusion. The resulting NRG1 fusion proteins may still act as ligands for HER3 if they retain an intact EGF-like domain. Cells may not be able to regulate production of NRG1 fusion proteins, leading to tumor growth and proliferation driven by overactivation of HER3 and downstream PI3K/AKT and MAPK pathways.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Characteristics of NRG1 fusions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">NRG1 fusion proteins contain components of both the NRG1 protein and the protein described by its fusion partner. At least 50% of known NRG1 fusions contain CD74, ATP1B1, SDC4, or RBPM5 as the fusion partner. It is not known at this time if there are any prognostic or functional differences between NRG1 fusions with different partners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Importantly, when NRG1 fusions are found in a tumor, other known oncogenic drivers such as KRAS, EGFR, ALK, ROS1, and RET mutations are typically absent. Because of this, NRG1 fusions are considered oncogenic driver alterations given they are predominantly mutually exclusive when detected in patients with cancer. As a mutually exclusive oncogenic driver, we believe a targeted monotherapy approach has a strong potential to treat tumors that harbor an NRG1 fusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Incidence of NRG1 fusions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To our knowledge, the most comprehensive assessment of the incidence rate of NRG1 fusions was published in 2019 by Jonna et al. in <i style="font-style:italic;">Clinical Cancer Research</i> with an analysis of 21,858 samples and updated at the 2020 annual meeting of the American Society of Clinical Oncology, or ASCO, based on an updated analysis of 44,570 tumor samples. Based on the observed incidence rate of approximately 0.2% and the estimated number of new cancer cases in the United States in 2020 reported in Cancer Facts and Figures 2020 by the American Cancer Society, we estimate the incidence of new patients with tumors harboring an NRG1 fusion in the United States is approximately 3,200 per&#160;year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">NRG1 fusions have been identified in more than ten unique solid tumor types to date in the published literature, and we expect that the reported number of tumor types harboring an NRG1 fusion will grow as research continues to advance. Separate reports in the published literature suggest that the prevalence of NRG1 fusions may be enriched in specific tumor subtypes; prevalence in invasive mucinous adenocarcinoma, or IMA, a subtype of NSCLC, has been reported to be up to 27-31%; prevalence in pancreatic ductal adenocarcinoma, a subtype of pancreatic cancer, has been reported to be up to 6%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The wide range of tumor types in which an NRG1 fusion has been identified make it a strong candidate for a tumor-agnostic development strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">NRG1 fusions lead to a poor prognosis</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">There are currently no approved therapeutics specifically targeting tumors harboring an NRG1 fusion. Evidence available to date suggests that patients with tumors harboring an NRG1 fusion have a poor prognosis and limited response to currently available therapies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A research report published in <i style="font-style:italic;">Oncotarget</i> in 2016 by Shin et al. presented an analysis of disease-free survival, or DFS, and overall survival, or OS, in patients with tumors harboring an NRG1 fusion. In all patients analyzed (n=59) the presence of an NRG1 fusion resulted in inferior OS and a trend towards shorter DFS, compared to those without NRG1 fusions. To remove the confounding factor of stage of disease, a sub analysis was done on patients with stage 1 disease (n=45) where patients with tumors harboring an NRG1 fusion showed significantly inferior OS and DFS as compared to those with tumors without an NRG1 fusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A 2021 <i style="font-style:italic;">Journal of Clinical Oncology</i> report by Drilon et al. reported an analysis from a global multicenter network of thoracic oncologists participating in an NRG1 fusion global registry trial, who identified 110 NSCLC patients with </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">pathologically confirmed NRG1 fusions and evaluated their response to chemotherapy, immunotherapy, chemotherapy plus immunotherapy, or off-label use of afatinib. They reported that 0-20% of patients achieved an objective response to platinum-doublet-based chemotherapy (n = 15), taxane-based chemotherapy (n = 7), immunotherapy (n = 5), or chemotherapy plus an immunotherapy (n = 9), and only 25% of patients achieved an objective response to off-label afatinib (n = 20). In this retrospective trial, it was determined that treatment with afatinib resulted in a median progression-free survival, or PFS, of 2.8 months. Limited durability is likely attributed to the fact that HER3 is a pseudo-kinase, and therefore inhibition of HER3 is not amenable to targeting by small molecule tyrosine kinase inhibitors, such as afatinib, which inhibits EGFR, HER2, and HER4. Given afatinib does not inhibit HER3, only partial inhibition of downstream signaling (PI3K/AKT and MAPK) is observed, which allows tumor cells harboring an NRG1 fusion to continue to grow and proliferate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Evidence that targeting HER3 may be an optimal approach for treating tumors harboring an NRG1 fusions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There have been several clinical case reports published or presented on the potential of ERBB-family inhibition as a therapeutic intervention for patients with tumors harboring an NRG1 fusion. These include reports on the off-label use of afatinib as well as a few cases with monoclonal antibodies and small molecule inhibitors targeting ERBB family members. Clinical activity, including objective responses, have been reported with varying durations of response.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As reported by Drilon et al. in a 2018 report in <i style="font-style:italic;">Cancer Discovery</i>, small molecule inhibition of EGFR, HER2, and HER4 with afatinib was not as effective as the use of HER3-targeted therapy. The administration of afatinib in an <i style="font-style:italic;">in vivo</i> NRG1 fusion model of ovarian cancer (OV-10-0050) with a CLU-NRG1 fusion resulted in a mixed response to treatment. A potential reason for the limited effect of afatinib observed is that treatment with afatinib did not result in complete shutdown of downstream signaling through the PI3K/AKT pathway. In contrast, the specific inhibition of HER3 by the anti-HER3 monoclonal antibody (GSK2849330) induced complete, or near-complete, regressions and a near-complete suppression of downstream signaling in the same model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Additionally described in the report, the only response observed in the Phase 1 clinical trial of GSK2849330 was in a patient with a NSCLC tumor harboring an NRG1 fusion who had been treated previously with several lines of systemic therapy (chemotherapy and immune therapy) with no response to any of these treatments. Targeted therapy with the anti-HER3 monoclonal antibody GSK2849330 resulted in a durable partial response of 19 months, which exceeded the duration of disease control achieved on all prior systemic lines of therapy in aggregate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Seribantumab was included as part of a case series presentation at the Australasian Gastro-Intestinal Trials Group 2021 Annual Scientific Meeting. A patient with treatment-refractory metastatic pancreatic cancer had their tumor genomically profiled through the MoST program, was found to harbor an NRG1 fusion, and subsequently received treatment with seribantumab through a compassionate use program provided by Elevation Oncology. As of the data cut-off for the presentation, treatment with seribantumab resulted in durable clinical benefit for over 9 months, an approximately 90% reduction in the cancer biomarker CA19-9, and an ongoing 3 month confirmed partial response per RECIST criteria with a maximum tumor reduction of over 50%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;">Our Approach</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our operational platform is designed for continued success by expanding on the promise of precision medicine and using the significant opportunities available to address multiple genomically defined cancers with first-in-class and best-in-class therapies. We are focused on developing drugs to target genomic alterations that are predominantly mutually exclusive with other known driver alterations. By targeting these unique oncogenic driver events and tailoring the best therapeutic approach, we believe we can increase the potential for therapeutic, clinical, and regulatory success in genomically defined patient populations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Target Identification</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have established industry-wide partnerships with NGS companies to enable the identification of actionable targets. We also collaborate with academic and clinical researchers, diagnostic leaders, and community oncology practices to evaluate emerging genomic research for potential targets.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Therapeutic Candidate Selection</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Following target identification, we select attractive assets in a capital-efficient manner through a targeted search for the appropriate chemical matter to address the identified target. We start by assessing existing compounds based on their mechanistic properties, observed or predicted risk-benefit profile, chemical and manufacturing properties, intellectual property, and other parameters on a case-by-case basis. We then in-license, acquire, or when there is not suitable existing chemical matter, may embark upon a drug discovery campaign with collaborators to create an appropriate candidate for future drug development. These processes allow us to select the asset that we believe may have the highest probability of technical success for the treatment of patients with genomically defined cancers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Optimized Clinical Trial and Regulatory Execution</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We aim to drive operational success by implementing process innovations that we believe may enable us to efficiently advance product candidates through clinical development in genomically defined patient populations. Given these populations are often relatively rare, we have built an innovative clinical enrollment model that recognizes the importance and impact of each individual patient. We also seek to employ expedited regulatory strategies such as Breakthrough Therapy Designation, Fast Track Designation, Priority Review, Accelerated Approval, and other collaborative mechanisms with the FDA and regulatory agencies outside the United States to optimize clinical development where applicable. We utilize our robust network of strategic partnerships to enhance patient enrollment through real-time identification and referral of genomically defined patient populations into clinical studies. Patients can be enrolled through identification at, or active referral to, core trial sites at academic medical institutions, and new trial sites can be rapidly activated through a process of &#8220;just-in-time&#8221; site initiation through a network of specialized community oncology centers. We have executed multiple strategic collaborations to support just-in-time site initiation to date. For example, through collaborations with Caris Life Sciences, Tempus, and The US Oncology Network we currently have access to approximately 400 clinical trial sites globally in support of our Phase 2 CRESTONE trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Lead Program</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Seribantumab for solid tumors harboring an NRG1 fusion</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our lead program targets a genomically defined patient population whose tumors are driven by NRG1 gene fusions and predominantly mutually exclusive with other known driver alterations. Following our focused approach described above:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We confirmed that NRG1 fusions are likely to be a clinically actionable biomarker and identified HER3 inhibition with a monoclonal antibody as a selective targeted therapeutic approach for tumors driven by an NRG1 fusion.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The anti-HER3 monoclonal antibody seribantumab was specifically chosen as a therapeutic candidate with the potential to selectively target tumors harboring an NRG1 fusion and support an efficient development pathway as a Phase</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> </b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2-ready asset.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We designed the Phase 2 CRESTONE trial with &#8220;just-in-time&#8221; site initiation and early review of response signals, which we believe addresses inefficiencies of clinical development within rare, genomically defined patient populations, and potentially enables submission of a biologics license application, or BLA, to the FDA pursuant to an accelerated approval pathway in the United States.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We acquired seribantumab (formerly MM-121) from the previous sponsor in July 2019 following robust evaluation of HER3 inhibitors and their potential for development specifically for patients with tumors harboring an NRG1 fusion. The clinical development program of seribantumab by the previous sponsor was focused on patients with overexpression or amplification of HER3 or NRG1, with limited anti-tumor efficacy. Importantly, patients with tumors harboring an NRG1 gene fusion were not specifically selected for inclusion in these studies. We believe that patients with tumors harboring an NRG1 fusion represent the most appropriate patient population to evaluate the potential of seribantumab and that our product candidate offers significant potential for efficacy in these patients.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We selected seribantumab for development in patients with tumors harboring an NRG1 fusion, in part due to the following key characteristics.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Seribantumab&#8217;s unique mechanism of action inhibits ligand-dependent activation of HER3, and likely through the inhibition of ERBB dimerization, destabilizes the entire ERBB family of proteins.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Previous clinical studies in more than 800 patients demonstrating that seribantumab had been generally well tolerated in clinical trials with mostly Grade 1/2 adverse events.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our ability to determine the predicted active dose of seribantumab from preclinical models of tumors harboring an NRG1 fusion.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Seribantumab&#8217;s favorable pharmacokinetic profile that we believe is well suited to optimized schedules and may provide a biologically effective dose in patients with tumors harboring an NRG1 fusion.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The manufacturing process for seribantumab has been shown to be commercially scalable.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Risks for development in genomically defined patient population have the potential to be addressed through the design of our Phase 2 CRESTONE trial of seribantumab.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Mechanism of action</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Seribantumab is a fully human IgG2 monoclonal antibody that binds to HER3 and competes with the NRG1 fusion protein, preventing activation of the HER3 signaling cascade that is believed to sustain proliferation and survival of tumor cells harboring an NRG1 fusion. NRG1 fusions may act as a ligand to HER3, allowing HER3 to dimerize to HER2 and other ERBB family members and subsequently over-activating the downstream PI3K/AKT and MAPK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Seribantumab is a fully human IgG2 monoclonal antibody that binds to a unique epitope on HER3 that prevents the ligand-induced activation of HER3, as well as disrupts the ability of HER3 to dimerize with HER2, and to a lesser extent, the other ERBB family members EGFR and HER4. By inhibiting the dimerization of HER3 with other ERBB family members, seribantumab reduces the activation of these receptors in addition to the ligand-dependent activation of HER3, and subsequent activation of PI3K/AKT and MAPK, downstream signaling pathways that are commonly implicated in tumor growth and proliferation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Previous sponsor&#8217;s Phase 1 monotherapy trial NCT00734305 (safety and pharmacokinetics)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The initial monotherapy trial conducted by the previous sponsor was a Phase 1 open label, dose escalation trial in which six cohorts of patients were enrolled followed by an expansion cohort using a maximum loading dose of 40 mg/kg followed by weekly dosing at 20 mg/kg. Overall, a total of 43 patients were exposed to seribantumab in this initial safety and pharmacology trial. The majority of adverse events observed in the monotherapy trial were transient and mild to moderate in severity. The most commonly reported adverse events were Grade 1 or 2 rash, nausea, diarrhea, and fatigue. There was one serious adverse event, or SAE, considered possibly related to seribantumab in trials conducted to date, a Grade 4 confusional state at the lowest dose level tested, 3.2 mg/kg. The event resolved after treatment discontinuation and no other dose limiting toxicities, or DLTs, were reported in this or other dose escalation cohorts in the Phase 1 monotherapy study. A maximum tolerated dose, or MTD, was not determined in this trial.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:242pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">Our preclinical characterization</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We sponsored a series of preclinical studies to determine the <i style="font-style:italic;">in vitro</i> and <i style="font-style:italic;">in vivo</i> properties of seribantumab specifically in NRG1 fusion models, some of which were published by Odintsov et al. in <i style="font-style:italic;">Clinical Cancer Research</i> in 2021. Experiments were conducted in NRG1 fusion models, including patient-derived xenograft, or PDX mouse models. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Key findings from our preclinical testing of seribantumab include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Inhibition of HER3 resulted in reduction of tumor growth in NRG1 fusion driven tumors.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Seribantumab reduced tumor growth to a greater extent than both clinically achievable and supra-clinical doses of afatinib in multiple NRG1 fusion models of cancer.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Seribantumab inhibited ligand-dependent activation of HER3 and phosphorylation of all other ERBB family members.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Seribantumab inhibited HER3 dimerization with HER2 due to the unique epitope on HER3 to which seribantumab binds.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The active dose of seribantumab was determined and confirmed across multiple NRG1 fusion model.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 2. Seribantumab inhibits signaling through HER3 and blocks HER3-HER2 dimerization.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="elev-20211231x10k003.jpg" alt="Graphical user interface, application, table&#10;&#10;Description automatically generated" style="display:inline-block;height:242pt;width:468pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Figure 2. </b>[<b style="font-weight:bold;">Left</b>] Treatment of the LUAD0061AS3 cell line (which has an SLC3A2-NRG1 fusion) with seribantumab showed dose-dependent inhibition of HER3, HER2, EGFR, HER4, and AKT phosphorylation <i style="font-style:italic;">in vitro</i>. [<b style="font-weight:bold;">Middle</b>] Treatment of a LUAD0061AS3 PDX model confirmed reduction of HER3 and HER2 phosphorylation as well as reduction of phosphorylation of downstream AKT and ERK following a single flat dose of seribantumab (0.6 mg, 0.75 mg or 1 mg) <i style="font-style:italic;">in vivo</i>. Tumors were removed at 2-, 24-, or 168-hours post-drug administration, to determine impact on signaling activity over time. All doses of seribantumab resulted in reduced phosphorylation of HER2, HER3, AKT, and ERK1/2 by the 2h time point, with higher doses being more effective at the longer time points. However, at the 24h and 168h time points, reactivation of HER3, AKT and ERK1/2 protein phosphorylation was observed, despite consistent </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:248pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">inhibition of HER2. Figures reproduced with permission from Clinical Cancer Research. [<b style="font-weight:bold;">Right</b>] MDA-MB-175-VII is a breast cancer model with a DOC4-NRG1 fusion. Immunoprecipitation (IP) of HER3 was followed by immunoblot (IB, Western blot) analysis for HER2 or HER3. In this NRG1 fusion containing cell line, HER3-HER2 dimers were detected under serum-depleted conditions. Treatment with NRG1-&#223;1 ligand did not increase HER3-HER2 association beyond basal levels, suggesting near-maximum association. Reduced levels of HER2 in the HER3 precipitate extracted following treatment with seribantumab suggests that seribantumab is able to block HER3-HER2 dimerization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 3. Preclinical proof of concept (</b><i style="font-style:italic;">in vivo</i><b style="font-weight:bold;">): Seribantumab drives tumor regression in a lung SLC3A2-NRG1 fusion PDX model (LUAD-0061AS3).</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="elev-20211231x10k004.jpg" alt="Chart&#10;&#10;Description automatically generated" style="display:inline-block;height:248pt;width:468pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 3:</b> The LUAD-0061AS3 PDX model was developed from a lung cancer specimen with an SLCA3A2/NRG1 fusion and was used to test repeat dosing of seribantumab <i style="font-style:italic;">in vivo</i>. Notably, this specimen was derived from a patient who had progressed after prior standard therapy and progression on afatinib therapy. In this trial, PDX tumors (approximately 3 mm<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup>) were implanted subcutaneously into the flanks of immunodeficient mice. Treatment was initiated when the tumors reached a volume of 150-200 mm<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup>. Each treatment group consisted of 7 mice while 5 mice were used in the vehicle control group. Treatment started on day 14 of the experiment and consisted of vehicle (PBS), seribantumab (0.6, 0.75 or 1 mg per dose BIW, or afatinib (5, 10, or 15 mg/kg QD). A dose-related decline in tumor volume was observed across all doses of seribantumab, with the best response observed with the 1 mg/kg dose where maximal tumor regression was approximately 60%. Afatinib was not associated with tumor regression at 5 mg/kg; however tumor regression of approximately 30% was observed at a dose of 15 mg/kg, which is approximately 3-fold higher than the clinically achievable dose of 40 mg/day in humans.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:243pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 4. Preclinical proof of concept (</b><i style="font-style:italic;">in vivo</i><b style="font-weight:bold;">):</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Seribantumab drives near-complete tumor regression in an ovarian CLU-NRG1 fusion PDX model (OV-10-0050).</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="elev-20211231x10k005.jpg" alt="Chart&#10;&#10;Description automatically generated" style="display:inline-block;height:242.5pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:468pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 4: </b>The OV-10-0050 PDX model was developed from an ovarian cancer specimen with a CLU-NRG1 fusion. Seribantumab at doses of 2.5 mg, 5 mg, and 10 mg BIW were tested. Near complete and complete tumor regressions were observed across the entire dose range, with complete tumor regressions observed in nearly all animals at the highest dose level of 10 mg BIW. Afatinib dosed at 5 mg/kg QD did not induce tumor regressions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Based on the collective results from these studies, we believe that the active dose of seribantumab necessary to reduce HER3 and downstream ERBB signaling, reduce the growth of tumors, and extend the duration of response ranges from approximately 1 mg BIW and up to at least 10 mg BIW in these preclinical cancer models driven by an NRG1 fusion, which is approximately equivalent to a 260 mg&#8201;-&#8201;2.6 g fixed dose in humans and well within the 3 gram weekly clinical dose of seribantumab. The inhibitory capability of seribantumab was evident in tumor types with different tissues of origin (lung and ovarian) and different NRG1 fusion partners (SLCA32-NRG1 and CLU-NRG1, respectively).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Optimized Clinical Trial and Regulatory Execution: Phase 2 Tumor-Agnostic CRESTONE trial (NCT04383210)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In July 2020, we initiated our Phase 2 CRESTONE trial following a Type C meeting with FDA as the first clinical trial of seribantumab in patients with solid tumors driven by an NRG1 fusion. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The CRESTONE trial is as an open-label, international, multi-center, tumor-agnostic Phase 2 trial in adult patients with recurrent, locally advanced or metastatic solid tumors that harbor an NRG1 gene fusion and have progressed after at least one prior line of standard therapy. Patients will be enrolled into one of three cohorts depending on prior treatments received and the presence or absence of an NRG1 fusion with intact EGF-like domain that is mutually exclusive with any other actionable molecular alteration. The trial is designed as a potentially registrational trial, contingent on continued discussions with the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A cohort design has been introduced to proactively control for innate biological variability in NRG1 fusions, such as impact of the expression of an intact EGF-like domain, as well as potential variability in response due to prior treatment with other inhibitors of the ERBB family. Cohort 1 is designated as the pivotal cohort and therefore has the most </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">stringent eligibility criteria. Cohorts 2 and 3 are exploratory in nature, and not intended to contribute to the population supporting a potential registration application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">All patient tumors will be tested for an NRG1 fusion based on local CLIA-certified or similarly accredited lab testing of tumor tissue prior to initiating further screening procedures. All patients must have received at least one prior line of standard therapy.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Cohort 1 (Pivotal): At least 55 patients with a centrally confirmed NRG1 fusion who have not been previously treated with an EGFR-, HER2-, or HER3-directed therapy. Patients eligible for Cohort 1 must have a tumor with an NRG1 fusion with an intact EGF-like domain and no other known and actionable oncogenic driver alterations. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Cohort 2 (Exploratory): Up to ten patients with tumors harboring an NRG1 fusion with an intact EGF-like domain and no other known and actionable oncogenic driver alterations, and who are relapsed/refractory to prior EGFR-, HER2-, or HER3-directed therapy.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Cohort 3 (Exploratory): Up to ten patients who have (i) tumors harboring an NRG1 fusion without an intact EGF-like domain, (ii) tumors with other NRG1 alterations, (iii) tumors with additional known alterations without standard treatment options, or (iv) insufficient tissue biopsies available for central confirmation of NRG1 fusion status.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The primary endpoint of the CRESTONE trial is to determine the ORR by independent radiologic review according to RECIST 1.1. Tumor assessments will be measured and recorded by the local radiologist beginning at week 6. Independent central review of scans will be conducted for patients enrolled in Cohort 1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Key secondary endpoints include DOR, PFS, OS, Clinical Benefit Rate (CBR; CR, PR, SD &gt; 24 weeks), and the safety profile of seribantumab in patients with a tumor harboring an NRG1 fusion. Patients are expected to be treated until investigator-assessed progressive disease or unacceptable toxicity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">After all screening procedures and determination of eligibility for trial treatment (including a local NRG1 fusion positive testing result) have been completed, eligible patients will be assigned to the appropriate cohort based upon prior treatment history and local NRG1 fusion testing results. We expect to complete enrollment of the first 20 patients in Cohort 1 of the CRESTONE study in mid-2022, and to present initial clinical data from approximately 10 patients from Cohort 1 of the CRESTONE study treated with seribantumab at 3 grams weekly at a major medical meeting in mid-2022. We believe that the design and conduct of CRESTONE, subject to discussions with the FDA, may support submission of a BLA for accelerated approval in advanced solid tumors harboring an NRG1 fusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Key design components of CRESTONE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Several important design considerations have been built into the CRESTONE protocol that we believe may optimize for efficient conduct and a clean signal in the primary efficacy analysis population.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A tumor-agnostic trial design maximizes opportunity for patient eligibility in this rare, genomically defined population.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To avoid introduction of delays in patient screening leading to delayed initiation of treatment in this aggressive disease, patient eligibility is based on readily accessible, local CLIA-certified testing including PCR, FISH, DNA- or RNA-based NGS testing.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To control for variability introduced by screening through local CLIA-certified testing, all patients in Cohort 1 will also have a central confirmatory test by RNA-based NGS to confirm the presence of an NRG1 fusion to help rule out any false-positive test results that may come from their prior local CLIA-certified testing. Only </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patients with a centrally confirmed NRG1 fusion are included in the primary efficacy analysis population for statistical analysis.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Due to the currently limited understanding of clinical impact of prior exposure to anti-ERBB therapy, patients that have received prior anti-ERBB therapy are excluded from Cohort 1. These patients may be enrolled into Cohort 2.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The current literature suggests that an NRG1 fusion must retain a functional EGF-like binding domain to enable ligand-dependent HER3 signaling. Therefore, patients with an NRG1 fusion that lacks an EGF-like domain are excluded from Cohort 1. These patients may instead be enrolled in Cohort 3.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Patients with co-expression of other known oncogenic drivers are excluded from Cohort 1. We believe that seribantumab as a monotherapy has the greatest potential for positive clinical outcomes in tumors uniquely driven by an NRG1 fusion. Patients with co-expression of other known oncogenic drivers, where there is no suitable alternative therapy to target these oncogenic drivers, may instead be enrolled in Cohort 3.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Because NRG1 fusions are often found in more aggressive tumor types, it is important to achieve steady state of seribantumab as quickly as possible for disease control. The design of CRESTONE includes a proactive safety run-in and dose optimization phase to ensure that all subsequent patients comprising the primary efficacy analysis population are receiving an optimal dose specific to the NRG1 fusion population.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patient identification and clinical conduct in CRESTONE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We proactively addressed key challenges in identifying and enrolling patients into trials for rare genomically defined tumors. We are employing multiple innovative models designed to ensure Good Clinical Practice and enhance enrollment of our Phase 2 CRESTONE trial through real-time nationwide identification of patients with tumors harboring an NRG1 fusion from our academic core sites and within our partner networks, in a capital-efficient manner. Through these mechanisms, we are rapidly alerted when any patient with an NRG1 fusion is identified across major diagnostic networks and have access to approximately 400 potential clinical trial sites in total.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Currently, patients may be enrolled onto CRESTONE via three mechanisms:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Enrollment at core sites:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> These clinical trial sites are located at major academic and community medical centers and are strategically selected due to their deep clinical trial experience and an existing ability to locally test for NRG1 fusions. These sites are activated on a permanent basis for the duration of the trial.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Referral to core sites from diagnostic partner networks:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> We have partnered with diagnostic providers such as Ashion Analytics (now Exact Sciences), NeoGenomics, and Strata Oncology and anticipate the potential to engage in additional partnerships in the future. These partnerships allow us access to diagnostic data generated using comprehensive DNA- and RNA-based NGS assays for the presence of an NRG1 fusion. When a patient with a tumor that has an NRG1 fusion is identified in their networks, we are alerted and put in touch with the treating physician to determine if the patient is eligible for CRESTONE with the treating physician being notified of the most proximal CRESTONE site.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">&#8220;On-demand&#8221; site initiation:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Our partnerships with diagnostic providers such as Caris Life Sciences and Tempus, and health networks like The US Oncology Network (through their Selected Trials for Accelerate Rollout program), give us access to pre-qualified sites that can be quickly activated in approximately 14 days or fewer following the identification of a patient with a tumor harboring an NRG1 fusion that meets trial entry criteria and qualifies for CRESTONE. These sites are in addition to the core sites participating in CRESTONE.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We believe that recent advances in genomic testing, and subsequent increased adoption of RNA-based NGS, will result in improved identification of patients with tumors harboring an NRG1 fusion. In addition to academic and community-based medical centers that are routinely conducting testing, there are multiple commercial diagnostic companies that </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">include NRG1 fusions on their CLIA-certified testing panels. Some examples of these companies are: Ashion Analytics (now Exact Sciences), Caris, Illumina, Invitae (ArcherDx), NeoGenomics, Strata Oncology, Tempus and ThermoFisher, among others. In addition, Foundation Medicine can detect gene fusions potentially indicative of an NRG1 fusion through the identification of common NRG1 fusion partners, such as CD74. We anticipate partnering with a diagnostic provider to develop a companion diagnostic for seribantumab use in patients with tumors harboring an NRG1 fusion. This may be done in parallel to the CRESTONE trial or as a post-marketing commitment following a potential accelerated approval contingent upon continued discussion with the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We believe that the number of genomic tests that are conducted across tumor types, and the number of companies that include NRG1 fusions on their test panels, will continue to increase over time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Manufacturing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacturing of our product candidates for clinical testing, as well as for commercial manufacturing if any of our product candidates obtain marketing approval. We also rely, and expect to continue to rely, on third parties to package, label, store and distribute our investigational product candidates, as well as our commercial products if marketing approval is obtained. We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are currently party to a manufacturing agreement with Samsung Biologics Co.,&#160;Ltd., or Samsung, for the manufacturing of seribantumab drug substance and the performance of associated quality related services. Options for redundant or replacement supply are under active evaluation. Seribantumab is currently being manufactured at a scale appropriate for clinical trials and has previously been manufactured at a scale suitable for commercialization. To the extent we approach commercialization for seribantumab or any other product candidates, we expect that we would identify and qualify additional manufacturers to provide the drug substance and fill finish services as a part of such commercialization plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We generally expect to rely on third parties for the manufacturing of any companion diagnostics we may develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Competition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that our technology, the expertise of our team, and our development experience and scientific knowledge provide us with competitive advantages, we face increasing competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions. Product candidates that we successfully develop and commercialize may compete with existing therapies and new therapies that may become available in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We compete directly with companies that focus on oncology and companies dedicating their resources to cancer therapies. With the proliferation of new drugs and therapies into oncology, we expect to face increasingly intense competition as new technologies become available and new therapeutic candidates are clinically developed or approved therapies are explored for new indications. Any candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Many of our competitors, either alone or with their collaborators, have significantly greater financial resources, established presence in the market, and expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">through collaborative arrangements with large and established companies. Additional mergers and acquisitions may result in even more resources being concentrated in our competitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The key competitive factors affecting the success of all of our therapeutic antibody candidates, if approved, are likely to be their efficacy, safety, dosing convenience, price, the effectiveness of companion diagnostics in guiding the use of related therapeutics, the level of generic competition and the availability of reimbursement from government and other third-party payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our commercial potential could be reduced or eliminated if our competitors develop and commercialize products that are safer or more effective, have fewer or less severe side effects, and are more convenient or less expensive than products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we can, which could result in our competitors establishing a strong market position before we are able to enter the market or could otherwise make our development more complicated. We believe the key competitive factors affecting the success of all of our programs are likely to be efficacy, safety and patient convenience. Even if our antibody candidates achieve marketing approval, they may be priced at a significant premium over competitive products if any have been approved by then.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There are a number of biological and biotechnology companies that currently are pursuing the development of precision oncology therapies for patients with undrugged, genetically-defined cancers with high unmet need. In particular, we expect that our current lead product candidate, seribantumab, will compete against other ERBB or HER3 inhibitors that are in development for targeting tumors with an NRG1 fusion, including those of Merus N.V. (zenocutuzumab&#8201;&#8212;&#8201;MCLA-128), Hummingbird Bioscience&#160;Ltd. (HMBD-001&#8201;&#8212;&#8201;10D1F), GamaMabs Pharma (9F7-F11), and AVEO Oncology (AV-203). We may face further competition from companies pursuing the development of product candidates that are ERBB or HER3 inhibitors not currently in defined clinical plans for targeting tumors with an NRG1 fusion, including ISU ABXIS, Daiichi Sankyo, Celldex, GlaxoSmithKline, Boehringer Ingelheim, or others. Development efforts and clinical results of these other future product candidates may be unsuccessful, which could result in a negative perception of HER3 inhibitors, for instance, and negatively impact the regulatory approval process of our lead product candidate, which could have a material and adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Asset purchase, licensing and collaboration agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Previous sponsor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2019, we entered into an asset purchase agreement with the previous sponsor, pursuant to which we acquired the previous sponsor&#8217;s anti-HER3 antibody programs, or the Acquired Product Candidates, including seribantumab. Upon closing of the asset purchase agreement in July&#160;2019, we paid the previous sponsor an upfront cash payment of $3.5&#160;million. In addition to the foregoing payment, we may become obligated to pay the previous sponsor up to $54.5&#160;million in additional potential development, regulatory approval and commercial-based milestone payments, consisting of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$3.0&#160;million for achievement of the primary endpoint in the first registrational clinical trial of any Acquired Product Candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">up to $16.5&#160;million in total payments for the achievement of various regulatory approval and reimbursement-based milestones in the United States, Europe and Japan; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">up to $35.0&#160;million in total payments for achieving various cumulative worldwide net sales targets between $100.0&#160;million and $300.0&#160;million for the Acquired Product Candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Dyax</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pursuant to the asset purchase agreement with the previous sponsor, and in connection with the closing of the asset purchase agreement, we (i)&#160;assumed all of the previous sponsor&#8217;s obligations and rights under the amended and restated collaboration agreement, or the Dyax collaboration agreement, between the previous sponsor and Dyax Corp., or Dyax, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">which was entered into in January&#160;2007, including an exclusive, worldwide product license to clinically develop or commercialize seribantumab and (ii)&#160;agreed to be bound to the terms of a sublicense agreement between the previous sponsor and Dyax entered into in June&#160;2008. Under the Dyax collaboration agreement, Dyax used its proprietary phage display technology to identify antibodies that bind to targets of interest to us as therapeutics or diagnostics. Seribantumab was identified through the Dyax collaboration agreement. In January&#160;2016, Dyax was acquired by Shire plc, which was subsequently acquired by Takeda Pharmaceutical Company Limited in January&#160;2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may be required to make additional maximum aggregate development and regulatory milestone payments of up to approximately $9.3&#160;million for seribantumab. In addition, Dyax is entitled to tiered mid single digit&#160;royalties based on net sales of seribantumab. Our obligation to pay royalties to Dyax continues on a country-by-country basis until the later of a specified number of&#160;years after the first commercial sale of seribantumab in such country and the expiration of the patent rights covering the product in such country. We are obligated to use commercially reasonable efforts to develop and commercialize the antibodies for which we obtain a commercial license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This agreement will remain in effect, unless terminated earlier, for so long as we or any of our affiliates or sublicensees continue to develop or commercialize products that remain royalty-bearing under the agreement. Either party may terminate the agreement in the event of an uncured material breach by the other party. We also may terminate the agreement in its entirety or on a product-by-product basis at any time upon 90&#160;days&#8217; prior written notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Ligand Pharmaceuticals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the asset purchase agreement with the previous sponsor, and in connection with the closing of the asset purchase agreement, we purchased from the previous sponsor all of the right, title and interest in and to the commercial license agreement between the previous sponsor and Selexis SA, or Selexis, for non-exclusive rights to technology for use in the manufacture of certain biologic products. Under this agreement, we are required to make aggregate milestone payments of up to &#8364;0.9&#160;million, per licensed product, and pay royalties of less than one&#160;percent on net sales of product, which royalty payments expire in 2026. The obligation to pay royalties with respect to each product sold in a country continues until the expiration of the patent rights covering the product in such country. Either party may terminate the agreement in the event of an uncured material breach by the other party. We also have the right to terminate the agreement at any time upon 60&#160;days&#8217; prior written notice. In November of 2021, the Selexis agreement was assigned to Ligand Pharmaceuticals Incorporated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Caris Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2021, we entered into a collaboration agreement with Caris, or the Caris Agreement. Under the terms of the Caris Agreement, Caris will identify targets for the collaboration and provide those targets to Elevation at regular intervals for review and approval. Once a target is selected by the collaboration&#8217;s joint steering committee, the collaboration will retain access to the selected targets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The financial terms surrounding development and commercialization of each product candidate identified for the collaboration and included in the Caris Agreement vary based on the level of participation elected by each party in the development and commercialization efforts following identification of a target. There are no upfront or milestone payments or royalties due to either party under the collaboration. With respect to proceeds from any potential commercial transaction related to a product resulting from the collaboration, Caris will be entitled to a tiered initial&#160;percentage ranging from the mid-single digits to low teens based on the product candidate&#8217;s potential peak sales revenue with the remaining proceeds allocated based on each party&#8217;s pro&#160;rata share of expenses incurred in development of the product. In the case of an out-licensing transaction of an asset instead of a sale, Caris and we will split all consideration received in the transaction in a similar manner. The Caris Agreement provides flexibility for Caris and us to jointly develop and commercialize, or for either us or Caris to incur development and commercialization expenses. The ultimate&#160;percentage of proceeds payable to us and Caris will depend on the level of development and commercialization participation elected by each party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We will own the intellectual property rights to the therapeutics developed under the collaboration, and Caris will own the intellectual property rights to the diagnostics developed under the collaboration.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Either party may terminate the Caris Agreement for uncured material breach by the other party or in the case of the other party&#8217;s insolvency. The term of the Caris Agreement is three&#160;years, automatically renewing for one-year terms. Either party may terminate the agreement at the end of a term by written notice to the other, subject to the continuation of exclusivity with respect to any target selected by the joint steering committee, so long as commercially reasonable efforts are used to discover, identify, develop and/or commercialize a therapeutic related to such target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We strive to protect the proprietary technologies that we believe are important to our business, including seeking and maintaining patent protection intended to cover the compositions of matter of our product candidate, its methods of use, and other inventions that are important to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our success will depend significantly on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions, and know-how related to our business, to defend and enforce our patents, to preserve the confidentiality of our trade secrets, and to operate without infringing valid and enforceable patents and other proprietary rights of third parties. We also rely on know-how and continuing technological innovation to develop, strengthen, and maintain our proprietary position in the field of precision oncology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our wholly owned patent portfolio includes a patent family with claims directed to antibodies and related compositions covering seribantumab, as well as methods of treating cancer using such antibodies and compositions. The family contains three U.S. patents directed to seribantumab which expire in February&#160;2028 and a fourth U.S. patent which expires in October&#160;2029 (including 614&#160;days of Patent Term Adjustment), subject to any disclaimers or extensions. The family also contains a pending U.S. application, which if issued, would expire in February&#160;2028, subject to any disclaimers or extensions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, the above-discussed patent family includes granted patents in China, Europe, Hong Kong, Israel, and Japan with claims directed to compositions of matter covering seribantumab and related methods of therapy. These patents expire in February&#160;2028, subject to any disclaimers or extensions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our patent portfolio further includes an additional early-stage, unpublished patent family specifically covering the use of seribantumab to treat patients harboring an NRG1 fusion according to our CRESTONE clinical trial dosing regimen. Any patents issuing from this family would expire in March&#160;2042, subject to any disclaimers or extensions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In the countries in which we file, the patent term is 20&#160;years from the earliest non-provisional filing date, subject to any disclaimers or extensions. The term of a patent in the United States can be adjusted due to any failure of the United States Patent and Trademark Office following certain statutory and regulation deadlines for issuing a patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the United States, the patent term of a patent that covers an FDA-approved drug may also be eligible for patent term extension, which permits patent term restoration as compensation for a portion of the patent term lost during the FDA regulatory review process. The Hatch-Waxman Act permits a patent term extension of up to five&#160;years beyond the original expiration of the patent. The protection provided by a patent varies from country to country, and is dependent on the type of patent granted, the scope of the patent claims, and the legal remedies available in a given country. Additionally, we expect seribantumab to be subject to biological exclusivity in the United States for twelve&#160;years from BLA approval under the Biologics Price Competition and Innovation Act of 2009. See &#8220;Government Regulation and Product Approval&#8201;&#8212;&#8201;Biosimilars.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the course of the individual&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Governmental Regulation and Product Approval</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">FDA Approval Process</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the United States, biological products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act, or the FDC Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products. Biological products used for the prevention, treatment, or cure of a disease or condition of a human being are subject to regulation under the FDC Act, with the exception that the section of the FDC Act that governs the approval of drugs via new drug applications, or NDAs, does not apply to the approval of biologics. In contrast, biologics are approved for marketing under provisions of the Public Health Service Act, or PHSA, via a BLA. However, the application process and requirements for approval of BLAs are very similar to those for NDAs. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as clinical hold, FDA refusal to approve pending BLAs, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, and criminal prosecution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Biological product development for a new product in the United States typically involves preclinical laboratory and animal tests, the submission to the FDA of an investigational new drug application, or IND, which must become effective before clinical testing may commence, and adequate and well-controlled clinical trials to establish the safety and effectiveness of the drug for each indication for which FDA approval is sought. Satisfaction of FDA pre-market approval requirements typically takes many&#160;years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product or disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Preclinical tests include laboratory evaluation of product chemistry, formulation, and toxicity, as well as animal trials to assess the characteristics and potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements, including Good Laboratory Practices. The results of preclinical testing are submitted to the FDA as part of an IND along with other information, including information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long-term preclinical tests, such as tests of reproductive toxicity and carcinogenicity in animals, may continue after the IND is submitted. A 30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If the FDA has neither commented on nor questioned the IND within this 30-day period, the clinical trial proposed in the IND may begin. Clinical trials involve the administration of the investigational drug or biologic to healthy volunteers or patients under the supervision of a qualified investigator. Clinical trials must be conducted: (i)&#160;in compliance with federal regulations; (ii)&#160;in compliance with Good Clinical Practice, or GCP, an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators, and monitors; as well as (iii)&#160;under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The FDA may order the temporary or permanent discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA regulations or presents an unacceptable risk to the clinical trial patients. Imposition of a clinical hold may be full or partial. The study protocol and informed consent information for patients in clinical trials must also be submitted to an institutional review board, or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">IRB, for approval. The IRB will also monitor the clinical trial until completed. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#8217;s requirements, or may impose other conditions. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated checkpoints based on access to certain data from the trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Clinical trials to support BLAs for marketing approval are typically conducted in three sequential phases. In Phase&#160;1, the initial introduction of the drug or biologic into patients, the product is tested to assess safety, dosage tolerance, metabolism, pharmacokinetics, pharmacological actions, side effects associated with drug exposure, and to obtain early evidence of a treatment effect if possible. Phase&#160;2 usually involves trials in a limited patient population to determine the effectiveness of the biologic for a particular indication, determine optimal dose and regimen, and to identify common adverse effects and safety risks. If a compound demonstrates evidence of effectiveness and an acceptable safety profile in Phase&#160;2 evaluations, Phase&#160;3 trials are undertaken to obtain additional information about clinical effects and confirm efficacy and safety in a larger number of patients, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the overall benefit-risk relationship of the biologic and to provide adequate information for the labeling of the product. In most cases, the FDA requires two adequate and well-controlled Phase&#160;3 clinical trials to demonstrate the safety and efficacy of the biologic. In rare instances, a single Phase&#160;3 trial may be sufficient when either (1)&#160;the trial is a large, multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible or (2)&#160;the single trial is supported by other confirmatory evidence. Approval on the basis of a single trial may be subject to a requirement for additional post-approval studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">These phases may overlap or be combined. For example, a Phase&#160;1/2 clinical trial may contain both a dose-escalation stage and a dose-expansion stage, the latter of which may confirm tolerability at the recommended dose for expansion in future clinical trials (as in traditional Phase&#160;1 clinical trials) and provide insight into the anti-tumor effects of the investigational therapy in selected subpopulation(s). Typically, during the development of oncology therapies, all subjects enrolled in Phase&#160;1 clinical trials are disease-affected patients and, as a result, considerably more information on clinical activity may be collected during such trials than during Phase&#160;1 clinical trials for non-oncology therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, the manufacturer of an investigational biologic in a Phase&#160;2 or Phase&#160;3 clinical trial for a serious or life-threatening disease is required to make available, such as by posting on its website, its policy on evaluating and responding to requests for expanded access to such investigational drug or biologic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">After completion of the required clinical testing, a BLA is prepared and submitted to the FDA. FDA approval of the BLA is required before marketing and distribution of the product may begin in the United States. The BLA must include the results of all preclinical, clinical, and other testing and a compilation of data relating to the product&#8217;s pharmacology, chemistry, manufacture, and controls. The cost of preparing and submitting a BLA is substantial. The submission of most BLAs is additionally subject to a substantial application user fee. Under an approved BLA, the applicant is also subject to an annual program fee. These fees typically increase annually. A BLA for a drug that has been designated as an orphan drug is not subject to an application fee, unless the BLA includes an indication for other than a rare disease or condition. The FDA has 60&#160;days from its receipt of a BLA to determine whether the application will be filed based on the FDA&#8217;s determination that it is adequately organized and sufficiently complete to permit substantive review. Once the submission is filed, the FDA begins an in-depth review. The FDA has agreed to certain performance goals to complete the review of BLAs. Most applications are classified as Standard Review products that are reviewed within ten&#160;months of the date the FDA files the BLA; applications classified as Priority Review are reviewed within six&#160;months of the date the FDA files the BLA. A BLA can be classified for Priority Review when the FDA determines the biologic has the potential to treat a serious or life-threatening condition and, if approved, would be a significant improvement in safety or effectiveness compared to available therapies. The review process for both standard and priority reviews may be extended by the FDA for three or more additional&#160;months to consider certain late-submitted information, or information intended to clarify information already provided in the BLA submission.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The FDA may also refer applications for novel biologic products, as well as biologic products that present difficult questions of safety or efficacy, to be reviewed by an advisory committee&#8201;&#8212;&#8201;typically a panel that includes clinicians, statisticians and other experts&#8201;&#8212;&#8201;for review, evaluation, and a recommendation as to whether the BLA should be approved. The FDA is not bound by the recommendation of an advisory committee, but generally follows such recommendations. Before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the biologic product is manufactured. The FDA will not approve the product unless compliance with current good manufacturing practice, or cGMP is satisfactory and the BLA contains data that provide substantial evidence that the drug is safe and effective, or the biologic is safe, pure, potent, and effective, in the respective claimed indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">After the FDA evaluates the BLA and completes any clinical and manufacturing site inspections, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies in the BLA submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application for approval. If, or when, those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six&#160;months depending on the type of information included. An approval letter authorizes commercial marketing and distribution of the biologic with specific prescribing information for specific indications. As a condition of BLA approval, the FDA may require a risk evaluation and mitigation strategy, or REMS, to help ensure that the benefits of the biologic outweigh the potential risks to patients. A REMS can include medication guides, communication plans for healthcare professionals, and elements to assure a product&#8217;s safe use, or ETASU. An ETASU can include, but is not limited to, special training or certification for prescribing or dispensing the product, dispensing the product only under certain circumstances, special monitoring, and the use of patient-specific registries. The requirement for a REMS can materially affect the potential market and profitability of the product. Moreover, the FDA may require substantial post-approval testing and surveillance to monitor the product&#8217;s safety or efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing. Changes to some of the conditions established in an approved BLA, including changes in indications, product labeling, manufacturing processes or facilities, require submission and FDA approval of a new BLA, or supplement to an approved BLA, before the change can be implemented. A BLA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing BLA supplements as it does in reviewing original BLAs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fast Track Designation and Priority Review</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">FDA is required to facilitate the development, and expedite the review, of drugs or biologic products that are intended for the treatment of a serious or life-threatening disease or condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs for the condition. Fast track designation may be granted for products that are intended to treat a serious or life-threatening disease or condition for which there is no effective treatment and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to both the product and the specific indication for which it is being studied. Any product submitted to FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Priority review may be granted for products that are intended to treat a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. FDA will attempt to direct additional resources to the evaluation of an application designated for priority review in an effort to facilitate the review.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Breakthrough Therapy Designation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FDA is also required to expedite the development and review of applications for approval of products that are intended to treat a serious or life-threatening disease or condition where preliminary clinical evidence indicates that the biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. Under the breakthrough therapy program, the sponsor of a new product candidate may request that FDA designate the product </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">candidate for a specific indication as a breakthrough therapy concurrent with, or after, the submission of the IND for the product candidate. FDA must determine if the product candidate qualifies for breakthrough therapy designation within 60&#160;days of receipt of the sponsor&#8217;s request. The FDA may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development process, providing timely advice to the product sponsor regarding development and approval, involving more senior staff in the review process, assigning a cross-disciplinary project lead for the review team and taking other steps to design the clinical studies in an efficient manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accelerated Approval</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Accelerated approval may be granted for a product that is intended to treat a serious or life-threatening condition and that generally provides a meaningful therapeutic advantage to patients over existing treatments. A product eligible for accelerated approval may be approved on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. The accelerated approval pathway is most often used in settings in which the course of a disease is long, and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the development and approval of products for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large studies to demonstrate a clinical or survival benefit. The accelerated approval pathway is contingent on a sponsor&#8217;s agreement to conduct additional post-approval confirmatory studies to verify and describe the product&#8217;s clinical benefit. These confirmatory trials must be completed with due diligence and, in most cases, the FDA may require that the trial be designed, initiated, and/or fully enrolled prior to approval. Failure to conduct required post-approval studies, or to confirm a clinical benefit during post-marketing studies, would allow the FDA to withdraw the product from the market on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Orphan Drugs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the Orphan Drug Act, FDA may grant orphan drug designation to products intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States but for which there is no reasonable expectation that the cost of developing and making the product for this type of disease or condition will be recovered from sales of the product in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Orphan drug designation must be requested before submitting a BLA. After FDA grants orphan drug designation, the identity of the drug and its potential orphan use are disclosed publicly by FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The first BLA applicant to receive FDA approval for a particular active moiety to treat a rare disease for which it has such designation is entitled to a seven-year exclusive marketing period in the U.S. for that product, for that indication. During the seven-year exclusivity period, FDA may not approve any other applications to market the same drug for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity by means of greater effectiveness, greater safety, or providing a major contribution to patient care, or in instances of drug supply issues. Orphan drug exclusivity does not prevent FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition. Other benefits of orphan drug designation include tax credits for certain research and an exemption from the BLA application fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Disclosure of Clinical Trial Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sponsors of clinical trials of FDA-regulated products, including drugs and biologic products, are required to register and disclose certain clinical trial information on the website www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of a clinical trial are then made </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">public as part of the registration. Sponsors are also obligated to disclose the results of their clinical trials after completion. Disclosure of the results of clinical trials can be delayed in certain circumstances for up to two&#160;years after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress of clinical development programs as well as clinical trial design.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Pediatric Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the Pediatric Research Equity Act, or PREA, BLAs, or supplements to BLAs must contain data to assess the safety and effectiveness of the biological product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the biological product is safe and effective. The FDA may grant full or partial waivers, or deferrals, for submission of data. Unless otherwise required by regulation, PREA does not apply to any biological product with orphan product designation except a product with a new active ingredient that is a molecularly targeted cancer product intended for the treatment of an adult cancer and directed at a molecular target determined by FDA to be substantially relevant to the growth or progression of a pediatric cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Best Pharmaceuticals for Children Act, or BPCA, provides a six-month extension of any non-patent exclusivity for a biologic if certain conditions are met. Conditions for exclusivity include the FDA&#8217;s determination that information relating to the use of a new biologic in the pediatric population may produce health benefits in that population, FDA making a written request for pediatric studies, and the applicant agreeing to perform, and reporting on, the requested studies within the statutory timeframe. Applications under the BPCA are treated as priority applications, with all of the benefits that designation confers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Additional Controls for Biologics</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To help reduce the increased risk of the introduction of adventitious agents, the PHSA emphasizes the importance of manufacturing controls for products whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend biologics licenses in situations where there exists a danger to public health, to prepare or procure products in the event of shortages and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction or spread of communicable diseases within the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">After a BLA is approved, the product may also be subject to official lot release as a condition of approval. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the lot manufacturing history and the results of all of the manufacturer&#8217;s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products, such as viral vaccines, before allowing the manufacturer to release the lots for distribution. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products. As with drugs, after approval of a BLA, biologics manufacturers must address any safety issues that arise, are subject to recalls or a halt in manufacturing, and are subject to periodic inspection after approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Post-Approval Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Once a BLA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and promotion of biologics, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the Internet. Although physicians may prescribe legally available drugs for off-label uses, manufacturers may not market or promote such off-label uses. Biologics may be marketed only for the approved indications and in accordance with the provisions of the approved labeling.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adverse event reporting and submission of periodic safety summary reports is required following FDA approval of a BLA. The FDA also may require post-marketing testing, known as Phase&#160;4 testing, REMS, and surveillance to monitor the effects of an approved product, or the FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control, biological product manufacture, packaging, and labeling procedures must </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">continue to conform to cGMPs after approval. Biologics manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the agency inspects a biologic product&#8217;s manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality-control to maintain compliance with cGMPs. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with required regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Biosimilars</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Biologics Price Competition and Innovation Act of 2009, or BPCIA, creates an abbreviated approval pathway for biological products shown to be highly similar to or interchangeable with an FDA-licensed reference biological product. Biosimilarity sufficient to reference a prior FDA-approved product requires that there be no differences in conditions of use, route of administration, dosage form, and strength, and no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency. Biosimilarity must be shown through analytical trials, animal trials, and a clinical trial or trials, unless the Secretary of Health and Human Services waives a required element. A biosimilar product may be deemed interchangeable with a previously approved product if it meets the higher hurdle of demonstrating that it can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. To date, a number of biosimilar products and two interchangeable products have been approved under the BPCIA. Complexities associated with the larger, and often more complex, structures of biological products, as well as the process by which such products are manufactured, pose some hurdles to biosimilar product implementation, which is still being evaluated by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A reference biologic is granted 12&#160;years of exclusivity from the time of first licensure, or BLA approval, of the reference product, and no application for a biosimilar can be submitted for four&#160;years from the date of licensure of the reference product. The first biologic product submitted under the biosimilar abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against a finding of interchangeability for other biologics for the same condition of use for the lesser of (i)&#160;one&#160;year after first commercial marketing of the first interchangeable biosimilar, (ii)&#160;18&#160;months after the first interchangeable biosimilar is approved if there is no patent challenge, (iii)&#160;eighteen&#160;months after resolution of a lawsuit over the patents of the reference biologic in favor of the first interchangeable biosimilar applicant, or (iv)&#160;42&#160;months after the first interchangeable biosimilar&#8217;s application has been approved if a patent lawsuit is ongoing within the 42-month period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">FDA Approval and Regulation of Companion Diagnostics</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If safe and effective use of a product depends on an <i style="font-style:italic;">in vitro</i> diagnostic, then the FDA generally will require approval or clearance of that diagnostic, known as a companion diagnostic, before or at the same time that the FDA approves the therapeutic product. In August&#160;2014, the FDA issued final guidance clarifying the requirements that will apply to approval of therapeutic products and <i style="font-style:italic;">in vitro</i> companion diagnostics. According to the guidance, if FDA determines that a companion diagnostic device is essential to the safe and effective use of a new therapeutic product or indication, FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic device is not approved or cleared for that indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Approval or clearance of the companion diagnostic device will ensure that the device has been adequately evaluated and has adequate performance characteristics in the intended population. The review of <i style="font-style:italic;">in vitro</i> companion diagnostics in conjunction with the review of our products will, therefore, likely involve coordination of review by CDER and the FDA&#8217;s Office of In Vitro Diagnostics and Radiological Health. We anticipate partnering with a diagnostic provider to develop a companion diagnostic for seribantumab use in patients with tumors harboring an NRG1 fusion. Review and approval of a companion diagnostic is typically done in parallel with development of the therapeutic product.&#160; However, it is possible that FDA may permit approval of the companion diagnostic for seribantumab as a post-marketing commitment following a potential regulatory approval.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the FDC Act, <i style="font-style:italic;">in vitro</i> diagnostics, including companion diagnostics, are regulated as medical devices. In the United States, the FDC Act and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption applies, diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. The two primary types of FDA marketing authorization applicable to a medical device are premarket notification, also called 510(k)&#160;clearance, and premarket approval, or PMA approval. The vast majority of companion diagnostics require PMA approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The PMA process, including the gathering of clinical and preclinical data and the submission to and review by the FDA, can take several&#160;years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are subject to an application fee. In addition, PMAs for certain devices must generally include the results from extensive preclinical and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic, a PMA application typically requires data regarding analytical and clinical validation studies. As part of the PMA review, the FDA will typically inspect the manufacturer&#8217;s facilities for compliance with the Quality System Regulation, or QSR, which imposes elaborate testing, control, documentation and other quality assurance requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">PMA approval is not guaranteed, and the FDA may ultimately respond to a PMA submission with a not approvable determination based on deficiencies in the application and require additional clinical trial or other data that may be expensive and time-consuming to generate and that can substantially delay approval. If the FDA&#8217;s evaluation of the PMA application is favorable, the FDA typically issues an approvable letter requiring the applicant&#8217;s agreement to specific conditions, such as changes in labeling, or specific additional information, such as submission of final labeling, in order to secure final approval of the PMA. If the FDA&#8217;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary, in which case the PMA approval may be delayed for several&#160;months or&#160;years while the trials are conducted and then the data submitted in an amendment to the PMA. If the FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved indications, which can be more limited than those originally sought by the applicant. The PMA can include post-approval conditions that the FDA believes necessary to ensure the safety and effectiveness of the device, including, among other things, additional testing and/or restrictions on labeling, promotion, sale and distribution. Once granted, PMA approval may be withdrawn by the FDA if compliance with post approval requirements, conditions of approval or other regulatory standards are not maintained, or problems are identified following initial marketing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">After a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also register their establishments and list their devices with the FDA. A medical device manufacturer&#8217;s manufacturing processes and the processes of the specification developer and repackager/relabeler (if different from the manufacturer) and initial importer (if manufactured outside of the United States), are required to comply with the applicable portions of the QSR, which cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging and shipping of medical devices. Facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Healthcare Laws</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal laws have been applied to restrict certain general business and marketing practices in the pharmaceutical industry. These laws include anti-kickback, false claims, transparency and health information privacy laws and other healthcare laws and regulations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid, or other federally financed healthcare programs. The Patient Protection and Affordable Care Act as amended by the Health Care and Education Reconciliation Act, or the ACA, amended the intent element of the federal Anti-Kickback Statute so that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to commit a violation. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers, among others, on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Additionally, the ACA amended the federal Anti-Kickback Statute such that a violation of that statute can serve as a basis for liability under the federal civil False Claims Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Federal civil and criminal false claims laws, including the federal civil False Claims Act, prohibit any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid. This includes claims made to programs where the federal government reimburses, such as Medicare and Medicaid, as well as programs where the federal government is a direct purchaser, such as when it purchases off the Federal Supply Schedule. Pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. In addition, certain marketing practices, including off-label promotion, may also violate false claims laws. Most states also have statutes or regulations similar to the federal Anti-Kickback Statute and civil False Claims Act, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Other federal statutes pertaining to healthcare fraud and abuse include the civil monetary penalties statute, which prohibits, among other things, the offer or payment of remuneration to a Medicaid or Medicare beneficiary that the offeror or payor knows or should know is likely to influence the beneficiary to order a receive a reimbursable item or service from a particular supplier, and the additional federal criminal statutes created by the Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibit, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program or obtain by means of false or fraudulent pretenses, representations or promises any money or property owned by or under the control of any healthcare benefit program in connection with the delivery of or payment for healthcare benefits, items or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, impose obligations on certain healthcare providers, health plans, and healthcare clearinghouses, known as covered entities, as well as their business associates and their subcontractors that perform certain services involving the storage, use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information. HITECH increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, many state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, and often are not pre-empted by HIPAA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Further, pursuant to the ACA, the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, issued a final rule&#160;that requires certain manufacturers of prescription drugs to collect and annually report information on certain payments or transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) physician assistants, certain types of advance practice nurses, and teaching hospitals, as well as ownership and investment interests held by </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">physicians and their immediate family members. The reported data is made available in searchable form on a public website on an annual basis. Failure to submit required information may result in civil monetary penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Analogous state and foreign anti-kickback and false claims laws that may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non- governmental third-party payors, including private insurers, or that apply regardless of payor. In addition, several states now require prescription drug companies to report certain expenses relating to the marketing and promotion of drug products and to report gifts and payments to individual healthcare practitioners in these states. Other states prohibit various marketing-related activities, such as the provision of certain kinds of gifts or meals. Further, certain states require the posting of information relating to clinical studies and their outcomes. Some states require the reporting of certain drug pricing information, including information pertaining to and justifying price increases. In addition, certain states require pharmaceutical companies to implement compliance programs and/or marketing codes. Several additional states are considering similar proposals. Certain states and local jurisdictions also require the registration of pharmaceutical sales representatives. Additionally, we may also be subject to state and foreign laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Efforts to ensure that business arrangements with third parties comply with applicable state, federal, and foreign healthcare laws and regulations involve substantial costs. If a drug company&#8217;s operations are found to be in violation of any such requirements, it may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, the curtailment or restructuring of its operations, loss of eligibility to obtain approvals from the FDA, exclusion from participation in government contracting, healthcare reimbursement or other federal or state government healthcare programs, including Medicare and Medicaid, integrity oversight and reporting obligations, imprisonment, and reputational harm. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action for an alleged or suspected violation can cause a drug company to incur significant legal expenses and divert management&#8217;s attention from the operation of the business, even if such action is successfully defended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">U.S. Healthcare Reform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the United States there have been, and continue to be, proposals by the federal government, state governments, regulators and third-party payors to control or manage the increased costs of health care and, more generally, to reform the U.S. healthcare system. The pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. For example, in March&#160;<span style="white-space:pre-wrap;">2010, the ACA was enacted, which intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms, substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. Healthcare reforms that have been adopted, and that may be adopted in the future, could result in further reductions in coverage and levels of reimbursement for pharmaceutical products, increases in rebates payable under U.S. government rebate programs and additional downward pressure on pharmaceutical product prices.  On September 9, 2021, the Biden administration published a wide-ranging list of policy proposals, most of which would need to be carried out by Congress, to reduce drug prices and drug payment. The Department of Health and Human Services, or HHS, plan includes, among other reform measures, proposals to lower prescription drug prices, including by allowing Medicare to negotiate prices and disincentivizing price increases, and to support market changes that strengthen supply chains, promote biosimilars and generic drugs, and increase price transparency. Many similar proposals, including the plans to give Medicare Part D authority to negotiate drug prices, require drug manufacturers to pay rebates on drugs whose prices increase greater than the rate of inflation, and cap out-of-pocket costs, have already been included in policy statements and legislation currently being considered by Congress. It is unclear to what extent these and other statutory, regulatory, and administrative initiatives will be enacted and implemented. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We expect that additional state and federal healthcare reform measures will be adopted in the future. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Coverage and Reimbursement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Patients in the United States and elsewhere generally rely on third-party payors to reimburse part or all of the costs associated with their prescription drugs. Accordingly, market acceptance of our drug products is dependent on the extent to which third-party coverage and reimbursement is available from government health administration authorities (including in connection with government healthcare programs, such as Medicare and Medicaid in the United States), private healthcare insurers and other healthcare funding organizations. Significant uncertainty exists as to the coverage and reimbursement status of any drug products for which we may obtain regulatory approval. Coverage decisions may not favor new drug products when more established or lower-cost therapeutic alternatives are already available. Patients are unlikely to use our products unless reimbursement is adequate to cover all or a significant portion of the cost of our drug products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Coverage and reimbursement policies for drug products can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for drug products among third-party payors in the United States. There may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time-consuming and costly which will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage or adequate reimbursement will be obtained. It is difficult to predict at this time what government authorities and third-party payors will decide with respect to coverage and reimbursement for our drug products. Additionally, we may develop, either by ourselves or with collaborators, companion diagnostic tests for our product candidates for certain indications. We, or our collaborators, if any, will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we seek for our product candidates, once approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The market for our product candidates will depend significantly on access to third-party payors&#8217; drug formularies or lists of medications for which third-party payors provide coverage and reimbursement. Competition to be included in such formularies often leads to downward pricing pressures. In particular, third-party payors may refuse to include a particular reference listed drug in their formularies or otherwise restrict patient access to a reference listed drug when a less costly generic equivalent or other alternative is available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The U.S. government, state legislatures and foreign governmental entities have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and coverage and requirements for substitution of generic products for branded prescription drugs. Adoption of government controls and measures and tightening of restrictive policies in jurisdictions with existing controls and measures, could exclude or limit our drugs products from coverage and limit payments for pharmaceuticals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, we expect that the increased emphasis on managed care and cost containment measures in the United States by third-party payors and government authorities to continue and will place pressure on pharmaceutical pricing and coverage. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more drug products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employees and human capital resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of February 28, 2022, we had 35 full-time employees. Of these employees, five held Ph.D. or Pharm.D degrees, and 26 were engaged in research, development and technical operations. From time to time, we also retain independent contractors and consultants to support our organization. None of our employees are represented by a labor union or covered by collective bargaining agreements, and we believe our relationship with our employees is good.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purpose of our incentive share plan is to attract, retain and motivate selected employees, consultants and directors through the granting of incentive share-based compensation awards and cash-based performance bonus awards.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Facilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are a remote-first company, meaning that substantially all of our employees work remotely. As a result of this strategy, we do not maintain a corporate headquarters or lease any corporate facilities. We believe that our facilities are adequate to meet our needs for the immediate future, and that, should we need additional physical office space, suitable additional space will be available in the future on commercially reasonable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Legal proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">From time to time, we may be involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity and reputational harm, and other factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Corporate information </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our principal executive offices are located at 888 Seventh Ave, 12th Floor, New York, New York 10106 and our telephone number is (716) 371 1125. Our website address is www. elevationoncology.com. Information contained on or accessible through our website is not a part of this Annual Report. The following filings are available through the Securities and Exchange Commission, or the SEC, which maintains an Internet site at www.sec.gov, and through our website as soon as reasonably practicable after we file them with the SEC: Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, as well as any amendments to such reports and all other filings pursuant to Section 13(a) or 15(d) of the Securities Act of 1933, as amended, or the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_361b4053_d9ff_403d_9da9_469497bfc25b"></a><a id="Item1ARiskFactors_90125"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1A. Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investing in our common stock involves a high degree of risk. Before making your decision to invest in shares of our common stock, you should carefully consider and read carefully all of the risks described below, together with the other information contained in this Annual Report, including our financial statements and the related notes and the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in this Annual Report, before deciding whether to invest in our common stock. We cannot assure you that any of the events discussed below will not occur. These events could have a material and adverse impact on our business, financial condition, results of operations and prospects. Unless otherwise indicated, references to our business being harmed in these risk factors will include harm to our business, reputation, financial condition, results of operations, net revenue and future prospects. In such event, the trading price of our common stock could decline, and you could lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations and the market price of our common stock. This Annual Report also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this Annual Report.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risk Factor Summary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following summarizes the most material risks that make an investment in our securities risky or speculative. If any of the following risks occur or persist, our business, financial condition and results of operations could be materially harmed and the price of our common stock could significantly decline.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have a limited operating history, which may make it difficult to evaluate the success of our business to date and to assess our future viability. We have incurred significant operating losses since our inception in 2019 and have not generated any revenue. We expect to incur continued losses for the foreseeable future and may never achieve or maintain profitability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are highly dependent on the success of our lead product candidate, seribantumab. We have not completed clinical development or obtained regulatory approval for any product candidate. We may never obtain approval for seribantumab or any other product candidate.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The COVID-19 pandemic could adversely impact our business, including the conduct of our clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we experience delays or difficulties in enrolling patients in our ongoing or planned clinical trials, our receipt of necessary regulatory approval could be delayed or prevented.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Adverse side effects or other safety risks associated with seribantumab or our other future product candidates could delay or preclude approval, cause us to suspend or discontinue clinical trials or abandon further development, limit the commercial profile of an approved product or result in significant negative consequences following marketing approval, if any.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may in the future seek to engage in strategic transactions to acquire or in-license new products, product candidates or technologies. If we are unable to realize the benefits from such transactions, it may adversely affect our ability to develop and commercialize product candidates, negatively impact our cash position, increase our expenses and present significant distractions to our management.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The development and commercialization of biological products are subject to extensive regulation, and we may not obtain regulatory approvals for seribantumab or any other future product candidates, on a timely basis or at all.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to successfully develop, validate, obtain regulatory approval of and commercialize companion diagnostic tests for seribantumab or any future product candidates that require or would benefit from such tests, </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or experience significant delays in doing so, we may not realize the full commercial potential of these product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Manufacturing biological products is complex and subject to product loss for a variety of reasons. We rely on third-party suppliers, including single source suppliers, to manufacture clinical supplies of our lead product candidate and we intend to rely on third parties to produce commercial supplies of any approved product.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The incidence and prevalence for target patient populations of seribantumab and our future product candidates have not been established with precision. If the market opportunities for our product candidates are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, then our revenue potential and ability to achieve profitability will be adversely affected.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We expect to significantly expand our development and regulatory capabilities as we grow our company, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to obtain and maintain sufficient patent protection for our product candidates, or if the scope of the patent protection is not sufficiently broad, third parties, including our competitors, could develop and commercialize products similar or identical to ours, and our ability to commercialize our seribantumab and our future product candidates may be adversely affected.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks related to our financial position and need for additional capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have a limited operating history, which may make it difficult to evaluate the success of our business to date and to assess our future viability. We have incurred significant operating losses since our inception in 2019 and have not generated any revenue. We expect to incur continued losses for the foreseeable future and may never achieve or maintain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Investment in drug development is a highly speculative undertaking and involves a substantial degree of risk. We commenced operations in 2019 and are a clinical-stage biologics company with a limited operating history. We have not yet commercialized any product, nor do we expect to generate revenue from sales of any products for several&#160;years, if at all. Consequently, there have been limited operations upon which you can evaluate our business, and predictions about our future success or viability may not be as cancer therapies. For the&#160;years ended December&#160;31, 2021 and 2020, we had a net loss of $32.0 million and $17.3 million, respectively. As of December 31, 2021, we had an accumulated deficit of $55.2 million. We expect to continue to incur significant research and development and other expenses related to our ongoing operations, which we anticipate will result in net losses for at least the next several&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Since our inception, we have focused substantially all of our efforts and financial resources on the acquisition and clinical development of our lead product candidate, seribantumab. To date, we have funded our operations with proceeds from sales of shares of our convertible preferred stock and our initial public offering. From our inception through December 31, 2021, we received an aggregate of $97.2 million in net proceeds from sale of our convertible preferred stock. We received an aggregate of $97.1 million in net proceeds from our initial public offering. As of December 31, 2021, our cash and cash equivalents were $146.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We expect to incur increasing levels of operating losses for the foreseeable future, particularly as we advance seribantumab and potential future product candidates through clinical development. Our prior losses, combined with expected future losses, have had, and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital. We expect our research and development expenses to significantly increase in connection with our additional planned clinical trials for seribantumab, including our ongoing Phase 2 clinical trial, CRESTONE, and the planned exploratory cohorts, and the development of other future product candidates we may choose to pursue. In addition, if we obtain marketing approval for seribantumab or another future product candidate, we will incur significant sales, marketing and outsourced manufacturing expenses in connection with the commercialization of seribantumab or such </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">other future product candidate. After our initial public offering, we incurred and will continue to incur additional costs associated with operating as a public company. As a result, we expect to continue to incur significant and increasing operating losses for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our ability to become profitable depends upon our ability to generate revenue. To date, we have not generated any revenue and we do not know when, or if, we will generate any revenue. We do not expect to generate significant revenue unless and until we obtain marketing approval for, and begin to sell, seribantumab or another future product candidate. Our ability to generate revenue and become profitable will depend on a number of factors, including, but not limited to, our ability to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successfully meet our clinical endpoints in our Phase 2 CRESTONE clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiate and successfully complete all safety, pharmacokinetic and other registrational-enabling studies required to obtain U.S. and foreign marketing approval for seribantumab as a treatment for patients with solid tumors driven by an NRG1 gene fusion;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiate and complete successful later-stage clinical trials that meet their clinical endpoints;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submit a BLA for seribantumab to the FDA that is filed by the FDA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain marketing approval for seribantumab and our other potential future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish licenses, collaborations or strategic partnerships that may increase the value of our programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successfully manufacture or contract with others to manufacture seribantumab and our other future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commercialize seribantumab, if approved, by building a sales force or entering into collaborations with third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain, maintain, protect and defend our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">achieve market acceptance of seribantumab and our other potential future product candidates with the medical community and with third-party payors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">attract, hire and retain additional administrative, clinical, regulatory and scientific personnel.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In cases where we are successful in obtaining regulatory approval to market our product candidates, our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to obtain coverage and reimbursement, and whether we own the commercial rights for that territory. If the number of our addressable patients is significantly lower than we estimate, the indication approved by regulatory authorities is narrower than we expect, or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if they are approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Because of the numerous risks and uncertainties associated with drug development, we are unable to accurately predict the timing or amount of increased expenses we will incur and when, or if, we will be able to achieve profitability. If we decide to or are required by the FDA or regulatory authorities in other jurisdictions to perform studies or clinical trials in addition to those we currently anticipate, or if there are any delays in establishing appropriate manufacturing </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">arrangements for, in initiating or completing our current and planned clinical trials for, or in the development of, our product candidates, our expenses could increase materially and our potential profitability could be further delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Accordingly, you should not rely upon the results of any quarterly or annual periods as predictions or indications of future operating performance. We expect our financial condition and operating results to fluctuate from quarter-to-quarter and&#160;year-to-year due to a variety of factors, many of which are beyond our control. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product offerings or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We require substantial additional funding to pursue our business objectives. If we are unable to raise additional capital when needed or on terms acceptable to us, we could be forced to delay, reduce or terminate our research or drug development programs, any future commercialization efforts or other operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Identifying and developing potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes&#160;years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and begin selling any approved product. We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the clinical development of seribantumab and seek to develop or acquire additional product candidates. We expect increased expenses as we continue our research and development activities, initiate additional clinical trials and seek marketing approval for seribantumab and our future product candidates. In addition, if we obtain marketing approval for seribantumab, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Furthermore, following the closing of our initial public offering, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. Adequate additional financing may not be available to us on favorable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. If we are unable to raise additional capital when needed or on favorable terms, we could be forced to delay, reduce or eliminate our research and development programs, our commercialization plans or other operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We believe that our existing cash and cash equivalents as of December 31, 2021 will enable us to fund our operating expenses and capital expenditure requirements into the second quarter of 2023. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Changes beyond our control may occur that would cause us to use our available capital before that time, including changes in and progress of our drug development activities and changes in government regulations. Our future capital requirements will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress, timing and results of preclinical studies and clinical trials for seribantumab or any future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disruptions or delays in enrollment of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which we develop, in-license or acquire other product candidates or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and development requirements of other future product candidates that we may pursue, and other indications for seribantumab that we may pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs, timing and outcome of obtaining regulatory approvals of seribantumab or future product candidates and any companion diagnostics that we may pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope and costs of making arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both clinical and commercial supplies of seribantumab or future product candidates;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in growing our organization to the size needed to allow for the research, development and potential commercialization of seribantumab or future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with commercializing any approved product candidates, including establishing sales, marketing and distribution capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with completing any post-marketing studies or trials required by the FDA or other regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the revenue, if any, received from commercial sales of seribantumab, if approved, or any other future product candidates that receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims that we may become subject to, including any litigation costs and the outcome of such litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with potential product liability claims, including the costs associated with obtaining insurance against such claims and with defending against such claims; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to the extent we pursue strategic collaborations, including collaborations to commercialize seribantumab or to develop any future product candidates, our ability to establish and maintain collaborations on favorable terms, if at all, as well as the timing and amount of any milestone or royalty payments that we are required to make or are eligible to receive under any such collaborations.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We require additional capital to complete our planned clinical development programs for our current product candidates to obtain regulatory approval. Our ability to raise additional funds will depend on financial, economic and market conditions and other factors over which we may have no or limited control. If adequate funds are not available on commercially acceptable terms when needed, we may be forced to delay, reduce or terminate the development or commercialization of seribantumab or future product candidates or we may be unable to take advantage of future business opportunities. Furthermore, any additional capital-raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize seribantumab and future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish proprietary rights to our technologies or product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts or grant rights to third parties to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks related to the design and development of our product candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are highly dependent on the success of our lead product candidate, seribantumab. We have not completed clinical development or obtained regulatory approval for any product candidate. We may never obtain approval for seribantumab or any other product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our future success is highly dependent on our ability to obtain regulatory approval for, and then successfully commercialize or identify a strategic partner to commercialize, our lead product candidate, seribantumab. Seribantumab is currently being evaluated in a Phase 2 clinical trial, which we refer to as CRESTONE. We currently have no products that are approved for sale in any jurisdiction. Seribantumab or any of our other future product candidates may not achieve success in their clinical trials or obtain regulatory approval. If we do not obtain regulatory approval for seribantumab and successfully commercialize seribantumab in one or more indications or if we experience significant delays in doing so, we may never generate any revenue or become profitable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our ability to generate product revenues, which we do not expect will occur for many&#160;years, if ever, will depend heavily on the successful development and eventual commercialization of seribantumab or other future product candidates. The success of seribantumab or any other future product candidate will depend on several factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful completion of preclinical studies and clinical trials, including our CRESTONE trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timely and successful enrollment of patients in, and completion of, clinical trials with favorable results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">demonstration of safety, efficacy and acceptable risk-benefit profiles of seribantumab and our future product candidates to the satisfaction of the FDA and other regulatory agencies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability, or that of our collaborators, to develop and obtain clearance or approval of companion diagnostics, on a timely basis, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt and related terms of marketing approvals from applicable regulatory authorities for seribantumab and our future product candidates, including the completion of any required post-marketing studies or trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">raising additional funds necessary to complete the clinical development of and commercialization of seribantumab;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successfully identifying and developing, acquiring or in-licensing additional product candidates to expand our pipeline;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of an IND by the FDA or other similar clinical trial applications from other regulatory authorities for clinical trials for future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining patent, trade secret and other intellectual property protection and regulatory exclusivity for seribantumab and our future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">making arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both clinical and commercial supplies of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if approved, whether alone or in collaboration with third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of our products, if approved, by patients, the medical community and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectively competing with other therapies available on the market or in development;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining third-party payor coverage and adequate reimbursement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining a continued acceptable safety profile of any products following regulatory approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Many of these factors are beyond our control, and it is possible that none of our product candidates, including seribantumab, will ever obtain regulatory approval even if we expend substantial time and resources seeking such approval. If we experience significant delays or are otherwise unable to successfully commercialize our product candidates, it would materially harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Drug development is a lengthy and expensive process, and clinical testing is uncertain as to the outcome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We currently have one product candidate in Phase 2 clinical development, and the risk of failure is high. We are unable to predict when or if seribantumab will prove effective and safe in humans or will obtain marketing approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidate in humans. Clinical testing is expensive, difficult to design and implement, can take many&#160;years to complete and is uncertain as to the outcome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A failure of one or more clinical trials can occur at any stage of testing. The outcomes of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials or of clinical trials of the same product candidates in other indications, and interim or preliminary results of a clinical trial do not necessarily predict final results. For example, Merrimack Pharmaceuticals,&#160;Inc., or the previous sponsor, terminated its Phase 2 clinical trial of seribantumab in combination with docetaxel in patients with heregulin positive non-small cell lung cancer based on an interim analysis that demonstrated that the addition of seribantumab to docetaxel did not improve progression-free survival over docetaxel alone in this patient population. The previous sponsor also terminated its Phase 2 clinical trial of seribantumab in combination with fulvestrant in patients with heregulin positive, hormone receptor positive, ERBB2 (HER2) negative, metastatic breast cancer based on the interim analysis of the results of the non-small lung cancer trial. Although our CRESTONE trial of seribantumab is in a tumor-agnostic NRG1 fusion indication and therefore differs from the previous trials conducted by the previous sponsor, we may observe similar outcomes that could limit our ability to receive regulatory approval for seribantumab. While we believe that oncogenic driver events are a primary cause for the oncogenesis and progression of certain tumors, the signaling pathways in cancer are complex and treatment with a monotherapy may not produce a durable clinical benefit and combinations with other anti-cancer agents may need to be explored. There are no approved therapies for patients with tumors harboring an NRG1 fusion and our approach of inhibiting HER3 may not result in a durable clinical outcome. In addition, while some results in patients, such as observations of stable disease, may suggest encouraging clinical activity with respect to seribantumab, we expect that stable disease would not be considered to be a sufficient response for regulatory approval purposes. Furthermore, we may observe adverse safety events in the CRESTONE trial or later trials that were not observed in prior trials, which would alter the anticipated risk-benefit profile of seribantumab and reduce the likelihood that seribantumab receives regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The COVID-19 pandemic could adversely impact our business, including the conduct of our clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The ongoing COVID-19 pandemic, both in the United States and in other countries in which we have planned or have active clinical trial sites and where our third-party manufacturers operate, could cause significant disruptions that could severely impact our business, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or difficulties in screening, enrolling and maintaining patients in our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability or unwillingness of subjects to travel to the clinical trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays, difficulties or incompleteness in data collection and analysis and other related activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased implementation of protocol required clinical trial activities and quality of source data verification at clinical trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations in employee resources that would otherwise be focused on the conduct of our clinical trials and our other research and development activities, including because of sickness of employees or their families or mitigation measures such as lock-downs and social distancing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays due to production shortages resulting from any events affecting raw material supply or manufacturing capabilities domestically and abroad;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption in global and domestic shipping that may affect the transport of clinical trial materials, such as investigational drug products used in our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in local regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, delays or require us to discontinue the clinical trials altogether;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of regulatory authorities such as FDA or European Medicines Agency, or </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the European Medicines Agency, or </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">EMA, to accept data from clinical trials in affected geographies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse impacts on global economic conditions which could have an adverse effect on our business and financial condition, including impairing our ability to raise capital when needed.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Such disruptions could impede, delay, limit or prevent completion of our ongoing clinical trials and preclinical studies or commencement of new clinical trials and ultimately lead to the delay or denial of regulatory approval of seribantumab, which would seriously harm our operations and financial condition and increase our costs and expenses. Furthermore, if either we or any third party in the supply chain for materials used in the production of our product candidates are adversely impacted by restrictions resulting from the COVID-19 pandemic, our supply chain may be disrupted, limiting our ability to manufacture product candidates for our clinical trials. We are in close contact with our clinical research organizations, or CROs, our contract manufacturing organizations, or CMOs, and clinical sites as we seek to mitigate the impact of COVID-19 on our CRESTONE trial and current timelines. Measures we have taken in response to COVID-19 include, where feasible, conducting remote clinical trial site activations and data monitoring, and limiting on-site patient visits by adjusting patient assessments and protocol. However, despite these efforts, we have experienced limited delays in trial site initiations, patient participation and patient enrollment in some of our clinical trials and we may continue to experience some delays in our clinical trials and preclinical studies and delays in data collection and analysis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">These negative impacts could be exacerbated as the COVID-19 pandemic and the response to it continues to evolve. The COVID-19 pandemic could also affect the business of the FDA, EMA or other health authorities, which could result in delays in meetings related to planned or completed clinical trials and ultimately of reviews and approvals of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">seribantumab. The extent to which the pandemic impacts our business and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the success of mass vaccination efforts globally, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken by governmental authorities to contain and address the challenges posed by COVID-19.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may incur additional costs or experience delays in completing, or ultimately be unable to complete the development and/or commercialization of seribantumab or our other future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any delays in the commencement or completion of our ongoing, planned or future clinical trials could significantly increase our product development costs. We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to obtain marketing approval or commercialize seribantumab or our future product candidates, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators, institutional review boards, or IRBs, or ethics committees, or ECs, may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA may disagree as to the design or implementation of our clinical trials or with our recommended Phase 2 doses for seribantumab, or with respect to any of our future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective CROs and prospective trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials for seribantumab or our future product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials, delay or halt clinical trials or abandon product development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of adequate funding to continue clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of patients required for clinical trials may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or may be lower than we anticipate due to challenges in recruiting and enrolling suitable patients who meet the trial criteria, participants may drop out of these clinical trials at a higher rate than we anticipate or the duration of these clinical trials may be longer than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competition for clinical trial participants from investigational and approved therapies may make it more difficult to enroll patients in our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may experience difficulties in maintaining contact with patients after treatment, resulting in incomplete data;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we or third-party collaborators may fail to obtain regulatory approval of companion diagnostic tests, if required, on a timely basis, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our third-party contractors may fail to meet their contractual obligations to us in a timely manner, or at all, or may fail to comply with regulatory requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may have to suspend or terminate clinical trials for various reasons, including a finding by us or by a Data Monitoring Committee for a trial that the participants are being exposed to unacceptable health risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seribantumab or our future product candidates may have undesirable or unexpected side effects or other unexpected characteristics, causing us or our investigators, regulators or IRBs or ECs to suspend or terminate the trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of clinical trials may be greater than we anticipate;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes to clinical trial protocols;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the supply or quality of seribantumab or our future product candidates or other materials necessary to conduct clinical trials may be insufficient or inadequate and result in delays or suspension of our clinical trials; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of the ongoing COVID-19 pandemic, which may slow potential enrollment, reduce the number of eligible patients for clinical trials, or reduce the number of patients who remain in our trials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Delays, including delays caused by the above factors, can be costly and could negatively affect our ability to complete a clinical trial or obtain timely marketing approvals. We do not know whether any of our planned preclinical studies or clinical trials will begin on a timely basis or at all, will need to be restructured or will be completed on schedule, or at all. For example, the FDA may place a partial or full clinical hold on the CRESTONE trial or any of our future clinical trials for a variety of reasons, including safety concerns and noncompliance with regulatory requirements. If we are not able to complete successful clinical trials, we will not be able to obtain regulatory approval and will not be able to commercialize seribantumab or our future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Significant preclinical or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates, which would limit our future revenues and harm our commercial prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we experience delays or difficulties in enrolling patients in our ongoing or planned clinical trials, our receipt of necessary regulatory approval could be delayed or prevented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may not be able to initiate or continue our ongoing or planned clinical trials if we are unable to identify and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or comparable foreign regulatory authorities. In addition, some of our competitors currently have ongoing clinical trials for product candidates that would treat the same patients as our lead clinical product candidate, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. This is acutely relevant for our development of seribantumab for the treatment of patients with solid tumors driven by an NRG1 gene fusion, which are rare genomic alterations. Enrolling patients for our clinical trials requires promptly identifying cancer patients with NRG1 fusions and placing these patients in one of our qualified sites in a timely manner. We rely on several diagnostic partners to conduct initial testing to identify patients with NRG1 fusions that are eligible for the CRESTONE trial. If one or more of these partners encounters delays or is otherwise unable to conduct these tests and identify potential patients, enrollment in our clinical trials may be substantially delayed. In addition, these partners work with several other companies, including our competitors, and may divert resources to collaborations with these other companies, which may detrimentally affect enrollment in our clinical trials. Patient enrollment is also affected by other factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the severity of the disease under investigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to recruit clinical trial investigators of appropriate competencies and experience;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the incidence and prevalence of our target indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinicians&#8217; and patients&#8217; awareness of genomic testing mechanisms to screen patients for NRG1 gene fusions and perceptions as to the potential advantages and risks of our product candidates in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competing studies or trials with similar eligibility criteria;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">invasive procedures required to enroll patients and to obtain evidence of the product candidates&#8217; performance during clinical trials;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">availability and efficacy of approved medications for the disease under investigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eligibility criteria defined in the protocol for the trial in question;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size and nature of the patient population required for analysis of the trial&#8217;s primary endpoints;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">efforts to facilitate timely enrollment in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether we are subject to a partial or full clinical hold on any of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reluctance of physicians to encourage patient participation in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to monitor patients adequately during and after treatment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain patient consents; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">proximity and availability of clinical trial sites for prospective patients.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our inability to enroll and maintain a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials, including due to the COVID-19 pandemic, may result in increased development costs, which would cause the value of our company to decline, limit our ability to obtain additional financing and delay or limit our ability to obtain regulatory approval for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Adverse side effects or other safety risks associated with seribantumab or our other future product candidates could delay or preclude approval, cause us to suspend or discontinue clinical trials or abandon further development, limit the commercial profile of an approved product or result in significant negative consequences following marketing approval, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As is the case with biologics generally, we have observed side effects and adverse events associated with seribantumab. Although seribantumab has been evaluated in over 800 patients in clinical trials to date, unexpected side effects may still arise in our ongoing or any future clinical trial. These side effects have included rashes, diarrhea, nausea, fatigue and hypomagnesemia. Additionally, reported treatment emergent serious adverse events, or SAEs, included one patient at the lowest dose cohort (3.2mg/kg), who experienced Grade 4 confusional state determined to be possibly related to seribantumab, and which was considered to be the only dose limiting toxicity, or DLT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Results of our ongoing and planned clinical trials, which will include testing of seribantumab at doses and on schedules that have not been previously tested clinically, could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects could result in the delay, suspension or termination of clinical trials by us or regulatory authorities for a number of reasons. Furthermore, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of subjects and limited duration of exposure, rare and severe side effects of our product candidates or those of our competitors may only be uncovered with a significantly larger number of patients exposed to the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Additionally, due to the high mortality rates of the cancers for which we are initially pursuing development and the pretreated nature of many patients in our ongoing clinical trial of seribantumab, a material&#160;percentage of patients in these clinical trials may die during a trial. If we elect to, or are required to, delay, suspend or terminate any clinical trial, whether due to a patient death or otherwise, the commercial prospects of seribantumab or our future product candidates will be harmed and our ability to generate product revenues will be delayed or eliminated. SAEs observed in clinical trials could hinder or prevent market acceptance of our product candidates, which would harm our commercial prospects our financial condition and our reputation.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Moreover, if seribantumab or any of our future product candidates is associated with undesirable or unexpected side effects in clinical trials, we may elect to abandon or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for the product candidate, even if it is approved. We may also be required to modify our trial plans based on findings in our clinical trials. Side effects could also affect patient recruitment or the ability of enrolled patients to complete a trial. Many drugs that initially showed promise in early stage testing have later been found to cause side effects that prevented further development. In addition, regulatory authorities may draw different conclusions, require additional testing to confirm these determinations, require more restrictive labeling or deny regulatory approval of the product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">It is possible that, as we test our product candidates in larger, longer and more extensive clinical trials, including with different dosing regimens, or as the use of our product candidates becomes more widespread following any regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by patients. If such side effects become known later in development or upon approval, if any, such findings may harm our business, financial condition, results of operations and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, if our lead product candidate receives marketing approval, and we or others later identify undesirable side effects caused by treatment with such drug, a number of potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw approval of the drug;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to recall a product or change the way the drug is administered to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require additional warnings in the labeling, such as a contraindication or a boxed warning, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to implement an REMS, or create a medication guide outlining the risks of such side effects for distribution to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional restrictions may be imposed on the marketing or promotion of the particular product or the manufacturing processes for the product or any component thereof;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we could be sued and held liable for harm caused to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be subject to regulatory investigations and government enforcement actions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the drug could become less competitive; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any of these events could prevent us from achieving or maintaining market acceptance of our product candidates, if approved, and could significantly harm our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Preliminary, interim and topline data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available and is subject to audit and verification procedures that could result in material changes in the final data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">From time to time, we may publicly disclose preliminary, interim or topline data from our clinical trials, such as the planned interim data analysis for our open-label CRESTONE trial. These updates will be based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">comprehensive review of the data related to the particular study or trial. Additionally, interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data becomes available. Therefore, positive interim results in any ongoing clinical trial may not be predictive of such results in the completed study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data has been received and fully evaluated. Topline data also remains subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data is available. In addition, we may report interim analyses of only certain endpoints rather than all endpoints. Adverse changes between preliminary or interim data and final data could significantly harm our business and prospects. Further, additional disclosure of interim data by us or by our competitors in the future could result in volatility in the price of our common stock. See the description of risks under the heading &#8220;Risks Related to our Common Stock&#8221; for more disclosure related to the risk of volatility in our stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is typically selected from a more extensive amount of available information. You or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, product candidate or our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Additionally, our CRESTONE trial and potentially other future clinical trials we conduct may be open-label trials in which both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved product or placebo. Open-label clinical trials typically test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If the preliminary or topline data that we report differs from late, final or actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, seribantumab, or any other future product candidates may be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may in the future seek to engage in strategic transactions to acquire or in-license new products, product candidates or technologies. If we are unable to realize the benefits from such transactions, it may adversely affect our ability to develop and commercialize product candidates, negatively impact our cash position, increase our expenses and present significant distractions to our management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may consider strategic transactions, such as additional collaborations, acquisitions of companies, asset purchases, joint ventures and in-licensing of new products, product candidates or technologies that we believe will complement or augment our existing business. For example, in 2019, we acquired our lead product candidate, seribantumab, pursuant to an asset acquisition agreement with the previous sponsor. If we acquire assets with promising markets or technologies, we may not be able to realize the benefit of acquiring such assets if we are not able to successfully integrate them with our existing technologies. We may encounter numerous difficulties in developing, testing, manufacturing and marketing any new products resulting from a strategic acquisition that delay or prevent us from realizing their expected benefits or enhancing our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Following any such strategic transaction, we may not achieve any expected synergies to justify the transaction. For example, such transactions may require us to incur non-recurring or other charges, increase our near-term and long- term expenditures and pose significant integration or implementation challenges or disrupt our management or business. These transactions would entail numerous operational and financial risks, including, but not limited to, exposure to unknown liabilities, disruption of our business and diversion of our management&#8217;s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the transaction or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and could have a material and adverse effect on our business, financial condition, results of operations and prospects. Conversely, any failure to enter any strategic transaction that would be beneficial to us could delay the development and potential commercialization of our product candidates and could have a negative impact on the competitiveness of any product candidate that reaches market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other future product candidates or for other indications that later prove to have greater commercial potential.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to that product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may in the future conduct clinical trials for seribantumab or other product candidates outside the United States, and the FDA or comparable foreign regulatory authorities may not accept data from such trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may in the future choose to conduct one or more clinical trials outside the United States. Further, we may open sites for our CRESTONE trial that are located outside the United States. The acceptance of trial data from clinical trials conducted outside the United States or another jurisdiction by the FDA or comparable regulatory authorities may be subject to certain conditions or may not be accepted at all. In cases where data from clinical trials conducted outside the United States is intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of these data alone unless the data is applicable to the U.S. population and U.S. medical practice and the trials were performed by clinical investigators of recognized competence and pursuant to GCP, regulations. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many other regulatory authorities have similar approval requirements. In addition, such trials would be subject to the applicable local laws of the respective jurisdictions where the trials are conducted. There can be no assurance that the FDA, EMA or any comparable regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA, EMA or any comparable regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in product candidates that we may develop not receiving approval for commercialization in the applicable jurisdiction.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks related to government regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The development and commercialization of biological products are subject to extensive regulation, and we may not obtain regulatory approvals for seribantumab or any other future product candidates, on a timely basis or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The clinical development, manufacturing, labeling, packaging, storage, recordkeeping, advertising, promotion, export, import, marketing, distribution, adverse event reporting, including the submission of safety, and other post-marketing information and reports, and other possible activities relating to seribantumab, currently our only product candidate in clinical trials, as well as any other product candidates that we may develop in the future, are subject to extensive regulation. Marketing approval of biologics in the United States requires the submission of a BLA to the FDA, and we are not permitted to market any product candidate in the United States until we obtain approval from the FDA of the BLA for that product. A BLA must be supported by extensive clinical and preclinical data, as well as extensive information regarding pharmacology, chemistry, manufacturing and controls. Our product candidates must also be approved by comparable regulatory authorities in other jurisdictions prior to commercialization in those jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">FDA approval of a BLA is not guaranteed, and the review and approval process is an expensive and uncertain process that may take several&#160;years. Of the large number of drugs in development in the United States, only a small&#160;percentage will successfully complete the FDA regulatory approval process and will be commercialized. Accordingly, there can be no assurance that any of our product candidates will receive regulatory approval in the United States, or other jurisdictions. Most applications for standard review biologic products are reviewed within 10 to 12&#160;months; most applications for priority review biologics are reviewed in six to eight&#160;months. Priority review can be applied to biologics that the FDA determines may offer significant improvement in safety or effectiveness compared to marketed products or where no adequate therapy exists. The review process for both standard and priority review may be extended by the FDA for three additional&#160;months to consider certain late-submitted information, or information intended to clarify information already provided in the submission. The FDA does not always meet its goal dates for standard and priority BLAs, and the review process can be extended by FDA requests for additional information or clarification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The FDA also has substantial discretion in the approval process. The number and types of preclinical studies and clinical trials that will be required for BLA approval varies depending on the product candidate, the disease or the condition that the product candidate is designed to treat and the regulations applicable to any particular product candidate. For example, if successful, we believe that the CRESTONE trial may be sufficient to support FDA approval of a BLA for seribantumab, but the FDA may disagree with the sufficiency of our data and require additional clinical trials. In addition, development programs that span many tumor types are relatively novel, and, to date, the FDA has approved only a handful of therapies to treat multiple tumor types based on a common biomarker. We cannot be sure that the FDA will accept our BLA for seribantumab or our other product candidates. Further, depending upon the results of the CRESTONE trial, we may choose to seek Subpart H accelerated approval for seribantumab, which would require completion of a confirmatory trial to validate its clinical benefit. Despite the time and expense associated with preclinical studies and clinical trials, failure can occur at any stage. The results of preclinical and early clinical trials of seribantumab or any other future product candidate may not be predictive of the results of our later-stage clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Clinical trial failure may result from a multitude of factors including flaws in trial design, dose selection, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits, and failure in clinical trials can occur at any stage. Companies in the biologics industry frequently suffer setbacks in the advancement of clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Based upon negative or inconclusive results, we may decide, or regulators may require us, to conduct additional clinical trials or preclinical studies. In addition, data obtained from clinical trials is susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which may further delay, limit or prevent marketing approval.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The FDA could delay, limit or deny approval of a product candidate for many reasons, including because the FDA:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may not deem our product candidate to be safe and effective;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determines that the product candidate does not have an acceptable benefit-risk profile;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determines in the case of a BLA seeking accelerated approval that the BLA does not provide evidence that the product candidate represents a meaningful advantage over available therapies for each tumor type;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determines that the objective response rate, or ORR, and duration of response are not clinically meaningful;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determines that a tissue agnostic indication is not appropriate, for example, because a consistent anti-tumor effect is not observed across multiple tumor types or the response is too heavily weighted on a specific tumor type;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may not agree that the data collected from preclinical studies and clinical trials are acceptable or sufficient to support the submission of a BLA or other submission or to obtain regulatory approval, and may impose requirements for additional preclinical studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may determine that adverse events experienced by participants in our clinical trials represent an unacceptable level of risk;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may determine that the population studied in the clinical trial may not be sufficiently broad or representative to assure safety in the full population for which we seek approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may not accept clinical data from trials, which are conducted at clinical facilities or in countries where the standard of care is potentially different from that of the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may disagree regarding the formulation, labeling and/or specifications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may not approve the manufacturing processes associated with our product candidate or may determine that a manufacturing facility does not have an acceptable compliance status;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may change approval policies or adopt new regulations; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may not file a submission due to, among other reasons, the content or formatting of the submission.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have not obtained FDA approval for any product. This lack of experience may impede our ability to obtain FDA approval in a timely manner, if at all, for seribantumab.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we experience delays in obtaining approval or if we fail to obtain approval of seribantumab, our commercial prospects will be harmed and our ability to generate revenues will be materially impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The accelerated approval pathway for seribantumab may not lead to a faster development or regulatory review or approval process and does not increase the likelihood that it will receive marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the FDA&#8217;s accelerated approval program, the FDA may approve a drug or biologic for a serious or life-threatening illness that provides meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. We may seek accelerated approval for seribantumab on the basis of ORR with an acceptable duration of response, a surrogate endpoint that we believe is reasonably likely to predict clinical benefit. Whether the ORR we observe in CRESTONE will be adequate to support an accelerated approval for a tissue </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">agnostic indication for seribantumab will depend on a number of factors, including the response rate, the durability of the responses, the observed toxicity profile, prior therapies received, and the consistency of the ORR across tumor types, with efficacy not heavily weighted toward a specific tumor type. This analysis may be complicated by whether there is an available therapy against which to compare seribantumab for certain tumor types based on the patients we enroll.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For drugs or biologics granted accelerated approval, post-marketing confirmatory trials are required to describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. These confirmatory trials must be completed with due diligence and, in some cases, the FDA may require that the trial be designed, initiated and/or fully enrolled prior to approval. If any of our competitors were to receive full approval on the basis of a confirmatory trial for an indication for which we are seeking accelerated approval before we receive accelerated approval, the indication we are seeking may no longer qualify as a condition for which there is an unmet medical need and accelerated approval of our product candidate would be more difficult or may not occur. Many cancer therapies rely on accelerated approval, and the treatment landscape can change quickly as the FDA converts accelerated approvals to full approvals on the basis of successful confirmatory trials. Moreover, the FDA may withdraw approval of our product candidate approved under the accelerated approval pathway if, for example:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the trial or trials required to verify the predicted clinical benefit of our product candidate fail to verify such benefit or do not demonstrate sufficient clinical benefit to justify the risks associated with the candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other evidence demonstrates that our product candidate is not shown to be safe or effective under the conditions of use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we fail to conduct any required post-approval trial of our product candidate with due diligence; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we disseminate false or misleading promotional materials relating to the relevant product candidate.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our failure to obtain marketing approval in jurisdictions outside the United States would prevent seribantumab from being marketed in those jurisdictions, and any approval we are granted for it in the United States would not assure approval in other jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In order to market and sell our products in any jurisdiction outside the United States, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to submit for marketing approvals and may not receive necessary approvals to commercialize our products in any market, which would impair our financial prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not be able to obtain or maintain orphan drug designation or exclusivity for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Regulatory authorities in some jurisdictions, including the United States, may designate drugs for relatively small patient populations as &#8220;orphan drugs.&#8221; Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or if the disease or condition affects more than 200,000 individuals in the United States and there is no reasonable expectation that the cost of developing the drug for the type of disease or condition will be recovered from sales of the product in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Orphan drug designation entitles a party to financial incentives, such as opportunities for grant funding towards clinical trial costs, tax advantages and user fee waivers. Additionally, if a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven&#160;years, except in certain circumstances, such as a showing of clinical superiority (i.e., another product is safer, more effective or makes a major contribution to patient care) over the product with orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity. Competitors, however, may receive approval of different products for the same indication for which the orphan product has exclusivity, or obtain approval for the same product but for a different indication than that for which the orphan product has exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The FDA has granted orphan drug designation to seribantumab in the United States for patients with heregulin- positive non-small-cell lung cancer. We may apply for an additional orphan drug designation in the United States or other geographies for seribantumab or our future product candidates. However, obtaining an orphan drug designation can be difficult, and we may not be successful in doing so. Even if we obtain orphan drug designation for a product candidate in specific indications, we may not be the first to obtain regulatory approval of the product candidate for the orphan-designated indication, due to the uncertainties associated with developing biological products. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for orphan designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Orphan drug designation does not ensure that we will receive marketing exclusivity in a particular market, and we cannot assure you that any future application for orphan drug designation in any other geography or with respect to any other future product candidate will be granted. Orphan drug designation neither shortens the development time or regulatory review time of a drug, nor gives the drug any advantage in the regulatory review or approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">A Breakthrough Therapy Designation by the FDA for any of our current or future product candidates may not lead to a faster development or regulatory review or approval process, and it would not increase the likelihood that the product candidate will receive marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may seek a Breakthrough Therapy Designation for seribantumab or our future product candidates. A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical data at the time of the submission of the BLA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Designation as a breakthrough therapy is at the discretion of the FDA. Accordingly, even if we believe that a product candidate meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy Designation for a drug may not result in a faster development process, review, or approval compared to drugs considered for approval under conventional FDA procedures and it would not assure ultimate approval by the FDA. In addition, even if the product candidate qualifies as a breakthrough therapy, the FDA may later decide that the product candidate no longer meets the conditions for qualification or that the time period for FDA review or approval will not be shortened.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we decide to pursue a Fast Track Designation by the FDA, it may not lead to a faster development or regulatory review or approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We may seek Fast Track Designation for seribantumab or our future product candidates. If a drug or biologic is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the product sponsor may apply for FDA Fast Track Designation. The FDA has broad discretion whether to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to successfully develop, validate, obtain regulatory approval of and commercialize companion diagnostic tests for seribantumab or any future product candidates that require or would benefit from such tests, or experience significant delays in doing so, we may not realize the full commercial potential of these product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A companion diagnostic is a medical device, often an <i style="font-style:italic;">in vitro </i>device, which provides information that is essential for the safe and effective use of a corresponding therapeutic drug or biologic product. A companion diagnostic can be used to identify patients who are most likely to benefit from the therapeutic product. We plan to engage a third-party provider to develop companion diagnostic tests to identify NRG1 fusions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A companion diagnostic is generally developed in conjunction with the clinical program for an associated therapeutic product. To date, the FDA has generally required premarket approval of companion diagnostics for cancer therapies. Generally, when a companion diagnostic is essential to the safe and effective use of a drug product, the FDA requires that the companion diagnostic be approved before or concurrent with approval of the therapeutic product and before a product can be commercialized. The approval of a companion diagnostic as part of the therapeutic product&#8217;s labeling limits the use of the therapeutic product to only those patients who express the specific genetic alteration that the companion diagnostic was developed to detect. However, it is possible that FDA may permit approval of the companion diagnostic for seribantumab as a post-marketing commitment following a potential regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Development of a companion diagnostic could include additional meetings with regulatory authorities, such as a pre- submission meeting and the requirement to submit an investigational device exemption application. In the case of a companion diagnostic that is designated as &#8220;significant risk device,&#8221; approval of an investigational device exemption by the FDA and IRB is required before such diagnostic is used in conjunction with the clinical trials for a corresponding product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To be successful in developing, validating, obtaining approval of and commercializing a companion diagnostic, we or our collaborators will need to address a number of scientific, technical, regulatory and logistical challenges. We have no prior experience with medical device or diagnostic test development. If we choose to develop and seek FDA approval for companion diagnostic tests on our own, we will require additional personnel. We may rely on third parties for the design, development, testing, validation and manufacture of companion diagnostic tests for our therapeutic product candidates that require such tests, the application for and receipt of any required regulatory approvals, and the commercial supply of these companion diagnostics. If these parties are unable to successfully develop companion diagnostics for these therapeutic product candidates, or experience delays in doing so, we may be unable to enroll enough patients for our current and planned clinical trials, the development of these therapeutic product candidates may be adversely affected, these therapeutic product candidates may not obtain marketing approval, and we may not realize the full commercial potential of any of these therapeutics that obtain marketing approval. For any product candidate for which a companion diagnostic is necessary to select patients who may benefit from use of the product candidate, any failure to successfully develop a companion diagnostic may cause or contribute to delayed enrollment of our clinical trials, and may prevent us from initiating a pivotal trial. In addition, the commercial success of any product candidate that requires a companion diagnostic will be tied to and dependent upon the receipt of required regulatory approvals and the continued ability of such third parties to make the companion diagnostic commercially available to us on reasonable terms in the relevant geographies. Any failure to do so could materially harm our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if we obtain marketing approval for a product candidate, the terms of approvals, ongoing regulation of our products or other post-approval restrictions may limit how we manufacture and market our products and compliance with such requirements may involve substantial resources, which could materially impair our ability to generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Any product candidates for which we receive accelerated approval from the FDA are required to undergo one or more confirmatory clinical trials. If such a product candidate fails to meet its safety and efficacy endpoints in such </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">confirmatory clinical trials, the regulatory authority may withdraw its conditional approval. There is no assurance that any such product will successfully advance through its confirmatory clinical trial(s). Therefore, even if a product candidate receives accelerated approval from the FDA, such approval may be withdrawn at a later date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Even if marketing approval of a product candidate is granted, an approved product and its manufacturer and marketer are subject to ongoing review and extensive regulation, which may include the requirement to implement a REMS or to conduct costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We must also comply with requirements concerning advertising and promotion for our product candidates for which we obtain marketing approval. Promotional communications with respect to prescription drugs or biologics are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved labeling. Thus, we will not be able to promote any products we develop for indications or uses for which they are not approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, manufacturers of approved products and those manufacturers&#8217; facilities are required to ensure that quality control and manufacturing procedures conform to current good manufacturing practices, or cGMPs, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements. We and our CMOs will be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMPs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Accordingly, even if we obtain marketing approval for a product candidate, we and our CMOs will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control. If we are not able to comply with post-approval regulatory requirements, we could have the marketing approvals for our products withdrawn by regulatory authorities and our ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. As a result, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Any product candidate for which we obtain marketing approval will be subject to ongoing enforcement of post-marketing requirements by regulatory agencies, and we could be subject to substantial penalties, including withdrawal of our product from the market, if we fail to comply with all regulatory requirements or if we experience unanticipated problems with our products, when and if any of them are approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post- approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include, but are not limited to, restrictions governing promotion of an approved product, submissions of safety and other post- marketing information and reports, registration and listing requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, and requirements regarding drug distribution and the distribution of samples to physicians and recordkeeping.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The FDA and other federal and state agencies, including the Department of Justice, closely regulate compliance with all requirements governing prescription drug and biologic products, including requirements pertaining to their marketing and promotion in accordance with the provisions of the approved labeling and manufacturing of products in accordance with cGMP requirements. For example, the FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off- label uses may be subject to significant liability. Violations of such requirements may lead to investigations alleging violations of the FDC Act, and other statutes, including the False Claims Act and other federal and state healthcare fraud and abuse laws as well as state consumer protection laws. Our failure to comply with all regulatory requirements, and later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes, may yield various results, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">litigation involving patients taking our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on such products, manufacturers or manufacturing processes;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the labeling or marketing of a product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on product distribution or use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to conduct post-marketing studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warning or untitled letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of the products from the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to approve pending applications or supplements to approved applications that we submit;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recall of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, restitution or disgorgement of profits or revenues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension or withdrawal of marketing approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">damage to relationships with any potential collaborators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unfavorable press coverage and damage to our reputation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to permit the import or export of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Non-compliance by us or any future collaborator with regulatory requirements, including safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population can also result in significant financial penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our current and future relationships with customers and third-party payors may be subject to applicable anti- kickback, fraud and abuse, transparency, health privacy, and other healthcare laws and regulations, which could expose us to significant penalties, including criminal, civil, and administrative penalties, contractual damages, reputational harm and diminished profits and future earnings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Healthcare providers, including physicians, and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare providers, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we research, as well as, market, sell and distribute any products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations that may be applicable to our business include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal civil and criminal false claims laws, including the False Claims Act, which can be enforced by civil whistleblower or qui tam actions on behalf of the government, and criminal false claims laws and the civil </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">monetary penalties law, prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented false or fraudulent claims for payment by a federal government program, or making a false statement or record material to payment of a false claim or avoiding, decreasing or concealing an obligation to pay money to the federal government;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, regardless of the payor (e.g. public or private), and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates and their subcontractors that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security, and transmission of such individually identifiable health information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Physician Payments Sunshine Act&#8217;s transparency requirements under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, collectively referred to as the ACA, requires certain manufacturers of drugs, devices, biologics and medical supplies to annually report to the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, information related to payments and other transfers of value provided to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), physician assistants, certain types of advance practice nurses and teaching hospitals, as well as ownership and investment interests held by physicians, and their immediate family members. The reported information is made available on a public website; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">analogous state laws and regulations such as state anti-kickback and false claims laws and analogous non-U.S. fraud and abuse laws and regulations, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers. Some state laws require biologics companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance regulations promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, marketing expenditures, or drug pricing, including price increases. State and local laws require the registration of pharmaceutical sales representatives. State and non-U.S. laws that also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional integrity reporting and oversight obligations, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to significant criminal, civil and administrative sanctions, including exclusions from government funded healthcare programs, which could have a material adverse effect on our business, results of operations, financial condition and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may face difficulties from healthcare legislative reform measures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Existing regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March&#160;2010, the Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Reconciliation Act, or together, the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. The ACA, among other things, (i)&#160;subjected therapeutic biologics to potential competition by lower-cost biosimilars by creating a licensure framework for follow-on biologic products, (ii)&#160;prescribed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs and therapeutic biologics that are inhaled, infused, instilled, implanted or injected, (iii)&#160;increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, (iv)&#160;established annual fees and taxes on manufacturers of certain branded prescription drugs and therapeutic biologics, (v)&#160;established a Medicare Part&#160;D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts (now 70%) off negotiated prices of applicable brand drugs and therapeutic biologics to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs and therapeutic biologics to be covered under Medicare Part&#160;D, (vi)&#160;expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability, (vii)&#160;expanded the entities eligible for discounts under the Public Health program (viii)&#160;created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research and (ix)&#160;established a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There have been executive, legislative and judicial efforts to modify, repeal or otherwise invalidate all or certain aspects of the ACA. By way of example, the Tax Cuts and Jobs Act included, among other things, a provision repealing the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a&#160;<span style="white-space:pre-wrap;">year that is commonly referred to as the &#8220;individual mandate.&#8221;  On June&#160;17, 2021, the United States Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. On January&#160;28, 2021, President Biden issued an executive order to initiate a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which began on February&#160;15, 2021 and closed on August&#160;15, 2021. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules&#160;that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is uncertain how any such challenges and healthcare measures of the Biden administration will impact the ACA and our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted to reduce healthcare expenditures. U.S. federal government agencies also currently face potentially significant spending reductions, which may further impact healthcare expenditures, uncluding reductions of Medicare payments to providers of 2% per fiscal&#160;year, which began in 2013 and will remain in effect through 2030, with the exception of a temporary suspension from May&#160;1, 2020 through March&#160;31, 2022 due to the COVID-19 pandemic, unless additional Congressional action is taken. The Medicare reductions phase back in starting with a 1% reduction in effect from April 1, 2022 to June 30, 2022 before increasing to the full 2% reduction. Moreover, on January&#160;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five&#160;years. If federal spending is further reduced, anticipated budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA or the National Institutes of Health to continue to function at current levels. Amounts allocated to federal grants and contracts may be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely review and approve research and development, manufacturing, and marketing activities, which may delay our ability to develop, market and sell any products we may develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Moreover, payment methodologies, including payment for companion diagnostics, may be subject to changes in healthcare legislation and regulatory initiatives. For example, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement methodology based on average sales prices for physician-administered drugs. In addition, this legislation provided authority for limiting the number of drugs that will be covered in any therapeutic class. While the MMA only applies to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the MMA may result in a similar reduction in payments from private payors. In addition, CMS has begun bundling the Medicare payments for certain laboratory tests ordered while a patient received services in a hospital outpatient setting and, beginning in 2018, CMS will pay for clinical laboratory services based on a weighted average of reported prices that private payors, Medicare Advantage plans, and Medicaid Managed Care plans pay for laboratory services. Further, on March&#160;16, 2018, CMS finalized its National Coverage Determination, or NCD, for certain diagnostic laboratory tests using next generation sequencing that are approved by the FDA as a companion <i style="font-style:italic;">in vitro </i>diagnostic and used in a cancer with an FDA-approved companion diagnostic indication. Under the NCD, diagnostic tests that gain FDA approval or clearance as an <i style="font-style:italic;">in vitro </i>companion diagnostic will automatically receive full coverage and be available for patients with recurrent, metastatic relapsed, refractory or stages III and IV cancer. Additionally, the NCD extended coverage to repeat testing when the patient has a new primary diagnosis of cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, in July 2021, President Biden issued an executive order pertaining to drug pricing, which expressed support for legislation allowing direct negotiation in Medicare Part D and inflationary rebates, and directed various executive branch agencies to take actions to lower drug prices and promote generic competition. Several pending legislative efforts, including President Biden&#8217;s larger Build Back Better legislative agenda and draft bill text, incorporate these drug pricing reforms in addition to inflationary rebates on Part B and Part D drugs that would be payable on commercial and governmental program utilization, policies aimed at redesigning the Medicare Part D benefit and adopting drug price transparency measures. Drug manufacturers who are unwilling to negotiate with Medicare would be subject to additional excise taxes. Additionally, the plan would impose tax penalties on drug manufacturers that increase the prices of drug products faster than the rate of inflation. If elements of the recently announced prescription drug pricing plan become law, our pricing strategy and commercial prospects may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Additionally, on September 9, 2021, the Biden administration published a wide-ranging list of policy proposals, most of which would need to be carried out by Congress, to reduce drug prices and drug payment. This plan includes, among other reform measures, proposals to lower prescription drug prices, including by allowing Medicare to negotiate prices and disincentivizing price increases, and to support market changes that strengthen supply chains, promote biosimilars and generic drugs, and increase price transparency. Many similar proposals, including the plans to give Medicare Part D authority to negotiate drug prices, require drug manufacturers to pay rebates on drugs whose prices increase greater than the rate of inflation, and cap out-of-pocket costs, have already been included in policy statements and legislation currently being considered by Congress. It is unclear to what extent these new proposals or any future legislation or regulations by the Biden Administration will have on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additionally, on May&#160;30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 was signed into law. The law, among other things, provides a federal framework for certain patients to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA authorization under an FDA expanded access program; however, manufacturers are not obligated to provide investigational new drug products under the current federal right to try law. We may choose to seek an expanded access program for our product candidates, or to utilize comparable rules&#160;in other countries that allow the use of a drug, on a named patient basis or under a compassionate use program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We expect that additional state and federal healthcare reform measures will be adopted in the future.  Such reform measures may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Governments outside of the United States tend to impose strict price controls, which may adversely affect our revenues, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In some countries, particularly the countries of the EU, the pricing of prescription biological products is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our lead product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU member states, and parallel trade, such as arbitrage between low-priced and high-priced member states, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for biological products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries. In addition, the recent withdrawal of the United Kingdom from its membership in the EU, often referred to as &#8220;Brexit&#8221;, could lead to legal and regulatory uncertainty in the United Kingdom and may lead to the United Kingdom and EU adopting divergent laws and regulations, including those related to the pricing of prescription biological products, as the United Kingdom determines which EU laws to replicate or replace. If the United Kingdom were to significantly alter its regulations affecting the pricing of prescription biological products, we could face significant new costs. As a result, Brexit could impair our ability to transact business in the EU and the United Kingdom.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain product candidates and products outside of the United States and require us to develop and implement costly compliance programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we expand our operations outside of the United States, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, authorizing payment or offering anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of such third party in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the company, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the biological products industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing or selling certain product candidates and products outside of the United States, which could limit our growth potential and increase our development costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We and our third-party contractors are subject to numerous foreign, federal, state and local environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources, including any available insurance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, our leasing and operation of real property may subject us to liability pursuant to certain of these laws or regulations. Under existing U.S. environmental laws and regulations, current or previous owners or operators of real property and entities that disposed or arranged for the disposal of hazardous substances may be held strictly, jointly and severally liable for the cost of investigating or remediating contamination caused by hazardous substance releases, even if they did not know of and were not responsible for the releases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We could incur significant costs and liabilities which may adversely affect our financial condition and operating results for failure to comply with such laws and regulations, including, among other things, civil or criminal fines and penalties, property damage and personal injury claims, costs associated with upgrades to our facilities or changes to our operating procedures, or injunctions limiting or altering our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Although we maintain liability insurance to cover us for costs and expenses we may incur due to injuries to our employees, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations, which are becoming increasingly more stringent, may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are subject to certain U.S. and certain other anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations. We can face serious consequences for violations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. and other anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations prohibit, among other things, companies and their employees, agents, CROs, CMOs, legal counsel, accountants, consultants, contractors and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of these laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences. We have direct or indirect interactions with officials and employees of government agencies or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">government-affiliated hospitals, universities and other organizations. We also expect our non-U.S. activities to increase over time. We expect to rely on third parties for research, preclinical studies and clinical trials and/or to obtain necessary permits, licenses, patent registrations and other marketing approvals. We can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks related to our reliance on third parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We rely, and intend to continue to rely, on third parties to conduct our clinical trials and perform all of our research and preclinical studies. If these third parties do not satisfactorily carry out their contractual duties, fail to comply with applicable regulatory requirements or do not meet expected deadlines, our development programs may be delayed or subject to increased costs or we may be unable to obtain regulatory approval, each of which may have an adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We do not have the ability to independently conduct all aspects of our preclinical testing or clinical trials ourselves. As a result, we are dependent on third parties to conduct our ongoing CRESTONE trial and our ongoing and planned preclinical studies and clinical trials of our future product candidates. The timing of the initiation and completion of these trials will therefore be partially controlled by such third parties and may result in delays to our development programs. Specifically, we expect CROs, clinical investigators and consultants to play a significant role in the conduct of these trials and the subsequent collection and analysis of data. However, these CROs and other third parties are not our employees, and we will not be able to control all aspects of their activities. Nevertheless, we are responsible for ensuring that each clinical trial is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCP, requirements, which are regulations and guidelines enforced by the FDA for product candidates in clinical development. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, clinical trial investigators and clinical trial sites. If we or any of our CROs or clinical trial sites fail to comply with applicable GCP requirements, the data generated in our clinical trials may be deemed unreliable, and the FDA may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, the FDA will determine that our clinical trials comply with GCPs. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure, or the failure of third parties on whom we rely, to comply with these regulations may require us to stop and/or repeat clinical trials, which would delay the marketing approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There is no guarantee that any such CROs, clinical trial investigators or other third parties on which we rely will devote adequate time and resources to our development activities or perform as contractually required. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, otherwise perform in a substandard manner, or terminate their engagements with us, the timelines for our development programs may be extended or delayed or our development activities may be suspended or terminated. If our clinical trial site terminates for any reason, we may experience the loss of follow-up information on subjects enrolled in such clinical trial unless we are able to transfer those subjects to another qualified clinical trial site, which may be difficult or impossible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors, for whom they may also be conducting clinical trials or other biological product development activities that could harm our competitive position. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for seribantumab or any other future product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our products.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Manufacturing biological products is complex and subject to product loss for a variety of reasons. We rely on third-party suppliers, including single source suppliers, to manufacture clinical supplies of our lead product candidate and we intend to rely on third parties to produce commercial supplies of any approved product. This reliance on third parties increases the risk that we will not have sufficient quantities of our lead product candidate or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We do not have any manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of seribantumab and our future product candidates for clinical testing, product development purposes, to support regulatory application submissions, as well as for commercial manufacture if a product candidate obtains marketing approval. In addition, we expect to contract with analytical laboratories for release and stability testing of our product candidates. We acquire our clinical supply of seribantumab from our contract manufacturer on an ongoing basis after the completion of stability testing, and have periodically encountered delays in receiving such clinical supply. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts. In addition, the ongoing COVID-19 pandemic may result in disruptions to the operations or an extended shutdown of certain businesses, which could include certain of our contract manufacturers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may be unable to establish any agreements with third-party manufacturers or do so on favorable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reliance on the third party for regulatory, compliance and quality assurance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reliance on the third party for product development, analytical testing, and data generation to support regulatory applications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of qualified backup suppliers for those components or materials that are currently purchased from a sole or single source supplier;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">operations of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier, the issuance of an FDA Form&#160;483 notice or warning letter or other enforcement action by FDA or other regulatory authority;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible breach of the manufacturing agreement by the third party;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible misappropriation of our proprietary information, including our trade secrets and know-how;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">carrier disruptions or increased costs that are beyond our control; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to deliver our drugs under specified storage conditions and in a timely manner.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have only limited clinical trial supply arrangements in place for seribantumab, and these arrangements do not extend to commercial supply. We acquire many key materials on a purchase order basis. As a result, we do not have long-term committed arrangements with respect to seribantumab or any future product candidate. We will need to establish one or more agreements with third parties in order to develop and scale up our drug manufacturing process, conduct drug testing and generate data to support one or more regulatory submissions. If we obtain marketing approval for seribantumab or any future product candidate, we will need to establish an agreement for commercial manufacture with a third party.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, we currently use two suppliers for certain key components of our manufacturing process. Even if we are able to replace any raw materials or other materials with an alternative, such alternatives may cost more, result in lower yields or not be as suitable for our purposes. In addition, some of the materials that we use to manufacture our product candidates are complex materials, which may be more difficult to substitute. Therefore, any disruptions arising from our current supplier could result in delays and additional regulatory submissions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. If the FDA determines that our CMOs are not in compliance with FDA laws and regulations, including those governing cGMPs, the FDA may not approve a BLA until the deficiencies are corrected or we replace the manufacturer in our application with a manufacturer that is in compliance. Moreover, our failure, or the failure of our third-party manufacturers and suppliers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products. In addition, approved products and the facilities at which they are manufactured are required to maintain ongoing compliance with extensive FDA requirements and the requirements of other similar agencies, including ensuring that quality control and manufacturing procedures conform to cGMP requirements. As such, our CMOs are subject to continual review and periodic inspections to assess compliance with cGMPs. Furthermore, although we do not have day-to-day control over the operations of our CMOs, we are responsible for ensuring compliance with applicable laws and regulations, including cGMPs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Further, if we make manufacturing or formulation changes to our product candidates or add or change CMOs in the future, the FDA or other regulatory authorities will require a demonstration of the comparability of the new product to the prior product, including potentially through a clinical bridging study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, our third-party manufacturers and suppliers are subject to numerous environmental, health and safety laws and regulations, including those governing the handling, use, storage, treatment and disposal of waste products, and failure to comply with such laws and regulations could result in significant costs associated with civil or criminal fines and penalties for such third parties. Based on the severity of regulatory actions that may be brought against these third parties in the future, our clinical or commercial supply of drug and packaging and other services could be interrupted or limited, which could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our product candidates and any products that we may develop may compete with other future product candidates and products for access to manufacturing facilities. As a result, we may not obtain access to these facilities on a priority basis or at all. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As we prepare for potential commercialization, we will need to take steps to increase the scale of production of our lead product candidate. Although seribantumab was previously manufactured at commercial scale, we have not yet scaled up the manufacturing process for commercialization since acquiring seribantumab. Third party manufacturers may be unable to successfully increase the manufacturing capacity for seribantumab in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up or commercial activities. For example, if microbial, viral or other contaminations are discovered in the clinical trial supply of seribantumab or in the manufacturing facilities in which it is made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently have arrangements in place for redundant supply or a second source for bulk drug substances. If our current CMOs for preclinical and clinical testing cannot perform as agreed, we may be required to replace such CMOs. Although we believe that there are several potential alternative manufacturers who could manufacture seribantumab, we may incur added costs and delays in identifying and qualifying any such replacement manufacturer or we may not be able to reach agreement with any alternative manufacturer. Further, our third-party manufacturers may experience manufacturing or shipping difficulties due to resource constraints or as a result of natural disasters, labor disputes, unstable political environments or public health epidemics such as the COVID-19 pandemic. If our current third-party manufacturers cannot perform as agreed, we may be required to replace such manufacturers and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">we may be unable to replace them on a timely basis or at all. Further, to meet the demand for COVID-19 vaccine production, manufacturers are required to prioritize rated orders issued by the Federal Emergency Management Agency pursuant to the U.S. Defense Production Act of 1950, or the DPA. The potential for manufacturing facilities and materials to be commandeered under the DPA, or equivalent foreign legislation, could make it more difficult to obtain materials or manufacturing slots for the products needed for our clinical trials, which could lead to delays in these trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our current and anticipated future dependence upon others for the manufacture of our lead product candidate or products may adversely affect our future profit margins and our ability to commercialize any products that obtain marketing approval on a timely and competitive basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may enter into collaborations with third parties for the development and commercialization of seribantumab and any future product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of seribantumab and our future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may seek third-party collaborators for the development and commercialization of seribantumab or our future product candidates on a select basis. We have not entered into any collaborations to date. Our likely collaborators for any future collaboration arrangements include large and mid-size biologics companies, regional and national biologics companies and biotechnology companies. We will face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a future collaboration will depend, among other things, upon our assessment of the future collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we do enter into any such arrangements with any third parties, we will likely have limited control over the amount and timing of resources that our future collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on our future collaborators&#8217; abilities and efforts to successfully perform the functions assigned to them in these arrangements. Collaborations with future collaborators involving our product candidates would pose numerous risks to us, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations and may not perform their obligations as expected;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may de-emphasize or not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#8217; strategic focus, including as a result of a sale or disposition of a business unit or development function, or available funding or external factors such as an acquisition that diverts resources or creates competing priorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaborator with marketing and distribution rights to multiple products may not commit sufficient resources to the marketing and distribution of our product relative to other products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not properly obtain, maintain, defend or enforce our intellectual property rights or may use our proprietary information and intellectual property in such a way as to invite litigation or other intellectual property related proceedings that could jeopardize or invalidate our proprietary information and intellectual property or expose us to potential litigation or other intellectual property related proceedings;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our products or product candidates or that result in costly litigation or arbitration that diverts management attention and resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if a future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we establish one or more collaborations, all of the risks relating to product development, regulatory approval and commercialization described herein would also apply to the activities of any such future collaborators.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks related to commercialization of our product candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The incidence and prevalence for target patient populations of seribantumab and our future product candidates have not been established with precision. If the market opportunities for our product candidates are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, then our revenue potential and ability to achieve profitability will be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The total addressable market opportunity for seribantumab and any other future product candidates we may develop will ultimately depend upon, among other things, the diagnosis criteria included in the final labeling for each such product candidate if it is approved for sale for these indications, acceptance by the medical community, patient access, drug and any related companion diagnostic pricing and their reimbursement. Additionally, for enrollment in the CRESTONE trial, we are utilizing novel RNA-based testing methodologies to identify NRG1 gene fusions due to the methodology&#8217;s higher sensitivity compared to DNA-based testing methodologies for identifying oncogenic fusions. We may continue to prioritize novel RNA-based testing methodologies to identify NRG1 gene fusions for seribantumab. The total addressable market opportunity for seribantumab and any other future product candidates we may develop will depend upon commercially available RNA-based next generation sequencing testing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may initially seek regulatory approval of seribantumab or our future product candidates as therapies for relapsed or refractory patients. The number of patients in our targeted commercial markets and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our drugs or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If seribantumab or our future product candidates receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. For example, current cancer treatments, such as existing targeted therapies, chemotherapy, and radiation therapy, are well established in the medical community, and doctors may continue to rely on these treatments. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efficacy and potential advantages compared to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the acceptance of our product candidates as front-line treatments for various indications;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects, in particular compared to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations or warnings contained in the labeling approved by the FDA or other regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size of the target patient population;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to offer our products for sale at competitive prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the convenience and ease of administration compared to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the strength of marketing and distribution support;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publicity for our product candidates and competing products and treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the existence of distribution and/or use restrictions, such as through a REMS;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of third-party payor coverage and adequate reimbursement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of any marketing approval in relation to other product approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">support from patient advocacy groups; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any restrictions on the use of our products together with other medications.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We currently have no marketing and sales organization and have no experience as a company in commercializing products and we may have to invest significant resources to develop these capabilities. If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have never commercialized a product candidate and we currently have no sales or marketing infrastructure and have no experience in the sale, marketing or distribution of biological products. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, acquiring the rights to our product candidate and undertaking preclinical studies and clinical trials of our product candidate. To achieve commercial success for any product for which we obtain marketing approval, we will need to establish sales, marketing and distribution capabilities, either ourselves or through collaboration or other arrangements with third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There are risks involved with establishing our own sales and marketing capabilities. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. These efforts are expected to be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Factors that may inhibit our efforts to commercialize our products on our own include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to raise financing necessary to build our commercialization infrastructure;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability of sales personnel to obtain access to physicians or educate an adequate number of physicians as to the benefits of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unfavorable third-party payor coverage and reimbursement in any geography;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Furthermore, developing a sales and marketing organization requires significant investment, is time-consuming and could delay the launch of our product candidate. We may not be able to build an effective sales and marketing organization in the United States, the EU or other key global markets. If we are unable to build our own distribution and marketing capabilities or to find suitable partners for the commercialization of our product candidate, we may have difficulties generating revenue from them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we enter into arrangements with third parties to perform sales and marketing services, our product revenues and our profitability, if any, are likely to be lower than if we were to market and sell any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to market and sell our product candidates or may be unable to do so on terms that are acceptable to us. We likely will have little control over such third parties, and any of these third parties may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing any product candidate for which we receive marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The development and commercialization of biological products is highly competitive. We face competition with respect to our current product candidates and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major biologics companies, specialty biologics companies and existing or emerging biotechnology companies, academic research institutions and governmental agencies and public and private research institutions worldwide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There are a number of biological and biotechnology companies that currently are pursuing the development of precision oncology therapies for patients with undrugged, genetically-defined cancers with high unmet need. In particular, we expect that seribantumab will compete against other ERBB or HER3 inhibitors that target tumors with an NRG1 gene fusion. Several such candidates are currently in clinical development, including those of Merus N.V. (zenocutuzumab&#160;&#8212; MCLA-128), Rain Therapeutics,&#160;Inc. (tarloxotinib), Hummingbird Bioscience&#160;Ltd. (HMBD-001&#160;&#8212; 10D1F), GamaMabs Pharma (9F7-F11) and AVEO Pharmaceuticals,&#160;Inc. (AV-203). We may face further competition from companies pursuing the development of product candidates that are ERBB or HER3 inhibitors not currently in defined clinical plans for targeting tumors with an NRG1 fusion, including ISU ABXIS Co., Ltd, Daiichi Sankyo Company, Ltd, Celldex Therapeutics,&#160;Inc., GlaxoSmithKline PLC, Boehringer Ingelheim International GmbH, or others. Development efforts with respect to, and clinical trial results of, these potentially competitive product candidates may be unsuccessful, which could result in a negative perception of HER3 inhibitors in general, for instance, which could in turn negatively impact the regulatory approval process for seribantumab.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Many of the companies against which we are competing or against which we may compete in the future, either alone or through collaborations, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific, management and sales </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and marketing personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Furthermore, we also face competition more broadly across the oncology market for cost-effective and reimbursable cancer treatments. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. While seribantumab or our future product candidates, if approved, may compete with these existing drugs and other therapies, to the extent they are ultimately used in combination with or as an adjunct to these therapies, our product candidates may not be competitive with them. Some of these drugs are branded and subject to patent protection, and others are available on a generic basis. Insurers and other third-party payors may also encourage the use of generic products or specific branded products. As a result, obtaining market acceptance of, and gaining significant share of the market for, our product candidates may pose challenges. In addition, many companies are developing new oncology therapeutics, and we cannot predict what the standard of care will be as product candidates progress through clinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient to administer, are less expensive or with a more favorable labeling than seribantumab or our future product candidates. Our competitors also may obtain FDA, foreign regulatory authority, or other marketing or regulatory approval for their products more rapidly than any approval we may obtain for ours, which could result in our competitors establishing a strong market position before we are able to enter the market, thereby limiting our potential for commercial success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if we are able to commercialize any product candidates, the products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product candidate in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues, if any, we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if such product candidates obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our ability to commercialize any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from third-party payors, including government healthcare programs, private health insurers and other organizations. Third-party payors decide which medications they will pay for and establish reimbursement levels. In the United States, the principal decisions about reimbursement for new medicines are typically made by the CMS, which decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payors often, but not always, follow CMS&#8217;s decisions regarding coverage and reimbursement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third- party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available for any product that we commercialize and, even if these are available, the level of reimbursement may not be satisfactory. Reimbursement may affect the demand for, or the price of, any product candidate for which we obtain marketing approval. Obtaining and maintaining coverage and adequate reimbursement for our products may be difficult. We may be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and adequate reimbursement are not available or reimbursement is available only to limited </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Additionally, we may develop, either by ourselves or with collaborators, companion diagnostic tests for our lead product candidate for certain indications. We, or our collaborators, if any, will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we seek for our product candidates, if approved. While we have not yet developed any companion diagnostic test for our product candidates, if we do, there is significant uncertainty regarding our ability to obtain coverage and adequate reimbursement for the same reasons that are applicable to our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There may also be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or similar regulatory authorities outside of the United States. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, intellectual property, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies, but also have their own methods and approval process apart from Medicare determinations. Our inability to promptly obtain coverage and adequate reimbursement rates from third- party payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States, or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, our product candidates may lose any marketing approval that may have been obtained and we may not achieve or sustain profitability, which would adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercialize any products that we may develop. If we cannot successfully defend ourselves against any claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for any product candidates or products that we may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injury to our reputation and significant negative media attention;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation of investigations by regulators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of clinical trial participants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant time and costs to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion of management and scientific resources from our business operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to trial participants or patients;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduced resources of our management to pursue our business strategy; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize any products that we may develop.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our current product liability insurance coverage for the United States and certain other jurisdictions may not be adequate to cover all liabilities that we may incur. We likely will need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of seribantumab or our future product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. A successful product liability claim or series of claims brought against us could decrease our cash and adversely affect our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks related to employee matters and our operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We expect to significantly expand our development and regulatory capabilities as we grow our company, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, we had 23 full-time employees. We expect significant growth in the number of our employees and the scope of our operations, particularly in the areas of clinical development, clinical operations, manufacturing, late-stage regulatory affairs, finance, accounting, business operations, public company compliance, communications and other corporate development functions, and, if seribantumab or any of our future product candidates receives marketing approval, sales, marketing and distribution. If we acquire additional product candidates or enter into future collaborations, we may have to further expand our employee base beyond our current projections, which may include further preclinical research and development or later-stage regulatory operations. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth and with developing sales, marketing and distribution infrastructure, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Further, rapid expansion of our workforce while remaining a virtual company and working through the COVID-19 pandemic may have a detrimental impact on employee morale and cohesion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Further, we currently rely, and for the foreseeable future will continue to rely, in substantial part on certain third-party contract organizations, advisors and consultants to provide certain services, including assuming substantial responsibilities for the conduct of our clinical trials and the manufacturing of seribantumab or any future product candidates. We cannot assure you that the services of such third-party contract organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by our vendors or consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of seribantumab or any future product candidates or otherwise advance our business. We cannot assure you that we will be able to properly manage our existing vendors or consultants or find other competent outside vendors and consultants on economically reasonable terms, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we are not able to effectively manage growth and expand our organization, we may not be able to successfully implement the tasks necessary to further develop and commercialize seribantumab or our future product candidates and, accordingly, we may not achieve our research, development and commercialization goals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our future success depends on our ability to retain key employees and to attract, retain and motivate qualified personnel and manage our human capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract, motivate and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the development and management expertise of Shawn Leland, our founder and Chief Executive Officer, as well as the other principal members of our management, scientific and clinical teams. We currently do not maintain key person insurance on these individuals. Although we have entered into employment agreements with our executive officers, each of them may terminate their employment with us at any time. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and manufacturing strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. Recruiting and retaining qualified finance and accounting personnel will also be critical to our success. We may not be able to attract or retain qualified personnel in the future due to the intense competition for a limited number of qualified personnel among pharmaceutical companies. Many of the other pharmaceutical companies against which we compete have greater financial and other resources, different risk profiles and a longer history in the industry than we do. Our competitors may provide higher compensation, more diverse opportunities and/or better opportunities for career advancement. Any or all of these competing factors may limit our ability to continue to attract and retain high quality personnel, which could negatively affect our ability to successfully develop and commercialize our lead product candidate and to grow our business and operations as currently contemplated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our employees, clinical trial investigators, CROs, CMOs, consultants, vendors and any potential commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are exposed to the risk of fraud or other misconduct by our employees, clinical trial investigators, CROs, CMOs, consultants, vendors and any potential commercial partners. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates: (i)&#160;FDA regulations or those of comparable foreign regulatory authorities, including those laws that require the reporting of true, complete and accurate information, (ii)&#160;manufacturing standards, (iii)&#160;federal and state health and data privacy, security, fraud and abuse, government price reporting, transparency reporting requirements, and other healthcare laws and regulations in the United States and abroad, (iv)&#160;sexual harassment and other workplace misconduct or (v)&#160;laws that require the true, complete and accurate reporting of financial information or data. Such misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have adopted a code of conduct applicable to all of our employees, as well as a disclosure program and other applicable policies and procedures, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional integrity reporting and oversight obligations, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are a virtual company and our business depends on the efficient and uninterrupted operation of our information technology systems and those of our third-party CROs, CMOs, or other vendors, contractors or consultants, may fail or suffer security breaches, cyber-attacks, loss or leakage of data and other disruptions, which could result in a material disruption of our development programs, compromise sensitive information related to our business or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are a virtual company and our business success depends on the security and efficient and uninterrupted operation of our information technology systems and we may be unable to adequately protect our information technology systems from cyber-attacks, which could result in the disclosure of confidential information, damage our reputation, and subject us to significant financial and legal exposure. We are increasingly dependent upon information technology systems, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">infrastructure and data to operate our business. In the ordinary course of business, we collect, store and transmit confidential information (including but not limited to intellectual property, proprietary business information and sensitive personal information). It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We also have outsourced elements of our operations to third parties, and as a result we manage a number of third-party CROs, CMOs, vendors, and other contractors and consultants who have access to our confidential information. System failures or outages, including any potential disruptions due to significantly increased global demand on certain cloud-based systems during the remote work environment resulting from the COVID-19 pandemic, could compromise our ability to perform these functions in a timely manner, which could harm our ability to conduct business or delay our financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Despite the implementation of security measures, given their size and complexity and the increasing amounts of confidential information that they maintain, our internal information technology systems and those of our third-party CROs, CMOs, vendors and other contractors and consultants are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, accidents by our employees or third party service providers, natural disasters, terrorism, war, global pandemics, and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, third-party CROs, CMOs, vendors, contractors, consultants, business partners and/or other third parties, or from cyber-attacks or supply chain attacks by malicious third parties (including the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information), which may compromise our system infrastructure, or that of our third-party CROs, CMOs, vendors and other contractors and consultants, or lead to data leakage. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity, and sophistication of attempted attacks and intrusions from around the world have increased. The COVID-19 pandemic is generally increasing the attack surface available for exploitation, as more companies and individuals work online and remotely, and as such, the risk of a cybersecurity incident occurring, and our investment in risk mitigations against such an incident, are increasing. For example, there has been an increase in phishing and spam email attacks as well as social engineering attempts from &#8220;hackers&#8221; hoping to use the recent COVID-19 pandemic to their advantage. We may not be able to anticipate all types of security threats, nor implement preventive measures effective against all such security threats. The techniques used by cyber criminals change frequently, may not be recognized until launched and can originate from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates, terrorist organizations, or hostile foreign governments or agencies. Any breach, loss or compromise of clinical trial participant personal data may also subject us to civil fines and penalties, including under HIPAA, and other relevant state and federal privacy laws in the United States. If the information technology systems of our third-party CROs, CMOs, vendors and other contractors and consultants become subject to disruptions or security breaches, we may have insufficient recourse against such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature from occurring.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">While we have not experienced any such system failure, accident or security breach to date, we cannot assure you that our data protection efforts and our investment in information technology will prevent significant breakdowns, data leakages, breaches in our systems, or those of our third-party CROs, CMOs, vendors and other contractors and consultants, or other cyber incidents that could have a material adverse effect upon our reputation, business, operations, or financial condition. For example, if such an event were to occur and cause interruptions in our operations, or those of our third-party CROs, CMOs, vendors and other contractors and consultants, it could result in a material disruption of our programs and the development of our lead product candidate could be delayed. In addition, the loss of clinical trial data for seribantumab or any other future product candidates could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. Furthermore, significant disruptions of our internal information technology systems or those of our third-party CROs, CMOs, vendors and other contractors and consultants, or security breaches could result in the loss, misappropriation and/or unauthorized access, use, or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information, and sensitive personal information), which could result in financial, legal, business and reputational harm to us.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A security breach may cause us to breach customer contracts. Our agreements with certain customers may require us to use industry-standard or reasonable measures to safeguard sensitive personal information or confidential information. A security breach could lead to claims by our customers, their end users, or other relevant stakeholders that we have failed to comply with such legal or contractual obligations. As a result, we could be subject to legal action or our customers could end their relationships with us. There can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities or damages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, litigation resulting from security breaches may adversely affect our business. Unauthorized access to our platform, systems, networks, or physical facilities could result in litigation with our customers, our customers&#8217; end users, or other relevant stakeholders. These proceedings could force us to spend money in defense or settlement, divert management&#8217;s time and attention, increase our costs of doing business, or adversely affect our reputation. We could be required to fundamentally change our business activities and practices or modify our solutions and/or platform capabilities in response to such litigation, which could have an adverse effect on our business. If a security breach were to occur and the confidentiality, integrity or availability of our data or the data of our partners, our customers or our customers&#8217; end users was disrupted, we could incur significant liability, or our platform, systems or networks may be perceived as less desirable, which could negatively affect our business and damage our reputation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may not have adequate insurance coverage with respect to security breaches or disruptions. The successful assertion of one or more large claims against us that exceeds our available insurance coverage, or results in changes to our insurance policies (including premium increases or the imposition of large deductible or co-insurance requirements), could have an adverse effect on our business. In addition, we cannot be sure that our existing insurance coverage and coverage for errors and omissions will continue to be available on acceptable terms or that our insurers will not deny coverage as to any future claim.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are subject to stringent and changing laws, regulations, rules, policies, standards, and contractual obligations related to privacy and data security. Our actual or perceived failure to comply with such obligations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We and any potential collaborators may be subject to federal, state and other data protection laws and regulations (i.e., laws and regulations that address privacy and data security). The regulatory framework for privacy, data security and data transfers worldwide is rapidly evolving and there has been an increasing focus on privacy and data protection issues with the potential to affect our business and as a result, interpretation and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. Failure to comply with any of these laws and regulations could result in enforcement actions against us, including fines, public censure, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws and federal and state consumer protection laws (e.g., Section&#160;5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA, as amended by HITECH. Depending on the facts and circumstances, we could be subject to penalties if we obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, the state of California recently enacted the California Consumer Privacy Act, or CCPA, which creates new individual privacy rights for California consumers (as defined in the CCPA) and places increased privacy and security obligations on entities handling certain personal data of consumers or households. The CCPA requires covered companies to provide new disclosures to consumers about such companies&#8217; data collection, use and sharing practices, provide such consumers new ways to opt-out of certain sales or transfers of personal information, and provide consumers with a private right of action for data breaches. The CCPA went into effect on January&#160;1, 2020 and may </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">impact our business activities and exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data and protected health information. Additionally, although not effective until January&#160;1, 2023, the California Privacy Rights Act, or the CPRA, which expands upon the CCPA, was recently passed in California. The CCPA gives (and the CPRA will give) California residents expanded privacy rights, including the right to request correction, access, and deletion of their personal information, the right to opt out of certain personal information sharing, and the right to receive detailed information about how their personal information is processed. The CCPA and CPRA provide for unlimited civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA and CPRA may increase our compliance costs and potential liability, particularly in the event of a data breach. Additionally, the CCPA has prompted a number of proposals in the U.S. for new federal and state-level privacy legislation that, if passed, could increase our potential liability, increase our compliance costs, and adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Additionally, laws, regulations, rules&#160;and standards in many foreign jurisdictions apply broadly to the collection, use, retention, security, disclosure, transfer and other processing of personal information, which may impose significant compliance obligations on us. For example, in the EU, the processing of personal data, is governed by the provisions of the General Data Protection Regulation, or the GDPR.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2018, the GDPR took effect in the European Economic Area, or the EEA. The GDPR governs the collection, use, disclosure, transfer or other processing of personal data of natural persons. Among other things, the GDPR imposes strict obligations on the ability to process health-related and other personal data of data subjects in the EEA, including in relation to use, collection, analysis and transfer (including cross-border transfers) of such personal data. The GDPR includes requirements relating to the consent of the individuals to whom the personal data relates, including detailed notices for clinical trial subjects and investigators. The GDPR also includes certain requirements regarding the security of personal data and notification of data processing obligations or security incidents to appropriate data protection authorities or data subjects, as well as requirements for establishing a lawful basis on which personal data can be processed. In addition, the GDPR increases the scrutiny of cross-border transfers of personal data from clinical trial sites located in the EEA to the United States and other jurisdictions that the European Commission does not recognize as having &#8220;adequate&#8221; data protection laws, and imposes substantial fines for breaches and violations (up to the greater of &#8364;20 million or 4% of our consolidated annual worldwide gross revenue). Further, recent legal developments in Europe have created complexity and compliance uncertainty regarding certain transfers of information from the EEA to the United States. For example, on June&#160;16, 2020, the Court of Justice of the European Union, or the CJEU, declared the EU-U.S. Privacy Shield framework, or the Privacy Shield, to be invalid. As a result, Privacy Shield is no longer a valid mechanism for transferring personal data from the EEA to the United States. Moreover, it is uncertain whether the standard contractual clauses will also be invalidated by the European courts or legislature, which seems possible given the rationale behind the CJEU&#8217;s concerns about U.S. law and practice on government surveillance. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We also may make public statements about our use and disclosure of personal information through our privacy policy and press statements. Although we endeavor to comply with our public statements and documentation, we may at times fail to do so or be alleged to have failed to do so. Despite our efforts, we may not be successful in achieving compliance if our employees or vendors fail to comply with our policies, certifications, and documentation. The publication of our privacy policy and other statements that provide promises and assurances about data privacy and security can subject us to potential government or legal action if they are found to be deceptive, unfair or misrepresentative of our actual practices. Any failure, real or perceived, by us to comply with our posted privacy policies or with any legal or regulatory requirements, standards, certifications or orders or other privacy or consumer protection-related laws and regulations applicable to us could cause our customers to reduce their use of our solutions and services and could materially and adversely affect our business, results of operations, financial condition, cash flows and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compliance with U.S. and foreign data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, transfer, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with U.S. and foreign data protection laws and regulations could result in government enforcement actions (which could include civil, criminal, and administrative penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business. Moreover, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We or the third parties upon whom we depend may be adversely affected by natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, public health epidemic, including the COVID-19 pandemic, power shortage, telecommunication failure or other natural or manmade accidents or incidents that result in us being unable to fully utilize our facilities, or the manufacturing facilities of our third-party CMOs, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Extreme weather conditions or other natural disasters could further disrupt our operations and have a material and adverse effect on our business, financial condition, results of operations and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our facilities, that damaged critical infrastructure, such as our research facilities or the manufacturing facilities of our third-party CMOs, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Operating as a virtual company, our employees conduct business outside of any leased or owned facilities. These locations may be subject to additional security and other risk factors due to the limited control of our employees. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, or the manufacturing facilities of our third-party CMOs, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption could have a material and adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in tax laws or regulations that are applied adversely to us may have a material adverse effect on our business, cash flow, financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, the Tax Cuts and Jobs Act, enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Cuts and Jobs Act may affect us, and certain aspects of the Tax Cuts and Jobs Act could be repealed or modified in future legislation. For example, the CARES Act modified certain provisions of the Tax Cuts and Jobs Act. In addition, it is uncertain if and to what extent various states will conform to the Tax Cuts and Jobs Act, the CARES Act, or any other newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Cuts and Jobs Act, the CARES Act or future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve profitability. Under the Tax Cuts and Jobs Act, as modified by the CARES Act, unused U.S. federal net operating losses generated in tax&#160;years beginning after December&#160;31, 2017, will not expire and may be carried forward indefinitely but the deductibility of such federal net operating losses may be limited to 80% of current&#160;year </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">taxable income. It is uncertain if and to what extent various states will conform to the Tax Cuts and Jobs Act or the CARES Act. In addition, both our current and our future unused losses and other tax attributes may be subject to limitation under Sections 382 and 383 of the U.S. Internal Revenue Code of 1986, as amended, or the Code, if we undergo, or have undergone, an &#8220;ownership change,&#8221; generally defined as a greater than 50&#160;percentage point change (by value) in our equity ownership by certain stockholders over a three-year period. We have not completed a Section&#160;382 study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since our formation due to the complexity and cost associated with such a study and the fact that there may be additional ownership changes in the future. As a result, if we undergo an ownership change (or if we previously underwent such an ownership change), our ability to use all of our pre-change net operating loss carryforwards and other pre-change tax attributes (such as research tax credits) to offset our post-change income or taxes may be limited. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. In addition, at the state level, there may be periods during which the use of net operating losses is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result, even if we attain profitability, we may be unable to use all or a material portion of our net operating losses and other tax attributes, which could adversely affect our future cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks related to intellectual property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to obtain and maintain sufficient patent protection for our product candidates, or if the scope of the patent protection is not sufficiently broad, third parties, including our competitors, could develop and commercialize products similar or identical to ours, and our ability to commercialize seribantumab and our future product candidates may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our success depends in large part on our ability to protect our proprietary technologies that we believe are important to our business, including pursuing, obtaining and maintaining patent protection in the United States and other countries intended to cover the compositions of matter of seribantumab and our future product candidates, their methods of use, related technologies and other inventions that are important to our business. In addition to patent protection, we also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. If we do not adequately pursue, obtain, maintain, protect or enforce our intellectual property, third parties, including our competitors, may be able to erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The patent application and approval process is expensive, time-consuming and complex. We may not be able to file, prosecute and maintain all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions. We also cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdictions. It is also possible that we will fail to identify patentable aspects of our product candidates before it is too late to obtain patent protection. Moreover, depending on the terms of any future license agreements to which we may become a party, we may not have the right to control the preparation, filing, and prosecution of patent applications, or to maintain the patents, covering technology licensed from third parties. Therefore, these patents and patent applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Furthermore, the patent position of biotechnology and pharmaceutical companies generally is highly uncertain. No consistent policy regarding the breadth of claims allowed in biotechnology and pharmaceutical patents has emerged to date in the United States or in many foreign jurisdictions. The standards applied by the United States Patent and Trademark Office, or the USPTO, and foreign patent offices in granting patents are not always applied uniformly or predictably. In addition, the determination of patent rights with respect to biological and pharmaceutical products commonly involves complex legal and factual questions, which have in recent&#160;years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Thus, we cannot offer any assurances about which, if any, patents will be issued, the breadth of any such patents, whether any issued patents will be found invalid and unenforceable or will be threatened by third parties or whether any issued patents will effectively prevent others from commercializing competing technologies and product candidates. While we have filed patent applications covering aspects of our current lead product candidate, we currently have only one U.S. application specifically covering the use of seribantumab to treat patients with tumors harboring an NRG1 fusion according to our CRESTONE clinical dosing regimen. Any patents issuing from this currently unpublished application would expire in 2042, subject to any disclaimers or extensions.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until at least one patent issues from such applications. Assuming the other requirements for patentability are met, currently, the first to file a patent application is generally entitled to the patent. However, prior to March&#160;16, 2013, in the United States, the first to invent was entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. Since patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we were the first to file or invent (prior to March&#160;16, 2013) any patent application related to our current or future product candidates. In addition, we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, collaborators, CROs, CMOs, hospitals, independent treatment centers, consultants, independent contractors, suppliers, advisors and other third parties; however, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. Furthermore, if third parties have filed patent applications related to our current or future product candidates or technology, we may not be able to obtain our own patent rights to those product candidates or technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Moreover, because the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, our patents or pending patent applications may be challenged in the courts or patent offices in the United States and abroad. For example, we may be subject to a third-party pre-issuance submission of prior art to the USPTO or become involved in post-grant review procedures, oppositions, derivations, revocation, reexaminations, inter partes review or interference proceedings, in the United States or elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party rights. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge priority of invention or other features of patentability. Such challenges may result in loss of exclusivity or in our patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products or limit the duration of the patent protection of our technology and products. Such challenges also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, our patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. Moreover, some of our patents and patent applications may in the future be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our pending and future patent applications may not result in patents being issued that protect our product candidates, in whole or in part, or which effectively prevent others from commercializing competitive products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. In addition, the laws of other countries may not protect our rights to the same extent or in the same manner as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage. Moreover, the coverage claimed in a patent application can be significantly reduced before the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">patent is issued and its scope can be reinterpreted after issuance. Consequently, we do not know whether our lead product candidate will be protectable or remain protected by valid and enforceable patents. Our competitors and other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner. Our competitors and other third parties may also seek approval to market their own products similar to or otherwise competitive with our products. Alternatively, our competitors or other third parties may seek to market generic versions or &#8220;follow-on&#8221; versions of any approved products by submitting abbreviated new drug applications, or ANDAs, or new drug applications under Section&#160;505(b)(2)&#160;of the Federal Food, Drug, and Cosmetic Act, or FDCA, respectively, to the FDA during which they may claim that patents owned by us are invalid, unenforceable or not infringed. In these circumstances, we may need to defend or assert our patents, or both, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find our patents invalid or unenforceable, or that our competitors are competing in a non-infringing manner. Thus, even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Furthermore, future patents may be subject to a reservation of rights by one or more third parties. For example, to the extent the research resulting in future patent rights or technologies is funded in the future in part by the U.S. government, the government could have certain rights in any resulting patents and technology, including a non-exclusive license authorizing the government to use the invention or to have others use the invention on its behalf for non-commercial purposes. If the U.S. government then decides to exercise these rights, it is not required to engage us as its contractor in connection with doing so. These rights may also permit the government to disclose our confidential information to third parties and to exercise march-in rights to use or allow third parties to use our licensed technology. The government may also exercise its march-in rights if it determines that action is necessary because we failed to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such government-funded inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. Any exercise by the government of aforementioned proprietary rights could harm our competitive position, business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology and pharmaceutical industries involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Recent patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act, or the Leahy-Smith Act, signed into law in September&#160;2011, could increase those uncertainties and costs. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. For example, the Leahy-Smith Act allows third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. In addition, the Leahy-Smith Act has transformed the U.S. patent system from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. The first-to-file provisions, however, only became effective on March&#160;16, 2013. It is not yet clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could make it more difficult to obtain patent protection for our inventions and increase the uncertainties and costs surrounding the prosecution of our or our potential collaboration partners&#8217; patent applications and the enforcement or defense of our or our future collaboration partners&#8217; issued patents, all of which could harm our business, results of operations, financial condition and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, the patent positions of companies in the development and commercialization of biologics are particularly uncertain. The U.S. Supreme Court has ruled on several patent cases in recent&#160;years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Additionally, there have been recent proposals for additional changes to the patent laws of the United States and other countries that, if adopted, could impact our ability to enforce our proprietary technology. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may become involved in lawsuits or administrative disputes to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Competitors and other third parties may infringe, misappropriate or otherwise violate our patents, trademarks, copyrights, trade secrets or other intellectual property. To counter infringement, misappropriation or other violations, we may be required to file infringement, misappropriation or other violation claims, which can be expensive and time consuming and divert the time and attention of our management and business and scientific personnel. In addition, many of our adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we can.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe, misappropriate or otherwise violate their patents or their other intellectual property, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In patent litigation in the United States, counterclaims challenging the validity, enforceability or scope of asserted patents are commonplace. Similarly, third parties may initiate legal proceedings against us seeking a declaration that certain of our intellectual property is non-infringed, invalid or unenforceable. The outcome of any such proceeding is generally unpredictable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. If a defendant were to prevail on a legal assertion of invalidity or unenforceability of our patents covering one of our product candidates, we could lose at least a part, and perhaps all, of the patent protection covering such a product candidate. Competing drugs may also be sold in other countries in which our patent coverage might not exist or be as strong. If we lose a foreign patent lawsuit, alleging our infringement of a competitor&#8217;s patents, we could be prevented from marketing our product candidates in one or more foreign countries. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for&#160;years before they are concluded. Even if we ultimately prevail </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Furthermore, third parties may also raise invalidity or unenforceability claims before administrative bodies in the United States or foreign authorities, even outside the context of litigation. Such mechanisms include re-examination, inter partes review, post-grant review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation, cancellation or amendment to our patents in such a way that they no longer cover and protect our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or written description. Grounds for an unenforceability assertion could be an allegation that someone connected with the prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution of the patent. With respect to the validity of our patents, for example, we cannot be certain that there is no invalidating prior art of which we, our licensors, our patent counsel and the patent examiner were unaware during prosecution. Moreover, it is possible that prior art may exist that we are aware of but do not believe is relevant to our current or future patents, but that could nevertheless be determined to render our patents invalid. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we could lose at least part, and perhaps all, of the patent protection on our lead product candidate. Any such loss of patent protection could have a material adverse impact on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not be able to effectively protect or enforce our intellectual property and proprietary rights throughout the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Filing, prosecuting and defending patents with respect to our product candidates in all countries throughout the world would be prohibitively expensive, and the laws of other countries may not protect our rights to the same extent as the laws of the United States. The requirements for patentability may differ in certain countries, particularly in developing countries. In addition, any future intellectual property license agreements may not always include worldwide rights. Consequently, competitors and other third parties may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may obtain patent protection, but where patent enforcement is not as strong as that in the United States and where our ability to enforce our patents to stop infringing activities may be inadequate. These products may compete with our products in such territories and in jurisdictions where we do not have any patent rights or where any future patent claims or other intellectual property or proprietary rights may not be effective or sufficient to prevent them from competing with us, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Moreover, our ability to protect and enforce our intellectual property and proprietary rights may be adversely affected by unforeseen changes in foreign intellectual property laws. Additionally, the laws of some countries outside of the United States and Europe do not afford intellectual property protection to the same extent as the laws of the United States and Europe. Many companies have encountered significant problems in protecting and defending intellectual property and proprietary rights in certain jurisdictions. The legal systems of some countries, including, for example, India, China and other developing countries, do not view favorably the enforcement of patents and other intellectual property or proprietary rights, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement, misappropriation or other violation of our patents or other intellectual property or proprietary rights. For example, many countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. Consequently, we may not be able to prevent third parties from practicing our inventions in certain countries outside the United States and Europe. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be adversely affected. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and resources from other aspects of our business, could put our patents, trademarks or other intellectual property and proprietary rights at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Furthermore, while we intend to protect our intellectual property and proprietary rights in major markets for our products, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our products. Accordingly, our efforts to protect our intellectual property and proprietary rights in such countries may be inadequate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are sued for infringing, misappropriating or otherwise violating intellectual property or proprietary rights of third parties, such litigation or disputes could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our commercial success depends, in part, on our ability to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and other proprietary rights of third parties. If any third-party patents, patent applications or other proprietary rights are found to cover our product candidates or any related companion diagnostics or their compositions, methods of use or manufacturing, we may be required to pay damages, which could be substantial, and we would not be free to manufacture or market our product candidates or to do so without obtaining a license, which may not be available on commercially reasonable terms, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may in the future become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property or proprietary rights with respect to our product candidates and technologies we use in our business. Our competitors or other third parties may assert infringement claims against us, alleging that our product candidates are covered by their patents. We cannot be certain that we do not infringe existing patents or that we will not infringe patents that may be granted in the future. Furthermore, because patent applications can take many&#160;years to issue and may be confidential for 18&#160;months or more after filing, and because patent claims can be revised before issuance, there may be applications now pending which may later result in issued patents that may be infringed by the manufacture, use or sale of our product candidates. If a patent holder believes our product candidate infringes its patent rights, the patent holder may sue us even if we have received patent protection for our technology. Moreover, we may face patent infringement claims from non-practicing entities that have no relevant drug revenue and against whom our own patent portfolio may thus have no deterrent effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There is a substantial amount of intellectual property litigation in the biotechnology and biological product industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property or proprietary rights with respect to our product candidates, including interference proceedings before the USPTO. Third parties may assert infringement, misappropriation or other claims against us based on existing or future intellectual property or proprietary rights. The outcome of intellectual property litigation and other disputes is subject to uncertainties that cannot be adequately quantified in advance. The biological product and biotechnology industries have produced a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of using or manufacturing products. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we were sued for patent infringement, we would need to demonstrate that our product candidates, products or methods of use, manufacturing or other applicable activities either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be successful in doing so. However, proving invalidity or unenforceability is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we believe third-party intellectual property claims are without merit, there is no assurance that a court would find in our favor on questions of infringement, validity, or enforceability. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and business and scientific personnel could be diverted in pursuing these proceedings, which could significantly harm our business and operating results. In addition, we may not have sufficient resources to bring these actions to a successful conclusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If we are found to infringe, misappropriate or otherwise violate a third party&#8217;s intellectual property or proprietary rights and we are unsuccessful in demonstrating that such intellectual property or proprietary rights are invalid or unenforceable, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product. Alternatively, we may be required to obtain a license from such third party in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">order to use the infringing technology and continue developing, manufacturing or marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain such a license, it could be granted on non- exclusive terms, thereby giving our competitors and other third parties access to the same technologies licensed to us. In addition, we could be found liable for significant monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed such third-party patent rights. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be subject to claims by third parties asserting that our employees or consultants or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Some of our employees and consultants are currently or have been previously employed at universities or at other biotechnology or biologics companies, including our competitors or potential competitors. These employees and consultants may have executed proprietary rights, non-disclosure and non-competition agreements, or similar agreements, in connection with such other current or previous employment. Although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of third parties. Litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property or personnel or sustain damages. Such intellectual property could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms or at all. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our management. Any of the foregoing would have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, while it is our policy to require our employees, consultants and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own, which may result in claims by or against us related to the ownership of such intellectual property. In addition, such agreements may not be self-executing such that the intellectual property subject to such agreements may not be assigned to us without additional assignments being executed, and we may fail to obtain such assignments. In addition, such agreements may be breached. In addition, we have multiple sponsored research agreements relating to our lead product candidate with various academic institutions. Some of these academic institutions may not have intellectual property assignments or similar agreements with their employees and consultants, which may result in claims by or against us related to ownership of any intellectual property. Accordingly, we may be forced to bring claims against third parties, or defend claims that they may bring against us to determine the ownership of what we regard as our intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our senior management and scientific personnel, which would have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Rights to improvements to our product candidates may be held by third parties, which could require us to obtain a license to such rights. Such a license may not be available on commercially reasonable terms, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have entered into agreements with third parties to conduct clinical testing of our product candidates, which provide that improvements to our product candidates may be owned solely by a party or jointly between the parties. If we determine that rights to such improvements owned solely by a third party are necessary to commercialize our product candidates or maintain our competitive advantage, we may need to obtain a license from such third party in order to use the improvements and continue developing, manufacturing or marketing the product candidates. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain such a license, it could be granted on non-exclusive terms, thereby giving our competitors and other third parties access to the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">same technologies licensed to us. Failure to obtain a license on commercially reasonable terms or at all, or to obtain an exclusive license, could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. If we determine that rights to improvements jointly owned between us and a third party are necessary to commercialize our product candidates or maintain our competitive advantage, we may need to obtain an exclusive license from such third party. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such improvements, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our intellectual property in order to enforce such intellectual property against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We or any future licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we or any future licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our or any future licensors&#8217; ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or any future licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The term of our patents may be inadequate to protect our competitive position on our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. For example, our wholly owned patent portfolio includes a patent family with claims directed to antibodies and related compositions covering seribantumab, as well as methods of treating cancer using such antibodies and compositions. The family contains three U.S. patents directed to seribantumab which expire in February&#160;2028 and a fourth U.S. patent which expires in October&#160;2029 (including 614&#160;days of Patent Term Adjustment), subject to any disclaimers or extensions. The family also contains a pending U.S. application, which if issued, would expire in February&#160;2028, subject to any disclaimers or extensions. In addition, the above-discussed patent family includes granted patents in China, Europe, Hong Kong, Israel, and Japan with claims directed to compositions of matter covering seribantumab and related methods of therapy. These patents expire in February&#160;2028, subject to any disclaimers or extensions. Depending upon the timing, duration and other factors relating to any FDA marketing approval we receive for our lead product candidate, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984, or the Hatch-Waxman Amendments. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we are prosecuting patents. In the United States, the Hatch-Waxman Amendments permit a patent term extension of up to five&#160;years beyond the normal expiration of the patent, limited to the approved indication (or any additional indications approved during the period of extension), as compensation for patent term lost to the regulatory review process during which the sponsor was unable to commercially market its new product. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval, only one patent applicable to an approved drug is eligible for the extension and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended, and the application for the extension must be submitted prior to the expiration of the patent. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available for our patents, may refuse to grant extensions to our patents, or may grant more limited extensions than we request. We may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">failing to satisfy applicable requirements. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our competitors and other third parties may be able to obtain approval of competing products following our patent expiration and take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case. Any of the foregoing would have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent offices, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on any issued patent are due to be paid to the USPTO and patent offices in foreign countries in several stages over the lifetime of the patent. The USPTO and patent offices in foreign countries require compliance with a number of procedural, documentary, fee payment and other requirements during the patent application process. In the future, we may rely on licensing partners to pay these fees due to U.S. and non-U.S. patent agencies and to comply with these other requirements with respect to any future licensed patents and patent applications. While an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of a patent or patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors and other third parties might be able to enter the market with similar or identical products of technology, which would have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our business would be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We rely on proprietary know-how and trade secret protection and confidentiality agreements to protect proprietary know-how or trade secrets that are not patentable or that we elect not to patent. We seek to protect our trade secrets and proprietary know-how in part by entering into non-disclosure and confidentiality agreements with parties who have access to such knowledge, such as our employees, consultants, independent contractors, advisors, CMOs, CROs, hospitals, independent treatment centers, suppliers, collaborators and other third parties. We also enter into confidentiality and invention or patent assignment agreements with employees and certain consultants. However, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary know-how. Additionally, our confidentiality agreements and other contractual protections may not be adequate to protect our intellectual property from unauthorized disclosure, third-party infringement or misappropriation. Any party with whom we have executed such an agreement may breach that agreement and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts in the United States and certain foreign jurisdictions are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent such third party, or those to whom they communicate such technology or information, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our business, financial condition, results of operations and prospects our business and competitive position could be materially harmed.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual property rights do not necessarily address all potential threats.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to make products similar to any product candidates we may develop or utilize similarly related technologies that are not covered by the claims of the patents that we may license or may own in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or any future license partners or current or future collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent application that we license or may own in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or any future license partners or current or future collaborators, might not have been the first to file patent applications covering certain of our or their inventions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing, misappropriating or otherwise violating any of our owned or licensed intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that our pending patent applications or those that we may own in the future will not lead to issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not develop additional proprietary technologies that are patentable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of others may harm our business; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may choose not to file a patent in order to maintain certain trade secrets or know how, and a third party may subsequently file a patent covering such intellectual property.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks related to our common stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The market price of our common stock is likely to be highly volatile, which could result in substantial losses for purchasers of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The market price of our common stock is likely to continue to be highly volatile and subject to wide fluctuations in response to various factors, some of which we cannot control. As a result of this volatility, investors may not be able to sell their common stock at or above the price initially paid for the stock. The market price for our common stock may be influenced by many factors, including the other risks described in this section of this Annual Report and the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enrollment or results of clinical trials of seribantumab or our future product candidates, or those of our competitors or our future collaborators, or changes in the development status of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory or legal developments in the United States and other countries, especially changes in laws or regulations applicable to seribantumab or any future product candidate;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of competitive products or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">introductions and announcements of new products by us, our future commercialization partners, or our competitors, and the timing of these introductions or announcements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actions taken by regulatory agencies with respect to our products, clinical studies, manufacturing process or sales and marketing terms;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated variations in our financial results or those of companies that are perceived to be similar to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of our efforts to acquire or in-license additional technologies, products or product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments concerning any future collaborations, including but not limited to those with development and commercialization partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market conditions in the biologics and biotechnology sectors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures or capital commitments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent protection for seribantumab or any future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability or inability to raise additional capital and the terms on which we raise it;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the recruitment or departure of key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the structure of healthcare payment systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common stock, other comparable companies or our industry generally;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our failure or the failure of our competitors to meet analysts&#8217; projections or guidance that we or our competitors may give to the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcement and expectation of additional financing efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">speculation in the press or investment community;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">share price and fluctuations of trading volume of our common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of our common stock by us, insiders or our stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the concentrated ownership of our common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in accounting principles;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">terrorist acts, acts of war or periods of widespread civil unrest;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">natural disasters and other calamities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic, industry and market conditions, or other events or factors, many of which are beyond our control, such as the COVID-19 pandemic.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, the stock market in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme price and volume fluctuations that have been often unrelated or disproportionate to the operating performance of the issuer. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other risks, including those described in this &#8220;Risk Factors&#8221; section, could have a dramatic and adverse impact on the market price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the past, securities class action litigation has often been brought against public companies following declines in the market price of their securities. This risk is especially relevant for biopharmaceutical companies, which have experienced significant stock price volatility in recent&#160;years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and our resources, which could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">A sale of a substantial number of shares of our common stock may cause the price of our common stock to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly. In connection with our initial public offering, each of our officers, directors and substantially all of our pre-initial public offering, or IPO stockholders entered into lock-up agreements with the underwriters that restricted their ability to sell or transfer their shares. These lock-up agreements expired on December 22, 2021. However, shares of our common stock held by our officers, directors and their affiliated entities will be subject to volume limitations under Rule 144 under the Securities Act. In addition, shares of our common stock that are subject to outstanding options will become eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements, the lock-up agreements and Rules 144 and 701 under the Securities Act. The holders of a significant portion of our outstanding common stock have rights, subject to some conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We cannot predict what effect, if any, sales of our shares in the public market or the availability of shares for sale will have on the market price of our common stock. However, future sales of substantial amounts of our common stock in the public market, including shares issued upon exercise of our outstanding options, or the perception that such sales may occur, could adversely affect the market price of our common stock, even if our business is doing well.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We also expect that significant additional capital may be needed in the future to continue our planned operations. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. To the extent that additional capital is raised through the sale and issuance of shares or other securities convertible into shares, our stockholders will be diluted. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our principal stockholders and management own a significant&#160;percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Based on the beneficial ownership of our common stock as of December 31, 2021, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially hold the majority of our outstanding voting stock. As a result, these stockholders, if acting together, have significant control over the outcome of corporate actions requiring stockholder approval, including the election of directors, amendment of our organizational documents, any merger, consolidation or sale of all or substantially all of our assets and any other significant corporate transaction. The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could delay or prevent a change of control of our company, even if such a change of control would benefit </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company or our assets and might affect the prevailing market price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; and we cannot be certain if the reduced reporting requirements applicable to &#8220;emerging growth companies&#8221; or &#8220;smaller reporting companies&#8221; will make our common stock less attractive to investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. For as long as we continue to be an &#8220;emerging growth company,&#8221; we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including (i)&#160;not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, (ii)&#160;reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and (iii)&#160;exemptions from the requirements of holding nonbinding advisory stockholder votes on executive compensation and stockholder approval of any golden parachute payments not approved previously. In addition, as an &#8220;emerging growth company,&#8221; we are only required to provide two&#160;years of audited financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We could be an &#8220;emerging growth company&#8221; until December&#160;31, 2026, although circumstances could cause us to lose that status earlier, including if we are deemed to be a &#8220;large accelerated filer,&#8221; which occurs when the market value of our common stock that is held by non-affiliates equals or exceeds $700 million as of the prior June&#160;30, or if we have total annual gross revenue of $1.07 billion or more during any fiscal&#160;year before that time, in which cases we would no longer be an &#8220;emerging growth company&#8221; as of the following December&#160;31, or if we issue more than $1.0 billion in non-convertible debt during any three-year period before that time, in which case we would no longer be an &#8220;emerging growth company&#8221; immediately. Even after we no longer qualify as an &#8220;emerging growth company,&#8221; we may still qualify as a &#8220;smaller reporting company,&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, if our revenues remain less than $100.0 million, and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the JOBS Act, &#8220;emerging growth companies&#8221; can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards. Until the date that we are no longer an &#8220;emerging growth company&#8221; or affirmatively and irrevocably opt out of the exemption provided by Section&#160;7(a)(2)(B)&#160;of the Securities Act, upon issuance of a new or revised accounting standard that applies to our financial statements and that has a different effective date for public and private companies, we will disclose the date on which adoption is required for non-emerging growth companies and the date on which we will adopt the recently issued accounting standard.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Anti-takeover provisions in our restated certificate of incorporation and bylaws and under Delaware law could prevent or delay an acquisition of us, which may be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management and, therefore, decrease the trading price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our restated certificate of incorporation and our amended and restated bylaws contain provisions that could delay or prevent a change in control of our company. These provisions could also make it difficult for stockholders to elect directors who are not nominated by current members of our board of directors or take other corporate actions, including effecting changes in our management. These provisions:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish a classified board of directors so that not all members of our board are elected at one time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">permit only the board of directors to establish the number of directors and fill vacancies on the board;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that directors may only be removed &#8220;for cause&#8221; and only with the approval of two-thirds of our stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require super-majority voting to amend some provisions in our amended and restated certificate of incorporation and amended and restated bylaws;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorize the issuance of &#8220;blank check&#8221; preferred stock that our board could use to implement a stockholder rights plan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eliminate the ability of our stockholders to call special meetings of stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prohibit cumulative voting; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, Section&#160;203 of the Delaware General Corporation Law, or DGCL, may discourage, delay or prevent a change in control of our company. Section&#160;203 imposes certain restrictions on mergers, business combinations and other transactions between us and holders of 15% or more of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any provision of our restated certificate of incorporation, amended and restated bylaws or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The exclusive forum provision in our organizational documents may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our restated certificate of incorporation, to the fullest extent permitted by law, provides that the Court of Chancery of the State of Delaware is the exclusive forum for: any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the DGCL, our restated certificate of incorporation, or our amended and restated bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. This exclusive forum provision does not apply to suits brought to enforce a duty or liability created by the Exchange Act. It could apply, however, to a suit that falls within one or more of the categories enumerated in the exclusive forum provision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This choice of forum provision may result in increased costs for investors to bring a claim. Further, this choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims. Alternatively, if a court were to find the choice of forum provisions contained in our restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all claims brought to enforce any duty or liability created by the Securities Act or the rules&#160;and regulations thereunder. Our amended and restated bylaws provide that the federal district courts of the United States of America, to the fullest extent permitted by law, shall be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, or a Federal Forum Provision. Our decision to adopt a Federal Forum Provision followed a decision by the Supreme Court of the State of Delaware holding that such provisions are facially valid under Delaware law. While there can be no </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">assurance that federal or state courts will follow the holding of the Delaware Supreme Court or determine that the Federal Forum Provision should be enforced in a particular case, application of the Federal Forum Provision means that suits brought by our stockholders to enforce any duty or liability created by the Securities Act must be brought in federal court and cannot be brought in state court.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Section&#160;27 of the Exchange Act creates exclusive federal jurisdiction over all claims brought to enforce any duty or liability created by the Exchange Act or the rules&#160;and regulations thereunder. In addition, neither the exclusive forum provision nor the Federal Forum Provision applies to suits brought to enforce any duty or liability created by the Exchange Act. Accordingly, actions by our stockholders to enforce any duty or liability created by the Exchange Act or the rules&#160;and regulations thereunder must be brought in federal court.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our stockholders will not be deemed to have waived our compliance with the federal securities laws and the regulations promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any person or entity purchasing or otherwise acquiring or holding any interest in any of our securities shall be deemed to have notice of and consented to our exclusive forum provisions, including the Federal Forum Provision. These provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum of their choosing for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. If a court were to find either exclusive-forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As a public company, we will incur significant legal, accounting, compliance and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Global Select Market and other applicable securities rules&#160;and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, we expect these rules&#160;and regulations to substantially increase our legal and financial compliance costs and to make some activities more time consuming and costly. For example, we expect that these rules&#160;and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain sufficient coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. The increased costs may require us to reduce costs in other areas of our business or increase the prices of our products once commercialized. Moreover, these rules&#160;and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are not currently required to comply with the SEC&#8217;s rules&#160;that implement Section&#160;404 of the Sarbanes-Oxley Act, and are therefore not required to make a formal assessment of the effectiveness of our internal control over financial reporting for that purpose. Pursuant to Section&#160;404, we will be required to furnish a report by our management on our internal control over financial reporting. However, while we remain an &#8220;emerging growth company,&#8221; we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. In addition, for as long as we are a smaller reporting company with less than $100 million in annual revenue, we would be exempt from the requirement to obtain an external audit on the effectiveness of internal control over financial reporting provided in Section&#160;404(b)&#160;of the Sarbanes-Oxley Act. To achieve compliance with Section&#160;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. This process will be time- consuming, costly and complicated. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section&#160;404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. In addition, if we are not able to continue to meet these requirements, we may not be able to remain listed on the Nasdaq Global Select Market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General risk factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If no or few securities or industry analysts commence or maintain coverage of us, the trading price for our common stock could be impacted negatively. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our preclinical studies and clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of such analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause a decline in our stock price or trading volume.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are subject to the periodic reporting requirements of the Exchange Act. We have designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules&#160;and forms of the SEC. However, any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system will be met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make required related party transaction disclosures. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected. In addition, we do not have a risk management program or processes or procedures for identifying and addressing risks to our business in other areas.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Failure to establish and maintain an effective system of internal controls could result in material misstatements of our financial statements or cause us to fail to meet our reporting obligations or fail to prevent fraud in which case, our stockholders could lose confidence in our financial reporting and the market price of our common stock could decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules&#160;and regulations of the Nasdaq Global Select Market. Under Section&#160;404 of the Sarbanes-Oxley Act, we will be required to furnish a report by our management on our internal control over financial reporting beginning with our second annual report on Form&#160;10-K. This assessment will need to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. However, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting until our first annual report required to be filed with the SEC following the date we are no longer an EGC. At such time as we are required to obtain auditor attestation, if we then have a material weakness, we would receive an adverse opinion regarding our internal control over financial reporting from our independent registered accounting firm. To achieve compliance with Section&#160;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, including through hiring additional financial and accounting personnel, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. During our evaluation of our internal control, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Furthermore, in connection with the future attestation process by our independent registered public accounting firm, we may encounter problems or delays in completing the implementation of any requested improvements and receiving a favorable attestation. If we cannot favorably assess the effectiveness of our internal control over financial reporting, or if our independent registered public accounting firm is unable to provide an unqualified attestation report on our internal controls, our stockholders could lose confidence in our reporting and the market price of our common stock could decline. In addition, we could be subject to sanctions or investigations by the Nasdaq Global Select Market, the SEC or other regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to securities litigation, which is expensive and could divert management attention.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The market price of our common stock may be volatile. The stock market in general, and pharmaceutical and biologics companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_172d49cd_a8db_4c51_95ff_d7538e949041"></a><a id="Item1BUnresolvedStaffComments_531438"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1B. Unresolved Staff Comments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a0fdad23_e4ce_40cd_8558_56c4896302dd"></a><a id="Item2Properties_617916"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;2. Properties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Not applicable.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7bf0075b_430f_44d2_9efa_8f648ea38008"></a><a id="Item3LegalProceedings_893927"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;3. Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At each reporting date, we evaluate whether or not a potential loss amount or a potential range of losses is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. We expense as incurred the costs related to such legal proceedings. We are not a part to any material legal matters or claims and did not have contingency reserves established for any litigation liabilities as of December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d32f36bf_cd0b_4a17_8a6a_17a4aa3746aa"></a><a id="Item4MineSafetyDisclosures_88552"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4. Mine Safety Disclosures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_5419d490_7c99_4498_b4a9_e0ed6df8eb2c"></a><a id="PARTII_234035"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">PART&#160;II</p><a id="Item5MarketforRegistrantsCommonEquity_45"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Market Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our common stock trades under the symbol &#8220;ELEV&#8221; on The Nasdaq Stock Market and has been publicly traded since June 25, 2021. Prior to this time, there was no public market for our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Holders of Our Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of February 28, 2022, there were approximately 17 holders of record of shares of our common stock. This number does not include stockholders for whom shares are held in &#8220;nominee&#8221; or &#8220;street&#8221; name.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Dividends</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available fund and any future earnings for use in the operation of our business and do not anticipate paying any dividends on our common stock in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition, operation results, capital requirements, general business conditions and other factors that our board of directors may deem relevant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Unregistered Sales of Equity Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of Proceeds from Public Offering of Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On June 29, 2021, we closed our initial public offering of common stock under a registration statement on Form S-1 (333-256787) that was declared effective by the Securities and Exchange Commission (the &#8220;SEC&#8221;) on June 25, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We received net proceeds of $91.1 million, after deducting underwriting discounts, commissions, and other expenses of $8.9 million. On July 19, 2021, in connection with our IPO, the underwriters exercised the right to purchase 403,407 shares of our common stock at a price of $16.00 per share for net proceeds of $6.0 million, after deduction underwriting discounts of $0.5 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There has been no material change in the planned use of proceeds from our IPO as described in the registration statement on Form S-1. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_3b3f44f4_405f_4ba6_8729_9eb7da6307f2"></a><a id="Item6SelectedFinancialData"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 6. [Reserved]</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ff552b77_e011_4b2f_987c_f1810d019d38"></a><a id="Item7ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes appearing elsewhere in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Annual Report, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are a precision oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Our vision is to elevate precision medicine to the forefront of every cancer treatment journey, as we believe that each patient living with cancer deserves the opportunity to benefit from a genomically-driven treatment decision. We utilize our deep expertise in developing drugs for rare, genomically defined patient populations and strategic collaborations with our diagnostic collaborators to work towards a future where each tumor&#8217;s unique genomic test result can be matched with a purpose-built precision medicine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are focused on identifying oncogenic drivers that are known to be predominantly mutually exclusive with other driver alterations, and pursuing innovations and efficiencies in the conduct of clinical trials that we believe may enable development of targeted therapeutics against those oncogenic drivers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our lead program is focused on NRG1 fusions, which are rare genomic alterations that have recently been identified as oncogenic driver alterations and that we believe have the potential to be therapeutically actionable through targeted HER3 inhibition. We have designed and initiated our potentially registration-enabling Phase&#160;2 CRESTONE trial to investigate the safety and efficacy of seribantumab, an anti-HER3 monoclonal antibody, in advanced solid tumors harboring an NRG1 fusion. We are conducting this trial in a tumor-agnostic fashion, such that any patient with a solid tumor that harbors an NRG1 fusion, regardless of the tissue of origin, may be eligible. We believe that the design and conduct of the CRESTONE trial has the possibility to produce results that may provide support for us to seek accelerated approval of seribantumab for patients with advanced solid tumors harboring an NRG1 fusion, subject to discussions with the FDA. Any accelerated marketing approval is subject to continued discussions with the FDA, and agreement on post-approval confirmatory trials to confirm an anticipated clinical benefit. If the CRESTONE trial meets its primary endpoint, and subject to continued discussions with the FDA, we anticipate submitting a BLA under an accelerated approval pathway for the treatment of patients with solid tumors harboring an NRG1 fusion. Even if the CRESTONE trial meets its primary endpoint, there can be no assurance that the FDA or other regulators will find such data sufficient to support a BLA submission or that additional trials will not be required. Further updates on the CRESTONE trial may be provided following additional information including, but not limited to, interactions with the FDA or other regulators, with whom we plan to discuss the interim clinical data and any resulting development pathways and opportunities. We expect to complete enrollment of the first 20 patients in Cohort 1 of the CRESTONE study in mid-2022, and to present initial clinical data from approximately 10 patients from Cohort 1 of the CRESTONE study treated with seribantumab at 3 grams weekly at a major medical meeting in mid-2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We were incorporated in April&#160;2019. We have devoted substantially all of our resources to developing our lead product candidate, initiating the CRESTONE clinical trial, building our intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. To date, we have financed our operations through private placements of convertible preferred stock and our IPO. On June 29, 2021, we closed our IPO and issued 6,250,000 shares of our common stock at a price of $16.00 per share, for net proceeds of $91.1 million, after deducting underwriting discounts, commissions, and other expenses of $8.9 million. In connection with the IPO, all shares of Series A and Series B convertible preferred stock outstanding automatically converted into 15,736,053 shares of common stock. On July 19, 2021, in connection with our IPO, the underwriters exercised the right to purchase 403,407 shares of our common stock at a price of $16.00 for net proceeds of $6.0 million. Prior to our IPO, we had received net proceeds of approximately $97.2 million from sales of our convertible preferred stock.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Since our inception, we have incurred significant operating losses on an aggregate basis. Our ability to generate product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more of our current or future product candidates. Our net losses were $32.0&#160;million and $17.3&#160;million for the years ended December&#160;31, 2021 and 2020, respectively. As of December&#160;31, 2021, we had an accumulated deficit of $55.2&#160;million. These losses have resulted primarily from costs incurred in connection with research and development activities, acquisition, patent investment, and general and administrative costs associated with our operations. We expect to continue to incur significant expenses and increasing operating losses for at least the next several&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our future capital requirements will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress, timing and results of preclinical studies and clinical trials for our current or any future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disruptions or delays in enrollment of our clinical trials due to the COVID-19 pandemic;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which we develop, in-license or acquire other pipeline product candidates or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and development requirements of other future product candidates that we may pursue, and other indications for our current product candidates that we may pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs, timing and outcome of obtaining regulatory approvals of our current or future product candidates and any companion diagnostics we may pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope and costs of making arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both clinical and commercial supplies of our current or future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in growing our organization to the size needed to allow for the research, development and potential commercialization of our current or future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with commercializing any approved product candidates, including establishing sales, marketing and distribution capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with completing any post-marketing studies or trials required by the Food and Drug Administration, or FDA, or other regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the revenue, if any, received from commercial sales of seribantumab, if approved, or any other future product candidates that receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims that we may become subject to, including any litigation costs and the outcome of such litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with potential product liability claims, including the costs associated with obtaining insurance against such claims and with defending against such claims; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to the extent we pursue strategic collaborations, including collaborations to commercialize seribantumab or to develop any future product candidates, our ability to establish and maintain collaborations on favorable terms, if at all, as well as the timing and amount of any milestone or royalty payments we are required to make or are eligible to receive under such collaborations, if any.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for seribantumab or our other future product candidates. If we obtain regulatory approval for any of our product candidates, we expect to incur significant expenses related to developing our internal </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">commercialization capability to support product sales, marketing and distribution. Further, upon the closing of this offering, we expect to incur additional costs associated with operating as a public company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As a result, we will need additional financing to support our continuing operations. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity or debt financings or other sources, which may include collaborations with third parties. Adequate additional financing may not be available to us on favorable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. If we are unable to raise capital or debt when needed or on favorable terms, we could be forced to delay, reduce or eliminate our research and development programs, our commercialization plans or other operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, we had cash and cash equivalents of $146.3&#160;million. We believe that our existing cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements into the second quarter of 2023. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8201;&#8212;&#8201;Liquidity and Capital Resources.&#8221; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impact of COVID-19</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The current COVID-19 pandemic has presented a substantial public health and economic challenge around the world and is affecting our employees, patients, communities and business operations, as well as contributing to significant volatility and negative pressure on the U.S. economy and in financial markets. The extent of the impact of COVID-19 on our operational and financial performance will continue to depend on certain developments, including the duration and spread of the outbreak, new variants, the vaccination and booster rate, impact on our clinical studies, employee or industry events, and effect on our suppliers and manufacturers, all of which are uncertain and cannot be predicted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">While we are currently continuing the clinical trials we have underway, COVID-19 precautions may directly or indirectly impact the timeline for some of our clinical trials. To date, we have been able to continue to enroll our patients in our Phase&#160;2 CRESTONE clinical trial and currently do not anticipate any interruptions of clinical enrollment. However, we are continuing to assess the potential impact of the COVID-19 pandemic on our current and future business and operations, including our expenses and clinical trials, as well as on our industry and the healthcare system.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including expenses, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Components of our Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our operating expenses since our inception have consisted solely of research and development costs and general and administrative costs. Research and development expenses consist primarily of costs incurred for our research activities, including the development of our product candidates, which include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">employee-related expenses, including salaries, related benefits, and stock-based compensation expense for employees engaged in research and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">external research and development expenses incurred in connection with the preclinical and clinical development of seribantumab, including expenses incurred under agreements with contract research organizations, and consultants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs incurred with contract manufacturing organizations that manufacture drug products for use in our preclinical studies and clinical trials of seribantumab;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fees paid to consultants for services directly related to our product development and regulatory efforts; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs related to compliance with regulatory requirements related to conducting our clinical activity.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development costs consist of salaries and benefits, including associated stock-based compensation, and fees paid to other entities that conduct certain research and development activities on our behalf. Research and development costs are expensed as incurred. We estimate preclinical study and clinical trial expenses based on the services performed pursuant to contracts with research institutions and contract research organizations, and clinical manufacturing organizations that conduct and manage preclinical studies and clinical trials on our behalf based on actual time and expenses incurred by them. Further, we accrue expenses related to clinical trials based on the level of patient activity according to the related agreement. We monitor patient enrollment levels and related activity to the extent reasonably possible and adjust estimates accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To date, all of our research and development expenses have been incurred to advance our lead product candidate, seribantumab. We expect that significant additional spending will be required to progress seribantumab through the remainder of its clinical development, as well as advance any future product candidate through clinical development. These expenses will primarily consist of expenses for the administration of clinical studies as well as manufacturing costs for clinical material supply. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The successful development and commercialization of seribantumab or our other future product candidates is highly uncertain. The success of seribantumab, or any other future product candidate will depend on several factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful completion of preclinical studies and clinical trials, including our CRESTONE trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of a BLA by the FDA, or other similar clinical trial applications from foreign regulatory authorities for seribantumab and our future clinical trials for our future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timely and successful enrollment of patients in, and completion of, clinical trials with favorable results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">demonstration of safety, efficacy and acceptable risk-benefit profiles of our product candidates, including our lead product candidate, seribantumab, to the satisfaction of the FDA and foreign regulatory agencies;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability, or that of our collaborators, to develop and obtain clearance or approval of companion diagnostics, on a timely basis, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt and related terms of marketing approvals from applicable regulatory authorities, including the completion of any required post-marketing studies or trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">raising additional funds necessary to complete clinical development of and commercialize our lead product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successfully identifying future acquisition, collaboration or in-license candidates to expand our product candidate pipeline;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining patent, trade secret and other intellectual property protection and regulatory exclusivity for our product candidates, including our lead product candidate, seribantumab;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">making arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both clinical and commercial supplies of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developing and implementing marketing and reimbursement strategies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of our products, if and when approved, by patients, the medical community and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectively competing with other therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining third-party payor coverage and adequate reimbursement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">protecting and enforcing our rights in our intellectual property portfolio; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining a continued acceptable safety profile of the products following approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Many of these factors are beyond our control, and it is possible that none of our product candidates, including our lead product candidate, seribantumab, will ever obtain regulatory approval even if we expend substantial time and resources seeking such approval. If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business. For example, our business could be substantially harmed if results of our ongoing CRESTONE clinical trial of seribantumab vary adversely from our expectations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive and administrative functions. General and administrative expenses also include legal fees relating to patent and corporate matters; professional fees for accounting, auditing, tax and consulting services; and insurance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We anticipate that our general and administrative expenses will increase in the future as we support our continued research activities and development of our product candidates. We also anticipate that our general and administrative expenses will increase as a result of increased payroll, expanded infrastructure and higher consulting, legal and tax-related services associated with maintaining compliance with stock exchange listing and SEC requirements, accounting and investor relations costs, and director and officer insurance premiums associated with being a public company. In addition, if we obtain regulatory approval for seribantumab, or any of our future product candidates, we expect to incur </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">significant expenses related to building a sales and marketing team to support product sales, and marketing and distribution activities, to the extent that such activities are not supported by one or more third-party collaborators.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Comparison of the years ended December&#160;31, 2021 and&#160;2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table summarizes our results of operations for the years ended December&#160;31, 2021 and 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:25.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 23,595</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,476</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,119</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,451</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,800</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,651</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 32,046</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17,276</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,770</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (32,046)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (17,276)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (14,770)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income (expenses), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (32,039)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (17,265)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (14,774)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;">Research and Development Expenses</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Seribantumab</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17,576</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,387</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,189</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">Unallocated and other research and development  expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,675</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,844</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 831</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unallocated personnel costs (including stock-based compensation)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,344</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,245</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,099</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total research and development expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 23,595</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,476</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,119</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:12pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Research and development expenses were $23.6 million for the year ended December 31, 2021, compared to $15.5 million for the year ended December 31, 2020. The increase of $8.1 million was primarily due to a $3.5 million increase in clinical trial expenses associated with the CRESTONE clinical trial, a $2.0 million increase in costs related to manufacturing clinical supply of seribantumab for use in the CRESTONE clinical trial, a $2.1 million increase in employee related costs, including stock-based compensation, and $0.5 million increase in other expenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses were $8.5&#160;million for the year ended December&#160;31, 2021, compared to $1.8&#160;million for the&#160;year ended December&#160;31, 2020. The increase of $6.7&#160;million was primarily due to an increase of $3.0&#160;million personnel costs, including stock-based compensation, $1.5 million in director and officer and other insurance, $1.3&#160;million of professional fees, and $0.9&#160;million of other expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Since our inception, we have not generated any revenue from product sales or any other sources and have incurred significant operating losses. We have not yet commercialized any products and we do not expect to generate revenue from sales of any product candidates for several&#160;years, if ever. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On June 29, 2021, we closed our IPO and issued 6,250,000 shares of our common stock for net proceeds of approximately $91.1 million. On July 19, 2021, in conjunction with our IPO, the underwriters exercised the right to purchase 403,407 shares of our common stock at a price of $16.00 per share for net proceeds of $6.0 million. &#160;Prior to our IPO, we had received net proceeds of approximately $97.2 million from the sale of our convertible preferred stock. As of December 31, 2021, we had cash and cash equivalents of $146.3 million. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table summarizes our sources and uses of cash for each of the periods presented:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Statement of cash flows data:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (30,167)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (12,298)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (71)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 97,051</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 90,029</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 66,884</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 77,660</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Operating Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2021, cash used in operating activities was $30.2&#160;million, which consisted primarily of our net loss of $32.0 million, partially offset by $1.6 million of stock-based compensation expense and $0.2&#160;million of cash used in changes in our operating assets and liabilities. Changes in our operating assets and liabilities consisted primarily of a decrease of $2.0 million in accrued expenses, due to the timing of payments related to research and development costs, partially offset by an increase of $1.7 million in prepaid expenses and other current assets, due to increased insurance due to operating as of public company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended December&#160;31, 2020, cash used in operating activities was $12.3&#160;million, which consisted primarily of our net loss of $17.3&#160;million, partially offset by $4.9&#160;million of cash provided by changes in our operating assets and liabilities. Changes in our operating assets and liabilities of $4.9&#160;million during the&#160;year ended December&#160;31, 2020, consisted of an increase of $6.2&#160;million in accounts payable and accrued expenses, partially offset by an increase of $1.3&#160;million of prepaid expenses and other assets. The increase in accounts payable and accrued expenses was largely due to the timing of payments related to research and development costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Investing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the year ended December&#160;31, 2021, there was no cash used in or provided by investing activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended December&#160;31, 2020 cash used in investing activities was $0.1&#160;million, and consisted of purchases of property and equipment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2021, cash provided by financing activities was $97.1 million, which consisted of net proceeds from the issuance of common stock upon the completion of our IPO. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended December&#160;31, 2020 cash provided by financing activities was $90.0&#160;million, which consisted primarily of net proceeds of $90.0&#160;million from the sale and issuance of our Series&#160;A and Series&#160;B convertible preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Funding Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials for seribantumab, and seek to develop, in-license or acquire additional product candidates. In addition, we expect to incur additional costs associated with operating as a public company. The timing and amount of our operating expenditures will depend largely on:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and progress of preclinical and clinical development activities;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful enrollment in and completion of clinical trials, including CRESTONE;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost to develop companion diagnostics as needed for each of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish agreements with third-party manufacturers for clinical supply for our clinical trials and, if any of our product candidates are approved, commercial manufacturing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">addition and retention of key research and development personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our efforts to enhance operational, financial and information management systems, and hire additional personnel, including personnel to support development of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we obtain marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the legal patent costs involved in prosecuting patent applications and enforcing patent claims and other intellectual property claims; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms and timing of any collaboration, license or other arrangement, including the terms and timing of any milestone payments thereunder.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We believe our cash and cash equivalents of $146.3 million as of December 31, 2021 will enable us to fund our operating expenses and capital expenditure requirements into the second quarter of 2023. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our future capital requirements will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress, timing and results of preclinical studies and clinical trials for our current or any future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disruptions or delays in enrollment of our clinical trials due to the COVID-19 pandemic;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which we develop, in-license or acquire other pipeline product candidates or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and development requirements of other future product candidates that we may pursue, and other indications for our current product candidates that we may pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs, timing and outcome of obtaining regulatory approvals of our current or future product candidates and any companion diagnostics we may pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope and costs of making arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both clinical and commercial supplies of our current or future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in growing our organization to the size needed to allow for the research, development and potential commercialization of our current or future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with commercializing any approved product candidates, including establishing sales, marketing and distribution capabilities;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with completing any post-marketing studies or trials required by the Food and Drug Administration, or FDA, or other regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the revenue, if any, received from commercial sales of seribantumab, if approved, or any other future product candidates that receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims that we may become subject to, including any litigation costs and the outcome of such litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with potential product liability claims, including the costs associated with obtaining insurance against such claims and with defending against such claims; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to the extent we pursue strategic collaborations, including collaborations to commercialize seribantumab or to develop any future product candidates, our ability to establish and maintain collaborations on favorable terms, if at all, as well as the timing and amount of any milestone or royalty payments we are required to make or are eligible to receive under such collaborations, if any.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for seribantumab or our other future product candidates. If we obtain regulatory approval for any of our product candidates, we expect to incur significant expenses related to developing our internal commercialization capability to support product sales, marketing and distribution. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity or debt financings or other sources, which may include collaborations with third parties. Adequate additional financing may not be available to us on favorable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. If we are unable to raise capital or debt when needed or on favorable terms, we could be forced to delay, reduce or eliminate our research and development programs, our commercialization plans or other operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Contractual Obligations and Commitments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We enter into contracts in the normal course of business with various third parties for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. These contracts do not contain any minimum purchase commitments and provide for termination upon notice. Payments due upon cancellation consist only of payments for services provided and expenses incurred up to the date of cancellation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2019, we entered into an asset purchase agreement with the previous sponsor, pursuant to which we acquired all rights and interest to patents, know-how, and inventory for assets related to seribantumab. If we are successful in developing and commercializing seribantumab, we may be obligated to pay the previous sponsor up to $54.5&#160;million in development, regulatory and sales milestone payments pursuant to the terms of the asset purchase agreement. Additionally, in conjunction with the asset purchase agreement with the previous sponsor, we assumed the rights and obligations under certain collaboration and license agreements which may require the payment of milestones and/or royalties on future sales of seribantumab. We are currently unable to estimate the timing or likelihood of achieving these milestones or generating future product sales. See &#8220;Business&#8201;&#8212;&#8201;Asset purchase, licensing and collaboration agreements&#8221; for additional information about these license agreements, including with respect to potential payments thereunder.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Policies and Significant Judgments and Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">While our significant accounting policies are described in more detail in the notes to our consolidated financial statements appearing at the end of this Annual Report, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs and Accruals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development costs consist of salaries and benefits, including associated stock-based compensation, and fees paid to other entities that conduct certain research and development activities on our behalf. Research and development costs are expensed as incurred. We estimate preclinical study and clinical trial expenses based on the services performed pursuant to contracts with research institutions and contract research organizations, and clinical manufacturing organizations that conduct and manage preclinical studies and clinical trials on our behalf based on actual time and expenses incurred by them. Further, we accrue expenses related to clinical trials based on the level of patient activity according to the related agreement. We monitor patient enrollment levels and related activity to the extent reasonably possible and adjusts estimates accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We account for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the services have been performed or when the goods have been received rather than when the payment is made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We measure stock-based compensation expense at the accounting measurement date based on the fair value of the award and recognize the expense on a straight-line basis over the requisite service period of the award, which is typically the vesting period. Compensation expense is measured using the fair value of the award at the grant date and is adjusted to reflect actual forfeitures as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We estimate the fair value of stock options using the Black-Scholes option pricing model that takes into account the fair value of our common stock, the exercise price, the expected term of the option, the expected volatility of our common stock, expected dividends on our common stock, and the risk-free interest rate over the expected life of the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected term&#160;&#8212;</i> We use the simplified method described in the Securities and Exchange Commission Staff Accounting Bulletin Topic 14.D.2 to calculate the expected term as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term for options granted to employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected volatility&#160;&#8212;</i> We estimate expected volatility based on the historical volatility of publicly traded peer companies and expect to continue to do so until such time as we have adequate historical data regarding the volatility of our traded stock price.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk-free interest rate&#160;&#8212;</i> The risk-free rate assumption is based on the U.S. Treasury yield curves whose terms are consistent with the expected term of the stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected dividend&#160;&#8212;</i> We have not issued any dividends and do not expect to issue dividends over the life of the options. As a result, we have estimated the dividend yield to be zero.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We classify stock-based compensation expense in our statement of operations in the same manner in which the award recipient&#8217;s payroll costs or service payments are classified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Determination of the Fair Value of Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Prior to the Company&#8217;s IPO in June 2021, the estimated fair value of our common stock was determined by our board of directors as of the date of each option grant. In order to determine the fair value of our common stock, our board of directors considered, among other things, the prices at which we sold convertible preferred stock and valuations of our common stock prepared by an unrelated third-party valuation firm, with input from management, in accordance with the guidance provided by the <i style="font-style:italic;">American Institute of Certified Public Accountants Practice Guide, Valuation of Privately Held-Company Equity Securities Issued as Compensation</i>. Given the absence of a public trading market for our common stock at the time, our board of directors exercised reasonable judgment and considered a number of objective and subjective factors to determine the best estimate of the fair value of our common stock, including (1)&#160;our stage of development and our business strategy; (2)&#160;the progress of our research and development programs; (3)&#160;the illiquid nature of our common stock; (4)&#160;the prices at which we sold convertible preferred stock and the superior rights and preferences of the convertible preferred stock relative to our common stock at the time of each grant; (5)&#160;external market conditions affecting the biotechnology industry, and trends within the biotechnology industry; (6)&#160;our financial position, including cash on hand, and our historical and forecasted performance and operating results; (7)&#160;the likelihood of achieving a liquidity event, such as an initial public offering, or IPO, or a sale of our company in light of prevailing market conditions; and (8)&#160;the analysis of IPOs and the market performance of similar companies in the biopharmaceutical industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As a public trading market for our common stock has been established, the fair value of our common stock is determined based on the quoted market price of our common stock. We classify stock-based compensation expense in our statement of operations in the same manner in which the award recipient&#8217;s payroll costs or service payments are classified.</p><a id="_08a514b4_0c69_410b_b9a1_b6221fff816d"></a><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">All of our cash and money market funds are held with a single financial institution. Due to its size, we believe this financial institution represents a minimal credit risk. Our money market funds are invested in high grade U.S. Treasuries with maturities of 90&#160;days or less. As a result, we believe our money market fund represents a minimal credit risk.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cc7a90fb_8777_4007_9ae9_7c0578c47624"></a><a id="Item8FinancialStatementsandSupplementalD"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;8. Consolidated Financial Statements and Supplementary Data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Index to Consolidated Financial Statements </b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.14%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:92.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:92.16%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Page</span></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:92.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Report"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (<ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:AuditorName" id="Narr_rCj4RaxrMkiA2-BVHg6tXQ">CohnReznick LLP</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:AuditorLocation" id="Narr_W4lJdwPBzUCCyGHa7lyQkg">Tysons, Virginia</ix:nonNumeric>, PCAOB <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="dei:AuditorFirmId" id="Narr__VZtWaqKg0iODX1Tg9QQ_g">596</ix:nonNumeric>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">104</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:92.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Balance_Sheet"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">105</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:92.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Consolidated_Statement_Of_Operations"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">106</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:92.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Consolidated_Statement_Of_Equity"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit</span></a>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">107</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:92.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Consolidated_Statement_Of_Cash_Flows"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">108</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b0c3c945_551c_4e38_bc8e_67ef17fdbc02"></a><a id="Report"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;">To the Board of Directors and Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 342pt 12pt 0pt;"><span style="letter-spacing:-0.05pt;">Elevation Oncology, Inc.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">Opinion </b>on<b style="font-weight:bold;letter-spacing:-0.1pt;"> </b>the Consolidated<b style="font-weight:bold;letter-spacing:-0.25pt;"> </b><b style="font-weight:bold;letter-spacing:-0.1pt;">Financial </b><b style="font-weight:bold;letter-spacing:-0.05pt;">Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.17;text-align:justify;margin:6pt 80.35pt 12pt 0pt;"><span style="letter-spacing:0.15pt;">We</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">have</span> <span style="letter-spacing:-0.1pt;">audited</span> <span style="letter-spacing:-0.05pt;">the</span> <span style="letter-spacing:-0.1pt;">accompanying</span> consolidated <span style="letter-spacing:-0.05pt;">balance</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">sheets</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">of</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.1pt;">Elevation Oncology, Inc. and Subsidiary</span> <span style="letter-spacing:-0.05pt;">(the</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">&#8220;Company&#8221;)</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">as</span> <span style="letter-spacing:-0.05pt;">of</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.1pt;">December</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.1pt;">31,</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.1pt;">2021</span> <span style="letter-spacing:-0.1pt;">and</span> <span style="letter-spacing:-0.1pt;">2020,</span> <span style="letter-spacing:-0.1pt;">and</span> <span style="letter-spacing:-0.05pt;">the</span> <span style="letter-spacing:-0.05pt;">related</span> consolidated <span style="letter-spacing:-0.1pt;">statements</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.2pt;">of</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.1pt;">operations,</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.05pt;">convertible preferred stock and stockholders&#8217; equity (deficit) </span><span style="letter-spacing:-0.1pt;">and</span> <span style="letter-spacing:-0.1pt;">cash</span> flows<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">for the years then ended,</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.1pt;">and</span> <span style="letter-spacing:-0.05pt;">the</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">related</span> <span style="letter-spacing:-0.05pt;">notes</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">(collectively</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">referred</span><span style="letter-spacing:-0.25pt;"> </span>to <span style="letter-spacing:-0.05pt;">as</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">the</span> <span style="letter-spacing:-0.1pt;">&#8220;financial</span><span style="letter-spacing:3.85pt;"> </span><span style="letter-spacing:-0.05pt;">statements&#8221;).</span><span style="letter-spacing:-0.1pt;"> </span>In <span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.1pt;">opinion, </span><span style="letter-spacing:-0.05pt;">the</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">financial</span> <span style="letter-spacing:-0.1pt;">statements</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">present</span><span style="letter-spacing:0.15pt;"> </span>fairly,<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">in</span> <span style="letter-spacing:-0.15pt;">all</span> <span style="letter-spacing:-0.05pt;">material</span> <span style="letter-spacing:-0.1pt;">respects, the financial position of the Company as of December 31, 2021 and 2020 and the results of their operations and their cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.05pt;">Basis</b> for<b style="font-weight:bold;letter-spacing:-0.25pt;"> </b><b style="font-weight:bold;letter-spacing:-0.1pt;">Opinion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.8pt 80.3pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">These</span> <span style="letter-spacing:-0.05pt;">financial</span><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:-0.1pt;">statements</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">are</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">the</span> <span style="letter-spacing:-0.05pt;">responsibility</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.2pt;">of</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.05pt;">the</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">Company&#8217;s</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">management.</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">Our</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">responsibility</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">is</span><span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:2.85pt;"> </span><span style="letter-spacing:-0.05pt;">express</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">an</span> <span style="letter-spacing:-0.05pt;">opinion</span> <span style="letter-spacing:-0.05pt;">on</span> <span style="letter-spacing:-0.05pt;">the</span> <span style="letter-spacing:-0.1pt;">Company&#8217;s</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">financial</span><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:-0.1pt;">statements</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">based</span> <span style="letter-spacing:-0.05pt;">on</span> <span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">audits.</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.15pt;">We</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">are</span> a <span style="letter-spacing:-0.05pt;">public</span><span style="letter-spacing:3.15pt;"> </span><span style="letter-spacing:-0.05pt;">accounting</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">firm</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">registered</span> <span style="letter-spacing:-0.05pt;">with</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">the</span> <span style="letter-spacing:-0.05pt;">Public</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">Company</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">Accounting</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">Oversight</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.05pt;">Board</span> <span style="letter-spacing:-0.05pt;">(United</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">States)</span><span style="letter-spacing:2.05pt;"> </span><span style="letter-spacing:-0.05pt;">(&#8220;PCAOB&#8221;)</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">and</span> <span style="letter-spacing:-0.05pt;">are</span> <span style="letter-spacing:-0.05pt;">required</span><span style="letter-spacing:-0.25pt;"> </span>to <span style="letter-spacing:-0.05pt;">be</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">independent</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.05pt;">with</span> <span style="letter-spacing:-0.1pt;">respect</span><span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">the</span> <span style="letter-spacing:-0.1pt;">Company</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">in</span> <span style="letter-spacing:-0.05pt;">accordance</span> <span style="letter-spacing:-0.05pt;">with</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">the</span> <span style="letter-spacing:-0.1pt;">U.S.</span><span style="letter-spacing:3.65pt;"> </span><span style="letter-spacing:-0.05pt;">federal</span><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:-0.05pt;">securities</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">laws</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">and</span> <span style="letter-spacing:-0.05pt;">the</span> <span style="letter-spacing:-0.05pt;">applicable</span> <span style="letter-spacing:-0.1pt;">rules</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">and</span> <span style="letter-spacing:-0.05pt;">regulations</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">of</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.05pt;">the</span> <span style="letter-spacing:-0.05pt;">Securities</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">and</span> <span style="letter-spacing:-0.1pt;">Exchange</span><span style="letter-spacing:3.15pt;"> </span><span style="letter-spacing:-0.05pt;">Commission</span> <span style="letter-spacing:-0.1pt;">and</span> <span style="letter-spacing:-0.05pt;">the</span> <span style="letter-spacing:-0.05pt;">PCAOB.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.17;text-align:justify;margin:0pt 80.3pt 12pt 0pt;"><span style="letter-spacing:0.15pt;">We</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">conducted</span> <span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">audits</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">in</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">accordance</span> <span style="letter-spacing:-0.05pt;">with</span> <span style="letter-spacing:-0.05pt;">the</span> <span style="letter-spacing:-0.15pt;">standards </span><span style="letter-spacing:-0.05pt;">of</span><span style="letter-spacing:0.4pt;"> </span><span style="letter-spacing:-0.05pt;">the</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">PCAOB</span><span style="letter-spacing:0.2pt;">. &#160;</span><span style="letter-spacing:-0.1pt;">Those</span> <span style="letter-spacing:-0.05pt;">standards</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">require</span> <span style="letter-spacing:-0.05pt;">that</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.2pt;">we</span><span style="letter-spacing:4.15pt;"> </span><span style="letter-spacing:-0.05pt;">plan</span> <span style="letter-spacing:-0.1pt;">and</span> <span style="letter-spacing:-0.1pt;">perform</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">the</span> <span style="letter-spacing:-0.1pt;">audit</span><span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">obtain</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">reasonable</span> <span style="letter-spacing:-0.05pt;">assurance</span> <span style="letter-spacing:-0.1pt;">about</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.1pt;">whether</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">the</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">financial</span> <span style="letter-spacing:-0.1pt;">statements</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">are</span><span style="letter-spacing:4.75pt;"> </span><span style="letter-spacing:-0.05pt;">free</span> <span style="letter-spacing:-0.2pt;">from</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.05pt;">material</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">misstatement,</span><span style="letter-spacing:-0.1pt;"> whether</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.1pt;">due</span> to <span style="letter-spacing:-0.05pt;">error</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">or</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">fraud.</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.05pt;">The</span> <span style="letter-spacing:-0.1pt;">Company</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">is</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">not</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.05pt;">required</span><span style="letter-spacing:-0.25pt;"> </span>to <span style="letter-spacing:-0.1pt;">have, nor</span><span style="letter-spacing:3.25pt;"> </span><span style="letter-spacing:-0.15pt;">were</span><span style="letter-spacing:0.25pt;"> </span><span style="letter-spacing:-0.15pt;">we</span> <span style="letter-spacing:-0.1pt;">engaged</span> to <span style="letter-spacing:-0.05pt;">perform,</span><span style="letter-spacing:-0.1pt;"> an </span><span style="letter-spacing:-0.05pt;">audit</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.2pt;">of</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:0.05pt;">its</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">internal</span> <span style="letter-spacing:-0.1pt;">control</span><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:-0.1pt;">over</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">financial</span><span style="letter-spacing:0.4pt;"> </span><span style="letter-spacing:-0.1pt;">reporting. </span>As<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">part</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.2pt;">of</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.1pt;">audits,</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.2pt;">we</span><span style="letter-spacing:4.85pt;"> </span><span style="letter-spacing:-0.05pt;">are</span> <span style="letter-spacing:-0.05pt;">required</span> to <span style="letter-spacing:-0.1pt;">obtain</span> <span style="letter-spacing:-0.05pt;">an</span> <span style="letter-spacing:-0.1pt;">understanding</span> <span style="letter-spacing:-0.2pt;">of</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.1pt;">internal</span><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:-0.15pt;">control</span><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:-0.1pt;">over</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">financial</span><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:-0.1pt;">reporting, but</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.1pt;">not</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">for</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">the</span> <span style="letter-spacing:-0.1pt;">purpose</span><span style="letter-spacing:5.65pt;"> </span><span style="letter-spacing:-0.05pt;">of</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.1pt;">expressing</span> <span style="letter-spacing:-0.05pt;">an</span> <span style="letter-spacing:-0.05pt;">opinion</span> <span style="letter-spacing:-0.05pt;">on</span> <span style="letter-spacing:-0.05pt;">the</span> <span style="letter-spacing:-0.1pt;">effectiveness</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">of</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.05pt;">the</span> <span style="letter-spacing:-0.1pt;">Company&#8217;s</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">internal</span><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:-0.1pt;">control</span><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:-0.1pt;">over</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">financial</span> <span style="letter-spacing:-0.05pt;">reporting.</span><span style="letter-spacing:4.85pt;"> </span><span style="letter-spacing:-0.05pt;">Accordingly,</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.2pt;">we</span> <span style="letter-spacing:-0.05pt;">express</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">no</span><span style="letter-spacing:0.25pt;"> </span><span style="letter-spacing:-0.1pt;">such</span> <span style="letter-spacing:-0.05pt;">opinion.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 78.6pt 12pt 0pt;"><span style="letter-spacing:-0.05pt;">Our</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">audits</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">included</span> <span style="letter-spacing:-0.05pt;">performing</span> <span style="letter-spacing:-0.1pt;">procedures</span><span style="letter-spacing:-0.15pt;"> </span>to <span style="letter-spacing:-0.1pt;">assess</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">the</span> <span style="letter-spacing:-0.05pt;">risks</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">of</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">material</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">misstatement</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.2pt;">of</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.05pt;">the financial</span><span style="letter-spacing:3.55pt;"> </span><span style="letter-spacing:-0.05pt;">statements,</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.1pt;">whether</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.1pt;">due</span> to <span style="letter-spacing:-0.05pt;">error</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">or</span><span style="letter-spacing:-0.4pt;"> </span>fraud,<span style="letter-spacing:-0.1pt;"> and</span><span style="letter-spacing:0.1pt;"> </span><span style="letter-spacing:-0.1pt;">performing</span> <span style="letter-spacing:-0.1pt;">procedures</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">that</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.1pt;">respond</span> to <span style="letter-spacing:-0.1pt;">those</span> <span style="letter-spacing:-0.1pt;">risks.</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.05pt;">Such</span><span style="letter-spacing:3.65pt;"> </span><span style="letter-spacing:-0.1pt;">procedures</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">included</span> <span style="letter-spacing:-0.05pt;">examining,</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.05pt;">on</span> a<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">test</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.1pt;">basis,</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.1pt;">evidence</span> <span style="letter-spacing:-0.05pt;">regarding</span> <span style="letter-spacing:-0.05pt;">the</span> <span style="letter-spacing:-0.1pt;">amounts</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">and</span> <span style="letter-spacing:-0.1pt;">disclosures</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">in</span> <span style="letter-spacing:-0.05pt;">the consolidated financial</span> <span style="letter-spacing:-0.1pt;">statements.</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.05pt;">Our</span><span style="letter-spacing:-0.15pt;"> </span>audits<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">also</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">included</span> <span style="letter-spacing:-0.1pt;">evaluating</span> <span style="letter-spacing:-0.05pt;">the</span> <span style="letter-spacing:-0.1pt;">accounting</span> <span style="letter-spacing:-0.05pt;">principles</span><span style="letter-spacing:-0.15pt;"> used</span> <span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:0.25pt;"> </span><span style="letter-spacing:-0.05pt;">significant</span><span style="letter-spacing:4.75pt;"> </span><span style="letter-spacing:-0.05pt;">estimates</span><span style="letter-spacing:-0.15pt;"> </span>made <span style="letter-spacing:-0.05pt;">by</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">management,</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.05pt;">as</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">well</span> <span style="letter-spacing:-0.05pt;">as</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">evaluating</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">the</span> <span style="letter-spacing:-0.1pt;">overall</span> <span style="letter-spacing:-0.05pt;">presentation</span> <span style="letter-spacing:-0.2pt;">of</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.05pt;">the</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">financial</span><span style="letter-spacing:2.45pt;"> </span><span style="letter-spacing:-0.05pt;">statements.</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.15pt;">We</span> <span style="letter-spacing:-0.05pt;">believe</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">that</span><span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.15pt;"> </span>audits<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">provide</span><span style="letter-spacing:-0.25pt;"> </span>a <span style="letter-spacing:-0.1pt;">reasonable</span> <span style="letter-spacing:-0.1pt;">basis</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">for </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">opinion.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.15pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><span style="letter-spacing:0.15pt;">/s/ CohnReznick LLP</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.15pt;">We</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">have</span> <span style="letter-spacing:-0.05pt;">served</span> <span style="letter-spacing:-0.05pt;">as</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">the</span> <span style="letter-spacing:-0.1pt;">Company&#8217;s</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">auditor</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">since</span><span style="letter-spacing:-0.1pt;"> 2020</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0.05pt 402.85pt 0pt 0pt;"><span style="letter-spacing:-0.1pt;">Tysons, Virginia</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0.05pt 402.85pt 12pt 0pt;"><span style="letter-spacing:-0.05pt;">March 2, 2022</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_234d687f_2b7a_4022_ba9b_302a54b22843"></a><a id="Balance_Sheet"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">ELEVATION ONCOLOGY,&#160;INC. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Consolidated Balance Sheets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">(in thousands, except share and per-share information)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_606828da_05d5_4983_bf25_7f32ef2401fa"></a><a id="Tc_HJMisg-kWEWV3tT-yON4AA_1_2"></a><a id="Tc_-uH_sUyJrE6R_psUPih3ug_2_2"></a><a id="Tc_AN-lD-tv00ymMRtnEPN1XQ_2_5"></a><a id="Tc_aTuSa0NIVEOiaC6XwVgbkg_3_0"></a><a id="Tc_wj81PJ1uT0uNrc2bRYKcqA_4_0"></a><a id="Tc_8p45k7JQ9EqZDPw0QbXHJQ_5_0"></a><a id="Tc_yDe0yGtkT0acJeXOG5EU_g_5_2"></a><a id="Tc_zrdY7RiPhk6M_RCKt5cZzQ_5_5"></a><a id="Tc_7B0rntm9EkW5AUaxRPVq4g_6_0"></a><a id="Tc_vl2GzOlPGEquc3WgjJUx3g_7_0"></a><a id="Tc_y0WXytl6J0e78p2MLNTxdg_8_0"></a><a id="Tc_An7z3y-oWU2hI6a2kXFV6Q_9_0"></a><a id="Tc_UEP-715k50WDdMrln0nrjw_10_0"></a><a id="Tc_-MMdNUX5sEGa_i2TZVe6nw_10_2"></a><a id="Tc_5As0J011YUGt2C0-bcSgIA_10_5"></a><a id="Tc_5XFZ0FNIQk-Tb5L3Wfk3Dg_11_0"></a><a id="Tc_C5dSCBdZ306RfzvQc5ZkVQ_12_0"></a><a id="Tc_craXH7G2zUSxHL15Kizc8A_13_0"></a><a id="Tc_tWxSEpDP10KUZNivFjRQsg_13_2"></a><a id="Tc_-Flwg7pCgEWlPxGjPIhdZA_13_5"></a><a id="Tc_pEvbyiAJrUugjsY_d1BB-w_14_0"></a><a id="Tc_OVPm8xBxdkiYp7n1cSXX3A_15_0"></a><a id="Tc_GSvx98gqEkOcFTka4uSNtA_16_0"></a><a id="Tc_lZy-Ejzr50mflAFUviBjpw_17_0"></a><a id="Tc_F3CXG6wEx06Wu2iX34j4Lw_18_0"></a><a id="Tc_sTDD34cv70Sn3KA73MODCA_19_0"></a><a id="Tc_aZpC1d-e6k-zljbFHdNyxw_20_0"></a><a id="Tc_Tc4gsvCmPUqOchHRF5HeUg_20_3"></a><a id="Tc_bDRmGNcaQ02ejzrlxI8BGA_21_0"></a><a id="Tc_nsjbGixhfEGPJOEvV0sEhg_21_3"></a><a id="Tc_8TT_8xl3AkGVVO5KGVb8bw_22_0"></a><a id="Tc_aMvEhhcfvEqQkoQqwJbNeQ_23_0"></a><a id="_24345c5c_d590_4c30_9c87_8b51bafb5353"></a><a id="_24345c5c_d590_4c30_9c87_8b51bafb5353_2"></a><a id="_24345c5c_d590_4c30_9c87_8b51bafb5353_3"></a><a id="Tc_A2eRJMBaHUW8KpvJD66iKA_24_0"></a><a id="Tc_Blhn6jrqgUKJbJEzAGGstQ_24_6"></a><a id="Tc_FkB23dXg0k2kp7FGoghR1A_25_0"></a><a id="Tc_Mea_hOlVKEe1bpgc9lS2aQ_26_0"></a><a id="Tc_buQRMoMQyEyJzlV4vILmZQ_27_0"></a><a id="Tc_QoxduiLMckq_PgWMQhkCvg_28_0"></a><a id="Tc_lCZEpIeWYkOdnCvzlPGWFg_28_2"></a><a id="Tc_cNfz97qopUiziPyN8l8vkQ_28_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_nG5z3mN37EyefMy5ZfQiAg_5_3">146,284</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_LJaTNmpyOU6gK1r_GPB0CA_5_6">79,400</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_YKLSgEGe8E2of040Vf1r-g_6_3">3,140</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_Myh9lWmf_0-Fya6ql2yzRA_6_6">1,386</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_YXcp02afzE6qoiLTtpa4kA_7_3">149,424</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_MlJcqhODukupFmjJz-YTEA_7_6">80,786</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_0SYgRvHM_kCxQrKXtnhg4A_8_3">38</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_JP7TSh5gTUy40NKbVuurFg_8_6">56</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_4Tx2SjWxsEeXeJUnOpw_Hw_9_3">32</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_EjSfjUuyyECLFuzju4wefQ_9_6">65</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_f09nQ7_0pEmLYbkyhrY8ng_10_3">149,494</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_iXTmKziVuUuiZ8IPMdPBxw_10_6">80,907</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities, Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_V639oK5jUEGiTiH8MUyadg_13_3">5,648</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_QNpoRnK3gUmtRfiJQRIcvg_13_6">5,679</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_0Kq_ulxgEkSyt7Ro-Ydk_Q_14_3">3,141</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_IFdLu2OdnUuCmQgA6TrN6w_14_6">1,106</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_CG9RzXMKYE2g6dDhQDf09g_15_3">8,789</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_Oc3qvXdiY0m9Tw_8vPzC2A_15_6">6,785</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted stock repurchase liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="elev:RestrictedStockRepurchaseLiability" scale="3" id="Tc_TRYBzT5MCkOGXBRzXnw7hw_17_3">8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="elev:RestrictedStockRepurchaseLiability" scale="3" id="Tc_cd4GmOB6eUWW-S5po0iCtw_17_6">15</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_ZUXHUlWNOEyviJu3K7HuLA_18_3">8,797</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_PICU933FPkKE3g4jFgd8Lg_18_6">6,800</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commitments and contingencies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Series A convertible preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_ufCfvphpqUaFsIu6eQ5ybg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_NwDcs_WRJUGG_fLhYSVqrQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_9Ab4mylPHU2468ViocO1Kw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_GmVz-xyAC0qi7KzdEKzJbg">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_9Ab4mylPHU2468ViocO1Kw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_Fq_sQamRqEaPY8V_RLNNyA">0</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_ufCfvphpqUaFsIu6eQ5ybg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_03JK3HwQ0ESsHoNgg_fpSw">32,450,000</ix:nonFraction> authorized, <span style="-sec-ix-hidden:Hidden_jYWxfVIF5k6FxM1xOsAXqg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_ku6MkFaccUqqx_e6Z90U5A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> as of <span style="-sec-ix-hidden:Hidden_ZzptvVV4KkGo2T3C4NAYcA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">December&#160;31,&#160;2021</span></span> and <span style="-sec-ix-hidden:Hidden_HJjRn8vxqEqc62bzyHayHw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2020</span></span>, respectively; aggregate liquidation preference of $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_9Ab4mylPHU2468ViocO1Kw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Narr_fXLx6eQ8s0edqQTgahobWw">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_ufCfvphpqUaFsIu6eQ5ybg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Narr_47EgtFN5jkKYehPCwG3HCA">32,450</ix:nonFraction> as of December&#160;31,&#160;2021 and 2020, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_ufCfvphpqUaFsIu6eQ5ybg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_yg-eevbPu0KrJJVHOzYzjw_20_6">32,373</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Series B convertible preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_n1P4tSrvdk-YvWRGsiNyRQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_LvnW26OOlkilG4_atU9L2Q"><ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_Nqt-0QbioUOT_-2LYCnQeA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_PiT9Zht4c0Wt7VIiSmisAg">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_Nqt-0QbioUOT_-2LYCnQeA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_YadOFy0h70KkItKARcIWqw">0</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_n1P4tSrvdk-YvWRGsiNyRQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_fqoWWFvUnEqUyHgUj7sp7g">34,043,889</ix:nonFraction> authorized, <span style="-sec-ix-hidden:Hidden_MhBVK9CA4ECtG86DjvMagA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_n2xdQHC12k-aBNJhOd4IKQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> as of <span style="-sec-ix-hidden:Hidden_qssCogmpFkSc9bE3w614Fw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">December&#160;31,&#160;2021</span></span> and <span style="-sec-ix-hidden:Hidden_srDnmenbtUiFZLni5r2PKw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2020</span></span>, respectively; aggregate liquidation preference of $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_Nqt-0QbioUOT_-2LYCnQeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Narr_xjE9gkIOyEq6rjZlmZVt8Q">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_n1P4tSrvdk-YvWRGsiNyRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Narr_MmAlySQ0cEmL_s5D5JAgtg">65,000</ix:nonFraction> as of December&#160;31,&#160;2021 and 2020, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_n1P4tSrvdk-YvWRGsiNyRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_Jzwv04WVHE285xg1dogvzg_21_6">64,815</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity (deficit):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_Cniyh7uXU0qYOSQx2bNUgg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_8bHodJkgcE-FwpiKboBZJQ">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_1yGerr0iGUmTaij6uEYVAA"><ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_lkSJB1-WnEe-vN1HSQBOyw">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of December&#160;31,&#160;2021; <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_BZ83hEzkgUijA5-hePLQ1w"><ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_ATMDzk3mpUW7Sp54Mm-6bw">no</ix:nonFraction></ix:nonFraction> shares issued or outstanding as of December&#160;31,&#160;2021 and 2020, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_IihsC53kEkWt42Ha6e4idQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_gbc1ZDXcAEe99kedebE1CQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_KN-9J-vEoUyh1bHqlRztUA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_0Cs-feBSsEalpNgRVISd1w">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_EMxcWQJH90yfge4m_JlbEw">500,000,000</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_TNBRyo5tcUKytNRqY5z7fA">86,000,000</ix:nonFraction> shares authorized as of December&#160;31,&#160;2021 and 2020, respectively; <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_KWaVoSuoQUuyie8dFHYneg">23,225,637</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_QRQ16rMtl0-140XAiSC4vw">836,177</ix:nonFraction> issued as of December&#160;31,&#160;2021 and 2020, respectively; <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_Mf9bAnvK0kyZDWwgntuwrA">23,205,915</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_e_R_MdnT3UO95ekLQYQRfw">800,679</ix:nonFraction> outstanding as of December&#160;31,&#160;2021 and 2020, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_ORvR4ZJqJkaMnsXnMJWu_Q_24_3">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_EjylD-OB5EmJZK_c6wn1CQ_25_3">195,881</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_WKXnxfdWEU2eAu7orCMWtw_25_6">66</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_xCrlj9nvgE61F2AAgLxRFA_26_3">55,186</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_6eREsNq43keDfL3MXQ3n3Q_26_6">23,147</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total stockholders&#8217; equity (deficit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_siA-qpOgOUCDuNtvwsJRAw_27_3">140,697</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_2F64kR6urUSH6YP69SuMJw_27_6">23,081</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_rHeHt3rXCEaX2Hsk9h-zvg_28_3">149,494</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_DMnd0JJ0XU-E-HQuU-wSTg_28_6">80,907</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">See accompanying notes to the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0cbc4517_cbd1_480c_9a26_c37d7a83279c"></a><a id="Consolidated_Statement_Of_Operations"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">ELEVATION ONCOLOGY,&#160;INC. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Consolidated Statements of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">(in thousands, except share and per-share information)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2e3e3ae2_8479_4b13_a4ca_7983845e893c"></a><a id="Tc_GZ17v6MOHUufHKgBWQ3wLA_1_2"></a><a id="Tc_FSYs-ybdZEKy_cbLBe-ctw_2_2"></a><a id="Tc__v_Zmq9r8U2NxiSEhIbQRQ_2_5"></a><a id="Tc_IsbhlOALsES9piw7OFS39g_3_0"></a><a id="Tc_2MriPEqd0kaHiQlbhblaBQ_4_0"></a><a id="Tc_RdiYceTgzkupShZFKHXRyg_4_2"></a><a id="Tc_1R5Q---O50m8FEM-l55fhw_4_5"></a><a id="Tc_N0QjD0T3oUyCzkK7rQ0YYg_5_0"></a><a id="Tc_hwmI0kVD2kKMHXEu1hab_g_6_0"></a><a id="Tc_KzO0CAgVYUuI9dyDnJ8R0Q_7_0"></a><a id="Tc_QdzaFoR6okaqVm2JjOzsOg_8_0"></a><a id="Tc_Hn3xWIK020upMgdU2-RiQQ_9_0"></a><a id="Tc_hlE8J4Zhn0y-303XxwytYw_9_2"></a><a id="Tc_UsngLSrvqkOKeShpau1rMA_9_5"></a><a id="Tc_LysfCZrr30G0OJxm44iwSA_10_0"></a><a id="Tc_ZAw6HPZOLkCI4EFGyaOurw_11_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_uXqcQl_Ktkq5ch6_XDOomA_4_3">23,595</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_VktptJyVs0O7Ng34HAewBQ_4_6">15,476</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_E8a3fi2PH0yLGUFRHeLcIQ_5_3">8,451</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_HJiTsoGmEkycA4qM0iFPWQ_5_6">1,800</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_m7FLW1d9I0O3WFP6-UFlGQ_6_3">32,046</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_bX5ZVQ9qOU6hB6jG7WfHyA_6_6">17,276</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_UKagIP6ZakiZubLCTVqzYg_7_3">32,046</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_mxei62BZM0yxMKIGfVOnUQ_7_6">17,276</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income (expenses), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_3XfjQTBv5U2O8T7uMDJZMw_8_3">7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_0OIcy9CMO0mA9DSJLXW6sA_8_6">11</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_d3xNlPGXwUOIxSC9Z3wnxw_9_3">32,039</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_WsXbQw0QBEeF3fiqgnpUlw_9_6">17,265</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_lgQGmvAd0kSfoX9eaEYLrw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_myexe0Bt1kK-l4HXd7ylZg_10_3">2.64</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_qV_WDEPC70Od3Xq9E6kzvw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_nGm09ovQDkuM-DzgIQXOpQ_10_6">21.80</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_OrMEB2VTxUGrtl3RHkWMVg_11_3">12,132,610</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_KOT3tYEIsUqzGSzjvOjKuw_11_6">791,821</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">See accompanying notes to the consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-style:italic;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:8%;padding-right:8%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_59481dc5_3284_414e_a17e_7dd9f1d21ca6"></a><a id="Consolidated_Statement_Of_Equity"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">ELEVATION ONCOLOGY,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">(in thousands, except share information)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_56933618_3e86_45c8_9ea3_e11c211e2b69"></a><a id="Tc_bHNVSuL9W06VQPbawHTQmQ_1_2"></a><a id="Tc_jwi4jlLpFEOzwQVTkoiP0Q_1_7"></a><a id="Tc_fA1jqnKDA0Wqab2lp98qjw_1_23"></a><a id="Tc_t0C0n8eGf0iLHQsyKDC-iw_2_2"></a><a id="Tc_SVNnlDWwpkqsf-I8RG6gvg_2_7"></a><a id="Tc_Ch97gzTYd0qkxI0v0QDB1Q_2_12"></a><a id="Tc_qLn7Kf3Qi0GrKs2u-Ail5g_2_17"></a><a id="Tc_V8rpsycBpEGh7_QXdeR3Mw_2_20"></a><a id="Tc_MV2Xwk_Z70u6_zRmldNlXg_2_23"></a><a id="Tc_J6spikysF0iEMFw45bp1MQ_3_2"></a><a id="Tc_KgewJlyjzkKtn9BjWWPhFQ_3_4"></a><a id="Tc_VY8e91DHvEKtC5JgFClHRA_3_7"></a><a id="Tc_C9FlXmKHS0uLHruKz3TZDw_3_9"></a><a id="Tc_boifxtATbUW7Y6GghXOakg_3_12"></a><a id="Tc_5XdMaYHCHEqkPkkxNf5RjQ_3_14"></a><a id="Tc_fM_jBcdGgUqz61g7W3Medg_3_17"></a><a id="Tc_S6A11Crtb0yLRv47_WKmhA_3_20"></a><a id="Tc_bH--GHTxaUSmldIcM66jGw_3_23"></a><a id="Tc_sHPTlmDcaE6xDe30WYFV3A_4_0"></a><a id="Tc_pskiZ5vHBUq34RQcIRYFAQ_4_4"></a><a id="Tc_z-lKllg-KkSiQNppYKYSwA_4_7"></a><a id="Tc_Z3TkQtknykOJKqgsKFdAWQ_4_9"></a><a id="Tc_N3B5vZaZe0a-RQH_dtnUfA_4_10"></a><a id="Tc_abMWIVTZ7kqW2Rubn6q-eg_4_14"></a><a id="Tc_rNEuf0-cbkqzQyljPEMjYA_4_15"></a><a id="Tc__GQQWA3HCEac9N_rxhvUPw_4_17"></a><a id="Tc_Aznxhl5aVUG-bp6JrR11aQ_4_20"></a><a id="Tc_4-TUZ0cxikKYIL6Qcmk7XA_4_23"></a><a id="Tc_4ppOXmf3RU6yTC5VZfbr3A_5_0"></a><a id="Tc_laRAKFsZRUSUjKR7tk_oIA_5_7"></a><a id="Tc_ZBpNf_SXDkyj1dcRkpUq-g_5_10"></a><a id="Tc_nnbFh1BfGUuGrtORXBPgDw_5_12"></a><a id="Tc_phIG9iCvH06tB1YAq7hHfA_5_15"></a><a id="Tc__VVBux8TfE2CoKN4rRAKQA_5_18"></a><a id="Tc_BgJEv3mEA0iNGUUG3O3qVA_5_21"></a><a id="Tc_V4FEAOViGk-g0fjT7s0Q0g_5_24"></a><a id="Tc_knExd60KK0-l_MtLYAjJwA_6_0"></a><a id="Tc_QLGaZgni5UKiLRkWULg0kg_6_2"></a><a id="Tc_V0e8y9IHl02XOvIyWUAnaA_6_5"></a><a id="Tc_LK9iM-k-DkWVbcC9mxAPRA_6_12"></a><a id="Tc_ry_OoVqa2UGCUlSAXzyBVg_6_15"></a><a id="Tc_b87czkN8YU-Hav6ONFCtgQ_6_18"></a><a id="Tc_tjq5JS0RDEGKSYM6yrde3w_6_21"></a><a id="Tc_Smt2xXp-L0CpZqJwFXhSnQ_6_24"></a><a id="Tc_9qreK_P8cEKvpL6ENG34tg_7_0"></a><a id="Tc_zxqC_E7RUESGa4kJajkqhA_7_2"></a><a id="Tc_JLhrw4bGJkqNWJgrdaZ7Lg_7_5"></a><a id="Tc_ggzwsHQjYk6FiLcDURVlCg_7_7"></a><a id="Tc_eKPwCjp0i0OaeQ1vW4K-0g_7_10"></a><a id="Tc_ySE6yBHjZ0WzVFA7V9es_g_7_12"></a><a id="Tc_p86XdL7SukC4fMdLVPdUAA_7_15"></a><a id="Tc_5vne3ytsO0uO9NZATlUbUA_7_21"></a><a id="Tc_B2X_hm37f0OGno16_kl8yQ_8_0"></a><a id="Tc_RGXxs52SyUiHuSVAz-zQlQ_8_2"></a><a id="Tc_xk2qBRLVzkiN6gt9SKEDGw_8_5"></a><a id="Tc_vV3VHDN8TEyY4FczdB23Ww_8_7"></a><a id="Tc_HkxCf3lCqkKuVFEuEfUaDA_8_10"></a><a id="Tc_0kDVEURJukC7f4rXEgIB1g_8_15"></a><a id="Tc_GmOpAmcsLUaaJY5WYTIpdA_8_21"></a><a id="Tc_SaHv9wCLtk6OCiWsMjIoug_9_0"></a><a id="Tc_zwm_IGJ96UupQXBUI7Xjeg_9_2"></a><a id="Tc_NcWne4l1HUuTN1EcBFKjUA_9_5"></a><a id="Tc_bdYPtWd_40STZMkcLqkHBA_9_7"></a><a id="Tc_gt4RvSVXVUS-Pb3Rn-MYkg_9_10"></a><a id="Tc_-HNn79RB0kCLfq-Bui5MSg_9_12"></a><a id="Tc_WPLqm0mY5kGCVmUZowWTUw_9_15"></a><a id="Tc_U8KY6pO8UEabB33LcVhlLg_9_18"></a><a id="Tc_OclX3lmz3U28C1x4aI3x8Q_10_0"></a><a id="Tc_6YUVhft9Jke1V7KIrnKqJw_10_4"></a><a id="Tc_SkmrJ2uF70CHdC5-8YLhBw_10_9"></a><a id="Tc_qiXh7EpRqkOeP5UmI5EEOg_10_14"></a><a id="Tc_uiwvmlWmRUSdiRvj_DqNiA_10_15"></a><a id="Tc_8LMDDYYj8kSDplW5fLjdBQ_10_17"></a><a id="Tc_bK0IU9KY20KUyUAd4XljJA_10_20"></a><a id="Tc_v_NKsFYHSEC2QV9IpbBNmQ_10_23"></a><a id="Tc_9oc26_xYREijOD0_D79Zqw_11_0"></a><a id="Tc_KUVp1yf6M0S7EwXz7cMl_w_11_2"></a><a id="Tc_CphRRB4ct0SQeUdVmBbhQA_11_5"></a><a id="Tc_JiHVgPRwrUaqX0sMlSwpfA_11_7"></a><a id="Tc_ja_EoZKUK0OeDX_shdQ2cQ_11_10"></a><a id="Tc_VHALlSLs90qkH53V9VTxgw_11_15"></a><a id="Tc_uU-T8Xn6p0aLmw_1yclDaA_11_21"></a><a id="Tc_f9pUotkuK0ukN22n2wa-ZA_12_0"></a><a id="Tc_fgF7VmKvJEimr19tBk7x_A_12_2"></a><a id="Tc_7uXXFkQ32E-OaamjWJ6xHg_12_5"></a><a id="Tc_73Yufrhc3EqLWnUGXMwpew_12_7"></a><a id="Tc_TxMb_49fP021LaFKHKJFRA_12_10"></a><a id="Tc_poxHCTmxnU29oO0zyDP5Yw_12_12"></a><a id="Tc_iJvSHlsKyUanBxHHcSD4ng_12_15"></a><a id="Tc_ly253g8c4kSalq6vll9bmQ_12_21"></a><a id="Tc_EoMZCXoYvEeA9nEy_y6EDw_13_0"></a><a id="Tc_pYsLRBwF9Uya2uCnJeFQhA_13_21"></a><a id="Tc_EVaF4p6A2Emk07C92h-y2A_14_0"></a><a id="Tc_6EPm4miyiUKLtsfzeEcbxg_14_2"></a><a id="Tc_-Is9thvncUC780C-CVML1A_14_5"></a><a id="Tc_b--2lyAhUUWDKAcf82WrRg_14_7"></a><a id="Tc_WTAAq6pTUkKZVCr6IuEpwg_14_10"></a><a id="Tc_clY8jmJKmUm-3b2iuZg5ag_14_12"></a><a id="Tc_ouqsCP3DP0CQbGVwJQoPzA_14_15"></a><a id="Tc_MSY_MXyZc0G2E5ncoz8tZw_14_18"></a><a id="Tc_VdMtU0jDckGrbIpb0yHOew_15_0"></a><a id="Tc_LPciWBMLXkOJXv3E_nEbKQ_15_2"></a><a id="Tc_07IbyWqYXUmqwUfO_R68tg_15_4"></a><a id="Tc_85GC_bujyU60hHJTbVQ_Sw_15_5"></a><a id="Tc_uMajVBumUkmqn6dHqxaQmQ_15_7"></a><a id="Tc_ovk-BdosTUKy9B0fCOswXQ_15_9"></a><a id="Tc_87DMfEa63k-tp5dHkAf71w_15_10"></a><a id="Tc_f6WEr0j65EqOeEVFB07MqA_15_14"></a><a id="Tc_4RMaS-kcZUW84w1Pg-Zzkw_15_17"></a><a id="Tc_pxk2QXs04kWZ97KMVTD46g_15_20"></a><a id="Tc_LRwJilIFukKiEd1znlC0zQ_15_23"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:25.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series&#160;A&#160;Convertible</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.65%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series&#160;B&#160;Convertible&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:25.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.65%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:25.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.3%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:4.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-in&#160;Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity (Deficit)</b></p></td></tr><tr><td style="vertical-align:bottom;width:25.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_JVADeYQhFU6aWETRRcQX9A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_6lO1mqiy50-zbvF0d71pLg_4_2">7,266,750</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_JVADeYQhFU6aWETRRcQX9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_gDw499TFAUq9Orjhk5AArw_4_5">7,190</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A0J2TcXim0O2TZxlcLKsxQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_d1MPjqJAGkGvsrnDklz2jw_4_12">788,847</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__MZL6V0mP0KADzeRWa2ESA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_vfdnvPeFjUai3IR8POGuLw_4_18">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WHl4WL9Hy0eii7jK-CXu0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_N60p0sWl_EqyXgXBDM4V-w_4_21">5,882</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2019_K5uh10LQgki3KgNzawcwuw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_CHbhbLHZ6USyB_OrYTsABA_4_24">5,873</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:25.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of Series A convertible preferred stock, net of issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_VfF2WbD_yE25ScPehNSjmg" decimals="-3" format="ixt:numdotdecimal" name="elev:TemporaryEquityStockIssuanceCosts" scale="3" id="Narr_8zfAUOBm0EmTrLKifbg1pg">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_VfF2WbD_yE25ScPehNSjmg" decimals="INF" format="ixt:numdotdecimal" name="elev:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_tygl-G67wUCJ5d6_XVhagw_5_2">25,183,250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_VfF2WbD_yE25ScPehNSjmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_GmguQdGQr0KG7KH-qvq3xQ_5_5">25,183</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:25.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of Series B convertible preferred stock, net of issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_aX2mfIiaaEaEvfSZZi_QiA" decimals="-3" format="ixt:numdotdecimal" name="elev:TemporaryEquityStockIssuanceCosts" scale="3" id="Narr_cA17ntlhvkaVMPX0Bjm6Ew">185</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_aX2mfIiaaEaEvfSZZi_QiA" decimals="INF" format="ixt:numdotdecimal" name="elev:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_uqsGBLXdIUut8kD8wyeLdA_6_7">34,043,889</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_aX2mfIiaaEaEvfSZZi_QiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_2UgGKDZoIUSxoNe0UfbAIA_6_10">64,815</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:25.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TK-bm7aGUEm31cUm-csY2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_fLVXetBDUkOVlyfHcTFluw_7_18">52</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_zZ8RSRzH7U67IoixyduqXQ_7_24">52</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vesting of restricted common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gO4tR77IjkWsJVcz9PCcFw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Tc_1BubEq7Rk0OjaleQsIZtKQ_8_12">11,832</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TK-bm7aGUEm31cUm-csY2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="Tc_ASvIKCGB20Wv65_vMcLAVQ_8_18">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="Tc__zqi46g8d0uOzrWWfJa1kw_8_24">5</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_U4BEo4pY0EeqeBvZSRXIWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_vgJwj7otAEC1PIx77MeqTw_9_21">17,265</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_90r2_AgQd0ClG8yWctsoVA_9_24">17,265</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:25.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_ufCfvphpqUaFsIu6eQ5ybg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_vACIzXihv02WLHHwa1j7VQ_10_2">32,450,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_ufCfvphpqUaFsIu6eQ5ybg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_tgxsDRjYkkm3VULEllMlfw_10_5">32,373</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_n1P4tSrvdk-YvWRGsiNyRQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_v_1rlEcuREGgasBqX9FI-Q_10_7">34,043,889</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_n1P4tSrvdk-YvWRGsiNyRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_3q8v6Tnxzku9jdUYNWnxdg_10_10">64,815</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_M2mN9gE5X0GijbROI6P7SQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_4-lZuMzspUG449umlqVYbA_10_12">800,679</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DkD0JhHZk0y1iDRPpYA5Ew" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_J9r5L83W0kSlFgM6pTb2dA_10_18">66</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0kC6nscYCki9dpypch09Sg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_ipczM0mTt06TCJ5wfse11Q_10_21">23,147</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Pk1O57aKXUy68Wirx8Jghw_10_24">23,081</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:25.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vesting of restricted common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kfgfNyUS-k-q6vIaH3KKEQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Tc_CRjFHq7370aKKMEwFacHoA_11_12">15,776</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T74WweuKoEO37FYC4NVKJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="Tc_b1J1DGnq-UeN2v_5E01vDQ_11_18">7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="Tc_gQGyf7i6Z0ORmD2CAe8CRg_11_24">7</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T74WweuKoEO37FYC4NVKJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_umdxOVsJnE67gH-25LDrDw_12_18">1,571</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_eGJzP8ASA0eYxCPDhxlbag_12_24">1,571</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of initial public offering common stock, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_FwKWSVbO8EC5cGAemvMKBw" decimals="INF" format="ixt:numdotdecimal" name="elev:TemporaryEquityEliminationOfSharesAsPartOfInitialPublicOffering" scale="0" id="Tc_6oVQ9aDqr0W_FPq9pNdfjg_13_2">32,450,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_FwKWSVbO8EC5cGAemvMKBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityEliminationAsPartofReorganization" scale="3" id="Tc_77insxl0Z0ypDDtfQ0bZQA_13_5">32,373</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_8x_tfsc7QkmeVVMEESIfJw" decimals="INF" format="ixt:numdotdecimal" name="elev:TemporaryEquityEliminationOfSharesAsPartOfInitialPublicOffering" scale="0" id="Tc_XHK9xPUOZk6zdXZw6swoHg_13_7">34,043,889</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_8x_tfsc7QkmeVVMEESIfJw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityEliminationAsPartofReorganization" scale="3" id="Tc_9DJR1gYcTEyJ16Sj80ppsg_13_10">64,815</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kfgfNyUS-k-q6vIaH3KKEQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_xllsC-6rYE6-vgMd8ohZdw_13_12">22,389,460</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kfgfNyUS-k-q6vIaH3KKEQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_abxdcySv70uxn_-8dTjR3g_13_15">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T74WweuKoEO37FYC4NVKJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_JLflK-2EC0WAsApWbvv7ng_13_18">194,237</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_dhyTbM3vvkuO-i7P_ZjaYQ_13_24">194,239</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ArLc6smPckCMtFZLqiXo_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_-yXByw31FEq84al1sINcyA_14_21">32,039</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_3mqyw2HjRU-FvKGk80fcqw_14_24">32,039</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:25.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;border-bottom:3px double #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_a4fg8WCqfESmafv_THdDEw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_1thh4ids4UWBcJ78SvVfxw_15_12">23,205,915</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_a4fg8WCqfESmafv_THdDEw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_n-rsxXuCPE6d7U26KBXSaQ_15_15">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pt55LruBbU6mC55DMIg-jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_RpScpYrZs0yrlnf4SDD9MQ_15_18">195,881</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_cyhJnqE1F0KJ0iWv1_oxBQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_twD8cWqZlE221352-ObPVQ_15_21">55,186</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_rqoqjGFqq0GZ2kOUFQ-xBA_15_24">140,697</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">See accompanying notes to the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-style:italic;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:84%;border:0;margin:30pt 8% 30pt 8%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_1227b22f_e68d_4078_b2ea_3d3ef44a68c2"></a><a id="Consolidated_Statement_Of_Cash_Flows"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">ELEVATION ONCOLOGY,&#160;INC. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Consolidated Statements of Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">(in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_abc23cf4_1b4f_4e27_aa48_e4a5b1404d6a"></a><a id="Tc_BlCvWgkvv0i7SjuMdSoJlA_1_2"></a><a id="Tc_fE1AA7o7nUST17zyO0shoA_2_2"></a><a id="Tc_8Y-ddXOcRkiLG_ovmqPSLg_2_5"></a><a id="Tc_WbIq7pJAJE6nCXdwmecpFQ_3_0"></a><a id="Tc_jLC-625dmEC8CdcZNNaaaQ_4_0"></a><a id="Tc_wlyRpA3ETUW-gcMy-G9SAA_4_2"></a><a id="Tc_oShS98O4sky3Wj2q6LOz8g_4_5"></a><a id="Tc_pkpdoS7O5kKsldfhZChMqw_5_0"></a><a id="Tc_yjdf8ja4ekWM3kXiayb6CQ_6_0"></a><a id="Tc_6e4Qg4blhUmwoscRjbT2cQ_7_0"></a><a id="Tc_YYlTCxHMz0ek1jEURSfTiw_8_0"></a><a id="Tc_7Fz8xNiDB0euhd3SKmsevw_9_0"></a><a id="Tc_qUGNa05zdEK5CClfDDhpaw_10_0"></a><a id="Tc_-dEyH4mFiUedzkNG1Sgs4w_10_3"></a><a id="Tc_Lzqp0ebtCEmchxRXXpFC4g_11_0"></a><a id="Tc_KhSzFo7vzU-c8re_bZfCPg_12_0"></a><a id="Tc_5qsTF3loukebNuyEsST7eA_13_0"></a><a id="Tc_Zj7t3UPEj0SRmAjQPVxHNA_14_0"></a><a id="Tc_if7ah_yJ20mJtqbrnPhWag_15_0"></a><a id="Tc_t-L1egrLCEOED30eNxaqHw_15_3"></a><a id="Tc_FEXZBXAqNE-R43nOyDNSKw_16_0"></a><a id="Tc_2auzds8KeUu-kw5-32yowQ_16_3"></a><a id="Tc_NHshC68-40KEGw_Qu63hZA_17_0"></a><a id="Tc_1T68cbgoH0KeItDlCf34tA_18_0"></a><a id="Tc_5dibs5lomEOcbzHhZMqV8w_18_3"></a><a id="Tc_eRg7aiViCEGCjpaSEdkvAg_19_0"></a><a id="Tc_jgBWnElJ70G-4ZYgLPT34w_19_6"></a><a id="Tc_PnA2bE13GEqk-J7yl4KLRg_20_0"></a><a id="Tc_aJ5fnO53aUWsz9OsvTe2fA_20_3"></a><a id="Tc_500UgcdikE-XMoAMexs1cg_21_0"></a><a id="Tc_8oa6GOxuzEKaMpDRm7-Omg_22_0"></a><a id="Tc_yebnMzVuLEqrfEpEAjgMvg_23_0"></a><a id="Tc_fNOGadxdGUCNAwQkR9FLrw_24_0"></a><a id="Tc_8w2K9xxdwEmvY3TLAfk_Og_25_0"></a><a id="Tc_b0wTqEfxaU-iIQv9uKXd3g_25_2"></a><a id="Tc_uu2Phvh8pE-v4aXuOxuAIg_25_5"></a><a id="Tc_cwI4qpl5okiK6b4viF8moQ_26_0"></a><a id="Tc_-B7NGwaA1kmSyej3DoWfPQ_27_0"></a><a id="Tc_0kRsHeLOy0mm4_WtopRULg_27_2"></a><a id="Tc_wHBE7hLwXk-KBY-IuYxB-g_27_3"></a><a id="Tc_-M2AEY_710qKB9BUA6C9vw_27_5"></a><a id="Tc_t382cBiDykCwaVJO4Wtw1A_28_0"></a><a id="Tc_b1BukNo2wk69Osaymbk5uQ_28_2"></a><a id="Tc_qwQVdb73eEWmNBR9fYipZw_28_5"></a><a id="Tc_2zP-nI7Jl0m6RIWEkCTtUw_28_6"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_6fp1qcuRykmOt1M7YXIvmA_4_3">32,039</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_-SGJ16KC50y1nM94nyLP9g_4_6">17,265</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reconciliation of net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_ITHMMMQPiEWhs7xeXqXivA_6_3">1,571</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_DGVMiJL8xUahS_alo_Y28w_6_6">52</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Depreciation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_izTvjez4Q0OvofBB3MvwZg_7_3">18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_YLktkVvHpEiQoRX2qoTOiA_7_6">15</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_enbnTHqFEUSIB-ho6g4KPQ_9_3">1,722</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_KAvgnOuk0061rUXyNijZ1Q_9_6">1,212</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Other assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="Tc_cpv0ctwDoECNVNcfpFolBA_10_6">65</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_0QiamoTpaE24VwHYs8nx4A_11_3">30</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_EWyNKWkm60Gt2bAOfRkEZw_11_6">5,219</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="Tc_RRFs00H5-EyiESVGUy8asQ_12_3">2,035</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="Tc_0FToWl9w3UWVpjoPYL6b2A_12_6">958</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_iC4pTO4anEqDLVuvD5DyDA_13_3">30,167</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_BygnTG6zlkKcWC7cNiB9rw_13_6">12,298</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_rpKeDdNnVk6Me52RFVEl6A_15_6">71</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_fVHUJcCz_E-vBtg2Zwr1Iw_16_6">71</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from the issuance of restricted common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-3" format="ixt:numdotdecimal" name="elev:ProceedsFromIssuanceOfRestrictedCommonStock" scale="3" id="Tc_KxnKKRWNOUqyYeJ7_4Nh3Q_18_6">20</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from issuance of common stock upon initial public offering, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_44RKiySAukuhID8wVlk6_g_19_3">97,062</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from the issuance of convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="3" id="Tc_Fx9l58g6ZEKPIkzAZzHTQg_20_6">90,183</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for issuance costs of convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Tc_m_--YUP2Z0uCHyEjOd0NdA_21_3">11</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Tc_egeEyO8LwEqlzu_s_io1KQ_21_6">174</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_jnvk7pk8iUKQ6pSZ6FKeEA_22_3">97,051</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_PYfzXhe28kanvOLWBpQg1Q_22_6">90,029</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_MY9oxjYlbU-BV02P71Fz7w_23_3">66,884</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_qFO1Ai1JQkaw5KlalYOypw_23_6">77,660</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents, beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_geYINy0V4U2WkPM67XZY1Q_24_3">79,400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2019_K5uh10LQgki3KgNzawcwuw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_yHumy77nHky7iEmu82facg_24_6">1,740</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents, end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_G7V5l_zcOUe_h3o0BYI3_A_25_3">146,284</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_hC5BfGfbzEeMWGKKpJlJHw_25_6">79,400</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Supplemental disclosure of non-cash financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issuance costs in accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-3" format="ixt:numdotdecimal" name="elev:IssuanceCostsIncludedInAccruedExpenses" scale="3" id="Tc_-YOo5ud_d0K6yGQ6Mrnxsg_27_6">11</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Conversion of convertible preferred stock upon IPO</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockAmountIssued1" scale="3" id="Tc_RMpCzRRjUE-UhaBA3nMrKQ_28_3">97,188</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">See accompanying notes to the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_5a1e7222_fd8d_47fa_a93b_86263a0d30b9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">ELEVATION ONCOLOGY,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk96452018"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:NatureOfOperations" id="Tb_dfY4NWtV1UWS_SE_hVX-hg" continuedAt="Tb_dfY4NWtV1UWS_SE_hVX-hg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. NATURE OF BUSINESS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Elevation Oncology,&#160;Inc. (the &#8220;Company&#8221; or &#8220;Elevation&#8221;), which was formerly known as 14ner,&#160;Inc., was incorporated under the laws of the State of Delaware on April&#160;29, 2019 (&#8220;Inception&#8221;). The Company is a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers. The Company acquired its lead product candidate, seribantumab, pursuant to an asset purchase agreement executed with Merrimack Pharmaceuticals,&#160;Inc. (the &#8220;previous sponsor&#8221;) during the period ended December&#160;31, 2019 (see Note&#160;9). Seribantumab has been shown preclinically to inhibit tumor growth driven by NRG1 fusions and is currently being tested in the Company&#8217;s Phase&#160;2 CRESTONE clinical trial for patients with tumors of any origin that have an NRG1 fusion. The Company is actively evaluating opportunities for pipeline expansion including prioritizing additional targeted therapy approaches in tumor types defined by genomic driver alterations.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:12pt 0pt 12pt 0pt;">Risks and Uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure, and extensive compliance-reporting capabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance that the Company&#8217;s research and development of its product candidates will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The current COVID-19 pandemic has presented a substantial public health and economic challenge around the world and is affecting our employees, patients, communities and business operations, as well as contributing to significant volatility and negative pressure on the U.S. economy and in financial markets. The extent of the impact of COVID-19 on the Company&#8217;s operational and financial performance will continue to depend on certain developments, including the duration and spread of the outbreak, new variants, the vaccination and booster rate, impact on the Company&#8217;s clinical studies, employee or industry events, and effect on our suppliers and manufacturers, all of which are uncertain and cannot be predicted. COVID-19 has not had a significant impact on the operations or financial results of the Company to date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In July 2019 and November 2020, the Company received gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_7_1_2019_To_7_31_2019_us-gaap_StatementClassOfStockAxis_elev_SeriesaAndBConvertiblePreferredStockMember_SRP5C8kaAkm-e3i0QZ6c-A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="6" id="Narr_E82NhtNA2kexkQ8HijoRMw"><ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_11_1_2020_To_11_30_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaAndBConvertiblePreferredStockMember_ge5GjDqHukSVK1DEMyGmNg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="6" id="Narr_RIrNQIJQ-E2vGJDcDcDqCA">97.2</ix:nonFraction></ix:nonFraction> million from the issuance and sale of its Series A and Series B convertible preferred stock (see Note 6).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On June 17, 2021, the Company effected a 1.0 for <span style="-sec-ix-hidden:Hidden_z6l6dXmz8E6xGt27fFRfuQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.225582</span></span> reverse stock split of its issued and outstanding shares of common stock and proportional adjustment to the existing conversion ratios for each series of the Company&#8217;s convertible preferred stock (see Note 6). Accordingly, all share and per share amounts for all periods presented in the accompanying consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this reverse stock split and adjustment of the preferred stock conversion ratios.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_dfY4NWtV1UWS_SE_hVX-hg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On June 29, 2021, the Company closed its initial public offering (&#8220;IPO&#8221;) and issued <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_6_29_2021_To_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_k4RdvBD3eEmW3XvTBybGKw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_bwGZfjVLWESeJ1AjQ24Sow">6,250,000</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" contextRef="As_Of_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_5rOsdDqIEUeymqVgYG3BtA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="Narr_ZIBLqeUJJkCjqoyof3Dd_Q">16.00</ix:nonFraction> per share for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_6_29_2021_To_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_k4RdvBD3eEmW3XvTBybGKw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_keX3Y_roHketlutcANW2nw">91.1</ix:nonFraction> million, after deducting underwriting discounts and commissions and expenses of $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_6_29_2021_To_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_k4RdvBD3eEmW3XvTBybGKw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_FRbQNcdySU6e53Y36Gr1NQ">8.9</ix:nonFraction> million. In connection with the IPO, all shares of Series A and Series B convertible preferred stock converted into <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_5rOsdDqIEUeymqVgYG3BtA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="Narr_8_64RQHnvkCq2aNZK-0vjA">15,736,053</ix:nonFraction> shares of common stock. On July 19, 2021, in connection with the Company&#8217;s IPO, the underwriters exercised the right to purchase <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_7_19_2021_To_7_19_2021_srt_CounterpartyNameAxis_elev_UnderwritersOfInitialPublicOfferingMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_VUvougWN80i1LCZg4HFYSw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_CPwR5WEHyUekIGXm5qFQ3Q">403,407</ix:nonFraction> shares of the Company&#8217;s common stock at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" contextRef="As_Of_7_19_2021_srt_CounterpartyNameAxis_elev_UnderwritersOfInitialPublicOfferingMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_nGisd7kOYEq_z_1_7FQduw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="Narr_TN6vuwieo0yslr0ItHkToQ">16.00</ix:nonFraction> per share for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_7_19_2021_To_7_19_2021_srt_CounterpartyNameAxis_elev_UnderwritersOfInitialPublicOfferingMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_VUvougWN80i1LCZg4HFYSw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_W7UynJLcJEGX2OMBhFDtsg">6.0</ix:nonFraction> million, after deduction underwriting discounts of $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_7_19_2021_To_7_19_2021_srt_CounterpartyNameAxis_elev_UnderwritersOfInitialPublicOfferingMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_VUvougWN80i1LCZg4HFYSw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_X_GeNBCK70aXolxQ9u13Iw">0.5</ix:nonFraction><span style="white-space:pre-wrap;"> million.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has historical losses from operations and anticipates that it will continue to incur losses for the foreseeable future as it continues the research and development of its product candidates. The Company incurred net losses of $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="6" id="Narr_IRSsV1PwXESHvGji7v_sqw">32.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="6" id="Narr_2OWt3oihfkih5jZF8Z9vUA">17.3</ix:nonFraction> million for the&#160;years ended December&#160;31, 2021 and 2020, respectively, and had an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_DM81tEH1UUyWXlY56ikk9A">55.2</ix:nonFraction> million as of December&#160;31, 2021. Through December&#160;31, 2021, the Company has funded its operations with proceeds from the sale of convertible preferred stock and common stock. The Company expects that its cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance date of the consolidated financial statements.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_nbaPLSC2wkWjHd3pBGJe4w" continuedAt="Tb_nbaPLSC2wkWjHd3pBGJe4w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_neTbvwh8r0Wg5Vm-eDp55w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;).</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:ConsolidationPolicyTextBlock" id="Tb_o50uglABREakf5LBjyI7ZQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Elevation Oncology Securities Corporation, which was established on November 19, 2021. All significant intercompany balances and transaction have been eliminated in consolidation.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:UseOfEstimates" id="Tb_8mgmGONx4EaHtfmisWAUcA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in accordance with GAAP requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company bases its estimates and assumptions on known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accruals for research and development expenses, the valuation of common stock and the assumptions used in the valuation of share-based compensation awards. Changes in estimates are recorded in the period in which they become known. Due to the risks and uncertainties involved in the Company&#8217;s business and evolving market conditions and, given the subjective element of the estimates and assumptions made, actual results may differ from estimated results.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_sHbfT2-n1UGkaLNZD7fXpA" continuedAt="Tb_sHbfT2-n1UGkaLNZD7fXpA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Segment Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available and regularly reviewed by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in <ix:nonFraction unitRef="Unit_Standard_segment_tfgErmtCo0qqRPYk0GJOUQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_4TGJWaDpREmfKQlsWyFqKg">one</ix:nonFraction> operating segment, which is the development of precision medicines for patients with genomically defined cancers. All material long-lived assets of the Company reside in the United States.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_nbaPLSC2wkWjHd3pBGJe4w_cont1" continuedAt="Tb_nbaPLSC2wkWjHd3pBGJe4w_cont2"><ix:continuation id="Tb_sHbfT2-n1UGkaLNZD7fXpA_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_ZER4DXhmN0GwwCH2-HnngQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with an original maturity of three&#160;months or less to be cash equivalents. As of December&#160;31, 2021 and 2020, cash equivalents consisted of money-market funds. The Company places its cash with a high-credit-quality financial institution domiciled in the United States.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_9vE6CKciOkWd4tjy13yHoA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk and Significant Suppliers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. The Company&#8217;s money market funds are invested in highly rated funds. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents and does not believe that it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is dependent on third-party manufacturers to supply products for research and development activities of its programs, including preclinical and clinical testing. These programs could be adversely affected by a significant interruption in the supply of such drug substance and drug products. During the&#160;year ended December&#160;31, 2021, the Company had <ix:nonFraction unitRef="Unit_Standard_item_P9iWedWUGEOmRWtbpyYLhQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_elev_MajorSuppliersMember_Lus3zfRWB02sxkyeP9gCsQ" decimals="INF" format="ixt-sec:numwordsen" name="elev:NumberOfMajorVendors" scale="0" id="Narr_189oVxZUlkGsqXiqOJkaTQ">two</ix:nonFraction> vendors that accounted for approximately <ix:nonFraction unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_elev_MajorSuppliersMember_Lus3zfRWB02sxkyeP9gCsQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_UKLLTtVcpEmr16ou8wKMDg">61</ix:nonFraction>% of its research and development expense. As of December&#160;31, 2021, the Company had <ix:nonFraction unitRef="Unit_Standard_item_P9iWedWUGEOmRWtbpyYLhQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsPayableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_elev_MajorSuppliersMember_Coj20v2H-ESbqbb3ODw3Ng" decimals="INF" format="ixt-sec:numwordsen" name="elev:NumberOfMajorVendors" scale="0" id="Narr_uWZMwKc2GUyRaXfZZKrYQg">one</ix:nonFraction> vendor that accounted for approximately <ix:nonFraction unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsPayableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_elev_MajorSuppliersMember_Coj20v2H-ESbqbb3ODw3Ng" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_SU5kncAgMEWVZK5de3Cf6Q">74</ix:nonFraction>% of the total accounts payable. During the&#160;year ended December&#160;31, 2020, the Company had <ix:nonFraction unitRef="Unit_Standard_item_P9iWedWUGEOmRWtbpyYLhQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_elev_MajorSuppliersMember_NVyNryv-ik-_fhgfb89hIA" decimals="INF" format="ixt-sec:numwordsen" name="elev:NumberOfMajorVendors" scale="0" id="Narr_HoZ7Sk9akEOQjYAlA9SUPQ">one</ix:nonFraction> vendor that accounted for approximately <ix:nonFraction unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_elev_MajorSuppliersMember_NVyNryv-ik-_fhgfb89hIA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_icBTgs7hQ0KorhwZLtWuEg">46</ix:nonFraction>% of its research and development expense. The <span style="-sec-ix-hidden:Hidden_oYUMpxFyBEukUJ69xj1Vgw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">same</span></span> vendor also accounted for approximately <ix:nonFraction unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsPayableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_elev_MajorSuppliersMember_ocGPhsn9x0qpuSJ02J9oBA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_vHwWE-dH2k-NjBQVz6tOkA">95</ix:nonFraction>% of the total accounts payable as of December&#160;31, 2020.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_H9k0bma5YESEh3WFA6GWuQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Property and equipment consist of computer software that is recorded at cost and depreciated on a straight-line basis over the estimated useful lives of the assets. Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying value of assets may not be recoverable. Recoverability is measured by comparison of the asset&#8217;s book value to future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets. <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:AssetImpairmentCharges" scale="3" id="Narr_aIj-UI847ki_QVH90RF5vg">No</ix:nonFraction> impairment losses have been recorded through December&#160;31, 2021.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="elev:CloudComputingArrangementPolicyPolicyTextBlock" id="Tb_UPFc8rBXPUyvgkUf4eyqJg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cloud Computing Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company defers implementation costs incurred in cloud computing hosting arrangements in accordance with Accounting Standards Update (&#8220;ASU&#8221;) 2018-15 and amortizes these costs over the noncancelable term of the cloud computing arrangement, plus any optional renewal periods (1)&#160;that are reasonably certain to be exercised by the Company or (2)&#160;for which exercises of the renewal option is controlled by the cloud service provider. Costs incurred during the application development stage are capitalized within either prepaid expenses and other current assets, or in other assets, net on the Company&#8217;s balance sheet. Amortization of implementation costs are on a straight-line basis over the related hosting arrangement term and is reflected in research and development expenses in the consolidated statements of operations.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="elev:ClassificationAndAccretionOfConvertiblePreferredStockPolicyPolicyTextBlock" id="Tb_lpzSQ-2HI0CBfX4mh5lf4w" continuedAt="Tb_lpzSQ-2HI0CBfX4mh5lf4w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Classification and Accretion of Convertible Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company&#8217;s convertible preferred stock is classified outside of stockholders&#8217; deficit on the balance sheet because the holders of such shares have liquidation rights in the event of a deemed liquidation that, in certain situations, are not solely within the control of the Company and would require the redemption of the then-outstanding convertible preferred stock. The convertible preferred stock is not redeemable, except in the event of a deemed liquidation (see Note&#160;6). Because the occurrence of a deemed liquidation event is not currently probable, the carrying values of the convertible </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_nbaPLSC2wkWjHd3pBGJe4w_cont2" continuedAt="Tb_nbaPLSC2wkWjHd3pBGJe4w_cont3"><ix:continuation id="Tb_lpzSQ-2HI0CBfX4mh5lf4w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">preferred stock are not being accreted to their redemption values. Subsequent adjustments to the carrying values of the convertible preferred stock would be made only when a deemed liquidation event becomes probable. Upon the closing the Company&#8217;s IPO in June 2021, all outstanding convertible preferred stock automatically converted into shares of common stock.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Tb_bD3kZ7Z4nEmIk-a9LUU15w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2&#8212;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3&#8212;Non-observable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:LegalCostsPolicyTextBlock" id="Tb_YUCuvGVbp0STr6YlZDqSNA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The Company&#39;s cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note 3).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patent Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The legal and professional costs incurred by the Company to maintain its patent rights have been expensed as part of general and administrative expenses since inception. As of December&#160;31, 2021 and 2020, the Company has determined that these expenses have not met the criteria to be capitalized. Intellectual property-related&#160;expenses for the year ended December&#160;31, 2021 and&#160;2020 were $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LegalFees" scale="6" id="Narr_DKI-2mtT-0SaPgDkU71QyA">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LegalFees" scale="6" id="Narr_RUd3URN0yEu5_wWCjckk4A">0.1</ix:nonFraction> million, respectively.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_rIinS-HW0kG7MbyqD42bWA" continuedAt="Tb_rIinS-HW0kG7MbyqD42bWA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development costs consist of salaries and benefits, including associated stock-based compensation, and fees paid to other entities that conduct certain research and development activities on the Company&#8217;s behalf. Research and development costs are expensed as incurred. The Company estimates preclinical study and clinical trial expenses based on the services performed pursuant to contracts with research institutions and contract research organizations and clinical manufacturing organizations that conduct and manage preclinical studies and clinical trials on the Company&#8217;s behalf based on actual time and expenses incurred by them. Further, the Company accrues expenses related to clinical trials based on the level of patient activity according to the related agreement. The Company monitors patient enrollment levels and related activity to the extent reasonably possible and adjusts estimates accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the services have been performed or when the goods have been received rather than when the payment is made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to the Company&#8217;s prior estimates of accrued research and development expenses.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_nbaPLSC2wkWjHd3pBGJe4w_cont3" continuedAt="Tb_nbaPLSC2wkWjHd3pBGJe4w_cont4"><ix:continuation id="Tb_rIinS-HW0kG7MbyqD42bWA_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_zb55qe2ktEKLhRXjrTzQXg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company measures stock-based compensation cost at the accounting measurement date based on the fair value of the award and recognizes the expense on a straight-line basis over the requisite service period of the award, which is typically the vesting period. Compensation expense is measured using the fair value of the award at the grant date and is adjusted to reflect actual forfeitures as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company estimates the fair value of stock options using the Black-Scholes option pricing model that takes into account the exercise price, the fair value of the Company&#8217;s common stock, the expected term of the option, the expected volatility of the Company&#8217;s common stock, expected dividends on the Company&#8217;s common stock, and the risk-free interest rate over the expected life of the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Fair value of common stock&#8212;</i>Prior to IPO in June 2021, the Company valued its common stock by taking into consideration its most recently available valuation of common shares performed by management and the board of directors, as well as additional factors which may have changed since the date of the most recent contemporaneous valuation through the date of grant. Upon IPO, the fair value of the Company&#8217;s common stock is determined based on the quoted market price of its common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected term&#8212;</i>The Company uses the simplified method described in the Securities and Exchange Commission Staff Accounting Bulletin Topic 14.D.2 to calculate the expected term as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term for options granted to employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected volatility&#8212;</i>The Company estimates expected volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its traded stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk-free interest rate&#8212;</i>The risk-free rate assumption is based on the U.S. Treasury yield curves whose terms are consistent with the expected term of the stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected dividend&#8212;</i>The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be <ix:nonFraction unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="0" format="ixt-sec:numwordsen" name="elev:DividendYieldRate" scale="0" id="Narr_WZeXxsEN-ka2mIOHENN0iw">zero</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient&#8217;s payroll costs or service payments are classified.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_HGr7wA-7z0W5EYp4XXwZ3A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss per Common Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s net loss is equivalent to net loss attributable to common stockholders for all periods presented. Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed using the sum of the weighted average number of common shares outstanding during the period and the effect of dilutive securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company applies the two-class method to calculate its basic and diluted net loss per share as the Company has issued shares that meet the definition of participating securities. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. The Company&#8217;s participating securities contractually entitle the holders of such shares to participate in dividends; but do not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_oBjUxtVgVU-sZDXMauVNuA" continuedAt="Tb_oBjUxtVgVU-sZDXMauVNuA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_nbaPLSC2wkWjHd3pBGJe4w_cont4"><ix:continuation id="Tb_oBjUxtVgVU-sZDXMauVNuA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the&#160;year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. The Company accounts for uncertainty in income taxes recognized. If the tax position is deemed more likely than not to be sustained, it would then be assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. To date the Company has <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Narr_YPEgmQHziU-LD46f5s-Wwg">no</ix:nonFraction> uncertain tax positions and there have been <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="3" id="Narr_ET0ENIfJ0UinAs5_LOtVAg">no</ix:nonFraction> interest and penalties.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_NAaAjNfxyU2j6BB9VMvKrA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Recently issued accounting pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In December 2019, the Financial Accounting Standards Board issued Accounting Standards Update (&#8220;ASU&#8221;) 2019-12, <i style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</i>. Among other items, the amendments in ASU 2019-12 simplify the accounting treatment of tax law changes and year-to-date losses in interim periods. An entity generally recognizes the effects of a change in tax<i style="font-style:italic;"> </i>law in the period of enactment; however, there is an exception for tax laws with delayed effective dates. Under<i style="font-style:italic;"> </i>current guidance, an entity may not adjust its annual effective tax rate for a tax law change until the period in<i style="font-style:italic;"> </i>which the law is effective. This exception was removed under ASU 2019-12, thereby providing that all effects of a<i style="font-style:italic;"> </i>tax law change are recognized in the period of enactment, including adjustment of the estimated annual<i style="font-style:italic;"> </i>effective tax rate. Regarding year-to-date losses in interim periods, an entity is required to estimate its annual<i style="font-style:italic;"> </i>effective tax rate for the full fiscal year at the end of each interim period and use that rate to calculate its income<i style="font-style:italic;"> </i>taxes on a year-to-date basis. However, current guidance provides an exception that when a loss in an interim<i style="font-style:italic;"> </i>period exceeds the anticipated loss for the year, the income tax benefit is limited to the amount that would be<i style="font-style:italic;"> </i>recognized if the year-to-date loss were the anticipated loss for the full year. ASU 2019-12 removes this exception<i style="font-style:italic;"> </i>and provides that in this situation, an entity would compute its income tax benefit at each interim period based<i style="font-style:italic;"> </i>on its estimated annual effective tax rate. ASU 2019-12 is effective for fiscal years beginning after December 15,<i style="font-style:italic;"> </i>2021, with early adoption permitted. The Company has not elected to early adopt ASU 2019-12 and is currently<i style="font-style:italic;"> </i>evaluating the impact the adoption of the standard will have on its financial statements and related disclosures.</p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_aa30c02a_9302_498e_a100_2dda341753e3"></a><a id="Tc_tCXOeDs2P06i7RtclJuYjw_1_2"></a><a id="Tc_lM1o0rTxbUC92nErsT99ow_2_2"></a><a id="Tc_OMR75wfuRUGHQdudwOiw-Q_2_5"></a><a id="Tc_LLVpO43q5U-D8B1RPpDbfA_2_8"></a><a id="Tc_4pv3o2ZfK028ARneat_PrQ_2_11"></a><a id="Tc_RRcjeOQBUUqtR4zifsE1Bw_3_2"></a><a id="Tc_0RgqZ9kZFECguqzpXV-Xmw_4_0"></a><a id="Tc_nTYSfRSBaUavNkzRkPIHWg_4_2"></a><a id="Tc_ZPfaqLppk0-yUgDzst08SQ_4_5"></a><a id="Tc_PbhIv9otGEWqHTVqATwM8Q_4_6"></a><a id="Tc_8E6o7-EkVUWYt9sXIn5YEw_4_8"></a><a id="Tc_2N48u3gXOEqdlPdY8jyGRA_4_9"></a><a id="Tc_fvXWsdv610W-X0qZ1uV8gg_4_11"></a><a id="_9af13cf2_9414_45c8_bf16_3d3f09a23b31"></a><a id="Tc_uSQlfe45y0OuX-FwdgZPyQ_1_2"></a><a id="Tc_rUhWrSqZwEGpCmaOaOamUg_2_2"></a><a id="Tc_Tm8QL_OSOEm0fXvS5zL7vg_2_5"></a><a id="Tc__TyCdVyh9EG8htIRhaWpHw_2_8"></a><a id="Tc_ImzKF0eZNkOo6olt9M_qkQ_2_11"></a><a id="Tc_fAtNNIwcsU2SAL1Mdg9T6Q_3_2"></a><a id="Tc_AewVvhmQakOepsys-YqUEQ_4_0"></a><a id="Tc_tR3wywf4xEKgjtSv4YBvPw_4_2"></a><a id="Tc_N9-TpPlCoU2-6WJ9l-_1gg_4_5"></a><a id="Tc_CEuIJfP1s06mI0AV95pSnA_4_6"></a><a id="Tc_cH0ChbuezUurn5B8n2FhSg_4_8"></a><a id="Tc_X4p0lL0_WkWyJUf-vJpVOw_4_9"></a><a id="Tc_VJ3XasjuKUCTHqwkfOxyOA_4_11"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_vxDUbOcxnEqGahOIyL7SJA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="Tb_rX1XUoadW0SN1lS9qsr1-w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company&#8217;s financial assets subject to fair value measurements on a recurring basis and the level of inputs used for such measurements were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds included in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_LOXva3eCSEKs92ak-KtE4Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_6haQhpxgQ0-y-OJMY99QRg_4_3">106,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_TTW4gSp3Wk-9JNv7SpMKfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_FeIDQM4A_UWbelT2v5gglw_4_12">106,000</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds included in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_eDgOSR0ApUCe08Ub8rJKgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_4zRYqoKLBEOFBTXB1IcGzQ_4_3">76,013</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_ZJ2eCE9YL0WHbRPPPls1ig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_jwwnvvzvA0CyPZdfj2SvoQ_4_12">76,013</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">During the&#160;years ended December&#160;31, 2021and 2020, the Company had <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" scale="3" id="Narr_zmjmBcRyH0mX5bvUihOAug">no</ix:nonFraction> transfers between Level&#160;1, <span style="-sec-ix-hidden:Hidden_TDI7DkXArkaTliVYX6vraA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2</span></span> or <span style="-sec-ix-hidden:Hidden_JCM5oP1UqkKdMGQnvJ6z0g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3</span></span> financial assets.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_116d289f_d733_494f_b05d_e1b5ea451885"></a><a id="Tc_uJdLb8Ds8EO6Z0-UDtrDvA_1_2"></a><a id="Tc_rMeohFv8p0qv_7QhJPoRBA_1_5"></a><a id="Tc_P4vM0fhstECgXsVGbFDztQ_2_2"></a><a id="Tc_OpIacP2QF0iRU8StbSPK3A_2_5"></a><a id="Tc_l1URnyP1A0y4pnjMoZtECw_2_8"></a><a id="Tc_PRW5jMKFykGRUCTM_in6iQ_3_5"></a><a id="Tc_eZOVkdaiNUSJysVPO6mtNA_4_0"></a><a id="Tc_cp7af_JNvkaWt2m0eUpgFA_4_5"></a><a id="Tc_PsIKMm7Jt0qtLIVUFE6_-A_4_8"></a><a id="Tc_gpW2Omt3okmV0-uJZmQKjg_5_0"></a><a id="Tc_aHtoCmADkkyVC855sFeoLQ_6_0"></a><a id="Tc_ZuDVLZnZ3E-UEk1UV8sP_w_6_5"></a><a id="Tc_LwqF0hRDvkmdkJ0sPBMvWg_6_8"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_1-kzfqOuQUGh1LNYppLJ8g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. PROPERTY AND EQUIPMENT, NET</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_RqjXMbQ6Bkims9Yyn7-zaw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net, consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Useful&#160;Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_elev_ComputerSoftwareMember_g5ZhoAlXpUqrIOpTarHh5A" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_IXuo85Z2I0WXjXF1Rw9Vbw_4_3">4 years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_elev_ComputerSoftwareMember_NaXHz8_kV0qUWe08M_6KyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_ZLkVgWpJdEGVnVE9gDGdgQ_4_6">71</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_elev_ComputerSoftwareMember_YpEaJOWw7UCqEhZ5InjBgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_8t1b2-g7p0-jq3hiod_Bsw_4_9">71</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_6sprlGjsrkCm7KWTzm0tuw_5_6">33</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_Zbmi6fWl30u_wZBESegMWg_5_9">15</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Property and equipment, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_tyCTqTlqtkupo0tCfs565g_6_6">38</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_w_QoT7lPTEOHiV7rjB4DiQ_6_9">56</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company recorded less than $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_AIfL3vjSZUuRhq97AJyp4w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_sYsWajhSjUSoLJAeEV4Hbg">0.1</ix:nonFraction> million of depreciation expense during the&#160;years ended December&#160;31, 2021 and 2020.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_1816ac75_51db_4f4c_a2a1_604838b59346"></a><a id="Tc_mFh6cOccLkaT1aqr0woQWQ_1_2"></a><a id="Tc__f9Pc4GqLUmkO66fGivfGg_2_2"></a><a id="Tc_oef6fYLvIkulTVawBS2JVg_2_5"></a><a id="Tc_ttdU12fS-UW0gZ_UKnqjjQ_3_2"></a><a id="Tc_3pEhlCwshUSNl_Tz1qrsjA_4_0"></a><a id="Tc_aBmd6MY3FEGy6l4tbPidog_4_2"></a><a id="Tc_-djodkkRbEWTRJPTVSvHTQ_4_5"></a><a id="Tc_Gq9FVtdKFUiYEdUwTevfJQ_5_0"></a><a id="Tc_D9eD0DQ6eEyO5Tqark37Ww_6_0"></a><a id="Tc_U0lHoBbIVE2s1Vmg-iji-Q_7_0"></a><a id="Tc_EcOlsJcYqkuh7M-Iir5o7Q_8_0"></a><a id="Tc_4aJshfYCH0eae-y4QX0JNg_9_0"></a><a id="Tc_vPD-zZhbakyu1dY2e6HB2g_9_2"></a><a id="Tc_ALomqxfIgU63vOglBjHLvw_9_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="elev:AccruedLiabilitiesDisclosureTextBlock" id="Tb_-9mzM2ornESR2L6snfpxRw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. ACCRUED EXPENSES</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_ZHZtmqizuUWehJuCR-ceTg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued expenses consist of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued preclinical and clinical trial costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="elev:AccruedPreclinicalAndClinicalTrialCostsCurrent" scale="3" id="Tc_o_-mkYXbHEW7VeTCuwDaUw_4_3">1,260</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="elev:AccruedPreclinicalAndClinicalTrialCostsCurrent" scale="3" id="Tc_mXSsiqmwiECuaNbew3_rhQ_4_6">505</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="elev:AccruedCompensationCurrent" scale="3" id="Tc_VoIaWxJjM0a4BV8rhSafJQ_5_3">1,059</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="elev:AccruedCompensationCurrent" scale="3" id="Tc_O6chyPa9k0eXE3rJb3R6Bg_5_6">429</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued consulting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="elev:AccruedConsultingFeesCurrent" scale="3" id="Tc_SU9MKy_EU0KMQLQhHZbKvw_6_3">77</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="elev:AccruedConsultingFeesCurrent" scale="3" id="Tc_D09UqJOVG0OE9i-ipaPDdw_6_6">127</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_CkPJxzWh2UChAyurfw0kYA_7_3">499</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_WNA41NZ0nk6gTYLT_FR-Cg_7_6">28</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_P_IsEWKI-kK0gZXnNKhemA_8_3">246</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_3ssi-Im1AEaRgqFAcnM8iA_8_6">17</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total accrued expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_kE6Juhnk_ky3wVmpCApMuw_9_3">3,141</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_p51qZjNiekKzj2Ox3KnW5A_9_6">1,106</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="elev:TemporaryEquityDisclosureTextBlock" id="Tb_GGiTLgbXZEmTlouTjVApsA" continuedAt="Tb_GGiTLgbXZEmTlouTjVApsA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;">6. CONVERTIBLE PREFERRED STOCK</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company had issued Series&#160;A and Series&#160;B convertible preferred stock (collectively, the &#8220;Convertible Preferred Stock&#8221;). As of December&#160;31, 2020, the Company&#8217;s certificate of incorporation, as amended and restated, authorized the Company to issue <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_7ft91q3LSE2fhJACOiPE-w">66,493,889</ix:nonFraction> shares of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_HujKqJACF0uT50gZkowvKQ">0.0001</ix:nonFraction> par value convertible preferred stock, of which <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_ufCfvphpqUaFsIu6eQ5ybg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_wKsMGcFNg0620qIYWXYvYQ">32,450,000</ix:nonFraction> were designated as Series&#160;A convertible preferred stock (&#8220;Series&#160;A&#8221;) and <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_n1P4tSrvdk-YvWRGsiNyRQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_X2KPu2V-UEq9N_n-5V5OOA">34,043,889</ix:nonFraction> were designated as Series&#160;B convertible preferred stock (&#8220;Series&#160;B&#8221;). As of December 31, 2020, all of the Company&#8217;s Convertible Preferred Stock was classified outside of stockholders&#8217; deficit because the shares contained deemed liquidation rights that were a contingent redemption feature not solely within the control of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Series&#160;A</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On July&#160;12, 2019, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_7_12_2019_To_7_12_2019_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_CRrBhd5h4UWKceI00MOZ2A" decimals="INF" format="ixt:numdotdecimal" name="elev:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_6b6mjSW1Okiogo-0mRCTtg">5,450,000</ix:nonFraction> shares of Series&#160;A at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" contextRef="As_Of_7_12_2019_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_2gzfDx_IOkyEVrvBv9B-8A" decimals="INF" format="ixt:numdotdecimal" name="elev:TemporaryEquityIssuePricePerShare" scale="0" id="Narr_u8VwgTPScUa-37AT1vcyUQ">1.00</ix:nonFraction> per share (&#8220;Series&#160;A Original Issue Price&#8221;) pursuant to the Series&#160;A stock purchase agreement (the &#8220;Series&#160;A Purchase Agreement&#8221;), for gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_7_12_2019_To_7_12_2019_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_CRrBhd5h4UWKceI00MOZ2A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="6" id="Narr_NZzyMzBw4kuf5YP6QLkJRQ">5.5</ix:nonFraction> million. On August&#160;7, 2019, investors purchased an additional <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_8_7_2019_To_8_7_2019_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_jTYrUmLmVka6PZ8r-YiTkw" decimals="INF" format="ixt:numdotdecimal" name="elev:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr__XsnFrtP60uF-zqjJdxDeA">1,816,750</ix:nonFraction> shares of Series&#160;A at the Series&#160;A Original Issue Price, for gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_8_7_2019_To_8_7_2019_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_jTYrUmLmVka6PZ8r-YiTkw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="6" id="Narr_mBtHblqP0U6BkyeJ5y7tLw">1.8</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Upon achievement of the Milestone Closing (as defined in the Series&#160;A Purchase Agreement) and approval by the Company&#8217;s board of directors, the Company issued an additional <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_1_9_2020_To_1_9_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_gs0XV9bVfEqDcewwWOI9VQ" decimals="INF" format="ixt:numdotdecimal" name="elev:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_kXNTe0o7wEWAlMUFJyz1Jw">25,183,250</ix:nonFraction> shares of Series&#160;A at the Series&#160;A Original Issue Price on January&#160;9, 2020 for gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_9_2020_To_1_9_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_gs0XV9bVfEqDcewwWOI9VQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="6" id="Narr_0P-zLUaZZEymt3kbD3PZyg">25.2</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Series&#160;B</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On November&#160;10, 2020, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_11_10_2020_To_11_10_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_v3BvBhMCkkChJbjcubxA5w" decimals="INF" format="ixt:numdotdecimal" name="elev:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_aN4xNOLL40OPC-8iSpg49Q">34,043,889</ix:nonFraction> shares of Series&#160;B at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" contextRef="As_Of_11_10_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_CnPFfpHmG0CJMvYDja99aQ" decimals="INF" format="ixt:numdotdecimal" name="elev:TemporaryEquityIssuePricePerShare" scale="0" id="Narr_w4a0RYLo7EqokIYw1ZPnTA">1.9093</ix:nonFraction> per share (&#8220;Series&#160;B Original Issue Price&#8221;), pursuant to the Series&#160;B stock purchase agreement for gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_11_10_2020_To_11_10_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_v3BvBhMCkkChJbjcubxA5w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="6" id="Narr_7oG7Ug7ExUGoA9njPHzwXw">65.0</ix:nonFraction> million.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_GGiTLgbXZEmTlouTjVApsA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Conversion</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;white-space:pre-wrap;">Upon the closing the Company&#8217;s IPO in June 2021, all outstanding convertible preferred stock automatically converted into shares of common stock.  There are </span><span style="font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_EpGg59YM3Eu1afDfRYaHEQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_9itydpYRCUatTnheNU-A-w">10,000,000</ix:nonFraction></span><span style="font-style:normal;font-weight:normal;"> authorized preferred shares of December 31, 2021.</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_rirIQ9nAMUOWX5d78IRUAg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">7. COMMON STOCK</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">As of December&#160;31, 2021, the Company&#8217;s certificate of incorporation, as amended and restated, authorized the Company to issue <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_KUp93GoUk0isroI-jb3Jfw">500,000,000</ix:nonFraction> shares of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_o5ZDN9ss706H8bVinh48WA">0.0001</ix:nonFraction> par value common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Each share of common stock entitles the holder to <ix:nonFraction unitRef="Unit_Standard_Vote_IYKGbYhrlUq08si1HNSWpQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="INF" format="ixt-sec:numwordsen" name="elev:CommonStockNumberOfVotesPerShare" scale="0" id="Narr_OEjI4jI0Q02_YYicxRRDDQ">one</ix:nonFraction> vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Initial Public Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">On June 29, 2021, the Company closed its IPO and issued <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_6_29_2021_To_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_k4RdvBD3eEmW3XvTBybGKw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_PXRx2gi_e0WKKjl-rd0gCA">6,250,000</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" contextRef="As_Of_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_5rOsdDqIEUeymqVgYG3BtA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="Narr_2YPBrmYR9EepB_qgQ6hM5w">16.00</ix:nonFraction> per share for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_6_29_2021_To_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_k4RdvBD3eEmW3XvTBybGKw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_bCjKDs58Kkixju3d3ewypA">91.1</ix:nonFraction> million, after deducting underwriting discounts and commissions and expenses of $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_6_29_2021_To_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_k4RdvBD3eEmW3XvTBybGKw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_g9n2bert4EyB9Pfdh5LE0w">8.9</ix:nonFraction> million. In connection with the IPO, all shares of Series A and Series B convertible preferred stock converted into <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_5rOsdDqIEUeymqVgYG3BtA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="Narr_7tlX6JEyAkyfZO-B04vVHg">15,736,053</ix:nonFraction> shares of common stock. On July 19, 2021, in connection with the Company&#8217;s IPO, the underwriters exercised the right to purchase <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_7_19_2021_To_7_19_2021_srt_CounterpartyNameAxis_elev_UnderwritersOfInitialPublicOfferingMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_VUvougWN80i1LCZg4HFYSw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_pD_lBRlMvUm5J6K2YoEHww">403,407</ix:nonFraction> shares of the Company&#8217;s common stock at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" contextRef="As_Of_7_19_2021_srt_CounterpartyNameAxis_elev_UnderwritersOfInitialPublicOfferingMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_nGisd7kOYEq_z_1_7FQduw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="Narr_mWrNerIM40quzkGzc8DjxQ">16.00</ix:nonFraction> per share for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_7_19_2021_To_7_19_2021_srt_CounterpartyNameAxis_elev_UnderwritersOfInitialPublicOfferingMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_VUvougWN80i1LCZg4HFYSw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_Iz3FEsWAO0eNeRRBvO4Cqw">6.0</ix:nonFraction> million, after deduction underwriting discounts of $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_7_19_2021_To_7_19_2021_srt_CounterpartyNameAxis_elev_UnderwritersOfInitialPublicOfferingMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_VUvougWN80i1LCZg4HFYSw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_gttiH2-BL0Gm5KXJE42aew">0.5</ix:nonFraction><span style="white-space:pre-wrap;"> million.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">The Company has reserved a total of <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_NxHzSL_E9EuDveJa5W3g4g">27,565,320</ix:nonFraction> shares of common stock as of December 31, 2021 for common stock outstanding, the exercise of outstanding stock options and the number of shares remaining available for future grant under the Company&#8217;s 2021 Stock Incentive Plan. The Company had reserved a total of <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_SFc1ZIpi5k-JPI22EuQYYg">19,831,875</ix:nonFraction> shares of common stock as of December&#160;31, 2020 for common stock outstanding, the conversion of the outstanding shares of Convertible Preferred Stock, the exercise of outstanding stock options and the number of shares remaining available for future grant under the Company&#8217;s 2019 Stock Incentive Plan.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_668ef753_ec5a_4f4a_81bb_1ffdaa3f9bef"></a><a id="Tc_RduIi4Ph9EaFHY_GIUBBfQ_1_2"></a><a id="Tc_9NvfUbUNt0qc_IScB5K7VA_2_2"></a><a id="Tc_QLMzWtTiN0CcXYbttLYeVQ_2_5"></a><a id="Tc_jppXn5k8pk--dskD3DwEUA_3_2"></a><a id="Tc_WfNpelZPSkiCeHCG2GQGeQ_4_0"></a><a id="Tc_i6fxz-mF7U2pPhiLoEpDqw_4_2"></a><a id="Tc_Z184rTYDv0mzxv7bF-XaTA_4_5"></a><a id="Tc_oC8KVmI720WEZdHMauBY7Q_5_0"></a><a id="Tc_lY2nD1uf7k6NOTWKP-VJIA_6_0"></a><a id="Tc_LunfF9ZJ0UyTsaoNkYrvDg_6_2"></a><a id="Tc_6quUTGIusU2B31y-Bd1_xg_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_H_Sau28CyEC2LG4_Bqhcpg" continuedAt="Tb_H_Sau28CyEC2LG4_Bqhcpg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. STOCK-BASED COMPENSATION</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_YJeOcJusBU6lm6G7yXcvww" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation expense as reflected in the Company&#8217;s consolidated statements of operations was as follows (in thousand):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_X-9TCZuQqkap_YeDihjLvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_HmfsFhXhmkayFX3f7CTN0Q_4_3">244</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_xsmSF0gpPU6amqdGOgrEEw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_PsnrTowSpEKXvwAsYBr66A_4_6">24</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_O_Q119ip30KfTfvFf993FA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_miEVnhgu80SDGim8T9b-Mw_5_3">1,327</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_1KlIt4aZN0KI7qkDnMhwtg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_n16rGC9-fkuiW4CbvWf2VA_5_6">28</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation expense included in operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_CTfooCcO_E-td-ZmRfrYkw_6_3">1,571</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_ifWvj0UsbEyOzZsMn7k7Hg_6_6">52</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2021 Equity Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has two equity incentive plans: the 2019 Equity Incentive Plan (&#8220;2019 Plan&#8221;), and the 2021 Equity Incentive Plan (&#8220;2021 Plan&#8221;). New awards can only be granted under the 2021 Plan, under which it is able to issue equity to employees, board members, consultants, and advisors. The 2021 Plan became effective on June 24, 2021, the date the prospectus related to the Company&#39;s IPO was deemed effective by the SEC. The 2021 Plan authorizes the award of stock options, restricted stock awards (&#8220;RSAs&#8221;), stock appreciation rights (&#8220;SARs&#8221;), restricted stock units (&#8220;RSUs&#8221;), cash awards, performance awards and stock bonus awards. The Company has initially reserved <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_6_24_2021_us-gaap_PlanNameAxis_elev_StockIncentivePlan2019Member_g20HiHisykWL0YRlk71tPQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_f2YfanlKDkOCs1j0SJnsLQ">1,483,445</ix:nonFraction> shares of its common stock, plus any reserved shares not issued or subject to outstanding grants under the 2019 Plan on the effective date of the 2021 Plan, for issuance pursuant to awards granted under the 2021 Plan. Of this amount, <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_elev_EquityIncentivePlan2021Member_kp3FXbetX02QbQ8--SNfwg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_EGQWq4vmdk6lg9s4ICYXtA">1,720,291</ix:nonFraction> shares were available for future grants as of December 31, 2021. The number of shares reserved for issuance under the 2021 Plan will increase automatically on January 1 of each of 2022 through 2031 by the number of shares equal to the lesser of <ix:nonFraction unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_elev_EquityIncentivePlan2021Member_xaj81EG8zUqzxS8PpL1PjA" decimals="4" format="ixt:numdotdecimal" name="elev:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentageOfAggregateSharesOutstanding" scale="-2" id="Narr_0XVbaIi2FEOkaYq3L6X4rg">5</ix:nonFraction>% of the aggregate number of outstanding shares of the Company&#8217;s common stock as of the immediately preceding December 31, or a number as may be determined by our board of directors. As such, <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_PlanNameAxis_elev_EquityIncentivePlan2021Member_FexWjG0GeEO3y5ruEl4e1A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_6vrotXb0k0KEnXK0Ztyx8w">1,160,296</ix:nonFraction> shares were added to the Plan in January 2021.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_38475967_84e1_414c_a8e7_fec7a78dc1f2"></a><a id="Tc_QNwDs9ykT06NUNMRhaYy1w_1_4"></a><a id="Tc_JI56FJbrVEmBLlVXaqgZfw_1_7"></a><a id="Tc_iqKFfpzmjECHaYDJaY73uQ_2_4"></a><a id="Tc_X3ZLBTrtg0KsMl8TXPBGsA_2_7"></a><a id="Tc_bxHDtxtFGEGwrFMUulDVRA_2_9"></a><a id="Tc_VaVD8aUZTEGYzkpr9mpbLQ_3_2"></a><a id="Tc_dOkN6JwPUkmgM025w8ti0w_3_4"></a><a id="Tc_7q3Uxw7IzUWmOSTa6deH_g_3_7"></a><a id="Tc_UElLU0B6gk24aDP16uqplw_3_9"></a><a id="Tc_xfAmy7p4lUKn3nxzV0ODMQ_4_0"></a><a id="Tc_W4TNAsQmRE2KZipik5XxnA_4_4"></a><a id="Tc_-lkMI6NrGkqt96DWisLu1g_4_9"></a><a id="Tc_2khBPe2EZ0Wh6Hhx6w67yQ_5_0"></a><a id="Tc_7f8JoQt6aUOwoxH7a9QxgQ_5_4"></a><a id="Tc_yroWn-5HpE25Kz7XzLwceg_6_0"></a><a id="Tc_Isl7FE1JL0miVbKPFEl9WA_7_0"></a><a id="Tc_qDyapF2B1UqTqhaNMylKlQ_7_4"></a><a id="Tc_jOWsAwr_F0GyZf9e2x7Acw_7_9"></a><a id="Tc_c-mpUizGbkqaBol8545TJA_8_0"></a><a id="Tc_DkDiEblEZEC7DH6LzqYZIQ_8_4"></a><a id="Tc_LZ3ejIW8K0mzO995PsZYSQ_8_9"></a><a id="Tc_7SZBWGH2VEyB1Ll1AP_PbA_9_0"></a><a id="Tc_T_qPsN3pQEm79Fq01ihMzg_9_4"></a><a id="Tc_m05mYEpBmkqt1s0PFp9bHA_9_9"></a><a id="_2871bc5a_5255_47ce_b51c_f4de183f02d4"></a><a id="Tc_jbm4Y9_5MkKSZQ4Gu5fRfw_1_2"></a><a id="Tc_huZx8VYWD0ip9uDSe3X2lA_2_2"></a><a id="Tc_SgDLcD3hEEKWJCWVHihDag_2_4"></a><a id="Tc_pmpL-9J67USZND2v-5yeVA_3_0"></a><a id="Tc_2q37UTm3vky3QWNEsVLQ_w_3_2"></a><a id="Tc_JTwGBiUfk0KuQwIZVKYWkg_3_3"></a><a id="Tc_5bN91kGST0GebhMRpp7rmQ_3_4"></a><a id="Tc_aMB2FYCBeEStBU9HBNeGsg_3_5"></a><a id="Tc_dfXDHolCdkWl-luJSSsAHA_4_0"></a><a id="Tc_500ne_WL5EmXwOJqACnFoA_4_2"></a><a id="Tc_eF2LJxf6u0WNjnkMpNHx5g_4_3"></a><a id="Tc_rfCNFGuOvUif5Zu5EuM8Pg_4_4"></a><a id="Tc_GUzQBmMtD0SjrjX92YILXQ_4_5"></a><a id="Tc_O2Q-FxcbLkKfx8bsqEuhNw_5_0"></a><a id="Tc_9Yx4ZxpfZ0qzCbAjBgGkAA_5_2"></a><a id="Tc_MvD61RK0vEi_voukhWQLAA_5_3"></a><a id="Tc_tQJs1BCLukeDcX0u60KE7Q_5_4"></a><a id="Tc_vr5oE7T9W02Cv0EUHADEMQ_5_5"></a><a id="Tc_n-GUEUNcFkW6q6glH9txMA_6_0"></a><a id="Tc_DZLrqKUTAE2_hVd9xDnW-g_6_4"></a><ix:continuation id="Tb_H_Sau28CyEC2LG4_Bqhcpg_cont1" continuedAt="Tb_H_Sau28CyEC2LG4_Bqhcpg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2019 Stock Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The total number of shares of common stock available for issuance under the 2019 Plan was <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_elev_StockIncentivePlan2019Member_bUnBFZtU70qdI_31neYSXg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_gHZOqMtXlUyHrdqHgBqDFg">1,972,114</ix:nonFraction> shares when the 2019 Plan was adopted. In December&#160;2019 and November&#160;2020, the Company increased the number of shares of common stock reserved for issuance under the 2019 Plan by <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_12_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_elev_StockIncentivePlan2019Member_CdA7QcaLgEakV3EDPTac8Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_Fg6ZxPwpPEiEKT1Udmf8tg">144,950</ix:nonFraction> shares and <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_11_1_2020_To_11_30_2020_us-gaap_PlanNameAxis_elev_StockIncentivePlan2019Member_hYYP-cdGa0eXbji1S01uFg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr__HHaUq05I0W77uYCh_aPLQ">1,189,911</ix:nonFraction> shares, respectively. Shares underlying any awards that were forfeited, canceled, or reacquired by the Company prior to vesting, satisfied without the issuance of stock or otherwise terminated or shares that were withheld upon exercise of an option or settlement of an award to cover the exercise price or tax withholding were to be added back to the shares available for issuance under the 2019 Plan. For the year ended December 31, 2021, <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_elev_StockIncentivePlan2019Member_FlHgdUrdDkW1Tb42kpCKvQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_W2_JPzSuC0SKnzGtl9KfXA">1,016,337</ix:nonFraction> options were granted under the 2019 Plan. The 2019 Plan was terminated in connection with the Company&#8217;s IPO. The Company will not grant any additional awards under the 2019 Plan thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2021 Employee Stock Purchase Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has adopted the Employee Stock Purchase Plan (&#8220;ESPP&#8221;) which became effective June 24, 2021, the date the prospectus related to the Company&#39;s IPO was deemed effective by the SEC, to enable eligible employees to purchase shares of its common stock with accumulated payroll deductions at a discount beginning on a date to be determined by the board of directors or compensation committee. The ESPP is intended to qualify under Section 423 of the Code. The Company has initially reserved <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_6_24_2021_us-gaap_PlanNameAxis_elev_EmployeeStockPurchasePlan2021Member_Mo21NNEVb02WGxkNxv7paw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_GY2L8j17EEaulwwtki3caw">228,222</ix:nonFraction> shares of its common stock for sale under the ESPP. The aggregate number of shares reserved for sale under the ESPP will increase automatically on January 1st of each of 2022 through 2031 by the number of shares equal to the lesser of <ix:nonFraction unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw" contextRef="Duration_6_24_2021_To_6_24_2021_us-gaap_PlanNameAxis_elev_EmployeeStockPurchasePlan2021Member_ZFyW0T1vXkWCriwlsXAY-Q" decimals="2" format="ixt:numdotdecimal" name="elev:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentageOfAggregateSharesOutstanding" scale="-2" id="Narr_TURm9BGivUmqX8Mmn5QQXw">1</ix:nonFraction>% of the total outstanding shares of the Company&#8217;s common stock as of the immediately preceding December 31 (rounded to the nearest whole share) or a number of shares as may be determined by the board of directors in any particular year. As such, <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_PlanNameAxis_elev_EmployeeStockPurchasePlan2021Member_s1Fv3k0-skOD-lgjf_7L1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_-f8qP-wuGUGpv9ZYGoe3aw">232,059</ix:nonFraction> shares were added to the Plan in January 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The aggregate number of shares issued over the term of the ESPP, subject to stock-splits, recapitalizations or similar events, may not exceed <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_elev_EmployeeStockPurchasePlan2021Member_uSn9gG9lvkuJEppuSz4hoQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_9FcEBxlGSkaXr3SWaj5Quw">4,564,440</ix:nonFraction> shares of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Options</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_yKZTeCUPBEuOLt1JUmBUPg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A summary of stock option activity for employee and nonemployee awards under the 2019 and 2021 Plans is presented below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining&#160;Contractual&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term&#160;(years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_fvNwMv2xI0O_KHJemFRqlA_4_2">1,761,062</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_fdnzdqad-Uqd53LhEybrpA_4_5">0.95</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_kwlW1SKe2EC8mNC9RoovHA_4_7"> 9.54</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_wvmJQ81H2UmHvY6ZwnSAkQ_4_10">723</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_aj1UgOh7Dky4l6HYQF_aHg_5_2">1,309,400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_6PWOfut3n0StIb5Xt3jNEw_5_5">7.80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="Tc_qGpIEyA210iaMPZ-HgRv6w_6_2">48,663</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_Iovb6AmS5k29_1QmhHTEqQ_6_5">3.98</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_3hT9NHKbQE-4MNaldA84_w_7_2">3,021,799</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_w3SghX_2-UWHsv2bhzcNSg_7_5">3.71</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_7FRiBSJgGk-LZ9dHSfdWTw_7_7"> 8.94</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_ZVs2nxb0oUqqALnWuYPo4g_7_10">10,903</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="Tc_susL6Qlx_0u1wbeKlbHNBg_8_2">680,951</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_NKC4t3_ebECaZQXgBMFx_g_8_5">1.23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" format="ixt-sec:duryear" name="elev:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm" id="Tc_xW4587Xl40yp16_SjiK7TQ_8_7"> 8.39</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="elev:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedIntrinsicValue" scale="3" id="Tc_1D_y2TXsCkim_XxZOIlsQw_8_10">3,437</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and expected to vest at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Tc_DWZA3YjlTUWxoXSOM5MEXw_9_2">3,021,799</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_i-PF6yfeAUSZFpsOhmc8rQ_9_5">3.71</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Tc_adRC7I8PREympOuMF0sM5g_9_7"> 8.94</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="Tc_zhD4_o-lCkq_5Ckwl_9Mcg_9_10">10,903</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_mMOL7ljNgkabWjtwurKXYg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The weighted average grant-date fair value of stock options granted during the year ended December&#160;31, 2021 and 2020 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_NZHZ3vd5a0iPgybna8F0Sg">4.60</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_Z2I4M9puzEOQjuVQj3vwJA">0.73</ix:nonFraction> per share, respectively. The fair value of each stock option was estimated using a Black-Scholes option-pricing model with the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:33.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_mxri_Y2bREGGQBGPALKP6g">0.95</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_TF_qEYWmcUGSjpqvUxuoNg">1.35</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_O8mg_ImWjEmJ3NPBrmoCFA">0.2</ix:nonFraction>&#8722;<ix:nonFraction unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_7KNpgPtAAkahIlaPnnE8eQ">0.75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_HyxKt7oeqUWEewztHBCb2g">75</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_ND2dUp419k6_dB9kTH_4xA">77</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_R4xdhYGN9UKy_6muWzS0yg">74</ix:nonFraction>%&#8722;<ix:nonFraction unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_ruSkBCiWwUK6fwMvM_5WTQ">79</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_CfWjkoNOJU2uYmXaLa0VpQ_6_2"> 6</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_F-nfSSZM0Euu4OQJHKZe8Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3</span></span>&#8722;<span style="-sec-ix-hidden:Hidden_gGMsgb7BgEOGbQEJGMhgkw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6d66da73_5b3e_4870_8198_cf7aa811696d"></a><a id="Tc_chi6-VkrTk6D0YITBnDxIA_1_4"></a><a id="Tc_loO2tVcIKUqe6OkD8j8H3g_2_4"></a><a id="Tc_JV2ysAO5q0Kd3EBw3tfhLw_3_2"></a><a id="Tc_qH4wScvmjUqVkXk_qSi0JQ_3_4"></a><a id="Tc_EvvRAgzWF0etZKgxcKEzTA_4_0"></a><a id="Tc__Je0tc4N6E6n2ftlJOhtFg_4_2"></a><a id="Tc_9Hr9sUucnECpDVjPIDHZCw_4_4"></a><a id="Tc_Wjs-bmGvT0qR8lJKO9W_mA_4_5"></a><a id="Tc_X7Cg6-e5sE642IjSbla1IA_5_0"></a><a id="Tc_7hFyUerFGkKBybLHf662Mg_6_0"></a><ix:continuation id="Tb_H_Sau28CyEC2LG4_Bqhcpg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The fair value of options that vested during the years ended December 31, 2021 and 2020 was $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="Narr_BubGtcSS-US3TyY2XSIO9A">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="Narr_6_rexnfVEEahwqHdjmeF-w">0</ix:nonFraction> million, respectively. The Company recorded stock-based compensation expense associated with stock option awards of $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qMQDBx_zA0eapJGtZe8uZQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_pn5OGkfnOEmc_un8eU6qNw">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_W0whaLuINkuS-MK09HdSLg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_XDuUwa5P0kuALVEgsXXZ9g">0.1</ix:nonFraction> million during the 12&#160;<span style="white-space:pre-wrap;">months ended December 31, 2021 and 2020, respectively.  As of December 31, 2021, there was </span>$<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="Narr_kgKVnOnBX0mvUG1C216_0w">6.4</ix:nonFraction> million of total unrecognized compensation cost related to unvested stock-based awards, which the Company expects to recognize over a remaining weighted-average period of <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_f34FShHPQUeUkrecHO_Iug">3.2</ix:nonNumeric>&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restricted Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The terms of the 2019 Plan permitted certain option holders to exercise options before their options were vested, subject to certain limitations. Upon early exercise, the awards become subject to a restricted stock agreement and are subject to the same vesting provisions in the original stock option awards. Shares issued as a result of early exercise that have not vested are subject to repurchase by the Company upon termination of the purchaser&#8217;s employment, at the lesser of the price paid by the purchaser or the fair value of the shares at the time of repurchase. Such shares are not deemed to be issued for accounting purposes until they vest and are therefore excluded from shares outstanding until the repurchase right lapses and the shares are no longer subject to the repurchase feature. The liability is reclassified into common stock and additional paid-in capital as the shares vest and the repurchase right lapses. Accordingly, the Company has recorded the unvested portion of the exercise proceeds of less than $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_4iKy94V-6UeB5pmDG5OepA" decimals="-4" format="ixt:numdotdecimal" name="elev:RestrictedStockRepurchaseLiability" scale="6" id="Narr_bnfc4flaCkykckp_IbRk1w"><ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_Hc0jKnnQ5EKY8gQMK3Ryuw" decimals="-4" format="ixt:numdotdecimal" name="elev:RestrictedStockRepurchaseLiability" scale="6" id="Narr_BxWSFBiIiUii1Tqwvt5xSA">0.01</ix:nonFraction></ix:nonFraction> million as a liability from the early exercise in the accompanying consolidated balance sheets as of December 31, 2021 and 2020, respectively. The Company recorded stock-based compensation expense associated with restricted common stock of less than $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_YAEGuEqxPEKdKNDxES3Gxg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_bUgjU4ktkk6j09prqpXCPg"><ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_deAfjK4lqEmKMKksWWn-jw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_cjpOkdhQeUG4sOCJEF3x3A">0.1</ix:nonFraction></ix:nonFraction> million during the 12 months ended December 31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restricted Stock Units</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company issues RSUs to employees that generally vest over a <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JBR44UJY20idUxeLVpC0GQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_nKSsJDC7Lk2tITU00f74dQ">four-year</ix:nonNumeric> period with <ix:nonFraction unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JBR44UJY20idUxeLVpC0GQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_CKK4oj6yfUiiK9kQU7fvqA">25</ix:nonFraction>% of awards vesting after one year and then quarterly thereafter. Any unvested shares will be forfeited upon termination of services. The fair value of an RSU is equal to the fair market value price of the Company&#8217;s common stock on the date of grant. RSU expense is amortized straight-line over the vesting period. </p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="Tb_Dk9o5aQOykiu0pxwfNxGpw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes activity related to restricted stock units:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;average</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">grant date</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JBR44UJY20idUxeLVpC0GQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_G4RcxYU5X0ykzfjgeTTHkQ_5_2">200,996</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JBR44UJY20idUxeLVpC0GQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_8yS8YZK6SU60jZz1l6uLSw_5_5">16.00</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OZUmi-gHpkqGwGuZU2171Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_44GWaJLN30-ceJCirGZsHg_6_2">200,996</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OZUmi-gHpkqGwGuZU2171Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_7mfBnriFLUqg7QmFa0wBhg_6_5">16.00</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company recorded stock-based compensation expense of $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JBR44UJY20idUxeLVpC0GQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_vQB1zu8SbEqgPR8ZPMEmLg">0.4</ix:nonFraction> million for the 12 months ended December 31, 2021, related to RSUs. As of December 31, 2021, the total unrecognized expense related to all RSUs was $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OZUmi-gHpkqGwGuZU2171Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="Narr_AmY9KDPW8k63QJJVrLw2YQ">2.8</ix:nonFraction> million, which the Company expects to recognize over a weighted-average period of <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JBR44UJY20idUxeLVpC0GQ" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_3iFKgVYOtEytg6ULDnChTA">3.4</ix:nonNumeric>&#160;years.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="elev:AssetPurchaseAndLicenseAgreementsDisclosureTextBlock" id="Tb_KXdW8b11tEu3ep-5ephgxA" continuedAt="Tb_KXdW8b11tEu3ep-5ephgxA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. ASSET PURCHASE AND LICENSE AGREEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2019, the Company entered into an asset purchase agreement with the previous sponsor, pursuant to which it acquired all rights and interest to patents, know-how, and inventory for assets related to seribantumab, a fully humanized immunoglobulin G2 monoclonal antibody against HER3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the asset purchase agreement, the Company made an upfront, non-refundable payment of $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_5_1_2019_To_5_31_2019_us-gaap_AssetAcquisitionAxis_elev_AssetPurchaseAgreementRelatingToSeribantumabMember_uhzmSNBzfkm5eBJiG2sU0Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="6" id="Narr_thRk93qjF0eeLdLxfSbZ7Q">3.5</ix:nonFraction> million at closing. If the Company succeeds in developing and commercializing seribantumab, the Company may be obligated to pay the previous sponsor up to $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AssetAcquisitionAxis_elev_AssetPurchaseAgreementRelatingToSeribantumabMember_tQNsHiiyPk60TadASippIw" decimals="-5" format="ixt:numdotdecimal" name="elev:CollaborationAndLicenseAgreementsMilestonePaymentsPayable" scale="6" id="Narr_dZ-TRBkpgUi5aCHCTC2bMA">54.5</ix:nonFraction> million in development, regulatory and sales milestone payments.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_KXdW8b11tEu3ep-5ephgxA_cont1" continuedAt="Tb_KXdW8b11tEu3ep-5ephgxA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the asset purchase agreement, the Company assumed the rights and obligations of the following collaboration and license agreements previously held by the previous sponsor:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Dyax&#8212;</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company assumed all rights and obligations provided for under the amended and restated collaboration agreement executed between Dyax Corp. (&#8220;Dyax&#8221;) and the previous sponsor (the &#8220;Dyax Agreement&#8221;). Pursuant to the Dyax Agreement, Dyax utilized its proprietary phage technology to identify antibodies that would bind to targets of interest to the previous sponsor. Additionally, Dyax granted to the previous sponsor a world-wide, non-exclusive, royalty free right to use and make any and all of the antibodies identified by Dyax for certain research purposes. Seribantumab was identified as a result of the research activities performed under the Dyax Agreement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the Dyax Agreement, the Company may be obligated to pay Dyax milestone payments of up to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AssetAcquisitionAxis_elev_DyaxAgreementMember_TIOCbS27gU2NoUyO8PZbQw" decimals="-5" format="ixt:numdotdecimal" name="elev:CollaborationAndLicenseAgreementsMilestonePaymentsPayable" scale="6" id="Narr_i0STenhLQUaeitYCnrFM6Q">9.3</ix:nonFraction> million if certain development and regulatory milestones are achieved. In addition, Dyax is entitled to mid-single digit royalties based on net sales of seribantumab. The Company&#8217;s obligation to pay royalties to Dyax continues on a product-by-product and country-by-country basis until the later of a specified number of&#160;years after the first commercial sale in such country and the expiration of the patent rights covering seribantumab in such country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Dyax Agreement will remain in effect, unless earlier terminated, for so long as the Company continues to develop or commercialize seribantumab. Either party may terminate the agreement in the event of an uncured material breach by the other party. The Company also has the right to terminate the agreement in its entirety or on a product-by-product basis at any time upon <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AssetAcquisitionAxis_elev_DyaxAgreementMember_cqZbVZ2gh06l0lshIvlOdA" format="ixt-sec:durwordsen" name="elev:CollaborationAndLicenseAgreementsNoticePeriod" id="Narr_5xvEfdJ28EaKs8tYMWkB7A">90&#160;days</ix:nonNumeric>&#8217; prior written notice.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Ligand Pharmaceuticals&#8212;</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company assumed all rights and obligations provided for under the amended commercial license agreement executed between Selexis SA (&#8220;Selexis&#8221;) and the previous sponsor (the &#8220;Selexis Agreement&#8221;). Pursuant to the Selexis Agreement, the Company received non-exclusive rights to technology for use in the manufacture of seribantumab and may be required to make milestone payments of up to approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_QZ9PiilgBE2N3HwLp8Y6Lg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AssetAcquisitionAxis_elev_SelexisAgreementMember_-Up5XNit8UCwOaN4IdjeDA" decimals="0" format="ixt:numdotdecimal" name="elev:CollaborationAndLicenseAgreementsMilestonePaymentsPayablePerLicensedProduct" scale="0" id="Narr_lqk0VqP6BE6vE5aACZ_hfg">900</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, per licensed product, if certain development and regulatory milestones are achieved. Additionally, Selexis may have the right to obtain a royalty of the greater of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_QZ9PiilgBE2N3HwLp8Y6Lg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AssetAcquisitionAxis_elev_SelexisAgreementMember_p3VwQWadQ02foloetZBlYw" decimals="-5" format="ixt:numdotdecimal" name="elev:CollaborationAndLicenseAgreementsRoyaltyPaymentsPayable" scale="6" id="Narr_dVyxFosHP0WBw0BZmJgjjw">0.2</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million annually and less than </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AssetAcquisitionAxis_elev_SelexisAgreementMember_p3VwQWadQ02foloetZBlYw" decimals="2" format="ixt-sec:numwordsen" name="elev:CollaborationAndLicenseAgreementsPercentageOfRoyaltyOnNetSalesOfLicensedProducts" scale="-2" id="Narr_nmhug-GPe0CGp1a9L5IWgw">one</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;percent on net sales of seribantumab. The obligation to pay royalties with respect to each product sold in a country continues until the expiration of the patent rights covering the product in such country. Either party may terminate the agreement in the event of an uncured material breach by the other party. The Company also has the right to terminate the agreement at any time upon </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AssetAcquisitionAxis_elev_SelexisAgreementMember_p3VwQWadQ02foloetZBlYw" format="ixt-sec:durwordsen" name="elev:CollaborationAndLicenseAgreementsNoticePeriod" id="Narr_agWUUlXVek-nnyHoZELStg"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">60&#160;days</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8217; prior written notice.</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"> </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In November of 2021, the Selexis agreement was assigned to Ligand Pharmaceuticals Incorporated.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">National Institute of Health</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212;The Company assumed all rights and obligations provided for under the amended commercial license agreement executed between the U.S. Public Health Service, a division of the U.S. Department of Health and Human Services (the &#8220;NIH&#8221;) and the previous sponsor (the &#8220;NIH Agreement&#8221;). Pursuant to the NIH Agreement, the Company received non-exclusive rights in the United States to patents related to certain antibodies associated with seribantumab. If certain development and regulatory milestones are achieved, the Company may be obligated to pay NIH additional milestone payments of up to approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AssetAcquisitionAxis_elev_NIHAgreementMember_I6LRl9X8GkOusRfsCtA2GQ" decimals="-5" format="ixt:numdotdecimal" name="elev:CollaborationAndLicenseAgreementsMilestonePaymentsPayable" scale="6" id="Narr_RGHCGyXym0-HpPxy7zYuSA">0.4</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million per licensed product.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company evaluated the asset purchase agreement with the previous sponsor under ASC Topic 805<i style="font-style:italic;">, Business Combinations,</i> and concluded that the transaction did not meet the requirements to be accounted for as a business combination and therefore was accounted for as an asset acquisition. Accordingly, the upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AssetAcquisitionAxis_elev_AssetPurchaseAgreementRelatingToSeribantumabMember_5HWpL8YS1E2KOC6PDwU83A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_IL-pwx9yTkqIONO4-_Amcg">3.5</ix:nonFraction> million was expensed as research and development expenses in the statement of operations for the year ended December&#160;31, 2019. Additionally, the Company concluded that all consideration to be paid under the asset purchase agreement is contingent in nature and will be recognized when the respective contingency is resolved. The Company assessed the contingent events which would result in the payment of a milestone as of December&#160;31, 2021 and 2020, and concluded <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AssetAcquisitionAxis_elev_AssetPurchaseAgreementRelatingToSeribantumabMember_6okAWYA92EqLCivJwShcTQ" decimals="-5" format="ixt-sec:numwordsen" name="elev:CollaborationAndLicenseAgreementsMilestonePaymentsPaid" scale="6" id="Narr_D0krXZNfhEiaXaOpI0aMtA"><ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AssetAcquisitionAxis_elev_AssetPurchaseAgreementRelatingToSeribantumabMember_5HWpL8YS1E2KOC6PDwU83A" decimals="-5" format="ixt-sec:numwordsen" name="elev:CollaborationAndLicenseAgreementsMilestonePaymentsPaid" scale="6" id="Narr_MqcrC2l8vU-eJS85Sfw8yQ">no</ix:nonFraction></ix:nonFraction> such payments were required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_KXdW8b11tEu3ep-5ephgxA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Research Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In June 2021, the Company entered into a collaboration agreement with Caris, or the Caris Agreement. Under the terms of the Caris Agreement, Caris will identify targets for the collaboration and provide those targets to the Company at regular intervals for review and approval. Once a target is selected by the collaboration&#8217;s joint steering committee, the collaboration will retain access to the selected targets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The financial terms surrounding development and commercialization of each product candidate identified for the collaboration and included in the Caris Agreement vary based on the level of participation elected by each party in the development and commercialization efforts following identification of a target. There are no upfront or milestone payments or royalties due to either party under the collaboration. With respect to proceeds from any potential commercial transaction related to a product resulting from the collaboration, Caris will be entitled to a tiered initial&#160;percentage ranging from the mid-single digits to low teens based on the product candidate&#8217;s potential peak sales revenue with the remaining proceeds allocated based on each party&#8217;s pro&#160;rata share of expenses incurred in development of the product. In the case of an out-licensing transaction of an asset instead of a sale, Caris and the Company will split all consideration received in the transaction in a similar manner. The Caris Agreement provides flexibility for Caris and the Company to jointly develop and commercialize, or for either the Company or Caris to incur development and commercialization expenses. The ultimate&#160;percentage of proceeds payable to the Company and Caris will depend on the level of development and commercialization participation elected by each party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company will own the intellectual property rights to the therapeutics developed under the collaboration, and Caris will own the intellectual property rights to the diagnostics developed under the collaboration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Either party may terminate the Caris Agreement for uncured material breach by the other party or in the case of the other party&#8217;s insolvency. The term of the Caris Agreement is <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_sZb_K3th-kWfL5-YVdEe1g" format="ixt-sec:durwordsen" name="elev:CollaborationAgreementTerm" id="Narr_4NRgvWr5wUa8hkHFgHn-fg">three years</ix:nonNumeric>, automatically renewing for <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_sZb_K3th-kWfL5-YVdEe1g" format="ixt-sec:durwordsen" name="elev:CollaborationAgreementRenewalTerm" id="Narr_PQEb2VFfvkux8fJADpRfIA">one-year</ix:nonNumeric> terms. Either party may terminate the agreement at the end of a term by written notice to the other, subject to the continuation of exclusivity with respect to any target selected by the Joint Steering Committee, so long as commercially reasonable efforts are used to discover, identify, develop and/or commercialize a therapeutic related to such target.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_aL4INDrd_kmJHVkFqZW_Zg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. COMMITMENTS AND CONTINGENCIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company, from time to time, may be involved in legal proceedings, regulatory actions, claims and litigation arising in the ordinary course of business. The Company was not a defendant in any lawsuits from Inception to the date of these consolidated financial statements.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_nymOpZ3zIk2OqsKYqStzIQ_1_2"></a><a id="Tc_C-DHV1fxYEGyM0MtfTFr4g_2_2"></a><a id="Tc_-sSSe3BVgUq-viDYdyVblg_2_4"></a><a id="Tc_N9bPR07rk06Dcvon2oZEnQ_3_0"></a><a id="Tc_SP8qWpogtk-kXdfOfkbLdw_3_3"></a><a id="Tc_WTo-okkYAEy9xtXZiAGbVA_3_5"></a><a id="Tc_0O44lKwUVEiRHwKCoLlIhQ_4_0"></a><a id="Tc_32xpDW9ufUyoBr2ClvemfQ_4_3"></a><a id="Tc_loYfEHCf20a8hdThfRAP2w_4_5"></a><a id="Tc_4rBYMot9fkubUwVFsVnAMA_5_0"></a><a id="Tc_gVm_16AZokKldmtRxv9aTw_5_3"></a><a id="Tc__qBHwMCQ50GHcSdP724RGQ_5_5"></a><a id="Tc_osaFspdTbEG43OoSpUauIw_6_0"></a><a id="Tc_mQP0y4NOeUm9zbqR2k2R5g_6_3"></a><a id="Tc_0-n_ojjuvk-uzMmeIObczA_6_5"></a><a id="Tc_61xl-EW-q0-Hqqky0DGTWw_7_0"></a><a id="Tc_O_1w6g6xpUC00g8qnDIemg_7_3"></a><a id="Tc_X-1JWWnhcEWpyE6LKKaGYg_7_4"></a><a id="Tc_siDR7e1kcEeZeoHfX9YRPg_7_5"></a><a id="Tc_PZljQ9BGxESr0J7TMlEb4A_8_0"></a><a id="Tc_JjPHm_tYK0WMrWz5iFvmcg_8_3"></a><a id="Tc_bAk_RFnVtUGz2XjmuEqIjg_8_5"></a><a id="Tc_f1jxwGWtoEWXBhbjpufRSA_9_0"></a><a id="Tc_3dc_I-htt0-hqMfNKCWeTw_9_2"></a><a id="Tc_4HcGq-26HUKbr4ptCx76uA_9_3"></a><a id="Tc_aYJNTHwMN0SJYbL_iSyLzw_9_4"></a><a id="Tc_oBLP5Goz3UGfTXS-YCnaqw_9_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_3GxBWEJhlkmYH93NNTxA5Q" continuedAt="Tb_3GxBWEJhlkmYH93NNTxA5Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. INCOME TAXES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="Narr_LHJFZVqoakOmhquTt20ItA"><ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="Narr_ci6RH4DKzEKnbry9u00lLA">No</ix:nonFraction></ix:nonFraction> provision for income taxes was recorded for the years ended December 31, 2021 and 2020. The Company has incurred net pre-tax losses in the United States only for all periods presented. The Company has not reflected any benefit of such net operating loss (&#8220;NOL&#8221;) carryforwards in the accompanying consolidated financial statements. The provision for income taxes differs from the amount expected by applying the federal statutory rate to the loss before taxes as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_lNj9zsTIp0yvahpbRavpxg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Profit before tax at federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_N1L5JnElF0G7taGAgaCqDw_3_2">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_2hsTu1-ZW06H4LjACTk46A_3_4">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State tax benefit, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_D7ddUUqCKE2hk8jD0zqVLA_4_2">0.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_TctIFeP2PEKm4BsiT-Dgww_4_4">0.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credit carryovers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="Tc_HJF_1sLGrE2g_wp8PACpTA_5_2">4.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="Tc_eD0NutyWNUqGycjPgFrGzg_5_4">1.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="3" format="ixt:numdotdecimal" name="elev:EffectiveIncomeTaxRateReconciliationPermanentDifferences" sign="-" scale="-2" id="Tc_woJqCGo2U0C3RpntM4lZeA_6_2">1.4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="3" format="ixt:numdotdecimal" name="elev:EffectiveIncomeTaxRateReconciliationPermanentDifferences" sign="-" scale="-2" id="Tc_D2yM8Z6DF02wVwz2hWjpJw_6_4">0.6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Return to Provision True Ups</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="3" format="ixt:numdotdecimal" name="elev:EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUpsPercent" scale="-2" id="Tc_lyfAwh5-wE68uRJkyiIo1w_7_2">0.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_K7MbdfSjqUu_d5QsWgRrkQ_8_2">24.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_nbS6nX_AVEyq1LeAaXdGQg_8_4">22.4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_737fb199_39be_4e07_b9cd_f91014402ed3"></a><a id="Tc_HfQJriIxdEGiEDgouKXrkg_1_2"></a><a id="Tc_5NyJcrcm4E-l5FUCE2VnqQ_2_2"></a><a id="Tc_1njfmt3wIUO4M381NEbpcA_2_5"></a><a id="Tc_e9P232ztgU23-BIOugJUUA_3_2"></a><a id="Tc_-A17MNwR7kGtVDNQ4YY0FQ_4_0"></a><a id="Tc_kmNp0XjLGU2oGkdj2ZUiyw_5_0"></a><a id="Tc_1Oe0WA2CZU-k177tXoCGYQ_5_2"></a><a id="Tc_Kn1iBQeKUkmJ-KErkXhcvg_5_5"></a><a id="Tc_EemuKExOQ0WHWVwyqn9nbQ_6_0"></a><a id="Tc_KCITSJiBS0-5zxn0865T-A_7_0"></a><a id="Tc_amNtziu0rUKjOH2o7yLvKw_7_6"></a><a id="Tc_88di_84FQkqG70zs2lvnDg_8_0"></a><a id="Tc_gFFQqMC31EiIUKZezq3T7w_8_6"></a><a id="Tc_or_JAx2xAEeeK9SxJPAyVQ_9_0"></a><a id="Tc_WSns1yhML0SDupmrryLm-g_10_0"></a><a id="Tc_Xu4mgyiQ3Ue9dUOuk3gj8Q_11_0"></a><a id="Tc_61Q_qFoXeEiQbiJGpmwUAg_12_0"></a><a id="Tc_rHVpGHtL4kWwLWzrFtc6Ow_13_0"></a><a id="Tc_KFI5yHLjM0Gwr2ekb7608w_13_3"></a><a id="Tc_M7zrsqXDjU2MorJ3mI5H4A_14_0"></a><a id="Tc_E34q4Ov_xkaVtj9Ew8imDw_15_0"></a><a id="Tc_ijx0qTq9GEOZeyjhQY5F0w_16_0"></a><a id="Tc_E-NSxAZ0VUGPUQQ5iyGeNw_16_2"></a><a id="Tc_tBFbFwgrW0GFqfGhx6rgyg_16_3"></a><a id="Tc_IWAs-CA4pkSys9j_E00JFg_16_5"></a><a id="Tc_6XGRmIIoDku-ARsAaAWsMA_16_6"></a><ix:continuation id="Tb_3GxBWEJhlkmYH93NNTxA5Q_cont1" continuedAt="Tb_3GxBWEJhlkmYH93NNTxA5Q_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In assessing the realizability of the net deferred tax assets, the Company considers all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the NOL carryforwards. The Company has recorded a valuation allowance against its deferred tax assets on December 31, 2021 and 2020 because the Company&#8217;s management believes that it is more likely than not that these assets will not be fully realized in the near future. The increase in the valuation allowance of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_8lN92wiSkkW-6uyLTySYSQ">7.9</ix:nonFraction> million in the year ended December 31, 2021 primarily relates to the generation of net operating losses and research and development credits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of December 31, 2021, the Company had federal NOL carryforwards of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_RFXCBSdsYE2_Vzi1sOOAOw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_sJJRFr6zI0mIRBMzj0dgCg">48.2</ix:nonFraction> million, all of which can be carried forward indefinitely, and state NOL carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_QVkXeAi9dEuUZNo7SoogXA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_AZdKSY4a5EG0iByIAgit3Q">3.5</ix:nonFraction> million, which begin to expire in 2040. The Company also has federal tax credits of $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_RFXCBSdsYE2_Vzi1sOOAOw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_TTCbxM-Tr0eJAHm_A1VZiA">1.5</ix:nonFraction> million and state tax credits of $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_QVkXeAi9dEuUZNo7SoogXA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_1D0G0Z304ECunKrrbiBKPQ">0.2</ix:nonFraction> million which may be used to offset future tax liabilities and will begin to expire in 2040. NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_84h3vvmd-k2Pjsazz0jQ6g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax asset (liability) in the accompanying consolidated balance sheets consists of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets and (liabilities)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net operating losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_RVbinJeZlUybkASuZfP4fw_5_3">10,303</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_ESsr7miulkuoZ-wxEJ8zcw_5_6">4,138</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_KFlmdY5YCUWUOObTH3svGg_6_3">1,697</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_MJDpeYFi4kOiws_3c6QVCQ_6_6">295</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="Tc_clbiTSm3IUCYFL_210FCOw_7_3">130</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_wFQgHZXfL0SkauXNN9ACOQ_8_3">151</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="Tc_72k5J6Tb4U2UoXVMPuvWdQ_9_3">666</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="Tc_PjcK99Jea0exPZXCgpZh5A_9_6">664</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gross deferred tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_fgg0WlasnkePt0xKjPsRAg_10_3">12,947</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_czk6aIFUOUWqbhprQDkP2w_10_6">5,097</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_Nt1dxHxRyk6SRQhEWkXS5w_11_3">12,945</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_ujrRXuP_uEeryA4s35Qi6w_11_6">5,083</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net deferred tax asset</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_rZT6t64UqUKL0cWXjmhygw_12_3">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_0cRWCbsBpU6THHEZ11xnCA_12_6">14</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="elev:DeferredTaxLiabilitiesStockBasedCompensation" scale="3" id="Tc_coJ1jq4dTkCY3C6vjoiqnA_13_6">2</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="Tc_LHNQh1wXhUK6czaqYLsJ5Q_14_3">2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="Tc_R3q_BW-wo0mQg6ZZczkocw_14_6">12</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred tax liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_PifboYsKyUanpbaoaX545g_15_3">2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_yZbuGj4Awk6S3MWyO0MqWQ_15_6">14</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net deferred tax asset (liability)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Subsequent ownership changes may further affect the limitation in future years. The Company has not conducted a study to assess whether a change of ownership has occurred or whether there have been multiple changes of ownership since Inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of ownership, as defined by Section 382 and 383 of the Internal Revenue Code, at any time since Inception, utilization of the NOL carryforwards or research and development tax credit carryforwards would be subject to the annual limitations under Section 382 and 383 of the Internal Revenue Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company will recognize both accrued interest and penalties related to uncertain tax positions in income tax expense. As of December 31, 2021, the Company had <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="Narr_tijG1kwiRku0XOB60_7-PQ">no</ix:nonFraction> accrued interest or penalties related to uncertain tax positions and <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" id="Narr_BXolBOKBx0eVsqnyIAsiJw">no</ix:nonFraction> amounts have been recognized in the Company&#8217;s statements of operations. Since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available. As of December 31, 2021, all tax returns remain open.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In response to the COVID-19 pandemic, the Coronavirus Aid, Relief, and Economic Security Act (&#8220;the CARES Act&#8221;), was signed into law in March 2020. The CARES Act lifts certain deduction limitations originally imposed by the Tax Cuts and Jobs Act of 2017 (&#8220;2017 Tax Act&#8221;). Corporate taxpayers may carryback NOLs originating during 2018 through 2020 for up to five years, which was not previously allowed under the 2017 Tax Act. The CARES Act also eliminates the 80% of taxable income limitations by allowing corporate entities to fully utilize NOL carryforwards to offset taxable </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_3GxBWEJhlkmYH93NNTxA5Q_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">income in 2018, 2019 or 2020. Taxpayers may generally deduct interest up to the sum of 50% of adjusted taxable income plus business interest income (30% limit under the 2017 Tax Act) for tax years beginning January 1, 2019 and 2020. The CARES Act allows taxpayers with alternative minimum tax credits to claim a refund in 2020 for the entire amount of the credits instead of recovering the credits through refunds over a period of years, as originally enacted by the 2017 Tax Act. The Company notes that these provisions did not have a material impact to the amounts recorded within this footnote.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_8049ce75_7258_4802_b78b_2c1930733247"></a><a id="Tc_3qQqihRCu0C16XMejnFa_A_1_2"></a><a id="Tc_UP5Oqj_Sok65pNCcZDbWnQ_2_2"></a><a id="Tc_SqbB01KEJk-f8lsLFqnlRg_2_5"></a><a id="Tc__1_8PbOVVkqw5srMuAcujg_3_0"></a><a id="Tc_42Yjs4K_IkWGRIYZ2-Bxzg_3_2"></a><a id="Tc_nZUyvD0e8UWIOgChfr1lfw_3_5"></a><a id="Tc_s9v-QZugAUuszJOmg7iRkg_4_0"></a><a id="Tc_LxqL9ERVxU2h_6L2XVThLw_5_0"></a><a id="Tc_WbUXEHl6aUi-Io99ZQf3Bg_1_2"></a><a id="Tc_XlUPHT6FF0aggtfoXrMl9w_2_2"></a><a id="Tc_NIiALsF0zk-o1oazVyj11A_2_4"></a><a id="Tc_QBRkpf0KTkG9ANoVfgFaiQ_3_0"></a><a id="Tc_01AEW3OXtU2cf8HUWG0PWg_3_2"></a><a id="Tc_RbIo8UtVVEqmPo6e3RrSJw_4_0"></a><a id="Tc_peg3FZOAeU2aPZgF5azvcA_5_0"></a><a id="Tc_H91BoJ68qU6wr58BwygIDw_6_0"></a><a id="Tc_1envb1kv3kejnAHGDHMqSw_6_4"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:EarningsPerShareTextBlock" id="Tb_Sj4mBt6Gp0OtFxt1m7PAJQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. NET LOSS PER SHARE</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_ZpIvfA28f0u8UYGBU8jEQg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table summarizes the computation of basic and diluted net loss per share of the Company (in thousands, except share and per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_WVhMIdMWJ0KXGa8zix1LjQ_3_3">32,039</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_g368zNLbE0CfLSq12ycGBg_3_6">17,265</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average common stock outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_RA2-2WPnj02jYNYfsoLW0g_4_3">12,132,610</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_7bDuh5hU302M8ryVwdg4-Q_4_6">791,821</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_7_nAdfS6MEueO81duCm77g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_YXAqZ_chjkSn1AwDyN_eEw_5_3">2.64</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_-xHMw6Cns0q3G7uP67l6TA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_o77xMy_7w0Gy3_V1DnZV3Q_5_6">21.80</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company&#8217;s potentially dilutive securities, which include convertible preferred stock, options to purchase common stock and unvested restricted stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_dEsJ4R6RQ0S2a3ThymSYmw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible preferred shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_eKa9OMO3pEGjRYGCoRthgA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc__7tejvRMWk6KTE0eLyLc4w_3_4">15,736,053</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_WIKQC4DzRE6vI_AOC5-AMw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_YTkoPGGDlEOEuxR_Bw8MPw_4_2">3,021,799</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_a5d4Y0z3Nk-SAUzQFRv89w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_GezfLUiQrUmQgt3QOfdDsw_4_4">1,761,062</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_QSMT7xTslESMy-UsUkueuA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_ALY4uNUZP0mihjquqBBB0A_5_2">19,721</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_XBvq6XI_aEGrm9k0W47ISg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_2nK739OoWkCG6JfxBeKoEQ_5_4">34,498</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_H_M1d8Hn4ki520t7iGj3Ng" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_Iaraw7MoVkymptJnjMJsmQ_6_2">200,996</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_ZlvahLM1ZEezp5bC2N-J8Q_7_2">3,242,516</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_6vtKcUxslESJhk9pNftnJw_7_4">17,531,613</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Tb_3VX9-82piUuh_ga2tvrjVA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13. DEFINED CONTRIBUTION PLAN</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has a defined-contribution plan under Section 401(k) of the Internal Revenue Code (the &#8220;401(k) Plan&#8221;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. As currently established, the Company is not required to make contributions to the 401(k) Plan. The Company made matching contributions of $<ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="Narr_03_lV2x3sU2H-D8w0rxIEg">0.1</ix:nonFraction> million for the year ended December 31, 2021. <ix:nonFraction unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ" contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="Narr_bj91Jtw-q0SfRFgjXam0rg">No</ix:nonFraction> contributions were made for the year ended December 31, 2020.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a483eeae_c976_44fa_8e02_de583328b032"></a><a id="Item9ChangesinandDisagreementswithAccoun"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_98121edb_fea5_49e8_aa2a_8992ffef4caa"></a><a id="Item9AControlsandProcedures_825120"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9A. Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements in accordance with GAAP. This Annual Report does not include a report of management&#8217;s assessment regarding internal control over financial reporting or an attestation report of the of the Company&#8217;s registered public accounting firm due to a transition period established by rules of the SEC for newly public companies. We will be required, under Section 404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting beginning with our Annual Report on Form 10-K for the year ending December 31, 2022. This assessment will need to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. The SEC defines a material weakness as a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of a company&#8217;s annual or interim consolidated financial statements will not be detected or prevented on a timely basis.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">In accordance with the provisions of the Sarbanes-Oxley Act, neither we nor our independent registered public accounting firm has performed an evaluation of our internal control over financial reporting during any period included in this annual report. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Changes in Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:8.1pt;margin:0pt;"><span style="font-size:8.1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the three months ended December 31, 2021 that have materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p><a id="_f87dc277_2e7a_460d_b366_2ccc5e380691"></a><a id="Item9BOtherInformation_23751"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9B. Other Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_4f066fb9_0ed7_4218_93b8_26f22cddb39b"></a><a id="Item9C_Disclosure_Regarding_Foreign_Jur"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_79390e97_3445_496f_924d_0d9a3d4b465f"></a><a id="PARTIII_833192"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">PART&#160;III</p><a id="Item10DirectorsExecutiveOfficersandCorpo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;10. Directors, Executive Officers, and Corporate Governance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Except to the extent provided below, the information required by this Item 10 will be included in the section captioned &#8220;Corporate Governance Matters&#8221; and the subsections thereof, &#8220;Class I Director Nominees,&#8221; &#8220;Class II Directors,&#8221; &#8220;Class III Directors,&#8221; &#8220;Executive Officers,&#8221; and &#8220;Section 16(a) Beneficial Ownership Reporting Compliance,&#8221; in our definitive proxy statement to be filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) with respect to our 2022 Annual Meeting of Stockholders within 120 days of the end of the fiscal year to which this report relates, which information is incorporated herein by reference</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We post our code of business conduct and ethics, which applies to all employees, including all executive officers, senior financial officers and directors, in the &#8220;Governance&#8221; sub-section of the &#8220;Investor Relations&#8221; section (https://investors.elevationoncology.com) of our corporate website at www.elevationoncology.com. Our code of business conduct and ethics complies with Item 406 of SEC Regulation S-K and the rules of Nasdaq. We intend to disclose any changes to the code that affect the provisions required by Item 406 of Regulation S-K, and any waivers of the code of ethics for our executive officers, senior financial officers or directors, on our corporate website.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_60ba498c_c820_4bb5_ad8d_542285f870d0"></a><a id="Item11ExecutiveCompensation_595598"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;11. Executive Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The information required by this Item 11 will be included in the section captioned &#8220;Executive Compensation&#8221; in our definitive proxy statement to be filed with the SEC with respect to our 2022 Annual Meeting of Stockholders within 120 days of the end of the fiscal year to which this report relates, which information is incorporated herein by reference.</span></p><a id="_cb010b8a_cd4d_4cb7_8684_05f23ed767bf"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The information required by this Item 12 will be included in the sections captioned &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Securities Authorized for Issuance under Equity Compensation Plans&#8221; in our definitive proxy statement to be filed with the SEC with respect to our 2022 Annual Meeting of Stockholders within 120 days of the end of the fiscal year to which this report relates, which information is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a5a4c4f8_8ad6_4b5b_a124_077a384f533a"></a><a id="Item13CertainRelationshipsandRelatedTran"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information required by this Item 13 will be included in the sections captioned &#8220;Related Person Transactions,&#8221; &#8220;Policies and Procedures for Related Person Transactions&#8221; and &#8220;Board Determination of Independence&#8221; in our definitive proxy statement to be filed with the SEC with respect to our 2022 Annual Meeting of Stockholders within 120 days of the end of the fiscal year to which this report relates, which information is incorporated herein by reference.</p><a id="_3ca28d3a_4ae8_4929_bd23_cdb67086c68d"></a><a id="Item14PrincipalAccountantsFeesandService"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;14. Principal Accountant&#8217;s Fees and Services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The information required by this Item 14 will be included in the section captioned &#8220;Audit Fees and Services&#8221; and the subsection thereof in our definitive proxy statement to be filed with the SEC with respect to our 2022 Annual Meeting of Stockholders within 120 days of the end of the fiscal year to which this report relates, which information is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_1944ac72_bdc4_4f8a_baae_2fcd0780f882"></a><a id="PartIV_195701"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Part&#160;IV</p><a id="Item15ExhibitsandFinancialStatementSched"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;15. Exhibits and Financial Statement Schedules</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:7.9pt;margin:0pt;"><span style="font-size:7.9pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Consolidated Financial Statements</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:8.1pt;margin:0pt;"><span style="font-size:8.1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">See Index to Consolidated Financial Statements at Item 8 herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:14.45pt;margin:0pt;"><span style="font-size:14.45pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">124</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Financial Statement Schedules</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:7.4pt;margin:0pt;"><span style="font-size:7.4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">All schedules are omitted because they are not applicable or the required information is shown in the consolidated financial statements or notes thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:16.25pt;margin:0pt;"><span style="font-size:16.25pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Exhibits</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:7.4pt;margin:0pt;"><span style="font-size:7.4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following is a list of exhibits filed as part of this Annual Report on Form 10-K.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:33.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:11.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:14.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:top;width:46.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated by Reference</b></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><br /><b style="font-weight:bold;">No.</b></p></td><td style="vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></td><td style="vertical-align:bottom;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File No.</b></p></td><td style="vertical-align:bottom;width:9.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:bottom;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing Date</b></p></td><td style="vertical-align:bottom;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">herewith</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.1 </p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1783032/000155837021011478/elev-20210630xex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Restated Certificate of Incorporation</span></a>. </p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-40523</p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1 </p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">August 12, 2021</p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1783032/000155837021011478/elev-20210630xex3d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Restated Bylaws</span></a>. </p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-40523</p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">August 12, 2021</p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1783032/000110465921082926/tm2111147d13_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Stock Certificate</span></a>.</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-256787</p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">June 21, 2021</p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="elev-20211231xex4d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934</span></a>.</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.3</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1783032/000110465921076988/tm2111147d8_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Investors&#8217; Rights Agreement, dated November 10, 2020 by and among Elevation Oncology, Inc. and certain of its stockholders</span></a>.</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-256787</p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">June 4, 2021</p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.1#</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1783032/000110465921082926/tm2111147d13_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Indemnity Agreement</span></a>.</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-256787</p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">June 21, 2021</p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.2#</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1783032/000110465921076988/tm2111147d8_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2019 Equity Incentive Plan, as amended, and forms of award agreements</span></a>.</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-256787</p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">June 4, 2021</p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.3#</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1783032/000110465921082926/tm2111147d13_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2021 Equity Incentive Plan, and forms of award agreements</span></a>.</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-256787</p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">June 21, 2021</p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.4#</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1783032/000110465921082926/tm2111147d13_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2021 Employee Stock Purchase Plan, and forms of award agreements</span></a>.</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-256787</p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.4</p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">June 21, 2021</p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">10.5</span><sup style="font-size:7.5pt;letter-spacing:0.2pt;line-height:100%;top:0pt;vertical-align:top;">&#708;</sup><span style="letter-spacing:0.2pt;">&#8224;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1783032/000110465921076988/tm2111147d8_ex10-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Asset Purchase Agreement dated May 28, 2019, by and between the Registrant and Merrimack Pharmaceuticals, Inc., as amended</span></a>.</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-256787</p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.5</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">June 4, 2021</p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">10.6</span><sup style="font-size:7.5pt;letter-spacing:0.2pt;line-height:100%;top:0pt;vertical-align:top;">&#708;</sup><span style="letter-spacing:0.2pt;">&#8224;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1783032/000110465921076988/tm2111147d8_ex10-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Collaboration Agreement dated January 24, 2007 between Dyax Corp. and Merrimack Pharmaceuticals, Inc., as amended</span></a>.</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-256787</p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.6</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">June 4, 2021</p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">10.7</span><sup style="font-size:7.5pt;letter-spacing:0.2pt;line-height:100%;top:0pt;vertical-align:top;">&#708;</sup><span style="letter-spacing:0.2pt;">&#8224;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1783032/000110465921076988/tm2111147d8_ex10-7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Commercial License Agreement dated June 4, 2008 between Selexis SA and Merrimack Pharmaceuticals, Inc.</span></a>.</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-256787</p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.7</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">June 4, 2021</p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.9#</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1783032/000110465921082926/tm2111147d13_ex10-9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement dated July 12, 2019 by and between Elevation Oncology, Inc. and Shawn Leland, as amended</span></a>.</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-256787</p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.9</p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">June 21, 2021</p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.10#</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1783032/000110465921081798/tm2111147d11_ex10-10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement dated June 6, 2021 by and between Elevation Oncology, Inc. and Joseph J. Ferra, Jr.</span></a>.</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-256787</p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.10</p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">June 16, 2021</p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.11#</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="elev-20211231xex10d11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement dated February 2, 2021 by and between Elevation Oncology, Inc. and Valerie Malyvanh Jansen, as amended.</span></a></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.12#<sup style="font-size:7.5pt;letter-spacing:0.2pt;line-height:100%;top:0pt;vertical-align:top;">&#708;</sup><span style="letter-spacing:0.2pt;">&#8224;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1783032/000110465921084523/tm2111147d20_ex10-11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Collaboration Agreement dated June 14, 2021, between Caris MPI, Inc. and Elevation Oncology, Inc.</span></a>.</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-256787</p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.11</p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">June 23, 2021</p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.13</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1783032/000155837021010811/tmb-20210802xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Change in Control and Severance Agreement</span></a>.</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-40523</p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.1</p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">August 6, 2021</p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">21.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="elev-20211231xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Subsidiaries of Registrant</span></a>.</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">23.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="elev-20211231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of CohnReznick LLP, Independent Registered Public Accounting Firm</span></a></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="elev-20211231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a>.</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.2</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="elev-20211231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a>.</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32*</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="elev-20211231xex32.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section&#160;1350, as Adopted Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a>.</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.INS</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;">XBRL Instance Document&#160;&#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">126</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.SCH</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;">XBRL Taxonomy Extension Schema Document.</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.CAL</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;">XBRL Taxonomy Extension Calculation Linkbase Document.</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.DEF</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;">XBRL Taxonomy Extension Definition Linkbase Document.</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.LAB</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;">XBRL Taxonomy Extension Label Linkbase Document.</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.PRE</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;">XBRL Taxonomy Extension Presentation Linkbase Document.</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;">Cover Page&#160;Interactive Data File (formatted in Inline XBRL and contained in Exhibit&#160;101).</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100.14%;"><tr style="height:1pt;"><td style="vertical-align:top;width:9.25%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:87.96%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:42.4pt;"><td style="vertical-align:top;width:9.25%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:42.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:3.75pt 0pt 1.5pt 0pt;">*</p></div></div></td><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0pt;"><div style="height:42.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:87.96%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:42.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">This certification is deemed not filed for purposes of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</p></div></div></td></tr><tr style="height:15pt;"><td style="vertical-align:top;width:9.25%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:3.75pt 0pt 1.5pt 0pt;">&#708;</p></div></div></td><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:87.96%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">Registrant has omitted portions of the exhibit as permitted under Item 601(b)(10) of Regulations S-K.</p></div></div></td></tr><tr style="height:42.4pt;"><td style="vertical-align:top;width:9.25%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:42.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:3.75pt 0pt 1.5pt 0pt;">&#8224;</p></div></div></td><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0pt;"><div style="height:42.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:87.96%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:42.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">Registrant has omitted schedules and exhibits pursuant to Item 601(a)(5) of Regulation S-K. The Registrant agrees to furnish supplementally a copy of the omitted schedules and exhibits to the SEC upon request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:19.9pt;"><td style="vertical-align:top;width:9.25%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:19.9pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:3.75pt 0pt 1.5pt 0pt;">#</p></div></div></td><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0pt;"><div style="height:19.9pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:87.96%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:19.9pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">Indicates management contract or compensatory plan.</p></div></div></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_77375cba_3bcb_4045_92a8_3a97a80a9d68"></a><a id="Item16Form10KSummary_301707"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;16. Form&#160;10-K Summary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">127</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_467cd5c7_9fd2_4a98_9499_03d6e860667e"></a><a id="Signatures"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:46.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ELEVATION ONCOLOGY, INC.</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 3, 2022</p></td><td style="vertical-align:bottom;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:46.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/Shawn Leland</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Shawn Leland</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">President, Chief Executive Officer and Director</i></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below on March 3, 2022 by the following persons on behalf of the registrant and in the capacities indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Shawn Leland, Pharm.D., R.Ph.</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">President, Chief Executive Officer and Director</p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Shawn Leland, Pharm.D., R.Ph.</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Joseph J. Ferra, Jr.</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chief Financial Officer and Corporate Secretary</p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Joseph J. Ferra, Jr.</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Steven A. Elms</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chairman of the Board</p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Steven A. Elms</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ R. Michael Carruthers</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">R. Michael Carruthers</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Timothy Clackson, Ph.D.</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Timothy Clackson, Ph.D.</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Lori Hu</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Lori Hu</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Colin Walsh, Ph.D.</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Colin Walsh, Ph.D.</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">128</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>elev-20211231xex4d2.htm
<DESCRIPTION>EX-4.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/2/2022 11:56:42 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 4.2</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">DESCRIPTION OF REGISTRANT&#8217;S SECURITIES</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">REGISTERED PURSUANT TO SECTION 12 OF THE</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">As of December 31, 2021, Elevation Oncology, Inc. (&#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) had common stock, $0.0001 par value per share, registered under Section 12 of the Securities Exchange Act of 1934, as amended, and listed on The Nasdaq Global Select Market under the trading symbol &#8220;ELEV.&#8221; </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">DESCRIPTION OF CAPITAL STOCK</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Our restated certificate of incorporation authorizes us to issue up to 500,000,000 shares of common stock, $0.0001 par value per share, and 10,000,000 shares of preferred stock, $0.0001 par value per share. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The following is a summary description of the material terms of our capital stock. The description of capital stock is intended as a summary and is qualified in its entirety by reference to our restated certificate of incorporation (&#8220;restated certificate of incorporation&#8221;), and our restated bylaws (&#8220;restated bylaws&#8221;), copies of which are filed as exhibits to our most recent Annual Report on Form 10-K and are incorporated by reference herein. We encourage you to read our restated certificate of incorporation, our restated bylaws and the applicable provisions of the Delaware General Corporation Law (the &#8220;DGCL&#8221;) for additional information.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a></font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Common stock</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Dividend rights</font><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of our common stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that our board of directors may determine.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Voting rights</font><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. We have not provided for cumulative voting for the election of directors in our restated certificate of incorporation, which means that holders of a majority of the shares of our common stock will be able to elect all of our directors. Our restated certificate of incorporation establishes a classified board of directors, to be divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms.&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">No preemptive or similar rights</font><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Our common stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions.&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Right to receive liquidation distributions</font><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Upon our liquidation, dissolution or winding-up, the assets legally available for distribution to our stockholders would be distributable ratably among the holders of our common stock and any participating preferred stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights of and the payment of liquidation preferences, if any, on any outstanding shares our of preferred stock.&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Preferred stock</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">No shares of our preferred stock are outstanding. Pursuant to our restated certificate of incorporation, our board of directors is authorized, subject to limitations prescribed by Delaware law, to issue preferred stock in one or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences and rights of the shares of each series and any of their qualifications, limitations or restrictions, in each case without further vote or action by our stockholders. Our board of directors will also be able to increase or decrease the number of shares of any series of preferred stock, but not below the number of shares of that series then </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">outstanding and not above the number of shares of that series authorized, without any further vote or action by our stockholders. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of our company and might adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock. We have no current plan to issue any shares of preferred stock.&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Registration rights</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Pursuant to the terms of the Amended and Restated Investors&#8217; Rights Agreement (the &#8220;IRA&#8221;), the holders of shares of our common stock will be entitled to rights with respect to the registration of these shares under the&#160;Securities Act&#160;as described below. We refer to these shares collectively as registrable securities.&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Demand registration rights</font><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Beginning from the earlier of three years after November 10, 2020 or 180 days after the completion of our initial public offering, the holders of not less than 50% of the then-outstanding registrable securities may make a request to us for the registration under the&#160;Securities Act&#160;of at least 40% of the registrable securities then outstanding if the anticipated aggregate offering price, net of selling expenses, would exceed $10.0 million. Within 10 days after the date such request is given, we are obligated to provide notice of such request to all holders of registrable securities and, as soon as practicable and in any event within 60 days after the date such request is given, to file a Form S-1 registration statement under the&#160;Securities Act&#160;covering all registrable securities that the initiating holders requested to be registered and any additional registrable securities requested to be included in such registration by any other holders. We are only required to file two registration statements that are declared effective upon exercise of these demand registration rights. We may postpone taking action with respect to such filing not more than twice during any 12-month period for a total period of not more than 120 days, if after receiving a request for registration, we furnish to the holders requesting such registration a certificate signed by our Chief Executive Officer stating that, in the good faith judgment of our board of directors, it would be materially detrimental to us and our stockholders;&#160;</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">provided that</i><font style="font-family:'Times New Roman','Times','serif';">&#160;we may not register any securities for our own account or that of any other stockholder during such 120-day period other than under certain circumstances.&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Form S-3 registration rights</font><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The holders of at least 10% of the then-outstanding registrable securities can request that we register all or part of their shares on Form S-3 if we are eligible to file a registration statement on Form S-3 and if the aggregate price to the public of the shares offered, net of selling expenses, is at least $5.0 million. Within ten days after such request is given, we are obligated to provide notice of such request to all holders of registrable securities and as soon as practicable and in any event within 45 days, file a Form S-3 registration statement, covering all registrable securities that the initiating holders requested to be registered and any additional registrable securities requested to be included in such registration by any other holders. We are only required to file two registration statements on Form S-3 in a 12-month period. We may postpone taking action with respect to such filing not more than twice during any 12-month period for a period of not more than 120 days, if after receiving a request for registration, we furnish to the holders requesting such registration a certificate signed by our Chief Executive Officer stating that, in the good faith judgment of our board of directors, it would be materially detrimental to us and our stockholders;&#160;</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">provided that</i><font style="font-family:'Times New Roman','Times','serif';">&#160;we may not register any securities for our own account or that of any other stockholder during such 120-day period other than under certain circumstances.&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Piggyback registration rights</font><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">If we register any of our securities for public sale, holders of then-outstanding registrable securities or their permitted transferees will have the right to include their registrable securities in the registration statement. However, this right does not apply to a registration related to any employee benefit plan or a corporate reorganization or other transaction covered by Rule&#160;145&#160;promulgated under the&#160;Securities Act&#160;or a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of our common stock. The underwriters of any underwritten offering will have the right to limit the number of shares </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">registered by these holders if they determine that marketing factors require limitation, in which case the number of shares to be registered will be apportioned pro rata among these holders, according to the total number of registrable securities originally requested by such holders to be included in the registration statement. However, the number of shares to be registered by these holders cannot be reduced below 20% of the registrable securities such holders requested to be included in such offering.&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Expenses of registration rights</font><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">We will pay all expenses, other than underwriting discounts and selling commissions incurred in connection with each of the registrations described above, including the reasonable fees and disbursements, not to exceed $50,000, of one counsel for the selling holders selected by holders of a majority of the registrable securities to be registered, provided however that the registrations described above are not subsequently withdrawn at the request of the holders of a majority in interest of the registerable securities (in which case all selling holders shall bear such expenses pro rata based upon the number of registrable securities that were to be included in the withdrawn registration) unless the holders of a majority of the registrable securities agree to forfeit their right to a registration as described above and provided further that if, at the time of such withdrawal, the holders of these rights shall have learned of a material adverse change in the condition, business, or prospects of the company from that known to the holders at the time of their request and have withdrawn the request with reasonable promptness after learning such information then the holders shall not be required to pay any of such expenses and shall not forfeit their rights. All underwriting discounts and selling commissions shall be borne and paid by the holders pro rata on the basis of the number of registrable securities registered on their behalf.&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Expiration of registration rights</font><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The registration rights described above will expire, with respect to any particular holder of these rights, on the earliest to occur of (i) the closing of a deemed liquidation event, as defined in our restated certificate of incorporation or (ii) such time after our initial public offering as the registerable securities held by such holder may be sold within any three-month period without restriction pursuant to Rule 144 or a similar exemption under the&#160;Securities Act.&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Anti-takeover provisions</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The provisions of the DGCL, our restated certificate of incorporation and our restated bylaws, could have the effect of delaying, deferring or discouraging another person from acquiring control of our company. These provisions, which are summarized below, may have the effect of discouraging takeover bids. They are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms.&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Delaware law</font><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">We are subject to the provisions of Section 203 of the DGCL regulating corporate takeovers. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years following the date on which the person became an interested stockholder unless:&#160;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, (i) shares owned by persons who are directors and also executive officers and (ii) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">at or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation and authorized at an annual or special meeting of stockholders, and not by written consent, </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">by the affirmative vote of at least 66.67% of the outstanding voting stock that is not owned by the interested stockholder.&#160;</font></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8203;Generally, a business combination includes a merger, asset or stock sale, or other transaction or series of transactions together resulting in a financial benefit to the interested stockholder. An interested stockholder is a person who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of a corporation&#8217;s outstanding voting stock. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our board of directors does not approve in advance. We also anticipate that Section 203 may also discourage attempts that might result in a premium over the market price for the shares of common stock held by stockholders.&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Restated certificate of incorporation and restated bylaw provisions</font><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Our restated certificate of incorporation and our restated bylaws include a number of provisions that could deter hostile takeovers or delay or prevent changes in control of our company, including the following:&#160;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;line-height:1.19;text-align:justify;">Board of directors vacancies.</i><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">&#160;Our restated certificate of incorporation and restated bylaws authorize only our board of directors to fill vacant directorships, including newly created seats. In addition, the number of directors constituting our board of directors is permitted to be set only by a resolution adopted by a majority vote of our entire board of directors. These provisions would prevent a stockholder from increasing the size of our board of directors and then gaining control of our board of directors by filling the resulting vacancies with its own nominees. This makes it more difficult to change the composition of our board of directors but promotes continuity of management.&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;line-height:1.19;text-align:justify;">Classified board.</i><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">&#160;Our restated certificate of incorporation and restated bylaws provide that our board of directors is classified into three classes of directors, each with staggered three-year terms. A third party may be discouraged from making a tender offer or otherwise attempting to obtain control of us as it is more difficult and time consuming for stockholders to replace a majority of the directors on a classified board of directors.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;line-height:1.19;text-align:justify;">Stockholder action; special meetings of stockholders.</i><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">&#160;Our restated certificate of incorporation provides that our stockholders may not take action by written consent but may only take action at annual or special meetings of our stockholders. As a result, a holder controlling a majority of our capital stock would not be able to amend our restated bylaws or remove directors without holding a meeting of our stockholders called in accordance with our restated bylaws. Further, our restated bylaws provide that special meetings of our stockholders may be called only by a majority of our board of directors, the chairperson of our board of directors, our Chief Executive Officer or our President, thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal of directors.&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;line-height:1.19;text-align:justify;">Advance notice requirements for stockholder proposals and director nominations.</i><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">&#160;Our restated bylaws provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. Our restated bylaws also specify certain requirements regarding the form and content of a stockholder&#8217;s notice. These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions might also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of our company.&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;line-height:1.19;text-align:justify;">No cumulative voting.</i><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">&#160;The DGCL provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless a corporation&#8217;s certificate of incorporation provides otherwise. Our restated certificate of incorporation and restated bylaws do not provide for cumulative voting.&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;line-height:1.19;text-align:justify;">Directors removed only for cause.</i><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">&#160;Our restated certificate of incorporation provides that stockholders may remove directors only for cause and only by the affirmative vote of the holders of at least two-thirds of our outstanding common stock.&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;line-height:1.19;text-align:justify;">Amendment of charter provisions.</i><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">&#160;Any amendment of the above expected provisions in our restated certificate of incorporation requires approval by the holders of at least two-thirds of our outstanding common stock.&#160;</font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;line-height:1.19;text-align:justify;">Issuance of undesignated preferred stock.</i><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">&#160;Our board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized but unissued shares of preferred stock would enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by merger, tender offer, proxy contest or other means.&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;line-height:1.19;text-align:justify;">Choice of forum.</i><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">&#160;Our restated certificate of incorporation provides that, to the fullest extent permitted by law, the Court of Chancery of the State of Delaware will be the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the DGCL, our restated certificate of incorporation or our restated bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. Our restated bylaws provide that the federal district courts of the United States of America will, to the fullest extent permitted by law, be the exclusive forum for resolving any complaint asserting a cause of action arising under the&#160;Securities Act, which we refer to as a Federal Forum Provision. Our decision to adopt a Federal Forum Provision followed a decision by the Supreme Court of the State of Delaware holding that such provisions are facially valid under Delaware law. While there can be no assurance that federal courts or state courts will follow the holding of the Delaware Supreme Court or determine that the Federal Forum Provision should be enforced in a particular case, application of the Federal Forum Provision means that suits brought by our stockholders to enforce any duty or liability created by the&#160;Securities Act&#160;must be brought in federal court and cannot be brought in state court. While neither the exclusive forum provision nor the Federal Forum Provision applies to suits brought to enforce any duty or liability created by the Exchange Act, Section 27 of the&#160;Exchange Act&#160;creates exclusive federal jurisdiction over all claims brought to enforce any duty or liability created by the&#160;Exchange Act&#160;or the rules and regulations thereunder. Accordingly, actions by our stockholders to enforce any duty or liability created by the&#160;Exchange Act&#160;or the rules and regulations thereunder also must be brought in federal court. Our stockholders will not be deemed to have waived our compliance with the federal securities laws and the regulations promulgated thereunder. Any person or entity purchasing or otherwise acquiring or holding any interest in any of our securities shall be deemed to have notice of and consented to our exclusive forum provisions, including the Federal Forum Provision. These provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum of their choosing for disputes with us or our directors, executive officers or other employees, which may discourage lawsuits against us and our directors, executive officers, and other employees.&#160;</font></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Transfer agent and registrar</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The transfer agent and registrar for our common stock is American Stock Transfer &amp; Trust Company, LLC. The transfer agent and registrar&#8217;s address is 6201 15th Avenue, Brooklyn, New York, 11219.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>3
<FILENAME>elev-20211231xex10d11.htm
<DESCRIPTION>EX-10.11
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/2/2022 11:56:45 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 10.11</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">February 2, 2021</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Valerie Malyvanh Jansen, MD, PhD<br>149 Burberry Glen Blvd <br>Nolensville, TN 37135</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">Re: Executive Employment Agreement </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Dear Valerie:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">On behalf of Elevation Oncology, Inc. (the &#8220;Company&#8221;), I am pleased to offer you employment with the Company. The purpose of this letter agreement (the &#8220;Agreement&#8221;) is to set forth the terms of your employment with the Company, should you accept our offer.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.</font></font><font style="font-size:12pt;">You will be employed to serve as the Company&#8217;s Vice President, Clinical Development, effective as of April 19, 2021 (the &#8220;Effective Date&#8221;). You will be a full-time employee of the Company, and you will report to the Chief Executive Officer (the &#8220;CEO&#8221;) and have such duties and responsibilities as are customary for such position. You agree to devote your full business time, best efforts, skill, knowledge, attention and energies to the advancement of the Company&#8217;s business and interests and to the performance of your duties and responsibilities as an employee of the Company. You agree to abide by the rules, regulations, personnel practices and policies of the Company and any changes therein that may be adopted from time to time by the Company. Initially, you will work on a remote basis: Should the Company establish a principal place of business operations, you will be expected to spend a meaningful amount of time at such location on terms and conditions as may be agreed between you and the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">2.</font></font><font style="font-size:12pt;">Your base salary will be at the rate of $27,083.33 monthly (equivalent to an annualized base salary of $325,000), subject to tax and other withholdings as required by law, and will be paid on the regularly scheduled payroll dates of the Company. The Board may elect to increase your base salary periodically based on your performance and/or industry standards for similarly situated executives.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.</font></font><font style="font-size:12pt;">Following the end of each fiscal year and subject to the approval of the Company&#8217;s Board (or a committee thereof), you will be eligible for a retention and performance bonus, targeted at 30% ($97,500) for a full year, or a prorated portion based upon your date of hire for the corresponding bonus period) of your annualized base salary as determined by the Board (or a committee thereof) in good faith based on your individual performance and the Company&#8217;s performance during the applicable fiscal year, including, without limitation, based on the completion of or progress towards the deliverables listed in </font><b style="font-size:12pt;font-weight:bold;">Attachment A</b><font style="font-size:12pt;"> as it relates to 2021. If a bonus is awarded, unless otherwise specifically provided by the Board &#160;or committee administering such plan, it shall be paid on or before January 31st of the year following the year in which such bonus was earned. You must be an active employee of the Company on the date</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">any bonus is distributed in order to be eligible for and to earn a bonus award, as it also serves as an incentive to remain employed by the Company. The Board may elect to increase your retention and performance bonus target based on your performance and/or industry standards for similarly situated executives.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">4.</font></font><font style="font-size:12pt;">You may participate in any and all benefit programs that the Company establishes and makes available to its employees from time to time, provided you are eligible under (and subject to all provisions of) the plan documents governing those programs. The benefit programs made available by the Company, and the rules, terms and conditions for participation in such benefit programs, may be changed by the Company at any time without advance notice (other than as required by such programs or under law). Until and unless the Company adopts a group health plan that applies to all Company employees, the Company will bear the cost of health insurance for you and your immediate family which may be effected by reimbursing COBRA premiums for continuation coverage with your former employer, provided, however, that such amount shall be subject to applicable taxes and withholdings. You will also be entitled to indemnification by the Company with respect to your service as an officer of the Company pursuant to an Indemnification Agreement substantially similar to the NVCA form agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">5.</font></font><font style="font-size:12pt;">You are eligible for five (5) weeks of vacation per calendar year to be taken at such times as will not materially interfere with the performance of your duties. The number of vacation days for which you are eligible shall accrue at the rate of 2.08 days per month that you are employed during such calendar year. Up to three (3) vacation days earned in one calendar year may be carried forward and used in the subsequent calendar year.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">6.</font></font><font style="font-size:12pt;">Subject to the approval of the Board, within sixty days of the Effective Date, the Company will grant to you a stock option (the &#8220;Initial Option Grant&#8221;) under the Company&#8217;s 2019 Stock Incentive Plan (the &#8220;Stock Plan&#8221;) to purchase 670,408 shares of common stock of the Company, at an exercise price equal to the fair market value of the common stock on the date of grant, as determined by the Board. The Initial Option Grant will be evidenced in writing by, and subject to the terms of the Stock Plan and a stock option agreement provided by the Company, which agreement will specify that (a) the options subject to the Initial Option Grant will vest, subject to your continued service, (x) as to 25% of the underlying shares on the first anniversary of your start date, and (y) as to the balance in equal 1/36</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> monthly installments thereafter until the fourth anniversary of your start date; and (b) the options subject to the Initial Option Grant shall vest, subject to your continued service, as to 100% of the underlying shares if, within 12 months following a Change of Control, (i) your employment with the Company or its acquirer or successor is terminated without Cause (as defined below), or (ii) you resign from employment with the Company or its acquirer or successor with Good Reason (as defined below).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.</font></font><font style="font-size:12pt;">In addition, the Board may elect to grant you additional stock options based on your performance, a material increase in the number of fully diluted shares of the Company&#8217;s common stock and/or industry standards for similarly situated executives.</font><font style="display:inline-block;width:11.06pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.</font></font><font style="font-size:12pt;">For purposes of this Agreement:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">&#8220;Cause&#8221; means any of: (a) your conviction of, or plea of guilty or nolo contendere to, any crime involving dishonesty or moral turpitude or any felony; or (b) a </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-&#160;<font style="font-size:12pt;">2</font><font style="font-size:12pt;">&#160;-</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">good faith finding by the Board in its sole discretion that you have (i) engaged in dishonesty, willful misconduct or gross negligence that has a material adverse effect on the Company, (ii) committed an act that materially injures the reputation, business or business relationships of the Company, (iii) materially breached the terms of any invention and non-disclosure agreement or non-competition and non-solicitation agreement with the Company which breach is not cured within ten days written notice thereof; or (iv) failed or refused to comply in any material respect with the Company&#8217;s material policies or procedures and in a manner that materially injures or would reasonably be expected to materially injure the reputation, business or business relationships of the Company, provided that in the case of (iv) that you were given written notice of such violation or failure by the Board and a period of 30 days to cure (provided that the Board determines that such violation or failure is curable).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">&#8220;Change of Control&#8221; shall mean, regardless of form thereof, consummation of (a) the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity, (b) a merger, reorganization or consolidation in which the outstanding shares of capital stock of the Company are converted into or exchanged for securities of the successor entity and the holders of the Company&#8217;s outstanding voting power immediately prior to such transaction do not own a majority of the outstanding voting power of the successor entity immediately upon completion of such transaction, (c) the sale of all or a majority of the outstanding capital stock of the Company to an unrelated person or entity or (d) any other transaction in which the owners of the Company&#8217;s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the successor entity immediately upon completion of the transaction; provided, however, that &#8220;Change of Control&#8221; shall not include any financing transaction of the Company (whether public or private) that would otherwise be and/or trigger a &#8220;Change of Control&#8221; under (c) and/or (d) above.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">&#8220;Good Reason&#8221; shall mean (i) any action by the Company which results in a material diminution in such position, authority, duties or responsibilities, (ii) a material reduction in the aggregate of your base compensation and benefits, other than a reduction in monthly base salary of no more than twenty percent (20%) as a result of across-the-board reductions or terminations affecting employees of the Company generally, or (iii) the Company&#8217;s material breach of Paragraph 3 of this Agreement; provided, however, that the conditions described immediately above in clauses (i) through (iii) shall not give rise to a termination for Good Reason, unless you have notified the Company in writing within thirty (30) days of the first occurrence of the facts and circumstances claimed to provide a basis for the termination for Good Reason, the Company has failed to correct the condition within thirty (30) days after the Company&#8217;s receipt of such written notice, and you actually terminate employment with the Company within sixty (60) days of the first occurrence of the condition.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">9.</font></font><font style="font-size:12pt;">You will be required to execute a Proprietary Information, Inventions, Non-Competition and Non-Solicitation Agreement in the form attached as </font><b style="font-size:12pt;font-weight:bold;">Attachment B</b><font style="font-size:12pt;"> (&#8220;Proprietary Information Agreement&#8221;) as a condition of employment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-&#160;<font style="font-size:12pt;">3</font><font style="font-size:12pt;">&#160;-</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.</font></font><font style="font-size:12pt;">You represent that you are not bound by any employment contract, restrictive covenant or other restriction preventing (or that purports to prevent) you from entering into employment with or carrying out your responsibilities for the Company, or which s in any way inconsistent with the terms of this letter.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">11.</font></font><font style="font-size:12pt;">You agree to provide to the Company, within three days of your hire date, documentation of your eligibility to work in the United States, as required by the Immigration Reform and Control Act of 1986. You acknowledge and agree that your employment is subject to and conditioned upon your eligibility to work in the United States.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">12.</font></font><font style="font-size:12pt;">This letter shall not be construed as an agreement, either expressed or implied, to employ you for any stated term, and shall in no way alter the Company&#8217;s policy of employment at will, under which both you and the Company remain free to terminate the employment relationship, with or without cause, at any time, with or without notice. Although your job duties, title, compensation and benefits, as well as the Company&#8217;s personnel policies and procedures, may change from time to time, the &#8220;at-will&#8221; nature of your employment may only be changed by a written agreement signed by you and the CEO, which expressly states the intention to modify the at-will nature of your employment. Similarly, nothing in this letter other than Paragraph 8 shall be construed as an agreement, either express or implied, to pay you any compensation or grant you any benefit beyond the end of your employment with the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">13.</font></font><font style="font-size:12pt;">The Company&#8217;s offer of at-will employment is contingent upon your authorization and successful completion of background and reference checks. You will be required to execute authorizations for the Company to obtain consumer reports and/or investigative consumer reports and use them in conducting background checks as a condition to your employment. The Company may obtain background reports both pre-employment and from time to time during your employment with the Company, as necessary.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">14.</font></font><font style="font-size:12pt;">The Company&#8217;s premises, including all workspaces, furniture, documents, and other tangible materials, and all information technology resources of the Company (including computers, data and other electronic files, and all internet and email, whether on Company premises or remote) are subject to oversight and inspection by the Company at any time. Company employees should have no expectation of privacy with regard to any Company premises, materials, resources, or information.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">15. This offer letter is your formal offer of employment and supersedes any and all prior or contemporaneous agreements, discussions and understandings, whether written or oral, relating to the subject matter of this letter or your employment with the Company. The resolution of any disputes under this letter will be governed by the laws of the State of Delaware.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">* * *</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-&#160;<font style="font-size:12pt;">4</font><font style="font-size:12pt;">&#160;-</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">If you agree with the provisions of this letter, please sign the enclosed duplicate of this letter in the space provided below and return it to me, by February 5, 2021. If you do not accept this offer by this date, this offer will be revoked.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;" align="center"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Very Truly Yours,</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Shawn M. Leland</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Shawn M. Leland, PharmD, RPh</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Founder and CEO</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The foregoing correctly sets forth the terms of my employment by Elevation Oncology, Inc. I am not relying on any representations pertaining to my employment other than those set forth above. I have read, understand, and agree to all of the above and hereby accept the Company&#8217;s offer of employment on the above terms and conditions. I understand that my employment with the Company is considered &#8220;at will&#8221; meaning that either the Company or I may terminate this employment relationship at any time for any reason without cause or notice. I further understand and agree that my employment is contingent upon my execution of the Proprietary Information Agreement.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;" align="center"><tr><td colspan="2" style="vertical-align:top;width:48.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Valerie Malyvanh Jansen</font></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;&#160;&#160;&#160;</font></p></td><td style="vertical-align:top;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Date:</font></p></td><td style="vertical-align:top;width:42.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">02/05/2021</font></p></td></tr><tr><td style="vertical-align:top;width:6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:42.75%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Valerie Malyvanh Jansen, MD, PhD</font></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-&#160;<font style="font-size:12pt;">5</font><font style="font-size:12pt;">&#160;-</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Attachment A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Bonus Criteria for 2021</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">[TBD]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Attachment B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Proprietary Information Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;"><img src="elev-20211231xex10d11001.jpg" alt="Graphic" style="display:inline-block;height:32.25pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:148.5pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">October 14, 2021</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Valerie Jansen, MD</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Via email: v</font><font style="font-size:12pt;">jansen@elevationoncology.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Valerie,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">I am very please to let you know that effective </font><b style="font-size:12pt;font-weight:bold;">October 19, 202l</b><font style="font-size:12pt;">, you will become Elevation Oncology&#8217;s first </font><b style="font-size:12pt;font-weight:bold;">Chief Medical Officer</b><font style="font-size:12pt;">. Your experience, hard work and drive along with your commitment to our mission and patients have contributed to this promotion. I also couldn&#8217;t be more proud to call you my co-worker and am so happy to offer you this promotion.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Your new base salary will be at the rate of </font><b style="font-size:12pt;font-weight:bold;">$36,666.67</b><font style="font-size:12pt;"> monthly (equivalent to an annualized base salary of </font><b style="font-size:12pt;font-weight:bold;">$440,000.04</b><font style="font-size:12pt;">), subject to tax and other withholdings as required by law. Additionally, your retention and performance bonus will be increased to </font><b style="font-size:12pt;font-weight:bold;">40%</b><font style="font-size:12pt;"> and will be under the same terms and conditions as noted in your initial offer agreement. With this promotion, we are also offering, under the Company&#8217;s 2021 Equity Incentive Plan (the &#8220;Stock Plan&#8221;), the ability to purchase an additional </font><b style="font-size:12pt;font-weight:bold;">40,000</b><font style="font-size:12pt;"> shares of common stock of the Company, at an exercise price equal to the fair market value of the common stock on the date of grant, as determined by the Board. Again, the terms and conditions of these options are the same as in your original offer letter but with a vesting schedule coinciding with the date of this promotion.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Valerie, I believe this new role with be rewarding for both you and Elevation Oncology.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:48.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">/s/ Shawn Leland</font></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">10/13/2021</font></p></td></tr><tr><td style="vertical-align:top;width:48.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Shawn Leland, Founder and CEO</font></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Date</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:48.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">/s/ Valerie Janse</font></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">10/17/2021</font></p></td></tr><tr><td style="vertical-align:top;width:48.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Valerie Janse, MD Chief Medical Officer</font></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Date</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>elev-20211231xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/2/2022 11:56:47 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 21.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:11pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The following table presents the name of significant subsidiaries of Elevation Oncology, Inc. and the location of jurisdiction or organization for such subsidiaries.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:middle;width:69.24%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:30.75%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:69.24%;margin:0pt;padding:0.25pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Name:</b></p></td><td style="vertical-align:top;width:30.75%;margin:0pt;padding:0.25pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Jurisdiction/Organization</b></p></td></tr><tr><td style="vertical-align:top;width:69.24%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"></td><td style="vertical-align:top;width:30.75%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"></td></tr><tr><td style="vertical-align:top;width:69.24%;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.25pt 0.25pt 0.25pt;"></td><td style="vertical-align:top;width:30.75%;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.25pt 0.25pt 0.25pt;"></td></tr><tr><td style="vertical-align:top;width:69.24%;margin:0pt;padding:0.25pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Elevation Oncology Securities Corporation</font></p></td><td style="vertical-align:top;width:30.75%;margin:0pt;padding:0.25pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Massachusetts</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>elev-20211231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/2/2022 11:56:49 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;">We consent to the incorporation by reference in the Registration Statement on Form S-8 (333-257377) of our report dated March 2, 2022, on our audits of the consolidated financial statements of Elevation Oncology, Inc. as of December 31, 2021 and 2020 and for the years then ended, included in this Annual Report on Form 10-K of Elevation Oncology, Inc. for the year ended December 31, 2021.  </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">/s/ CohnReznick LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Tysons, Virginia</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">March 2, 2022&#160;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>elev-20211231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/2/2022 11:56:51 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO RULE&#160;13a-14(a)&#160;OR 15d-14(a)&#160;OF<br>THE SECURITIES EXCHANGE ACT OF 1934,<br>AS ADOPTED PURSUANT TO SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I, Shawn Leland, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">I have reviewed this Annual Report on Form 10-K of <a name="_Hlk95485611"></a>Elevation Oncology, Inc.;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Based on my knowledge, the financial statements and other financial information included in this report, fairly present, in all material respects, the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s Board of Directors:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize, and report financial information; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:38.8pt;text-indent:-38.8pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.9%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Date: &#160;March 3, 2022</p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ Shawn Leland</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="white-space:pre-wrap;">     </font>Shawn Leland</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">President, Chief Executive Officer and Director</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>elev-20211231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/2/2022 11:56:53 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO RULE&#160;13a-14(a)&#160;OR 15d-14(a)&#160;OF<br>THE SECURITIES EXCHANGE ACT OF 1934,<br>AS ADOPTED PURSUANT TO SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I, Joseph J. Ferra, Jr., certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">I have reviewed this Annual Report on Form 10-K of Elevation Oncology, Inc.;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Based on my knowledge, the financial statements and other financial information included in this report, fairly present, in all material respects, the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s Board of Directors:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize, and report financial information; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.9%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Date: &#160;March 3, 2022</p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ Joseph J. Ferra, Jr.</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="white-space:pre-wrap;">     </font>Joseph J. Ferra, Jr.</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>8
<FILENAME>elev-20211231xex32.htm
<DESCRIPTION>EX-32
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/2/2022 11:56:56 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;32</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.35pt;margin:0pt;"><font style="font-size:1.35pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.45pt;margin:0pt;"><font style="font-size:0.45pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.55pt;margin:0pt;"><font style="font-size:10.55pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 5.05pt 0pt 0pt;">In connection with the Annual Report of Elevation Oncology, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ending December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Shawn Leland, President and Chief Executive Officer of the Company, and Joseph Ferra, Chief Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:8.25pt;margin:0pt;"><font style="font-size:8.25pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.05pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:27.95pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><font style="font-size:11.25pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.1pt;text-indent:-28.1pt;margin:0pt 27.35pt 0pt 28.1pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:27.9pt;text-indent:0pt;white-space:nowrap;">(2)</font>The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.55pt;margin:0pt;"><font style="font-size:10.55pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Dated: March 3, 2022</p></td><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Shawn Leland</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shawn Leland</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President, Chief Executive Officer and Director</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Dated: March 3, 2022</p></td><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Joseph J. Ferra, Jr.</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Joseph J. Ferra, Jr.</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>elev-20211231x10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 elev-20211231x10k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !6 'X# 2(  A$! Q$!_\0
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M&'[3.D7GR"*/><;W/11[\4 6**** $;[I^E>=^"-3UJ'PII\-MX9:ZMP7"W
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M41MH"D2&&,K$08UVC"$< CTQ4M)C"BBBD 4444 %%%% !1110 4444 %%%%
3!1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>elev-20211231x10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 elev-20211231x10k002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %4 G # 2(  A$! Q$!_\0
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M#_O@_P"-%@+=%5-E_P#\]H/^^#_C1LO_ /GM!_WP?\:+ 6Z*J;+_ /Y[0?\
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MZ*J;+_\ Y[0?]\'_ !HV7_\ SV@_[X/^-%@+=%5-E_\ \]H/^^#_ (T;+_\
MY[0?]\'_ !HL!;HJILO_ /GM!_WP?\:-E_\ \]H/^^#_ (T6 MT54V7_ /SV
M@_[X/^-&R_\ ^>T'_?!_QHL!;HJILO\ _GM!_P!\'_&C9?\ _/:#_O@_XT6
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZU[-13Y@L>$*/&,%I):7M]J:1I96[QW(CD?S S;BK[?F!'*DCG&*Z"\FU1O
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M;F. /Q)Q56Z\0Z19+>-<ZA!$+(H+DLV/*+?=S]: -.BLE/$^B/I$VK+J5O\
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M^12!C*=3TKM:**3=QA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/N/]PU/%_JD_W11T =1112 **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBC- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM_'<.C)%$=V6&,GT%=?1143FYN['&/*K!1114%!1110 4444 %%%% !1110
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M61MJ*,DUYU>ZW<KKJZFI.$.T)GC9Z5SUZT:=N8ZL+AYUF^1VM_5CT< *  ,
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MXE?[[2#@<L<<X_X#6MINE1:<TK(V3*%R-H &,] /K6((M=\HR133LZE1&LG
M((.=P[XXK7T078MI/M3RL=WRB48(XY[G(S6,Y2:U9O2C%/2)J4A-+7)^)KZ2
M>_\ [)2Y>UM(K<W5_<(<,(AP$4]B2#S6)VTZ;J2LC7U^ZN8-!NI[!3)<*AV[
M.2/4_A7F.FIJWB6X>..Z>>1!N82S8X^E>A^%+B-]+6%+2.RC4;H;;S=\@C;D
M,_H3R:Y3Q7H\_AC4X_$FD@+$'S-$.BD]?^ FFCTL#-0<J*2YGLWW[?,FA\#Z
MH!\SVRGTW$_TJXG@Z_3_ ):VY_$_X5U>DZE#J^EP7T&?+F7.#U![C\ZO8HN8
M3Q^(NU+\CCT\-:A'T,)^C5M+%)HNC2-!;-<W"H7\M.LC>@K6J*YB6>WDC<$J
MZE2 <$@^_:@YYXB=2RGL<EJ'BN\CM-8>!8D-E#$JL/G'VA^L>>AQD5V$98Q(
M7&'*C</>N/TSP[<7$UNMW:PV&F6<GF06$+;S))V>1NY[XKL1P*05O9JRA_7]
M?J+11108!1110 4444 %%%% !1110 53N_\ CZL_^NA_D:N53N_^/JS_ .NA
M_D::W!C]0_Y!]Q_N&IX_]4G^Z*@U#_D'W'^X:GB_U2?[HHZ .HHHI %%%% !
M1110 4444 %%%% #9(TEC:-U#(X*L#W!KE8O UO#NB2Z<6S/NV;>0/3-=915
MQJ2A\+$XI[D<$,=O D,2[8T4*H] *DHHJ!A1110 445D:QJGV"XM5&<%BS@?
MW>E.,7)V0F[:DFN3*FG/'U>4A44=2:<"^EZ"6*[W@A+%?4]<5'90B\G&H3LK
MG_EDBG(C'^-:;[0C;\!<<YZ8JF[+E%:^I@MK4MFH\]X+DO&9LQ':%4#D<YR?
M2D/B*5I+=4M4432 *7D_AW%3GC@Y%6()M"DW"-;0*LNT$A0&;&>/7K5J1],:
M/,C6NSC[V,<\C_&GIU1E[S6DC,D\2$6YD^S!?W:OS(,X;(&!CGD<U#;^)Y%4
MK+;&5U^9O+XPO'3U/-:<]UHL<*3R/:E8U)0C!('?%.\[1G".7LR%PRGY>,]*
M-.P>]_,00:WOMKFZE$:Q1HCJ ^?O>I ZU6'B9I[:X>&V57@7+"23'.2...>A
MK1\S2((I8PUI'&6Q(O !/O4<C:1'8O=I%;R0P@C,:!L>HX^M"MV!\W\Q47Q&
M(Y)$FA!;S"J;6^4XQGGV!S]*A/BB25F$=LJ*L;,Q9_0*1CCT:K<.HZ8Q\F&U
M8O&K-Y:P<J1PPQV//ZTEO>:++Y<<4";V(VQ^3@Y.1T_ Y^E/3L*\G]H8/$>Z
M6.)+7<\N2@\SL"WWN.#\IJQ/K:Q6MM.L.?/B,N&?;@  D9[GFGRW.F65Z\+1
M(DYC,[8CZ@<$Y]>34$^IZ8Z1HUJ\\(<)&5AW+N]!2LGT'=K>1:T:ZGOK:2YF
MVA7D(C4?PJ..?>M*F1!!&-B; >=N,8S3ZA[FT59:A1112&%%%% !1110 444
M4 %%%% !1110 5Q_CUKNWMK&\M<A8I2)"!G /K[5V%->-)4*2*&4\%6&0:N$
MN628I*ZL<18ZEJ6HZS90;\Q!@\@1<# ]:[FHH;6"WSY,*1YZ[5Q4M.I-2>BL
M*,;;A69J6EF[N(+J)PDT1_B&0PSG%:=%0G8HJ0VSK,9I6&0,*J]!FLAM6OY9
MH!!$C+,9"!MR55"!SR/>NB/2L2SO=)AN)=LAC)=F!F!4<G#;2>V1VJEKT,Y]
M%>Q&_B6&/9B!F!0,S;N$&2.< ^E1_P#"3QK"\CP;E1MI*M@D_-C [C"]:N2#
M0HIQ$XM!)*Q.,#D]?ZU+C1W*R_Z(<DQJV1U/4?K^M/W>Q'O?S(FT^^-ZLNZ+
MRWB?8PW9'0'K^-9U[X:@O]1U"XGE<Q7MJML\:\$!23D'\:T(KNS%T((63?*"
MV4Z,1C(SZXQ5VH>YO3G*.S*,&GVEC)/<0P 32A1(PZOM&%'Y5Q-KIMWX_D.H
M:G=M!I<4K1QV$)PV5.#O/K6KXN\5#PUJVE>82;68O]H0#)V\8(^AJQX/0-#?
M7JRP;+ZX-PMO%('\D$8P2.YQDT'=!5*-+VW5[/\ !FY;VUMI>GK!;1".W@3Y
M47L!6:FOE%MI;J )!<KNC97R5''+?G6XWW3FLM-*TM%E'E(5D4HP9LC:>JCG
MC--6ZGG3YF[IE8^*K10S""X91QD*.OIUJ:[\0VMI&'=')SAT&-R?AGGKVS1]
MDT>:YV#RR[#&P.<';@<C.,CBK5[I]E?[#=1A]@(!W$<'J..W IOEOL0O:6>J
M*$OB#"K)'8S-"P<K(64 A>IQG.*5_$UM'$#Y,K.!\Z# *_F:G.C:8V<Q<$EL
M!SCGKWZ&GR:1ILJ.[0*=Q#%U)!^48'(]N*/<[!:IW*4?B>.1=_V641LY2,Y&
M7X7&!VSN'6IHO$$$MPL(MYP=XC=CC",20 >?8]*?'I6D20AXXD\MT##YB!@@
M8(YXX _*G&UTJQC3<$12P())))&2#_.A\O1 O:+=D.H>(4LS,B6TCNAV*W 5
MGP#MZ^AI][J[V4$>ZV9[AHQ(ZJ0%09 ))SZFII--TV>=[AXT9V&6);CZX]?>
MB^M-.NG@:Z",^=L67(W=\>_3/X4>[V&U/74IGQ1:H 9()U#)O0D#YUYP1SWQ
M@4O_  DUL[X2WN&08W. ,#)(]<GD$5.-,TJ!&D:*((&$A9FR%*G(^@!/2I(]
M+TU8MJPH$..A]RP_4D_C1>'85JG=%%/$\;G<MG,8PF\D,I(YQ@C/7FGMXEMU
M\W-M-F/(P=O)!P1UZ\U.FD:6K!A$IP22Q<G.<=3GGH*?)H^GW#R,T.6=MS8<
MCGU !X-.\.P6J]RF?$]OC>EI<NF,[@%QTR>_85NJP= PZ$9%4DT>P2,1K;*%
MYXY[C'\JNJH50H& !@5,N7H7!27Q,6J=W_Q]6?\ UT/_ *":N53N_P#CZL_^
MNA_D:2W*8_4/^0?<?[AJ>+_5)_NBH-0_Y!]Q_N&IX_\ 5)_NBCH,=1112 **
M** "BBB@ HHHH **** "BBB@ HHHH **** "L^;1[6ZNFN+@-*QX"D\ 5H44
MTVMA-7(+>T@M01!$J9Z[>]%Y;B[LIK8L5$J%-P[9%3U!>2/%9321JS.J$JJ]
M2<=J-;@[6,(^&YG:1Y+J/,WRRA8L#;Q]WT/'6D'A6($_Z2QR#D%<]QM_(#'X
MU7M[O7)(RQ:3$1RN8O\ 6C<HP<^Q/Y5+ITE[-_:$LIG,AMA@,A4*_P V57UQ
MZUJ^9=3E_=MVY22?PN99Y72Z\I9"Q;:G)!_A/;%.E\.&9 6EC:;>6;*$*<H%
M(X.>U9K0:U (D+32F2V\B/:Q&W)'+'LV"1GVH2SU:Y:7<9H9+:W5/,+L2Q7?
M]WLQ(QS3L]^85X[<II1>&F69Y)+D2 Y RO8@@=?3/Z5;.AH=/N[02X6X"@D+
M]W"@?TJA!/?6FA74UP9%O$VDNP++CC&T?3KWS566^UEF6*(SLIW*KF(C>I)&
M>G!''6E:3>Y=X);&P=':&Y$MD\4*B%DV,I;)8@DDYR>E5+;PR()8YA<$3*@0
M$#C;D[EQZ'/X8JI"^K1JT]O-/)DH"LD77]T"3S[C%$VI:X87W12Q-PR%8\]<
ML ?H, ^YH2ET8N:#WBR[/X6CEDDD2YE1R0$&<A4V[<8/7@GFK,&AFW@AMTG/
MV>&998D(^[CJN?3/-93ZEK+Q2KG:T&POMCY8L,[1UP0/YUU%NS/;1.X8,R D
M-U!QWJ9.26K+@H-W2) ,4M%%9FX4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5STWAD-;%8I0)F=B[OD@J<_+C/'7MZ5T-%-2:V)E!2W.=
M7PP8[9(TFC\P,2SM'U!0+_2B7PP&F\Q)8RI 5HW3Y<8 [=^*Z*BJYY=R?8P[
M&+;Z2UM-I\2!?*MM[M(!@LQX Q^-;0Z445+;>Y48J.QR6N^"(O$FO)>ZC<O]
MEBC"1V\7!/<DG_"MO2M!TO14*Z?916^1ABHY/U/4UI44C>5>I*"@Y:+IT&R
MF-@.N#7'Q>'M0ELT(6&$,H#1%CDD;OG)QUY_3K782,4B9@I8@$@#O7,0:]?S
MOMC%L[%=Y #?)\K':??Y0/QK2'-K8XZJ@VN8!X9E/F!U@R ^QP3DLQ4Y/H1@
MTC^'+\;BEVC9W?*Q.,<A?T)!_"D7Q'?X&V&&;=C:Z XR0&(/T&[/TJ.+5M3N
MKK*311[W5HXF0_<,9//J./SJ_?ZF7[K9)CH_#]T&%L[-Y1B9G <[2V2$&?8$
M_D*U=)M[VWM7LKA(PBH=KKW)SQ^ [U6U+7)[73[*XC5!+,F\HPX. ,C/KS56
M37K]=HD^SQ)-G9(0<1 ,R_-_WR/SJ;2DBTZ<'H-7PW?1[MLR.VP $OQC"@KC
M'L<'WZ4#PU?! C- QZK*6)9.&&T>WS#\JGDU>YM='TQ_.A$D\9+R3YP2%S^9
MJ-M?U 0K*\<$(8.51P<DKCY/]XYJKS)M2&W6A3VT0N%5964EI8U!/G?/D ^V
M/Y58&CW$^BZ=&R(LT!)*N?NY!''N,_I5%M1U)R"LDF(RTA3NV-Q"_H*L#7KX
MPR.3;;(T+EU!;/*@=#@=?TH?.PBZ:+,&B3KIE[;2>2AG145%)*Y QN/N:KOH
M-_,!$Q@C@#E]JN3U ROTX-00Z]J,A:5S&0-FV%.K?,X)![@[1^=2KKVH.)/+
M^SN(D\PNJG##Y<J/<;L?A2M-,.:FT/;PU-&0T(@9026A8D+)R<9^@/Z5IZ-I
M3Z;%)YSB29R,OD] .!SZ5IH<H#3JS<VU9F\:48NZ"BBBI- JG=_\?5G_ -=#
M_P"@FKE4[O\ X^K/_KH?Y&FMP8_4/^0?<?[AJ>+_ %2?[HJ#4/\ D'W'^X:G
MB_U2?[HHZ .HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 !%)BEHH **** &LBNI5@"#V(IU%% "8HQ2T4 ,6-58E0 6.3@=:?110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%%  1D8JM;6%M:,Y@CVESEB223^)JS11<5D-$:@8  'L*3RUS
MG Z8Z4^B@8WRU( (!QTR*#&I&"H(]"*=10!#):PRO&[H"T9)0D?=S4AC4XR
M<>HIU% K#=@S1Y:8QM7!ZC%.HH&-\M1T51CIQ2"-1T4 >PI]%  !@4444 %%
M%% !5.[_ ./JS_ZZ'^1JY5.[_P"/JS_ZZ'^1IK<&/U#_ )!]Q_N&IXO]4G^Z
M*@U#G3[C_<-31?ZI/]T4=!=1]%%%(84444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI9W50.Y.*J0DW=V+C!$,8(CR/O$]3]*D73[1#D0)D>O-6>E @HHHI#"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
/ **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>elev-20211231x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 elev-20211231x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %R LL# 2(  A$! Q$!_\0
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M67_/K#_WP*- )_,3^^OYT>8G]]?SJ#^SK+_GUA_[X%']G67_ #ZP_P#? HT
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M-&: %HI,TM !11FC- !11FC- !11FC- !111F@ HHS1F@ HHS1F@ HI,T9H
M6BC-&: "BDS1F@!:*3-+F@ HHS1F@ HI,T9H 6BC-)F@!:*,T9H **3-+F@
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M[C=;6*9GG.\_+*,_*=HRI &<CG-='X"M/$%G;:HNDVL$5L]\&C.H1S0QM'M
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M0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF,*PM-)<1+OCC"G&&(_B)X  )K2MM9TZ[BBDAO(&$JJR#S &(/3CKG@_D:+
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M]!6R_P"_Z_XT?\)'HO\ T%;+_O\ K_C3_P#A']'_ .@79_\ ?E?\*/[ T?\
MZ!=G_P!^5_PH_=^8?OO+\3GS9^#&ENG:\MV%T9#-$U^QC<ORQV;]N23G@4^S
MM_!UC<QW,5Y:M/')YHEEO3(Y;84!)9B3A6( /3)Q6[_8&C_] NS_ ._*_P"%
M']@:/_T"[/\ [\K_ (4?N_,+5O+\3G+G3? ]W<RW$MS:^9*SM)LOV0/O(+ A
M7 ()4$CI6I/?>&+G2FTR6\TXV1C$7DB90H4= ,'C';'2K_\ 8&C_ /0+L_\
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M4#8XR3Q^?%8'@/6-4U-=0CU.\CN3"R&,AH2ZA@<[O))3&1QSGKGM0!V-%%%
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M:V$7****0PJG>?\ 'W8_]=3_ .@FKE4[S_C[L?\ KJ?_ $$TUN)ERD90ZE6
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M #Z6_P#W['^%'V&S_P"?2W_[]B@#RNZNKV>TU%+#Q!IFGI+>),EO)KB/N5<
M;7WDC/+,#@'@#H<]CXL\2:?<V^EMINMV$LT%]#-*L.K11 HK L#EQN!' %=$
M;2Q7[UM;#ZQK39+?3XHS));VRH!DL8U % 'D-]_:L]K>1CQ/IKR279E$JZU&
MK/Q* 1\X 0;H\#@K@X!P*]?@\6^'%MXUD\1:1O"@-B^C/..><U5MY]$NI/+@
M^PR/_=55)JY]@L_^?2W_ ._2_P"%#U H:YXJ\/SZ+=QP:QI5U*T9"P+JD<.\
M^F\,"OUJIX1\1Z/8>&;*UU'Q!IPNHU(D$NHQ2'.XG[V\Y&.G).,9K;^PV?\
MSZ6__?L4GV&S/_+I;_\ ?H46 XC7]9CNO%JW6D:[IEJ@M7C^V-J\91G9<#=%
MOX"]1A22V">!S=T/7+*R\!'3]0\1:;+J*QRH/*U:/S&RS;?WA;K@CG-=2UG8
MJ,FUM@/>-?\ "@6=BWW;6W/TC6@#RA[O5)EM#_PD>FJ\6E_9</K40"2"*16;
M*OG>S%"&YXSG!%=W\/=3M;?1(=,NM:L+B^::4Q1+?I-(4+$@8#'D#L"0*UY$
MTN%]DD=FK>C*H-9NKV]O'JOAIX8(D)U0?,B <>1-1N!V=%%%2,**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ K$NO$1M=2-G_8VJ2@.J">.%?+)(
M!R"6!(&><#L:VZ\SUZ[T >-H[07Y6^EG"W)-GYC0-M!C*L8SSD*.O )Z4 >F
M44R)62)5=R[  %B,9/K3Z "BBB@ HHHH **** "J>E_\@]/]YO\ T(U<JGI?
M_(/3ZM_Z$:?01<HHHI#"J=Y_Q]V/_74_^@FKE4[S_C[L?^NI_P#0336XF7**
M**0PHHHH XW6T\4S^-+:+2)W@T]((WE=U4PYW2!@1C+'&S@$=JR-5\+^++F^
MO)DU R))(Y6.-O*0YLS&&')*_O"/ES[UZ313N*QY+9^#?%$%]I5V!*J6?E&:
M)KSYY2)6+X(.WE2,Y'(!'!K:T/PMK(L-6M+R3[%87DSLMOYK2RJI0 ;9 V$(
M89S@D]3@UZ!11=CL><VGAWQ!9-H4LT-S>3K%.^IDW^T222J1@#..#C! X &*
MQ;?P;XO:^L)<36<44CLT:7Y80AFR0G). IP.N2#G ->P44)BL<KX"T;5=%T2
M6WU:4M(\Y>-"Y<HFU1R23R2"QP2,M6'X=M8KRQUZWG0/%)J]XKJ>XWFO1C7B
M*2ZY)J>LG0;?76M!J=R',,EH%\S>=V-_S8SZTTP-F^^&.AW)W0H\#]048XK=
MU?PW8ZWID-C>JS1Q$%<'!R!BN.SXW_Y]/$?_ ']L*,^-_P#GU\1_]_;"EIW
MW=(^'VCZ+JL>H6HE\V/.T,^1R,5KWWAS2]0NFN+JU260@#+>@KB\^-_^?7Q'
M_P!_;"C/C?\ Y]?$?_?VPH^8'>Z=I5IID#06D2QQL=Q4=,TQ]%T]R2;:/)Z\
M5PN?&_\ SZ^(_P#O[849\;_\^OB/_O[84:=P/2$C5(P@&%48 I0B@Y KS?/C
M?_GU\1_]_;"C/CC_ )]?$?\ W]L*-.X'I1YHQ7FO_%<?\^OB/_O[849\<?\
M/KXC_P"_MA1IW$=EIO\ R5)_^P+_ .UJ[:O+O CWW_"=W*:O%J::A_9N5^V/
M 1Y7FCIY7?=GK7J-#&@HHHI#"BBB@ KE9O'5G!XFN-$>RO&DAW#?"GF[B%1C
MA%RW20<X[&NJJG;Z58VM]<WT-LBW5RP::7'S-@ =?3"CCVH \]U+XH7MH;@1
M:4F8Y9XU>4E5?9/'$,<YSAR3G&#BI;7XBZE/KW]F26FGQ P;_.DF*HK^0LO+
M<@C+8P#G'/2N_DTVQE4K)9V[JV20T2D')!/;N0#^%)_96GF/RS8VVS@[?)7'
M QTQZ<?2JNNPM3C[3QW=W/A*75ET[?<6OF27"(K^68HY"K[7QMW[06VY-.7Q
MIJ"3"WOH]+LI&TO[?OEN&*H=P^5N.RGMG)'%=FEI;QVOV5((EM]I7R@@"X],
M=,5%)I>GS2&26QMG<KLW-$I.WTSCI2N@/,U^*VJ/,D2:1;.[6WF;5E8_/M+?
MHHSMZ]><\5VFEZS)K_@5M3DA6)YK>;*KG!VEER,\X.,C/K6L-'TP+M&GV@&P
MQX$*_=)R1TZ9[4Z^2*/2+F,C9"L# A .%VGH/I0V@.8TB6>'P+I<MK%YTZZ;
M 4CSC<?+7BH=+F\4SW$3WUO900'[Z*Q+@5SVDS^*DT6P6R6_:T%M&(&-C:Y,
M>T;3S<>F*N?:?&9_Y9WW_@#:_P#R356$=J0^[Y2 />E*R&,@,-^.#Z5Q/VGQ
MG_SSOO\ P!M?_DFC[3XT_P">=]_X VO_ ,DT6 VSIVO!T<:K$<'+(8N"*L:Q
MI5WJ44:VVI2V97[QC ^:N=^T^-/^>=]_X VO_P DT?:?&G_/.^_\ ;7_ .2:
M5AG0Z#IFH:8DT=[J#7BLV8V8<@>];%<+]I\:?\\[[_P!M?\ Y)H^T^-#_P L
M[[_P!M?_ ))IV [JBN&^T^-/^>=]_P" -K_\DT?:/&O_ #SOO_ &U_\ DFBP
MCJKO1K.]G\ZX1G;&/OD#\JE&G6HL39&+? 1M*L<Y%<A]I\:_\\[[_P  ;7_Y
M)H^T^-?^>=]_X VO_P DTK ;T7A+1K>\ANH+012PG*%"1^?K6W7#?:?&O_/.
M^_\  &U_^2:/M/C7_GG??^ -K_\ )-.P'<T<=.]<-]I\:?\ /.^_\ ;7_P"2
M:3[1XTS_ *J^SZ_8;7_Y)HL!W#Q)*NUU##.<&A8T3[J@5Q'VGQI_SSOO_ &U
M_P#DFC[3XU_YYWW_ ( VO_R318#J-1T/3M4.Z[MDD?& _1A^-4M5A6VO?"\,
M>=B:FJC)R<"":L3[1XT_YY7W_@#:_P#R326\FMR^(=#&N?;4A%[F'=:0(IE\
MJ3 )29B!C=VHL!Z;1114%!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %>2:_K][;^/I=-M[Z6&;^T+=@]NT:H\;",>7*/ON0 _ !^^,D"O6Z\2U
MHQ)\8T6'Q)=Z>5NED>*2V)5V94!2+ .=P50S' 'O0![:**!10 4444 %%%%
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M8[:6!H2,AQUS6S+>Z-.!YM[8/C^],A_K20WFBVV?)O+"//7;,@S^M &=8_\
M)6W_ .P%_P"UZ[BN#TNY@N?BR[V\\4RC0\$QN& /G^U=Y2&%%%% !1110 44
M44 %%%% &#<^++"RU^XTN[$D A@CF-RX_=G>S +GU^7\>?2N;D^*]F(LQ:7<
MR2 #*9(Y,QB !QSZ\9ZXZUVYTRS;4QJ7D+]L$7D^<."4SG!]><_G6?-X0T">
M$12Z7 R*NT#!&!O+\?\  B3]::L!@V?Q%^W:G=:=!HTS7-O 9BHE'948@@C*
MCY\ XY(/%;5EK*>(/!4FJ)"T(GMI?W;,"5(W*1D>X_\ U4]_!WA^2,(VEP$
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M"JIR" >:L?!R!([36)T$"B>:-]D"QJJ?*>!LD<^_S8//Y4?B';Q7?Q+T&(I
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M+>[O_$+RQ YFAWLV[VYXIW8A/^%6P?\ 07?_ ,!(Z/\ A5D'_06?_P !(Z]
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MQS_UP3_"C0#G/^%D:-_S[WW_ 'S'_P#%TO\ PLC1O^?>]_[YC_\ BZZ(Z5I
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MDZ=<P[I5^Y<0%DVJ",G<&:1FZ !1GJ* /5QTHI 1ZTM !1110 4444 %%%%
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M81KW<7B<WDBVTL/D9RI(&:O6D.L?V?(+F6/[4?N8'%<U]L^('_/H/_ 6W_\
MDJC[9X__ .?0?^ MO_\ )5*P&W#;>(?/C,US&8\_.!CI5G4-/U&>8/:WIC7'
M(SWKF_MGQ _Y]!_X"V__ ,E4?:_B!_SZ#_P%M_\ Y*IV"YUNEV]W;V["\F\V
M0GKGM5^N#^U_$#_GT'_@+;__ "51]L^('_/H/_ 6W_\ DJBP'6ZQISZGITEM
M',T+MT=>U8&F>#I[*[BGEU*20J<E<GFJ/VSX@?\ /H/_  %M_P#Y*H^V>/\
M_GU'_@+;_P#R518+FO?^%9+N]:=+^2-&_@]#5BV\."/2Y;.:Z>0R'[_<5@?:
M_B!_SZ#_ ,!K?_Y*H^V?$#_GT'_@-;__ "52L!J67@Y+.^BN!>2,J'.PCJ:Z
MC%<']L^('_/H/_ :W_\ DJC[7\0/^?0?^ MO_P#)5%@.[QFN7O?!=O=WTER+
MJ5-YSM'8UF?;/B!_SZ#_ ,!;?_Y*H^V?$#_GT'_@+;__ "53L!OW7AF"YT^&
MT,\B>5_$.IJ.P\*Q6-V)EN974#&QJQ/M?Q _Y]!_X"V__P E4"\^('_/J/\
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MH **** ./^(>@7WB'2[&WL+2&XDBNA(WFR!-HV,,C(/<BL7X;^$]?\-W4_\
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M(?%'78M,CN);>([G*[MI /%+:?%C5;BYBA^R1;G< 8S2YF!UO_"L+'_H(/\
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MTGQ&;J_6U<<LQ -,T+0K^TMKE)[D_O4VJ!_"?6LG2_"M\FJPR/)L5'W%AU-
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M?V?RK74$N6_UH;)V@8'.*]1K@M+MX+?XLR+!#'$IT/)"*%&?/]J[VD,****
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MHHH *XB;P7>7WCJ_UF:^DMK5@HA%LY65@8E0C<#\H!&<8Y.#FNWHHN!YY/\
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M'Q!7_EYC'_;:#_XQ1Y7Q!_Y^H_\ O]!_\8HL!VPM(=[-@DL<G)-2I&J)M48
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MG:C'\/\ 5KEKF^N]%FF/!<W: G\FJ6!_ EMILVG07VC1VDW^LC6Z3#?7YLT
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M[S_C[L?^NI_]!-7*IWG_ !]V/_74_P#H)IK<3+E%%%(84444 %%%% !1110
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MA?I5[7?^0IX:_P"PJ/\ T1-1=@=91114E!1110 4444 %%%% !1110 4444
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M:4P _#-9,_A7X=VY"RV%LK'L;B3_ .*J:R\%^ =1D>.UTR"1D )"SR''_CU
M&EX<NI]6^(\NI#2M4L[5-)^S[[VU:'+^<&P,]>#7H->;>&-"TS0/BC-;:7:+
M;0R:+YC(KLP+>=C/)/85Z32&%%%% !1110 4444 %%%% !4#V=K(SL]M"S/@
M.2@);Z^O2IZ* (UMX$"A88U"G< % P?6H=27?I=VN0-T+C+' 'RGJ:M54U7_
M )!%[_UP?_T$T >6Z1\1+>PT33[)K 2-;VT4)=;V'#%5 R/FZ<5<_P"%H6N?
M^0:?_ V#_P"*KJ/#<@C\(:,S$!1I\!))Z?NUJTNKV+OL6[B+>F\5>@CCO^%H
M6O\ T#3_ .!L'_Q5'_"T;7_H&'_P-@_^*KJI_$6F6[LDEW&&7J-PIC^)])CM
MQ,U]$$)P/F%+0#F/^%HVO_0-/_@;#_\ %4H^*5K_ - T_P#@;#_\5710^+]&
MGD")?1Y/3+5(?%.C!]O]HP$^F^C0#F/^%I6G_0-/_@;#_P#%4?\ "T;7_H&G
M_P #8?\ XJNTL]3M;[<+:X23;U"MG%6=QHT X/\ X6C:_P#0-/\ X&P?_%4?
M\+1M?^@8?_ V#_XJNYGN$MX&EE<*B#))/ %<P_Q#T&.38;P=<9'-&@&;_P +
M1M?^@8?_  -@_P#BJ9)\3+"9=LNDAU]&NX"/_0JU)_B)H,#[/M08^H%!^(F@
MBV,WVD\'&W'-&@&8GQ/LT4(FE[5'0+>0 #_QZG'XHVG_ $#3_P"!L'_Q57[7
MXC:'=7$<*W&TN=H)KK5?< 0>#1H!P7_"T;7_ *!I_P# V'_XJE'Q1M?^@:?_
M  -A_P#BJ[PM@$FN'O\ XF:997LUOAG,;%20*- (O^%HVO\ T#3_ .!L'_Q5
M'_"T;7_H&G_P-@_^*ITGQ/TP6BRJDNXG&"O%)9_$[3[BY2)PZACC@9HT :OQ
M/M%&!IC?^!T/_P 52P>+X?$OB/0;2*V6 Q7WGEFNXFW 0RC "DDGYOTHG^*6
MG)+)&B.2O'S#%:T^HQZJ?"EY%G9)J:GG_KA-3T [JBBBH&%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5/2O
M^0>GU;_T(U<JGI?_ "#T^K?^A&FMA%RBBBD,*IWG_'W8_P#74_\ H)JY5.\_
MX^['_KJ?_0336XF7****0PHHHH **** "O,]0\ Z]<ZGJ;P7>GK#?22[[F0$
MS&.1URO"Y 5 R@!\'C[O)KTRBFG8#R@?"W59[>[:\U*W>Y6R%K:-'D!L))&#
M(2NX#:RY )R1SG J6X^&VL3PW CO;6T66*=4MH)&\J/>8L(,I]S]VS' '+<#
MK7J5%',Q6$484#T%><>#T,MCXAC!(+:W?#([?O#7I%>=VGA?QGI%QJ2Z9=Z$
MUK=7\UVGVE)BX\QLX.#BD,\EU/X;^)5U29([1[B,N2LV\?,,]\U<M_A5X@_L
MV:1YEAF_A@#YW?4UZQ_9OQ!_Y^?#/_?N?_&C^S?B#_S\>&?^_<_^-,1X3%X$
M\337/V<:9<*0>6;A?SK:U?X7Z_:V<,L+&\(7YXU/*?3UKUS^S?B#_P _'AG_
M +]S_P"-']F_$'_GX\,_]^Y_\: /&]#^&>OZA-NN(GLH@/OO][/L*KZC\.O$
MME*P6R>X3/#Q'=G\*]L_LWX@_P#/QX9_[]3_ .-+_9OQ!_Y^/#'_ 'ZG_P :
M /)!\+M??1$N Y%P3DVS-C _QK*M/ 'B6ZO1;M8RPC/S2.<*/?/>O;_[-^(/
M_/QX9_[]S_XT?V;\0?\ GX\,_P#?J?\ QH \?U3X:^);2X/D1M>)CAU?G\C7
M9?#+P?JND74^HZF)(6==B0L>3[FNO_LWX@_\_'AG_OW/_C1_9WQ"_P"?CPS_
M -^Y_P#&@+"V'_)6W_[ 7_M>NXKC?#_A[Q#!XNEUS7+G3'S8_9$CLED'_+3?
MD[OQKLJ0PHHHH **** "BBB@ HHHH X;Q+)XDA\5VTEI!?S::/)V+:2!5!WG
MS?,X))V[< \$9[USUO#\1M0:"TEEN+*1YI+C[29!LC5T!5#@'.U@?EQW )KU
MJBG<5CRJV7Q[]KMQ$]^J?:P+AKL*R?ZUL%0"&\OR\9Y'.,5V&C_VE_PK]?[8
M,AU#[)+YWF_>S\W7\,5TM17$*W-M+ Q(61"A(ZX(Q0W<=CC;+3?[7^'FG6(F
M:$S:; H=>H_=K7'6/PFO5G#WFK#:K?\ +,')'XUWMKX/O[*S@M8/%6I+#!&L
M4:^1;G"J, ?ZOT%2_P#",:I_T-FI?]^+?_XW1H(XB?X3K+=,Z:K((SSM9,D?
MCFK4'PKLA8/!<7TTDA.5D5<;?P[UUW_",ZI_T-FI?^ ]O_\ &Z/^$9U3_H;-
M2_\  >W_ /C=&@'&1?":UBGA?^TYBJ'+*4'/ZU?O_A=HUY(TD4L]NY_N$$9^
MAKH_^$9U3_H;-2_\![?_ .-TO_",ZI_T-FI?^ ]O_P#&Z- ,KPKX*@\,O+*+
MJ2YED&,L, #Z5U&*S/\ A&=4_P"ALU+_ ,![?_XW1_PC.J?]#9J7_@/;_P#Q
MNGH!=N[2&^LY;6==T4JE6'L:XZV^%?AZ"8R.)YAG(5WX'Y5TG_",ZI_T-FI?
M^ ]O_P#&Z/\ A&=4_P"ALU+_ ,![?_XW2T QKOX<>'+R<2M:LC8QA'('Y5/:
M^ O#UK9/:BS\R-SEC(Q)_.M+_A&=4_Z&S4O_  'M_P#XW1_PC.J?]#9J7_@/
M;_\ QNC0#$M_AMX=M=02[CMY-R'*H9"5S]*ZX   #H*R_P#A&-4_Z&S4O_ >
MW_\ C=+_ ,(SJG_0V:E_X#V__P ;HT T\5SMWX&\/WNH->SV"-*YRV"0"?7%
M7_\ A&=4_P"ALU+_ ,![?_XW2?\ ",ZI_P!#9J7_ (#V_P#\;IZ 1OX6T22R
M%FVFV_D Y"[<8/UJ&V\&Z!:W27,.G1+*GW3Z5:_X1C5/^ALU+_P'M_\ XW1_
MPC&J?]#9J7_@/;__ !NEH!4U#P9H&I3>;<:?'YF<ED^4GZXHU6WAM+SPO!!&
M$C35%55 X \B:KG_  C.J?\ 0V:E_P" ]O\ _&Z(O"EP=0LKJ\U^^O%LYO/C
MBDBA5=^UER2J ]&/>GH!TM%%%2,**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "J>E?\@]/JW_ *$:N53TO_D'
MI_O-_P"A&FMA%RBBBD,*IWG_ !]V/_74_P#H)JY5.\_X^[+_ *Z'_P!!--;B
M9<HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *:SJN-S 9.!D]:=7-^(T<WMG)':332(" 1
M!YL8!*YW#:2.G!7F@#I**X=+O5T&0FIDE0C@Q2G+X.9!E>%Z87MZ4]Y]02)@
MAU5Y6A.Q_+F"QR?-DD;>1C:!UQ@T =K30ZL2 02.H]*Q= :YD0M,MZ, C_2=
MRXYSC:Q)/UR?2LQ-)U&(0^3:&)X4\NXDBF"O=Y=22"#D' 8Y;!^8@>M '6JZ
MN,JP(]C3LYKC[71]9@M@BM)"4C)14G RX5-H;'7D-UXH&FZU!B.V^T*JAP=U
MS\IR6.5^;J00.1QUXYR =A2!E;."#CKBL&PM-62\A::61;3+.4DEW.N"P52>
M<Y# GG^#WI_V.]2SU86T0MYYYV>%L@;AA1GCH3@]?6@#<I-P#!<C)YQ7/:59
M7]M<W,TRSL\D "-+/D!@S84C<>Q7GGOSFH](M-6M[J.>\B>3:'0!Y@Q4,8NY
M8G *R'J?UH Z1G5!EB /4FD\Q,XW#.,]>WK6)JL-QJVFV,JV<O$WFM#\F\+L
M<#A_ESR.#6=-HEY)%+$EFBREI'^TEDRR-&5$?'ID#'W<+D4 =89HQC+J,].>
MM*'5F(!!(ZC/2N9M] 9!''/:6\FR[$I?8H4H4(P%[8.,CN>:LZ=I]S;_ ""V
MCMYU+;[S"N9P6SCKGGKSTQWH W2ZA2Q88 SG-"R*_P!U@?H:XV#P]J%L(%:%
M)[>)(V,!<?,<DNG/'WOF';M6E96-Y!=WD]O9I9*ZQE8P$8/MW97@\9R.: .A
MW#&<CTIID13@L <9P3VKCQX?UAK1K$R0;)'^U--S@2[2",9S][#YZ9J=]*O+
MBWFCFTV(W4TPE-T61MH+*=O/)P/EQT(% '5&1%7<6 7U)XI#*BYRP&!DY/2L
M'[#=0>&S9?8HKB=78!2$*<L3O53@#KD+QCI[U172+VW9VBTY9BL>%\]T8N"L
M856YYVE2?3@8/- '6B12VT,,XSC/:E+JI ) )Z#UKCXM)NK(K*+2;;%'D2*Z
M^;M\GR_+&W.#N^;C@9K3UO3YKV:(I9)<C[/+%\[@"-V*8;)YXP>1S0!NYI:Y
M Z;K9O \PEECBE5E N" ^-P##YN.#DCCZ'C-RRMM971[R.8R+<,X,0,V6"X7
M< Q9L9.[&3W!XH Z.F&:,.4WKN&,KGD9Z5@65EJR7<4TTTX19!B-I]V(R9.&
MYP2 4YYZ=:@NM$O3>W$]NJAI9_,W,^>CPE3^ 5^/;Z4 =3165H,%]!:.M^TI
MD+ @2.&QP,X.3QG)_'H.E:M !5/2_P#D'I]6_P#0C5RJ>E_\@]/JW_H1IK81
M<HHHI#"JM]&[PK)&,R1,'4>N.H_+-6J* (X)X[B(21ME3^GM4E5Y;*&1RX#1
MN>K1L5)_+K4?V _\_EU_WV/\*>@%RBJ?V _\_EU_WV/\*/L!_P"?RZ_[['^%
M&@%RBJ?V _\ /Y=?]]C_  H^P'_G\NO^^Q_A1H!<HJG]@/\ S^77_?8_PH^P
M'_G\NO\ OL?X4: 7**I_8#_S^77_ 'V/\*/L!_Y_+K_OL?X4: 7**I_8#_S^
M77_?8_PH^P'_ )_+K_OL?X4: 7**I_8#_P _EU_WV/\ "C[ ?^?RZ_[['^%&
M@%RBJ?V _P#/Y=?]]C_"C[ ?^?RZ_P"^Q_A1H!<HJG]@/_/Y=?\ ?8_PH^P'
M_G\NO^^Q_A1H!<HJG]@/_/Y=?]]C_"C[ ?\ G\NO^^Q_A1H!<HJG]@/_ #^7
M7_?8_P */L!_Y_+K_OL?X4: 7**I_8#_ ,_EU_WV/\*/L!_Y_+K_ +['^%&@
M%RBJ?V _\_EU_P!]_P#UJ/L!_P"?RZ_[['^%&@%RBJ?V _\ /Y=?]]C_  H^
MP'_G\NO^^Q_A1H!<HJG]@/\ S^77_?P?X4?8#_S^77_?8_PHT N453^P'_G\
MNO\ OL?X4?8#_P _EU_WV/\ "C0"Y15/[ ?^?RZ_[['^%'V _P#/Y=?]]C_"
MC0"Y15/[ ?\ G\NO^^Q_A1]@/_/Y=?\ ?8_PHT N453^P'_G\NO^^Q_A1]@/
M_/Y=?]]C_"C0"Y15/[ ?^?RZ_P"^Q_A1]@/_ #^77_?8_P *- +E%4_L!_Y_
M+K_OL?X4?8#_ ,_EU_WV/\*- +E%4_L!_P"?RZ_[['^%'V _\_EU_P!]C_"C
M0"Y15/[ ?^?RZ_[['^%'V _\_EU_WV/\*- +E%4_L!_Y_+K_ +['^%'V _\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>elev-20211231x10k004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 elev-20211231x10k004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %N K,# 2(  A$! Q$!_\0
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MEC1#),_W47^9]!4874'Y,L$?L$+8_'(IV%<N454\J_\ ^?F'_OR?_BJ/*O\
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ME7__ #\P_P#?D_\ Q5'E7_\ S\P_]^3_ /%46\P+=%5/*O\ _GYA_P"_)_\
MBJ/*O_\ GYA_[\G_ .*HMY@6Z*J>5?\ _/S#_P!^3_\ %4>5?_\ /S#_ -^3
M_P#%46\P+=%5/*O_ /GYA_[\G_XJCRK_ /Y^8?\ OR?_ (JBWF!;HJIY5_\
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M*O\ _GYA_P"_)_\ BJ/*O_\ GYA_[\G_ .*HMY@6Z*J>5?\ _/S#_P!^3_\
M%4>5?_\ /S#_ -^3_C18"W15)CJ$7S?N9P.J@%#^')%6+>X2YCWID8.&4C!4
M^AHL!+1112 I6(\QY[EN6>0J#Z*IP!_.KM4],_X]#_UTD_\ 0C5RF]Q(****
M0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-P.H[&IO[+L/*N8OL5OY=RQ:=/*7$I/4L,?,?K2NNP6/&D\=^*;>RT:_6_\
MML+:6][?Q^3'D#S#&2N%'W,J<>QS74:CXOU*T^$^DZD+D#6=12"*.;RPV'?E
MGV '.%#' %=Q#H6DVZE8-,LH@4:/"0(OR-RR\#H>X[U*-+L%6V465N%M3FW
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MC H M1_%=9+#/_"/W8U1KB&&*P,R9D$L9E1M_0#8"3Z$8KL-#\0V.O:'8ZK
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M)JNGQVL)DCN)!'DSKGY,[3]\\D>E>OUR7Q+_ .1$O/\ KM;?^CXZ .MHHHH
M**** "BBB@ HHHH **** "BBB@ JM<:A9VC!;FZ@A8C($D@4D?C5FN8\:V%I
M/I4<\MK#)*MQ @=T!(4RJ",^AS014DXQ;1TD,T5Q$)(9$DC/1D.0?QI]0VMO
M#:0+#;PQPQ+T2-0H'T IFH7L6G6$UW-G9$I; ZD]@/<GB@M'-QZP&^(DEH+6
M;BV$);'3!W[O]WG&:ZVN4T*SFM?$LCW1S=W%D)Y_9FD/ ]@ !^%=70 4444
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M.7J_SB+<NRV7BPJS*?MT70X_Y:25['X=);PWI9)))M(N3_N"O&[O_CQ\6?\
M7]%_Z,DKV/PZ<>&M+_Z](O\ T 5I1W9U8+XGZ?JRUJ?_ ""KS_K@_P#Z":\L
MT^^N[/0=&6VN981)?R*XC<KN'R<''7J:]3U+_D%7G_7!_P#T$UY)!_R M"_[
M"$G\XZZ#T3T?1_$#ZIK>IZ>UNL:V3E0X?);YB.F..E;U<1X2_P"1R\2?]=F_
M]#:NWH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-M1:8+LFDC\Q04Q]W'4YXK)^+'C+PUJOPRU>ST_7=/NKF18MD4-PK,V)%)P
M?05HCX6*FOQS)J0.C+=PWK6+P99I8X_+7Y\_=(&2,5G?%CP=X:TKX9:O>6&@
MZ=:W,:Q;)8;959<R*#@@>A- %&Y(/BR4@\'1/_;:LZU_Y!GA7_L(2?\ HQ*T
M;D >+)0.G]B?^VU9MK_R#/"O_80D_P#1B5QRW9XM3XI>K_.(MW_QX^+/^OZ+
M_P!&25Z!H'B=EU'2/#OV/(;3XI//\S_IGG&W'MZUY_=_\>/BS_K^B_\ 1DE:
M]G<M9>,]/ND4,T.B+( >^(":<)6*HS<))KR_.1ZKJ7_()N_^N#_^@FO)K?\
MY >A?]A&3^<==UH.O3>(_!UW?S0I"Y66/:AR.!7"6_\ R M"_P"PA)_..NJ+
MNKGK1DIQ4ELS;LM4;1=8\5WZ1"5HION$X!S*1_6NVTS7+74([9#*BWDT"S&
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MZ=_W]K4T/2=-AT>S>+3[5&>WC+%85!8[1UXYK1^PVG_/K!_W[% '-?\ "S_
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MT_Y]8/\ OV*/L-I_SZP?]^Q0!S7_  L_P/\ ]#/IW_?VC_A9_@C_ *&?3O\
MO[72_8;3_GU@_P"_8H^PVG_/K!_W[% '-?\ "S_!'_0S:?\ ]_*/^%G^",9_
MX2;3_P#OY5#XIVEO'X#NV2")6\R+E4 /WQ7"V<,1\9:.#&F#X?4D;1U^S,<U
MO"ASPYK]_P #"=?EGRV[?B>D_P#"SO!/_0RZ?_W\H_X6?X)_Z&73_P#OY7C,
M$<9\)^'B47)U>4$XZC$5:=]%&#\0OW:_+<)MXZ?Z0>E:_5-;7_J]C/ZVK;?U
M:YZG_P +/\$?]#-IW_?VC_A9_@?_ *&?3O\ O[5CP79VS^"M%9[>%F-G'DE
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MFA%6T_K1A/+J-+13;OKK_P .B2ST"&#QBEPVKI-LEW;7SYK/C&#QCKWKT)<
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MC8Y*M*3J<RVT_"YY3!_R*7AW_L,2_P HJT[_ *_$3_KX3_TI-9L'_(I>'?\
ML,2_RBK2O_O?$7_KX3_TI-=WVOG_ .W(XGM\O_;6>P>"?^1(T3_KSC_]!K>K
M!\$_\B/HG_7G'_Z"*WJ\B?Q,]:'PH****DH**** "L[7=.?5M$NK&-U1YE #
M-T'(/]*T:*4HJ2:8TVG='F<FGOI7B_PY8R.KO#!M++T/S.:T_AE_R"K_ /Z^
M/_913/$'_)2=&_ZYC^;T_P"&7_(+O_\ KX_]E%>=225>R[O\D=U1WHW?9?FS
MKK[3++4XEBO[2"YC5MRK,@8 ],\USGC32=/M_"^MW\-G#'=RVQ5YE0!F&1P3
M^ _*NNK&\66-QJ7A74;*TC\RXFB*HFX#)SZGBN^<;Q9QP=I(\FT__D)> _\
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M'3+>QMII(44EUFDV("2@QL.&.",YP"<4>SAV0<\NY2'@3Q O33_!7_@%-_\
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M?_H-;U<<_B9V0^%!1114E!1110 4444 <'X@_P"2DZ-_US'\WI_PR_Y!=_\
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M8Y';)D!+>Y^7&.<]:]!HH Y[PKX8;PZE]+<Z@^H7]_/Y]S<M&(PQ"A0 HX
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M<XY[4 >O:1_R!+#_ *]X_P#T$5=JII2/'H]DDBE'6WC#*1R#M'%6Z "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KP&_(S\1!GGST_#_ $@U[]6'XC\-
MPZ_H=WIRNML;DJ6F2,$\,&YZ9Z?K6]"K[-Z];?F85Z3J+3I?\AO@G_D2-$_Z
M\X__ $&MZJ&BZ:-'T6RTX2F46T*Q;R,;L#&<=JOUE)WDV:P5HI,****DH***
M* "BBB@!K(&YP,^N*R/#WAZ'P];3003R2K*^\F3''&.PK9HJ7!-J74:DTK!1
M115""FO&D@PZ*PZX(S3J*  #%%%% !5*Z_Y"%E]7_P#0:NU2NO\ D(67U?\
M]!IK<&7:***0%/3/^/0_]=)/_0C5RJ>F?\>A_P"NDG_H1JY3>XD%%%%(8444
M4 %%%% !1110 4444 %%%% !1110!A>-;2>_\#Z[:6L337$UA-'%&@R68H0
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MM^<90GMU'O5+Q[XK\2Z3XKU1--N[N.SL+6WG/EQ0M#'N9MS2[AO(P/X<G@T
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ML4ZPJ7E*N@4RG;]S:S8;@9Z'(%32VWB.#Q3!KEK;7Z07;2R7\L,+><(/M2(
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MHH **** "BBB@ HHHH **** "BBB@ JE=?\ (0LOJ_\ Z#5VJ5U_R$++ZO\
M^@TUN)EVBBBD,IZ9_P >A_ZZ2?\ H1JY5/3/^/0_]=)/_0C5RF]Q(****0PH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @AL[>WN+
MB>*%$EN&#3,!RY P"??  J>BB@#,U3P[H^M3V\VIZ9:W<EN<Q--$&*'KQGZ5
MIXXQ110!FZ;X>T?1KBXGTW3;6TEN3F9X8@I<YSSCZFM+%%% $$]G;W4D$D\*
M2/;OYD189V-@C(]\$C\:GHHH **** "BBB@ HHHH **** (+FRMKPPFXA20P
MR"6,L,[''1A[\FI^U%% !69JGA[1];D@DU33;6\:W;=$9X@Q0^V?H*TZ* $P
M,8K-T[P[H^DWEQ=Z?IEK:W%R29I(8@K/SGDCWYK3HH *@N;.WO!$+B%)1%(L
ML>X9VNO1A[BIZ* "BBB@ II8#OCZTV>-Y;>2..4Q.RD+( "5..#@\'%<1K_@
M+4-=-H;KQ!+.89/X[=$VH?O8V@9/ Z\5$VULKE12>[L=W5+4=7T[1XDEU*_M
MK.-VVJUQ*L88^@)-5M+TS4;*8M=:U+>Q;-JQ-!&@4\<Y4 ^U<A\4=)NM1.ER
MVNGW]PT(G FLHXYS&64#:\+C#HV,$Y&,>]4FVM1,]#1TD171E9& *LIR"/6J
MKZK81WHLWO;=;HLJB$R@/E@2HQUR0K$?0^E>,+8?$."XEC,-_:A-,VPPV>3
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MA+<7KS-MM7A:!1]W/^L\P#MFI;S07UC2]9;[+-<:I:>*/-5%8_*AEA(;;G!
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P#??_UJ/[>7_GW/_??_ -:CE8KFQ16/_;Z_\^Y_[[_^M1_;Z_\ /N?^^_\
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M?^^__K4?V\O_ #[G_OO_ .M1RL+FQ16/_;R_\^Y_[[_^M1_;Z_\ /N?^^_\
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M[_\ K4?V\O\ S[G_ +[_ /K4<K"YL45C_P!OK_S[G_OO_P"M1_;Z_P#/N?\
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&HHHI#/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>elev-20211231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 elev-20211231x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %H K<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^JL]V4E\
MB"/S9B,D9P%'J35ECM4GT&:J::O^BB8\O-^\8^N>GZ4T( FH'DSP*?01D_UI
M?*O_ /GYA_[\G_XJK=%%PL5/*O\ _GYA_P"_)_\ BJ/*O_\ GYA_[\G_ .*J
MW11<94\J_P#^?F'_ +\G_P"*H\J__P"?F'_OR?\ XJK=%%P*GE7_ /S\P_\
M?D__ !5'E7__ #\P_P#?D_\ Q56Z*+@5/*O_ /GYA_[\G_XJCRK_ /Y^8?\
MOR?_ (JK=%%P*GE7_P#S\P_]^3_\51Y5_P#\_,/_ 'Y/_P 55NBBX%3RK_\
MY^8?^_)_^*H\J_\ ^?F'_OR?_BJMT47 J>5?_P#/S#_WY/\ \51Y5_\ \_,/
M_?D__%5;HHN!4\J__P"?F'_OR?\ XJCRK_\ Y^8?^_)_^*JW11<"IY5__P _
M,/\ WY/_ ,51Y5__ ,_,/_?D_P#Q56Z*+@5/*O\ _GYA_P"_)_\ BJ/*O_\
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M_P#\_,/_ 'Y/_P 55NBBX%3RK_\ Y^8?^_)_^*H\J_\ ^?F'_OR?_BJMT47
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MS>O*#/="18XA&H9@0 "3AATK,U'QWXDL/[7D.GZ68]"CA.H+YDF96?D^4>P
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!2/_ "&5_P"N!_\
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MQ75I=!+UIK1BT+27TS;2>O5NAZ$=Q7FLOC/Q,-$TV6'73+<7-U>QNVRW7"Q
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MTVTU76FT=9_MDBW%U;0J[11A#&9%.0"26X&*I'Q_XAFET,-JD-HFJP1&Y;R
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MDYP,^N*NT4 51IE@MA]@6SMQ9[=OV<1+Y>/3;C&*B71=+73S8+IUH+(G)MQ
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M/_H0HIB+4O\ J7_W34.G?\@VV_ZY+_*II?\ 4O\ [IJ#3O\ D&VW_7-?Y4=
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M!O'H?6D31M-1'1;"U5)!AU$2@-]>*OT4^9]Q<D>Q333;*-(T2T@5(FWQJ(P
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MD1:>2)I#:R;&8.(]J'&'.X@8&:)OB7X7M[/3[J2_<17Q;R\0N3&%;:QD&,H
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MA/F5[&I;7$5W;QW$#AXI!N5AT(J6CI106%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 57OA(UA<+%Y/F&)MGGC,><'&[_9]?:K%4M7M6OM'O;14
M5VGMY(@KL5!+*1@D<@<]10!X_P")?%NJZV+&VMM3AT8P.\,EQ:ZC_HDLAV["
M)XU;&,$^6X7KU->Q:9$T6GP>;+'/.8T,TZ* )7V@%^/7%>3>'8[OP<E]92^!
M-=O;B[5(Y,-!/ Z+D*-RA1CYC]X9]:]-\.2ZA+I2G4-*ATHJ=D-I%,)/+B
M4$@  ]>!P!B@#B?B+X>T?7O%/AW2)=/MC>:G,S7%V8P91;P+O90V.,D@9^M<
MAXBCL=/^)LEY;2V%[?IJ-E;Q:/-IY$BQA0 T;GD8QG*C'K7O)BC:19"BEUR%
M8CD9ZX---M UPLYAC,RC:)"HW >F>M 'S]X,&[Q=H,=B%7Q(ESJAU4R*=P!^
MX9>Y7.,?I7H.MV_Q&&@:B;F^\-F#[++Y@C@FW%=ISCYNN*] 6VA29YEB197&
M'<* S?4]ZH^(_P#D6-6_Z\IO_0#0!G?#[=_PKSP[NQG^SX>G^X*Z2N<\ ?\
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M5C;&2>PO$G65XFMV,2N"JJQY+X)(=< $DYZ<468'744U&+(K%2I(R5/44Z@
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M='5E)C)SVZC.*[:L'QCKLOAOPW/J,$43RJ\<:&=BL2%W"[G(Z*,Y/TI#.?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ&[:=+29K5%DN!&QB1SA6;'
M)[#- 'BGCG3_ !+I'B#7=:L;?Q!!ISE9I9['4X88V"H!NV;2W&.IR>*]IL6W
MV%N^XMNB4[BVXGCU'7ZU\_\ B>WDF\4-_P )!H?AQ-5O"K-!+KTJ!^ !E00
M#CVS7T';(4M8E,:QD( 43[J\=![4 <MXI\%3^);A]GB"_L;2X@^S7=I%AHY4
MSDX#?<8]-P[5G_\ "J]/37H[V#4+F'3EN8+M]."J4>:)=J-N/S8QU'>N^HH
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M888CX@P6SO\ [0.?,]]G_COM3+]E_LJ/SFE%DMO>GP]RV#+]L7R_+]]O3VH
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MH\4_\CYX?_WE_P#0ZY=/^1>\1_\ 7W%_Z&U,ZS3T:86_BZUG*[A'I:.0.^(
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MKU*B@#BO^%@S_P#0E>*O_ $?_%4?\+"G_P"A*\5?^ (_^*KM:* .*_X6#/\
M]"5XJ_\  $?_ !5'_"P9_P#H2O%7_@"/_BJ[6B@#BO\ A8,__0E>*O\ P!'_
M ,51_P +!G_Z$KQ5_P" (_\ BJ[6B@#BO^%@S_\ 0E>*O_ $?_%4?\+"G_Z$
MKQ5_X C_ .*KM:* .*_X6#/_ -"5XJ_\ 1_\51_PL&?_ *$KQ5_X C_XJNUH
MH XK_A8,_P#T)7BK_P  1_\ %4?\+!G_ .A*\5?^ (_^*KM:* .*_P"%@S_]
M"5XJ_P# $?\ Q5'_  L&?_H2O%7_ ( C_P"*KM:* .*_X6%/_P!"5XJ_\ 1_
M\51_PL*?_H2O%7_@"/\ XJNUHH XK_A8,_\ T)7BK_P!'_Q5'_"P9_\ H2O%
M7_@"/_BJ[6B@#BO^%@S_ /0E>*O_  !'_P 51_PL&?\ Z$KQ5_X C_XJNUHH
M XK_ (6#/_T)7BK_ , 1_P#%4?\ "P9_^A*\5?\ @"/_ (JNUHH XK_A8,__
M $)7BK_P!'_Q5=C!*9[>.4QO'O4-LD&&7(S@CU%244 %%%% %(_\AE?^O<_^
MA"B@_P#(97_K@?\ T(44Q%J7_4O_ +IJ'3O^0;;?]<E_E4TO^I?_ '34.G?\
M@VV_ZY+_ "HZ!U+-<C\2[FZM?!-RUG-=1S/-#$!:'$KAI%4HC?PD@D9]ZZZN
M8^(%FNH>#;NU=;%E=H\K?736\1PX/+J01_6D,J?#FVN+71[F.XMM>M\3?*FL
MSK(^-H^YMZ+_ %S79&O._A*(HK#6;1(;*-[>\57-G>R74;YC4Y#N3ZXP/2O1
M* /G&2_N[1]2AFU))WU-UEFOK+4)76*!KU4=&4X"'! !&. :COM8OFTYHGUB
M[2WTRVO)=(D6Y8&:1+L)'\V?WF$X&<\&O?U\.:(@O ND6*B]_P"/H"W7]]_O
M\?-^-#^'M%>&TA?2;)H[([K9# N(3ZH,?+^% '%ZG>:[<>/_  I'J6E6]M:+
M>3^1.ESO:3]P_5-HV\>YKT>N1\4D?\)AX,_Z_9__ $G>NCU#4[/2K-[N]G6&
M!.KM_GF@3:2NRW4<S,L3F/;O .W=TS[UQ'BCQ[:Q:)OT*]2:Z<KAE0MY:D\E
MLC /L:J:'<:OXG\/_;-3UL6EL"T86+$32D=W?L.>BXI7U.?ZS%S]G#5VOY$5
MG\0=7O-0ELH;"UNI%W*%MB^6P/O D8P#Z_AFLKP-IT\'BZ2XO[>Y >.0!WM9
M K%N22S 8&,]:H^#I'L/$<DRV23I)&ZM'$&<A2.BY/ Z9)/2K'A.PAU/Q$MM
M<$B(JYVAL;N.A]1ZBA+N<]&A4J<LZSU3V+7AZ?SO$C)I^GZ7;2MN,<IB.( J
MD$KSZ5H>$["RM_%S.-7M;ADR(]HP9BRDDKSVKI-(\,7.F:L;PR:>5;AEBM-A
M QCY3N^7/?UKI5AB4Y6- ?4+3/022V,G5-&NM1NHI8]4DMTA<21QK"C;7 (W
M9//0FKATJSF5&O+:WNIPH5II85+-C\*NT4#&I&D2+'&JHBC"JHP /04ZBB@
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MC;QY'>ZS:EM +:6C/(?(EPX5@./F]^]<_/\ \B7X>_Z_[C^:5K7/_(P>//\
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M=J<_C.S-O'*PG0):[6QEP&+ >^,GZ5'XGT^^;36;4-7O[FZ210;9X<(,\;@
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M XS4NKAXN[EIZ,I4Z\EI'7U1U^K>+;/2K6TN1;W-W%=*SH;=5) "[LD,01D
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MO+K\_P#TE&:Z?UU.97_DG-__ -A>/_T4]=MI/_):+#_L'1_^DXKB5_Y)S?\
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MSP]_U_W'\TK7N?\ D8/'?_7M+_Z,2M/Z_ 3W^_\ ,K6O_,B?]=W_ /2BF?\
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M96&SCD4?,/7(SZ&H[GX@^+K.R,<NJ1,9SI\INQ!%&+9)X7=E&[Y<950"WJ:
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M.&'/H10!9HJKIVI6FK6$5]8S":VF!,<@! ;!([^X-6J "BBB@ HHHH ****
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ML/3'4&@#LZ*X[3_B7H6I7>F06Z7?_$P2-TD:,!8S(7"*_P W#$QL.,\XKL:
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MI(9]8T^*6/\ UB/=(K)R!R">.2!^-2KK.F/?_8%U"T-Y_P ^XF7S.F[[N<]
M3]!0!>HKCC\2-)35I;"2QU1%CNY++[6UN/(:9 24#!NIQQD"J]O\6/#EQ#92
M;;R/[9=PVD8DB4$-+&LBL?F^[AQD^O:@#N:*Y_P[XPTWQ--<1627$;0J''G*
M%\Q-[IO7!.1NC85T% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 4C_ ,AE?^N!_P#0A10?^0RO_7 _^A"BF(M2_P"I?_=-0Z=_R#;;_KFO\JFE
M_P!2_P#NFH=._P"0;;?]<U_E1T LT444AA1110 4444 %%%% !1110 4444
M%%%% !1110!G:II*:H(P]U>0!,_\>T[1Y^N.M<EI_P -OLFNW-Z^K7/DON\O
MRI&27YCD[G!Y_K7?57CO[2:<P174#RC.460%ACKQ093H4YM2DM4)8V8L+1+=
M9II@N<//(7<_4GK7E'B#P!XBNO$.O/II6.P:.:\T]O-"DW4R(D@X.5X5\'_;
MZU[!5#^VM-&K2:5]LB^WQP_:'@W?,L><;C[9H-3QB+X=>))+*626RG6>&SE^
MPH;I5,,AF1E48<@<!V R0,UK2^$/$?\ ;HN;G2YKZW-Y</;@:CY(MF:YWB4X
M.<&/C R>,8KU#3M;T[5M,_M*QNXYK+YOWPX7Y>IR>WO3[+5K#4998[.YCF:)
M4=PASA77<ISZ$<T >0>'/ _B[3_$VAW-S')';VPCRR7"XA0%]\9&[G=D' !!
MSU&*]LK-&OZ4=6_LH7D?V[<4\CG=D('(_P"^2#4][JEEIWD_;+A(?.<I'N_B
M(4L?R"D_A0!;HK-T;7]*\0VKW.DWT-Y C[&>(Y ; ./R(K2SQ0 45G:IKVEZ
M((3J5Y';"9ML9?/S'C_$?G6AF@!:*Q=4\6Z!HE_#8ZGJMM:W,V"D<CX."< G
MT&>,G%1)XV\-R:I/IBZO;F^@+B2#)W H"6 &.2 #P* -X@,"#T-9=UH5O.JB
M+]S@Y) SFK]K=07MI#=6TBR03()(W4\,I&01^%1WFI66GA#>7<%N')"F60)G
MZ9/-5&33T)E&,E9A;:?;VQ#I&!(!@MZUSWCKPU>>)=/M+>V33KB.*4O+;:@A
MV2#:0"'7YD8'D%<=P:ZB.1)8UDC971@&5E.00>A!JAK.OZ7X>LUN]6O8K6!F
MV*SG[S>@ Y/0U+=]QI);'E9^#^MF2,RZM:W.;54>25I-R2+$Z +UROS 9)Z9
MX-:%Y\+]06XTZ;3_ .R0MG%8CR)E81R/ )=^0%Z,9 <]>I->GVE[;7]I%=VD
MR3V\RAXY(SE64]"#52X\0:5::DFGSWL<=V[1JL1SDE]VP?CL;\J!GED7PEUZ
M*ZL#]OTTPV^URJ!DVD^9N487Y@/,X+'@#&!FKMO\*[^SGTV6!M,_T7[#O7#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT?V@/^?6Z_[]&BBBR /[0'_/K=?]^C1_: _Y];K_ +]&BBBR /[0'_/K=?\
M?HT?V@/^?6Z_[]&BBBR /[0'_/K=?]^C1_: _P"?6Z_[]&BBBR /[0'_ #ZW
M7_?HT?V@/^?6Z_[]&BBBR /[0'_/K=?]^C1_: _Y];K_ +]&BBBR /[0'_/K
M=?\ ?HT?V@/^?6Z_[]&BBBR /[0'_/K=?]^J/[0'_/K=?]^C1119 ']H#_GU
MNO\ OT:/[0'_ #ZW7_?HT4460!_: _Y];K_OT:/[0'_/K=?]^C1119 ']H#_
M )];K_OT:/[0'_/K=?\ ?HT4460!_: _Y];K_OT:/[0'_/K=?]^C1119 ']H
M#_GUNO\ OT:/[0'_ #ZW7_?HT4460!_: _Y];K_OT:/[0'_/K=?]^C1119 '
M]H#_ )];K_OT:/[0'_/K=?\ ?HT4460!_: _Y];K_OT:/[0'_/K=?]^C1119
M ']H#_GUNO\ OT:/[0'_ #ZW7_?JBBBR /[0'_/K=?\ ?HT?V@/^?6Z_[]&B
MBBR /[0'_/K=?]^C1_: _P"?6Z_[]&BBBR /[0'_ #ZW7_?HT?V@/^?6Z_[]
M&BBBR /[0'_/K=?]^C1_: _Y];K_ +]&BBBR /[0'_/K=?\ ?HT?V@/^?6Z_
M[]&BBBR /[0'_/K=?]^C1_: _P"?6Z_[]&BBBR /[0'_ #ZW7_?HT?V@/^?6
MZ_[]&BBBR /[0'_/K=?]^C1_: _Y];K_ +]&BBBR /[0'_/K=?\ ?HT?V@/^
M?6Z_[]&BBBR /[0'_/K=?]^C1_: _P"?6Z_[]&BBBR /[0'_ #ZW7_?HT?V@
M/^?6Z_[]&BBBR /[0'_/K=?]^C1_: _Y];K_ +]&BBBR /[0'_/K=?\ ?HT?
MV@/^?6Z_[]&BBBR /[0'_/K=?]^J/[0'_/K=?]^C1119 ']H#_GUNO\ OT:/
M[0'_ #ZW7_?HT4460!_: _Y];K_OT:/[0'_/K=?]^C1119 ']H#_ )];K_OT
M:/[0'_/K=?\ ?HT4460!_: _Y];K_OT:/[0'_/K=?]^C1119 ']H#_GUNO\
MOT:/[0'_ #ZW7_?HT4460!_: _Y];K_OT:/M4\O$-K(I_O2_*!^'6BBDTD!+
3:V_V=&W-OD<[G<_Q&BBBI&?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>elev-20211231xex10d11001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 elev-20211231xex10d11001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  K ,8# 2(  A$! Q$!_\0
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M_;64DH6XN0QB3'W@HR:S=,\2VVJWBVT5CJ$+E2VZ>V**,=LGO5/5L_\ "?\
MA_CCR9_Y"G8#J*Q-8\5Z3H5S';7TLJRR)Y@2.)G.W.,G K;KB]4U6VT?Q_\
M:;P3-&VG!%$4)D.=^>@R:2 UM&\8Z-KMZ;2PEF:8(7Q) Z#'U(K4L]2MK^2Y
MCMW+/:R^5*I!!5L9_D:IZ3X@T_6IG6S$^Z-<GS;=X\#_ ($!52W9=/\ &MW;
M8 748%N$XZNGRM^F#18#9FOK:WNX+664+/<9\I.[8&33KJ[M[*UDNKF58H(U
MW.[' 4>IKG-._P")MXWO[]E!ATZ,6D)_VSRY_D*7Q*@U?4].\/XW12O]INQV
M,2?PGZG'Y4[ =)#/%<P)/"XDBD4,CJ<A@>A%8<_C?PY:SS0SZK$LL+%9%VM\
MI'&.E,\+,;)K[09"<V,I\D'_ )XMRGUQTIOCF**/P=J4JPQ^8$!!*CKN%"6M
M@+.F^,-!U?4%L;#4$FN2I<1A&' [\C%:B7EM+>2VJ3*UQ$ 9$'50>F:996\,
M=K"R01(WEKRJ =JP]&7/CKQ"_'W8!_X[2 W;[4;/3+9KF^N8K>%>KR-C_P#7
M679>,?#NHW*VUMJ]NTS?=1B4+?3(&:S;"TM?$7BG5[N^C%PFG3"UMX9!E$(
M+-CIDD]:VM5\.Z9K-FUM>64+ CY7" ,A]5/:F] -3/;O45M>6][$9;:>.5 Q
M4LC9&1U%8/@N]N+KPWMNI#+/:RR6[.?X@I(!_+%<KX=,WAS3+?78]SZ?<R.E
M_'_<.\A9%^G>CE ]':\MXIQ!),BRE=X0MR5Z9HKF[SR)?'4;,BNK:82K=?\
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,6F 8'K11WHI7 __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>15
<FILENAME>elev-20211231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/2/2022 11:56:19 PM-->
<!--Modified on: 3/2/2022 11:56:19 PM-->
<xsd:schema targetNamespace="http://www.elevationoncology.com/20211231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:elev="http://www.elevationoncology.com/20211231" xmlns:dei="http://xbrl.sec.gov/dei/2021q4">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsDetails" id="DisclosureFairValueMeasurementsOfFinancialAssetsDetails">
        <link:definition>40301 - Disclosure - FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetDetails" id="DisclosurePropertyAndEquipmentNetDetails">
        <link:definition>40401 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureAccruedExpensesDetails" id="DisclosureAccruedExpensesDetails">
        <link:definition>40501 - Disclosure - ACCRUED EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails" id="DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails">
        <link:definition>41104 - Disclosure - INCOME TAXES - Schedule of net deferred tax asset (liability) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>00300 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>00305 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureNatureOfBusinessLiquidityDetails" id="DisclosureNatureOfBusinessLiquidityDetails">
        <link:definition>40101 - Disclosure - NATURE OF BUSINESS - Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureConvertiblePreferredStockDetails" id="DisclosureConvertiblePreferredStockDetails">
        <link:definition>40601 - Disclosure - CONVERTIBLE PREFERRED STOCK (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureCommonStockInitialPublicOfferingDetails" id="DisclosureCommonStockInitialPublicOfferingDetails">
        <link:definition>40702 - Disclosure - COMMON STOCK - Initial Public Offering (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureStockBasedCompensationExpenseDetails" id="DisclosureStockBasedCompensationExpenseDetails">
        <link:definition>40801 - Disclosure - STOCK-BASED COMPENSATION - Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockIncentivePlanDetails" id="DisclosureStockBasedCompensationStockIncentivePlanDetails">
        <link:definition>40802 - Disclosure - STOCK-BASED COMPENSATION - Stock incentive plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureStockBasedCompensationAssumptionsDetails" id="DisclosureStockBasedCompensationAssumptionsDetails">
        <link:definition>40804 - Disclosure - STOCK-BASED COMPENSATION - Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureStockBasedCompensationEarlyExerciseOfEmployeeOptionsDetails" id="DisclosureStockBasedCompensationEarlyExerciseOfEmployeeOptionsDetails">
        <link:definition>40805 - Disclosure - STOCK-BASED COMPENSATION - Early Exercise of Employee Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" id="DisclosureStockBasedCompensationRestrictedStockUnitsDetails">
        <link:definition>40806 - Disclosure - STOCK-BASED COMPENSATION - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsDetails" id="DisclosureAssetPurchaseAndLicenseAgreementsDetails">
        <link:definition>40901 - Disclosure - ASSET PURCHASE AND LICENSE AGREEMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsOtherResearchArrangementsDetails" id="DisclosureAssetPurchaseAndLicenseAgreementsOtherResearchArrangementsDetails">
        <link:definition>40902 - Disclosure - ASSET PURCHASE AND LICENSE AGREEMENTS - Other Research Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureIncomeTaxesNarrativeDetails" id="DisclosureIncomeTaxesNarrativeDetails">
        <link:definition>41103 - Disclosure - INCOME TAXES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" id="DisclosureNetLossPerShareAntidilutiveSecuritiesDetails">
        <link:definition>41202 - Disclosure - NET LOSS PER SHARE - Antidilutive securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureNatureOfBusiness" id="DisclosureNatureOfBusiness">
        <link:definition>10101 - Disclosure - NATURE OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssets" id="DisclosureFairValueMeasurementsOfFinancialAssets">
        <link:definition>10301 - Disclosure - FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>10401 - Disclosure - PROPERTY AND EQUIPMENT, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>10501 - Disclosure - ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureConvertiblePreferredStock" id="DisclosureConvertiblePreferredStock">
        <link:definition>10601 - Disclosure - CONVERTIBLE PREFERRED STOCK</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureCommonStock" id="DisclosureCommonStock">
        <link:definition>10701 - Disclosure - COMMON STOCK</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>10801 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreements" id="DisclosureAssetPurchaseAndLicenseAgreements">
        <link:definition>10901 - Disclosure - ASSET PURCHASE AND LICENSE AGREEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>11001 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11101 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>11201 - Disclosure - NET LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureRetirementPlan" id="DisclosureRetirementPlan">
        <link:definition>11301 - Disclosure - RETIREMENT PLAN</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsTables" id="DisclosureFairValueMeasurementsOfFinancialAssetsTables">
        <link:definition>30303 - Disclosure - FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>30403 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>30503 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>30803 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31103 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>31203 - Disclosure - NET LOSS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureCommonStockDetails" id="DisclosureCommonStockDetails">
        <link:definition>40701 - Disclosure - COMMON STOCK (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockOptionsDetails" id="DisclosureStockBasedCompensationStockOptionsDetails">
        <link:definition>40803 - Disclosure - STOCK-BASED COMPENSATION - Stock options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails">
        <link:definition>41101 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>41102 - Disclosure - INCOME TAXES - Schedule of effective income tax rate reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureNetLossPerShareDetails" id="DisclosureNetLossPerShareDetails">
        <link:definition>41201 - Disclosure - NET LOSS PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureRetirementPlanDetails" id="DisclosureRetirementPlanDetails">
        <link:definition>41301 - Disclosure - RETIREMENT PLAN (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="elev-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="elev-20211231_cal.xml" xlink:title="Calculation Links, all" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="elev-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="elev-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.elevationoncology.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xsd:element name="RestrictedStockRepurchaseLiability" id="elev_RestrictedStockRepurchaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" id="elev_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TemporaryEquityStockIssuanceCosts" id="elev_TemporaryEquityStockIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ComputerSoftwareMember" id="elev_ComputerSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedLiabilitiesDisclosureTextBlock" id="elev_AccruedLiabilitiesDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedPreclinicalAndClinicalTrialCostsCurrent" id="elev_AccruedPreclinicalAndClinicalTrialCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="AccruedCompensationCurrent" id="elev_AccruedCompensationCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="AccruedConsultingFeesCurrent" id="elev_AccruedConsultingFeesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="MajorSuppliersMember" id="elev_MajorSuppliersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfMajorVendors" id="elev_NumberOfMajorVendors" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TemporaryEquityIssuePricePerShare" id="elev_TemporaryEquityIssuePricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="StockIncentivePlan2019Member" id="elev_StockIncentivePlan2019Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborationAgreementTerm" id="elev_CollaborationAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TemporaryEquityDisclosureTextBlock" id="elev_TemporaryEquityDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommonStockNumberOfVotesPerShare" id="elev_CommonStockNumberOfVotesPerShare" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm" id="elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedIntrinsicValue" id="elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="CollaborationAndLicenseAgreementsMilestonePaymentsPayable" id="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="CollaborationAndLicenseAgreementsNoticePeriod" id="elev_CollaborationAndLicenseAgreementsNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborationAndLicenseAgreementsMilestonePaymentsPayablePerLicensedProduct" id="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayablePerLicensedProduct" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="CollaborationAndLicenseAgreementsRoyaltyPaymentsPayable" id="elev_CollaborationAndLicenseAgreementsRoyaltyPaymentsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="CollaborationAndLicenseAgreementsPercentageOfRoyaltyOnNetSalesOfLicensedProducts" id="elev_CollaborationAndLicenseAgreementsPercentageOfRoyaltyOnNetSalesOfLicensedProducts" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborationAndLicenseAgreementsMilestonePaymentsPaid" id="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="SeriesaConvertiblePreferredStockMember" id="elev_SeriesaConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SeriesBConvertiblePreferredStockMember" id="elev_SeriesBConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborationAgreementRenewalTerm" id="elev_CollaborationAgreementRenewalTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AssetPurchaseAgreementRelatingToSeribantumabMember" id="elev_AssetPurchaseAgreementRelatingToSeribantumabMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SelexisAgreementMember" id="elev_SelexisAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DyaxAgreementMember" id="elev_DyaxAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NIHAgreementMember" id="elev_NIHAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="UnderwritersOfInitialPublicOfferingMember" id="elev_UnderwritersOfInitialPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EquityIncentivePlan2021Member" id="elev_EquityIncentivePlan2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentageOfAggregateSharesOutstanding" id="elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentageOfAggregateSharesOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EmployeeStockPurchasePlan2021Member" id="elev_EmployeeStockPurchasePlan2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TemporaryEquityEliminationOfSharesAsPartOfInitialPublicOffering" id="elev_TemporaryEquityEliminationOfSharesAsPartOfInitialPublicOffering" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProceedsFromIssuanceOfRestrictedCommonStock" id="elev_ProceedsFromIssuanceOfRestrictedCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="IssuanceCostsIncludedInAccruedExpenses" id="elev_IssuanceCostsIncludedInAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationPermanentDifferences" id="elev_EffectiveIncomeTaxRateReconciliationPermanentDifferences" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DeferredTaxLiabilitiesStockBasedCompensation" id="elev_DeferredTaxLiabilitiesStockBasedCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="AssetPurchaseAndLicenseAgreementsAbstract" id="elev_AssetPurchaseAndLicenseAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AssetPurchaseAndLicenseAgreementsDisclosureTextBlock" id="elev_AssetPurchaseAndLicenseAgreementsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CloudComputingArrangementPolicyPolicyTextBlock" id="elev_CloudComputingArrangementPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ClassificationAndAccretionOfConvertiblePreferredStockPolicyPolicyTextBlock" id="elev_ClassificationAndAccretionOfConvertiblePreferredStockPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DividendYieldRate" id="elev_DividendYieldRate" type="xbrli:pureItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUpsPercent" id="elev_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUpsPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SeriesaAndBConvertiblePreferredStockMember" id="elev_SeriesaAndBConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>16
<FILENAME>elev-20211231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/2/2022 11:56:19 PM-->
<!--Modified on: 3/2/2022 11:56:19 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureFairValueMeasurementsOfFinancialAssetsDetails" roleURI="http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.elevationoncology.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails" roleURI="http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637818621783734910" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_637818621783734910" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637818621783734910" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637818621783734910" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637818621783734910" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637818621783734910" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637818621783734910" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637818621783734910" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637818621783734910" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_637818621783734910" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637818621783734910" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637818621783734910" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637818621783734910" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_637818621783734910" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637818621783734910" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637818621783734910" xlink:to="us-gaap_LiabilitiesCurrent_637818621783734910" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637818621783734910" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637818621783734910" xlink:to="us-gaap_AccountsPayableCurrent_637818621783734910" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637818621783744912" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637818621783734910" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637818621783744912" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_RestrictedStockRepurchaseLiability" xlink:label="elev_RestrictedStockRepurchaseLiability_637818621783744912" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637818621783734910" xlink:to="elev_RestrictedStockRepurchaseLiability_637818621783744912" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637818621783744912" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_637818621783744912" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637818621783744912" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637818621783744912" xlink:to="us-gaap_AdditionalPaidInCapital_637818621783744912" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637818621783744912" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637818621783744912" xlink:to="us-gaap_PreferredStockValue_637818621783744912" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637818621783744912" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637818621783744912" xlink:to="us-gaap_CommonStockValue_637818621783744912" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637818621783744912" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637818621783744912" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637818621783744912" order="4" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637818621783744912" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_637818621783744912" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637818621783754910" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637818621783754910" order="4" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637818621783754910" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_637818621783754910" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637818621783754910" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637818621783754910" xlink:to="us-gaap_OperatingExpenses_637818621783754910" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637818621783754910" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637818621783754910" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637818621783754910" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637818621783754910" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637818621783754910" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637818621783754910" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637818621783754910" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637818621783754910" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637818621783754910" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637818621783754910" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_ProceedsFromIssuanceOfRestrictedCommonStock" xlink:label="elev_ProceedsFromIssuanceOfRestrictedCommonStock_637818621783764911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637818621783754910" xlink:to="elev_ProceedsFromIssuanceOfRestrictedCommonStock_637818621783764911" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637818621783764911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637818621783754910" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637818621783764911" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637818621783764911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637818621783754910" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637818621783764911" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_637818621783764911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637818621783754910" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_637818621783764911" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818621783764911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818621783764911" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637818621783764911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818621783764911" xlink:to="us-gaap_Depreciation_637818621783764911" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_637818621783764911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818621783764911" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_637818621783764911" order="2" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637818621783764911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818621783764911" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637818621783764911" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637818621783764911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818621783764911" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637818621783764911" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637818621783774910" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818621783764911" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637818621783774910" order="5" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637818621783774910" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818621783764911" xlink:to="us-gaap_ShareBasedCompensation_637818621783774910" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637818621783774910" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818621783764911" xlink:to="us-gaap_ProfitLoss_637818621783774910" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637818621783774910" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637818621783774910" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637818621783774910" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637818621783774910" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637818621783774910" order="1" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637818621783774910" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637818621783774910" order="1" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40401 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637818621783784911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637818621783784911" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637818621783784911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637818621783784911" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.elevationoncology.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - ACCRUED EXPENSES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_AccruedCompensationCurrent" xlink:label="elev_AccruedCompensationCurrent_637818621783784911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="elev_AccruedCompensationCurrent_637818621783784911" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_AccruedConsultingFeesCurrent" xlink:label="elev_AccruedConsultingFeesCurrent_637818621783784911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="elev_AccruedConsultingFeesCurrent_637818621783784911" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_AccruedPreclinicalAndClinicalTrialCostsCurrent" xlink:label="elev_AccruedPreclinicalAndClinicalTrialCostsCurrent_637818621783784911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="elev_AccruedPreclinicalAndClinicalTrialCostsCurrent_637818621783784911" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_637818621783784911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_637818621783784911" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637818621783784911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637818621783784911" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails" xlink:type="extended" xlink:title="41104 - Disclosure - INCOME TAXES - Schedule of net deferred tax asset (liability) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_637818621783784911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_637818621783784911" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_DeferredTaxLiabilitiesStockBasedCompensation" xlink:label="elev_DeferredTaxLiabilitiesStockBasedCompensation_637818621783794945" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_637818621783784911" xlink:to="elev_DeferredTaxLiabilitiesStockBasedCompensation_637818621783794945" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637818621783794945" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_637818621783784911" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637818621783794945" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637818621783794945" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet_637818621783794945" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637818621783794945" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_637818621783794945" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637818621783794945" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637818621783794945" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_637818621783794945" xlink:to="us-gaap_DeferredTaxAssetsGross_637818621783794945" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637818621783794945" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637818621783794945" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637818621783794945" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637818621783794945" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637818621783794945" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637818621783794945" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_637818621783794945" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637818621783794945" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_637818621783794945" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_637818621783794945" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637818621783794945" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_637818621783794945" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637818621783794945" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637818621783794945" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637818621783794945" order="5" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>17
<FILENAME>elev-20211231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/2/2022 11:56:19 PM-->
<!--Modified on: 3/2/2022 11:56:19 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" roleURI="http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" roleURI="http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureNatureOfBusinessLiquidityDetails" roleURI="http://www.elevationoncology.com/role/DisclosureNatureOfBusinessLiquidityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureFairValueMeasurementsOfFinancialAssetsDetails" roleURI="http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureConvertiblePreferredStockDetails" roleURI="http://www.elevationoncology.com/role/DisclosureConvertiblePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureCommonStockInitialPublicOfferingDetails" roleURI="http://www.elevationoncology.com/role/DisclosureCommonStockInitialPublicOfferingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureStockBasedCompensationExpenseDetails" roleURI="http://www.elevationoncology.com/role/DisclosureStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureStockBasedCompensationStockIncentivePlanDetails" roleURI="http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockIncentivePlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureStockBasedCompensationAssumptionsDetails" roleURI="http://www.elevationoncology.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureStockBasedCompensationEarlyExerciseOfEmployeeOptionsDetails" roleURI="http://www.elevationoncology.com/role/DisclosureStockBasedCompensationEarlyExerciseOfEmployeeOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureStockBasedCompensationRestrictedStockUnitsDetails" roleURI="http://www.elevationoncology.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureAssetPurchaseAndLicenseAgreementsDetails" roleURI="http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureAssetPurchaseAndLicenseAgreementsOtherResearchArrangementsDetails" roleURI="http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsOtherResearchArrangementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.elevationoncology.com/role/DisclosureIncomeTaxesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" roleURI="http://www.elevationoncology.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.elevationoncology.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.elevationoncology.com/role/DisclosureStandardAndCustomAxisDomainDefaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:title="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:title="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:title="definition: ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis to ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="CumulativeEffectPeriodOfAdoptionAxis" xlink:title="CumulativeEffectPeriodOfAdoptionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="CumulativeEffectPeriodOfAdoptionDomain" xlink:title="CumulativeEffectPeriodOfAdoptionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CumulativeEffectPeriodOfAdoptionAxis" xlink:to="CumulativeEffectPeriodOfAdoptionDomain" xlink:title="definition: CumulativeEffectPeriodOfAdoptionAxis to CumulativeEffectPeriodOfAdoptionDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="AdjustmentsForNewAccountingPronouncementsAxis" xlink:title="AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="TypeOfAdoptionMember" xlink:title="TypeOfAdoptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="TypeOfAdoptionMember" xlink:title="definition: AdjustmentsForNewAccountingPronouncementsAxis to TypeOfAdoptionMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="definition: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="AssetAcquisitionAxis" xlink:title="AssetAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="AssetAcquisitionDomain" xlink:title="AssetAcquisitionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AssetAcquisitionAxis" xlink:to="AssetAcquisitionDomain" xlink:title="definition: AssetAcquisitionAxis to AssetAcquisitionDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain" xlink:title="definition: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="FairValueByAssetClassAxis" xlink:title="FairValueByAssetClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByAssetClassAxis" xlink:to="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:title="definition: FairValueByAssetClassAxis to FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" use="optional" order="1.0" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_SeriesaConvertiblePreferredStockMember" xlink:label="elev_SeriesaConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="elev_SeriesaConvertiblePreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_SeriesBConvertiblePreferredStockMember" xlink:label="elev_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="elev_SeriesBConvertiblePreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_RestrictedStockRepurchaseLiability" xlink:label="elev_RestrictedStockRepurchaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="elev_RestrictedStockRepurchaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_Liabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Consolidated Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_SeriesaConvertiblePreferredStockMember" xlink:label="elev_SeriesaConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="elev_SeriesaConvertiblePreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_SeriesBConvertiblePreferredStockMember" xlink:label="elev_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="elev_SeriesBConvertiblePreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders Equity (Deficit)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_SeriesaConvertiblePreferredStockMember" xlink:label="elev_SeriesaConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="elev_SeriesaConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_SeriesBConvertiblePreferredStockMember" xlink:label="elev_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="elev_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="elev_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="elev_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityEliminationAsPartofReorganization" xlink:label="us-gaap_TemporaryEquityEliminationAsPartofReorganization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityEliminationAsPartofReorganization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_TemporaryEquityEliminationOfSharesAsPartOfInitialPublicOffering" xlink:label="elev_TemporaryEquityEliminationOfSharesAsPartOfInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="elev_TemporaryEquityEliminationOfSharesAsPartOfInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="extended" xlink:title="00305 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders Equity (Deficit) (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_SeriesaConvertiblePreferredStockMember" xlink:label="elev_SeriesaConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="elev_SeriesaConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_SeriesBConvertiblePreferredStockMember" xlink:label="elev_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="elev_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_TemporaryEquityStockIssuanceCosts" xlink:label="elev_TemporaryEquityStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="elev_TemporaryEquityStockIssuanceCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.elevationoncology.com/role/DisclosureNatureOfBusinessLiquidityDetails" xlink:type="extended" xlink:title="40101 - Disclosure - NATURE OF BUSINESS - Liquidity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_SeriesaAndBConvertiblePreferredStockMember" xlink:label="elev_SeriesaAndBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="elev_SeriesaAndBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_UnderwritersOfInitialPublicOfferingMember" xlink:label="elev_UnderwritersOfInitialPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="elev_UnderwritersOfInitialPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsPayableMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_MajorSuppliersMember" xlink:label="elev_MajorSuppliersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="elev_MajorSuppliersMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_SupplierConcentrationRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_AssetImpairmentCharges" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_NumberOfMajorVendors" xlink:label="elev_NumberOfMajorVendors" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="elev_NumberOfMajorVendors" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_LegalFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_DividendYieldRate" xlink:label="elev_DividendYieldRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="elev_DividendYieldRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40401 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_ComputerSoftwareMember" xlink:label="elev_ComputerSoftwareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="elev_ComputerSoftwareMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.elevationoncology.com/role/DisclosureConvertiblePreferredStockDetails" xlink:type="extended" xlink:title="40601 - Disclosure - CONVERTIBLE PREFERRED STOCK (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_SeriesaConvertiblePreferredStockMember" xlink:label="elev_SeriesaConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="elev_SeriesaConvertiblePreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_SeriesBConvertiblePreferredStockMember" xlink:label="elev_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="elev_SeriesBConvertiblePreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="elev_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="elev_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_TemporaryEquityIssuePricePerShare" xlink:label="elev_TemporaryEquityIssuePricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="elev_TemporaryEquityIssuePricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.elevationoncology.com/role/DisclosureCommonStockInitialPublicOfferingDetails" xlink:type="extended" xlink:title="40702 - Disclosure - COMMON STOCK - Initial Public Offering (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_UnderwritersOfInitialPublicOfferingMember" xlink:label="elev_UnderwritersOfInitialPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="elev_UnderwritersOfInitialPublicOfferingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.elevationoncology.com/role/DisclosureStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40801 - Disclosure - STOCK-BASED COMPENSATION - Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockIncentivePlanDetails" xlink:type="extended" xlink:title="40802 - Disclosure - STOCK-BASED COMPENSATION - Stock incentive plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_EquityIncentivePlan2021Member" xlink:label="elev_EquityIncentivePlan2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="elev_EquityIncentivePlan2021Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_StockIncentivePlan2019Member" xlink:label="elev_StockIncentivePlan2019Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="elev_StockIncentivePlan2019Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_EmployeeStockPurchasePlan2021Member" xlink:label="elev_EmployeeStockPurchasePlan2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="elev_EmployeeStockPurchasePlan2021Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentageOfAggregateSharesOutstanding" xlink:label="elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentageOfAggregateSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentageOfAggregateSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.elevationoncology.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xlink:type="extended" xlink:title="40804 - Disclosure - STOCK-BASED COMPENSATION - Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.elevationoncology.com/role/DisclosureStockBasedCompensationEarlyExerciseOfEmployeeOptionsDetails" xlink:type="extended" xlink:title="40805 - Disclosure - STOCK-BASED COMPENSATION - Early Exercise of Employee Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_RestrictedStockRepurchaseLiability" xlink:label="elev_RestrictedStockRepurchaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="elev_RestrictedStockRepurchaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.elevationoncology.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended" xlink:title="40806 - Disclosure - STOCK-BASED COMPENSATION - Restricted Stock Units (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsDetails" xlink:type="extended" xlink:title="40901 - Disclosure - ASSET PURCHASE AND LICENSE AGREEMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_AssetPurchaseAgreementRelatingToSeribantumabMember" xlink:label="elev_AssetPurchaseAgreementRelatingToSeribantumabMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="elev_AssetPurchaseAgreementRelatingToSeribantumabMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_DyaxAgreementMember" xlink:label="elev_DyaxAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="elev_AssetPurchaseAgreementRelatingToSeribantumabMember" xlink:to="elev_DyaxAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_SelexisAgreementMember" xlink:label="elev_SelexisAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="elev_AssetPurchaseAgreementRelatingToSeribantumabMember" xlink:to="elev_SelexisAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_NIHAgreementMember" xlink:label="elev_NIHAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="elev_AssetPurchaseAgreementRelatingToSeribantumabMember" xlink:to="elev_NIHAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayable" xlink:label="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_CollaborationAndLicenseAgreementsNoticePeriod" xlink:label="elev_CollaborationAndLicenseAgreementsNoticePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="elev_CollaborationAndLicenseAgreementsNoticePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayablePerLicensedProduct" xlink:label="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayablePerLicensedProduct" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayablePerLicensedProduct" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_CollaborationAndLicenseAgreementsRoyaltyPaymentsPayable" xlink:label="elev_CollaborationAndLicenseAgreementsRoyaltyPaymentsPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="elev_CollaborationAndLicenseAgreementsRoyaltyPaymentsPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_CollaborationAndLicenseAgreementsPercentageOfRoyaltyOnNetSalesOfLicensedProducts" xlink:label="elev_CollaborationAndLicenseAgreementsPercentageOfRoyaltyOnNetSalesOfLicensedProducts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="elev_CollaborationAndLicenseAgreementsPercentageOfRoyaltyOnNetSalesOfLicensedProducts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_CollaborationAndLicenseAgreementsMilestonePaymentsPaid" xlink:label="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPaid" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsOtherResearchArrangementsDetails" xlink:type="extended" xlink:title="40902 - Disclosure - ASSET PURCHASE AND LICENSE AGREEMENTS - Other Research Arrangements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_CollaborationAgreementTerm" xlink:label="elev_CollaborationAgreementTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="elev_CollaborationAgreementTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_CollaborationAgreementRenewalTerm" xlink:label="elev_CollaborationAgreementRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="elev_CollaborationAgreementRenewalTerm" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.elevationoncology.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="41103 - Disclosure - INCOME TAXES - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.elevationoncology.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" xlink:type="extended" xlink:title="41202 - Disclosure - NET LOSS PER SHARE - Antidilutive securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>18
<FILENAME>elev-20211231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/2/2022 11:56:19 PM-->
<!--Modified on: 3/2/2022 11:56:19 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address State Or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_SeriesaConvertiblePreferredStockMember" xlink:label="elev_SeriesaConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_SeriesaConvertiblePreferredStockMember" xlink:to="elev_SeriesaConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_SeriesaConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining Series A convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_SeriesaConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Convertible Preferred Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_SeriesBConvertiblePreferredStockMember" xlink:label="elev_SeriesBConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_SeriesBConvertiblePreferredStockMember" xlink:to="elev_SeriesBConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining Series B convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Convertible Preferred Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current liabilities:</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_RestrictedStockRepurchaseLiability" xlink:label="elev_RestrictedStockRepurchaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_RestrictedStockRepurchaseLiability" xlink:to="elev_RestrictedStockRepurchaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_RestrictedStockRepurchaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of restricted stock repurchase liability as on the balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_RestrictedStockRepurchaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Repurchase Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="elev_RestrictedStockRepurchaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock repurchase liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="elev_RestrictedStockRepurchaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability from the early exercise</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity, Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity (deficit):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2021; no shares issued or outstanding as of December 31, 2021 and 2020, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.0001 par value; 500,000,000 and 86,000,000 shares authorized as of December 31, 2021 and 2020, respectively; 23,225,637 and 836,177 issued as of December 31, 2021 and 2020, respectively; 23,205,915 and 800,679 outstanding as of December 31, 2021 and 2020, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders equity, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders equity, Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity (deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities, convertible preferred stock and stockholders' equity (deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Par value of convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity, Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity, Beginning balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Liquidation Preference</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, liquidation preference</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expenses), net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, basic (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, diluted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares outstanding, basic (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common stock outstanding, basic (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares outstanding, diluted (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common stock outstanding, diluted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statements of Shareholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Temporary Equity [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of convertible preferred stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="elev_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="elev_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of new stock classified as temporary equity issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="elev_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of convertible preferred stock, net of issuance costs (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="elev_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityEliminationAsPartofReorganization" xlink:label="us-gaap_TemporaryEquityEliminationAsPartofReorganization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityEliminationAsPartofReorganization" xlink:to="us-gaap_TemporaryEquityEliminationAsPartofReorganization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityEliminationAsPartofReorganization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Elimination as Part of Reorganization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TemporaryEquityEliminationAsPartofReorganization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of initial public offering common stock, net</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_TemporaryEquityEliminationOfSharesAsPartOfInitialPublicOffering" xlink:label="elev_TemporaryEquityEliminationOfSharesAsPartOfInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_TemporaryEquityEliminationOfSharesAsPartOfInitialPublicOffering" xlink:to="elev_TemporaryEquityEliminationOfSharesAsPartOfInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_TemporaryEquityEliminationOfSharesAsPartOfInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption of temporary equity shares as the result of initial public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_TemporaryEquityEliminationOfSharesAsPartOfInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Elimination of Shares as Part of Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="elev_TemporaryEquityEliminationOfSharesAsPartOfInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of initial public offering common stock, net (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders equity, Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders equity, Beginning balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of restricted common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of restricted common stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of initial public offering common stock, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of initial public offering common stock, net (in shares)</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_TemporaryEquityStockIssuanceCosts" xlink:label="elev_TemporaryEquityStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_TemporaryEquityStockIssuanceCosts" xlink:to="elev_TemporaryEquityStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_TemporaryEquityStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of stock issuance costs relating to temporary equity recognized during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_TemporaryEquityStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="elev_TemporaryEquityStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Operating Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing activities</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_ProceedsFromIssuanceOfRestrictedCommonStock" xlink:label="elev_ProceedsFromIssuanceOfRestrictedCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_ProceedsFromIssuanceOfRestrictedCommonStock" xlink:to="elev_ProceedsFromIssuanceOfRestrictedCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_ProceedsFromIssuanceOfRestrictedCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from the additional restricted capital contribution to the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_ProceedsFromIssuanceOfRestrictedCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Restricted Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="elev_ProceedsFromIssuanceOfRestrictedCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the issuance of restricted common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock upon initial public offering, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the issuance of convertible preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for issuance costs of convertible preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, beginning of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of non-cash financing activities</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_IssuanceCostsIncludedInAccruedExpenses" xlink:label="elev_IssuanceCostsIncludedInAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_IssuanceCostsIncludedInAccruedExpenses" xlink:to="elev_IssuanceCostsIncludedInAccruedExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_IssuanceCostsIncludedInAccruedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of issuance costs which are included in accrued expenses during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_IssuanceCostsIncludedInAccruedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance Costs Included In Accrued Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="elev_IssuanceCostsIncludedInAccruedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance costs in accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Amount Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible preferred stock upon IPO</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NATURE OF BUSINESS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NATURE OF BUSINESS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PROPERTY AND EQUIPMENT, NET</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PROPERTY AND EQUIPMENT, NET</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ACCRUED EXPENSES</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_AccruedLiabilitiesDisclosureTextBlock" xlink:label="elev_AccruedLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_AccruedLiabilitiesDisclosureTextBlock" xlink:to="elev_AccruedLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_AccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of information pertaining to accrued liabilities classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_AccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="elev_AccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ACCRUED EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONVERTIBLE PREFERRED STOCK</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_TemporaryEquityDisclosureTextBlock" xlink:label="elev_TemporaryEquityDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_TemporaryEquityDisclosureTextBlock" xlink:to="elev_TemporaryEquityDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_TemporaryEquityDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of information pertaining to temporary equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_TemporaryEquityDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="elev_TemporaryEquityDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONVERTIBLE PREFERRED STOCK</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMON STOCK.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMON STOCK</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCK-BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCK-BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_AssetPurchaseAndLicenseAgreementsAbstract" xlink:label="elev_AssetPurchaseAndLicenseAgreementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_AssetPurchaseAndLicenseAgreementsAbstract" xlink:to="elev_AssetPurchaseAndLicenseAgreementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_AssetPurchaseAndLicenseAgreementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Purchase and License Agreements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_AssetPurchaseAndLicenseAgreementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSET PURCHASE AND LICENSE AGREEMENTS</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_AssetPurchaseAndLicenseAgreementsDisclosureTextBlock" xlink:label="elev_AssetPurchaseAndLicenseAgreementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_AssetPurchaseAndLicenseAgreementsDisclosureTextBlock" xlink:to="elev_AssetPurchaseAndLicenseAgreementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_AssetPurchaseAndLicenseAgreementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for asset purchase and license agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_AssetPurchaseAndLicenseAgreementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Purchase and License Agreements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="elev_AssetPurchaseAndLicenseAgreementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSET PURCHASE AND LICENSE AGREEMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS AND CONTINGENCIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS AND CONTINGENCIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET LOSS PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET LOSS PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RETIREMENT PLAN</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement Benefits [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RETIREMENT PLAN</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principles of Consolidation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentrations of credit risk and significant suppliers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_CloudComputingArrangementPolicyPolicyTextBlock" xlink:label="elev_CloudComputingArrangementPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_CloudComputingArrangementPolicyPolicyTextBlock" xlink:to="elev_CloudComputingArrangementPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_CloudComputingArrangementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for cloud computing arrangement policy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_CloudComputingArrangementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cloud Computing Arrangement Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="elev_CloudComputingArrangementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cloud Computing Arrangements</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_ClassificationAndAccretionOfConvertiblePreferredStockPolicyPolicyTextBlock" xlink:label="elev_ClassificationAndAccretionOfConvertiblePreferredStockPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_ClassificationAndAccretionOfConvertiblePreferredStockPolicyPolicyTextBlock" xlink:to="elev_ClassificationAndAccretionOfConvertiblePreferredStockPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_ClassificationAndAccretionOfConvertiblePreferredStockPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy relating to classification and accretion of convertible preferred stock policy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_ClassificationAndAccretionOfConvertiblePreferredStockPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classification and Accretion of Convertible Preferred Stock Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="elev_ClassificationAndAccretionOfConvertiblePreferredStockPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classification and Accretion of Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="us-gaap_LegalCostsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalCostsPolicyTextBlock" xlink:to="us-gaap_LegalCostsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Costs, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LegalCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patent costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Common Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently Adopted Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair value measurements of financial assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of stock option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of assumptions used in estimation of fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of restricted stock units activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of effective income tax rate reconciliation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of net deferred tax asset (liability)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of computation of basic and diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of antidilutive securities excluded from computation of diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPO</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_SeriesaAndBConvertiblePreferredStockMember" xlink:label="elev_SeriesaAndBConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_SeriesaAndBConvertiblePreferredStockMember" xlink:to="elev_SeriesaAndBConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_SeriesaAndBConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining Series A and B convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_SeriesaAndBConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A and Series B convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_UnderwritersOfInitialPublicOfferingMember" xlink:label="elev_UnderwritersOfInitialPublicOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_UnderwritersOfInitialPublicOfferingMember" xlink:to="elev_UnderwritersOfInitialPublicOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_UnderwritersOfInitialPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the underwriters of the initial public stock offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_UnderwritersOfInitialPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriters</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Sale of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Public Offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse stock split ratio</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Number of Shares Issued in Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Consideration Received on Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from sale of stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares from conversion of preferred stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplier [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplier [Domain]</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_MajorSuppliersMember" xlink:label="elev_MajorSuppliersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_MajorSuppliersMember" xlink:to="elev_MajorSuppliersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_MajorSuppliersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents number of suppliers member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_MajorSuppliersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Major suppliers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplier Concentration Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of significant accounting policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Impairment Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment losses</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_NumberOfMajorVendors" xlink:label="elev_NumberOfMajorVendors" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_NumberOfMajorVendors" xlink:to="elev_NumberOfMajorVendors_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_NumberOfMajorVendors_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of major vendors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_NumberOfMajorVendors_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Major Vendors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="elev_NumberOfMajorVendors_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of vendors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal and professional costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Uncertain tax positions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest and penalties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits, income tax penalties and interest expense</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_DividendYieldRate" xlink:label="elev_DividendYieldRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_DividendYieldRate" xlink:to="elev_DividendYieldRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_DividendYieldRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of dividend yielded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_DividendYieldRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend Yield Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="elev_DividendYieldRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of dividend yielded</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money Market Funds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value measurements of financial assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets, Level 1 to Level 2 Transfers, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers from Level 1 to Level 2, Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets, Level 2 to Level 1 Transfers, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers from Level 2 to Level 1, Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers into (out of) Level 3, Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_ComputerSoftwareMember" xlink:label="elev_ComputerSoftwareMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_ComputerSoftwareMember" xlink:to="elev_ComputerSoftwareMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_ComputerSoftwareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to computer software.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_ComputerSoftwareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated Useful Life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_AccruedPreclinicalAndClinicalTrialCostsCurrent" xlink:label="elev_AccruedPreclinicalAndClinicalTrialCostsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_AccruedPreclinicalAndClinicalTrialCostsCurrent" xlink:to="elev_AccruedPreclinicalAndClinicalTrialCostsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_AccruedPreclinicalAndClinicalTrialCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for preclinical and clinical costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_AccruedPreclinicalAndClinicalTrialCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Preclinical and Clinical Trial Costs, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="elev_AccruedPreclinicalAndClinicalTrialCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued preclinical and clinical trial costs</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_AccruedCompensationCurrent" xlink:label="elev_AccruedCompensationCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_AccruedCompensationCurrent" xlink:to="elev_AccruedCompensationCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_AccruedCompensationCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for compensation for employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_AccruedCompensationCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Compensation, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="elev_AccruedCompensationCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_AccruedConsultingFeesCurrent" xlink:label="elev_AccruedConsultingFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_AccruedConsultingFeesCurrent" xlink:to="elev_AccruedConsultingFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_AccruedConsultingFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for consulting services. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_AccruedConsultingFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Consulting Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="elev_AccruedConsultingFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued consulting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued professional services</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, by Class of Stock [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_TemporaryEquityIssuePricePerShare" xlink:label="elev_TemporaryEquityIssuePricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_TemporaryEquityIssuePricePerShare" xlink:to="elev_TemporaryEquityIssuePricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_TemporaryEquityIssuePricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Per share price of temporary equity issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_TemporaryEquityIssuePricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Issue Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="elev_TemporaryEquityIssuePricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Original issue price</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_CommonStockNumberOfVotesPerShare" xlink:label="elev_CommonStockNumberOfVotesPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_CommonStockNumberOfVotesPerShare" xlink:to="elev_CommonStockNumberOfVotesPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_CommonStockNumberOfVotesPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of votes that each holder of the common stock is entitled to cast.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_CommonStockNumberOfVotesPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Number Of Votes Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="elev_CommonStockNumberOfVotesPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of votes per common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock reserved</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense included in operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_EquityIncentivePlan2021Member" xlink:label="elev_EquityIncentivePlan2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_EquityIncentivePlan2021Member" xlink:to="elev_EquityIncentivePlan2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_EquityIncentivePlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the 2021 Equity Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_EquityIncentivePlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Equity Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_StockIncentivePlan2019Member" xlink:label="elev_StockIncentivePlan2019Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_StockIncentivePlan2019Member" xlink:to="elev_StockIncentivePlan2019Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_StockIncentivePlan2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2019 Stock incentive plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_StockIncentivePlan2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019 Stock incentive plan</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_EmployeeStockPurchasePlan2021Member" xlink:label="elev_EmployeeStockPurchasePlan2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_EmployeeStockPurchasePlan2021Member" xlink:to="elev_EmployeeStockPurchasePlan2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_EmployeeStockPurchasePlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the 2021 Employee Stock Purchase Plan (ESPP).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_EmployeeStockPurchasePlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Employee Stock Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total number of shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional number of shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remained available for future grant</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentageOfAggregateSharesOutstanding" xlink:label="elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentageOfAggregateSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentageOfAggregateSharesOutstanding" xlink:to="elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentageOfAggregateSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentageOfAggregateSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of additional shares authorized for issuance under share-based payment arrangement, as a percentage of total outstanding shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentageOfAggregateSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage of Aggregate Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentageOfAggregateSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional number of shares authorized (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at beginning of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested at end of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest at end of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end of period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at beginning of period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested at end of period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest at end of period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average remaining contractual term and Aggregate intrinsic value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end of period (in years)</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm" xlink:label="elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm" xlink:to="elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual term for option awards vested, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested at end of period (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest at end of period (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end of period (in dollars)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at beginning of period (in dollars)</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedIntrinsicValue" xlink:label="elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedIntrinsicValue" xlink:to="elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The aggregate intrinsic value of options vested.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested at end of period (in dollars)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest at end of period (in dollars)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant-date fair value of stock options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value assumptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate, Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate, Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volatility, Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volatility, Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of options vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected remaining weighted-average period for recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested restricted stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested RSUs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested at end of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested at beginning of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average grant date fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested at end of period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested at beginning of period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Domain]</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_AssetPurchaseAgreementRelatingToSeribantumabMember" xlink:label="elev_AssetPurchaseAgreementRelatingToSeribantumabMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_AssetPurchaseAgreementRelatingToSeribantumabMember" xlink:to="elev_AssetPurchaseAgreementRelatingToSeribantumabMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_AssetPurchaseAgreementRelatingToSeribantumabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to asset purchase agreement relating to seribantumab, a fully humanized immunoglobulin G2 monoclonal antibody against HER3.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_AssetPurchaseAgreementRelatingToSeribantumabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Purchase Agreement relating to Seribantumab</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_DyaxAgreementMember" xlink:label="elev_DyaxAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_DyaxAgreementMember" xlink:to="elev_DyaxAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_DyaxAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Dyax agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_DyaxAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dyax</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_SelexisAgreementMember" xlink:label="elev_SelexisAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_SelexisAgreementMember" xlink:to="elev_SelexisAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_SelexisAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Selexis agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_SelexisAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selexis</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_NIHAgreementMember" xlink:label="elev_NIHAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_NIHAgreementMember" xlink:to="elev_NIHAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_NIHAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to U.S. Department of Health and Human Services agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_NIHAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">National Institute of Health</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition, Consideration Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront payment</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayable" xlink:label="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayable" xlink:to="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of development, regulatory and sales milestone payments payable under the collaboration and license agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration And License Agreements, Milestone Payments Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments payable</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_CollaborationAndLicenseAgreementsNoticePeriod" xlink:label="elev_CollaborationAndLicenseAgreementsNoticePeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_CollaborationAndLicenseAgreementsNoticePeriod" xlink:to="elev_CollaborationAndLicenseAgreementsNoticePeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_CollaborationAndLicenseAgreementsNoticePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number days of prior written notice to terminate the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_CollaborationAndLicenseAgreementsNoticePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration And License Agreements, Notice Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="elev_CollaborationAndLicenseAgreementsNoticePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of days written prior notice to terminate agreement</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayablePerLicensedProduct" xlink:label="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayablePerLicensedProduct" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayablePerLicensedProduct" xlink:to="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayablePerLicensedProduct_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayablePerLicensedProduct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of development, regulatory and sales milestone payments payable under the collaboration and license agreements for per licensed product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayablePerLicensedProduct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration And License Agreements, Milestone Payments Payable, Per Licensed Product</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayablePerLicensedProduct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments payable, per licensed product</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_CollaborationAndLicenseAgreementsRoyaltyPaymentsPayable" xlink:label="elev_CollaborationAndLicenseAgreementsRoyaltyPaymentsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_CollaborationAndLicenseAgreementsRoyaltyPaymentsPayable" xlink:to="elev_CollaborationAndLicenseAgreementsRoyaltyPaymentsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_CollaborationAndLicenseAgreementsRoyaltyPaymentsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of royalty payments payable under the collaboration and license agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_CollaborationAndLicenseAgreementsRoyaltyPaymentsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration And License Agreements, Royalty Payments Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="elev_CollaborationAndLicenseAgreementsRoyaltyPaymentsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty payments payable</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_CollaborationAndLicenseAgreementsPercentageOfRoyaltyOnNetSalesOfLicensedProducts" xlink:label="elev_CollaborationAndLicenseAgreementsPercentageOfRoyaltyOnNetSalesOfLicensedProducts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_CollaborationAndLicenseAgreementsPercentageOfRoyaltyOnNetSalesOfLicensedProducts" xlink:to="elev_CollaborationAndLicenseAgreementsPercentageOfRoyaltyOnNetSalesOfLicensedProducts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_CollaborationAndLicenseAgreementsPercentageOfRoyaltyOnNetSalesOfLicensedProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of royalty on net sales of licensed products under the collaboration and license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_CollaborationAndLicenseAgreementsPercentageOfRoyaltyOnNetSalesOfLicensedProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration And License Agreements, Percentage Of Royalty On Net Sales Of Licensed Products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="elev_CollaborationAndLicenseAgreementsPercentageOfRoyaltyOnNetSalesOfLicensedProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of royalty on net sales of licensed products</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_CollaborationAndLicenseAgreementsMilestonePaymentsPaid" xlink:label="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPaid" xlink:to="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of development, regulatory and sales milestone payments paid under the collaboration and license agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration And License Agreements, Milestone Payments Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments paid</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Caris Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Research Arrangements</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_CollaborationAgreementTerm" xlink:label="elev_CollaborationAgreementTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_CollaborationAgreementTerm" xlink:to="elev_CollaborationAgreementTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_CollaborationAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of the collaboration agreement in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_CollaborationAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="elev_CollaborationAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of agreement (in years)</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_CollaborationAgreementRenewalTerm" xlink:label="elev_CollaborationAgreementRenewalTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_CollaborationAgreementRenewalTerm" xlink:to="elev_CollaborationAgreementRenewalTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_CollaborationAgreementRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Renewal term of the collaboration agreement in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_CollaborationAgreementRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="elev_CollaborationAgreementRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Renewal term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit before tax at federal statutory rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State tax benefit, net of federal benefit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development credit carryovers</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="elev_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:to="elev_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent differences.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Permanent Differences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="elev_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Permanent differences</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUpsPercent" xlink:label="elev_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUpsPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUpsPercent" xlink:to="elev_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUpsPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUpsPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to return to provision true ups.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUpsPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Return to Provision True Ups, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="elev_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUpsPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Return to Provision True Ups</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carry forwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets and Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets and (liabilities)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Goodwill and Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross deferred tax asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax asset</label>
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_DeferredTaxLiabilitiesStockBasedCompensation" xlink:label="elev_DeferredTaxLiabilitiesStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elev_DeferredTaxLiabilitiesStockBasedCompensation" xlink:to="elev_DeferredTaxLiabilitiesStockBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elev_DeferredTaxLiabilitiesStockBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax liability attributable to taxable temporary differences from stock-based compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elev_DeferredTaxLiabilitiesStockBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Stock Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="elev_DeferredTaxLiabilitiesStockBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax asset (liability)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest and penalties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities excluded from computation (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Matching contributions</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>19
<FILENAME>elev-20211231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/2/2022 11:56:19 PM-->
<!--Modified on: 3/2/2022 11:56:19 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" roleURI="http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" roleURI="http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureNatureOfBusiness" roleURI="http://www.elevationoncology.com/role/DisclosureNatureOfBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureFairValueMeasurementsOfFinancialAssets" roleURI="http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosurePropertyAndEquipmentNet" roleURI="http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureAccruedExpenses" roleURI="http://www.elevationoncology.com/role/DisclosureAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureConvertiblePreferredStock" roleURI="http://www.elevationoncology.com/role/DisclosureConvertiblePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureCommonStock" roleURI="http://www.elevationoncology.com/role/DisclosureCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureStockBasedCompensation" roleURI="http://www.elevationoncology.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureAssetPurchaseAndLicenseAgreements" roleURI="http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.elevationoncology.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureIncomeTaxes" roleURI="http://www.elevationoncology.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureNetLossPerShare" roleURI="http://www.elevationoncology.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureRetirementPlan" roleURI="http://www.elevationoncology.com/role/DisclosureRetirementPlan" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureFairValueMeasurementsOfFinancialAssetsTables" roleURI="http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosurePropertyAndEquipmentNetTables" roleURI="http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureAccruedExpensesTables" roleURI="http://www.elevationoncology.com/role/DisclosureAccruedExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.elevationoncology.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.elevationoncology.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.elevationoncology.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureNatureOfBusinessLiquidityDetails" roleURI="http://www.elevationoncology.com/role/DisclosureNatureOfBusinessLiquidityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureFairValueMeasurementsOfFinancialAssetsDetails" roleURI="http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.elevationoncology.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureConvertiblePreferredStockDetails" roleURI="http://www.elevationoncology.com/role/DisclosureConvertiblePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureCommonStockDetails" roleURI="http://www.elevationoncology.com/role/DisclosureCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureCommonStockInitialPublicOfferingDetails" roleURI="http://www.elevationoncology.com/role/DisclosureCommonStockInitialPublicOfferingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureStockBasedCompensationExpenseDetails" roleURI="http://www.elevationoncology.com/role/DisclosureStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureStockBasedCompensationStockIncentivePlanDetails" roleURI="http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockIncentivePlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureStockBasedCompensationStockOptionsDetails" roleURI="http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureStockBasedCompensationAssumptionsDetails" roleURI="http://www.elevationoncology.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureStockBasedCompensationEarlyExerciseOfEmployeeOptionsDetails" roleURI="http://www.elevationoncology.com/role/DisclosureStockBasedCompensationEarlyExerciseOfEmployeeOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureStockBasedCompensationRestrictedStockUnitsDetails" roleURI="http://www.elevationoncology.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureAssetPurchaseAndLicenseAgreementsDetails" roleURI="http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureAssetPurchaseAndLicenseAgreementsOtherResearchArrangementsDetails" roleURI="http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsOtherResearchArrangementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.elevationoncology.com/role/DisclosureIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.elevationoncology.com/role/DisclosureIncomeTaxesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails" roleURI="http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureNetLossPerShareDetails" roleURI="http://www.elevationoncology.com/role/DisclosureNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" roleURI="http://www.elevationoncology.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="elev-20211231.xsd#DisclosureRetirementPlanDetails" roleURI="http://www.elevationoncology.com/role/DisclosureRetirementPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637818621784304922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_637818621784304922" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_637818621784304922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentAnnualReport_637818621784304922" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637818621784304922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637818621784304922" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637818621784304922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentTransitionReport_637818621784304922" order="4" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637818621784304922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_637818621784304922" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637818621784304922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_637818621784304922" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637818621784304922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637818621784304922" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637818621784304922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637818621784304922" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637818621784314923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637818621784314923" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637818621784314923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637818621784314923" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637818621784314923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637818621784314923" order="11" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637818621784314923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637818621784314923" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637818621784314923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_637818621784314923" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637818621784314923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_637818621784314923" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637818621784314923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637818621784314923" order="15" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637818621784314923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637818621784314923" order="16" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637818621784314923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_637818621784314923" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637818621784314923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_637818621784314923" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637818621784314923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637818621784314923" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_637818621784314923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_637818621784314923" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637818621784324922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityShellCompany_637818621784324922" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637818621784324922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_637818621784324922" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637818621784324922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_637818621784324922" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637818621784324922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_637818621784324922" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_637818621784324922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_637818621784324922" order="25" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_637818621784324922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_637818621784324922" order="26" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_637818621784324922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_637818621784324922" order="27" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_637818621784324922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityPublicFloat_637818621784324922" order="28" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637818621784324922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637818621784324922" order="29" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName_637818621784324922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorName_637818621784324922" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_637818621784334924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorFirmId_637818621784334924" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_637818621784334924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorLocation_637818621784334924" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637818621784334924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637818621784334924" order="33" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637818621784334924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637818621784334924" order="34" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637818621784334924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637818621784334924" order="35" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637818621784334924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637818621784334924" order="36" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637818621784344929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_637818621784344929" order="37" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637818621784344929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_637818621784344929" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637818621784344929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637818621784344929" xlink:to="us-gaap_StatementClassOfStockAxis_637818621784344929" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637818621784344929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637818621784344929" xlink:to="us-gaap_ClassOfStockDomain_637818621784344929" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_SeriesaConvertiblePreferredStockMember" xlink:label="elev_SeriesaConvertiblePreferredStockMember_637818621784344929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637818621784344929" xlink:to="elev_SeriesaConvertiblePreferredStockMember_637818621784344929" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_SeriesBConvertiblePreferredStockMember" xlink:label="elev_SeriesBConvertiblePreferredStockMember_637818621784344929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637818621784344929" xlink:to="elev_SeriesBConvertiblePreferredStockMember_637818621784344929" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637818621784344929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637818621784344929" xlink:to="us-gaap_StatementLineItems_637818621784344929" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637818621784344929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818621784344929" xlink:to="us-gaap_AssetsAbstract_637818621784344929" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637818621784344929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637818621784344929" xlink:to="us-gaap_AssetsCurrentAbstract_637818621784344929" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637818621784344929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637818621784344929" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637818621784344929" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637818621784344929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637818621784344929" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637818621784344929" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637818621784354922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637818621784344929" xlink:to="us-gaap_AssetsCurrent_637818621784354922" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637818621784354922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637818621784344929" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637818621784354922" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637818621784354922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637818621784344929" xlink:to="us-gaap_OtherAssetsNoncurrent_637818621784354922" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637818621784354922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637818621784344929" xlink:to="us-gaap_Assets_637818621784354922" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637818621784354922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818621784344929" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637818621784354922" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract_637818621784354922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637818621784354922" xlink:to="us-gaap_LiabilitiesAbstract_637818621784354922" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637818621784354922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_637818621784354922" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637818621784354922" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637818621784354922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637818621784354922" xlink:to="us-gaap_AccountsPayableCurrent_637818621784354922" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637818621784354922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637818621784354922" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637818621784354922" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637818621784354922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637818621784354922" xlink:to="us-gaap_LiabilitiesCurrent_637818621784354922" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_637818621784354922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_637818621784354922" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_637818621784354922" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_RestrictedStockRepurchaseLiability" xlink:label="elev_RestrictedStockRepurchaseLiability_637818621784354922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637818621784354922" xlink:to="elev_RestrictedStockRepurchaseLiability_637818621784354922" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637818621784364923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_637818621784354922" xlink:to="us-gaap_Liabilities_637818621784364923" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637818621784364923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_637818621784354922" xlink:to="us-gaap_CommitmentsAndContingencies_637818621784364923" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637818621784364923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_637818621784354922" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637818621784364923" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637818621784364923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637818621784354922" xlink:to="us-gaap_StockholdersEquityAbstract_637818621784364923" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637818621784364923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637818621784364923" xlink:to="us-gaap_PreferredStockValue_637818621784364923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637818621784364923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637818621784364923" xlink:to="us-gaap_CommonStockValue_637818621784364923" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637818621784364923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637818621784364923" xlink:to="us-gaap_AdditionalPaidInCapital_637818621784364923" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637818621784364923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637818621784364923" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637818621784364923" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637818621784364923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637818621784364923" xlink:to="us-gaap_StockholdersEquity_637818621784364923" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637818621784374926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637818621784354922" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637818621784374926" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Consolidated Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637818621784374926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_637818621784374926" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637818621784374926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637818621784374926" xlink:to="us-gaap_StatementClassOfStockAxis_637818621784374926" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637818621784374926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637818621784374926" xlink:to="us-gaap_ClassOfStockDomain_637818621784374926" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_SeriesaConvertiblePreferredStockMember" xlink:label="elev_SeriesaConvertiblePreferredStockMember_637818621784374926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637818621784374926" xlink:to="elev_SeriesaConvertiblePreferredStockMember_637818621784374926" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_SeriesBConvertiblePreferredStockMember" xlink:label="elev_SeriesBConvertiblePreferredStockMember_637818621784374926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637818621784374926" xlink:to="elev_SeriesBConvertiblePreferredStockMember_637818621784374926" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637818621784374926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637818621784374926" xlink:to="us-gaap_StatementLineItems_637818621784374926" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_637818621784374926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818621784374926" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_637818621784374926" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_637818621784374926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818621784374926" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_637818621784374926" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_637818621784374926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818621784374926" xlink:to="us-gaap_TemporaryEquitySharesIssued_637818621784374926" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_637818621784374926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818621784374926" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_637818621784374926" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_637818621784384923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818621784374926" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_637818621784384923" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637818621784384923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818621784374926" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637818621784384923" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637818621784384923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818621784374926" xlink:to="us-gaap_PreferredStockSharesAuthorized_637818621784384923" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_637818621784384923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818621784374926" xlink:to="us-gaap_PreferredStockSharesIssued_637818621784384923" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637818621784384923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818621784374926" xlink:to="us-gaap_PreferredStockSharesOutstanding_637818621784384923" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637818621784384923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818621784374926" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637818621784384923" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637818621784384923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818621784374926" xlink:to="us-gaap_CommonStockSharesAuthorized_637818621784384923" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637818621784384923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818621784374926" xlink:to="us-gaap_CommonStockSharesIssued_637818621784384923" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637818621784384923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818621784374926" xlink:to="us-gaap_CommonStockSharesOutstanding_637818621784384923" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_637818621784394922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_637818621784394922" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637818621784394922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637818621784394922" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637818621784394922" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637818621784394922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637818621784394922" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637818621784394922" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637818621784394922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637818621784394922" xlink:to="us-gaap_OperatingExpenses_637818621784394922" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637818621784394922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_637818621784394922" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637818621784394922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637818621784394922" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637818621784394922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_637818621784394922" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637818621784394922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic_637818621784394922" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637818621784394922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_637818621784394922" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637818621784394922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637818621784394922" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637818621784394922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637818621784394922" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders Equity (Deficit)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637818621784394922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_637818621784394922" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637818621784394922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637818621784394922" xlink:to="us-gaap_StatementClassOfStockAxis_637818621784394922" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_SeriesaConvertiblePreferredStockMember" xlink:label="elev_SeriesaConvertiblePreferredStockMember_637818621784404926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637818621784394922" xlink:to="elev_SeriesaConvertiblePreferredStockMember_637818621784404926" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_SeriesBConvertiblePreferredStockMember" xlink:label="elev_SeriesBConvertiblePreferredStockMember_637818621784404926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637818621784394922" xlink:to="elev_SeriesBConvertiblePreferredStockMember_637818621784404926" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637818621784404926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637818621784394922" xlink:to="us-gaap_ClassOfStockDomain_637818621784404926" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637818621784404926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637818621784394922" xlink:to="us-gaap_StatementEquityComponentsAxis_637818621784404926" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637818621784404926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637818621784404926" xlink:to="us-gaap_CommonStockMember_637818621784404926" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637818621784404926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637818621784404926" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637818621784404926" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637818621784404926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637818621784404926" xlink:to="us-gaap_RetainedEarningsMember_637818621784404926" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637818621784404926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637818621784404926" xlink:to="us-gaap_EquityComponentDomain_637818621784404926" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637818621784404926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637818621784394922" xlink:to="us-gaap_StatementLineItems_637818621784404926" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637818621784404926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818621784404926" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637818621784404926" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637818621784404926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637818621784404926" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637818621784404926" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_637818621784404926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637818621784404926" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_637818621784404926" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_637818621784404926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637818621784404926" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_637818621784404926" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="elev_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_637818621784404926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637818621784404926" xlink:to="elev_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_637818621784404926" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityEliminationAsPartofReorganization" xlink:label="us-gaap_TemporaryEquityEliminationAsPartofReorganization_637818621784414924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637818621784404926" xlink:to="us-gaap_TemporaryEquityEliminationAsPartofReorganization_637818621784414924" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_TemporaryEquityEliminationOfSharesAsPartOfInitialPublicOffering" xlink:label="elev_TemporaryEquityEliminationOfSharesAsPartOfInitialPublicOffering_637818621784414924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637818621784404926" xlink:to="elev_TemporaryEquityEliminationOfSharesAsPartOfInitialPublicOffering_637818621784414924" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637818621784414924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637818621784404926" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637818621784414924" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_637818621784414924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637818621784404926" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_637818621784414924" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637818621784414924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818621784404926" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637818621784414924" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637818621784414924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637818621784414924" xlink:to="us-gaap_StockholdersEquity_637818621784414924" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637818621784414924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637818621784414924" xlink:to="us-gaap_SharesOutstanding_637818621784414924" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_637818621784414924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637818621784414924" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_637818621784414924" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_637818621784414924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637818621784414924" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_637818621784414924" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637818621784414924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637818621784414924" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637818621784414924" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637818621784424923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637818621784414924" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637818621784424923" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637818621784424923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637818621784414924" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637818621784424923" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637818621784424923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637818621784414924" xlink:to="us-gaap_NetIncomeLoss_637818621784424923" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637818621784424923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637818621784414924" xlink:to="us-gaap_StockholdersEquity_637818621784424923" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637818621784424923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637818621784414924" xlink:to="us-gaap_SharesOutstanding_637818621784424923" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="extended" xlink:title="00305 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders Equity (Deficit) (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637818621784424923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_637818621784424923" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637818621784424923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637818621784424923" xlink:to="us-gaap_StatementClassOfStockAxis_637818621784424923" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637818621784424923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637818621784424923" xlink:to="us-gaap_ClassOfStockDomain_637818621784424923" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_SeriesaConvertiblePreferredStockMember" xlink:label="elev_SeriesaConvertiblePreferredStockMember_637818621784434924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637818621784424923" xlink:to="elev_SeriesaConvertiblePreferredStockMember_637818621784434924" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_SeriesBConvertiblePreferredStockMember" xlink:label="elev_SeriesBConvertiblePreferredStockMember_637818621784434924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637818621784424923" xlink:to="elev_SeriesBConvertiblePreferredStockMember_637818621784434924" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637818621784434924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637818621784424923" xlink:to="us-gaap_StatementLineItems_637818621784434924" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_TemporaryEquityStockIssuanceCosts" xlink:label="elev_TemporaryEquityStockIssuanceCosts_637818621784434924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818621784434924" xlink:to="elev_TemporaryEquityStockIssuanceCosts_637818621784434924" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637818621784434924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637818621784434924" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637818621784434924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637818621784434924" xlink:to="us-gaap_ProfitLoss_637818621784434924" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637818621784434924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637818621784434924" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637818621784434924" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637818621784434924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637818621784434924" xlink:to="us-gaap_ShareBasedCompensation_637818621784434924" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637818621784434924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637818621784434924" xlink:to="us-gaap_Depreciation_637818621784434924" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637818621784434924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637818621784434924" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637818621784434924" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637818621784434924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637818621784434924" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637818621784434924" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_637818621784434924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637818621784434924" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_637818621784434924" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637818621784434924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637818621784434924" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637818621784434924" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637818621784434924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637818621784434924" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637818621784434924" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818621784444922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637818621784434924" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818621784444922" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637818621784444922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637818621784444922" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637818621784444922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637818621784444922" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637818621784444922" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637818621784444922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637818621784444922" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637818621784444922" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637818621784444922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637818621784444922" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_ProceedsFromIssuanceOfRestrictedCommonStock" xlink:label="elev_ProceedsFromIssuanceOfRestrictedCommonStock_637818621784444922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637818621784444922" xlink:to="elev_ProceedsFromIssuanceOfRestrictedCommonStock_637818621784444922" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637818621784444922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637818621784444922" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637818621784444922" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_637818621784444922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637818621784444922" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_637818621784444922" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637818621784444922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637818621784444922" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637818621784444922" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637818621784444922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637818621784444922" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637818621784444922" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637818621784444922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637818621784444922" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637818621784454924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637818621784454924" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6378186217844549241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6378186217844549241" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637818621784454924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637818621784454924" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_IssuanceCostsIncludedInAccruedExpenses" xlink:label="elev_IssuanceCostsIncludedInAccruedExpenses_637818621784454924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637818621784454924" xlink:to="elev_IssuanceCostsIncludedInAccruedExpenses_637818621784454924" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1_637818621784454924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637818621784454924" xlink:to="us-gaap_ConversionOfStockAmountIssued1_637818621784454924" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureNatureOfBusiness" xlink:type="extended" xlink:title="10101 - Disclosure - NATURE OF BUSINESS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_637818621784534924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations_637818621784534924" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_637818621784534924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_637818621784534924" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssets" xlink:type="extended" xlink:title="10301 - Disclosure - FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637818621784544928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637818621784544928" order="1" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNet" xlink:type="extended" xlink:title="10401 - Disclosure - PROPERTY AND EQUIPMENT, NET" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637818621784544928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637818621784544928" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureAccruedExpenses" xlink:type="extended" xlink:title="10501 - Disclosure - ACCRUED EXPENSES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="AccruedLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_AccruedLiabilitiesDisclosureTextBlock" xlink:label="elev_AccruedLiabilitiesDisclosureTextBlock_637818621784544928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="elev_AccruedLiabilitiesDisclosureTextBlock_637818621784544928" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureConvertiblePreferredStock" xlink:type="extended" xlink:title="10601 - Disclosure - CONVERTIBLE PREFERRED STOCK" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="TemporaryEquityAbstract" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_TemporaryEquityDisclosureTextBlock" xlink:label="elev_TemporaryEquityDisclosureTextBlock_637818621784544928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TemporaryEquityAbstract" xlink:to="elev_TemporaryEquityDisclosureTextBlock_637818621784544928" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureCommonStock" xlink:type="extended" xlink:title="10701 - Disclosure - COMMON STOCK" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637818621784544928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637818621784544928" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="10801 - Disclosure - STOCK-BASED COMPENSATION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637818621784554930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637818621784554930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreements" xlink:type="extended" xlink:title="10901 - Disclosure - ASSET PURCHASE AND LICENSE AGREEMENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_AssetPurchaseAndLicenseAgreementsAbstract" xlink:label="AssetPurchaseAndLicenseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_AssetPurchaseAndLicenseAgreementsDisclosureTextBlock" xlink:label="elev_AssetPurchaseAndLicenseAgreementsDisclosureTextBlock_637818621784554930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetPurchaseAndLicenseAgreementsAbstract" xlink:to="elev_AssetPurchaseAndLicenseAgreementsDisclosureTextBlock_637818621784554930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="11001 - Disclosure - COMMITMENTS AND CONTINGENCIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637818621784554930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637818621784554930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11101 - Disclosure - INCOME TAXES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_637818621784554930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_637818621784554930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="11201 - Disclosure - NET LOSS PER SHARE" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_637818621784554930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_637818621784554930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureRetirementPlan" xlink:type="extended" xlink:title="11301 - Disclosure - RETIREMENT PLAN" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_637818621784564924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_637818621784564924" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637818621784564924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637818621784564924" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock_637818621784564924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock_637818621784564924" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637818621784564924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_637818621784564924" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_637818621784564924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_637818621784564924" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637818621784564924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637818621784564924" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_637818621784564924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_637818621784564924" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637818621784564924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637818621784564924" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_CloudComputingArrangementPolicyPolicyTextBlock" xlink:label="elev_CloudComputingArrangementPolicyPolicyTextBlock_637818621784564924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="elev_CloudComputingArrangementPolicyPolicyTextBlock_637818621784564924" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_ClassificationAndAccretionOfConvertiblePreferredStockPolicyPolicyTextBlock" xlink:label="elev_ClassificationAndAccretionOfConvertiblePreferredStockPolicyPolicyTextBlock_637818621784564924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="elev_ClassificationAndAccretionOfConvertiblePreferredStockPolicyPolicyTextBlock_637818621784564924" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_637818621784564924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_637818621784564924" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="us-gaap_LegalCostsPolicyTextBlock_637818621784574924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_LegalCostsPolicyTextBlock_637818621784574924" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_637818621784574924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_637818621784574924" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637818621784574924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637818621784574924" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637818621784574924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637818621784574924" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_637818621784574924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_637818621784574924" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637818621784574924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637818621784574924" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsTables" xlink:type="extended" xlink:title="30303 - Disclosure - FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_637818621784574924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_637818621784574924" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetTables" xlink:type="extended" xlink:title="30403 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_637818621784574924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_637818621784574924" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureAccruedExpensesTables" xlink:type="extended" xlink:title="30503 - Disclosure - ACCRUED EXPENSES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="AccruedLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637818621784584922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637818621784584922" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="30803 - Disclosure - STOCK-BASED COMPENSATION (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637818621784584922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637818621784584922" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637818621784584922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637818621784584922" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637818621784584922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637818621784584922" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_637818621784584922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_637818621784584922" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31103 - Disclosure - INCOME TAXES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637818621784584922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637818621784584922" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637818621784584922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637818621784584922" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="31203 - Disclosure - NET LOSS PER SHARE (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637818621784594925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637818621784594925" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637818621784594925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637818621784594925" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureNatureOfBusinessLiquidityDetails" xlink:type="extended" xlink:title="40101 - Disclosure - NATURE OF BUSINESS - Liquidity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637818621784594925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637818621784594925" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637818621784594925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637818621784594925" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637818621784594925" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637818621784594925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637818621784594925" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637818621784594925" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637818621784594925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637818621784594925" xlink:to="us-gaap_IPOMember_637818621784594925" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637818621784594925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637818621784594925" xlink:to="us-gaap_StatementClassOfStockAxis_637818621784594925" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637818621784594925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637818621784594925" xlink:to="us-gaap_ClassOfStockDomain_637818621784594925" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_SeriesaAndBConvertiblePreferredStockMember" xlink:label="elev_SeriesaAndBConvertiblePreferredStockMember_637818621784594925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637818621784594925" xlink:to="elev_SeriesaAndBConvertiblePreferredStockMember_637818621784594925" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637818621784594925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637818621784594925" xlink:to="srt_CounterpartyNameAxis_637818621784594925" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637818621784594925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637818621784594925" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637818621784594925" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_UnderwritersOfInitialPublicOfferingMember" xlink:label="elev_UnderwritersOfInitialPublicOfferingMember_637818621784594925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637818621784594925" xlink:to="elev_UnderwritersOfInitialPublicOfferingMember_637818621784594925" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_637818621784604925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637818621784594925" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_637818621784604925" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637818621784604925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637818621784604925" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637818621784604925" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_637818621784604925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637818621784604925" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_637818621784604925" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_637818621784604925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637818621784604925" xlink:to="us-gaap_SaleOfStockPricePerShare_637818621784604925" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_637818621784604925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637818621784604925" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_637818621784604925" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637818621784604925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637818621784604925" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637818621784604925" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_637818621784604925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637818621784604925" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_637818621784604925" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637818621784604925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637818621784604925" xlink:to="us-gaap_NetIncomeLoss_637818621784604925" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637818621784604925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637818621784604925" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637818621784604925" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_637818621784604925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637818621784604925" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_637818621784604925" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable_637818621784614926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskTable_637818621784614926" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_637818621784614926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_637818621784614926" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_637818621784614926" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_637818621784614926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_637818621784614926" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_637818621784614926" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember_637818621784614926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_637818621784614926" xlink:to="us-gaap_AccountsPayableMember_637818621784614926" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637818621784614926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_637818621784614926" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637818621784614926" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_637818621784614926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_637818621784614926" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_637818621784614926" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_637818621784614926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_637818621784614926" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_637818621784614926" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_MajorSuppliersMember" xlink:label="elev_MajorSuppliersMember_637818621784614926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_637818621784614926" xlink:to="elev_MajorSuppliersMember_637818621784614926" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_637818621784614926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_637818621784614926" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_637818621784614926" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_637818621784614926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_637818621784614926" xlink:to="us-gaap_ConcentrationRiskTypeDomain_637818621784614926" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember_637818621784614926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_637818621784614926" xlink:to="us-gaap_SupplierConcentrationRiskMember_637818621784614926" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems_637818621784614926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_637818621784614926" xlink:to="us-gaap_ConcentrationRiskLineItems_637818621784614926" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_637818621784614926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_637818621784614926" xlink:to="us-gaap_NumberOfOperatingSegments_637818621784614926" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges_637818621784624924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_637818621784614926" xlink:to="us-gaap_AssetImpairmentCharges_637818621784624924" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_NumberOfMajorVendors" xlink:label="elev_NumberOfMajorVendors_637818621784624924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_637818621784614926" xlink:to="elev_NumberOfMajorVendors_637818621784624924" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1_637818621784624924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_637818621784614926" xlink:to="us-gaap_ConcentrationRiskPercentage1_637818621784624924" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees_637818621784624924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_637818621784614926" xlink:to="us-gaap_LegalFees_637818621784624924" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_637818621784624924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_637818621784614926" xlink:to="us-gaap_UnrecognizedTaxBenefits_637818621784624924" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_637818621784624924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_637818621784614926" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_637818621784624924" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_DividendYieldRate" xlink:label="elev_DividendYieldRate_637818621784624924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_637818621784614926" xlink:to="elev_DividendYieldRate_637818621784624924" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_637818621784624924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_637818621784624924" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_637818621784624924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable_637818621784624924" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_637818621784624924" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_637818621784624924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_637818621784624924" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_637818621784624924" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_637818621784634925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_637818621784624924" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_637818621784634925" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_637818621784634925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable_637818621784624924" xlink:to="us-gaap_FinancialInstrumentAxis_637818621784634925" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637818621784634925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_637818621784634925" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637818621784634925" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_637818621784634925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637818621784634925" xlink:to="us-gaap_MoneyMarketFundsMember_637818621784634925" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637818621784634925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable_637818621784624924" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637818621784634925" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637818621784634925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637818621784634925" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637818621784634925" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_637818621784634925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637818621784634925" xlink:to="us-gaap_FairValueInputsLevel1Member_637818621784634925" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637818621784634925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable_637818621784624924" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637818621784634925" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_637818621784634925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637818621784634925" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_637818621784634925" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637818621784634925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637818621784634925" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637818621784634925" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_637818621784634925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637818621784634925" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_637818621784634925" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_637818621784634925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637818621784634925" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_637818621784634925" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_637818621784634925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637818621784634925" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_637818621784634925" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40401 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637818621784644923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637818621784644923" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_637818621784644923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637818621784644923" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_637818621784644923" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637818621784644923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_637818621784644923" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637818621784644923" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_ComputerSoftwareMember" xlink:label="elev_ComputerSoftwareMember_637818621784644923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637818621784644923" xlink:to="elev_ComputerSoftwareMember_637818621784644923" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637818621784644923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637818621784644923" xlink:to="srt_RangeAxis_637818621784644923" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637818621784644923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637818621784644923" xlink:to="srt_RangeMember_637818621784644923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637818621784644923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637818621784644923" xlink:to="srt_MaximumMember_637818621784644923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637818621784644923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637818621784644923" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637818621784644923" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_637818621784644923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637818621784644923" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_637818621784644923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637818621784644923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637818621784644923" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637818621784644923" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637818621784644923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637818621784644923" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637818621784644923" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637818621784644923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637818621784644923" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637818621784644923" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637818621784644923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637818621784644923" xlink:to="us-gaap_Depreciation_637818621784644923" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - ACCRUED EXPENSES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="AccruedLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_AccruedPreclinicalAndClinicalTrialCostsCurrent" xlink:label="elev_AccruedPreclinicalAndClinicalTrialCostsCurrent_637818621784654927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="elev_AccruedPreclinicalAndClinicalTrialCostsCurrent_637818621784654927" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_AccruedCompensationCurrent" xlink:label="elev_AccruedCompensationCurrent_637818621784654927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="elev_AccruedCompensationCurrent_637818621784654927" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_AccruedConsultingFeesCurrent" xlink:label="elev_AccruedConsultingFeesCurrent_637818621784654927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="elev_AccruedConsultingFeesCurrent_637818621784654927" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_637818621784654927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_637818621784654927" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637818621784654927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637818621784654927" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637818621784654927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637818621784654927" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureConvertiblePreferredStockDetails" xlink:type="extended" xlink:title="40601 - Disclosure - CONVERTIBLE PREFERRED STOCK (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="TemporaryEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_637818621784654927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_637818621784654927" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637818621784654927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637818621784654927" xlink:to="us-gaap_StatementClassOfStockAxis_637818621784654927" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637818621784654927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637818621784654927" xlink:to="us-gaap_ClassOfStockDomain_637818621784654927" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_SeriesaConvertiblePreferredStockMember" xlink:label="elev_SeriesaConvertiblePreferredStockMember_637818621784654927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637818621784654927" xlink:to="elev_SeriesaConvertiblePreferredStockMember_637818621784654927" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_SeriesBConvertiblePreferredStockMember" xlink:label="elev_SeriesBConvertiblePreferredStockMember_637818621784654927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637818621784654927" xlink:to="elev_SeriesBConvertiblePreferredStockMember_637818621784654927" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637818621784654927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637818621784654927" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637818621784654927" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637818621784664926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637818621784654927" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637818621784664926" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637818621784664926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637818621784664926" xlink:to="us-gaap_IPOMember_637818621784664926" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_637818621784664926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637818621784654927" xlink:to="us-gaap_TemporaryEquityLineItems_637818621784664926" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_637818621784664926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637818621784664926" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_637818621784664926" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_637818621784664926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637818621784664926" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_637818621784664926" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="elev_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_637818621784664926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637818621784664926" xlink:to="elev_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_637818621784664926" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_TemporaryEquityIssuePricePerShare" xlink:label="elev_TemporaryEquityIssuePricePerShare_637818621784664926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637818621784664926" xlink:to="elev_TemporaryEquityIssuePricePerShare_637818621784664926" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_637818621784664926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637818621784664926" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_637818621784664926" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureCommonStockDetails" xlink:type="extended" xlink:title="40701 - Disclosure - COMMON STOCK (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637818621784664926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_637818621784664926" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637818621784664926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637818621784664926" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_CommonStockNumberOfVotesPerShare" xlink:label="elev_CommonStockNumberOfVotesPerShare_637818621784674927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="elev_CommonStockNumberOfVotesPerShare_637818621784674927" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureCommonStockInitialPublicOfferingDetails" xlink:type="extended" xlink:title="40702 - Disclosure - COMMON STOCK - Initial Public Offering (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637818621784674927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637818621784674927" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637818621784674927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637818621784674927" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637818621784674927" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637818621784674927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637818621784674927" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637818621784674927" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637818621784674927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637818621784674927" xlink:to="us-gaap_IPOMember_637818621784674927" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637818621784674927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637818621784674927" xlink:to="srt_CounterpartyNameAxis_637818621784674927" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637818621784674927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637818621784674927" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637818621784674927" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_UnderwritersOfInitialPublicOfferingMember" xlink:label="elev_UnderwritersOfInitialPublicOfferingMember_637818621784674927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637818621784674927" xlink:to="elev_UnderwritersOfInitialPublicOfferingMember_637818621784674927" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_637818621784674927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637818621784674927" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_637818621784674927" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_637818621784674927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637818621784674927" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_637818621784674927" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_637818621784674927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637818621784674927" xlink:to="us-gaap_SaleOfStockPricePerShare_637818621784674927" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_637818621784674927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637818621784674927" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_637818621784674927" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637818621784674927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637818621784674927" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637818621784674927" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_637818621784684925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637818621784674927" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_637818621784684925" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637818621784684925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637818621784674927" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637818621784684925" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40801 - Disclosure - STOCK-BASED COMPENSATION - Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637818621784684925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637818621784684925" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637818621784684925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637818621784684925" xlink:to="us-gaap_IncomeStatementLocationAxis_637818621784684925" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637818621784684925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637818621784684925" xlink:to="us-gaap_IncomeStatementLocationDomain_637818621784684925" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637818621784684925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637818621784684925" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637818621784684925" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637818621784684925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637818621784684925" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637818621784684925" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637818621784684925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637818621784684925" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637818621784684925" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637818621784684925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637818621784684925" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637818621784684925" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockIncentivePlanDetails" xlink:type="extended" xlink:title="40802 - Disclosure - STOCK-BASED COMPENSATION - Stock incentive plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818621784684925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818621784684925" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637818621784684925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818621784684925" xlink:to="us-gaap_PlanNameAxis_637818621784684925" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637818621784694927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637818621784684925" xlink:to="us-gaap_PlanNameDomain_637818621784694927" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_EquityIncentivePlan2021Member" xlink:label="elev_EquityIncentivePlan2021Member_637818621784694927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637818621784694927" xlink:to="elev_EquityIncentivePlan2021Member_637818621784694927" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_StockIncentivePlan2019Member" xlink:label="elev_StockIncentivePlan2019Member_637818621784694927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637818621784694927" xlink:to="elev_StockIncentivePlan2019Member_637818621784694927" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_EmployeeStockPurchasePlan2021Member" xlink:label="elev_EmployeeStockPurchasePlan2021Member_637818621784694927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637818621784694927" xlink:to="elev_EmployeeStockPurchasePlan2021Member_637818621784694927" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637818621784694927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818621784684925" xlink:to="srt_RangeAxis_637818621784694927" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637818621784694927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637818621784694927" xlink:to="srt_RangeMember_637818621784694927" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637818621784694927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637818621784694927" xlink:to="srt_MaximumMember_637818621784694927" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818621784694927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818621784684925" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818621784694927" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637818621784694927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818621784694927" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637818621784694927" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637818621784694927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818621784694927" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637818621784694927" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_637818621784694927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818621784694927" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_637818621784694927" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637818621784694927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818621784694927" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637818621784694927" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentageOfAggregateSharesOutstanding" xlink:label="elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentageOfAggregateSharesOutstanding_637818621784694927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818621784694927" xlink:to="elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentageOfAggregateSharesOutstanding_637818621784694927" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637818621784704929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818621784694927" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637818621784704929" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockOptionsDetails" xlink:type="extended" xlink:title="40803 - Disclosure - STOCK-BASED COMPENSATION - Stock options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637818621784704929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637818621784704929" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637818621784704929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637818621784704929" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637818621784704929" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637818621784704929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637818621784704929" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637818621784704929" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_637818621784704929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637818621784704929" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_637818621784704929" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6378186217847049291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637818621784704929" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6378186217847049291" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_637818621784704929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637818621784704929" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_637818621784704929" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637818621784704929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637818621784704929" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637818621784704929" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637818621784704929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637818621784704929" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637818621784704929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637818621784704929" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637818621784704929" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637818621784704929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637818621784704929" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637818621784704929" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_637818621784714930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637818621784704929" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_637818621784714930" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637818621784714930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637818621784704929" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637818621784714930" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_637818621784714930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637818621784704929" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_637818621784714930" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_637818621784714930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637818621784704929" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_637818621784714930" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637818621784714930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637818621784714930" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637818621784714930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637818621784714930" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637818621784714930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm" xlink:label="elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_637818621784714930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637818621784714930" xlink:to="elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_637818621784714930" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_637818621784714930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637818621784714930" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_637818621784714930" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637818621784714930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637818621784714930" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637818621784714930" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6378186217847149301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637818621784714930" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6378186217847149301" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedIntrinsicValue" xlink:label="elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedIntrinsicValue_637818621784714930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637818621784714930" xlink:to="elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedIntrinsicValue_637818621784714930" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_637818621784724930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637818621784714930" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_637818621784724930" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637818621784724930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637818621784724930" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xlink:type="extended" xlink:title="40804 - Disclosure - STOCK-BASED COMPENSATION - Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818621784724930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818621784724930" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637818621784724930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818621784724930" xlink:to="us-gaap_AwardTypeAxis_637818621784724930" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637818621784724930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637818621784724930" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637818621784724930" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637818621784724930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637818621784724930" xlink:to="us-gaap_EmployeeStockOptionMember_637818621784724930" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637818621784724930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818621784724930" xlink:to="srt_RangeAxis_637818621784724930" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637818621784724930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637818621784724930" xlink:to="srt_RangeMember_637818621784724930" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637818621784724930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637818621784724930" xlink:to="srt_MinimumMember_637818621784724930" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637818621784724930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637818621784724930" xlink:to="srt_MaximumMember_637818621784724930" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818621784724930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818621784724930" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818621784724930" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637818621784734927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818621784724930" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637818621784734927" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_637818621784734927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637818621784734927" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_637818621784734927" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_637818621784734927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637818621784734927" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_637818621784734927" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_637818621784734927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637818621784734927" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_637818621784734927" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_637818621784734927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637818621784734927" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_637818621784734927" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637818621784734927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637818621784734927" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637818621784734927" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_637818621784734927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818621784724930" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_637818621784734927" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637818621784734927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818621784724930" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637818621784734927" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_637818621784734927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818621784724930" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_637818621784734927" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637818621784734927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818621784724930" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637818621784734927" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureStockBasedCompensationEarlyExerciseOfEmployeeOptionsDetails" xlink:type="extended" xlink:title="40805 - Disclosure - STOCK-BASED COMPENSATION - Early Exercise of Employee Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818621784744927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818621784744927" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637818621784744927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818621784744927" xlink:to="us-gaap_AwardTypeAxis_637818621784744927" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637818621784744927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637818621784744927" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637818621784744927" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_637818621784744927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637818621784744927" xlink:to="us-gaap_RestrictedStockMember_637818621784744927" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818621784744927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818621784744927" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818621784744927" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_RestrictedStockRepurchaseLiability" xlink:label="elev_RestrictedStockRepurchaseLiability_637818621784744927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818621784744927" xlink:to="elev_RestrictedStockRepurchaseLiability_637818621784744927" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637818621784744927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818621784744927" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637818621784744927" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended" xlink:title="40806 - Disclosure - STOCK-BASED COMPENSATION - Restricted Stock Units (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818621784744927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818621784744927" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637818621784744927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818621784744927" xlink:to="us-gaap_AwardTypeAxis_637818621784744927" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637818621784744927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637818621784744927" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637818621784744927" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_637818621784744927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637818621784744927" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_637818621784744927" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818621784744927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818621784744927" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818621784744927" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637818621784754927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818621784744927" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637818621784754927" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637818621784754927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818621784744927" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637818621784754927" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637818621784754927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818621784744927" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637818621784754927" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637818621784754927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637818621784754927" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637818621784754927" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637818621784754927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637818621784754927" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637818621784754927" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6378186217847549271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637818621784754927" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6378186217847549271" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637818621784754927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818621784744927" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637818621784754927" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637818621784754927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637818621784754927" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637818621784754927" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637818621784754927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637818621784754927" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637818621784754927" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6378186217847549271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637818621784754927" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6378186217847549271" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637818621784754927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818621784744927" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637818621784754927" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_637818621784754927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818621784744927" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_637818621784754927" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637818621784754927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818621784744927" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637818621784754927" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsDetails" xlink:type="extended" xlink:title="40901 - Disclosure - ASSET PURCHASE AND LICENSE AGREEMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_AssetPurchaseAndLicenseAgreementsAbstract" xlink:label="AssetPurchaseAndLicenseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable_637818621784764933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetPurchaseAndLicenseAgreementsAbstract" xlink:to="us-gaap_AssetAcquisitionTable_637818621784764933" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_637818621784764933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_637818621784764933" xlink:to="us-gaap_AssetAcquisitionAxis_637818621784764933" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_637818621784764933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis_637818621784764933" xlink:to="us-gaap_AssetAcquisitionDomain_637818621784764933" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_AssetPurchaseAgreementRelatingToSeribantumabMember" xlink:label="elev_AssetPurchaseAgreementRelatingToSeribantumabMember_637818621784764933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain_637818621784764933" xlink:to="elev_AssetPurchaseAgreementRelatingToSeribantumabMember_637818621784764933" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_DyaxAgreementMember" xlink:label="elev_DyaxAgreementMember_637818621784764933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="elev_AssetPurchaseAgreementRelatingToSeribantumabMember_637818621784764933" xlink:to="elev_DyaxAgreementMember_637818621784764933" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_SelexisAgreementMember" xlink:label="elev_SelexisAgreementMember_637818621784764933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="elev_AssetPurchaseAgreementRelatingToSeribantumabMember_637818621784764933" xlink:to="elev_SelexisAgreementMember_637818621784764933" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_NIHAgreementMember" xlink:label="elev_NIHAgreementMember_637818621784764933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="elev_AssetPurchaseAgreementRelatingToSeribantumabMember_637818621784764933" xlink:to="elev_NIHAgreementMember_637818621784764933" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637818621784764933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_637818621784764933" xlink:to="srt_RangeAxis_637818621784764933" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637818621784764933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637818621784764933" xlink:to="srt_RangeMember_637818621784764933" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637818621784764933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637818621784764933" xlink:to="srt_MaximumMember_637818621784764933" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems_637818621784764933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_637818621784764933" xlink:to="us-gaap_AssetAcquisitionLineItems_637818621784764933" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_637818621784764933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_637818621784764933" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_637818621784764933" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayable" xlink:label="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayable_637818621784774927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_637818621784764933" xlink:to="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayable_637818621784774927" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_CollaborationAndLicenseAgreementsNoticePeriod" xlink:label="elev_CollaborationAndLicenseAgreementsNoticePeriod_637818621784774927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_637818621784764933" xlink:to="elev_CollaborationAndLicenseAgreementsNoticePeriod_637818621784774927" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayablePerLicensedProduct" xlink:label="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayablePerLicensedProduct_637818621784774927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_637818621784764933" xlink:to="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayablePerLicensedProduct_637818621784774927" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_CollaborationAndLicenseAgreementsRoyaltyPaymentsPayable" xlink:label="elev_CollaborationAndLicenseAgreementsRoyaltyPaymentsPayable_637818621784774927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_637818621784764933" xlink:to="elev_CollaborationAndLicenseAgreementsRoyaltyPaymentsPayable_637818621784774927" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_CollaborationAndLicenseAgreementsPercentageOfRoyaltyOnNetSalesOfLicensedProducts" xlink:label="elev_CollaborationAndLicenseAgreementsPercentageOfRoyaltyOnNetSalesOfLicensedProducts_637818621784774927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_637818621784764933" xlink:to="elev_CollaborationAndLicenseAgreementsPercentageOfRoyaltyOnNetSalesOfLicensedProducts_637818621784774927" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637818621784774927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_637818621784764933" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637818621784774927" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_CollaborationAndLicenseAgreementsMilestonePaymentsPaid" xlink:label="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPaid_637818621784774927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_637818621784764933" xlink:to="elev_CollaborationAndLicenseAgreementsMilestonePaymentsPaid_637818621784774927" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsOtherResearchArrangementsDetails" xlink:type="extended" xlink:title="40902 - Disclosure - ASSET PURCHASE AND LICENSE AGREEMENTS - Other Research Arrangements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_AssetPurchaseAndLicenseAgreementsAbstract" xlink:label="elev_AssetPurchaseAndLicenseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637818621784774927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="elev_AssetPurchaseAndLicenseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637818621784774927" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637818621784774927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637818621784774927" xlink:to="us-gaap_TypeOfArrangementAxis_637818621784774927" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637818621784774927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637818621784774927" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637818621784774927" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember_637818621784784929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637818621784774927" xlink:to="us-gaap_CollaborativeArrangementMember_637818621784784929" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637818621784784929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637818621784774927" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637818621784784929" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_CollaborationAgreementTerm" xlink:label="elev_CollaborationAgreementTerm_637818621784784929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637818621784784929" xlink:to="elev_CollaborationAgreementTerm_637818621784784929" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_CollaborationAgreementRenewalTerm" xlink:label="elev_CollaborationAgreementRenewalTerm_637818621784784929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637818621784784929" xlink:to="elev_CollaborationAgreementRenewalTerm_637818621784784929" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - INCOME TAXES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637818621784784929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637818621784784929" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended" xlink:title="41102 - Disclosure - INCOME TAXES - Schedule of effective income tax rate reconciliation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637818621784784929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637818621784784929" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637818621784784929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637818621784784929" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637818621784784929" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637818621784784929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637818621784784929" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637818621784784929" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637818621784784929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637818621784784929" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637818621784784929" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="elev_EffectiveIncomeTaxRateReconciliationPermanentDifferences_637818621784794925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637818621784784929" xlink:to="elev_EffectiveIncomeTaxRateReconciliationPermanentDifferences_637818621784794925" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUpsPercent" xlink:label="elev_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUpsPercent_637818621784794925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637818621784784929" xlink:to="elev_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUpsPercent_637818621784794925" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637818621784794925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637818621784784929" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637818621784794925" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="41103 - Disclosure - INCOME TAXES - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_637818621784794925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable_637818621784794925" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_637818621784794925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637818621784794925" xlink:to="us-gaap_IncomeTaxAuthorityAxis_637818621784794925" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_637818621784794925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_637818621784794925" xlink:to="us-gaap_IncomeTaxAuthorityDomain_637818621784794925" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_637818621784794925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637818621784794925" xlink:to="us-gaap_DomesticCountryMember_637818621784794925" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_637818621784794925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637818621784794925" xlink:to="us-gaap_StateAndLocalJurisdictionMember_637818621784794925" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_637818621784794925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637818621784794925" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_637818621784794925" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637818621784794925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637818621784794925" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637818621784794925" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_637818621784794925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637818621784794925" xlink:to="us-gaap_OperatingLossCarryforwards_637818621784794925" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_637818621784794925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637818621784794925" xlink:to="us-gaap_TaxCreditCarryforwardAmount_637818621784794925" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails" xlink:type="extended" xlink:title="41104 - Disclosure - INCOME TAXES - Schedule of net deferred tax asset (liability) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637818621784804926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637818621784804926" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637818621784804926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637818621784804926" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637818621784804926" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637818621784804926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637818621784804926" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637818621784804926" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_637818621784804926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637818621784804926" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_637818621784804926" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637818621784804926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637818621784804926" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637818621784804926" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_637818621784804926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637818621784804926" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_637818621784804926" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637818621784804926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637818621784804926" xlink:to="us-gaap_DeferredTaxAssetsGross_637818621784804926" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637818621784804926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637818621784804926" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637818621784804926" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637818621784804926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637818621784804926" xlink:to="us-gaap_DeferredTaxAssetsNet_637818621784804926" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="elev-20211231.xsd#elev_DeferredTaxLiabilitiesStockBasedCompensation" xlink:label="elev_DeferredTaxLiabilitiesStockBasedCompensation_637818621784804926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637818621784804926" xlink:to="elev_DeferredTaxLiabilitiesStockBasedCompensation_637818621784804926" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637818621784804926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637818621784804926" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637818621784804926" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_637818621784804926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637818621784804926" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_637818621784804926" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_637818621784804926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637818621784804926" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_637818621784804926" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_637818621784814927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_637818621784814927" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_637818621784814927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_637818621784814927" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureNetLossPerShareDetails" xlink:type="extended" xlink:title="41201 - Disclosure - NET LOSS PER SHARE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637818621784814927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss_637818621784814927" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637818621784814927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637818621784814927" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637818621784814927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637818621784814927" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637818621784814927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic_637818621784814927" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637818621784814927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_637818621784814927" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" xlink:type="extended" xlink:title="41202 - Disclosure - NET LOSS PER SHARE - Antidilutive securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637818621784814927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637818621784814927" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637818621784824928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637818621784814927" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637818621784824928" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637818621784824928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637818621784824928" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637818621784824928" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember_637818621784824928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637818621784824928" xlink:to="us-gaap_ConvertiblePreferredStockMember_637818621784824928" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637818621784824928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637818621784824928" xlink:to="us-gaap_EmployeeStockOptionMember_637818621784824928" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_637818621784824928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637818621784824928" xlink:to="us-gaap_RestrictedStockMember_637818621784824928" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_637818621784824928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637818621784824928" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_637818621784824928" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637818621784824928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637818621784814927" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637818621784824928" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637818621784824928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637818621784824928" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637818621784824928" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.elevationoncology.com/role/DisclosureRetirementPlanDetails" xlink:type="extended" xlink:title="41301 - Disclosure - RETIREMENT PLAN (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_637818621784824928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_1" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_637818621784824928" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970584537512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ELEVATION ONCOLOGY,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-1771427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">888 Seventh Ave, 12th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">371-1125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ELEV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,205,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">CohnReznick LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tysons, Virginia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001783032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970581093880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 146,284<span></span>
</td>
<td class="nump">$ 79,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,140<span></span>
</td>
<td class="nump">1,386<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">149,424<span></span>
</td>
<td class="nump">80,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, net</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">149,494<span></span>
</td>
<td class="nump">80,907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,648<span></span>
</td>
<td class="nump">5,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,141<span></span>
</td>
<td class="nump">1,106<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">8,789<span></span>
</td>
<td class="nump">6,785<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_RestrictedStockRepurchaseLiability', window );">Restricted stock repurchase liability</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">8,797<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2021; no shares issued or outstanding as of December 31, 2021 and 2020, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 500,000,000 and 86,000,000 shares authorized as of December 31, 2021 and 2020, respectively; 23,225,637 and 836,177 issued as of December 31, 2021 and 2020, respectively; 23,205,915 and 800,679 outstanding as of December 31, 2021 and 2020, respectively</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">195,881<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(55,186)<span></span>
</td>
<td class="num">(23,147)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">140,697<span></span>
</td>
<td class="num">(23,081)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders' equity (deficit)</a></td>
<td class="nump">$ 149,494<span></span>
</td>
<td class="nump">80,907<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=elev_SeriesaConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,373<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=elev_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,815<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_RestrictedStockRepurchaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of restricted stock repurchase liability as on the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_RestrictedStockRepurchaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=elev_SeriesaConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=elev_SeriesaConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=elev_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=elev_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970584800952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,493,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">86,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">23,225,637<span></span>
</td>
<td class="nump">836,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">23,205,915<span></span>
</td>
<td class="nump">800,679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=elev_SeriesaConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,450,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,450,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,450,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 32,450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=elev_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">34,043,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">34,043,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">34,043,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=elev_SeriesaConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=elev_SeriesaConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=elev_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=elev_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970584429240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 23,595<span></span>
</td>
<td class="nump">$ 15,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">8,451<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">32,046<span></span>
</td>
<td class="nump">17,276<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(32,046)<span></span>
</td>
<td class="num">(17,276)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expenses), net</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (32,039)<span></span>
</td>
<td class="num">$ (17,265)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (2.64)<span></span>
</td>
<td class="num">$ (21.80)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (2.64)<span></span>
</td>
<td class="num">$ (21.80)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">12,132,610<span></span>
</td>
<td class="nump">791,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">12,132,610<span></span>
</td>
<td class="nump">791,821<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970583458936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Series A Convertible Preferred Stock [Member]</div></th>
<th class="th"><div>Series B Convertible Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 7,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">7,266,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="nump">$ 25,183<span></span>
</td>
<td class="nump">$ 64,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of convertible preferred stock, net of issuance costs (in shares)</a></td>
<td class="nump">25,183,250<span></span>
</td>
<td class="nump">34,043,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 32,373<span></span>
</td>
<td class="nump">$ 64,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">32,450,000<span></span>
</td>
<td class="nump">34,043,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders equity, Beginning balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="num">$ (5,882)<span></span>
</td>
<td class="num">$ (5,873)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders equity, Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">788,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,265)<span></span>
</td>
<td class="num">(17,265)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders equity, Ending balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="num">(23,147)<span></span>
</td>
<td class="num">(23,081)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders equity, Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityEliminationAsPartofReorganization', window );">Issuance of initial public offering common stock, net</a></td>
<td class="num">$ (32,373)<span></span>
</td>
<td class="num">$ (64,815)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_TemporaryEquityEliminationOfSharesAsPartOfInitialPublicOffering', window );">Issuance of initial public offering common stock, net (in shares)</a></td>
<td class="num">(32,450,000)<span></span>
</td>
<td class="num">(34,043,889)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of initial public offering common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">194,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194,239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of initial public offering common stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,389,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,039)<span></span>
</td>
<td class="num">(32,039)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders equity, Ending balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 195,881<span></span>
</td>
<td class="num">$ (55,186)<span></span>
</td>
<td class="nump">$ 140,697<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders equity, Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,205,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_TemporaryEquityEliminationOfSharesAsPartOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redemption of temporary equity shares as the result of initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_TemporaryEquityEliminationOfSharesAsPartOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityEliminationAsPartofReorganization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redemption of temporary equity as the result of a triggering event associated with the temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityEliminationAsPartofReorganization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970584442840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders Equity (Deficit) (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=elev_SeriesaConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_TemporaryEquityStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=elev_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_TemporaryEquityStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 185<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_TemporaryEquityStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of stock issuance costs relating to temporary equity recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_TemporaryEquityStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=elev_SeriesaConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=elev_SeriesaConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=elev_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=elev_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970584676760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (32,039)<span></span>
</td>
<td class="num">$ (17,265)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Reconciliation of net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,571<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,722)<span></span>
</td>
<td class="num">(1,212)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(30)<span></span>
</td>
<td class="nump">5,219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">2,035<span></span>
</td>
<td class="nump">958<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(30,167)<span></span>
</td>
<td class="num">(12,298)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_ProceedsFromIssuanceOfRestrictedCommonStock', window );">Proceeds from the issuance of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock upon initial public offering, net of issuance costs</a></td>
<td class="nump">97,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from the issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Cash paid for issuance costs of convertible preferred stock</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(174)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">97,051<span></span>
</td>
<td class="nump">90,029<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase in cash and cash equivalents</a></td>
<td class="nump">66,884<span></span>
</td>
<td class="nump">77,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">79,400<span></span>
</td>
<td class="nump">1,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">146,284<span></span>
</td>
<td class="nump">79,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_IssuanceCostsIncludedInAccruedExpenses', window );">Issuance costs in accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of convertible preferred stock upon IPO</a></td>
<td class="nump">$ 97,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_IssuanceCostsIncludedInAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of issuance costs which are included in accrued expenses during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_IssuanceCostsIncludedInAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_ProceedsFromIssuanceOfRestrictedCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional restricted capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_ProceedsFromIssuanceOfRestrictedCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970586488632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>NATURE OF BUSINESS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NATURE OF BUSINESS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. NATURE OF BUSINESS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Elevation Oncology,&#160;Inc. (the &#8220;Company&#8221; or &#8220;Elevation&#8221;), which was formerly known as 14ner,&#160;Inc., was incorporated under the laws of the State of Delaware on April&#160;29, 2019 (&#8220;Inception&#8221;). The Company is a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers. The Company acquired its lead product candidate, seribantumab, pursuant to an asset purchase agreement executed with Merrimack Pharmaceuticals,&#160;Inc. (the &#8220;previous sponsor&#8221;) during the period ended December&#160;31, 2019 (see Note&#160;9). Seribantumab has been shown preclinically to inhibit tumor growth driven by NRG1 fusions and is currently being tested in the Company&#8217;s Phase&#160;2 CRESTONE clinical trial for patients with tumors of any origin that have an NRG1 fusion. The Company is actively evaluating opportunities for pipeline expansion including prioritizing additional targeted therapy approaches in tumor types defined by genomic driver alterations.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:12pt 0pt 12pt 0pt;">Risks and Uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure, and extensive compliance-reporting capabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance that the Company&#8217;s research and development of its product candidates will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The current COVID-19 pandemic has presented a substantial public health and economic challenge around the world and is affecting our employees, patients, communities and business operations, as well as contributing to significant volatility and negative pressure on the U.S. economy and in financial markets. The extent of the impact of COVID-19 on the Company&#8217;s operational and financial performance will continue to depend on certain developments, including the duration and spread of the outbreak, new variants, the vaccination and booster rate, impact on the Company&#8217;s clinical studies, employee or industry events, and effect on our suppliers and manufacturers, all of which are uncertain and cannot be predicted. COVID-19 has not had a significant impact on the operations or financial results of the Company to date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In July 2019 and November 2020, the Company received gross proceeds of $97.2 million from the issuance and sale of its Series A and Series B convertible preferred stock (see Note 6).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On June 17, 2021, the Company effected a 1.0 for <span style="-sec-ix-hidden:Hidden_z6l6dXmz8E6xGt27fFRfuQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.225582</span></span> reverse stock split of its issued and outstanding shares of common stock and proportional adjustment to the existing conversion ratios for each series of the Company&#8217;s convertible preferred stock (see Note 6). Accordingly, all share and per share amounts for all periods presented in the accompanying consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this reverse stock split and adjustment of the preferred stock conversion ratios.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On June 29, 2021, the Company closed its initial public offering (&#8220;IPO&#8221;) and issued 6,250,000 shares of its common stock at a price of $16.00 per share for net proceeds of $91.1 million, after deducting underwriting discounts and commissions and expenses of $8.9 million. In connection with the IPO, all shares of Series A and Series B convertible preferred stock converted into 15,736,053 shares of common stock. On July 19, 2021, in connection with the Company&#8217;s IPO, the underwriters exercised the right to purchase 403,407 shares of the Company&#8217;s common stock at a price of $16.00 per share for net proceeds of $6.0 million, after deduction underwriting discounts of $0.5<span style="white-space:pre-wrap;"> million.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has historical losses from operations and anticipates that it will continue to incur losses for the foreseeable future as it continues the research and development of its product candidates. The Company incurred net losses of $32.0 million and $17.3 million for the&#160;years ended December&#160;31, 2021 and 2020, respectively, and had an accumulated deficit of $55.2 million as of December&#160;31, 2021. Through December&#160;31, 2021, the Company has funded its operations with proceeds from the sale of convertible preferred stock and common stock. The Company expects that its cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance date of the consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970586408808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Elevation Oncology Securities Corporation, which was established on November 19, 2021. All significant intercompany balances and transaction have been eliminated in consolidation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in accordance with GAAP requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company bases its estimates and assumptions on known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accruals for research and development expenses, the valuation of common stock and the assumptions used in the valuation of share-based compensation awards. Changes in estimates are recorded in the period in which they become known. Due to the risks and uncertainties involved in the Company&#8217;s business and evolving market conditions and, given the subjective element of the estimates and assumptions made, actual results may differ from estimated results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Segment Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available and regularly reviewed by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment, which is the development of precision medicines for patients with genomically defined cancers. All material long-lived assets of the Company reside in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with an original maturity of three&#160;months or less to be cash equivalents. As of December&#160;31, 2021 and 2020, cash equivalents consisted of money-market funds. The Company places its cash with a high-credit-quality financial institution domiciled in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk and Significant Suppliers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. The Company&#8217;s money market funds are invested in highly rated funds. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents and does not believe that it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is dependent on third-party manufacturers to supply products for research and development activities of its programs, including preclinical and clinical testing. These programs could be adversely affected by a significant interruption in the supply of such drug substance and drug products. During the&#160;year ended December&#160;31, 2021, the Company had two vendors that accounted for approximately 61% of its research and development expense. As of December&#160;31, 2021, the Company had one vendor that accounted for approximately 74% of the total accounts payable. During the&#160;year ended December&#160;31, 2020, the Company had one vendor that accounted for approximately 46% of its research and development expense. The <span style="-sec-ix-hidden:Hidden_oYUMpxFyBEukUJ69xj1Vgw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">same</span></span> vendor also accounted for approximately 95% of the total accounts payable as of December&#160;31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Property and equipment consist of computer software that is recorded at cost and depreciated on a straight-line basis over the estimated useful lives of the assets. Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying value of assets may not be recoverable. Recoverability is measured by comparison of the asset&#8217;s book value to future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets. No impairment losses have been recorded through December&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cloud Computing Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company defers implementation costs incurred in cloud computing hosting arrangements in accordance with Accounting Standards Update (&#8220;ASU&#8221;) 2018-15 and amortizes these costs over the noncancelable term of the cloud computing arrangement, plus any optional renewal periods (1)&#160;that are reasonably certain to be exercised by the Company or (2)&#160;for which exercises of the renewal option is controlled by the cloud service provider. Costs incurred during the application development stage are capitalized within either prepaid expenses and other current assets, or in other assets, net on the Company&#8217;s balance sheet. Amortization of implementation costs are on a straight-line basis over the related hosting arrangement term and is reflected in research and development expenses in the consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Classification and Accretion of Convertible Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company&#8217;s convertible preferred stock is classified outside of stockholders&#8217; deficit on the balance sheet because the holders of such shares have liquidation rights in the event of a deemed liquidation that, in certain situations, are not solely within the control of the Company and would require the redemption of the then-outstanding convertible preferred stock. The convertible preferred stock is not redeemable, except in the event of a deemed liquidation (see Note&#160;6). Because the occurrence of a deemed liquidation event is not currently probable, the carrying values of the convertible </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">preferred stock are not being accreted to their redemption values. Subsequent adjustments to the carrying values of the convertible preferred stock would be made only when a deemed liquidation event becomes probable. Upon the closing the Company&#8217;s IPO in June 2021, all outstanding convertible preferred stock automatically converted into shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2&#8212;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3&#8212;Non-observable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The Company's cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note 3).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patent Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The legal and professional costs incurred by the Company to maintain its patent rights have been expensed as part of general and administrative expenses since inception. As of December&#160;31, 2021 and 2020, the Company has determined that these expenses have not met the criteria to be capitalized. Intellectual property-related&#160;expenses for the year ended December&#160;31, 2021 and&#160;2020 were $0.2 million and $0.1 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development costs consist of salaries and benefits, including associated stock-based compensation, and fees paid to other entities that conduct certain research and development activities on the Company&#8217;s behalf. Research and development costs are expensed as incurred. The Company estimates preclinical study and clinical trial expenses based on the services performed pursuant to contracts with research institutions and contract research organizations and clinical manufacturing organizations that conduct and manage preclinical studies and clinical trials on the Company&#8217;s behalf based on actual time and expenses incurred by them. Further, the Company accrues expenses related to clinical trials based on the level of patient activity according to the related agreement. The Company monitors patient enrollment levels and related activity to the extent reasonably possible and adjusts estimates accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the services have been performed or when the goods have been received rather than when the payment is made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to the Company&#8217;s prior estimates of accrued research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company measures stock-based compensation cost at the accounting measurement date based on the fair value of the award and recognizes the expense on a straight-line basis over the requisite service period of the award, which is typically the vesting period. Compensation expense is measured using the fair value of the award at the grant date and is adjusted to reflect actual forfeitures as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company estimates the fair value of stock options using the Black-Scholes option pricing model that takes into account the exercise price, the fair value of the Company&#8217;s common stock, the expected term of the option, the expected volatility of the Company&#8217;s common stock, expected dividends on the Company&#8217;s common stock, and the risk-free interest rate over the expected life of the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Fair value of common stock&#8212;</i>Prior to IPO in June 2021, the Company valued its common stock by taking into consideration its most recently available valuation of common shares performed by management and the board of directors, as well as additional factors which may have changed since the date of the most recent contemporaneous valuation through the date of grant. Upon IPO, the fair value of the Company&#8217;s common stock is determined based on the quoted market price of its common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected term&#8212;</i>The Company uses the simplified method described in the Securities and Exchange Commission Staff Accounting Bulletin Topic 14.D.2 to calculate the expected term as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term for options granted to employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected volatility&#8212;</i>The Company estimates expected volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its traded stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk-free interest rate&#8212;</i>The risk-free rate assumption is based on the U.S. Treasury yield curves whose terms are consistent with the expected term of the stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected dividend&#8212;</i>The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be zero.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient&#8217;s payroll costs or service payments are classified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss per Common Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s net loss is equivalent to net loss attributable to common stockholders for all periods presented. Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed using the sum of the weighted average number of common shares outstanding during the period and the effect of dilutive securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company applies the two-class method to calculate its basic and diluted net loss per share as the Company has issued shares that meet the definition of participating securities. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. The Company&#8217;s participating securities contractually entitle the holders of such shares to participate in dividends; but do not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the&#160;year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. The Company accounts for uncertainty in income taxes recognized. If the tax position is deemed more likely than not to be sustained, it would then be assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. To date the Company has no uncertain tax positions and there have been no interest and penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Recently issued accounting pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In December 2019, the Financial Accounting Standards Board issued Accounting Standards Update (&#8220;ASU&#8221;) 2019-12, <i style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</i>. Among other items, the amendments in ASU 2019-12 simplify the accounting treatment of tax law changes and year-to-date losses in interim periods. An entity generally recognizes the effects of a change in tax<i style="font-style:italic;"> </i>law in the period of enactment; however, there is an exception for tax laws with delayed effective dates. Under<i style="font-style:italic;"> </i>current guidance, an entity may not adjust its annual effective tax rate for a tax law change until the period in<i style="font-style:italic;"> </i>which the law is effective. This exception was removed under ASU 2019-12, thereby providing that all effects of a<i style="font-style:italic;"> </i>tax law change are recognized in the period of enactment, including adjustment of the estimated annual<i style="font-style:italic;"> </i>effective tax rate. Regarding year-to-date losses in interim periods, an entity is required to estimate its annual<i style="font-style:italic;"> </i>effective tax rate for the full fiscal year at the end of each interim period and use that rate to calculate its income<i style="font-style:italic;"> </i>taxes on a year-to-date basis. However, current guidance provides an exception that when a loss in an interim<i style="font-style:italic;"> </i>period exceeds the anticipated loss for the year, the income tax benefit is limited to the amount that would be<i style="font-style:italic;"> </i>recognized if the year-to-date loss were the anticipated loss for the full year. ASU 2019-12 removes this exception<i style="font-style:italic;"> </i>and provides that in this situation, an entity would compute its income tax benefit at each interim period based<i style="font-style:italic;"> </i>on its estimated annual effective tax rate. ASU 2019-12 is effective for fiscal years beginning after December 15,<i style="font-style:italic;"> </i>2021, with early adoption permitted. The Company has not elected to early adopt ASU 2019-12 and is currently<i style="font-style:italic;"> </i>evaluating the impact the adoption of the standard will have on its financial statements and related disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970586460904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company&#8217;s financial assets subject to fair value measurements on a recurring basis and the level of inputs used for such measurements were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds included in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 106,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 106,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds included in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 76,013</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 76,013</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">During the&#160;years ended December&#160;31, 2021and 2020, the Company had no transfers between Level&#160;1, <span style="-sec-ix-hidden:Hidden_TDI7DkXArkaTliVYX6vraA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2</span></span> or <span style="-sec-ix-hidden:Hidden_JCM5oP1UqkKdMGQnvJ6z0g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3</span></span> financial assets.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970586444168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. PROPERTY AND EQUIPMENT, NET</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net, consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Useful&#160;Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 71</p></td></tr><tr><td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (33)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15)</p></td></tr><tr><td style="vertical-align:bottom;width:65.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Property and equipment, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 56</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company recorded less than $0.1 million of depreciation expense during the&#160;years ended December&#160;31, 2021 and 2020.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970586447992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>ACCRUED EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_AccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. ACCRUED EXPENSES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued expenses consist of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued preclinical and clinical trial costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 505</p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,059</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 429</p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued consulting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 127</p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28</p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 246</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 17</p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total accrued expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,106</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_AccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of information pertaining to accrued liabilities classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_AccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970589283560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE PREFERRED STOCK<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>CONVERTIBLE PREFERRED STOCK</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_TemporaryEquityDisclosureTextBlock', window );">CONVERTIBLE PREFERRED STOCK</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;">6. CONVERTIBLE PREFERRED STOCK</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company had issued Series&#160;A and Series&#160;B convertible preferred stock (collectively, the &#8220;Convertible Preferred Stock&#8221;). As of December&#160;31, 2020, the Company&#8217;s certificate of incorporation, as amended and restated, authorized the Company to issue 66,493,889 shares of $0.0001 par value convertible preferred stock, of which 32,450,000 were designated as Series&#160;A convertible preferred stock (&#8220;Series&#160;A&#8221;) and 34,043,889 were designated as Series&#160;B convertible preferred stock (&#8220;Series&#160;B&#8221;). As of December 31, 2020, all of the Company&#8217;s Convertible Preferred Stock was classified outside of stockholders&#8217; deficit because the shares contained deemed liquidation rights that were a contingent redemption feature not solely within the control of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Series&#160;A</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On July&#160;12, 2019, the Company sold 5,450,000 shares of Series&#160;A at a price of $1.00 per share (&#8220;Series&#160;A Original Issue Price&#8221;) pursuant to the Series&#160;A stock purchase agreement (the &#8220;Series&#160;A Purchase Agreement&#8221;), for gross proceeds of $5.5 million. On August&#160;7, 2019, investors purchased an additional 1,816,750 shares of Series&#160;A at the Series&#160;A Original Issue Price, for gross proceeds of $1.8 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Upon achievement of the Milestone Closing (as defined in the Series&#160;A Purchase Agreement) and approval by the Company&#8217;s board of directors, the Company issued an additional 25,183,250 shares of Series&#160;A at the Series&#160;A Original Issue Price on January&#160;9, 2020 for gross proceeds of $25.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Series&#160;B</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On November&#160;10, 2020, the Company sold 34,043,889 shares of Series&#160;B at a price of $1.9093 per share (&#8220;Series&#160;B Original Issue Price&#8221;), pursuant to the Series&#160;B stock purchase agreement for gross proceeds of $65.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Conversion</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;white-space:pre-wrap;">Upon the closing the Company&#8217;s IPO in June 2021, all outstanding convertible preferred stock automatically converted into shares of common stock.  There are </span><span style="font-style:normal;font-weight:normal;">10,000,000</span><span style="font-style:normal;font-weight:normal;"> authorized preferred shares of December 31, 2021.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_TemporaryEquityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of information pertaining to temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_TemporaryEquityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970586421688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMON STOCK<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>COMMON STOCK.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">COMMON STOCK</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">7. COMMON STOCK</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">As of December&#160;31, 2021, the Company&#8217;s certificate of incorporation, as amended and restated, authorized the Company to issue 500,000,000 shares of $0.0001 par value common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Initial Public Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">On June 29, 2021, the Company closed its IPO and issued 6,250,000 shares of its common stock at a price of $16.00 per share for net proceeds of $91.1 million, after deducting underwriting discounts and commissions and expenses of $8.9 million. In connection with the IPO, all shares of Series A and Series B convertible preferred stock converted into 15,736,053 shares of common stock. On July 19, 2021, in connection with the Company&#8217;s IPO, the underwriters exercised the right to purchase 403,407 shares of the Company&#8217;s common stock at a price of $16.00 per share for net proceeds of $6.0 million, after deduction underwriting discounts of $0.5<span style="white-space:pre-wrap;"> million.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">The Company has reserved a total of 27,565,320 shares of common stock as of December 31, 2021 for common stock outstanding, the exercise of outstanding stock options and the number of shares remaining available for future grant under the Company&#8217;s 2021 Stock Incentive Plan. The Company had reserved a total of 19,831,875 shares of common stock as of December&#160;31, 2020 for common stock outstanding, the conversion of the outstanding shares of Convertible Preferred Stock, the exercise of outstanding stock options and the number of shares remaining available for future grant under the Company&#8217;s 2019 Stock Incentive Plan.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970586380440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. STOCK-BASED COMPENSATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation expense as reflected in the Company&#8217;s consolidated statements of operations was as follows (in thousand):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 244</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 24</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,327</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation expense included in operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 52</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2021 Equity Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has two equity incentive plans: the 2019 Equity Incentive Plan (&#8220;2019 Plan&#8221;), and the 2021 Equity Incentive Plan (&#8220;2021 Plan&#8221;). New awards can only be granted under the 2021 Plan, under which it is able to issue equity to employees, board members, consultants, and advisors. The 2021 Plan became effective on June 24, 2021, the date the prospectus related to the Company's IPO was deemed effective by the SEC. The 2021 Plan authorizes the award of stock options, restricted stock awards (&#8220;RSAs&#8221;), stock appreciation rights (&#8220;SARs&#8221;), restricted stock units (&#8220;RSUs&#8221;), cash awards, performance awards and stock bonus awards. The Company has initially reserved 1,483,445 shares of its common stock, plus any reserved shares not issued or subject to outstanding grants under the 2019 Plan on the effective date of the 2021 Plan, for issuance pursuant to awards granted under the 2021 Plan. Of this amount, 1,720,291 shares were available for future grants as of December 31, 2021. The number of shares reserved for issuance under the 2021 Plan will increase automatically on January 1 of each of 2022 through 2031 by the number of shares equal to the lesser of 5% of the aggregate number of outstanding shares of the Company&#8217;s common stock as of the immediately preceding December 31, or a number as may be determined by our board of directors. As such, 1,160,296 shares were added to the Plan in January 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2019 Stock Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The total number of shares of common stock available for issuance under the 2019 Plan was 1,972,114 shares when the 2019 Plan was adopted. In December&#160;2019 and November&#160;2020, the Company increased the number of shares of common stock reserved for issuance under the 2019 Plan by 144,950 shares and 1,189,911 shares, respectively. Shares underlying any awards that were forfeited, canceled, or reacquired by the Company prior to vesting, satisfied without the issuance of stock or otherwise terminated or shares that were withheld upon exercise of an option or settlement of an award to cover the exercise price or tax withholding were to be added back to the shares available for issuance under the 2019 Plan. For the year ended December 31, 2021, 1,016,337 options were granted under the 2019 Plan. The 2019 Plan was terminated in connection with the Company&#8217;s IPO. The Company will not grant any additional awards under the 2019 Plan thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2021 Employee Stock Purchase Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has adopted the Employee Stock Purchase Plan (&#8220;ESPP&#8221;) which became effective June 24, 2021, the date the prospectus related to the Company's IPO was deemed effective by the SEC, to enable eligible employees to purchase shares of its common stock with accumulated payroll deductions at a discount beginning on a date to be determined by the board of directors or compensation committee. The ESPP is intended to qualify under Section 423 of the Code. The Company has initially reserved 228,222 shares of its common stock for sale under the ESPP. The aggregate number of shares reserved for sale under the ESPP will increase automatically on January 1st of each of 2022 through 2031 by the number of shares equal to the lesser of 1% of the total outstanding shares of the Company&#8217;s common stock as of the immediately preceding December 31 (rounded to the nearest whole share) or a number of shares as may be determined by the board of directors in any particular year. As such, 232,059 shares were added to the Plan in January 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The aggregate number of shares issued over the term of the ESPP, subject to stock-splits, recapitalizations or similar events, may not exceed 4,564,440 shares of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A summary of stock option activity for employee and nonemployee awards under the 2019 and 2021 Plans is presented below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining&#160;Contractual&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term&#160;(years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,761,062</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9.54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 723</p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,309,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (48,663)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,021,799</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,903</p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 680,951</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,437</p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and expected to vest at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,021,799</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,903</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The weighted average grant-date fair value of stock options granted during the year ended December&#160;31, 2021 and 2020 was $4.60 and $0.73 per share, respectively. The fair value of each stock option was estimated using a Black-Scholes option-pricing model with the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:33.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.95 - 1.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.2&#8722;0.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">75-77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">74%&#8722;79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_F-nfSSZM0Euu4OQJHKZe8Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3</span></span>&#8722;<span style="-sec-ix-hidden:Hidden_gGMsgb7BgEOGbQEJGMhgkw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The fair value of options that vested during the years ended December 31, 2021 and 2020 was $0.6 million and $0 million, respectively. The Company recorded stock-based compensation expense associated with stock option awards of $1.1 million and $0.1 million during the 12&#160;<span style="white-space:pre-wrap;">months ended December 31, 2021 and 2020, respectively.  As of December 31, 2021, there was </span>$6.4 million of total unrecognized compensation cost related to unvested stock-based awards, which the Company expects to recognize over a remaining weighted-average period of 3.2&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restricted Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The terms of the 2019 Plan permitted certain option holders to exercise options before their options were vested, subject to certain limitations. Upon early exercise, the awards become subject to a restricted stock agreement and are subject to the same vesting provisions in the original stock option awards. Shares issued as a result of early exercise that have not vested are subject to repurchase by the Company upon termination of the purchaser&#8217;s employment, at the lesser of the price paid by the purchaser or the fair value of the shares at the time of repurchase. Such shares are not deemed to be issued for accounting purposes until they vest and are therefore excluded from shares outstanding until the repurchase right lapses and the shares are no longer subject to the repurchase feature. The liability is reclassified into common stock and additional paid-in capital as the shares vest and the repurchase right lapses. Accordingly, the Company has recorded the unvested portion of the exercise proceeds of less than $0.01 million as a liability from the early exercise in the accompanying consolidated balance sheets as of December 31, 2021 and 2020, respectively. The Company recorded stock-based compensation expense associated with restricted common stock of less than $0.1 million during the 12 months ended December 31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restricted Stock Units</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company issues RSUs to employees that generally vest over a four-year period with 25% of awards vesting after one year and then quarterly thereafter. Any unvested shares will be forfeited upon termination of services. The fair value of an RSU is equal to the fair market value price of the Company&#8217;s common stock on the date of grant. RSU expense is amortized straight-line over the vesting period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes activity related to restricted stock units:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;average</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">grant date</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 200,996</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16.00</p></td></tr><tr><td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 200,996</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16.00</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company recorded stock-based compensation expense of $0.4 million for the 12 months ended December 31, 2021, related to RSUs. As of December 31, 2021, the total unrecognized expense related to all RSUs was $2.8 million, which the Company expects to recognize over a weighted-average period of 3.4&#160;years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970586472296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSET PURCHASE AND LICENSE AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_AssetPurchaseAndLicenseAgreementsAbstract', window );"><strong>ASSET PURCHASE AND LICENSE AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_AssetPurchaseAndLicenseAgreementsDisclosureTextBlock', window );">ASSET PURCHASE AND LICENSE AGREEMENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. ASSET PURCHASE AND LICENSE AGREEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2019, the Company entered into an asset purchase agreement with the previous sponsor, pursuant to which it acquired all rights and interest to patents, know-how, and inventory for assets related to seribantumab, a fully humanized immunoglobulin G2 monoclonal antibody against HER3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the asset purchase agreement, the Company made an upfront, non-refundable payment of $3.5 million at closing. If the Company succeeds in developing and commercializing seribantumab, the Company may be obligated to pay the previous sponsor up to $54.5 million in development, regulatory and sales milestone payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the asset purchase agreement, the Company assumed the rights and obligations of the following collaboration and license agreements previously held by the previous sponsor:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Dyax&#8212;</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company assumed all rights and obligations provided for under the amended and restated collaboration agreement executed between Dyax Corp. (&#8220;Dyax&#8221;) and the previous sponsor (the &#8220;Dyax Agreement&#8221;). Pursuant to the Dyax Agreement, Dyax utilized its proprietary phage technology to identify antibodies that would bind to targets of interest to the previous sponsor. Additionally, Dyax granted to the previous sponsor a world-wide, non-exclusive, royalty free right to use and make any and all of the antibodies identified by Dyax for certain research purposes. Seribantumab was identified as a result of the research activities performed under the Dyax Agreement.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the Dyax Agreement, the Company may be obligated to pay Dyax milestone payments of up to approximately $9.3 million if certain development and regulatory milestones are achieved. In addition, Dyax is entitled to mid-single digit royalties based on net sales of seribantumab. The Company&#8217;s obligation to pay royalties to Dyax continues on a product-by-product and country-by-country basis until the later of a specified number of&#160;years after the first commercial sale in such country and the expiration of the patent rights covering seribantumab in such country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Dyax Agreement will remain in effect, unless earlier terminated, for so long as the Company continues to develop or commercialize seribantumab. Either party may terminate the agreement in the event of an uncured material breach by the other party. The Company also has the right to terminate the agreement in its entirety or on a product-by-product basis at any time upon 90&#160;days&#8217; prior written notice.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Ligand Pharmaceuticals&#8212;</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company assumed all rights and obligations provided for under the amended commercial license agreement executed between Selexis SA (&#8220;Selexis&#8221;) and the previous sponsor (the &#8220;Selexis Agreement&#8221;). Pursuant to the Selexis Agreement, the Company received non-exclusive rights to technology for use in the manufacture of seribantumab and may be required to make milestone payments of up to approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;900</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, per licensed product, if certain development and regulatory milestones are achieved. Additionally, Selexis may have the right to obtain a royalty of the greater of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;0.2</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million annually and less than </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;percent on net sales of seribantumab. The obligation to pay royalties with respect to each product sold in a country continues until the expiration of the patent rights covering the product in such country. Either party may terminate the agreement in the event of an uncured material breach by the other party. The Company also has the right to terminate the agreement at any time upon </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">60&#160;days</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8217; prior written notice.</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"> </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In November of 2021, the Selexis agreement was assigned to Ligand Pharmaceuticals Incorporated.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">National Institute of Health</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212;The Company assumed all rights and obligations provided for under the amended commercial license agreement executed between the U.S. Public Health Service, a division of the U.S. Department of Health and Human Services (the &#8220;NIH&#8221;) and the previous sponsor (the &#8220;NIH Agreement&#8221;). Pursuant to the NIH Agreement, the Company received non-exclusive rights in the United States to patents related to certain antibodies associated with seribantumab. If certain development and regulatory milestones are achieved, the Company may be obligated to pay NIH additional milestone payments of up to approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.4</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million per licensed product.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company evaluated the asset purchase agreement with the previous sponsor under ASC Topic 805<i style="font-style:italic;">, Business Combinations,</i> and concluded that the transaction did not meet the requirements to be accounted for as a business combination and therefore was accounted for as an asset acquisition. Accordingly, the upfront payment of $3.5 million was expensed as research and development expenses in the statement of operations for the year ended December&#160;31, 2019. Additionally, the Company concluded that all consideration to be paid under the asset purchase agreement is contingent in nature and will be recognized when the respective contingency is resolved. The Company assessed the contingent events which would result in the payment of a milestone as of December&#160;31, 2021 and 2020, and concluded no such payments were required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Research Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In June 2021, the Company entered into a collaboration agreement with Caris, or the Caris Agreement. Under the terms of the Caris Agreement, Caris will identify targets for the collaboration and provide those targets to the Company at regular intervals for review and approval. Once a target is selected by the collaboration&#8217;s joint steering committee, the collaboration will retain access to the selected targets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The financial terms surrounding development and commercialization of each product candidate identified for the collaboration and included in the Caris Agreement vary based on the level of participation elected by each party in the development and commercialization efforts following identification of a target. There are no upfront or milestone payments or royalties due to either party under the collaboration. With respect to proceeds from any potential commercial transaction related to a product resulting from the collaboration, Caris will be entitled to a tiered initial&#160;percentage ranging from the mid-single digits to low teens based on the product candidate&#8217;s potential peak sales revenue with the remaining proceeds allocated based on each party&#8217;s pro&#160;rata share of expenses incurred in development of the product. In the case of an out-licensing transaction of an asset instead of a sale, Caris and the Company will split all consideration received in the transaction in a similar manner. The Caris Agreement provides flexibility for Caris and the Company to jointly develop and commercialize, or for either the Company or Caris to incur development and commercialization expenses. The ultimate&#160;percentage of proceeds payable to the Company and Caris will depend on the level of development and commercialization participation elected by each party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company will own the intellectual property rights to the therapeutics developed under the collaboration, and Caris will own the intellectual property rights to the diagnostics developed under the collaboration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Either party may terminate the Caris Agreement for uncured material breach by the other party or in the case of the other party&#8217;s insolvency. The term of the Caris Agreement is three years, automatically renewing for one-year terms. Either party may terminate the agreement at the end of a term by written notice to the other, subject to the continuation of exclusivity with respect to any target selected by the Joint Steering Committee, so long as commercially reasonable efforts are used to discover, identify, develop and/or commercialize a therapeutic related to such target.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_AssetPurchaseAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Purchase and License Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_AssetPurchaseAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_AssetPurchaseAndLicenseAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset purchase and license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_AssetPurchaseAndLicenseAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970586486472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. COMMITMENTS AND CONTINGENCIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company, from time to time, may be involved in legal proceedings, regulatory actions, claims and litigation arising in the ordinary course of business. The Company was not a defendant in any lawsuits from Inception to the date of these consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970586089432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. INCOME TAXES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">No provision for income taxes was recorded for the years ended December 31, 2021 and 2020. The Company has incurred net pre-tax losses in the United States only for all periods presented. The Company has not reflected any benefit of such net operating loss (&#8220;NOL&#8221;) carryforwards in the accompanying consolidated financial statements. The provision for income taxes differs from the amount expected by applying the federal statutory rate to the loss before taxes as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Profit before tax at federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State tax benefit, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credit carryovers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Return to Provision True Ups</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In assessing the realizability of the net deferred tax assets, the Company considers all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the NOL carryforwards. The Company has recorded a valuation allowance against its deferred tax assets on December 31, 2021 and 2020 because the Company&#8217;s management believes that it is more likely than not that these assets will not be fully realized in the near future. The increase in the valuation allowance of approximately $7.9 million in the year ended December 31, 2021 primarily relates to the generation of net operating losses and research and development credits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of December 31, 2021, the Company had federal NOL carryforwards of approximately $48.2 million, all of which can be carried forward indefinitely, and state NOL carryforwards of $3.5 million, which begin to expire in 2040. The Company also has federal tax credits of $1.5 million and state tax credits of $0.2 million which may be used to offset future tax liabilities and will begin to expire in 2040. NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax asset (liability) in the accompanying consolidated balance sheets consists of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets and (liabilities)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net operating losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,303</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,138</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,697</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 295</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 130</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 151</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 666</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 664</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gross deferred tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,947</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,097</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,945)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,083)</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net deferred tax asset</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12)</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred tax liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14)</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net deferred tax asset (liability)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Subsequent ownership changes may further affect the limitation in future years. The Company has not conducted a study to assess whether a change of ownership has occurred or whether there have been multiple changes of ownership since Inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of ownership, as defined by Section 382 and 383 of the Internal Revenue Code, at any time since Inception, utilization of the NOL carryforwards or research and development tax credit carryforwards would be subject to the annual limitations under Section 382 and 383 of the Internal Revenue Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company will recognize both accrued interest and penalties related to uncertain tax positions in income tax expense. As of December 31, 2021, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#8217;s statements of operations. Since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available. As of December 31, 2021, all tax returns remain open.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In response to the COVID-19 pandemic, the Coronavirus Aid, Relief, and Economic Security Act (&#8220;the CARES Act&#8221;), was signed into law in March 2020. The CARES Act lifts certain deduction limitations originally imposed by the Tax Cuts and Jobs Act of 2017 (&#8220;2017 Tax Act&#8221;). Corporate taxpayers may carryback NOLs originating during 2018 through 2020 for up to five years, which was not previously allowed under the 2017 Tax Act. The CARES Act also eliminates the 80% of taxable income limitations by allowing corporate entities to fully utilize NOL carryforwards to offset taxable </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">income in 2018, 2019 or 2020. Taxpayers may generally deduct interest up to the sum of 50% of adjusted taxable income plus business interest income (30% limit under the 2017 Tax Act) for tax years beginning January 1, 2019 and 2020. The CARES Act allows taxpayers with alternative minimum tax credits to claim a refund in 2020 for the entire amount of the credits instead of recovering the credits through refunds over a period of years, as originally enacted by the 2017 Tax Act. The Company notes that these provisions did not have a material impact to the amounts recorded within this footnote.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970586518680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. NET LOSS PER SHARE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table summarizes the computation of basic and diluted net loss per share of the Company (in thousands, except share and per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32,039)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,265)</p></td></tr><tr><td style="vertical-align:bottom;width:74.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average common stock outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,132,610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 791,821</p></td></tr><tr><td style="vertical-align:bottom;width:74.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_7_nAdfS6MEueO81duCm77g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.64)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_-xHMw6Cns0q3G7uP67l6TA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21.80)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company&#8217;s potentially dilutive securities, which include convertible preferred stock, options to purchase common stock and unvested restricted stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible preferred shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 15,736,053</p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,021,799</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,761,062</p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 19,721</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 34,498</p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 200,996</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,242,516</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 17,531,613</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970589977368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RETIREMENT PLAN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>RETIREMENT PLAN</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">RETIREMENT PLAN</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13. DEFINED CONTRIBUTION PLAN</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has a defined-contribution plan under Section 401(k) of the Internal Revenue Code (the &#8220;401(k) Plan&#8221;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. As currently established, the Company is not required to make contributions to the 401(k) Plan. The Company made matching contributions of $0.1 million for the year ended December 31, 2021. No contributions were made for the year ended December 31, 2020.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970583441352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Elevation Oncology Securities Corporation, which was established on November 19, 2021. All significant intercompany balances and transaction have been eliminated in consolidation.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in accordance with GAAP requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company bases its estimates and assumptions on known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accruals for research and development expenses, the valuation of common stock and the assumptions used in the valuation of share-based compensation awards. Changes in estimates are recorded in the period in which they become known. Due to the risks and uncertainties involved in the Company&#8217;s business and evolving market conditions and, given the subjective element of the estimates and assumptions made, actual results may differ from estimated results.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Segment Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available and regularly reviewed by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment, which is the development of precision medicines for patients with genomically defined cancers. All material long-lived assets of the Company reside in the United States.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with an original maturity of three&#160;months or less to be cash equivalents. As of December&#160;31, 2021 and 2020, cash equivalents consisted of money-market funds. The Company places its cash with a high-credit-quality financial institution domiciled in the United States.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of credit risk and significant suppliers</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk and Significant Suppliers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. The Company&#8217;s money market funds are invested in highly rated funds. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents and does not believe that it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is dependent on third-party manufacturers to supply products for research and development activities of its programs, including preclinical and clinical testing. These programs could be adversely affected by a significant interruption in the supply of such drug substance and drug products. During the&#160;year ended December&#160;31, 2021, the Company had two vendors that accounted for approximately 61% of its research and development expense. As of December&#160;31, 2021, the Company had one vendor that accounted for approximately 74% of the total accounts payable. During the&#160;year ended December&#160;31, 2020, the Company had one vendor that accounted for approximately 46% of its research and development expense. The <span style="-sec-ix-hidden:Hidden_oYUMpxFyBEukUJ69xj1Vgw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">same</span></span> vendor also accounted for approximately 95% of the total accounts payable as of December&#160;31, 2020.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Property and equipment consist of computer software that is recorded at cost and depreciated on a straight-line basis over the estimated useful lives of the assets. Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying value of assets may not be recoverable. Recoverability is measured by comparison of the asset&#8217;s book value to future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets. No impairment losses have been recorded through December&#160;31, 2021.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_CloudComputingArrangementPolicyPolicyTextBlock', window );">Cloud Computing Arrangements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cloud Computing Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company defers implementation costs incurred in cloud computing hosting arrangements in accordance with Accounting Standards Update (&#8220;ASU&#8221;) 2018-15 and amortizes these costs over the noncancelable term of the cloud computing arrangement, plus any optional renewal periods (1)&#160;that are reasonably certain to be exercised by the Company or (2)&#160;for which exercises of the renewal option is controlled by the cloud service provider. Costs incurred during the application development stage are capitalized within either prepaid expenses and other current assets, or in other assets, net on the Company&#8217;s balance sheet. Amortization of implementation costs are on a straight-line basis over the related hosting arrangement term and is reflected in research and development expenses in the consolidated statements of operations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_ClassificationAndAccretionOfConvertiblePreferredStockPolicyPolicyTextBlock', window );">Classification and Accretion of Convertible Preferred Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Classification and Accretion of Convertible Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company&#8217;s convertible preferred stock is classified outside of stockholders&#8217; deficit on the balance sheet because the holders of such shares have liquidation rights in the event of a deemed liquidation that, in certain situations, are not solely within the control of the Company and would require the redemption of the then-outstanding convertible preferred stock. The convertible preferred stock is not redeemable, except in the event of a deemed liquidation (see Note&#160;6). Because the occurrence of a deemed liquidation event is not currently probable, the carrying values of the convertible </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">preferred stock are not being accreted to their redemption values. Subsequent adjustments to the carrying values of the convertible preferred stock would be made only when a deemed liquidation event becomes probable. Upon the closing the Company&#8217;s IPO in June 2021, all outstanding convertible preferred stock automatically converted into shares of common stock.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2&#8212;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3&#8212;Non-observable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></td></tr></table><div style="margin-top:12pt;"/><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalCostsPolicyTextBlock', window );">Patent costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The Company's cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note 3).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patent Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The legal and professional costs incurred by the Company to maintain its patent rights have been expensed as part of general and administrative expenses since inception. As of December&#160;31, 2021 and 2020, the Company has determined that these expenses have not met the criteria to be capitalized. Intellectual property-related&#160;expenses for the year ended December&#160;31, 2021 and&#160;2020 were $0.2 million and $0.1 million, respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development costs consist of salaries and benefits, including associated stock-based compensation, and fees paid to other entities that conduct certain research and development activities on the Company&#8217;s behalf. Research and development costs are expensed as incurred. The Company estimates preclinical study and clinical trial expenses based on the services performed pursuant to contracts with research institutions and contract research organizations and clinical manufacturing organizations that conduct and manage preclinical studies and clinical trials on the Company&#8217;s behalf based on actual time and expenses incurred by them. Further, the Company accrues expenses related to clinical trials based on the level of patient activity according to the related agreement. The Company monitors patient enrollment levels and related activity to the extent reasonably possible and adjusts estimates accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the services have been performed or when the goods have been received rather than when the payment is made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to the Company&#8217;s prior estimates of accrued research and development expenses.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company measures stock-based compensation cost at the accounting measurement date based on the fair value of the award and recognizes the expense on a straight-line basis over the requisite service period of the award, which is typically the vesting period. Compensation expense is measured using the fair value of the award at the grant date and is adjusted to reflect actual forfeitures as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company estimates the fair value of stock options using the Black-Scholes option pricing model that takes into account the exercise price, the fair value of the Company&#8217;s common stock, the expected term of the option, the expected volatility of the Company&#8217;s common stock, expected dividends on the Company&#8217;s common stock, and the risk-free interest rate over the expected life of the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Fair value of common stock&#8212;</i>Prior to IPO in June 2021, the Company valued its common stock by taking into consideration its most recently available valuation of common shares performed by management and the board of directors, as well as additional factors which may have changed since the date of the most recent contemporaneous valuation through the date of grant. Upon IPO, the fair value of the Company&#8217;s common stock is determined based on the quoted market price of its common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected term&#8212;</i>The Company uses the simplified method described in the Securities and Exchange Commission Staff Accounting Bulletin Topic 14.D.2 to calculate the expected term as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term for options granted to employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected volatility&#8212;</i>The Company estimates expected volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its traded stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk-free interest rate&#8212;</i>The risk-free rate assumption is based on the U.S. Treasury yield curves whose terms are consistent with the expected term of the stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected dividend&#8212;</i>The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be zero.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient&#8217;s payroll costs or service payments are classified.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss per Common Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s net loss is equivalent to net loss attributable to common stockholders for all periods presented. Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed using the sum of the weighted average number of common shares outstanding during the period and the effect of dilutive securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company applies the two-class method to calculate its basic and diluted net loss per share as the Company has issued shares that meet the definition of participating securities. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. The Company&#8217;s participating securities contractually entitle the holders of such shares to participate in dividends; but do not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the&#160;year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. The Company accounts for uncertainty in income taxes recognized. If the tax position is deemed more likely than not to be sustained, it would then be assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. To date the Company has no uncertain tax positions and there have been no interest and penalties.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Recently issued accounting pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In December 2019, the Financial Accounting Standards Board issued Accounting Standards Update (&#8220;ASU&#8221;) 2019-12, <i style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</i>. Among other items, the amendments in ASU 2019-12 simplify the accounting treatment of tax law changes and year-to-date losses in interim periods. An entity generally recognizes the effects of a change in tax<i style="font-style:italic;"> </i>law in the period of enactment; however, there is an exception for tax laws with delayed effective dates. Under<i style="font-style:italic;"> </i>current guidance, an entity may not adjust its annual effective tax rate for a tax law change until the period in<i style="font-style:italic;"> </i>which the law is effective. This exception was removed under ASU 2019-12, thereby providing that all effects of a<i style="font-style:italic;"> </i>tax law change are recognized in the period of enactment, including adjustment of the estimated annual<i style="font-style:italic;"> </i>effective tax rate. Regarding year-to-date losses in interim periods, an entity is required to estimate its annual<i style="font-style:italic;"> </i>effective tax rate for the full fiscal year at the end of each interim period and use that rate to calculate its income<i style="font-style:italic;"> </i>taxes on a year-to-date basis. However, current guidance provides an exception that when a loss in an interim<i style="font-style:italic;"> </i>period exceeds the anticipated loss for the year, the income tax benefit is limited to the amount that would be<i style="font-style:italic;"> </i>recognized if the year-to-date loss were the anticipated loss for the full year. ASU 2019-12 removes this exception<i style="font-style:italic;"> </i>and provides that in this situation, an entity would compute its income tax benefit at each interim period based<i style="font-style:italic;"> </i>on its estimated annual effective tax rate. ASU 2019-12 is effective for fiscal years beginning after December 15,<i style="font-style:italic;"> </i>2021, with early adoption permitted. The Company has not elected to early adopt ASU 2019-12 and is currently<i style="font-style:italic;"> </i>evaluating the impact the adoption of the standard will have on its financial statements and related disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_ClassificationAndAccretionOfConvertiblePreferredStockPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy relating to classification and accretion of convertible preferred stock policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_ClassificationAndAccretionOfConvertiblePreferredStockPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_CloudComputingArrangementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cloud computing arrangement policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_CloudComputingArrangementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149975-122751<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970586395640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of fair value measurements of financial assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company&#8217;s financial assets subject to fair value measurements on a recurring basis and the level of inputs used for such measurements were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds included in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 106,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 106,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds included in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 76,013</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 76,013</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970586520344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net, consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Useful&#160;Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 71</p></td></tr><tr><td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (33)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15)</p></td></tr><tr><td style="vertical-align:bottom;width:65.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Property and equipment, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 56</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970586478296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>ACCRUED EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued expenses consist of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued preclinical and clinical trial costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 505</p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,059</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 429</p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued consulting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 127</p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28</p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 246</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 17</p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total accrued expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,106</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970584660376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation expense as reflected in the Company&#8217;s consolidated statements of operations was as follows (in thousand):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 244</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 24</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,327</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation expense included in operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 52</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A summary of stock option activity for employee and nonemployee awards under the 2019 and 2021 Plans is presented below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining&#160;Contractual&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term&#160;(years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,761,062</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9.54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 723</p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,309,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (48,663)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,021,799</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,903</p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 680,951</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,437</p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and expected to vest at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,021,799</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,903</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used in estimation of fair value</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The weighted average grant-date fair value of stock options granted during the year ended December&#160;31, 2021 and 2020 was $4.60 and $0.73 per share, respectively. The fair value of each stock option was estimated using a Black-Scholes option-pricing model with the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:33.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.95 - 1.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.2&#8722;0.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">75-77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">74%&#8722;79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_F-nfSSZM0Euu4OQJHKZe8Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3</span></span>&#8722;<span style="-sec-ix-hidden:Hidden_gGMsgb7BgEOGbQEJGMhgkw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of restricted stock units activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes activity related to restricted stock units:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;average</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">grant date</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 200,996</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16.00</p></td></tr><tr><td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 200,996</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16.00</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970586432040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective income tax rate reconciliation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Profit before tax at federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State tax benefit, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credit carryovers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Return to Provision True Ups</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of net deferred tax asset (liability)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax asset (liability) in the accompanying consolidated balance sheets consists of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets and (liabilities)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net operating losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,303</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,138</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,697</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 295</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 130</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 151</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 666</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 664</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gross deferred tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,947</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,097</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,945)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,083)</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net deferred tax asset</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12)</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred tax liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14)</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net deferred tax asset (liability)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970589259352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of computation of basic and diluted net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table summarizes the computation of basic and diluted net loss per share of the Company (in thousands, except share and per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32,039)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,265)</p></td></tr><tr><td style="vertical-align:bottom;width:74.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average common stock outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,132,610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 791,821</p></td></tr><tr><td style="vertical-align:bottom;width:74.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_7_nAdfS6MEueO81duCm77g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.64)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_-xHMw6Cns0q3G7uP67l6TA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21.80)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible preferred shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 15,736,053</p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,021,799</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,761,062</p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 19,721</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 34,498</p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 200,996</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,242,516</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 17,531,613</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970583126664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF BUSINESS - Liquidity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 19, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 29, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Jun. 17, 2021</div></th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Initial Public Offering</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,039<span></span>
</td>
<td class="nump">17,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,186<span></span>
</td>
<td class="nump">23,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=elev_SeriesaAndBConvertiblePreferredStockMember', window );">Series A and Series B convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Initial Public Offering</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,200<span></span>
</td>
<td class="nump">$ 97,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Initial Public Offering</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of shares from conversion of preferred stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,736,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Underwriters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Initial Public Offering</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (in shares) | shares</a></td>
<td class="nump">403,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=elev_SeriesaAndBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=elev_SeriesaAndBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=elev_UnderwritersOfInitialPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=elev_UnderwritersOfInitialPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970589903672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>segment </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>item</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal and professional costs</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest and penalties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_DividendYieldRate', window );">Percentage of dividend yielded</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember', window );">Accounts payable | Major suppliers | Supplier Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_NumberOfMajorVendors', window );">Number of vendors | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Major suppliers | Supplier Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_NumberOfMajorVendors', window );">Number of vendors | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">61.00%<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_DividendYieldRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of dividend yielded</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_DividendYieldRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_NumberOfMajorVendors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of major vendors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_NumberOfMajorVendors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=elev_MajorSuppliersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=elev_MajorSuppliersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970584683384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair value measurements of financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Transfers from Level 1 to Level 2, Assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Transfers from Level 2 to Level 1, Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Transfers into (out of) Level 3, Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair value measurements of financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">106,000<span></span>
</td>
<td class="nump">$ 76,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money Market Funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair value measurements of financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">$ 106,000<span></span>
</td>
<td class="nump">$ 76,013<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970583078632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">$ (33)<span></span>
</td>
<td class="num">$ (15)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=elev_ComputerSoftwareMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=elev_ComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=elev_ComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970584368808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>ACCRUED EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_AccruedPreclinicalAndClinicalTrialCostsCurrent', window );">Accrued preclinical and clinical trial costs</a></td>
<td class="nump">$ 1,260<span></span>
</td>
<td class="nump">$ 505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_AccruedCompensationCurrent', window );">Accrued compensation</a></td>
<td class="nump">1,059<span></span>
</td>
<td class="nump">429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_AccruedConsultingFeesCurrent', window );">Accrued consulting</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services</a></td>
<td class="nump">499<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">246<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 3,141<span></span>
</td>
<td class="nump">$ 1,106<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_AccruedCompensationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for compensation for employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_AccruedCompensationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_AccruedConsultingFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for consulting services. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_AccruedConsultingFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_AccruedPreclinicalAndClinicalTrialCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for preclinical and clinical costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_AccruedPreclinicalAndClinicalTrialCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970584043176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE PREFERRED STOCK (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 10, 2020</div></th>
<th class="th"><div>Jan. 09, 2020</div></th>
<th class="th"><div>Aug. 07, 2019</div></th>
<th class="th"><div>Jul. 12, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,493,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Par value of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=elev_SeriesaConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,450,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Par value of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,183,250<span></span>
</td>
<td class="nump">1,816,750<span></span>
</td>
<td class="nump">5,450,000<span></span>
</td>
<td class="nump">25,183,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_TemporaryEquityIssuePricePerShare', window );">Original issue price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,200<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=elev_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,043,889<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Par value of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">34,043,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,043,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_TemporaryEquityIssuePricePerShare', window );">Original issue price</a></td>
<td class="nump">$ 1.9093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds</a></td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_TemporaryEquityIssuePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share price of temporary equity issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_TemporaryEquityIssuePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=elev_SeriesaConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=elev_SeriesaConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=elev_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=elev_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970586563944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMON STOCK (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>COMMON STOCK.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized | shares</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">86,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_CommonStockNumberOfVotesPerShare', window );">Number of votes per common stock | Vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_CommonStockNumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of votes that each holder of the common stock is entitled to cast.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_CommonStockNumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970583012056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMON STOCK - Initial Public Offering (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 19, 2021</div></th>
<th class="th"><div>Jun. 29, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Initial Public Offering</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,565,320<span></span>
</td>
<td class="nump">19,831,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Initial Public Offering</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of shares from conversion of preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,736,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Underwriters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Initial Public Offering</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (in shares)</a></td>
<td class="nump">403,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=elev_UnderwritersOfInitialPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=elev_UnderwritersOfInitialPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970586691640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in operating expenses</a></td>
<td class="nump">$ 1,571<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in operating expenses</a></td>
<td class="nump">244<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in operating expenses</a></td>
<td class="nump">$ 1,327<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970584090472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Stock incentive plan (Details) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 24, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,309,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=elev_EquityIncentivePlan2021Member', window );">2021 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,160,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remained available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,720,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=elev_EquityIncentivePlan2021Member', window );">2021 Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentageOfAggregateSharesOutstanding', window );">Additional number of shares authorized (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=elev_StockIncentivePlan2019Member', window );">2019 Stock incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Total number of shares authorized</a></td>
<td class="nump">1,483,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,972,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,189,911<span></span>
</td>
<td class="nump">144,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,016,337<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=elev_EmployeeStockPurchasePlan2021Member', window );">2021 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Total number of shares authorized</a></td>
<td class="nump">228,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentageOfAggregateSharesOutstanding', window );">Additional number of shares authorized (as a percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=elev_EmployeeStockPurchasePlan2021Member', window );">2021 Employee Stock Purchase Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Total number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,564,440<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentageOfAggregateSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement, as a percentage of total outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentageOfAggregateSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=elev_EquityIncentivePlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=elev_EquityIncentivePlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=elev_StockIncentivePlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=elev_StockIncentivePlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=elev_EmployeeStockPurchasePlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=elev_EmployeeStockPurchasePlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970584074776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Stock options (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">1,761,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,309,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Cancelled (in shares)</a></td>
<td class="num">(48,663)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">3,021,799<span></span>
</td>
<td class="nump">1,761,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested at end of period (in shares)</a></td>
<td class="nump">680,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at end of period (in shares)</a></td>
<td class="nump">3,021,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 0.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">7.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled (in dollars per share)</a></td>
<td class="nump">3.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in dollars per share)</a></td>
<td class="nump">3.71<span></span>
</td>
<td class="nump">$ 0.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested at end of period (in dollars per share)</a></td>
<td class="nump">1.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest at end of period (in dollars per share)</a></td>
<td class="nump">$ 3.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-average remaining contractual term and Aggregate intrinsic value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at end of period (in years)</a></td>
<td class="text">8 years 11 months 8 days<span></span>
</td>
<td class="text">9 years 6 months 14 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm', window );">Vested at end of period (in years)</a></td>
<td class="text">8 years 4 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest at end of period (in years)</a></td>
<td class="text">8 years 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at beginning of period (in dollars)</a></td>
<td class="nump">$ 723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at end of period (in dollars)</a></td>
<td class="nump">10,903<span></span>
</td>
<td class="nump">$ 723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedIntrinsicValue', window );">Vested at end of period (in dollars)</a></td>
<td class="nump">3,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest at end of period (in dollars)</a></td>
<td class="nump">$ 10,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value of stock options granted</a></td>
<td class="nump">$ 4.60<span></span>
</td>
<td class="nump">$ 0.73<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate intrinsic value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards vested, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970581146040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Assumptions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, Minimum</a></td>
<td class="nump">0.95%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, Maximum</a></td>
<td class="nump">1.35%<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, Minimum</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, Maximum</a></td>
<td class="nump">77.00%<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options vested</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,571<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected remaining weighted-average period for recognition</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970581133256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Early Exercise of Employee Options (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_RestrictedStockRepurchaseLiability', window );">Liability from the early exercise</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,571<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_RestrictedStockRepurchaseLiability', window );">Liability from the early exercise</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_RestrictedStockRepurchaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of restricted stock repurchase liability as on the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_RestrictedStockRepurchaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970583064040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Restricted Stock Units (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,571<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected remaining weighted-average period for recognition</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">200,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at end of period (in shares)</a></td>
<td class="nump">200,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at end of period (in dollars per share)</a></td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected remaining weighted-average period for recognition</a></td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970583503208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSET PURCHASE AND LICENSE AGREEMENTS (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=elev_AssetPurchaseAgreementRelatingToSeribantumabMember', window );">Asset Purchase Agreement relating to Seribantumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Upfront payment</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_CollaborationAndLicenseAgreementsMilestonePaymentsPaid', window );">Milestone payments paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=elev_AssetPurchaseAgreementRelatingToSeribantumabMember', window );">Asset Purchase Agreement relating to Seribantumab | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayable', window );">Milestone payments payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=elev_DyaxAgreementMember', window );">Dyax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_CollaborationAndLicenseAgreementsNoticePeriod', window );">Number of days written prior notice to terminate agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=elev_DyaxAgreementMember', window );">Dyax | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayable', window );">Milestone payments payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=elev_SelexisAgreementMember', window );">Selexis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_CollaborationAndLicenseAgreementsNoticePeriod', window );">Number of days written prior notice to terminate agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_CollaborationAndLicenseAgreementsRoyaltyPaymentsPayable', window );">Royalty payments payable | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_CollaborationAndLicenseAgreementsPercentageOfRoyaltyOnNetSalesOfLicensedProducts', window );">Percentage of royalty on net sales of licensed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=elev_SelexisAgreementMember', window );">Selexis | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayablePerLicensedProduct', window );">Milestone payments payable, per licensed product | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=elev_NIHAgreementMember', window );">National Institute of Health | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayable', window );">Milestone payments payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_CollaborationAndLicenseAgreementsMilestonePaymentsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of development, regulatory and sales milestone payments paid under the collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_CollaborationAndLicenseAgreementsMilestonePaymentsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of development, regulatory and sales milestone payments payable under the collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayablePerLicensedProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of development, regulatory and sales milestone payments payable under the collaboration and license agreements for per licensed product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayablePerLicensedProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_CollaborationAndLicenseAgreementsNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number days of prior written notice to terminate the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_CollaborationAndLicenseAgreementsNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_CollaborationAndLicenseAgreementsPercentageOfRoyaltyOnNetSalesOfLicensedProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty on net sales of licensed products under the collaboration and license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_CollaborationAndLicenseAgreementsPercentageOfRoyaltyOnNetSalesOfLicensedProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_CollaborationAndLicenseAgreementsRoyaltyPaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of royalty payments payable under the collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_CollaborationAndLicenseAgreementsRoyaltyPaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=elev_AssetPurchaseAgreementRelatingToSeribantumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=elev_AssetPurchaseAgreementRelatingToSeribantumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=elev_DyaxAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=elev_DyaxAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=elev_SelexisAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=elev_SelexisAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=elev_NIHAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=elev_NIHAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970586604120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSET PURCHASE AND LICENSE AGREEMENTS - Other Research Arrangements (Details) - Caris Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Other Research Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_CollaborationAgreementTerm', window );">Term of agreement (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_CollaborationAgreementRenewalTerm', window );">Renewal term (in years)</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_CollaborationAgreementRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Renewal term of the collaboration agreement in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_CollaborationAgreementRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_CollaborationAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the collaboration agreement in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_CollaborationAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970586038184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970583067400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of effective income tax rate reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Profit before tax at federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax benefit, net of federal benefit</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credit carryovers</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_EffectiveIncomeTaxRateReconciliationPermanentDifferences', window );">Permanent differences</a></td>
<td class="num">(1.40%)<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUpsPercent', window );">Return to Provision True Ups</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(24.50%)<span></span>
</td>
<td class="num">(22.40%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_EffectiveIncomeTaxRateReconciliationPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_EffectiveIncomeTaxRateReconciliationPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUpsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to return to provision true ups.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUpsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970583098616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 7.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">48.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">3.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970584611048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of net deferred tax asset (liability) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Deferred tax assets and (liabilities)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 10,303<span></span>
</td>
<td class="nump">$ 4,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit</a></td>
<td class="nump">1,697<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued Expenses</a></td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">666<span></span>
</td>
<td class="nump">664<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax asset</a></td>
<td class="nump">12,947<span></span>
</td>
<td class="nump">5,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(12,945)<span></span>
</td>
<td class="num">(5,083)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_elev_DeferredTaxLiabilitiesStockBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">$ (14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized tax benefits, income tax penalties and interest expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elev_DeferredTaxLiabilitiesStockBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from stock-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elev_DeferredTaxLiabilitiesStockBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elev_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970586631704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (32,039)<span></span>
</td>
<td class="num">$ (17,265)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common stock outstanding, basic (in shares)</a></td>
<td class="nump">12,132,610<span></span>
</td>
<td class="nump">791,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common stock outstanding, diluted (in shares)</a></td>
<td class="nump">12,132,610<span></span>
</td>
<td class="nump">791,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (2.64)<span></span>
</td>
<td class="num">$ (21.80)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (2.64)<span></span>
</td>
<td class="num">$ (21.80)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970583946936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Antidilutive securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation (in shares)</a></td>
<td class="nump">3,242,516<span></span>
</td>
<td class="nump">17,531,613<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,736,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation (in shares)</a></td>
<td class="nump">3,021,799<span></span>
</td>
<td class="nump">1,761,062<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation (in shares)</a></td>
<td class="nump">19,721<span></span>
</td>
<td class="nump">34,498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation (in shares)</a></td>
<td class="nump">200,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139970589999192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RETIREMENT PLAN (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>RETIREMENT PLAN</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Matching contributions</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>elev-20211231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:elev="http://www.elevationoncology.com/20211231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="elev-20211231.xsd" xlink:type="simple"/>
    <context id="As_Of_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_EpGg59YM3Eu1afDfRYaHEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_Nqt-0QbioUOT_-2LYCnQeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_9Ab4mylPHU2468ViocO1Kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_n1P4tSrvdk-YvWRGsiNyRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_ufCfvphpqUaFsIu6eQ5ybg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_JVADeYQhFU6aWETRRcQX9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gO4tR77IjkWsJVcz9PCcFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kfgfNyUS-k-q6vIaH3KKEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_17_2021_To_6_17_2021_3W9jop6fm0qg9b5Wd2MRJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
        </entity>
        <period>
            <startDate>2021-06-17</startDate>
            <endDate>2021-06-17</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_cyhJnqE1F0KJ0iWv1_oxBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pt55LruBbU6mC55DMIg-jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0kC6nscYCki9dpypch09Sg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DkD0JhHZk0y1iDRPpYA5Ew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WHl4WL9Hy0eii7jK-CXu0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__MZL6V0mP0KADzeRWa2ESA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_a4fg8WCqfESmafv_THdDEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_M2mN9gE5X0GijbROI6P7SQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A0J2TcXim0O2TZxlcLKsxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_elev_StockIncentivePlan2019Member_FlHgdUrdDkW1Tb42kpCKvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elev:StockIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_elev_EquityIncentivePlan2021Member_kp3FXbetX02QbQ8--SNfwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elev:EquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_elev_EmployeeStockPurchasePlan2021Member_uSn9gG9lvkuJEppuSz4hoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elev:EmployeeStockPurchasePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_elev_StockIncentivePlan2019Member_bUnBFZtU70qdI_31neYSXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elev:StockIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_24_2021_us-gaap_PlanNameAxis_elev_StockIncentivePlan2019Member_g20HiHisykWL0YRlk71tPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elev:StockIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-24</instant>
        </period>
    </context>
    <context id="As_Of_6_24_2021_us-gaap_PlanNameAxis_elev_EmployeeStockPurchasePlan2021Member_Mo21NNEVb02WGxkNxv7paw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elev:EmployeeStockPurchasePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-24</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_1_31_2021_us-gaap_PlanNameAxis_elev_EquityIncentivePlan2021Member_FexWjG0GeEO3y5ruEl4e1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elev:EquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_1_31_2021_us-gaap_PlanNameAxis_elev_EmployeeStockPurchasePlan2021Member_s1Fv3k0-skOD-lgjf_7L1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elev:EmployeeStockPurchasePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2020_To_11_30_2020_us-gaap_PlanNameAxis_elev_StockIncentivePlan2019Member_hYYP-cdGa0eXbji1S01uFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elev:StockIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_elev_StockIncentivePlan2019Member_CdA7QcaLgEakV3EDPTac8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elev:StockIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_5J7V4aHIqEu2qGXL8dmwwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_SJCr4vEUZkeX-7Wij1oC_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_7_19_2021_srt_CounterpartyNameAxis_elev_UnderwritersOfInitialPublicOfferingMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_nGisd7kOYEq_z_1_7FQduw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">elev:UnderwritersOfInitialPublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-19</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_elev_ComputerSoftwareMember_g5ZhoAlXpUqrIOpTarHh5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">elev:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_elev_ComputerSoftwareMember_NaXHz8_kV0qUWe08M_6KyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">elev:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_elev_ComputerSoftwareMember_YpEaJOWw7UCqEhZ5InjBgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">elev:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_11_1_2020_To_11_30_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaAndBConvertiblePreferredStockMember_ge5GjDqHukSVK1DEMyGmNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesaAndBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_7_31_2019_us-gaap_StatementClassOfStockAxis_elev_SeriesaAndBConvertiblePreferredStockMember_SRP5C8kaAkm-e3i0QZ6c-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesaAndBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="Duration_7_19_2021_To_7_19_2021_srt_CounterpartyNameAxis_elev_UnderwritersOfInitialPublicOfferingMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_VUvougWN80i1LCZg4HFYSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">elev:UnderwritersOfInitialPublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-19</startDate>
            <endDate>2021-07-19</endDate>
        </period>
    </context>
    <context id="Duration_6_29_2021_To_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_k4RdvBD3eEmW3XvTBybGKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-29</startDate>
            <endDate>2021-06-29</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_QVkXeAi9dEuUZNo7SoogXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_RFXCBSdsYE2_Vzi1sOOAOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ArLc6smPckCMtFZLqiXo_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_U4BEo4pY0EeqeBvZSRXIWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OZUmi-gHpkqGwGuZU2171Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_AIfL3vjSZUuRhq97AJyp4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_5rOsdDqIEUeymqVgYG3BtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-29</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_K5uh10LQgki3KgNzawcwuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_LOXva3eCSEKs92ak-KtE4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_TTW4gSp3Wk-9JNv7SpMKfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_eDgOSR0ApUCe08Ub8rJKgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_ZJ2eCE9YL0WHbRPPPls1ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_5_1_2019_To_5_31_2019_us-gaap_AssetAcquisitionAxis_elev_AssetPurchaseAgreementRelatingToSeribantumabMember_uhzmSNBzfkm5eBJiG2sU0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">elev:AssetPurchaseAgreementRelatingToSeribantumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_H_M1d8Hn4ki520t7iGj3Ng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_QSMT7xTslESMy-UsUkueuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_WIKQC4DzRE6vI_AOC5-AMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_XBvq6XI_aEGrm9k0W47ISg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_a5d4Y0z3Nk-SAUzQFRv89w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_eKa9OMO3pEGjRYGCoRthgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JBR44UJY20idUxeLVpC0GQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_deAfjK4lqEmKMKksWWn-jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_X-9TCZuQqkap_YeDihjLvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_O_Q119ip30KfTfvFf993FA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qMQDBx_zA0eapJGtZe8uZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_YAEGuEqxPEKdKNDxES3Gxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_xsmSF0gpPU6amqdGOgrEEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_1KlIt4aZN0KI7qkDnMhwtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_W0whaLuINkuS-MK09HdSLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T74WweuKoEO37FYC4NVKJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TK-bm7aGUEm31cUm-csY2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_10_2020_To_11_10_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_v3BvBhMCkkChJbjcubxA5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-10</startDate>
            <endDate>2020-11-10</endDate>
        </period>
    </context>
    <context id="Duration_1_9_2020_To_1_9_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_gs0XV9bVfEqDcewwWOI9VQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-09</startDate>
            <endDate>2020-01-09</endDate>
        </period>
    </context>
    <context id="Duration_8_7_2019_To_8_7_2019_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_jTYrUmLmVka6PZ8r-YiTkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-07</startDate>
            <endDate>2019-08-07</endDate>
        </period>
    </context>
    <context id="Duration_7_12_2019_To_7_12_2019_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_CRrBhd5h4UWKceI00MOZ2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-12</startDate>
            <endDate>2019-07-12</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_aX2mfIiaaEaEvfSZZi_QiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_VfF2WbD_yE25ScPehNSjmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_11_10_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_CnPFfpHmG0CJMvYDja99aQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-10</instant>
        </period>
    </context>
    <context id="As_Of_7_12_2019_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_2gzfDx_IOkyEVrvBv9B-8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-12</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_8x_tfsc7QkmeVVMEESIfJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_FwKWSVbO8EC5cGAemvMKBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elev:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_24_2021_To_6_24_2021_us-gaap_PlanNameAxis_elev_EmployeeStockPurchasePlan2021Member_ZFyW0T1vXkWCriwlsXAY-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elev:EmployeeStockPurchasePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-24</startDate>
            <endDate>2021-06-24</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_elev_EquityIncentivePlan2021Member_xaj81EG8zUqzxS8PpL1PjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elev:EquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_Hc0jKnnQ5EKY8gQMK3Ryuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_4iKy94V-6UeB5pmDG5OepA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_elev_MajorSuppliersMember_Lus3zfRWB02sxkyeP9gCsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">elev:MajorSuppliersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsPayableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_elev_MajorSuppliersMember_Coj20v2H-ESbqbb3ODw3Ng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">elev:MajorSuppliersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_elev_MajorSuppliersMember_NVyNryv-ik-_fhgfb89hIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">elev:MajorSuppliersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsPayableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_elev_MajorSuppliersMember_ocGPhsn9x0qpuSJ02J9oBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">elev:MajorSuppliersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AssetAcquisitionAxis_elev_SelexisAgreementMember_p3VwQWadQ02foloetZBlYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">elev:SelexisAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AssetAcquisitionAxis_elev_DyaxAgreementMember_cqZbVZ2gh06l0lshIvlOdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">elev:DyaxAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AssetAcquisitionAxis_elev_SelexisAgreementMember_-Up5XNit8UCwOaN4IdjeDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">elev:SelexisAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AssetAcquisitionAxis_elev_NIHAgreementMember_I6LRl9X8GkOusRfsCtA2GQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">elev:NIHAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AssetAcquisitionAxis_elev_DyaxAgreementMember_TIOCbS27gU2NoUyO8PZbQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">elev:DyaxAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AssetAcquisitionAxis_elev_AssetPurchaseAgreementRelatingToSeribantumabMember_tQNsHiiyPk60TadASippIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">elev:AssetPurchaseAgreementRelatingToSeribantumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AssetAcquisitionAxis_elev_AssetPurchaseAgreementRelatingToSeribantumabMember_5HWpL8YS1E2KOC6PDwU83A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">elev:AssetPurchaseAgreementRelatingToSeribantumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AssetAcquisitionAxis_elev_AssetPurchaseAgreementRelatingToSeribantumabMember_6okAWYA92EqLCivJwShcTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">elev:AssetPurchaseAgreementRelatingToSeribantumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_sZb_K3th-kWfL5-YVdEe1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_jS2k487EQUu-QYmxTZAUcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_2_28_2022_0iopzwH18EKRlw9y-_pRlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783032</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_EUR_QZ9PiilgBE2N3HwLp8Y6Lg">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_Vote_IYKGbYhrlUq08si1HNSWpQ">
        <measure>elev:Vote</measure>
    </unit>
    <unit id="Unit_Standard_item_P9iWedWUGEOmRWtbpyYLhQ">
        <measure>elev:item</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_segment_tfgErmtCo0qqRPYk0GJOUQ">
        <measure>elev:segment</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      id="Hidden_K13RrqlPFE27bIg-y8uIZQ"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      id="Hidden_HoXiDjL9KUya9PanvcAhGA"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      id="Hidden_IihsC53kEkWt42Ha6e4idQ"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      id="Hidden_gbc1ZDXcAEe99kedebE1CQ"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="INF"
      id="Hidden_R2buor0_jUO0guY27S8VsA"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">12132610</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="INF"
      id="Hidden_BqZZNrCzsUOWgY-YXUKdWg"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">791821</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="2"
      id="Hidden_7_nAdfS6MEueO81duCm77g"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">-2.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="2"
      id="Hidden_-xHMw6Cns0q3G7uP67l6TA"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">-21.80</us-gaap:EarningsPerShareDiluted>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_ufCfvphpqUaFsIu6eQ5ybg"
      decimals="INF"
      id="Hidden_ku6MkFaccUqqx_e6Z90U5A"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">32450000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_9Ab4mylPHU2468ViocO1Kw"
      decimals="INF"
      id="Hidden_ZzptvVV4KkGo2T3C4NAYcA"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_ufCfvphpqUaFsIu6eQ5ybg"
      decimals="INF"
      id="Hidden_HJjRn8vxqEqc62bzyHayHw"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">32450000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_Nqt-0QbioUOT_-2LYCnQeA"
      decimals="INF"
      id="Hidden_MhBVK9CA4ECtG86DjvMagA"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_n1P4tSrvdk-YvWRGsiNyRQ"
      decimals="INF"
      id="Hidden_n2xdQHC12k-aBNJhOd4IKQ"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">34043889</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_Nqt-0QbioUOT_-2LYCnQeA"
      decimals="INF"
      id="Hidden_qssCogmpFkSc9bE3w614Fw"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_n1P4tSrvdk-YvWRGsiNyRQ"
      decimals="INF"
      id="Hidden_srDnmenbtUiFZLni5r2PKw"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">34043889</us-gaap:TemporaryEquitySharesIssued>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tc_5nGLAUE2rU6TAKy5hXTqOg_2_1">0001783032</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tc_o3eQF_L8N0OqtIr3RfmLpw_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tc_mlovOEvAMUqbRF8xlg7E2Q_4_1">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tc_OCi8xxSZfEOI8bfebf95ew_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Narr_RALZcJuwKE6aiFgL8kS8fQ">false</dei:AmendmentFlag>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_6_17_2021_To_6_17_2021_3W9jop6fm0qg9b5Wd2MRJg"
      decimals="4"
      id="Hidden_z6l6dXmz8E6xGt27fFRfuQ"
      unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw">0.2367</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Hidden_TDI7DkXArkaTliVYX6vraA"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-3"
      id="Hidden_JCM5oP1UqkKdMGQnvJ6z0g"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="INF"
      id="Hidden_wqu_jCGum0WRLQslcXomKg"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="INF"
      id="Hidden_UQWf1rcSfkun50qyxX6iDQ"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_9Ab4mylPHU2468ViocO1Kw"
      decimals="INF"
      id="Hidden_jYWxfVIF5k6FxM1xOsAXqg"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="2"
      id="Hidden_lgQGmvAd0kSfoX9eaEYLrw"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">-2.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="2"
      id="Hidden_qV_WDEPC70Od3Xq9E6kzvw"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">-21.80</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="0"
      id="Hidden_2IktuLtwpEq_DQqGsb7Oow"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">12132610</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="0"
      id="Hidden_ZVTobD-be0Gfz_GRdyN0kw"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">791821</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <elev:NumberOfMajorVendors
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsPayableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_elev_MajorSuppliersMember_ocGPhsn9x0qpuSJ02J9oBA"
      decimals="INF"
      id="Hidden_oYUMpxFyBEukUJ69xj1Vgw"
      unitRef="Unit_Standard_item_P9iWedWUGEOmRWtbpyYLhQ">1</elev:NumberOfMajorVendors>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_5J7V4aHIqEu2qGXL8dmwwg"
      id="Hidden_F-nfSSZM0Euu4OQJHKZe8Q">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_SJCr4vEUZkeX-7Wij1oC_Q"
      id="Hidden_gGMsgb7BgEOGbQEJGMhgkw">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <dei:DocumentType
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Narr_giofxSKi7E6tj13AimfsUA">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Narr_KjIRybTGPESS95iFaRy_pw">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Narr_ORKcESvs2UKL5ipbae1eXA">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Narr_5tBYze1xKkyBIuH9wSc3aQ">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Narr_XMk6MC5fN0qtDvxLeViydQ">001-40523</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Narr_ULiShuh5k0ujGkvzUzSaZw">ELEVATION ONCOLOGY,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tc_RWYltIqTz0iKVH1PZh79ng_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tc_mZn7Hnk9EUuTThtmtkDhRw_1_1">84-1771427</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Narr_FhvMK5G9tE25bjjvDgaA0g">888 Seventh Ave, 12th Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Narr_GIwWapLXCEqpaYxThhMU3w">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Narr_4EjsTjn0I0edfxCgqeB61A">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tc_BfpGf5tyikW_F3JMaVo4gg_3_1">10106</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Narr_3CfmxA6PnkqCk94KXiFshw">716</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Narr_OrxEkVnm-UyBVOnvcpQcwQ">371-1125</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Narr_90yKaRo6ikC4t0c92pLrEg">Common stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Narr_BTYqdpAEU0Ou3gaiQqUqQA">ELEV</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Narr_k4_AE7s6tUqQhOYEl7lW6w">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Narr_jWsKjNLZ40iQGWRhEdf3CA">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Narr_YtrP4Ed12E-G7aLRfTQiyg">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Narr_drpQVD4kUEODFsKqR3q7lA">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Narr_tK9UQceJ9EGyp9e_tbTjdw">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Narr_aHaRI5UGSUqWaOSeJoBI9g">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Narr_hyfo7n8cN0e0j_Th-Lq4rQ">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Narr_DXsYmlbIO0KfQ2swamYYJw">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Narr_b3zDsfsLWEOkDNn0q3mI9g">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Narr_M8XVfPGisECa0_FRFJj7lw">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Narr_BsXhi5EFLUSuZb7J139iiw">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2021_jS2k487EQUu-QYmxTZAUcw"
      decimals="-5"
      id="Narr_TcP3IEUDNUSlJg_hFaCsyw"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">210600000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_2_28_2022_0iopzwH18EKRlw9y-_pRlw"
      decimals="INF"
      id="Narr_dEpiw9I8X0KRMe_Z6GUE7A"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">23205915</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Narr_rCj4RaxrMkiA2-BVHg6tXQ">CohnReznick LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Narr_W4lJdwPBzUCCyGHa7lyQkg">Tysons, Virginia</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Narr__VZtWaqKg0iODX1Tg9QQ_g">596</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_nG5z3mN37EyefMy5ZfQiAg_5_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">146284000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_LJaTNmpyOU6gK1r_GPB0CA_5_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">79400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_YKLSgEGe8E2of040Vf1r-g_6_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">3140000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_Myh9lWmf_0-Fya6ql2yzRA_6_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">1386000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_YXcp02afzE6qoiLTtpa4kA_7_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">149424000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_MlJcqhODukupFmjJz-YTEA_7_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">80786000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_0SYgRvHM_kCxQrKXtnhg4A_8_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">38000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_JP7TSh5gTUy40NKbVuurFg_8_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">56000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_4Tx2SjWxsEeXeJUnOpw_Hw_9_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">32000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_EjSfjUuyyECLFuzju4wefQ_9_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">65000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_f09nQ7_0pEmLYbkyhrY8ng_10_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">149494000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_iXTmKziVuUuiZ8IPMdPBxw_10_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">80907000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_V639oK5jUEGiTiH8MUyadg_13_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">5648000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_QNpoRnK3gUmtRfiJQRIcvg_13_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">5679000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_0Kq_ulxgEkSyt7Ro-Ydk_Q_14_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">3141000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_IFdLu2OdnUuCmQgA6TrN6w_14_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">1106000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_CG9RzXMKYE2g6dDhQDf09g_15_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">8789000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_Oc3qvXdiY0m9Tw_8vPzC2A_15_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">6785000</us-gaap:LiabilitiesCurrent>
    <elev:RestrictedStockRepurchaseLiability
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_TRYBzT5MCkOGXBRzXnw7hw_17_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">8000</elev:RestrictedStockRepurchaseLiability>
    <elev:RestrictedStockRepurchaseLiability
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_cd4GmOB6eUWW-S5po0iCtw_17_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">15000</elev:RestrictedStockRepurchaseLiability>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_ZUXHUlWNOEyviJu3K7HuLA_18_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">8797000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_PICU933FPkKE3g4jFgd8Lg_18_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">6800000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_ufCfvphpqUaFsIu6eQ5ybg"
      decimals="INF"
      id="Narr_NwDcs_WRJUGG_fLhYSVqrQ"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_9Ab4mylPHU2468ViocO1Kw"
      decimals="INF"
      id="Narr_GmVz-xyAC0qi7KzdEKzJbg"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_9Ab4mylPHU2468ViocO1Kw"
      decimals="INF"
      id="Narr_Fq_sQamRqEaPY8V_RLNNyA"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_ufCfvphpqUaFsIu6eQ5ybg"
      decimals="INF"
      id="Narr_03JK3HwQ0ESsHoNgg_fpSw"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">32450000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_9Ab4mylPHU2468ViocO1Kw"
      decimals="-3"
      id="Narr_fXLx6eQ8s0edqQTgahobWw"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">0</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_ufCfvphpqUaFsIu6eQ5ybg"
      decimals="-3"
      id="Narr_47EgtFN5jkKYehPCwG3HCA"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">32450000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_ufCfvphpqUaFsIu6eQ5ybg"
      decimals="-3"
      id="Tc_yg-eevbPu0KrJJVHOzYzjw_20_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">32373000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_n1P4tSrvdk-YvWRGsiNyRQ"
      decimals="INF"
      id="Narr_LvnW26OOlkilG4_atU9L2Q"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_Nqt-0QbioUOT_-2LYCnQeA"
      decimals="INF"
      id="Narr_PiT9Zht4c0Wt7VIiSmisAg"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_Nqt-0QbioUOT_-2LYCnQeA"
      decimals="INF"
      id="Narr_YadOFy0h70KkItKARcIWqw"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_n1P4tSrvdk-YvWRGsiNyRQ"
      decimals="INF"
      id="Narr_fqoWWFvUnEqUyHgUj7sp7g"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">34043889</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_Nqt-0QbioUOT_-2LYCnQeA"
      decimals="-3"
      id="Narr_xjE9gkIOyEq6rjZlmZVt8Q"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">0</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_n1P4tSrvdk-YvWRGsiNyRQ"
      decimals="-3"
      id="Narr_MmAlySQ0cEmL_s5D5JAgtg"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">65000000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_n1P4tSrvdk-YvWRGsiNyRQ"
      decimals="-3"
      id="Tc_Jzwv04WVHE285xg1dogvzg_21_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">64815000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="INF"
      id="Narr_Cniyh7uXU0qYOSQx2bNUgg"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="INF"
      id="Narr_8bHodJkgcE-FwpiKboBZJQ"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="INF"
      id="Narr_1yGerr0iGUmTaij6uEYVAA"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="INF"
      id="Narr_lkSJB1-WnEe-vN1HSQBOyw"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="INF"
      id="Narr_BZ83hEzkgUijA5-hePLQ1w"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="INF"
      id="Narr_ATMDzk3mpUW7Sp54Mm-6bw"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="INF"
      id="Narr_KN-9J-vEoUyh1bHqlRztUA"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="INF"
      id="Narr_0Cs-feBSsEalpNgRVISd1w"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="INF"
      id="Narr_EMxcWQJH90yfge4m_JlbEw"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="INF"
      id="Narr_TNBRyo5tcUKytNRqY5z7fA"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">86000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="INF"
      id="Narr_KWaVoSuoQUuyie8dFHYneg"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">23225637</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="INF"
      id="Narr_QRQ16rMtl0-140XAiSC4vw"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">836177</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="INF"
      id="Narr_Mf9bAnvK0kyZDWwgntuwrA"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">23205915</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="INF"
      id="Narr_e_R_MdnT3UO95ekLQYQRfw"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">800679</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_ORvR4ZJqJkaMnsXnMJWu_Q_24_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">2000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_EjylD-OB5EmJZK_c6wn1CQ_25_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">195881000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_WKXnxfdWEU2eAu7orCMWtw_25_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">66000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_xCrlj9nvgE61F2AAgLxRFA_26_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">-55186000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_6eREsNq43keDfL3MXQ3n3Q_26_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">-23147000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_siA-qpOgOUCDuNtvwsJRAw_27_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">140697000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_2F64kR6urUSH6YP69SuMJw_27_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">-23081000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_rHeHt3rXCEaX2Hsk9h-zvg_28_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">149494000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_DMnd0JJ0XU-E-HQuU-wSTg_28_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">80907000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-3"
      id="Tc_uXqcQl_Ktkq5ch6_XDOomA_4_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">23595000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-3"
      id="Tc_VktptJyVs0O7Ng34HAewBQ_4_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">15476000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-3"
      id="Tc_E8a3fi2PH0yLGUFRHeLcIQ_5_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">8451000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-3"
      id="Tc_HJiTsoGmEkycA4qM0iFPWQ_5_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">1800000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-3"
      id="Tc_m7FLW1d9I0O3WFP6-UFlGQ_6_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">32046000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-3"
      id="Tc_bX5ZVQ9qOU6hB6jG7WfHyA_6_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">17276000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-3"
      id="Tc_UKagIP6ZakiZubLCTVqzYg_7_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">-32046000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-3"
      id="Tc_mxei62BZM0yxMKIGfVOnUQ_7_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">-17276000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-3"
      id="Tc_3XfjQTBv5U2O8T7uMDJZMw_8_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">7000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-3"
      id="Tc_0OIcy9CMO0mA9DSJLXW6sA_8_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">11000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-3"
      id="Tc_d3xNlPGXwUOIxSC9Z3wnxw_9_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">-32039000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-3"
      id="Tc_WsXbQw0QBEeF3fiqgnpUlw_9_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">-17265000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="2"
      id="Tc_myexe0Bt1kK-l4HXd7ylZg_10_3"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">-2.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="2"
      id="Tc_nGm09ovQDkuM-DzgIQXOpQ_10_6"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">-21.80</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="0"
      id="Tc_OrMEB2VTxUGrtl3RHkWMVg_11_3"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">12132610</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="0"
      id="Tc_KOT3tYEIsUqzGSzjvOjKuw_11_6"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">791821</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_JVADeYQhFU6aWETRRcQX9A"
      decimals="INF"
      id="Tc_6lO1mqiy50-zbvF0d71pLg_4_2"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">7266750</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_JVADeYQhFU6aWETRRcQX9A"
      decimals="-3"
      id="Tc_gDw499TFAUq9Orjhk5AArw_4_5"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">7190000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A0J2TcXim0O2TZxlcLKsxQ"
      decimals="INF"
      id="Tc_d1MPjqJAGkGvsrnDklz2jw_4_12"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">788847</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__MZL6V0mP0KADzeRWa2ESA"
      decimals="-3"
      id="Tc_vfdnvPeFjUai3IR8POGuLw_4_18"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WHl4WL9Hy0eii7jK-CXu0g"
      decimals="-3"
      id="Tc_N60p0sWl_EqyXgXBDM4V-w_4_21"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">-5882000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_K5uh10LQgki3KgNzawcwuw"
      decimals="-3"
      id="Tc_CHbhbLHZ6USyB_OrYTsABA_4_24"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">-5873000</us-gaap:StockholdersEquity>
    <elev:TemporaryEquityStockIssuanceCosts
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_VfF2WbD_yE25ScPehNSjmg"
      decimals="-3"
      id="Narr_8zfAUOBm0EmTrLKifbg1pg"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">0</elev:TemporaryEquityStockIssuanceCosts>
    <elev:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_VfF2WbD_yE25ScPehNSjmg"
      decimals="INF"
      id="Tc_tygl-G67wUCJ5d6_XVhagw_5_2"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">25183250</elev:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_VfF2WbD_yE25ScPehNSjmg"
      decimals="-3"
      id="Tc_GmguQdGQr0KG7KH-qvq3xQ_5_5"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">25183000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <elev:TemporaryEquityStockIssuanceCosts
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_aX2mfIiaaEaEvfSZZi_QiA"
      decimals="-3"
      id="Narr_cA17ntlhvkaVMPX0Bjm6Ew"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">185000</elev:TemporaryEquityStockIssuanceCosts>
    <elev:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_aX2mfIiaaEaEvfSZZi_QiA"
      decimals="INF"
      id="Tc_uqsGBLXdIUut8kD8wyeLdA_6_7"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">34043889</elev:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_aX2mfIiaaEaEvfSZZi_QiA"
      decimals="-3"
      id="Tc_2UgGKDZoIUSxoNe0UfbAIA_6_10"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">64815000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TK-bm7aGUEm31cUm-csY2Q"
      decimals="-3"
      id="Tc_fLVXetBDUkOVlyfHcTFluw_7_18"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">52000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-3"
      id="Tc_zZ8RSRzH7U67IoixyduqXQ_7_24"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">52000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gO4tR77IjkWsJVcz9PCcFw"
      decimals="INF"
      id="Tc_1BubEq7Rk0OjaleQsIZtKQ_8_12"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">11832</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TK-bm7aGUEm31cUm-csY2Q"
      decimals="-3"
      id="Tc_ASvIKCGB20Wv65_vMcLAVQ_8_18"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">5000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-3"
      id="Tc__zqi46g8d0uOzrWWfJa1kw_8_24"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">5000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_U4BEo4pY0EeqeBvZSRXIWg"
      decimals="-3"
      id="Tc_vgJwj7otAEC1PIx77MeqTw_9_21"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">-17265000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-3"
      id="Tc_90r2_AgQd0ClG8yWctsoVA_9_24"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">-17265000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_ufCfvphpqUaFsIu6eQ5ybg"
      decimals="INF"
      id="Tc_vACIzXihv02WLHHwa1j7VQ_10_2"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">32450000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_ufCfvphpqUaFsIu6eQ5ybg"
      decimals="-3"
      id="Tc_tgxsDRjYkkm3VULEllMlfw_10_5"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">32373000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_n1P4tSrvdk-YvWRGsiNyRQ"
      decimals="INF"
      id="Tc_v_1rlEcuREGgasBqX9FI-Q_10_7"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">34043889</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_n1P4tSrvdk-YvWRGsiNyRQ"
      decimals="-3"
      id="Tc_3q8v6Tnxzku9jdUYNWnxdg_10_10"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">64815000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_M2mN9gE5X0GijbROI6P7SQ"
      decimals="INF"
      id="Tc_4-lZuMzspUG449umlqVYbA_10_12"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">800679</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DkD0JhHZk0y1iDRPpYA5Ew"
      decimals="-3"
      id="Tc_J9r5L83W0kSlFgM6pTb2dA_10_18"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">66000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0kC6nscYCki9dpypch09Sg"
      decimals="-3"
      id="Tc_ipczM0mTt06TCJ5wfse11Q_10_21"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">-23147000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_Pk1O57aKXUy68Wirx8Jghw_10_24"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">-23081000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kfgfNyUS-k-q6vIaH3KKEQ"
      decimals="INF"
      id="Tc_CRjFHq7370aKKMEwFacHoA_11_12"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">15776</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T74WweuKoEO37FYC4NVKJA"
      decimals="-3"
      id="Tc_b1J1DGnq-UeN2v_5E01vDQ_11_18"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">7000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-3"
      id="Tc_gQGyf7i6Z0ORmD2CAe8CRg_11_24"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">7000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T74WweuKoEO37FYC4NVKJA"
      decimals="-3"
      id="Tc_umdxOVsJnE67gH-25LDrDw_12_18"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">1571000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-3"
      id="Tc_eGJzP8ASA0eYxCPDhxlbag_12_24"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">1571000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <elev:TemporaryEquityEliminationOfSharesAsPartOfInitialPublicOffering
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_FwKWSVbO8EC5cGAemvMKBw"
      decimals="INF"
      id="Tc_6oVQ9aDqr0W_FPq9pNdfjg_13_2"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">32450000</elev:TemporaryEquityEliminationOfSharesAsPartOfInitialPublicOffering>
    <us-gaap:TemporaryEquityEliminationAsPartofReorganization
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_FwKWSVbO8EC5cGAemvMKBw"
      decimals="-3"
      id="Tc_77insxl0Z0ypDDtfQ0bZQA_13_5"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">32373000</us-gaap:TemporaryEquityEliminationAsPartofReorganization>
    <elev:TemporaryEquityEliminationOfSharesAsPartOfInitialPublicOffering
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_8x_tfsc7QkmeVVMEESIfJw"
      decimals="INF"
      id="Tc_XHK9xPUOZk6zdXZw6swoHg_13_7"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">34043889</elev:TemporaryEquityEliminationOfSharesAsPartOfInitialPublicOffering>
    <us-gaap:TemporaryEquityEliminationAsPartofReorganization
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_8x_tfsc7QkmeVVMEESIfJw"
      decimals="-3"
      id="Tc_9DJR1gYcTEyJ16Sj80ppsg_13_10"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">64815000</us-gaap:TemporaryEquityEliminationAsPartofReorganization>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kfgfNyUS-k-q6vIaH3KKEQ"
      decimals="INF"
      id="Tc_xllsC-6rYE6-vgMd8ohZdw_13_12"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">22389460</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kfgfNyUS-k-q6vIaH3KKEQ"
      decimals="-3"
      id="Tc_abxdcySv70uxn_-8dTjR3g_13_15"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T74WweuKoEO37FYC4NVKJA"
      decimals="-3"
      id="Tc_JLflK-2EC0WAsApWbvv7ng_13_18"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">194237000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-3"
      id="Tc_dhyTbM3vvkuO-i7P_ZjaYQ_13_24"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">194239000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ArLc6smPckCMtFZLqiXo_Q"
      decimals="-3"
      id="Tc_-yXByw31FEq84al1sINcyA_14_21"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">-32039000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-3"
      id="Tc_3mqyw2HjRU-FvKGk80fcqw_14_24"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">-32039000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_a4fg8WCqfESmafv_THdDEw"
      decimals="INF"
      id="Tc_1thh4ids4UWBcJ78SvVfxw_15_12"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">23205915</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_a4fg8WCqfESmafv_THdDEw"
      decimals="-3"
      id="Tc_n-rsxXuCPE6d7U26KBXSaQ_15_15"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pt55LruBbU6mC55DMIg-jw"
      decimals="-3"
      id="Tc_RpScpYrZs0yrlnf4SDD9MQ_15_18"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">195881000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_cyhJnqE1F0KJ0iWv1_oxBQ"
      decimals="-3"
      id="Tc_twD8cWqZlE221352-ObPVQ_15_21"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">-55186000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_rqoqjGFqq0GZ2kOUFQ-xBA_15_24"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">140697000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-3"
      id="Tc_6fp1qcuRykmOt1M7YXIvmA_4_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">-32039000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-3"
      id="Tc_-SGJ16KC50y1nM94nyLP9g_4_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">-17265000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-3"
      id="Tc_ITHMMMQPiEWhs7xeXqXivA_6_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">1571000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-3"
      id="Tc_DGVMiJL8xUahS_alo_Y28w_6_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">52000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-3"
      id="Tc_izTvjez4Q0OvofBB3MvwZg_7_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">18000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-3"
      id="Tc_YLktkVvHpEiQoRX2qoTOiA_7_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">15000</us-gaap:Depreciation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-3"
      id="Tc_enbnTHqFEUSIB-ho6g4KPQ_9_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">1722000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-3"
      id="Tc_KAvgnOuk0061rUXyNijZ1Q_9_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">1212000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-3"
      id="Tc_cpv0ctwDoECNVNcfpFolBA_10_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">65000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-3"
      id="Tc_0QiamoTpaE24VwHYs8nx4A_11_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">-30000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-3"
      id="Tc_EWyNKWkm60Gt2bAOfRkEZw_11_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">5219000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-3"
      id="Tc_RRFs00H5-EyiESVGUy8asQ_12_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">2035000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-3"
      id="Tc_0FToWl9w3UWVpjoPYL6b2A_12_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">958000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-3"
      id="Tc_iC4pTO4anEqDLVuvD5DyDA_13_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">-30167000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-3"
      id="Tc_BygnTG6zlkKcWC7cNiB9rw_13_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">-12298000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-3"
      id="Tc_rpKeDdNnVk6Me52RFVEl6A_15_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">71000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-3"
      id="Tc_fVHUJcCz_E-vBtg2Zwr1Iw_16_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">-71000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <elev:ProceedsFromIssuanceOfRestrictedCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-3"
      id="Tc_KxnKKRWNOUqyYeJ7_4Nh3Q_18_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">20000</elev:ProceedsFromIssuanceOfRestrictedCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-3"
      id="Tc_44RKiySAukuhID8wVlk6_g_19_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">97062000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-3"
      id="Tc_Fx9l58g6ZEKPIkzAZzHTQg_20_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">90183000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-3"
      id="Tc_m_--YUP2Z0uCHyEjOd0NdA_21_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">11000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-3"
      id="Tc_egeEyO8LwEqlzu_s_io1KQ_21_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">174000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-3"
      id="Tc_jnvk7pk8iUKQ6pSZ6FKeEA_22_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">97051000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-3"
      id="Tc_PYfzXhe28kanvOLWBpQg1Q_22_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">90029000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-3"
      id="Tc_MY9oxjYlbU-BV02P71Fz7w_23_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">66884000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-3"
      id="Tc_qFO1Ai1JQkaw5KlalYOypw_23_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">77660000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_geYINy0V4U2WkPM67XZY1Q_24_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">79400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_K5uh10LQgki3KgNzawcwuw"
      decimals="-3"
      id="Tc_yHumy77nHky7iEmu82facg_24_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">1740000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_G7V5l_zcOUe_h3o0BYI3_A_25_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">146284000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_hC5BfGfbzEeMWGKKpJlJHw_25_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">79400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <elev:IssuanceCostsIncludedInAccruedExpenses
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-3"
      id="Tc_-YOo5ud_d0K6yGQ6Mrnxsg_27_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">11000</elev:IssuanceCostsIncludedInAccruedExpenses>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-3"
      id="Tc_RMpCzRRjUE-UhaBA3nMrKQ_28_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">97188000</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_dfY4NWtV1UWS_SE_hVX-hg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;1. NATURE OF BUSINESS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Elevation Oncology,&#160;Inc. (the &#x201c;Company&#x201d; or &#x201c;Elevation&#x201d;), which was formerly known as 14ner,&#160;Inc., was incorporated under the laws of the State of Delaware on April&#160;29, 2019 (&#x201c;Inception&#x201d;). The Company is a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers. The Company acquired its lead product candidate, seribantumab, pursuant to an asset purchase agreement executed with Merrimack Pharmaceuticals,&#160;Inc. (the &#x201c;previous sponsor&#x201d;) during the period ended December&#160;31, 2019 (see Note&#160;9). Seribantumab has been shown preclinically to inhibit tumor growth driven by NRG1 fusions and is currently being tested in the Company&#x2019;s Phase&#160;2 CRESTONE clinical trial for patients with tumors of any origin that have an NRG1 fusion. The Company is actively evaluating opportunities for pipeline expansion including prioritizing additional targeted therapy approaches in tumor types defined by genomic driver alterations.&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:12pt 0pt 12pt 0pt;"&gt;Risks and Uncertainties&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure, and extensive compliance-reporting capabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;There can be no assurance that the Company&#x2019;s research and development of its product candidates will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The current COVID-19 pandemic has presented a substantial public health and economic challenge around the world and is affecting our employees, patients, communities and business operations, as well as contributing to significant volatility and negative pressure on the U.S. economy and in financial markets. The extent of the impact of COVID-19 on the Company&#x2019;s operational and financial performance will continue to depend on certain developments, including the duration and spread of the outbreak, new variants, the vaccination and booster rate, impact on the Company&#x2019;s clinical studies, employee or industry events, and effect on our suppliers and manufacturers, all of which are uncertain and cannot be predicted. COVID-19 has not had a significant impact on the operations or financial results of the Company to date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Liquidity &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In July 2019 and November 2020, the Company received gross proceeds of $97.2 million from the issuance and sale of its Series A and Series B convertible preferred stock (see Note 6).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On June 17, 2021, the Company effected a 1.0 for &lt;span style="-sec-ix-hidden:Hidden_z6l6dXmz8E6xGt27fFRfuQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;4.225582&lt;/span&gt;&lt;/span&gt; reverse stock split of its issued and outstanding shares of common stock and proportional adjustment to the existing conversion ratios for each series of the Company&#x2019;s convertible preferred stock (see Note 6). Accordingly, all share and per share amounts for all periods presented in the accompanying consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this reverse stock split and adjustment of the preferred stock conversion ratios.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On June 29, 2021, the Company closed its initial public offering (&#x201c;IPO&#x201d;) and issued 6,250,000 shares of its common stock at a price of $16.00 per share for net proceeds of $91.1 million, after deducting underwriting discounts and commissions and expenses of $8.9 million. In connection with the IPO, all shares of Series A and Series B convertible preferred stock converted into 15,736,053 shares of common stock. On July 19, 2021, in connection with the Company&#x2019;s IPO, the underwriters exercised the right to purchase 403,407 shares of the Company&#x2019;s common stock at a price of $16.00 per share for net proceeds of $6.0 million, after deduction underwriting discounts of $0.5&lt;span style="white-space:pre-wrap;"&gt; million.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has historical losses from operations and anticipates that it will continue to incur losses for the foreseeable future as it continues the research and development of its product candidates. The Company incurred net losses of $32.0 million and $17.3 million for the&#160;years ended December&#160;31, 2021 and 2020, respectively, and had an accumulated deficit of $55.2 million as of December&#160;31, 2021. Through December&#160;31, 2021, the Company has funded its operations with proceeds from the sale of convertible preferred stock and common stock. The Company expects that its cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance date of the consolidated financial statements.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="Duration_7_1_2019_To_7_31_2019_us-gaap_StatementClassOfStockAxis_elev_SeriesaAndBConvertiblePreferredStockMember_SRP5C8kaAkm-e3i0QZ6c-A"
      decimals="-5"
      id="Narr_E82NhtNA2kexkQ8HijoRMw"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">97200000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="Duration_11_1_2020_To_11_30_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaAndBConvertiblePreferredStockMember_ge5GjDqHukSVK1DEMyGmNg"
      decimals="-5"
      id="Narr_RIrNQIJQ-E2vGJDcDcDqCA"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">97200000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_6_29_2021_To_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_k4RdvBD3eEmW3XvTBybGKw"
      decimals="INF"
      id="Narr_bwGZfjVLWESeJ1AjQ24Sow"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">6250000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_5rOsdDqIEUeymqVgYG3BtA"
      decimals="2"
      id="Narr_ZIBLqeUJJkCjqoyof3Dd_Q"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">16.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_6_29_2021_To_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_k4RdvBD3eEmW3XvTBybGKw"
      decimals="-5"
      id="Narr_keX3Y_roHketlutcANW2nw"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">91100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_6_29_2021_To_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_k4RdvBD3eEmW3XvTBybGKw"
      decimals="-5"
      id="Narr_FRbQNcdySU6e53Y36Gr1NQ"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">8900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_5rOsdDqIEUeymqVgYG3BtA"
      decimals="INF"
      id="Narr_8_64RQHnvkCq2aNZK-0vjA"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">15736053</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_7_19_2021_To_7_19_2021_srt_CounterpartyNameAxis_elev_UnderwritersOfInitialPublicOfferingMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_VUvougWN80i1LCZg4HFYSw"
      decimals="INF"
      id="Narr_CPwR5WEHyUekIGXm5qFQ3Q"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">403407</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_7_19_2021_srt_CounterpartyNameAxis_elev_UnderwritersOfInitialPublicOfferingMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_nGisd7kOYEq_z_1_7FQduw"
      decimals="2"
      id="Narr_TN6vuwieo0yslr0ItHkToQ"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">16.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_7_19_2021_To_7_19_2021_srt_CounterpartyNameAxis_elev_UnderwritersOfInitialPublicOfferingMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_VUvougWN80i1LCZg4HFYSw"
      decimals="-5"
      id="Narr_W7UynJLcJEGX2OMBhFDtsg"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">6000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_7_19_2021_To_7_19_2021_srt_CounterpartyNameAxis_elev_UnderwritersOfInitialPublicOfferingMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_VUvougWN80i1LCZg4HFYSw"
      decimals="-5"
      id="Narr_X_GeNBCK70aXolxQ9u13Iw"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">500000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-5"
      id="Narr_IRSsV1PwXESHvGji7v_sqw"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">-32000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-5"
      id="Narr_2OWt3oihfkih5jZF8Z9vUA"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">-17300000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-5"
      id="Narr_DM81tEH1UUyWXlY56ikk9A"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">-55200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_nbaPLSC2wkWjHd3pBGJe4w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Principles of Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Elevation Oncology Securities Corporation, which was established on November 19, 2021. All significant intercompany balances and transaction have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in accordance with GAAP requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company bases its estimates and assumptions on known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accruals for research and development expenses, the valuation of common stock and the assumptions used in the valuation of share-based compensation awards. Changes in estimates are recorded in the period in which they become known. Due to the risks and uncertainties involved in the Company&#x2019;s business and evolving market conditions and, given the subjective element of the estimates and assumptions made, actual results may differ from estimated results.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Segment Information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available and regularly reviewed by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment, which is the development of precision medicines for patients with genomically defined cancers. All material long-lived assets of the Company reside in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly liquid investments with an original maturity of three&#160;months or less to be cash equivalents. As of December&#160;31, 2021 and 2020, cash equivalents consisted of money-market funds. The Company places its cash with a high-credit-quality financial institution domiciled in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentrations of Credit Risk and Significant Suppliers&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. The Company&#x2019;s money market funds are invested in highly rated funds. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents and does not believe that it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is dependent on third-party manufacturers to supply products for research and development activities of its programs, including preclinical and clinical testing. These programs could be adversely affected by a significant interruption in the supply of such drug substance and drug products. During the&#160;year ended December&#160;31, 2021, the Company had two vendors that accounted for approximately 61% of its research and development expense. As of December&#160;31, 2021, the Company had one vendor that accounted for approximately 74% of the total accounts payable. During the&#160;year ended December&#160;31, 2020, the Company had one vendor that accounted for approximately 46% of its research and development expense. The &lt;span style="-sec-ix-hidden:Hidden_oYUMpxFyBEukUJ69xj1Vgw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;same&lt;/span&gt;&lt;/span&gt; vendor also accounted for approximately 95% of the total accounts payable as of December&#160;31, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment consist of computer software that is recorded at cost and depreciated on a straight-line basis over the estimated useful lives of the assets. Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying value of assets may not be recoverable. Recoverability is measured by comparison of the asset&#x2019;s book value to future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets. No impairment losses have been recorded through December&#160;31, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cloud Computing Arrangements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company defers implementation costs incurred in cloud computing hosting arrangements in accordance with Accounting Standards Update (&#x201c;ASU&#x201d;) 2018-15 and amortizes these costs over the noncancelable term of the cloud computing arrangement, plus any optional renewal periods (1)&#160;that are reasonably certain to be exercised by the Company or (2)&#160;for which exercises of the renewal option is controlled by the cloud service provider. Costs incurred during the application development stage are capitalized within either prepaid expenses and other current assets, or in other assets, net on the Company&#x2019;s balance sheet. Amortization of implementation costs are on a straight-line basis over the related hosting arrangement term and is reflected in research and development expenses in the consolidated statements of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Classification and Accretion of Convertible Preferred Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company&#x2019;s convertible preferred stock is classified outside of stockholders&#x2019; deficit on the balance sheet because the holders of such shares have liquidation rights in the event of a deemed liquidation that, in certain situations, are not solely within the control of the Company and would require the redemption of the then-outstanding convertible preferred stock. The convertible preferred stock is not redeemable, except in the event of a deemed liquidation (see Note&#160;6). Because the occurrence of a deemed liquidation event is not currently probable, the carrying values of the convertible &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;preferred stock are not being accreted to their redemption values. Subsequent adjustments to the carrying values of the convertible preferred stock would be made only when a deemed liquidation event becomes probable. Upon the closing the Company&#x2019;s IPO in June 2021, all outstanding convertible preferred stock automatically converted into shares of common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;1&#x2014;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;2&#x2014;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;3&#x2014;Non-observable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;The Company's cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note 3).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Patent Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The legal and professional costs incurred by the Company to maintain its patent rights have been expensed as part of general and administrative expenses since inception. As of December&#160;31, 2021 and 2020, the Company has determined that these expenses have not met the criteria to be capitalized. Intellectual property-related&#160;expenses for the year ended December&#160;31, 2021 and&#160;2020 were $0.2 million and $0.1 million, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs consist of salaries and benefits, including associated stock-based compensation, and fees paid to other entities that conduct certain research and development activities on the Company&#x2019;s behalf. Research and development costs are expensed as incurred. The Company estimates preclinical study and clinical trial expenses based on the services performed pursuant to contracts with research institutions and contract research organizations and clinical manufacturing organizations that conduct and manage preclinical studies and clinical trials on the Company&#x2019;s behalf based on actual time and expenses incurred by them. Further, the Company accrues expenses related to clinical trials based on the level of patient activity according to the related agreement. The Company monitors patient enrollment levels and related activity to the extent reasonably possible and adjusts estimates accordingly.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the services have been performed or when the goods have been received rather than when the payment is made.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to the Company&#x2019;s prior estimates of accrued research and development expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company measures stock-based compensation cost at the accounting measurement date based on the fair value of the award and recognizes the expense on a straight-line basis over the requisite service period of the award, which is typically the vesting period. Compensation expense is measured using the fair value of the award at the grant date and is adjusted to reflect actual forfeitures as they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company estimates the fair value of stock options using the Black-Scholes option pricing model that takes into account the exercise price, the fair value of the Company&#x2019;s common stock, the expected term of the option, the expected volatility of the Company&#x2019;s common stock, expected dividends on the Company&#x2019;s common stock, and the risk-free interest rate over the expected life of the option.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Fair value of common stock&#x2014;&lt;/i&gt;Prior to IPO in June 2021, the Company valued its common stock by taking into consideration its most recently available valuation of common shares performed by management and the board of directors, as well as additional factors which may have changed since the date of the most recent contemporaneous valuation through the date of grant. Upon IPO, the fair value of the Company&#x2019;s common stock is determined based on the quoted market price of its common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected term&#x2014;&lt;/i&gt;The Company uses the simplified method described in the Securities and Exchange Commission Staff Accounting Bulletin Topic 14.D.2 to calculate the expected term as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term for options granted to employees.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected volatility&#x2014;&lt;/i&gt;The Company estimates expected volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its traded stock price.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Risk-free interest rate&#x2014;&lt;/i&gt;The risk-free rate assumption is based on the U.S. Treasury yield curves whose terms are consistent with the expected term of the stock options.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected dividend&#x2014;&lt;/i&gt;The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be zero.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient&#x2019;s payroll costs or service payments are classified.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net Loss per Common Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s net loss is equivalent to net loss attributable to common stockholders for all periods presented. Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed using the sum of the weighted average number of common shares outstanding during the period and the effect of dilutive securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company applies the two-class method to calculate its basic and diluted net loss per share as the Company has issued shares that meet the definition of participating securities. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. The Company&#x2019;s participating securities contractually entitle the holders of such shares to participate in dividends; but do not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;financial statements or in the Company&#x2019;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the&#160;year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. The Company accounts for uncertainty in income taxes recognized. If the tax position is deemed more likely than not to be sustained, it would then be assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. To date the Company has no uncertain tax positions and there have been no interest and penalties.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recently issued accounting pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2019, the Financial Accounting Standards Board issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2019-12, &lt;i style="font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/i&gt;. Among other items, the amendments in ASU 2019-12 simplify the accounting treatment of tax law changes and year-to-date losses in interim periods. An entity generally recognizes the effects of a change in tax&lt;i style="font-style:italic;"&gt; &lt;/i&gt;law in the period of enactment; however, there is an exception for tax laws with delayed effective dates. Under&lt;i style="font-style:italic;"&gt; &lt;/i&gt;current guidance, an entity may not adjust its annual effective tax rate for a tax law change until the period in&lt;i style="font-style:italic;"&gt; &lt;/i&gt;which the law is effective. This exception was removed under ASU 2019-12, thereby providing that all effects of a&lt;i style="font-style:italic;"&gt; &lt;/i&gt;tax law change are recognized in the period of enactment, including adjustment of the estimated annual&lt;i style="font-style:italic;"&gt; &lt;/i&gt;effective tax rate. Regarding year-to-date losses in interim periods, an entity is required to estimate its annual&lt;i style="font-style:italic;"&gt; &lt;/i&gt;effective tax rate for the full fiscal year at the end of each interim period and use that rate to calculate its income&lt;i style="font-style:italic;"&gt; &lt;/i&gt;taxes on a year-to-date basis. However, current guidance provides an exception that when a loss in an interim&lt;i style="font-style:italic;"&gt; &lt;/i&gt;period exceeds the anticipated loss for the year, the income tax benefit is limited to the amount that would be&lt;i style="font-style:italic;"&gt; &lt;/i&gt;recognized if the year-to-date loss were the anticipated loss for the full year. ASU 2019-12 removes this exception&lt;i style="font-style:italic;"&gt; &lt;/i&gt;and provides that in this situation, an entity would compute its income tax benefit at each interim period based&lt;i style="font-style:italic;"&gt; &lt;/i&gt;on its estimated annual effective tax rate. ASU 2019-12 is effective for fiscal years beginning after December 15,&lt;i style="font-style:italic;"&gt; &lt;/i&gt;2021, with early adoption permitted. The Company has not elected to early adopt ASU 2019-12 and is currently&lt;i style="font-style:italic;"&gt; &lt;/i&gt;evaluating the impact the adoption of the standard will have on its financial statements and related disclosures.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_neTbvwh8r0Wg5Vm-eDp55w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_o50uglABREakf5LBjyI7ZQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Principles of Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Elevation Oncology Securities Corporation, which was established on November 19, 2021. All significant intercompany balances and transaction have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_8mgmGONx4EaHtfmisWAUcA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in accordance with GAAP requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company bases its estimates and assumptions on known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accruals for research and development expenses, the valuation of common stock and the assumptions used in the valuation of share-based compensation awards. Changes in estimates are recorded in the period in which they become known. Due to the risks and uncertainties involved in the Company&#x2019;s business and evolving market conditions and, given the subjective element of the estimates and assumptions made, actual results may differ from estimated results.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_sHbfT2-n1UGkaLNZD7fXpA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Segment Information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available and regularly reviewed by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment, which is the development of precision medicines for patients with genomically defined cancers. All material long-lived assets of the Company reside in the United States.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="INF"
      id="Narr_4TGJWaDpREmfKQlsWyFqKg"
      unitRef="Unit_Standard_segment_tfgErmtCo0qqRPYk0GJOUQ">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_ZER4DXhmN0GwwCH2-HnngQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly liquid investments with an original maturity of three&#160;months or less to be cash equivalents. As of December&#160;31, 2021 and 2020, cash equivalents consisted of money-market funds. The Company places its cash with a high-credit-quality financial institution domiciled in the United States.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_9vE6CKciOkWd4tjy13yHoA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentrations of Credit Risk and Significant Suppliers&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. The Company&#x2019;s money market funds are invested in highly rated funds. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents and does not believe that it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is dependent on third-party manufacturers to supply products for research and development activities of its programs, including preclinical and clinical testing. These programs could be adversely affected by a significant interruption in the supply of such drug substance and drug products. During the&#160;year ended December&#160;31, 2021, the Company had two vendors that accounted for approximately 61% of its research and development expense. As of December&#160;31, 2021, the Company had one vendor that accounted for approximately 74% of the total accounts payable. During the&#160;year ended December&#160;31, 2020, the Company had one vendor that accounted for approximately 46% of its research and development expense. The &lt;span style="-sec-ix-hidden:Hidden_oYUMpxFyBEukUJ69xj1Vgw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;same&lt;/span&gt;&lt;/span&gt; vendor also accounted for approximately 95% of the total accounts payable as of December&#160;31, 2020.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <elev:NumberOfMajorVendors
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_elev_MajorSuppliersMember_Lus3zfRWB02sxkyeP9gCsQ"
      decimals="INF"
      id="Narr_189oVxZUlkGsqXiqOJkaTQ"
      unitRef="Unit_Standard_item_P9iWedWUGEOmRWtbpyYLhQ">2</elev:NumberOfMajorVendors>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_elev_MajorSuppliersMember_Lus3zfRWB02sxkyeP9gCsQ"
      decimals="2"
      id="Narr_UKLLTtVcpEmr16ou8wKMDg"
      unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw">0.61</us-gaap:ConcentrationRiskPercentage1>
    <elev:NumberOfMajorVendors
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsPayableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_elev_MajorSuppliersMember_Coj20v2H-ESbqbb3ODw3Ng"
      decimals="INF"
      id="Narr_uWZMwKc2GUyRaXfZZKrYQg"
      unitRef="Unit_Standard_item_P9iWedWUGEOmRWtbpyYLhQ">1</elev:NumberOfMajorVendors>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsPayableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_elev_MajorSuppliersMember_Coj20v2H-ESbqbb3ODw3Ng"
      decimals="2"
      id="Narr_SU5kncAgMEWVZK5de3Cf6Q"
      unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw">0.74</us-gaap:ConcentrationRiskPercentage1>
    <elev:NumberOfMajorVendors
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_elev_MajorSuppliersMember_NVyNryv-ik-_fhgfb89hIA"
      decimals="INF"
      id="Narr_HoZ7Sk9akEOQjYAlA9SUPQ"
      unitRef="Unit_Standard_item_P9iWedWUGEOmRWtbpyYLhQ">1</elev:NumberOfMajorVendors>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_elev_MajorSuppliersMember_NVyNryv-ik-_fhgfb89hIA"
      decimals="2"
      id="Narr_icBTgs7hQ0KorhwZLtWuEg"
      unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw">0.46</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsPayableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_elev_MajorSuppliersMember_ocGPhsn9x0qpuSJ02J9oBA"
      decimals="2"
      id="Narr_vHwWE-dH2k-NjBQVz6tOkA"
      unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw">0.95</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_H9k0bma5YESEh3WFA6GWuQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment consist of computer software that is recorded at cost and depreciated on a straight-line basis over the estimated useful lives of the assets. Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying value of assets may not be recoverable. Recoverability is measured by comparison of the asset&#x2019;s book value to future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets. No impairment losses have been recorded through December&#160;31, 2021.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-3"
      id="Narr_aIj-UI847ki_QVH90RF5vg"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">0</us-gaap:AssetImpairmentCharges>
    <elev:CloudComputingArrangementPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_UPFc8rBXPUyvgkUf4eyqJg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cloud Computing Arrangements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company defers implementation costs incurred in cloud computing hosting arrangements in accordance with Accounting Standards Update (&#x201c;ASU&#x201d;) 2018-15 and amortizes these costs over the noncancelable term of the cloud computing arrangement, plus any optional renewal periods (1)&#160;that are reasonably certain to be exercised by the Company or (2)&#160;for which exercises of the renewal option is controlled by the cloud service provider. Costs incurred during the application development stage are capitalized within either prepaid expenses and other current assets, or in other assets, net on the Company&#x2019;s balance sheet. Amortization of implementation costs are on a straight-line basis over the related hosting arrangement term and is reflected in research and development expenses in the consolidated statements of operations.&lt;/p&gt;</elev:CloudComputingArrangementPolicyPolicyTextBlock>
    <elev:ClassificationAndAccretionOfConvertiblePreferredStockPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_lpzSQ-2HI0CBfX4mh5lf4w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Classification and Accretion of Convertible Preferred Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company&#x2019;s convertible preferred stock is classified outside of stockholders&#x2019; deficit on the balance sheet because the holders of such shares have liquidation rights in the event of a deemed liquidation that, in certain situations, are not solely within the control of the Company and would require the redemption of the then-outstanding convertible preferred stock. The convertible preferred stock is not redeemable, except in the event of a deemed liquidation (see Note&#160;6). Because the occurrence of a deemed liquidation event is not currently probable, the carrying values of the convertible &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;preferred stock are not being accreted to their redemption values. Subsequent adjustments to the carrying values of the convertible preferred stock would be made only when a deemed liquidation event becomes probable. Upon the closing the Company&#x2019;s IPO in June 2021, all outstanding convertible preferred stock automatically converted into shares of common stock.&lt;/p&gt;</elev:ClassificationAndAccretionOfConvertiblePreferredStockPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_bD3kZ7Z4nEmIk-a9LUU15w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;1&#x2014;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;2&#x2014;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;3&#x2014;Non-observable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:LegalCostsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_YUCuvGVbp0STr6YlZDqSNA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;The Company's cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note 3).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Patent Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The legal and professional costs incurred by the Company to maintain its patent rights have been expensed as part of general and administrative expenses since inception. As of December&#160;31, 2021 and 2020, the Company has determined that these expenses have not met the criteria to be capitalized. Intellectual property-related&#160;expenses for the year ended December&#160;31, 2021 and&#160;2020 were $0.2 million and $0.1 million, respectively.&lt;/p&gt;</us-gaap:LegalCostsPolicyTextBlock>
    <us-gaap:LegalFees
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-5"
      id="Narr_DKI-2mtT-0SaPgDkU71QyA"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">200000</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-5"
      id="Narr_RUd3URN0yEu5_wWCjckk4A"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">100000</us-gaap:LegalFees>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_rIinS-HW0kG7MbyqD42bWA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs consist of salaries and benefits, including associated stock-based compensation, and fees paid to other entities that conduct certain research and development activities on the Company&#x2019;s behalf. Research and development costs are expensed as incurred. The Company estimates preclinical study and clinical trial expenses based on the services performed pursuant to contracts with research institutions and contract research organizations and clinical manufacturing organizations that conduct and manage preclinical studies and clinical trials on the Company&#x2019;s behalf based on actual time and expenses incurred by them. Further, the Company accrues expenses related to clinical trials based on the level of patient activity according to the related agreement. The Company monitors patient enrollment levels and related activity to the extent reasonably possible and adjusts estimates accordingly.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the services have been performed or when the goods have been received rather than when the payment is made.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to the Company&#x2019;s prior estimates of accrued research and development expenses.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_zb55qe2ktEKLhRXjrTzQXg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company measures stock-based compensation cost at the accounting measurement date based on the fair value of the award and recognizes the expense on a straight-line basis over the requisite service period of the award, which is typically the vesting period. Compensation expense is measured using the fair value of the award at the grant date and is adjusted to reflect actual forfeitures as they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company estimates the fair value of stock options using the Black-Scholes option pricing model that takes into account the exercise price, the fair value of the Company&#x2019;s common stock, the expected term of the option, the expected volatility of the Company&#x2019;s common stock, expected dividends on the Company&#x2019;s common stock, and the risk-free interest rate over the expected life of the option.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Fair value of common stock&#x2014;&lt;/i&gt;Prior to IPO in June 2021, the Company valued its common stock by taking into consideration its most recently available valuation of common shares performed by management and the board of directors, as well as additional factors which may have changed since the date of the most recent contemporaneous valuation through the date of grant. Upon IPO, the fair value of the Company&#x2019;s common stock is determined based on the quoted market price of its common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected term&#x2014;&lt;/i&gt;The Company uses the simplified method described in the Securities and Exchange Commission Staff Accounting Bulletin Topic 14.D.2 to calculate the expected term as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term for options granted to employees.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected volatility&#x2014;&lt;/i&gt;The Company estimates expected volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its traded stock price.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Risk-free interest rate&#x2014;&lt;/i&gt;The risk-free rate assumption is based on the U.S. Treasury yield curves whose terms are consistent with the expected term of the stock options.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected dividend&#x2014;&lt;/i&gt;The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be zero.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient&#x2019;s payroll costs or service payments are classified.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <elev:DividendYieldRate
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="0"
      id="Narr_WZeXxsEN-ka2mIOHENN0iw"
      unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw">0</elev:DividendYieldRate>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_HGr7wA-7z0W5EYp4XXwZ3A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net Loss per Common Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s net loss is equivalent to net loss attributable to common stockholders for all periods presented. Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed using the sum of the weighted average number of common shares outstanding during the period and the effect of dilutive securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company applies the two-class method to calculate its basic and diluted net loss per share as the Company has issued shares that meet the definition of participating securities. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. The Company&#x2019;s participating securities contractually entitle the holders of such shares to participate in dividends; but do not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_oBjUxtVgVU-sZDXMauVNuA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;financial statements or in the Company&#x2019;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the&#160;year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. The Company accounts for uncertainty in income taxes recognized. If the tax position is deemed more likely than not to be sustained, it would then be assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. To date the Company has no uncertain tax positions and there have been no interest and penalties.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Narr_YPEgmQHziU-LD46f5s-Wwg"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-3"
      id="Narr_ET0ENIfJ0UinAs5_LOtVAg"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_NAaAjNfxyU2j6BB9VMvKrA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recently issued accounting pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2019, the Financial Accounting Standards Board issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2019-12, &lt;i style="font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/i&gt;. Among other items, the amendments in ASU 2019-12 simplify the accounting treatment of tax law changes and year-to-date losses in interim periods. An entity generally recognizes the effects of a change in tax&lt;i style="font-style:italic;"&gt; &lt;/i&gt;law in the period of enactment; however, there is an exception for tax laws with delayed effective dates. Under&lt;i style="font-style:italic;"&gt; &lt;/i&gt;current guidance, an entity may not adjust its annual effective tax rate for a tax law change until the period in&lt;i style="font-style:italic;"&gt; &lt;/i&gt;which the law is effective. This exception was removed under ASU 2019-12, thereby providing that all effects of a&lt;i style="font-style:italic;"&gt; &lt;/i&gt;tax law change are recognized in the period of enactment, including adjustment of the estimated annual&lt;i style="font-style:italic;"&gt; &lt;/i&gt;effective tax rate. Regarding year-to-date losses in interim periods, an entity is required to estimate its annual&lt;i style="font-style:italic;"&gt; &lt;/i&gt;effective tax rate for the full fiscal year at the end of each interim period and use that rate to calculate its income&lt;i style="font-style:italic;"&gt; &lt;/i&gt;taxes on a year-to-date basis. However, current guidance provides an exception that when a loss in an interim&lt;i style="font-style:italic;"&gt; &lt;/i&gt;period exceeds the anticipated loss for the year, the income tax benefit is limited to the amount that would be&lt;i style="font-style:italic;"&gt; &lt;/i&gt;recognized if the year-to-date loss were the anticipated loss for the full year. ASU 2019-12 removes this exception&lt;i style="font-style:italic;"&gt; &lt;/i&gt;and provides that in this situation, an entity would compute its income tax benefit at each interim period based&lt;i style="font-style:italic;"&gt; &lt;/i&gt;on its estimated annual effective tax rate. ASU 2019-12 is effective for fiscal years beginning after December 15,&lt;i style="font-style:italic;"&gt; &lt;/i&gt;2021, with early adoption permitted. The Company has not elected to early adopt ASU 2019-12 and is currently&lt;i style="font-style:italic;"&gt; &lt;/i&gt;evaluating the impact the adoption of the standard will have on its financial statements and related disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_vxDUbOcxnEqGahOIyL7SJA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;3. FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company&#x2019;s financial assets subject to fair value measurements on a recurring basis and the level of inputs used for such measurements were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="13" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds included in cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 106,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 106,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="13" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds included in cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 76,013&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 76,013&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;During the&#160;years ended December&#160;31, 2021and 2020, the Company had no transfers between Level&#160;1, &lt;span style="-sec-ix-hidden:Hidden_TDI7DkXArkaTliVYX6vraA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;2&lt;/span&gt;&lt;/span&gt; or &lt;span style="-sec-ix-hidden:Hidden_JCM5oP1UqkKdMGQnvJ6z0g;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;3&lt;/span&gt;&lt;/span&gt; financial assets.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_rX1XUoadW0SN1lS9qsr1-w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company&#x2019;s financial assets subject to fair value measurements on a recurring basis and the level of inputs used for such measurements were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="13" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds included in cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 106,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 106,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="13" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds included in cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 76,013&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 76,013&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_LOXva3eCSEKs92ak-KtE4Q"
      decimals="-3"
      id="Tc_6haQhpxgQ0-y-OJMY99QRg_4_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">106000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_TTW4gSp3Wk-9JNv7SpMKfw"
      decimals="-3"
      id="Tc_FeIDQM4A_UWbelT2v5gglw_4_12"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">106000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_eDgOSR0ApUCe08Ub8rJKgA"
      decimals="-3"
      id="Tc_4zRYqoKLBEOFBTXB1IcGzQ_4_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">76013000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_ZJ2eCE9YL0WHbRPPPls1ig"
      decimals="-3"
      id="Tc_jwwnvvzvA0CyPZdfj2SvoQ_4_12"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">76013000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Narr_zmjmBcRyH0mX5bvUihOAug"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_1-kzfqOuQUGh1LNYppLJ8g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;4. PROPERTY AND EQUIPMENT, NET&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property and equipment, net, consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Useful&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="10" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;4 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 71&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (33)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Property and equipment, net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 56&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company recorded less than $0.1 million of depreciation expense during the&#160;years ended December&#160;31, 2021 and 2020.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_RqjXMbQ6Bkims9Yyn7-zaw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property and equipment, net, consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Useful&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="10" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;4 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 71&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (33)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Property and equipment, net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 56&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_elev_ComputerSoftwareMember_g5ZhoAlXpUqrIOpTarHh5A"
      id="Tc_IXuo85Z2I0WXjXF1Rw9Vbw_4_3">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_elev_ComputerSoftwareMember_NaXHz8_kV0qUWe08M_6KyQ"
      decimals="-3"
      id="Tc_ZLkVgWpJdEGVnVE9gDGdgQ_4_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">71000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_elev_ComputerSoftwareMember_YpEaJOWw7UCqEhZ5InjBgQ"
      decimals="-3"
      id="Tc_8t1b2-g7p0-jq3hiod_Bsw_4_9"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">71000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_6sprlGjsrkCm7KWTzm0tuw_5_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">33000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_Zbmi6fWl30u_wZBESegMWg_5_9"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">15000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_tyCTqTlqtkupo0tCfs565g_6_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">38000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_w_QoT7lPTEOHiV7rjB4DiQ_6_9"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">56000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_AIfL3vjSZUuRhq97AJyp4w"
      decimals="-5"
      id="Narr_sYsWajhSjUSoLJAeEV4Hbg"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">100000</us-gaap:Depreciation>
    <elev:AccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_-9mzM2ornESR2L6snfpxRw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;5. ACCRUED EXPENSES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued expenses consist of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued preclinical and clinical trial costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,260&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 505&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,059&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 429&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued consulting&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 127&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued professional services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 499&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 28&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 246&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total accrued expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,141&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,106&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</elev:AccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_ZHZtmqizuUWehJuCR-ceTg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued expenses consist of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued preclinical and clinical trial costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,260&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 505&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,059&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 429&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued consulting&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 127&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued professional services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 499&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 28&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 246&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total accrued expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,141&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,106&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <elev:AccruedPreclinicalAndClinicalTrialCostsCurrent
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_o_-mkYXbHEW7VeTCuwDaUw_4_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">1260000</elev:AccruedPreclinicalAndClinicalTrialCostsCurrent>
    <elev:AccruedPreclinicalAndClinicalTrialCostsCurrent
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_mXSsiqmwiECuaNbew3_rhQ_4_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">505000</elev:AccruedPreclinicalAndClinicalTrialCostsCurrent>
    <elev:AccruedCompensationCurrent
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_VoIaWxJjM0a4BV8rhSafJQ_5_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">1059000</elev:AccruedCompensationCurrent>
    <elev:AccruedCompensationCurrent
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_O6chyPa9k0eXE3rJb3R6Bg_5_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">429000</elev:AccruedCompensationCurrent>
    <elev:AccruedConsultingFeesCurrent
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_SU9MKy_EU0KMQLQhHZbKvw_6_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">77000</elev:AccruedConsultingFeesCurrent>
    <elev:AccruedConsultingFeesCurrent
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_D09UqJOVG0OE9i-ipaPDdw_6_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">127000</elev:AccruedConsultingFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_CkPJxzWh2UChAyurfw0kYA_7_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">499000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_WNA41NZ0nk6gTYLT_FR-Cg_7_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">28000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_P_IsEWKI-kK0gZXnNKhemA_8_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">246000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_3ssi-Im1AEaRgqFAcnM8iA_8_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">17000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_kE6Juhnk_ky3wVmpCApMuw_9_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">3141000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_p51qZjNiekKzj2Ox3KnW5A_9_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">1106000</us-gaap:AccruedLiabilitiesCurrent>
    <elev:TemporaryEquityDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_GGiTLgbXZEmTlouTjVApsA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;"&gt;6. CONVERTIBLE PREFERRED STOCK&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company had issued Series&#160;A and Series&#160;B convertible preferred stock (collectively, the &#x201c;Convertible Preferred Stock&#x201d;). As of December&#160;31, 2020, the Company&#x2019;s certificate of incorporation, as amended and restated, authorized the Company to issue 66,493,889 shares of $0.0001 par value convertible preferred stock, of which 32,450,000 were designated as Series&#160;A convertible preferred stock (&#x201c;Series&#160;A&#x201d;) and 34,043,889 were designated as Series&#160;B convertible preferred stock (&#x201c;Series&#160;B&#x201d;). As of December 31, 2020, all of the Company&#x2019;s Convertible Preferred Stock was classified outside of stockholders&#x2019; deficit because the shares contained deemed liquidation rights that were a contingent redemption feature not solely within the control of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Series&#160;A&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On July&#160;12, 2019, the Company sold 5,450,000 shares of Series&#160;A at a price of $1.00 per share (&#x201c;Series&#160;A Original Issue Price&#x201d;) pursuant to the Series&#160;A stock purchase agreement (the &#x201c;Series&#160;A Purchase Agreement&#x201d;), for gross proceeds of $5.5 million. On August&#160;7, 2019, investors purchased an additional 1,816,750 shares of Series&#160;A at the Series&#160;A Original Issue Price, for gross proceeds of $1.8 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon achievement of the Milestone Closing (as defined in the Series&#160;A Purchase Agreement) and approval by the Company&#x2019;s board of directors, the Company issued an additional 25,183,250 shares of Series&#160;A at the Series&#160;A Original Issue Price on January&#160;9, 2020 for gross proceeds of $25.2 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Series&#160;B&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On November&#160;10, 2020, the Company sold 34,043,889 shares of Series&#160;B at a price of $1.9093 per share (&#x201c;Series&#160;B Original Issue Price&#x201d;), pursuant to the Series&#160;B stock purchase agreement for gross proceeds of $65.0 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Conversion&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;white-space:pre-wrap;"&gt;Upon the closing the Company&#x2019;s IPO in June 2021, all outstanding convertible preferred stock automatically converted into shares of common stock.  There are &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;10,000,000&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; authorized preferred shares of December 31, 2021.&lt;/span&gt;&lt;/p&gt;</elev:TemporaryEquityDisclosureTextBlock>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="INF"
      id="Narr_7ft91q3LSE2fhJACOiPE-w"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">66493889</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="INF"
      id="Narr_HujKqJACF0uT50gZkowvKQ"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_ufCfvphpqUaFsIu6eQ5ybg"
      decimals="INF"
      id="Narr_wKsMGcFNg0620qIYWXYvYQ"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">32450000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_n1P4tSrvdk-YvWRGsiNyRQ"
      decimals="INF"
      id="Narr_X2KPu2V-UEq9N_n-5V5OOA"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">34043889</us-gaap:TemporaryEquitySharesAuthorized>
    <elev:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_12_2019_To_7_12_2019_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_CRrBhd5h4UWKceI00MOZ2A"
      decimals="INF"
      id="Narr_6b6mjSW1Okiogo-0mRCTtg"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">5450000</elev:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <elev:TemporaryEquityIssuePricePerShare
      contextRef="As_Of_7_12_2019_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_2gzfDx_IOkyEVrvBv9B-8A"
      decimals="INF"
      id="Narr_u8VwgTPScUa-37AT1vcyUQ"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">1.00</elev:TemporaryEquityIssuePricePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="Duration_7_12_2019_To_7_12_2019_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_CRrBhd5h4UWKceI00MOZ2A"
      decimals="-5"
      id="Narr_NZzyMzBw4kuf5YP6QLkJRQ"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">5500000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <elev:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_7_2019_To_8_7_2019_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_jTYrUmLmVka6PZ8r-YiTkw"
      decimals="INF"
      id="Narr__XsnFrtP60uF-zqjJdxDeA"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">1816750</elev:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="Duration_8_7_2019_To_8_7_2019_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_jTYrUmLmVka6PZ8r-YiTkw"
      decimals="-5"
      id="Narr_mBtHblqP0U6BkyeJ5y7tLw"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">1800000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <elev:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_9_2020_To_1_9_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_gs0XV9bVfEqDcewwWOI9VQ"
      decimals="INF"
      id="Narr_kXNTe0o7wEWAlMUFJyz1Jw"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">25183250</elev:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="Duration_1_9_2020_To_1_9_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_gs0XV9bVfEqDcewwWOI9VQ"
      decimals="-5"
      id="Narr_0P-zLUaZZEymt3kbD3PZyg"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">25200000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <elev:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_11_10_2020_To_11_10_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_v3BvBhMCkkChJbjcubxA5w"
      decimals="INF"
      id="Narr_aN4xNOLL40OPC-8iSpg49Q"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">34043889</elev:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <elev:TemporaryEquityIssuePricePerShare
      contextRef="As_Of_11_10_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_CnPFfpHmG0CJMvYDja99aQ"
      decimals="INF"
      id="Narr_w4a0RYLo7EqokIYw1ZPnTA"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">1.9093</elev:TemporaryEquityIssuePricePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="Duration_11_10_2020_To_11_10_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesBConvertiblePreferredStockMember_v3BvBhMCkkChJbjcubxA5w"
      decimals="-5"
      id="Narr_7oG7Ug7ExUGoA9njPHzwXw"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">65000000.0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_EpGg59YM3Eu1afDfRYaHEQ"
      decimals="INF"
      id="Narr_9itydpYRCUatTnheNU-A-w"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">10000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_rirIQ9nAMUOWX5d78IRUAg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;"&gt;7. COMMON STOCK&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;As of December&#160;31, 2021, the Company&#x2019;s certificate of incorporation, as amended and restated, authorized the Company to issue 500,000,000 shares of $0.0001 par value common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Initial Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;On June 29, 2021, the Company closed its IPO and issued 6,250,000 shares of its common stock at a price of $16.00 per share for net proceeds of $91.1 million, after deducting underwriting discounts and commissions and expenses of $8.9 million. In connection with the IPO, all shares of Series A and Series B convertible preferred stock converted into 15,736,053 shares of common stock. On July 19, 2021, in connection with the Company&#x2019;s IPO, the underwriters exercised the right to purchase 403,407 shares of the Company&#x2019;s common stock at a price of $16.00 per share for net proceeds of $6.0 million, after deduction underwriting discounts of $0.5&lt;span style="white-space:pre-wrap;"&gt; million.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;The Company has reserved a total of 27,565,320 shares of common stock as of December 31, 2021 for common stock outstanding, the exercise of outstanding stock options and the number of shares remaining available for future grant under the Company&#x2019;s 2021 Stock Incentive Plan. The Company had reserved a total of 19,831,875 shares of common stock as of December&#160;31, 2020 for common stock outstanding, the conversion of the outstanding shares of Convertible Preferred Stock, the exercise of outstanding stock options and the number of shares remaining available for future grant under the Company&#x2019;s 2019 Stock Incentive Plan.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="INF"
      id="Narr_KUp93GoUk0isroI-jb3Jfw"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="INF"
      id="Narr_o5ZDN9ss706H8bVinh48WA"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <elev:CommonStockNumberOfVotesPerShare
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="INF"
      id="Narr_OEjI4jI0Q02_YYicxRRDDQ"
      unitRef="Unit_Standard_Vote_IYKGbYhrlUq08si1HNSWpQ">1</elev:CommonStockNumberOfVotesPerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_6_29_2021_To_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_k4RdvBD3eEmW3XvTBybGKw"
      decimals="INF"
      id="Narr_PXRx2gi_e0WKKjl-rd0gCA"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">6250000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_5rOsdDqIEUeymqVgYG3BtA"
      decimals="2"
      id="Narr_2YPBrmYR9EepB_qgQ6hM5w"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">16.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_6_29_2021_To_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_k4RdvBD3eEmW3XvTBybGKw"
      decimals="-5"
      id="Narr_bCjKDs58Kkixju3d3ewypA"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">91100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_6_29_2021_To_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_k4RdvBD3eEmW3XvTBybGKw"
      decimals="-5"
      id="Narr_g9n2bert4EyB9Pfdh5LE0w"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">8900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_5rOsdDqIEUeymqVgYG3BtA"
      decimals="INF"
      id="Narr_7tlX6JEyAkyfZO-B04vVHg"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">15736053</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_7_19_2021_To_7_19_2021_srt_CounterpartyNameAxis_elev_UnderwritersOfInitialPublicOfferingMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_VUvougWN80i1LCZg4HFYSw"
      decimals="INF"
      id="Narr_pD_lBRlMvUm5J6K2YoEHww"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">403407</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_7_19_2021_srt_CounterpartyNameAxis_elev_UnderwritersOfInitialPublicOfferingMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_nGisd7kOYEq_z_1_7FQduw"
      decimals="2"
      id="Narr_mWrNerIM40quzkGzc8DjxQ"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">16.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_7_19_2021_To_7_19_2021_srt_CounterpartyNameAxis_elev_UnderwritersOfInitialPublicOfferingMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_VUvougWN80i1LCZg4HFYSw"
      decimals="-5"
      id="Narr_Iz3FEsWAO0eNeRRBvO4Cqw"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">6000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_7_19_2021_To_7_19_2021_srt_CounterpartyNameAxis_elev_UnderwritersOfInitialPublicOfferingMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_VUvougWN80i1LCZg4HFYSw"
      decimals="-5"
      id="Narr_gttiH2-BL0Gm5KXJE42aew"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">500000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="INF"
      id="Narr_NxHzSL_E9EuDveJa5W3g4g"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">27565320</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="INF"
      id="Narr_SFc1ZIpi5k-JPI22EuQYYg"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">19831875</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_H_Sau28CyEC2LG4_Bqhcpg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;8. STOCK-BASED COMPENSATION&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock-based compensation expense as reflected in the Company&#x2019;s consolidated statements of operations was as follows (in thousand):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 244&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 24&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,327&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 28&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock-based compensation expense included in operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,571&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 52&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;2021 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has two equity incentive plans: the 2019 Equity Incentive Plan (&#x201c;2019 Plan&#x201d;), and the 2021 Equity Incentive Plan (&#x201c;2021 Plan&#x201d;). New awards can only be granted under the 2021 Plan, under which it is able to issue equity to employees, board members, consultants, and advisors. The 2021 Plan became effective on June 24, 2021, the date the prospectus related to the Company's IPO was deemed effective by the SEC. The 2021 Plan authorizes the award of stock options, restricted stock awards (&#x201c;RSAs&#x201d;), stock appreciation rights (&#x201c;SARs&#x201d;), restricted stock units (&#x201c;RSUs&#x201d;), cash awards, performance awards and stock bonus awards. The Company has initially reserved 1,483,445 shares of its common stock, plus any reserved shares not issued or subject to outstanding grants under the 2019 Plan on the effective date of the 2021 Plan, for issuance pursuant to awards granted under the 2021 Plan. Of this amount, 1,720,291 shares were available for future grants as of December 31, 2021. The number of shares reserved for issuance under the 2021 Plan will increase automatically on January 1 of each of 2022 through 2031 by the number of shares equal to the lesser of 5% of the aggregate number of outstanding shares of the Company&#x2019;s common stock as of the immediately preceding December 31, or a number as may be determined by our board of directors. As such, 1,160,296 shares were added to the Plan in January 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2019 Stock Incentive Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The total number of shares of common stock available for issuance under the 2019 Plan was 1,972,114 shares when the 2019 Plan was adopted. In December&#160;2019 and November&#160;2020, the Company increased the number of shares of common stock reserved for issuance under the 2019 Plan by 144,950 shares and 1,189,911 shares, respectively. Shares underlying any awards that were forfeited, canceled, or reacquired by the Company prior to vesting, satisfied without the issuance of stock or otherwise terminated or shares that were withheld upon exercise of an option or settlement of an award to cover the exercise price or tax withholding were to be added back to the shares available for issuance under the 2019 Plan. For the year ended December 31, 2021, 1,016,337 options were granted under the 2019 Plan. The 2019 Plan was terminated in connection with the Company&#x2019;s IPO. The Company will not grant any additional awards under the 2019 Plan thereafter.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2021 Employee Stock Purchase Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has adopted the Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;) which became effective June 24, 2021, the date the prospectus related to the Company's IPO was deemed effective by the SEC, to enable eligible employees to purchase shares of its common stock with accumulated payroll deductions at a discount beginning on a date to be determined by the board of directors or compensation committee. The ESPP is intended to qualify under Section 423 of the Code. The Company has initially reserved 228,222 shares of its common stock for sale under the ESPP. The aggregate number of shares reserved for sale under the ESPP will increase automatically on January 1st of each of 2022 through 2031 by the number of shares equal to the lesser of 1% of the total outstanding shares of the Company&#x2019;s common stock as of the immediately preceding December 31 (rounded to the nearest whole share) or a number of shares as may be determined by the board of directors in any particular year. As such, 232,059 shares were added to the Plan in January 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The aggregate number of shares issued over the term of the ESPP, subject to stock-splits, recapitalizations or similar events, may not exceed 4,564,440 shares of the Company&#x2019;s common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock Options&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;A summary of stock option activity for employee and nonemployee awards under the 2019 and 2021 Plans is presented below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&#160;Contractual&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&#160;(years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,761,062&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 0.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 9.54&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 723&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,309,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (48,663)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3.98&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,021,799&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 10,903&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 680,951&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,437&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested and expected to vest at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,021,799&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 10,903&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The weighted average grant-date fair value of stock options granted during the year ended December&#160;31, 2021 and 2020 was $4.60 and $0.73 per share, respectively. The fair value of each stock option was estimated using a Black-Scholes option-pricing model with the following assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:33.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.95 - 1.35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.2&#x2212;0.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;75-77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;74%&#x2212;79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_F-nfSSZM0Euu4OQJHKZe8Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;3&lt;/span&gt;&lt;/span&gt;&#x2212;&lt;span style="-sec-ix-hidden:Hidden_gGMsgb7BgEOGbQEJGMhgkw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of options that vested during the years ended December 31, 2021 and 2020 was $0.6 million and $0 million, respectively. The Company recorded stock-based compensation expense associated with stock option awards of $1.1 million and $0.1 million during the 12&#160;&lt;span style="white-space:pre-wrap;"&gt;months ended December 31, 2021 and 2020, respectively.  As of December 31, 2021, there was &lt;/span&gt;$6.4 million of total unrecognized compensation cost related to unvested stock-based awards, which the Company expects to recognize over a remaining weighted-average period of 3.2&#160;years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Restricted Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The terms of the 2019 Plan permitted certain option holders to exercise options before their options were vested, subject to certain limitations. Upon early exercise, the awards become subject to a restricted stock agreement and are subject to the same vesting provisions in the original stock option awards. Shares issued as a result of early exercise that have not vested are subject to repurchase by the Company upon termination of the purchaser&#x2019;s employment, at the lesser of the price paid by the purchaser or the fair value of the shares at the time of repurchase. Such shares are not deemed to be issued for accounting purposes until they vest and are therefore excluded from shares outstanding until the repurchase right lapses and the shares are no longer subject to the repurchase feature. The liability is reclassified into common stock and additional paid-in capital as the shares vest and the repurchase right lapses. Accordingly, the Company has recorded the unvested portion of the exercise proceeds of less than $0.01 million as a liability from the early exercise in the accompanying consolidated balance sheets as of December 31, 2021 and 2020, respectively. The Company recorded stock-based compensation expense associated with restricted common stock of less than $0.1 million during the 12 months ended December 31, 2021 and 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company issues RSUs to employees that generally vest over a four-year period with 25% of awards vesting after one year and then quarterly thereafter. Any unvested shares will be forfeited upon termination of services. The fair value of an RSU is equal to the fair market value price of the Company&#x2019;s common stock on the date of grant. RSU expense is amortized straight-line over the vesting period. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes activity related to restricted stock units:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;grant date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;fair value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 200,996&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16.00&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 200,996&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16.00&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recorded stock-based compensation expense of $0.4 million for the 12 months ended December 31, 2021, related to RSUs. As of December 31, 2021, the total unrecognized expense related to all RSUs was $2.8 million, which the Company expects to recognize over a weighted-average period of 3.4&#160;years.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_YJeOcJusBU6lm6G7yXcvww">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock-based compensation expense as reflected in the Company&#x2019;s consolidated statements of operations was as follows (in thousand):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 244&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 24&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,327&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 28&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock-based compensation expense included in operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,571&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 52&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_X-9TCZuQqkap_YeDihjLvg"
      decimals="-3"
      id="Tc_HmfsFhXhmkayFX3f7CTN0Q_4_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">244000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_xsmSF0gpPU6amqdGOgrEEw"
      decimals="-3"
      id="Tc_PsnrTowSpEKXvwAsYBr66A_4_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">24000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_O_Q119ip30KfTfvFf993FA"
      decimals="-3"
      id="Tc_miEVnhgu80SDGim8T9b-Mw_5_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">1327000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_1KlIt4aZN0KI7qkDnMhwtg"
      decimals="-3"
      id="Tc_n16rGC9-fkuiW4CbvWf2VA_5_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">28000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-3"
      id="Tc_CTfooCcO_E-td-ZmRfrYkw_6_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">1571000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-3"
      id="Tc_ifWvj0UsbEyOzZsMn7k7Hg_6_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">52000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_6_24_2021_us-gaap_PlanNameAxis_elev_StockIncentivePlan2019Member_g20HiHisykWL0YRlk71tPQ"
      decimals="INF"
      id="Narr_f2YfanlKDkOCs1j0SJnsLQ"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">1483445</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_elev_EquityIncentivePlan2021Member_kp3FXbetX02QbQ8--SNfwg"
      decimals="INF"
      id="Narr_EGQWq4vmdk6lg9s4ICYXtA"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">1720291</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <elev:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentageOfAggregateSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_elev_EquityIncentivePlan2021Member_xaj81EG8zUqzxS8PpL1PjA"
      decimals="4"
      id="Narr_0XVbaIi2FEOkaYq3L6X4rg"
      unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw">0.05</elev:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentageOfAggregateSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_PlanNameAxis_elev_EquityIncentivePlan2021Member_FexWjG0GeEO3y5ruEl4e1A"
      decimals="INF"
      id="Narr_6vrotXb0k0KEnXK0Ztyx8w"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">1160296</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_elev_StockIncentivePlan2019Member_bUnBFZtU70qdI_31neYSXg"
      decimals="INF"
      id="Narr_gHZOqMtXlUyHrdqHgBqDFg"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">1972114</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_12_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_elev_StockIncentivePlan2019Member_CdA7QcaLgEakV3EDPTac8Q"
      decimals="INF"
      id="Narr_Fg6ZxPwpPEiEKT1Udmf8tg"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">144950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_11_1_2020_To_11_30_2020_us-gaap_PlanNameAxis_elev_StockIncentivePlan2019Member_hYYP-cdGa0eXbji1S01uFg"
      decimals="INF"
      id="Narr__HHaUq05I0W77uYCh_aPLQ"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">1189911</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_elev_StockIncentivePlan2019Member_FlHgdUrdDkW1Tb42kpCKvQ"
      decimals="INF"
      id="Narr_W2_JPzSuC0SKnzGtl9KfXA"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">1016337</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_6_24_2021_us-gaap_PlanNameAxis_elev_EmployeeStockPurchasePlan2021Member_Mo21NNEVb02WGxkNxv7paw"
      decimals="INF"
      id="Narr_GY2L8j17EEaulwwtki3caw"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">228222</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <elev:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentageOfAggregateSharesOutstanding
      contextRef="Duration_6_24_2021_To_6_24_2021_us-gaap_PlanNameAxis_elev_EmployeeStockPurchasePlan2021Member_ZFyW0T1vXkWCriwlsXAY-Q"
      decimals="2"
      id="Narr_TURm9BGivUmqX8Mmn5QQXw"
      unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw">0.01</elev:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentageOfAggregateSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_PlanNameAxis_elev_EmployeeStockPurchasePlan2021Member_s1Fv3k0-skOD-lgjf_7L1g"
      decimals="INF"
      id="Narr_-f8qP-wuGUGpv9ZYGoe3aw"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">232059</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_elev_EmployeeStockPurchasePlan2021Member_uSn9gG9lvkuJEppuSz4hoQ"
      decimals="INF"
      id="Narr_9FcEBxlGSkaXr3SWaj5Quw"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">4564440</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_yKZTeCUPBEuOLt1JUmBUPg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;A summary of stock option activity for employee and nonemployee awards under the 2019 and 2021 Plans is presented below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&#160;Contractual&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&#160;(years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,761,062&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 0.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 9.54&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 723&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,309,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (48,663)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3.98&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,021,799&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 10,903&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 680,951&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,437&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested and expected to vest at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,021,799&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 10,903&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="INF"
      id="Tc_fvNwMv2xI0O_KHJemFRqlA_4_2"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">1761062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="2"
      id="Tc_fdnzdqad-Uqd53LhEybrpA_4_5"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      id="Tc_kwlW1SKe2EC8mNC9RoovHA_4_7">P9Y6M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_wvmJQ81H2UmHvY6ZwnSAkQ_4_10"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">723000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="INF"
      id="Tc_aj1UgOh7Dky4l6HYQF_aHg_5_2"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">1309400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="2"
      id="Tc_6PWOfut3n0StIb5Xt3jNEw_5_5"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">7.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="INF"
      id="Tc_qGpIEyA210iaMPZ-HgRv6w_6_2"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">48663</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="2"
      id="Tc_Iovb6AmS5k29_1QmhHTEqQ_6_5"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">3.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="INF"
      id="Tc_3hT9NHKbQE-4MNaldA84_w_7_2"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">3021799</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="2"
      id="Tc_w3SghX_2-UWHsv2bhzcNSg_7_5"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">3.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tc_7FRiBSJgGk-LZ9dHSfdWTw_7_7">P8Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_ZVs2nxb0oUqqALnWuYPo4g_7_10"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">10903000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="INF"
      id="Tc_susL6Qlx_0u1wbeKlbHNBg_8_2"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">680951</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="2"
      id="Tc_NKC4t3_ebECaZQXgBMFx_g_8_5"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">1.23</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <elev:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tc_xW4587Xl40yp16_SjiK7TQ_8_7">P8Y4M20D</elev:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm>
    <elev:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedIntrinsicValue
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_1D_y2TXsCkim_XxZOIlsQw_8_10"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">3437000</elev:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="INF"
      id="Tc_DWZA3YjlTUWxoXSOM5MEXw_9_2"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">3021799</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="2"
      id="Tc_i-PF6yfeAUSZFpsOhmc8rQ_9_5"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">3.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tc_adRC7I8PREympOuMF0sM5g_9_7">P8Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_zhD4_o-lCkq_5Ckwl_9Mcg_9_10"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">10903000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_mMOL7ljNgkabWjtwurKXYg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The weighted average grant-date fair value of stock options granted during the year ended December&#160;31, 2021 and 2020 was $4.60 and $0.73 per share, respectively. The fair value of each stock option was estimated using a Black-Scholes option-pricing model with the following assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:33.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.95 - 1.35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.2&#x2212;0.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;75-77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;74%&#x2212;79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_F-nfSSZM0Euu4OQJHKZe8Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;3&lt;/span&gt;&lt;/span&gt;&#x2212;&lt;span style="-sec-ix-hidden:Hidden_gGMsgb7BgEOGbQEJGMhgkw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="2"
      id="Narr_NZHZ3vd5a0iPgybna8F0Sg"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">4.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="2"
      id="Narr_Z2I4M9puzEOQjuVQj3vwJA"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">0.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="4"
      id="Narr_mxri_Y2bREGGQBGPALKP6g"
      unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw">0.0095</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="4"
      id="Narr_TF_qEYWmcUGSjpqvUxuoNg"
      unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw">0.0135</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="3"
      id="Narr_O8mg_ImWjEmJ3NPBrmoCFA"
      unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="4"
      id="Narr_7KNpgPtAAkahIlaPnnE8eQ"
      unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw">0.0075</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="4"
      id="Narr_HyxKt7oeqUWEewztHBCb2g"
      unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="4"
      id="Narr_ND2dUp419k6_dB9kTH_4xA"
      unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw">0.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="2"
      id="Narr_R4xdhYGN9UKy_6muWzS0yg"
      unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="2"
      id="Narr_ruSkBCiWwUK6fwMvM_5WTQ"
      unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw">0.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tc_CfWjkoNOJU2uYmXaLa0VpQ_6_2">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-5"
      id="Narr_BubGtcSS-US3TyY2XSIO9A"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-5"
      id="Narr_6_rexnfVEEahwqHdjmeF-w"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qMQDBx_zA0eapJGtZe8uZQ"
      decimals="-5"
      id="Narr_pn5OGkfnOEmc_un8eU6qNw"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">1100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_W0whaLuINkuS-MK09HdSLg"
      decimals="-5"
      id="Narr_XDuUwa5P0kuALVEgsXXZ9g"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-5"
      id="Narr_kgKVnOnBX0mvUG1C216_0w"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">6400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Narr_f34FShHPQUeUkrecHO_Iug">P3Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <elev:RestrictedStockRepurchaseLiability
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_4iKy94V-6UeB5pmDG5OepA"
      decimals="-4"
      id="Narr_bnfc4flaCkykckp_IbRk1w"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">10000.00</elev:RestrictedStockRepurchaseLiability>
    <elev:RestrictedStockRepurchaseLiability
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_Hc0jKnnQ5EKY8gQMK3Ryuw"
      decimals="-4"
      id="Narr_BxWSFBiIiUii1Tqwvt5xSA"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">10000.00</elev:RestrictedStockRepurchaseLiability>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_YAEGuEqxPEKdKNDxES3Gxg"
      decimals="-5"
      id="Narr_bUgjU4ktkk6j09prqpXCPg"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_deAfjK4lqEmKMKksWWn-jw"
      decimals="-5"
      id="Narr_cjpOkdhQeUG4sOCJEF3x3A"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JBR44UJY20idUxeLVpC0GQ"
      id="Narr_nKSsJDC7Lk2tITU00f74dQ">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JBR44UJY20idUxeLVpC0GQ"
      decimals="4"
      id="Narr_CKK4oj6yfUiiK9kQU7fvqA"
      unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_Dk9o5aQOykiu0pxwfNxGpw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes activity related to restricted stock units:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;grant date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;fair value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 200,996&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16.00&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 200,996&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16.00&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JBR44UJY20idUxeLVpC0GQ"
      decimals="INF"
      id="Tc_G4RcxYU5X0ykzfjgeTTHkQ_5_2"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">200996</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JBR44UJY20idUxeLVpC0GQ"
      decimals="2"
      id="Tc_8yS8YZK6SU60jZz1l6uLSw_5_5"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">16.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OZUmi-gHpkqGwGuZU2171Q"
      decimals="INF"
      id="Tc_44GWaJLN30-ceJCirGZsHg_6_2"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">200996</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OZUmi-gHpkqGwGuZU2171Q"
      decimals="2"
      id="Tc_7mfBnriFLUqg7QmFa0wBhg_6_5"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">16.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JBR44UJY20idUxeLVpC0GQ"
      decimals="-5"
      id="Narr_vQB1zu8SbEqgPR8ZPMEmLg"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OZUmi-gHpkqGwGuZU2171Q"
      decimals="-5"
      id="Narr_AmY9KDPW8k63QJJVrLw2YQ"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">2800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JBR44UJY20idUxeLVpC0GQ"
      id="Narr_3iFKgVYOtEytg6ULDnChTA">P3Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <elev:AssetPurchaseAndLicenseAgreementsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_KXdW8b11tEu3ep-5ephgxA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;9. ASSET PURCHASE AND LICENSE AGREEMENTS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In May&#160;2019, the Company entered into an asset purchase agreement with the previous sponsor, pursuant to which it acquired all rights and interest to patents, know-how, and inventory for assets related to seribantumab, a fully humanized immunoglobulin G2 monoclonal antibody against HER3.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the asset purchase agreement, the Company made an upfront, non-refundable payment of $3.5 million at closing. If the Company succeeds in developing and commercializing seribantumab, the Company may be obligated to pay the previous sponsor up to $54.5 million in development, regulatory and sales milestone payments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the asset purchase agreement, the Company assumed the rights and obligations of the following collaboration and license agreements previously held by the previous sponsor:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Dyax&#x2014;&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The Company assumed all rights and obligations provided for under the amended and restated collaboration agreement executed between Dyax Corp. (&#x201c;Dyax&#x201d;) and the previous sponsor (the &#x201c;Dyax Agreement&#x201d;). Pursuant to the Dyax Agreement, Dyax utilized its proprietary phage technology to identify antibodies that would bind to targets of interest to the previous sponsor. Additionally, Dyax granted to the previous sponsor a world-wide, non-exclusive, royalty free right to use and make any and all of the antibodies identified by Dyax for certain research purposes. Seribantumab was identified as a result of the research activities performed under the Dyax Agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the terms of the Dyax Agreement, the Company may be obligated to pay Dyax milestone payments of up to approximately $9.3 million if certain development and regulatory milestones are achieved. In addition, Dyax is entitled to mid-single digit royalties based on net sales of seribantumab. The Company&#x2019;s obligation to pay royalties to Dyax continues on a product-by-product and country-by-country basis until the later of a specified number of&#160;years after the first commercial sale in such country and the expiration of the patent rights covering seribantumab in such country.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Dyax Agreement will remain in effect, unless earlier terminated, for so long as the Company continues to develop or commercialize seribantumab. Either party may terminate the agreement in the event of an uncured material breach by the other party. The Company also has the right to terminate the agreement in its entirety or on a product-by-product basis at any time upon 90&#160;days&#x2019; prior written notice.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Ligand Pharmaceuticals&#x2014;&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The Company assumed all rights and obligations provided for under the amended commercial license agreement executed between Selexis SA (&#x201c;Selexis&#x201d;) and the previous sponsor (the &#x201c;Selexis Agreement&#x201d;). Pursuant to the Selexis Agreement, the Company received non-exclusive rights to technology for use in the manufacture of seribantumab and may be required to make milestone payments of up to approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x20ac;900&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;, per licensed product, if certain development and regulatory milestones are achieved. Additionally, Selexis may have the right to obtain a royalty of the greater of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x20ac;0.2&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; million annually and less than &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;percent on net sales of seribantumab. The obligation to pay royalties with respect to each product sold in a country continues until the expiration of the patent rights covering the product in such country. Either party may terminate the agreement in the event of an uncured material breach by the other party. The Company also has the right to terminate the agreement at any time upon &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;60&#160;days&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x2019; prior written notice.&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt; &lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;In November of 2021, the Selexis agreement was assigned to Ligand Pharmaceuticals Incorporated.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;National Institute of Health&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x2014;The Company assumed all rights and obligations provided for under the amended commercial license agreement executed between the U.S. Public Health Service, a division of the U.S. Department of Health and Human Services (the &#x201c;NIH&#x201d;) and the previous sponsor (the &#x201c;NIH Agreement&#x201d;). Pursuant to the NIH Agreement, the Company received non-exclusive rights in the United States to patents related to certain antibodies associated with seribantumab. If certain development and regulatory milestones are achieved, the Company may be obligated to pay NIH additional milestone payments of up to approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$0.4&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; million per licensed product.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company evaluated the asset purchase agreement with the previous sponsor under ASC Topic 805&lt;i style="font-style:italic;"&gt;, Business Combinations,&lt;/i&gt; and concluded that the transaction did not meet the requirements to be accounted for as a business combination and therefore was accounted for as an asset acquisition. Accordingly, the upfront payment of $3.5 million was expensed as research and development expenses in the statement of operations for the year ended December&#160;31, 2019. Additionally, the Company concluded that all consideration to be paid under the asset purchase agreement is contingent in nature and will be recognized when the respective contingency is resolved. The Company assessed the contingent events which would result in the payment of a milestone as of December&#160;31, 2021 and 2020, and concluded no such payments were required.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Other Research Arrangements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2021, the Company entered into a collaboration agreement with Caris, or the Caris Agreement. Under the terms of the Caris Agreement, Caris will identify targets for the collaboration and provide those targets to the Company at regular intervals for review and approval. Once a target is selected by the collaboration&#x2019;s joint steering committee, the collaboration will retain access to the selected targets. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The financial terms surrounding development and commercialization of each product candidate identified for the collaboration and included in the Caris Agreement vary based on the level of participation elected by each party in the development and commercialization efforts following identification of a target. There are no upfront or milestone payments or royalties due to either party under the collaboration. With respect to proceeds from any potential commercial transaction related to a product resulting from the collaboration, Caris will be entitled to a tiered initial&#160;percentage ranging from the mid-single digits to low teens based on the product candidate&#x2019;s potential peak sales revenue with the remaining proceeds allocated based on each party&#x2019;s pro&#160;rata share of expenses incurred in development of the product. In the case of an out-licensing transaction of an asset instead of a sale, Caris and the Company will split all consideration received in the transaction in a similar manner. The Caris Agreement provides flexibility for Caris and the Company to jointly develop and commercialize, or for either the Company or Caris to incur development and commercialization expenses. The ultimate&#160;percentage of proceeds payable to the Company and Caris will depend on the level of development and commercialization participation elected by each party.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company will own the intellectual property rights to the therapeutics developed under the collaboration, and Caris will own the intellectual property rights to the diagnostics developed under the collaboration.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Either party may terminate the Caris Agreement for uncured material breach by the other party or in the case of the other party&#x2019;s insolvency. The term of the Caris Agreement is three years, automatically renewing for one-year terms. Either party may terminate the agreement at the end of a term by written notice to the other, subject to the continuation of exclusivity with respect to any target selected by the Joint Steering Committee, so long as commercially reasonable efforts are used to discover, identify, develop and/or commercialize a therapeutic related to such target.&lt;/p&gt;</elev:AssetPurchaseAndLicenseAgreementsDisclosureTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_5_1_2019_To_5_31_2019_us-gaap_AssetAcquisitionAxis_elev_AssetPurchaseAgreementRelatingToSeribantumabMember_uhzmSNBzfkm5eBJiG2sU0Q"
      decimals="-5"
      id="Narr_thRk93qjF0eeLdLxfSbZ7Q"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">3500000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <elev:CollaborationAndLicenseAgreementsMilestonePaymentsPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AssetAcquisitionAxis_elev_AssetPurchaseAgreementRelatingToSeribantumabMember_tQNsHiiyPk60TadASippIw"
      decimals="-5"
      id="Narr_dZ-TRBkpgUi5aCHCTC2bMA"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">54500000</elev:CollaborationAndLicenseAgreementsMilestonePaymentsPayable>
    <elev:CollaborationAndLicenseAgreementsMilestonePaymentsPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AssetAcquisitionAxis_elev_DyaxAgreementMember_TIOCbS27gU2NoUyO8PZbQw"
      decimals="-5"
      id="Narr_i0STenhLQUaeitYCnrFM6Q"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">9300000</elev:CollaborationAndLicenseAgreementsMilestonePaymentsPayable>
    <elev:CollaborationAndLicenseAgreementsNoticePeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AssetAcquisitionAxis_elev_DyaxAgreementMember_cqZbVZ2gh06l0lshIvlOdA"
      id="Narr_5xvEfdJ28EaKs8tYMWkB7A">P90D</elev:CollaborationAndLicenseAgreementsNoticePeriod>
    <elev:CollaborationAndLicenseAgreementsMilestonePaymentsPayablePerLicensedProduct
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AssetAcquisitionAxis_elev_SelexisAgreementMember_-Up5XNit8UCwOaN4IdjeDA"
      decimals="0"
      id="Narr_lqk0VqP6BE6vE5aACZ_hfg"
      unitRef="Unit_Standard_EUR_QZ9PiilgBE2N3HwLp8Y6Lg">900</elev:CollaborationAndLicenseAgreementsMilestonePaymentsPayablePerLicensedProduct>
    <elev:CollaborationAndLicenseAgreementsRoyaltyPaymentsPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AssetAcquisitionAxis_elev_SelexisAgreementMember_p3VwQWadQ02foloetZBlYw"
      decimals="-5"
      id="Narr_dVyxFosHP0WBw0BZmJgjjw"
      unitRef="Unit_Standard_EUR_QZ9PiilgBE2N3HwLp8Y6Lg">200000</elev:CollaborationAndLicenseAgreementsRoyaltyPaymentsPayable>
    <elev:CollaborationAndLicenseAgreementsPercentageOfRoyaltyOnNetSalesOfLicensedProducts
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AssetAcquisitionAxis_elev_SelexisAgreementMember_p3VwQWadQ02foloetZBlYw"
      decimals="2"
      id="Narr_nmhug-GPe0CGp1a9L5IWgw"
      unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw">0.01</elev:CollaborationAndLicenseAgreementsPercentageOfRoyaltyOnNetSalesOfLicensedProducts>
    <elev:CollaborationAndLicenseAgreementsNoticePeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AssetAcquisitionAxis_elev_SelexisAgreementMember_p3VwQWadQ02foloetZBlYw"
      id="Narr_agWUUlXVek-nnyHoZELStg">P60D</elev:CollaborationAndLicenseAgreementsNoticePeriod>
    <elev:CollaborationAndLicenseAgreementsMilestonePaymentsPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AssetAcquisitionAxis_elev_NIHAgreementMember_I6LRl9X8GkOusRfsCtA2GQ"
      decimals="-5"
      id="Narr_RGHCGyXym0-HpPxy7zYuSA"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">400000</elev:CollaborationAndLicenseAgreementsMilestonePaymentsPayable>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AssetAcquisitionAxis_elev_AssetPurchaseAgreementRelatingToSeribantumabMember_5HWpL8YS1E2KOC6PDwU83A"
      decimals="-5"
      id="Narr_IL-pwx9yTkqIONO4-_Amcg"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">3500000</us-gaap:ResearchAndDevelopmentExpense>
    <elev:CollaborationAndLicenseAgreementsMilestonePaymentsPaid
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AssetAcquisitionAxis_elev_AssetPurchaseAgreementRelatingToSeribantumabMember_6okAWYA92EqLCivJwShcTQ"
      decimals="-5"
      id="Narr_D0krXZNfhEiaXaOpI0aMtA"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">0</elev:CollaborationAndLicenseAgreementsMilestonePaymentsPaid>
    <elev:CollaborationAndLicenseAgreementsMilestonePaymentsPaid
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AssetAcquisitionAxis_elev_AssetPurchaseAgreementRelatingToSeribantumabMember_5HWpL8YS1E2KOC6PDwU83A"
      decimals="-5"
      id="Narr_MqcrC2l8vU-eJS85Sfw8yQ"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">0</elev:CollaborationAndLicenseAgreementsMilestonePaymentsPaid>
    <elev:CollaborationAgreementTerm
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_sZb_K3th-kWfL5-YVdEe1g"
      id="Narr_4NRgvWr5wUa8hkHFgHn-fg">P3Y</elev:CollaborationAgreementTerm>
    <elev:CollaborationAgreementRenewalTerm
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_sZb_K3th-kWfL5-YVdEe1g"
      id="Narr_PQEb2VFfvkux8fJADpRfIA">P1Y</elev:CollaborationAgreementRenewalTerm>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_aL4INDrd_kmJHVkFqZW_Zg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;10. COMMITMENTS AND CONTINGENCIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company, from time to time, may be involved in legal proceedings, regulatory actions, claims and litigation arising in the ordinary course of business. The Company was not a defendant in any lawsuits from Inception to the date of these consolidated financial statements.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_3GxBWEJhlkmYH93NNTxA5Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;11. INCOME TAXES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;No provision for income taxes was recorded for the years ended December 31, 2021 and 2020. The Company has incurred net pre-tax losses in the United States only for all periods presented. The Company has not reflected any benefit of such net operating loss (&#x201c;NOL&#x201d;) carryforwards in the accompanying consolidated financial statements. The provision for income taxes differs from the amount expected by applying the federal statutory rate to the loss before taxes as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Profit before tax at federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State tax benefit, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 0.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 0.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development credit carryovers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Return to Provision True Ups&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 0.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (24.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In assessing the realizability of the net deferred tax assets, the Company considers all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the NOL carryforwards. The Company has recorded a valuation allowance against its deferred tax assets on December 31, 2021 and 2020 because the Company&#x2019;s management believes that it is more likely than not that these assets will not be fully realized in the near future. The increase in the valuation allowance of approximately $7.9 million in the year ended December 31, 2021 primarily relates to the generation of net operating losses and research and development credits.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;As of December 31, 2021, the Company had federal NOL carryforwards of approximately $48.2 million, all of which can be carried forward indefinitely, and state NOL carryforwards of $3.5 million, which begin to expire in 2040. The Company also has federal tax credits of $1.5 million and state tax credits of $0.2 million which may be used to offset future tax liabilities and will begin to expire in 2040. NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net deferred tax asset (liability) in the accompanying consolidated balance sheets consists of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets and (liabilities)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net operating losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 10,303&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,138&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,697&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 295&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 130&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 151&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 666&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 664&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Gross deferred tax asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12,947&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,097&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,945)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,083)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net deferred tax asset&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred tax liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net deferred tax asset (liability)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Subsequent ownership changes may further affect the limitation in future years. The Company has not conducted a study to assess whether a change of ownership has occurred or whether there have been multiple changes of ownership since Inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of ownership, as defined by Section 382 and 383 of the Internal Revenue Code, at any time since Inception, utilization of the NOL carryforwards or research and development tax credit carryforwards would be subject to the annual limitations under Section 382 and 383 of the Internal Revenue Code.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company will recognize both accrued interest and penalties related to uncertain tax positions in income tax expense. As of December 31, 2021, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#x2019;s statements of operations. Since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available. As of December 31, 2021, all tax returns remain open.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In response to the COVID-19 pandemic, the Coronavirus Aid, Relief, and Economic Security Act (&#x201c;the CARES Act&#x201d;), was signed into law in March 2020. The CARES Act lifts certain deduction limitations originally imposed by the Tax Cuts and Jobs Act of 2017 (&#x201c;2017 Tax Act&#x201d;). Corporate taxpayers may carryback NOLs originating during 2018 through 2020 for up to five years, which was not previously allowed under the 2017 Tax Act. The CARES Act also eliminates the 80% of taxable income limitations by allowing corporate entities to fully utilize NOL carryforwards to offset taxable &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;income in 2018, 2019 or 2020. Taxpayers may generally deduct interest up to the sum of 50% of adjusted taxable income plus business interest income (30% limit under the 2017 Tax Act) for tax years beginning January 1, 2019 and 2020. The CARES Act allows taxpayers with alternative minimum tax credits to claim a refund in 2020 for the entire amount of the credits instead of recovering the credits through refunds over a period of years, as originally enacted by the 2017 Tax Act. The Company notes that these provisions did not have a material impact to the amounts recorded within this footnote.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-5"
      id="Narr_LHJFZVqoakOmhquTt20ItA"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-5"
      id="Narr_ci6RH4DKzEKnbry9u00lLA"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_lNj9zsTIp0yvahpbRavpxg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Profit before tax at federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State tax benefit, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 0.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 0.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development credit carryovers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Return to Provision True Ups&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 0.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (24.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="3"
      id="Tc_N1L5JnElF0G7taGAgaCqDw_3_2"
      unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="3"
      id="Tc_2hsTu1-ZW06H4LjACTk46A_3_4"
      unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="3"
      id="Tc_D7ddUUqCKE2hk8jD0zqVLA_4_2"
      unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="3"
      id="Tc_TctIFeP2PEKm4BsiT-Dgww_4_4"
      unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="3"
      id="Tc_HJF_1sLGrE2g_wp8PACpTA_5_2"
      unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw">0.044</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="3"
      id="Tc_eD0NutyWNUqGycjPgFrGzg_5_4"
      unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <elev:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="3"
      id="Tc_woJqCGo2U0C3RpntM4lZeA_6_2"
      unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw">-0.014</elev:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <elev:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="3"
      id="Tc_D2yM8Z6DF02wVwz2hWjpJw_6_4"
      unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw">-0.006</elev:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <elev:EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUpsPercent
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="3"
      id="Tc_lyfAwh5-wE68uRJkyiIo1w_7_2"
      unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw">0.001</elev:EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUpsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="3"
      id="Tc_K7MbdfSjqUu_d5QsWgRrkQ_8_2"
      unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw">-0.245</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="3"
      id="Tc_nbS6nX_AVEyq1LeAaXdGQg_8_4"
      unitRef="Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw">-0.224</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-5"
      id="Narr_8lN92wiSkkW-6uyLTySYSQ"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">7900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_RFXCBSdsYE2_Vzi1sOOAOw"
      decimals="-5"
      id="Narr_sJJRFr6zI0mIRBMzj0dgCg"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">48200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_QVkXeAi9dEuUZNo7SoogXA"
      decimals="-5"
      id="Narr_AZdKSY4a5EG0iByIAgit3Q"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">3500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_RFXCBSdsYE2_Vzi1sOOAOw"
      decimals="-5"
      id="Narr_TTCbxM-Tr0eJAHm_A1VZiA"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">1500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_QVkXeAi9dEuUZNo7SoogXA"
      decimals="-5"
      id="Narr_1D0G0Z304ECunKrrbiBKPQ"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_84h3vvmd-k2Pjsazz0jQ6g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net deferred tax asset (liability) in the accompanying consolidated balance sheets consists of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets and (liabilities)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net operating losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 10,303&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,138&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,697&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 295&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 130&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 151&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 666&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 664&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Gross deferred tax asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12,947&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,097&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,945)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,083)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net deferred tax asset&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred tax liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net deferred tax asset (liability)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_RVbinJeZlUybkASuZfP4fw_5_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">10303000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_ESsr7miulkuoZ-wxEJ8zcw_5_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">4138000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_KFlmdY5YCUWUOObTH3svGg_6_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">1697000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_MJDpeYFi4kOiws_3c6QVCQ_6_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">295000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_clbiTSm3IUCYFL_210FCOw_7_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">130000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_wFQgHZXfL0SkauXNN9ACOQ_8_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">151000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_72k5J6Tb4U2UoXVMPuvWdQ_9_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">666000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_PjcK99Jea0exPZXCgpZh5A_9_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">664000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_fgg0WlasnkePt0xKjPsRAg_10_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">12947000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_czk6aIFUOUWqbhprQDkP2w_10_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">5097000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_Nt1dxHxRyk6SRQhEWkXS5w_11_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">12945000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_ujrRXuP_uEeryA4s35Qi6w_11_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">5083000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_rZT6t64UqUKL0cWXjmhygw_12_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">2000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_0cRWCbsBpU6THHEZ11xnCA_12_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">14000</us-gaap:DeferredTaxAssetsNet>
    <elev:DeferredTaxLiabilitiesStockBasedCompensation
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_coJ1jq4dTkCY3C6vjoiqnA_13_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">2000</elev:DeferredTaxLiabilitiesStockBasedCompensation>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_LHNQh1wXhUK6czaqYLsJ5Q_14_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">2000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_R3q_BW-wo0mQg6ZZczkocw_14_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">12000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-3"
      id="Tc_PifboYsKyUanpbaoaX545g_15_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">2000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg"
      decimals="-3"
      id="Tc_yZbuGj4Awk6S3MWyO0MqWQ_15_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">14000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg"
      decimals="-5"
      id="Narr_tijG1kwiRku0XOB60_7-PQ"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-5"
      id="Narr_BXolBOKBx0eVsqnyIAsiJw"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_Sj4mBt6Gp0OtFxt1m7PAJQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;12. NET LOSS PER SHARE&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The following table summarizes the computation of basic and diluted net loss per share of the Company (in thousands, except share and per share amounts):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (32,039)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,265)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average common stock outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12,132,610&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 791,821&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_7_nAdfS6MEueO81duCm77g;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.64)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_-xHMw6Cns0q3G7uP67l6TA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (21.80)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company&#x2019;s potentially dilutive securities, which include convertible preferred stock, options to purchase common stock and unvested restricted stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Convertible preferred shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 15,736,053&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,021,799&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,761,062&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested restricted stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 19,721&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 34,498&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested RSUs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 200,996&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,242,516&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 17,531,613&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_ZpIvfA28f0u8UYGBU8jEQg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The following table summarizes the computation of basic and diluted net loss per share of the Company (in thousands, except share and per share amounts):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (32,039)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,265)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average common stock outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12,132,610&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 791,821&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_7_nAdfS6MEueO81duCm77g;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.64)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_-xHMw6Cns0q3G7uP67l6TA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (21.80)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-3"
      id="Tc_WVhMIdMWJ0KXGa8zix1LjQ_3_3"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">-32039000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-3"
      id="Tc_g368zNLbE0CfLSq12ycGBg_3_6"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">-17265000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="INF"
      id="Tc_RA2-2WPnj02jYNYfsoLW0g_4_3"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">12132610</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="INF"
      id="Tc_7bDuh5hU302M8ryVwdg4-Q_4_6"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">791821</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="2"
      id="Tc_YXAqZ_chjkSn1AwDyN_eEw_5_3"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">-2.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="2"
      id="Tc_o77xMy_7w0Gy3_V1DnZV3Q_5_6"
      unitRef="Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g">-21.80</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_dEsJ4R6RQ0S2a3ThymSYmw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Convertible preferred shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 15,736,053&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,021,799&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,761,062&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested restricted stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 19,721&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 34,498&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested RSUs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 200,996&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,242,516&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 17,531,613&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_eKa9OMO3pEGjRYGCoRthgA"
      decimals="0"
      id="Tc__7tejvRMWk6KTE0eLyLc4w_3_4"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">15736053</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_WIKQC4DzRE6vI_AOC5-AMw"
      decimals="0"
      id="Tc_YTkoPGGDlEOEuxR_Bw8MPw_4_2"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">3021799</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_a5d4Y0z3Nk-SAUzQFRv89w"
      decimals="0"
      id="Tc_GezfLUiQrUmQgt3QOfdDsw_4_4"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">1761062</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_QSMT7xTslESMy-UsUkueuA"
      decimals="0"
      id="Tc_ALY4uNUZP0mihjquqBBB0A_5_2"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">19721</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_XBvq6XI_aEGrm9k0W47ISg"
      decimals="0"
      id="Tc_2nK739OoWkCG6JfxBeKoEQ_5_4"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">34498</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_H_M1d8Hn4ki520t7iGj3Ng"
      decimals="0"
      id="Tc_Iaraw7MoVkymptJnjMJsmQ_6_2"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">200996</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="0"
      id="Tc_ZlvahLM1ZEezp5bC2N-J8Q_7_2"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">3242516</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="0"
      id="Tc_6vtKcUxslESJhk9pNftnJw_7_4"
      unitRef="Unit_Standard_shares_s0fAi-9omkmV061racDAlg">17531613</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      id="Tb_3VX9-82piUuh_ga2tvrjVA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;13. DEFINED CONTRIBUTION PLAN&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has a defined-contribution plan under Section 401(k) of the Internal Revenue Code (the &#x201c;401(k) Plan&#x201d;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. As currently established, the Company is not required to make contributions to the 401(k) Plan. The Company made matching contributions of $0.1 million for the year ended December 31, 2021. No contributions were made for the year ended December 31, 2020.&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ"
      decimals="-5"
      id="Narr_03_lV2x3sU2H-D8w0rxIEg"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">100000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_HSSeknnTokGKGqDmqBSPbw"
      decimals="-5"
      id="Narr_bj91Jtw-q0SfRFgjXam0rg"
      unitRef="Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>71
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MR;+B,"$X)EP;J/L[QN3KB=YOJ/>7%O\#4$L#!!0    ( "$X8U2M/&5S@0,
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M.\GV7;A".I/!V),-<.CJB-Q8CV@9#]D9[W?TOR72*0\A-XJ]8*P7M*2'[$=
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M+7+[>& T9=((P/]W0NB/%[- >QFW_@]02P,$%     @ (3AC5$-+Z GG"0
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M/=>-)L:$G UORQZ?)X@T2+[PAH)!&X1R;RI%Z%:<+-.+G41IO\4?AF,SCK-
MTL?.?[)A\2-Q]!+[DE1ZS&[M;=@*'G#:D3<L&C ?\0H@-F@QN_UI;=>^)S1F
M>!A/ZEI*TA0*02T(NPHN*!N8U0 $Y@C_="6ZD'$SIJ]1,-OG8@HX(Z=?*:O)
MSS/00@Z2FO7)4/:,?WA4ADS[Y6/Q@E,G9_^0PV7\R/B4L8;X3)+K53 8P!>;
M'RV$V;Z2DPP1>-!VL_FNYP-XJFU7L6)VK,(7SI%N+7: *: QA3/L)[F46 A9
M&2>\G0L%O)(7+-."<\L!"8?(%MY3#;KHJWH =DU%F2@LG.LIL8QW<?,C5O%
M_MDOQV<_BQ4NJ$3R=ZDB>1VH2MZD 52CC21#@L]:1!EN$YL1.0)P[3P;N.5
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M)<!&>M^QIAOV":OK.W%X?9%F:>$Z(X*1C&5PBR;21X;\?<@+J?]..<8UR :
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MTI!0NF5.?R94UH&^9U*:G6$3-/^ZX4]02P,$%     @ (3AC5!0*QBV3 @
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MFSXH&X#^7$IS,NP+_&]D]@=02P,$%     @ (3AC5,VV<T+-!   8 P  !D
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MM4B'\&/_CL/W+B?]K5M?@7KE[[:NTU;2UA? [FMW?9[4M\:->7WWOF.:BF=
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M#P+RTXW3E?\@/=$.</"7!0A9&%J WZ<:M2?>T '-_U"X^ ]02P,$%     @
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M[%^>GP@;OL2$&V]*_OJ!7NM-SI<+.%Y96H#WI&AS0P+:SV$W_P-02P,$%
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M4<L*PXK^$6B\ ]FW6KO#Q&]P_.M,?@)02P,$%     @ (3AC5*)I!'>#%@
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M'S$!&FU8$*3H?:A:$[:(_4G7&VL,[)R4INK40;_9STV/#\\\?T*V]2L-2>
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M/ @H;8!93X70.\,6:)Z8\6]02P,$%     @ (3AC5!"L?..A @  2P8  !D
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MO:C7H%)5NK-AOJ:/)G$GZHT:*:&CEKDT6*#NR([JP>#D1P>M&%4.QC4;C,B
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M"B((S9G"E">)) <S0QB3H,A7O_\V]+WP2)-BKF6:Q()EM*$')9G1;#'ENK*
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MB8 2:J$1W(NT0+@J#*5\'O,NPFPGF\TOKQT.O+8[\!N4=)U1'T9.OYDWH1_
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MPX+^!%!9 _J>2VF.$QM@^+=8_P502P,$%     @ (3AC5"%![Q5=!   _A
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M/HAML]!7)0@3H,<WG*OWCCF-V\LW_0]02P,$%     @ (3AC5.W=UP/J P
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MCU_8/Y>7A\OLB*1+GGQGD3K,C+&!(AJ3(E%?^>E/6E_(TWPA3V3YC4[U7LM
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M;;#*2$^(),.^X!L@]&K%I@=ENDJT"C!+=67-I5!?F<+)X?SA;OS/^>AR/IV
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M O5]R;E\F>B^IVZ]A[\ 4$L#!!0    ( "$X8U04T'X9=@0  (<2   9
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;*V847.B.A3'OTK&V8=V9BLD($C'
M.J.V>^_.3K>=M=U]3N&(3(&X2=3VV]\$$+0@XIV^M"0DY_S."?F?F-&6\5>Q
M!)#H+8E3<=-;2KFZ-@SA+R&AHL]6D*HW"\83*E63AX98<:!!-BF)#6*:CI'0
M*.V-1UG?(Q^/V%K&40J/'(EUDE#^/H68;6]ZN+?K^!6%2ZD[C/%H14.8@WQ>
M/7+5,DHK091 *B*6(@Z+F]X$7\_(0$_(1OR.8"OVGI$.Y86Q5]WX'MST3$T$
M,?A2FZ#JWP9F$,?:DN+X6QCME3[UQ/WGG?5O6? JF!<J8,;B/U$@ES>]80\%
ML*#K6/YBVW^A""@#]%DLLK]H6XPU>\A?"\F28K(B2*(T_T_?BD3L35"!-D\@
MQ032=8)53+"R0'.R+*Q;*NEXQ-D6<3U:6=,/66ZRV2J:*-7+.)=<O8W4/#F>
M/SW,?EQ-)_.[6S1[N'^\^SF?/'U_^(FNT%PR_Q6QE4ZW0!>W(&D4BTOUYGE^
MBRZ^7*(OR$!B23D(%*7H.8VD^*HZU?/3DJT%30,Q,J2BU+X,OR":YD3D"!$F
MZ)ZE<BG071I <&C 4.&5,9)=C%/2:O$6_#ZR\%=$3((;@&;=IYLM.%:9<BNS
M9QVQ]Y!GM,6275JR,TOV,4MK*:3*<I2&B$KT F&4IKK!%F@%/&(!NE"+D2_1
M9=-2Y/:=S+[>\9LQ=AUL.F1D;!K !B78H!7L'TY3"2>]#^K>+=.S3;/9NU-Z
M=UJ]SVCJ*UTX[=^I^;^RAXYC-;MW2_?N.:L":=!]/=P:D:6^6=?S2J3\BZV/
M:UVW88D^;$7_#4(OV[G4PQJ-,S2] 6Z&\4H8KQ.,(H&WE9)]U9 ,;53WV83>
MR;P>(&*SDD^S=3/_R>J$QMP 5W5/H0+W(P%HQ2,?6C8YWI-H_!G;/&!Q3+G0
M77DJ&C-1^/+V4F'VO<&1/)"*D73>\1U!<H,8[Y&X_>$1D$I<L77&YN^(8M51
MK+YWC*629WR6/M>_V(YX=A.>BS]H0C&LX\I64H[;M;Q-$SKR#^K\N$^.R"RN
M9!ZWZ_S9 M$1UZGE\2#;A[155<!N)Z6XVBD%!WW,UM^&K\X[7!UHUS1&$GB2
MA30)0PXAE:#.4Y)'ZN#LHPV-UZV:4@D];E?ZDY_F.ZA,->>GW?(PGXHP1DE^
MCANB@+XWG01G)TQYA2EG9PG;#:8.,U!5%]RMO)P9?+O17?#VCIB8IXA)56N(
M^;G?^_$P3GCJMH:'853EC'QF.6O&SSVX^Z7CF)Z0JH:1]AK65:Z;D4C]2&9Z
MIO5!I(MAW<BKHD?:BUX'C6Z&MNKG(MMRC^!4=8^TU[W_*\S-C'8M8X>)/82L
MZAIIKVNUDUNHCS!7@5;<!8UX+K8:5!S\$ [SDTXCZJ!6.>R^\_$+J \R^^['
M<(R]G_0)\#"[Z1"J4JQ3F?_R+7O+VY1)=H?PH7^*KV?YG4AE)K^BN:=<[3R!
M8E@HDXI!@?'\UB-O2+;*+@Y>F)0LR1Z70 /@>H!ZOV!,[AK:07GW-/X/4$L#
M!!0    ( "$X8U2=7ME.W0,  +H.   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,Y+GAM;*U7:V^C.!3]*Q::D5II$K!)0CM*(N71T8Y6G59-._O9A9O$*N"L
M[3RZOWYM() '.-6H7Q(POL?G7,.YOOTM%V]R":#0+HE3.7"62JV^NZX,EY!0
MV>8K2/63.1<)5?I6+%RY$D"C+"B)7>)Y/3>A+'6&_6SL40S[?*UBEL*C0'*=
M)%2\CR'FVX&#G?W $ULLE1EPA_T57< ,U,OJ4>@[MT2)6 *I9#Q% N8#9X2_
M3T@6D,WXS6 K#ZZ1D?+*^9NY^1D-',\P@AA"92"H_MO !.+8(&D>_Q:@3KFF
M"3R\WJ/_R,1K,:]4PH3'_[!(+0?.C8,BF--UK)[X]B\H!'4-7LACF?VB;3XW
MZ#@H7$O%DR)8,TA8FO_379&(@P#2;0@@10 Y"<!-*_A%@)\)S9EELJ94T6%?
M\"T29K9&,Q=9;K)HK8:E9AMG2NBG3,>IX>SY8?)W:SR:W4W1Y.'^\>[7;/3\
M\^$7:J&1U'N[,LF6Z&H*BK)87NOQE]D477VY1E\02]'SDJ\E32/9=Y6F8T#=
ML%AZG"]-&I;&!-WS5"TENDLCB(X!7*VC%$/V8L;$BCB%L(U\_ T1C^ :0I./
MAWL6.GZ96S_#\QOP?E FT(;&:T"TRJ4%N%,"=S+@3@/P$Y-OK;D T#N@0(!4
M2% %W] ]2UFR3NKVPH[HM6^[7^LR=BF,>%\M@KJEH.X?"J*[)D%V1-SVZP79
MP[QV<!IV)*A7"NI9<7[SF"H6,_5NW10[2-!M>Z?IS45<B.N<QQVI"$H5P<=5
M-.^$'20(FE1<B+N]H.*F5'%C!;K;K73-@ CI-RM!5^] A;RNTV&'Z:$LTD+H
MMB1T:T4Z\ 4^1[RPV(U^ZT]=,.>5HP49FBG+FV'/T_ZT.<SE^9QJQA%)[%65
MP;/2G"D>OK5,C8Q0R!-]<) T*[VP,]=0Z_@Y9.^ !^X&^(1L,>N0;9<TT#TH
M9-A*]R45$/)%ROX[Y1MRJ6K)XO/$=KRFO)&*"/G8^R; G*-8ND#;[#0!48MN
M0.C3$5J!8#Q"^AB&"M:&:2U)^V)^_E8B@I*\ENJJ&M%WVVN*J_J%?2MXK7,=
M8U4E"W<^MQCBJGA@NVE_] .?7,#Q+W[AN/)_;/?@6KL\QJI<& >?G+K*&O'G
M>./D LYE<\25.V*[/3ZLE53Z2&D^'&D\:&^1MA-BY6K$^]QDDLJ!B-V!_L0P
MR;D'87SF[G6SSHS*/>@"$A"+K#F2FLDZ5?D9NAPM&[!1UG:<C(]U8Y:W415,
MWM7=4[%@NE;%,->0YK#D()$W2OF-XJNLUWCE2G<NV>52-Y<@S 3]?,ZYVM^8
M!<IV=?@_4$L#!!0    ( "$X8U2[&O8TN@(  .T'   9    >&PO=V]R:W-H
M965T<R]S:&5E=#0P+GAM;*V5R6[;,!"&7X40<DB )EJ\![( ;T6+-K$1)^V9
MEL86$4I42=J.W[XD);->A1YR$;>9G]\,*4ZX9?Q=I  2?60T%WTGE;)X=%T1
MIY!A\< *R-7*DO$,2S7D*U<4''!BG#+J!I[7=C-,<B<*S=R,1R%;2TIRF'$D
MUEF&^6X(E&W[CN_L)U[(*I5ZPHW" J]@#O*MF'$U<JU*0C+(!6$YXK#L.P/_
M<=33]L;@%X&M..@C'<F"L7<]^)[T'4\# 858:@6LF@V,@%(MI##^5)J.W5([
M'O;WZE]-["J6!18P8O0W263:=[H.2F")UU2^L.TWJ.)I:;V846&^:%O9>@Z*
MUT*RK')6!!G)RQ9_5'DX</#;5QR"RB$X=6A><6A4#@T3:$EFPAICB:.0LRWB
MVEJIZ8[)C?%6T9!<G^)<<K5*E)^,YJ_3T8_[X6 ^&:/1]&DV>9X/7K]/G]$]
MFF!.=VCR 3PF A!;HDE64+8#0--"GX% MV.0F%!QI\S?YF-T>W.';A#)T6O*
MU@+GB0A=J2CU7FY<$0U+HN *D1^@)Y;+5*!)GD!R+."J\&R,P3[&85"K.(;X
M 37\+RCP O\"T.C_W;T:G(9-></H-:ZE7++X_5[?O03%+%/_H\ ZG37232O=
M--+-*](_"5X02N0.+3G+D$P!@3E%J$[QTG&4DATCJ7_Z3=0-W<UA?LXM_)8U
M.0)M6=!6+>BU'"A0W;_(62JVCR@Z_@GJN5$KN(S:MJCM6M2W? -"*DZN&DYB
MW14:O^:\.E:[\]E7H6NENY]_%;KG*?9.$EQK<D3:LZ2]3[\+O?,;Z9V2UMN4
MJ.[!RYD!7YF"(A3&.I?E V-G;<T:F*?Z9'ZH:EE9>O[)E(7P"?,546\EA:62
M]!XZZHKRLKB4 \D*\SXOF%2OO>FFJAX#UP9J?<F8W _T!K;"1W\!4$L#!!0
M   ( "$X8U3-.R_;O0,  #$-   9    >&PO=V]R:W-H965T<R]S:&5E=#0Q
M+GAM;+57;6_C*!#^*\C:DUII6QOG?95$:I+>[>K4%S7-[F=J3V)4&W) DO9^
M_0%V;&]KT]QI[TL"F'EX9@8>AO&!BV>9 "CTDJ5,3KQ$J>T7WY=1 AF1EWP+
M3']9<Y$1I;MBX\NM !);HRSUPR#H^QFAS)N.[=B]F([Y3J64P;U <I=E1+S.
M(.6'B8>]X\ #W23*#/C3\99L8 EJM;T7NN>7*#'-@$G*&1*PGGA7^,L<CXR!
MG?&=PD'6VLBX\L3YL^E\BR=>8!A!"I$R$$3_[6$.:6J0-(^_"E"O7-,8UMM'
M]-^M\]J9)R)ASM,?-%;)Q!MZ*(8UV:7J@1^^0N%0S^!%/)7V%QV*N8&'HIU4
M/"N,-8.,LOR?O!2!J!F$O1:#L# (WQC@;HM!IS#H6$=S9M:M!5%D.A;\@(29
MK=%,P\;&6FMO*#-I7"JAOU)MIZ;+Q[OYGQ>SJ^7U LWO;NZO;Y=7C]_N;M$%
M>@"I!(T4Q&BI>/2,5HPJB<X6H A-Y;F>LEHNT-FG<_0)^4@F1(!$E.7S/NM!
MW7Y,^$X2%LNQKS1=LZ@?%=1F.;6PA1H.T0UG*I'HFL40_PS@:S]+9\.CL[/0
MB;B Z!)U\&<4!B%N(#0_W3QPT.F4L>]8O$X+W@^[QR"^('L0^LR@C2!,H9@H
M0&M"!=J3= >.A;KE0EV[4+<MR29]%V:WQRCBF98 2>PA@A?3AJ;<Y(@#BVBT
M8#_%O8$.VKX>K_>3>F$YY2>JO9)JSTEUQ01$?,/HWV^Y1ERJ)J*]=QSZW2!H
M9M$O6?2=+*YU7.S&%V"DD+(-.KQ-UA8$Y3'22HH*RH9F$T/W6AWT"D1(%*(L
MW^UZW\?D53KR/BC=&'P0S+T^P]J-A^7*A3<L\8;.#=NVCQS0HQ)ZY*3Z71,U
M8<ZCVA1%MWTWCZ*#"0XJ20Q.Y1(!4SK9C>+E!@E[ET'PFXM/3:*Q,^RWN^P)
M!.+K0F-=H&$%&CKY_6&T1N?Q3(MT#GO>Z&6.TJ\=+UTAC$;]Y@.&*^W#G=/V
M)E$(6&R\*T[41XPZ_XY1)9*X^__*,:Y$#KM5KA[\F*>I.?_:^]SM9J_?RQQN
M\[A2.>R6'G<.3B36/YU8I5O8+5S_Y<(J(.M$6N\!7"D>'O[B^Z@ K/,(AZU$
M*GW$;H'[M5?2!XL=[Z3N\4X*NZUWDE\K/C,0&UN32QV>'5-Y:5:.EG7_E:UV
MWXS/S'O %K453/Z8N"%B0YE$*:PU9' YT(=!Y/5YWE%\:TO<)ZYTP6R;B7[3
M@# 3]/<UY^K8,0N4KZ3I/U!+ P04    "  A.&-4\S@ 8WP$  #5$@  &0
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M> 984;8&BH,Y$72)F8I#O*R!IIW';%\&^TX>H%-;U"):";VX0(3W%9#?=4[
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MO[G:32T'HG IV&^:ZW+F??4@QR,Y,;T3S2-V]3B!F6#*?:'I8@,/LI/2HNK
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MP=T7HTFV ]HZ6M1N* Y"FQ%S9FG>-)0VP)P?A=!GQR;H7\GY.U!+ P04
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MAG)A0($V3O9Q&EG6REI7\A9!I0<AI]U*_BH4)'(I^+]EO^8@8,&-_HQ@N*[
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M!,($Z/,#Y^IDF 3]0Y?^!5!+ P04    "  A.&-4Z:]6?U #  #P%   #0
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( "$X8U0"W/OW9@0  'LA   /
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MN13E]T"">U]G3%-.!Q$RC6][U\ND&Z"H9I(1CM+]BK,2)28F9!K?LFE>%>(
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M55U2SQM2'?\[</S?P\?_ %!+ P04    "  A.&-4.(-O)L0!   -'@  &@
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MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ (3AC5)E<G",0!@
MG"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    "  A.&-4&(8?*2X&  "2&@  &               @($-"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ (3AC5+NA&'%(!0
M?14  !@              ("!<0X  'AL+W=O<FMS:&5E=',O<VAE970R+GAM
M;%!+ 0(4 Q0    ( "$X8U1].U5ZVP,  &L2   8              " @>\3
M  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  A.&-4K3QE
M<X$#  !P"P  &               @($ &   >&PO=V]R:W-H965T<R]S:&5E
M=#0N>&UL4$L! A0#%     @ (3AC5.]M8JI]!0  -AH  !@
M ("!MQL  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( "$X
M8U2TZSP13@(  ) %   8              " @6HA  !X;"]W;W)K<VAE971S
M+W-H965T-BYX;6Q02P$"% ,4    "  A.&-4@-8TQT(%  "8$P  &
M        @('N(P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%
M  @ (3AC5$-+Z GG"0  &A@  !@              ("!9BD  'AL+W=O<FMS
M:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( "$X8U26HE=4<!4  #X_   8
M              " @8,S  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"
M% ,4    "  A.&-4XZK1A@4#  #-"   &0              @($I20  >&PO
M=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( "$X8U2%!: /P@(
M /<&   9              " @65,  !X;"]W;W)K<VAE971S+W-H965T,3$N
M>&UL4$L! A0#%     @ (3AC5!0*QBV3 @  4@8  !D              ("!
M7D\  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  A.&-4
MS;9S0LT$  !@#   &0              @($H4@  >&PO=V]R:W-H965T<R]S
M:&5E=#$S+GAM;%!+ 0(4 Q0    ( "$X8U1V#P*F5 0   @+   9
M      " @2Q7  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%
M  @ (3AC5.KGB1RI#   3B8  !D              ("!MUL  'AL+W=O<FMS
M:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  A.&-4G-Y2O=(*  "M(
M&0              @(&7:   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+
M 0(4 Q0    ( "$X8U0&315B>P(  (T%   9              " @:!S  !X
M;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ (3AC5(',A>$<
M"@  &AL  !D              ("!4G8  'AL+W=O<FMS:&5E=',O<VAE970Q
M."YX;6Q02P$"% ,4    "  A.&-4'R'XM!,$   Y"@  &0
M@(&E@   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( "$X
M8U39>U:*_P(  ($&   9              " @>^$  !X;"]W;W)K<VAE971S
M+W-H965T,C N>&UL4$L! A0#%     @ (3AC5*)I!'>#%@  E$<  !D
M         ("!)8@  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
M    "  A.&-4@P*3MN0"   ["   &0              @('?G@  >&PO=V]R
M:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( "$X8U133&3]E0(  &X&
M   9              " @?JA  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
M4$L! A0#%     @ (3AC5!"L?..A @  2P8  !D              ("!QJ0
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  A.&-4>=!X
M/E4%  "&#P  &0              @(&>IP  >&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;%!+ 0(4 Q0    ( "$X8U2#@V8S @0  *H*   9
M  " @2JM  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @
M(3AC5-;+I85; P  9P@  !D              ("!8[$  'AL+W=O<FMS:&5E
M=',O<VAE970R-RYX;6Q02P$"% ,4    "  A.&-4(4'O%5T$  #^$   &0
M            @('UM   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4
M Q0    ( "$X8U1] *]"OP,  (H,   9              " @8FY  !X;"]W
M;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ (3AC5!&<N7[R @
M PD  !D              ("!?[T  'AL+W=O<FMS:&5E=',O<VAE970S,"YX
M;6Q02P$"% ,4    "  A.&-44U01F P#  !W"0  &0              @(&H
MP   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( "$X8U0L
M;WRREP(  (@'   9              " @>O#  !X;"]W;W)K<VAE971S+W-H
M965T,S(N>&UL4$L! A0#%     @ (3AC5.W=UP/J P  @Q   !D
M     ("!N<8  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "$X8U04T'X9=@0  (<2   9              "
M@>O7  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ (3AC
M5)U>V4[= P  N@X  !D              ("!F-P  'AL+W=O<FMS:&5E=',O
M<VAE970S.2YX;6Q02P$"% ,4    "  A.&-4NQKV-+H"  #M!P  &0
M        @(&LX   >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0
M   ( "$X8U3-.R_;O0,  #$-   9              " @9WC  !X;"]W;W)K
M<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ (3AC5/,X &-\!   U1(
M !D              ("!D><  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q0
M2P$"% ,4    "  A.&-4 [=CJ3,"   Q!0  &0              @(%$[
M>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( "$X8U2U;<&N
M( (  / $   9              " @:[N  !X;"]W;W)K<VAE971S+W-H965T
M-#0N>&UL4$L! A0#%     @ (3AC5.Z%%LPE P  90D  !D
M ("!!?$  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    "  A
M.&-4K=3XRJ\"  #>!P  &0              @(%A]   >&PO=V]R:W-H965T
M<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( "$X8U3;<'F0N ,  $0,   9
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M;',O+G)E;'-02P$"% ,4    "  A.&-4 MS[]V8$  ![(0  #P
M    @ %"" $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ (3AC5#B#;R;$
M 0  #1X  !H              ( !U0P! 'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ (3AC5("$^)W  0   !X  !,
M ( !T0X! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #H .@#-#P  PA !
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>101</ContextCount>
  <ElementCount>331</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>37</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - NATURE OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureNatureOfBusiness</Role>
      <ShortName>NATURE OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssets</Role>
      <ShortName>FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - PROPERTY AND EQUIPMENT, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - CONVERTIBLE PREFERRED STOCK</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureConvertiblePreferredStock</Role>
      <ShortName>CONVERTIBLE PREFERRED STOCK</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - COMMON STOCK</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureCommonStock</Role>
      <ShortName>COMMON STOCK</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - ASSET PURCHASE AND LICENSE AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreements</Role>
      <ShortName>ASSET PURCHASE AND LICENSE AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11101 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11201 - Disclosure - NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11301 - Disclosure - RETIREMENT PLAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureRetirementPlan</Role>
      <ShortName>RETIREMENT PLAN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30303 - Disclosure - FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssets</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30403 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30503 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.elevationoncology.com/role/DisclosureAccruedExpenses</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30803 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.elevationoncology.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>31103 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.elevationoncology.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>31203 - Disclosure - NET LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>NET LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.elevationoncology.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40101 - Disclosure - NATURE OF BUSINESS - Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureNatureOfBusinessLiquidityDetails</Role>
      <ShortName>NATURE OF BUSINESS - Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40301 - Disclosure - FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40401 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40501 - Disclosure - ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureAccruedExpensesDetails</Role>
      <ShortName>ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevationoncology.com/role/DisclosureAccruedExpensesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40601 - Disclosure - CONVERTIBLE PREFERRED STOCK (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureConvertiblePreferredStockDetails</Role>
      <ShortName>CONVERTIBLE PREFERRED STOCK (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevationoncology.com/role/DisclosureConvertiblePreferredStock</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40701 - Disclosure - COMMON STOCK (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureCommonStockDetails</Role>
      <ShortName>COMMON STOCK (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevationoncology.com/role/DisclosureCommonStock</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40702 - Disclosure - COMMON STOCK - Initial Public Offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureCommonStockInitialPublicOfferingDetails</Role>
      <ShortName>COMMON STOCK - Initial Public Offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40801 - Disclosure - STOCK-BASED COMPENSATION - Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureStockBasedCompensationExpenseDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40802 - Disclosure - STOCK-BASED COMPENSATION - Stock incentive plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockIncentivePlanDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Stock incentive plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40803 - Disclosure - STOCK-BASED COMPENSATION - Stock options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockOptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Stock options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40804 - Disclosure - STOCK-BASED COMPENSATION - Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureStockBasedCompensationAssumptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40805 - Disclosure - STOCK-BASED COMPENSATION - Early Exercise of Employee Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureStockBasedCompensationEarlyExerciseOfEmployeeOptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Early Exercise of Employee Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40806 - Disclosure - STOCK-BASED COMPENSATION - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40901 - Disclosure - ASSET PURCHASE AND LICENSE AGREEMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsDetails</Role>
      <ShortName>ASSET PURCHASE AND LICENSE AGREEMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreements</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40902 - Disclosure - ASSET PURCHASE AND LICENSE AGREEMENTS - Other Research Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsOtherResearchArrangementsDetails</Role>
      <ShortName>ASSET PURCHASE AND LICENSE AGREEMENTS - Other Research Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>41101 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureIncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevationoncology.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>41102 - Disclosure - INCOME TAXES - Schedule of effective income tax rate reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>INCOME TAXES - Schedule of effective income tax rate reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>41103 - Disclosure - INCOME TAXES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureIncomeTaxesNarrativeDetails</Role>
      <ShortName>INCOME TAXES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>41104 - Disclosure - INCOME TAXES - Schedule of net deferred tax asset (liability) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails</Role>
      <ShortName>INCOME TAXES - Schedule of net deferred tax asset (liability) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>41201 - Disclosure - NET LOSS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureNetLossPerShareDetails</Role>
      <ShortName>NET LOSS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevationoncology.com/role/DisclosureNetLossPerShareTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>41202 - Disclosure - NET LOSS PER SHARE - Antidilutive securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails</Role>
      <ShortName>NET LOSS PER SHARE - Antidilutive securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="elev-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41301 - Disclosure - RETIREMENT PLAN (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.elevationoncology.com/role/DisclosureRetirementPlanDetails</Role>
      <ShortName>RETIREMENT PLAN (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.elevationoncology.com/role/DisclosureRetirementPlan</ParentRole>
      <Position>50</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="elev-20211231x10k.htm">elev-20211231x10k.htm</File>
    <File>elev-20211231.xsd</File>
    <File>elev-20211231_cal.xml</File>
    <File>elev-20211231_def.xml</File>
    <File>elev-20211231_lab.xml</File>
    <File>elev-20211231_pre.xml</File>
    <File>elev-20211231xex10d11.htm</File>
    <File>elev-20211231xex21d1.htm</File>
    <File>elev-20211231xex23d1.htm</File>
    <File>elev-20211231xex31d1.htm</File>
    <File>elev-20211231xex31d2.htm</File>
    <File>elev-20211231xex32.htm</File>
    <File>elev-20211231xex4d2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>elev-20211231x10k001.jpg</File>
    <File>elev-20211231x10k002.jpg</File>
    <File>elev-20211231x10k003.jpg</File>
    <File>elev-20211231x10k004.jpg</File>
    <File>elev-20211231x10k005.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="386">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>77
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "elev-20211231x10k.htm": {
   "axisCustom": 0,
   "axisStandard": 19,
   "contextCount": 101,
   "dts": {
    "calculationLink": {
     "local": [
      "elev-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "elev-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "elev-20211231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "elev-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "elev-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "elev-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 385,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 27,
    "http://www.elevationoncology.com/20211231": 1,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 33
   },
   "keyCustom": 32,
   "keyStandard": 299,
   "memberCustom": 13,
   "memberStandard": 20,
   "nsprefix": "elev",
   "nsuri": "http://www.elevationoncology.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS",
     "role": "http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssets",
     "shortName": "FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - PROPERTY AND EQUIPMENT, NET",
     "role": "http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNet",
     "shortName": "PROPERTY AND EQUIPMENT, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "elev:AccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - ACCRUED EXPENSES",
     "role": "http://www.elevationoncology.com/role/DisclosureAccruedExpenses",
     "shortName": "ACCRUED EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "elev:AccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "elev:TemporaryEquityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - CONVERTIBLE PREFERRED STOCK",
     "role": "http://www.elevationoncology.com/role/DisclosureConvertiblePreferredStock",
     "shortName": "CONVERTIBLE PREFERRED STOCK",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "elev:TemporaryEquityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - COMMON STOCK",
     "role": "http://www.elevationoncology.com/role/DisclosureCommonStock",
     "shortName": "COMMON STOCK",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - STOCK-BASED COMPENSATION",
     "role": "http://www.elevationoncology.com/role/DisclosureStockBasedCompensation",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "elev:AssetPurchaseAndLicenseAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - ASSET PURCHASE AND LICENSE AGREEMENTS",
     "role": "http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreements",
     "shortName": "ASSET PURCHASE AND LICENSE AGREEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "elev:AssetPurchaseAndLicenseAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.elevationoncology.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - INCOME TAXES",
     "role": "http://www.elevationoncology.com/role/DisclosureIncomeTaxes",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - NET LOSS PER SHARE",
     "role": "http://www.elevationoncology.com/role/DisclosureNetLossPerShare",
     "shortName": "NET LOSS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Consolidated Balance Sheets",
     "role": "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - RETIREMENT PLAN",
     "role": "http://www.elevationoncology.com/role/DisclosureRetirementPlan",
     "shortName": "RETIREMENT PLAN",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS (Tables)",
     "role": "http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsTables",
     "shortName": "FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)",
     "role": "http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetTables",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "elev:AccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - ACCRUED EXPENSES (Tables)",
     "role": "http://www.elevationoncology.com/role/DisclosureAccruedExpensesTables",
     "shortName": "ACCRUED EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "elev:AccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "role": "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31103 - Disclosure - INCOME TAXES (Tables)",
     "role": "http://www.elevationoncology.com/role/DisclosureIncomeTaxesTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31203 - Disclosure - NET LOSS PER SHARE (Tables)",
     "role": "http://www.elevationoncology.com/role/DisclosureNetLossPerShareTables",
     "shortName": "NET LOSS PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - NATURE OF BUSINESS - Liquidity (Details)",
     "role": "http://www.elevationoncology.com/role/DisclosureNatureOfBusinessLiquidityDetails",
     "shortName": "NATURE OF BUSINESS - Liquidity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_11_1_2020_To_11_30_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaAndBConvertiblePreferredStockMember_ge5GjDqHukSVK1DEMyGmNg",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_segment_tfgErmtCo0qqRPYk0GJOUQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "role": "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_segment_tfgErmtCo0qqRPYk0GJOUQ",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "elev:TemporaryEquityDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_ogowJGQ-jEis9NJscSX80g",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS (Details)",
     "role": "http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)",
     "role": "http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetDetails",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "elev:AccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "elev:AccruedPreclinicalAndClinicalTrialCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - ACCRUED EXPENSES (Details)",
     "role": "http://www.elevationoncology.com/role/DisclosureAccruedExpensesDetails",
     "shortName": "ACCRUED EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "elev:AccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "elev:AccruedPreclinicalAndClinicalTrialCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "elev:TemporaryEquityDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_s0fAi-9omkmV061racDAlg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - CONVERTIBLE PREFERRED STOCK (Details)",
     "role": "http://www.elevationoncology.com/role/DisclosureConvertiblePreferredStockDetails",
     "shortName": "CONVERTIBLE PREFERRED STOCK (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_EpGg59YM3Eu1afDfRYaHEQ",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_s0fAi-9omkmV061racDAlg",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_s0fAi-9omkmV061racDAlg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - COMMON STOCK (Details)",
     "role": "http://www.elevationoncology.com/role/DisclosureCommonStockDetails",
     "shortName": "COMMON STOCK (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg",
      "decimals": "INF",
      "lang": null,
      "name": "elev:CommonStockNumberOfVotesPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_Vote_IYKGbYhrlUq08si1HNSWpQ",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - COMMON STOCK - Initial Public Offering (Details)",
     "role": "http://www.elevationoncology.com/role/DisclosureCommonStockInitialPublicOfferingDetails",
     "shortName": "COMMON STOCK - Initial Public Offering (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_s0fAi-9omkmV061racDAlg",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - STOCK-BASED COMPENSATION - Expense (Details)",
     "role": "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationExpenseDetails",
     "shortName": "STOCK-BASED COMPENSATION - Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_X-9TCZuQqkap_YeDihjLvg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_s0fAi-9omkmV061racDAlg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40802 - Disclosure - STOCK-BASED COMPENSATION - Stock incentive plan (Details)",
     "role": "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockIncentivePlanDetails",
     "shortName": "STOCK-BASED COMPENSATION - Stock incentive plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_1_31_2021_us-gaap_PlanNameAxis_elev_EquityIncentivePlan2021Member_FexWjG0GeEO3y5ruEl4e1A",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_s0fAi-9omkmV061racDAlg",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_NoXifQvp2kKByDzLsWRTLg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_s0fAi-9omkmV061racDAlg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40803 - Disclosure - STOCK-BASED COMPENSATION - Stock options (Details)",
     "role": "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockOptionsDetails",
     "shortName": "STOCK-BASED COMPENSATION - Stock options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_s0fAi-9omkmV061racDAlg",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40804 - Disclosure - STOCK-BASED COMPENSATION - Assumptions (Details)",
     "role": "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
     "shortName": "STOCK-BASED COMPENSATION - Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Consolidated Statements of Operations",
     "role": "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "elev:RestrictedStockRepurchaseLiability",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40805 - Disclosure - STOCK-BASED COMPENSATION - Early Exercise of Employee Options (Details)",
     "role": "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationEarlyExerciseOfEmployeeOptionsDetails",
     "shortName": "STOCK-BASED COMPENSATION - Early Exercise of Employee Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "elev:RestrictedStockRepurchaseLiability",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_Hc0jKnnQ5EKY8gQMK3Ryuw",
      "decimals": "-4",
      "lang": null,
      "name": "elev:RestrictedStockRepurchaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40806 - Disclosure - STOCK-BASED COMPENSATION - Restricted Stock Units (Details)",
     "role": "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
     "shortName": "STOCK-BASED COMPENSATION - Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JBR44UJY20idUxeLVpC0GQ",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - ASSET PURCHASE AND LICENSE AGREEMENTS (Details)",
     "role": "http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsDetails",
     "shortName": "ASSET PURCHASE AND LICENSE AGREEMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "elev:AssetPurchaseAndLicenseAgreementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_5_1_2019_To_5_31_2019_us-gaap_AssetAcquisitionAxis_elev_AssetPurchaseAgreementRelatingToSeribantumabMember_uhzmSNBzfkm5eBJiG2sU0Q",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AssetAcquisitionConsiderationTransferred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_sZb_K3th-kWfL5-YVdEe1g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "elev:CollaborationAgreementTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - ASSET PURCHASE AND LICENSE AGREEMENTS - Other Research Arrangements (Details)",
     "role": "http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsOtherResearchArrangementsDetails",
     "shortName": "ASSET PURCHASE AND LICENSE AGREEMENTS - Other Research Arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_sZb_K3th-kWfL5-YVdEe1g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "elev:CollaborationAgreementTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - INCOME TAXES (Details)",
     "role": "http://www.elevationoncology.com/role/DisclosureIncomeTaxesDetails",
     "shortName": "INCOME TAXES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41102 - Disclosure - INCOME TAXES - Schedule of effective income tax rate reconciliation (Details)",
     "role": "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "shortName": "INCOME TAXES - Schedule of effective income tax rate reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_KzyWCHq3mUiRbocyO9Dgaw",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41103 - Disclosure - INCOME TAXES - Narrative (Details)",
     "role": "http://www.elevationoncology.com/role/DisclosureIncomeTaxesNarrativeDetails",
     "shortName": "INCOME TAXES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41104 - Disclosure - INCOME TAXES - Schedule of net deferred tax asset (liability) (Details)",
     "role": "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails",
     "shortName": "INCOME TAXES - Schedule of net deferred tax asset (liability) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_PrJN_kYvCEmi08ceV1pUsg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - NET LOSS PER SHARE (Details)",
     "role": "http://www.elevationoncology.com/role/DisclosureNetLossPerShareDetails",
     "shortName": "NET LOSS PER SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_s0fAi-9omkmV061racDAlg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41202 - Disclosure - NET LOSS PER SHARE - Antidilutive securities (Details)",
     "role": "http://www.elevationoncology.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails",
     "shortName": "NET LOSS PER SHARE - Antidilutive securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_s0fAi-9omkmV061racDAlg",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_JVADeYQhFU6aWETRRcQX9A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders Equity (Deficit)",
     "role": "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_JVADeYQhFU6aWETRRcQX9A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41301 - Disclosure - RETIREMENT PLAN (Details)",
     "role": "http://www.elevationoncology.com/role/DisclosureRetirementPlanDetails",
     "shortName": "RETIREMENT PLAN (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_VfF2WbD_yE25ScPehNSjmg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "elev:TemporaryEquityStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00305 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders Equity (Deficit) (Parenthetical)",
     "role": "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_elev_SeriesaConvertiblePreferredStockMember_VfF2WbD_yE25ScPehNSjmg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "elev:TemporaryEquityStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_GlV70A1ZLEeGnrj773P-UQ",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - NATURE OF BUSINESS",
     "role": "http://www.elevationoncology.com/role/DisclosureNatureOfBusiness",
     "shortName": "NATURE OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "elev-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__SXhk8ZRmk-PWQBDUqeLNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 37,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r431",
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r431",
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r431",
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r431",
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r431",
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.elevationoncology.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "elev_AccruedCompensationCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.elevationoncology.com/role/DisclosureAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for compensation for employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Compensation, Current",
        "verboseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "AccruedCompensationCurrent",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elev_AccruedConsultingFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.elevationoncology.com/role/DisclosureAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for consulting services. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Consulting Fees, Current",
        "terseLabel": "Accrued consulting"
       }
      }
     },
     "localname": "AccruedConsultingFeesCurrent",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elev_AccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of information pertaining to accrued liabilities classified as current.",
        "label": "Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCRUED EXPENSES"
       }
      }
     },
     "localname": "AccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "elev_AccruedPreclinicalAndClinicalTrialCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.elevationoncology.com/role/DisclosureAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for preclinical and clinical costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Preclinical and Clinical Trial Costs, Current",
        "terseLabel": "Accrued preclinical and clinical trial costs"
       }
      }
     },
     "localname": "AccruedPreclinicalAndClinicalTrialCostsCurrent",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elev_AssetPurchaseAgreementRelatingToSeribantumabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to asset purchase agreement relating to seribantumab, a fully humanized immunoglobulin G2 monoclonal antibody against HER3.",
        "label": "Asset Purchase Agreement relating to Seribantumab"
       }
      }
     },
     "localname": "AssetPurchaseAgreementRelatingToSeribantumabMember",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elev_AssetPurchaseAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Purchase and License Agreements [Abstract]",
        "label": "ASSET PURCHASE AND LICENSE AGREEMENTS"
       }
      }
     },
     "localname": "AssetPurchaseAndLicenseAgreementsAbstract",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "xbrltype": "stringItemType"
    },
    "elev_AssetPurchaseAndLicenseAgreementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for asset purchase and license agreements.",
        "label": "Asset Purchase and License Agreements Disclosure [Text Block]",
        "terseLabel": "ASSET PURCHASE AND LICENSE AGREEMENTS"
       }
      }
     },
     "localname": "AssetPurchaseAndLicenseAgreementsDisclosureTextBlock",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "elev_ClassificationAndAccretionOfConvertiblePreferredStockPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy relating to classification and accretion of convertible preferred stock policy.",
        "label": "Classification and Accretion of Convertible Preferred Stock Policy [Policy Text Block]",
        "terseLabel": "Classification and Accretion of Convertible Preferred Stock"
       }
      }
     },
     "localname": "ClassificationAndAccretionOfConvertiblePreferredStockPolicyPolicyTextBlock",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "elev_CloudComputingArrangementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cloud computing arrangement policy.",
        "label": "Cloud Computing Arrangement Policy [Policy Text Block]",
        "terseLabel": "Cloud Computing Arrangements"
       }
      }
     },
     "localname": "CloudComputingArrangementPolicyPolicyTextBlock",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "elev_CollaborationAgreementRenewalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Renewal term of the collaboration agreement in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Collaboration Agreement, Renewal Term",
        "terseLabel": "Renewal term (in years)"
       }
      }
     },
     "localname": "CollaborationAgreementRenewalTerm",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsOtherResearchArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "elev_CollaborationAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of the collaboration agreement in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Collaboration Agreement, Term",
        "terseLabel": "Term of agreement (in years)"
       }
      }
     },
     "localname": "CollaborationAgreementTerm",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsOtherResearchArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "elev_CollaborationAndLicenseAgreementsMilestonePaymentsPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of development, regulatory and sales milestone payments paid under the collaboration and license agreements.",
        "label": "Collaboration And License Agreements, Milestone Payments Paid",
        "terseLabel": "Milestone payments paid"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsMilestonePaymentsPaid",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of development, regulatory and sales milestone payments payable under the collaboration and license agreements.",
        "label": "Collaboration And License Agreements, Milestone Payments Payable",
        "terseLabel": "Milestone payments payable"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsMilestonePaymentsPayable",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayablePerLicensedProduct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of development, regulatory and sales milestone payments payable under the collaboration and license agreements for per licensed product.",
        "label": "Collaboration And License Agreements, Milestone Payments Payable, Per Licensed Product",
        "terseLabel": "Milestone payments payable, per licensed product"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsMilestonePaymentsPayablePerLicensedProduct",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elev_CollaborationAndLicenseAgreementsNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number days of prior written notice to terminate the agreement.",
        "label": "Collaboration And License Agreements, Notice Period",
        "terseLabel": "Number of days written prior notice to terminate agreement"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsNoticePeriod",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "elev_CollaborationAndLicenseAgreementsPercentageOfRoyaltyOnNetSalesOfLicensedProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty on net sales of licensed products under the collaboration and license agreement.",
        "label": "Collaboration And License Agreements, Percentage Of Royalty On Net Sales Of Licensed Products",
        "terseLabel": "Percentage of royalty on net sales of licensed products"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsPercentageOfRoyaltyOnNetSalesOfLicensedProducts",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "elev_CollaborationAndLicenseAgreementsRoyaltyPaymentsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of royalty payments payable under the collaboration and license agreements.",
        "label": "Collaboration And License Agreements, Royalty Payments Payable",
        "terseLabel": "Royalty payments payable"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsRoyaltyPaymentsPayable",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elev_CommonStockNumberOfVotesPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of votes that each holder of the common stock is entitled to cast.",
        "label": "Common Stock, Number Of Votes Per Share",
        "terseLabel": "Number of votes per common stock"
       }
      }
     },
     "localname": "CommonStockNumberOfVotesPerShare",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureCommonStockDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "elev_ComputerSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to computer software.",
        "label": "Computer software"
       }
      }
     },
     "localname": "ComputerSoftwareMember",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elev_DeferredTaxLiabilitiesStockBasedCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from stock-based compensation.",
        "label": "Deferred Tax Liabilities, Stock Based Compensation",
        "negatedLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesStockBasedCompensation",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elev_DividendYieldRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of dividend yielded",
        "label": "Dividend Yield Rate",
        "terseLabel": "Percentage of dividend yielded"
       }
      }
     },
     "localname": "DividendYieldRate",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "elev_DyaxAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Dyax agreement.",
        "label": "Dyax"
       }
      }
     },
     "localname": "DyaxAgreementMember",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elev_EffectiveIncomeTaxRateReconciliationPermanentDifferences": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent differences.",
        "label": "Effective Income Tax Rate Reconciliation, Permanent Differences",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferences",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "elev_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUpsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to return to provision true ups.",
        "label": "Effective Income Tax Rate Reconciliation, Return to Provision True Ups, Percent",
        "terseLabel": "Return to Provision True Ups"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUpsPercent",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "elev_EmployeeStockPurchasePlan2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the 2021 Employee Stock Purchase Plan (ESPP).",
        "label": "2021 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlan2021Member",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elev_EquityIncentivePlan2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the 2021 Equity Incentive Plan.",
        "label": "2021 Equity Incentive Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2021Member",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elev_IssuanceCostsIncludedInAccruedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of issuance costs which are included in accrued expenses during the period.",
        "label": "Issuance Costs Included In Accrued Expenses",
        "terseLabel": "Issuance costs in accrued expenses"
       }
      }
     },
     "localname": "IssuanceCostsIncludedInAccruedExpenses",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elev_MajorSuppliersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents number of suppliers member.",
        "label": "Major suppliers"
       }
      }
     },
     "localname": "MajorSuppliersMember",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elev_NIHAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to U.S. Department of Health and Human Services agreement.",
        "label": "National Institute of Health"
       }
      }
     },
     "localname": "NIHAgreementMember",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elev_NumberOfMajorVendors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of major vendors.",
        "label": "Number Of Major Vendors",
        "terseLabel": "Number of vendors"
       }
      }
     },
     "localname": "NumberOfMajorVendors",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "elev_ProceedsFromIssuanceOfRestrictedCommonStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional restricted capital contribution to the entity.",
        "label": "Proceeds from Issuance of Restricted Common Stock",
        "terseLabel": "Proceeds from the issuance of restricted common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRestrictedCommonStock",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elev_RestrictedStockRepurchaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of restricted stock repurchase liability as on the balance sheet date.",
        "label": "Restricted Stock Repurchase Liability",
        "terseLabel": "Restricted stock repurchase liability",
        "verboseLabel": "Liability from the early exercise"
       }
      }
     },
     "localname": "RestrictedStockRepurchaseLiability",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationEarlyExerciseOfEmployeeOptionsDetails",
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elev_SelexisAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Selexis agreement.",
        "label": "Selexis"
       }
      }
     },
     "localname": "SelexisAgreementMember",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elev_SeriesBConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining Series B convertible preferred stock.",
        "label": "Series B Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesBConvertiblePreferredStockMember",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets",
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "elev_SeriesaAndBConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining Series A and B convertible preferred stock.",
        "label": "Series A and Series B convertible preferred stock"
       }
      }
     },
     "localname": "SeriesaAndBConvertiblePreferredStockMember",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureNatureOfBusinessLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elev_SeriesaConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining Series A convertible preferred stock.",
        "label": "Series A Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesaConvertiblePreferredStockMember",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets",
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentageOfAggregateSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement, as a percentage of total outstanding shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage of Aggregate Shares Outstanding",
        "terseLabel": "Additional number of shares authorized (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentageOfAggregateSharesOutstanding",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockIncentivePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedIntrinsicValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate intrinsic value of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Intrinsic Value",
        "terseLabel": "Vested at end of period (in dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedIntrinsicValue",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elev_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards vested, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested at end of period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "elev_StockIncentivePlan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2019 Stock incentive plan.",
        "label": "2019 Stock incentive plan"
       }
      }
     },
     "localname": "StockIncentivePlan2019Member",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elev_TemporaryEquityDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of information pertaining to temporary equity.",
        "label": "Temporary Equity Disclosure [Text Block]",
        "terseLabel": "CONVERTIBLE PREFERRED STOCK"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureTextBlock",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureConvertiblePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "elev_TemporaryEquityEliminationOfSharesAsPartOfInitialPublicOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redemption of temporary equity shares as the result of initial public offering.",
        "label": "Temporary Equity, Elimination of Shares as Part of Initial Public Offering",
        "negatedLabel": "Issuance of initial public offering common stock, net (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityEliminationOfSharesAsPartOfInitialPublicOffering",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "elev_TemporaryEquityIssuePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share price of temporary equity issued.",
        "label": "Temporary Equity, Issue Price Per Share",
        "terseLabel": "Original issue price"
       }
      }
     },
     "localname": "TemporaryEquityIssuePricePerShare",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureConvertiblePreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "elev_TemporaryEquityStockIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of stock issuance costs relating to temporary equity recognized during the period.",
        "label": "Temporary Equity, Stock Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuanceCosts",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elev_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of convertible preferred stock, net of issuance costs (in shares)",
        "verboseLabel": "Shares issued"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "elev_UnderwritersOfInitialPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the underwriters of the initial public stock offering.",
        "label": "Underwriters"
       }
      }
     },
     "localname": "UnderwritersOfInitialPublicOfferingMember",
     "nsuri": "http://www.elevationoncology.com/20211231",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureCommonStockInitialPublicOfferingDetails",
      "http://www.elevationoncology.com/role/DisclosureNatureOfBusinessLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r39",
      "r41",
      "r76",
      "r77",
      "r197",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureCommonStockInitialPublicOfferingDetails",
      "http://www.elevationoncology.com/role/DisclosureNatureOfBusinessLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r196",
      "r205",
      "r245",
      "r246",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r388",
      "r412",
      "r413",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsDetails",
      "http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r196",
      "r205",
      "r245",
      "r246",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r388",
      "r412",
      "r413",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r196",
      "r205",
      "r226",
      "r245",
      "r246",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r388",
      "r412",
      "r413",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsDetails",
      "http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r196",
      "r205",
      "r226",
      "r245",
      "r246",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r388",
      "r412",
      "r413",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsDetails",
      "http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r40",
      "r41",
      "r76",
      "r77",
      "r197",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureCommonStockInitialPublicOfferingDetails",
      "http://www.elevationoncology.com/role/DisclosureNatureOfBusinessLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r31",
      "r357"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations incurred and payable to vendors for goods and services received.",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/DisclosureAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAccruedExpensesDetails",
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCRUED EXPENSES"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r33"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/DisclosureAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r29",
      "r174"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r19",
      "r278",
      "r357"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r79",
      "r80",
      "r81",
      "r275",
      "r276",
      "r277",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r248",
      "r250",
      "r281",
      "r282"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Reconciliation of net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r250",
      "r272",
      "r280"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense included in operating expenses",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationEarlyExerciseOfEmployeeOptionsDetails",
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationExpenseDetails",
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsOtherResearchArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r321"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.",
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Asset Acquisition [Line Items]"
       }
      }
     },
     "localname": "AssetAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionTable": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset acquisition.",
        "label": "Asset Acquisition [Table]"
       }
      }
     },
     "localname": "AssetAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r61",
      "r171"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment losses"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r73",
      "r128",
      "r136",
      "r140",
      "r154",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r324",
      "r329",
      "r347",
      "r355",
      "r357",
      "r393",
      "r404"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r38",
      "r73",
      "r154",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r324",
      "r329",
      "r347",
      "r355",
      "r357"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r146",
      "r161"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r145",
      "r147",
      "r161",
      "r396"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r251",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationEarlyExerciseOfEmployeeOptionsDetails",
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r26",
      "r63"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r58",
      "r63",
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "periodStartLabel": "Cash and cash equivalents, beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r58",
      "r348"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r71",
      "r73",
      "r94",
      "r95",
      "r96",
      "r98",
      "r100",
      "r108",
      "r109",
      "r110",
      "r154",
      "r185",
      "r189",
      "r190",
      "r191",
      "r194",
      "r195",
      "r203",
      "r204",
      "r208",
      "r212",
      "r347",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://www.elevationoncology.com/role/DisclosureNatureOfBusinessLiquidityDetails",
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets",
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Caris Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsOtherResearchArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "verboseLabel": "Other Research Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsOtherResearchArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r35",
      "r182",
      "r397",
      "r408"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies.",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r184",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureCommonStockInitialPublicOfferingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r79",
      "r80",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureCommonStockDetails",
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureCommonStockDetails",
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18",
      "r357"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 500,000,000 and 86,000,000 shares authorized as of December 31, 2021 and 2020, respectively; 23,225,637 and 836,177 issued as of December 31, 2021 and 2020, respectively; 23,205,915 and 800,679 outstanding as of December 31, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RETIREMENT PLAN"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Deferred tax assets and (liabilities)"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r119",
      "r120",
      "r143",
      "r344",
      "r345",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r119",
      "r120",
      "r143",
      "r344",
      "r345",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r119",
      "r120",
      "r143",
      "r344",
      "r345",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r114",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of credit risk and significant suppliers"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r119",
      "r120",
      "r143",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "verboseLabel": "Concentration risk"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r117",
      "r119",
      "r120",
      "r121",
      "r344",
      "r346",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r119",
      "r120",
      "r143",
      "r344",
      "r345",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r70",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockAmountIssued1": {
     "auth_ref": [
      "r65",
      "r66",
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Issued",
        "terseLabel": "Conversion of convertible preferred stock upon IPO"
       }
      }
     },
     "localname": "ConversionOfStockAmountIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r203",
      "r204",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible preferred shares"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r16",
      "r17",
      "r215",
      "r221",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Number of shares from conversion of preferred stock (in shares)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureCommonStockInitialPublicOfferingDetails",
      "http://www.elevationoncology.com/role/DisclosureNatureOfBusinessLiquidityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r13",
      "r14",
      "r296",
      "r394",
      "r403"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r297"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r299"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax asset (liability)"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r299"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r304",
      "r305"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "verboseLabel": "Net operating losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r302",
      "r304",
      "r305"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credit"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r304",
      "r305"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r304",
      "r305"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r298"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r304",
      "r305"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Matching contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureRetirementPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r61",
      "r172"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation expense",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r49",
      "r84",
      "r85",
      "r86",
      "r87",
      "r88",
      "r92",
      "r94",
      "r98",
      "r99",
      "r100",
      "r104",
      "r105",
      "r335",
      "r336",
      "r399",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureNetLossPerShareDetails",
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r49",
      "r84",
      "r85",
      "r86",
      "r87",
      "r88",
      "r94",
      "r98",
      "r99",
      "r100",
      "r104",
      "r105",
      "r335",
      "r336",
      "r399",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureNetLossPerShareDetails",
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r101",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r74",
      "r289",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Profit before tax at federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r289",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r289",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State tax benefit, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r289",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Research and development credit carryovers"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Expected remaining weighted-average period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Outstanding stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails",
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMON STOCK."
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r45",
      "r46",
      "r47",
      "r79",
      "r80",
      "r81",
      "r83",
      "r89",
      "r91",
      "r107",
      "r155",
      "r220",
      "r223",
      "r275",
      "r276",
      "r277",
      "r307",
      "r308",
      "r334",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r414",
      "r415",
      "r416",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value, Assets, Level 1 to Level 2 Transfers, Amount",
        "terseLabel": "Transfers from Level 1 to Level 2, Assets"
       }
      }
     },
     "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value, Assets, Level 2 to Level 1 Transfers, Amount",
        "terseLabel": "Transfers from Level 2 to Level 1, Assets"
       }
      }
     },
     "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of fair value measurements of financial assets"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r198",
      "r200",
      "r201",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r241",
      "r338",
      "r361",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r337",
      "r338",
      "r340",
      "r341",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS."
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "FAIR VALUE MEASUREMENTS OF FINANCIAL ASSETS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r198",
      "r227",
      "r229",
      "r234",
      "r241",
      "r338",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net",
        "terseLabel": "Transfers into (out of) Level 3, Assets"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r198",
      "r200",
      "r201",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r241",
      "r361",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r148",
      "r149",
      "r151",
      "r152",
      "r153",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r162",
      "r163",
      "r164",
      "r165",
      "r199",
      "r218",
      "r333",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r166",
      "r167",
      "r169",
      "r170",
      "r391",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r166",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureCommonStockInitialPublicOfferingDetails",
      "http://www.elevationoncology.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://www.elevationoncology.com/role/DisclosureNatureOfBusinessLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r176",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r74",
      "r290",
      "r294",
      "r301",
      "r309",
      "r312",
      "r314",
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r75",
      "r90",
      "r91",
      "r127",
      "r288",
      "r310",
      "r313",
      "r411"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r44",
      "r286",
      "r287",
      "r294",
      "r295",
      "r300",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalCostsPolicyTextBlock": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.",
        "label": "Legal Costs, Policy [Policy Text Block]",
        "terseLabel": "Patent costs"
       }
      }
     },
     "localname": "LegalCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal Fees",
        "terseLabel": "Legal and professional costs"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r32",
      "r73",
      "r137",
      "r154",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r325",
      "r329",
      "r330",
      "r347",
      "r355",
      "r356"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r23",
      "r73",
      "r154",
      "r347",
      "r357",
      "r395",
      "r406"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, convertible preferred stock and stockholders' equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r34",
      "r73",
      "r154",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r325",
      "r329",
      "r330",
      "r347",
      "r355",
      "r356",
      "r357"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r111",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "NATURE OF BUSINESS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureNatureOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r58",
      "r59",
      "r62"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r42",
      "r43",
      "r47",
      "r48",
      "r62",
      "r73",
      "r82",
      "r84",
      "r85",
      "r86",
      "r87",
      "r90",
      "r91",
      "r97",
      "r128",
      "r135",
      "r138",
      "r139",
      "r141",
      "r154",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r336",
      "r347",
      "r398",
      "r409"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureNatureOfBusinessLiquidityDetails",
      "http://www.elevationoncology.com/role/DisclosureNetLossPerShareDetails",
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r128",
      "r135",
      "r138",
      "r139",
      "r141"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r302"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "verboseLabel": "Net operating loss carry forwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NATURE OF BUSINESS"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r33"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/DisclosureAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Accrued other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets, net"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expenses), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Cash paid for issuance costs of convertible preferred stock",
        "terseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureCommonStockInitialPublicOfferingDetails",
      "http://www.elevationoncology.com/role/DisclosureNatureOfBusinessLiquidityDetails",
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r226",
      "r228",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "RETIREMENT PLAN"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureRetirementPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r251",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r17",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r17",
      "r357"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2021; no shares issued or outstanding as of December 31, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r24",
      "r25"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock upon initial public offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Proceeds from the issuance of convertible preferred stock",
        "verboseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://www.elevationoncology.com/role/DisclosureNatureOfBusinessLiquidityDetails",
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r42",
      "r43",
      "r47",
      "r57",
      "r73",
      "r82",
      "r90",
      "r91",
      "r128",
      "r135",
      "r138",
      "r139",
      "r141",
      "r154",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r323",
      "r327",
      "r328",
      "r331",
      "r332",
      "r336",
      "r347",
      "r400"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r177",
      "r422",
      "r423",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY AND EQUIPMENT, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r28",
      "r173"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r175",
      "r357",
      "r401",
      "r407"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r27",
      "r175",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "verboseLabel": "Schedule of property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r284",
      "r389",
      "r427"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsDetails",
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationExpenseDetails",
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Unvested restricted stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails",
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationEarlyExerciseOfEmployeeOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Unvested RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails",
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r223",
      "r278",
      "r357",
      "r405",
      "r417",
      "r418"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureNatureOfBusinessLiquidityDetails",
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r79",
      "r80",
      "r81",
      "r83",
      "r89",
      "r91",
      "r155",
      "r275",
      "r276",
      "r277",
      "r307",
      "r308",
      "r334",
      "r414",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds from sale of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureCommonStockInitialPublicOfferingDetails",
      "http://www.elevationoncology.com/role/DisclosureNatureOfBusinessLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureCommonStockInitialPublicOfferingDetails",
      "http://www.elevationoncology.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://www.elevationoncology.com/role/DisclosureNatureOfBusinessLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureCommonStockInitialPublicOfferingDetails",
      "http://www.elevationoncology.com/role/DisclosureNatureOfBusinessLiquidityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Share price (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureCommonStockInitialPublicOfferingDetails",
      "http://www.elevationoncology.com/role/DisclosureNatureOfBusinessLiquidityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of antidilutive securities excluded from computation of diluted net loss per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Fair value measurements of financial assets"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsOtherResearchArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of net deferred tax asset (liability)"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Summary of computation of basic and diluted net loss per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of effective income tax rate reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r250",
      "r271",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r250",
      "r271",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Summary of restricted stock units activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r29",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r251",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationEarlyExerciseOfEmployeeOptionsDetails",
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r257",
      "r264",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of assumptions used in estimation of fair value"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockIncentivePlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested at end of period (in shares)",
        "periodStartLabel": "Unvested at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested at end of period (in dollars per share)",
        "periodStartLabel": "Unvested at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Fair value assumptions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Volatility, Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Volatility, Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationEarlyExerciseOfEmployeeOptionsDetails",
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Total number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Remained available for future grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted-average remaining contractual term and Aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockIncentivePlanDetails",
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value of stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Outstanding at end of period (in dollars)",
        "periodStartLabel": "Outstanding at beginning of period (in dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r259",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period (in dollars per share)",
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest at end of period (in dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest at end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r249",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationEarlyExerciseOfEmployeeOptionsDetails",
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r251",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by supplier.",
        "label": "Supplier [Axis]"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received.",
        "label": "Supplier [Domain]"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r269",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding at end of period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest at end of period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r256"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Vested at end of period (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Vested at end of period (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Stockholders equity, Ending balance (in shares)",
        "periodStartLabel": "Stockholders equity, Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r69",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r71",
      "r73",
      "r94",
      "r95",
      "r96",
      "r98",
      "r100",
      "r108",
      "r109",
      "r110",
      "r154",
      "r185",
      "r189",
      "r190",
      "r191",
      "r194",
      "r195",
      "r203",
      "r204",
      "r208",
      "r212",
      "r220",
      "r347",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://www.elevationoncology.com/role/DisclosureNatureOfBusinessLiquidityDetails",
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets",
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r37",
      "r45",
      "r46",
      "r47",
      "r79",
      "r80",
      "r81",
      "r83",
      "r89",
      "r91",
      "r107",
      "r155",
      "r220",
      "r223",
      "r275",
      "r276",
      "r277",
      "r307",
      "r308",
      "r334",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r414",
      "r415",
      "r416",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets",
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheets"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Shareholders' Equity"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r79",
      "r80",
      "r81",
      "r107",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets",
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r220",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of initial public offering common stock, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r220",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r220",
      "r223"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of initial public offering common stock, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r17",
      "r18",
      "r220",
      "r223"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r21",
      "r22",
      "r73",
      "r144",
      "r154",
      "r347",
      "r357"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Stockholders equity, Ending balance",
        "periodStartLabel": "Stockholders equity, Beginning balance",
        "totalLabel": "Total stockholders' equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets",
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity (deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r72",
      "r204",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r216",
      "r217",
      "r219",
      "r223",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "COMMON STOCK"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureNatureOfBusinessLiquidityDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureCommonStockInitialPublicOfferingDetails",
      "http://www.elevationoncology.com/role/DisclosureNatureOfBusinessLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureCommonStockInitialPublicOfferingDetails",
      "http://www.elevationoncology.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://www.elevationoncology.com/role/DisclosureNatureOfBusinessLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Initial Public Offering"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureCommonStockInitialPublicOfferingDetails",
      "http://www.elevationoncology.com/role/DisclosureNatureOfBusinessLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.",
        "label": "Supplier Concentration Risk"
       }
      }
     },
     "localname": "SupplierConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r302"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONVERTIBLE PREFERRED STOCK"
       }
      }
     },
     "localname": "TemporaryEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r9",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r185",
      "r189",
      "r190",
      "r191",
      "r194",
      "r195"
     ],
     "calculation": {
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Temporary equity, Ending balance",
        "periodStartLabel": "Temporary equity, Beginning balance",
        "terseLabel": "Convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheets",
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityEliminationAsPartofReorganization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redemption of temporary equity as the result of a triggering event associated with the temporary equity.",
        "label": "Temporary Equity, Elimination as Part of Reorganization",
        "negatedLabel": "Issuance of initial public offering common stock, net"
       }
      }
     },
     "localname": "TemporaryEquityEliminationAsPartofReorganization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Liquidation Preference",
        "terseLabel": "Convertible preferred stock, liquidation preference"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r9",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Convertible preferred stock, par value",
        "verboseLabel": "Par value of convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Convertible preferred stock, shares authorized",
        "verboseLabel": "Shares authorized"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Convertible preferred stock, shares issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Temporary equity, Ending balance (in shares)",
        "periodStartLabel": "Temporary equity, Beginning balance (in shares)",
        "terseLabel": "Convertible preferred stock, shares outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r148",
      "r149",
      "r151",
      "r152",
      "r153",
      "r199",
      "r218",
      "r333",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureFairValueMeasurementsOfFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureAssetPurchaseAndLicenseAgreementsOtherResearchArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r285",
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Interest and penalties",
        "verboseLabel": "Unrecognized tax benefits, income tax penalties and interest expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetLiabilityDetails",
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r112",
      "r113",
      "r115",
      "r116",
      "r122",
      "r123",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r93",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding, diluted (in shares)",
        "verboseLabel": "Weighted average common stock outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureNetLossPerShareDetails",
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r92",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding, basic (in shares)",
        "verboseLabel": "Weighted average common stock outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.elevationoncology.com/role/DisclosureNetLossPerShareDetails",
      "http://www.elevationoncology.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=27011672&loc=d3e149975-122751"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r428": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r429": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r430": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r431": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r432": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r433": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r434": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r435": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r436": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r437": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r438": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r439": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r440": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r441": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r442": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r443": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r444": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>78
<FILENAME>0001558370-22-002715-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-22-002715-xbrl.zip
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M]J9RD!*)K<<?I>"<>LLE9IO1?$H7#H5V@1T!$P>Y4D"=Q1B:G4DS9QCEF/5
M=Y) 3Q\' V/RFT1ZVO\T[-_WN\9P)N<CH\?AK#_\A,:CAWZW7T])2H*>Z<,S
M<,ZEUT-[F82V.QI^[DUF_=N''AI/>O>]R01FF-/9J/MKC65)+)=+UU%H]*4N
MV!Y[3]#P1G/ "5IA)J3%V/3(_MCJ))$=#$;# $J82_K"D2\=A>)KD,MY:8F3
MVN0!N,EPCN(((CM9SKD(CQ[>#RD^6>+:N#6FT%P!:AD1,F9] +R! M$UM$>
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MV^!UMB6IJ:=HQK#_2[85:8FG:,2C8Q'VRB '!MUWZLT["=M*\)RBR4&4<#?
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MG7E25O!L0M'XLH8\]"*PM"RKM4#RRX@+(J6G=(C/B(==R>L5]*0>HPE"G-6
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MC3 %KA7Q?L" _E'<9^TB;"]\V RG0ZQ.>UYE",I4O^#2PS&AKY"ZRD2G2Z@
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M_4XAU6_L6029/KI!\?]CKY 6,,>N>XO)JTE$KE*])B!,>FH8Z_$%SJ?ZK=R
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MA,HF4E%I."D'=2=/$6<00(KBK2M$F T<QV"I%F4,H3W-/HM)^/R?I#-KLUU
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M0]K!G=A3R-\0MW8C$DWG.+2'%R#I'#/J6ZH8U2QL)G:L?3\YQ'FV\8[TXN/
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MO.SI?91\&GJS>: +4,P;H["@O-A)>] 3&@6QS103H_018V#W41HJQR9-GL,
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MA>RL Q+K^F=%%]6$[<]!V,7T+5E^K^. 7U8G$72S[3%"1F]A9?U?22<KAED
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MSJ8K67:2(3%G=QKW),HPVZ3(:*@:W&GKB'^990>\2<D$=H/3NR<O[0XURIV
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MNS6G!EBRGH[_A(-#1,:MADF><:/$0T;,<TW@3O U2PSR?%;405:[8!9&0(>
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M+><1GF"W'F[UT%\"4WZ$^@M"1H2?K/HG9?"&"O 3$AJ40;HA6OZOH.EC8BZ
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M) +L:U> +?7W\0H?R>%P&OSMDI&+4+Y/(/&($,'SK2MXAJL5TIT;_0MM'L&
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M;IJ)!"_%"*1*]0F!\H['"'2V/Q]M@;-!P^MWQ_[AO>)P1=TBVT)AZ3XAPBY
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MRTM#I];0IQ&.13D\3Q>WS8IC]R?Z%OVX='3+16:&>GAO;W5HD>A16E%BGK"
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M'+1D"0&7@9,MSX8-J5"NL"%"<J^,$<[!SG>,5R3H(]1?@I/F#.\8:\E'JF9
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MRJ/9D?N?3.[KHDY_KN2_N)Y=V+-Q3._'6IU>M]/.Y7N5K=5*=Y+_MV %VQR
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M+?6OS4&L.3NXKIIC=7BE3I[GY$YFE9BB)-)OYWK,+1'7QE0MX%:V[NHP.O=
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M5/;&NN!J2<:-(0/>IQ)15: =P ) *<0AM(3,E=^"#FG&5O[@#(#H8!;;9[*
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M$/E*R:G%^K\ZL=L$)HA5IP:=,7?]5R4M->-U;*">362P8O O!,%\OR+&WC8
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MRK8PB"2-S#:,.+ <Y,-H&Q@SKOU07!TH[Y:IB9[OTLAC/2OW6-"&#$''F>I
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M&/O=K+B^7A29\PGWX F#U16&RBEA -?%JDKL:<*O+Y N/5OM$8<7VO)W0UW
M=PK>EI/;3L';1O3;\?X_A_=GZJ)CV9'?P0F;C[^4VV?BTO^M45C,F&K_;\>%
MMQSQ=UQX&]%OQX7_'"Z</0_Z\3GHH/0<1[> 'VL%DQ@S1W>LSM%+>7(6-?"E
MKG_SV9A:[<_'.O\$/?V*EJGQGI7X##!VSW#9(]4AY8W/=JKVMM-5/O&)B&/'
MY']O9/PSF7SA"EM+Z2XK6@=."A\-\<F/2KV8R1?B4G@6QK!#\X3#7U*A;7E!
M_S<LL=@Q\2VG&T7><?$MQ+\=%_]SN'@N4(OK?H,]!YALW1L.#?:)&(<OY>*Y
M>$CYGD_#F'EH(GO&KN3;<>TMIQ-%WE7$;2'^[;CVG\.U\T76[MU!KJJ!#DRZ
M-N5,%5NT%M@= B_EVOFX)&;!QO/(JR,3\:L]^%0N1EBQJVIA?GL!OC#G^G,]
M?<?>MYR@E,2.O6\A_NW8^Q_$W@O8!]:V#%3%6>F%QA.($VDE(;^8L1?BDC\^
M8]/S&7;,><O)8<><MQ+_=LSY#V+.!U6\,:1B\FL^\)JD1#*;5E[,E@_B$AM9
M"@V]8\A;3@([AKR5^+=CR'\00RZVYNZ%5HUVB8WSMXXL&YBMV3KQ[%_GS5*^
M& ]Y+Z1@>$D,+\'PNJ/I*K^_AMW7>&G3,5XF4S&=(;\O<J=9;SOIK&7D6U?5
MM"OCVES&56GEDDDEG_C5.JY=(=<6\Z.=8/]S!+LB'^HV95U22U.J>ICQ4^UT
M=)7:Z!@KX@UP+[6Z%!G%NYAE3PKFD?R)F(>LZ%\V)Y7Q'@^,:NP"&=M.,THB
M]8DP?\?!?V]L_#,YN!(P5+P&G)H.=YBE\^ET_N5]6Y5XB&&')]CQYBVGAAUO
MWDK\V_'F/X@W)T1G@5EU8H*BV].'5J<(ZR6Z>4!-"NJO_F(.G8C[_0MF4C -
MN^B43R3Y,Q%#_,[T[7EEERC16ML]8<?IMYRV=IQ^*_%OQ^G_($Z?%-R6\5&,
M1@ 31@^*X*L-F[PX6U1)Q@.>'IDFPL!Q)H?PB,B>R"GEOA>I8FH4]'> ^\ZU
MLO5DM&/J6XE_.Z;^!S'UU*6MFZH^)$8H"?^(4E:^1>VQKM(7,_44WL,@9@GE
M^@?M%G Z7L;%)]RIX]M.*SO.O97XM^/<N^R%2V*[E>N6DD]G9>47DQ>N=[D+
M.R+__8E\*_$XJIZE2],>[(U5TR_7V-?5'M5>K)ZE,?[%9UFHMPPFDMA,GK%3
MS;:>3G:JV5;BWXYK_V9<>TEYVL3&,T? =Q7YM.X-X+%9*RDK6?G%]VHIF;@D
M!I;$R#OVO.4$H22RGQFMUY,S?R[&SV!?2>Q8^&^"L7\L"U_:]R(GKE?*%X5&
MLU:J?T9T_F,06$GD%M#PFTO:!GU/CJ&\B$.^WSI36[W.IZ*LIH]__ W_\=]3
M#4ILQ-7>PN:2.$G(B_?V[KH$0%B2Y_^'*1.A1;/__J__"B^^3=1^U[8\4XNI
MEF'9^_^2V?^^AW;5XYPIP0BL2V-MFY)^C'1@XGUB3,C,$;O,YN/)?W]O6[8&
MO\C^HA ,DB+'D^E_2Z&_$1Q+L!R0:2P$,4'/,8-VW'WQFO\=H\7@2\MAW;+W
M;1;7'U,</3(N.QC@C_L))9Y!/("/8F,I)9Y-O]%1S=&-G4ER?C!S);Y1+?Z:
MLMY 1L,RU>!7;'BUI*!OQ-4HJ%=!D$BZ]L^7EI;/DJR6R;72V72RE<JGU!9)
MYSJM?"9-TOE<AJ@9[/B"L[ZY[&1@1+8A/560UFB'VIBRX4BN)94,.H[F7[\!
M:UE<9*,')-;M8>]?MZ<[4L$T/6)(-3JT;!>;DJ&A!701.]V3+#OZ\QZ\0B5D
M1 GY.R:0$W/&/BG?]_RO@TVM_4&JFDC?W:57)W3Q&\\)OD&'G?C6\NS@:SI5
M*>QMT@.XLM6IB']35[+IR-.QS[&%32(FND/WX#L ?P3RP5KVI(JIQMDLZ!Z$
M41S+T#66AN-X;4?7=+ Z%Y<AM2UB:XCVFE\4)5;&YV+'C*M:?HY=6;5F&>^"
M"/4A9;[/"\M=J-.>P)^Q,\OJX^=Y ])W0L\EG,03);KIX-UA;&F&6)H3+"T.
M8),<:P#'C]>![4DSRX,_3> 9\+/>F6UX5VK/)! ? P?.6>U)Q/'/MTT-G8[I
MGG^BXNL!F2U^-=$-8_&[H85L$ !L+#U.'5<?P/2+W^-&==-;^AX;>F-.P?(;
M.O):;7D<SUCZ<K+JRZ%M/0 Z+GUM$'-IT=/AJB=MBK7\:S?O?X]DX^B +,0&
MDH6WV*43HOX?]CVF,\D#OL@RXMP9$D?'<[&# &L-X" K I:EPA%C)ISA]I")
M2:;EP@=CT^D*[$$J=*@T 84 L*7!/FQXB\#,0/8('"1A(IG>H V\ ]9EZTX?
MUC!?K2Z2.HCC>(.A2-;33=7P&$'!4F$NC3JJK;>!F\!:!)2PZ;K4(1&V@0-1
MPZ&<H;%U T%T0!<TNW'IW+(I5E3N21,0MNSZ#?80@6T.AM35@Z[O8)GHFC&3
M5.Q)B<N@YEBW+1.WQ[F8"=3*]B+!GNTN@,.V!A)@)F5,"_X%JG(EF!VA##(9
M5%*# 4U"SC>8YYS#XP(/V&$( ('08R0(*P7(P($S1JB#T(#G ([LW(C@A28;
ML^TYNHE/PJOX,/!Q,3[874B;YDR\PF03[+FMFYR!(L(0494*% HS>P!U^ 89
MB2WN+(&!-+V#,@#)SV;$*;;-#DG@"C\D-MEZ#(%MX3P#TJ>,^Q@HZ7$9'-&>
MAB6XR<4Y!,+CLZINJ]X )F4:@\8O:^&K6R&[<3EX5):J BS97-'M,[ZP @+L
M40W0RJ%1>,P9CX;PAK,#CBBFWT0^<>FMK*3&QGG7 (;3(LA_,K#@>:80X'-F
M%XX@3/1X(\+^*RX=B);ZFGTZGDL_T385CS[1"&0F?F!#,8,'[2>##!VZ[__Q
M_16.(&(HAZP89@;B(F(&F2$$._J4:F'+\,%S4 B'K1K?,N-PB+K+Q&,Y_MN"
M7^9%&UGT4>$2F:-JG5N'+2+JROGO?^4SV?SWQ74M^'N63O9%]L?C]A>R3\*Q
MA;$YX"*&-00VV6;2SZ9=#VPIRP9J'X+4'P-U, YC#8#YHQX($TJX@C80O3<@
M;?8SCBKD,+RD><"Y@:5K3"]VYEBXY&_:X>0.)[_\0"$!>@3R:)"+B$N@)JC
M%'&[L!#0CX10#+YT420Y@9*Q0[H=TCT3Z7SCRO%Q#I:#Y@9#C@&_[0A13OS9
MM:V)V]MAU0ZK'A6OW +FI5HH4(7#1*,#Q*<.&B4AQ"(J.J90<P=$W-MQLQW>
MO8):-T!+DHC[)0 ?N9&G,N/:DGJ@MYE2EYH4H 'V(G')#L%V"/8<!.-N)"K1
M3@<[<8[1(<!N+J%3W6$7E?B.)DOT'D WDF!Y8$3;6%6U0[H=TCUJ& 0N8H%K
M3%]C#C\'?9A=UCB.N1>%[2K$+OZ%7E6+B53=U."X[-D.Y78H]QP^Q]TB>X%
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M"H((X;Q?5LK"6$ ;L"/8#SM.6Q0UXAM]TYJ80EU$\P1V;8)1 ,<R\%"QA3]
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M;HQAF9_#-!8*RP!U3U_$ XI/P/(U^9_L>@[0L;!\@^< +M=A/3&!\D,U>[P
MC2UZL4[-3QQD*5#AJC[?!VH- W5Y*7]T%I2L\=Q4W=Y<\\:539$RQM))A8H,
M:IEG^QR$G=%B/M@B6PDKFMQ5S4*2^-/\MCI@ZXS#^6$^46<W)"RYD#-O,YK$
MNNQ(8%EK<\:$V,;79M"EVBCN8-<'7+45Z6T!/OD%HX!P("K$[0CH*3=F_M[G
MC4YIV#CR=SV@H 1S/Q*K, R9+<M1VO8L;#'X+C:B$MY>"RT1W?6$O\=' 4Y)
MZHP7+>!]<J*Z!E/Z^+A1-R-8%Y:J^VZC2+TD2E!FF/G"C.<S!M)SR'))Q7VP
M$1+F G7QS%&LBH@NX;?M<8TH2/83H1/>U,E@$._X#5BZ=%YQ&Y<.>#6O37N\
MY;81=6/BV"'81O$W8NO[15%^G>QR.2M3W8;8X7-O[M9"EY8V,XG/*R)ULB(3
MS >DL)I\PX8][_=[ ;;%RG[X[:H1?&%Q=,P/"5-FD($\7^=<0-.Q98QI7#K2
M379S)W,"AH]E QM%\K(I2[9E5[YZ(.<8U_AMTJ\RN_2K7?K5ITF_^H,TTRW+
MOA+18-' )\31A83%: J3I8Q3#AP*/%?(2,X^14<!(5EX(A5#-[Q1E648#/!*
MKZZ(7 ^#!&4GF,,7)S@HFFNQ-GUY,\)W;_QQ$+#4UZY;W&Q8;+J@FUUN2Z/%
M5'XWC9#S\5VJ'(NB?0BFR_5 #;71OTLMSYE7G&JP6):HQZX$YO6HX>1I6#R@
MAY#?750G;%%#2MH<H]D#XJ8XOX.^H7?$$''I'+TD*R# 6]<)C9?5W_B#"+W'
M"75 $8O ;B9@4KE!YB#/V>"9%]\QSQNP%?02EF .=L? BLRHFSV@.MYOSJ9#
M(^SJ-PPQB2@6X:E-K&9&9<TU8$>!#XZ5C(*B8\VB"^0FT2P$ M"+B./Z95JF
M9<;"+^R)!A^B*CU<,.I:4]SI3*BB>'F0 PKBLMN(A6&#VC1F5\!\N%JFS_,V
M9>PM?J.RG^#I)]XX\X3[T-+\;'N85P<@!+UB0N<,%ME8%X6#0;(^=Y!C.LY
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M>,^+":H"(M(>NDV87MVUF-[CWP/#\X3XEKDQW /#+8:*!P^V:$P#^QG*QD<
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MH?'QDAI8,"85/MPSND$&[$!^*5">ECA%(I&&I5?I:BSB_>Y9;JQ<CNA1[^]
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M*, %3H8RPG]E%GPXI!F_8E?XF,?&@1/>DD/M/?O[@3P+GIKIF''D$W1A>$P
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MF]#V+3O"8>G)1H4,LOY#90>RX/$Y\ZB9AC- 3'Q7%FL^O^DG?P8,2KDM3C>
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MP+4+FDD<CYK]Y D3_XJA)\1N0Q/8$K4@G8X+_:24-P &J+D2P@NALR^1/\5
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M!G*[8YUI<N1WFX$?;E$ST]V:_-)K4HSBP:,)HP@. K-BAH\8+%CB,"8SN\M
M)JFBH8VTGLB_;L :>-SQ0?6\;^HM)R7_=Q&&Y ?ZYRU:N'==>+=CW3[X9FA2
MI]<MKUDZ?W6YSOMUS[GX[*)N5@O0FX2P/FL+@O!SV$59Z^Z"TB'_&F9Q>"M:
MG?_Z8/S[Y<==L5O1K/6[G/)GE\6'SU70?N-<Y"M=T2O<[(*YJN94867) ?OP
M-1U=>)GWJOL\N>%3/?'K2N;O2C]=_%'FSR(32 /:"G 1MURS$K- 3COXKCO"
M,//L:<1W?T@7Z@X7?,%??UHW6\9[TH_YUUEU?7Q7=;VKNM[6JJN$]$6;)@LH
M:"XV??#J-6[>_];'X^"$"3^T*!?%$TDS4)RQ01ED#)C*!CCC<D"M%W8_J6R*
M(2.;H:)])^#T$S-+' M<W2"HK]XQ6MOKF9C1:_>;TM[YN[W@Z:D5O-J@X:\]
M>8M5UZ80SS-"G2RJ=KNB6#^6 NB&$>6,#(G5!8AF-Y)FXC4K/&F+8Z8'=ME7
M1[.$X*L=P,MI@AWEA6]SN^JUD-\8+(2#1_*R=$U+!)U<9L=G%>5.5W/-.M('
M8G,T6M[CI]\5[\M%(8EP@X,^11+[,OM9:+G'Z_#@\8UA(R7GVY2:[*JY7I>@
MT#]4ZW[-])*4TTGR[7Q>6IPQ3K70M+)KF!( _&LPXV,G+4V")<V0F) *F[CJ
M5B*R6&%AKRMB(=B<KF@-GE8=7[>I+XL5<.2F+A2]R4'W!)=FHY>@::MXC? +
M64;<--0RR=,\;->NN9R=7,[DG\+VQ**;*.<#M,>;F'DEP\-8*8V?]3)83"IN
M:CF5\PJN7DY//:47*HA^OK-B \H/VRKEF*(63<*IL=LSIZICI,NLE=_17\P8
M$)-47M_Z;O@5(4R*5K2RM0KA>SQ'%7KX6M$0T)Q;RE6*X(5_;[%Y-U7KA&I5
M]&7!8@!.;H+0H'Z0AYE%X5\E2,/ $/2NHEY>+&'B#:/S \T(VAPBE>3ELEI5
MW+/6.),.[%]L1MMYB*3H GDT7J-A"8;'0#]5=&JCD7O.P%/&?:QAI.7QTT]J
M]$]XH4ZZA_O-' TU5E4AWRQ,F:@$U_'*L=_N([>H.M[(#17AJ:JU88I8>CO:
M2[HH>2\5K%X$ZDMTTSZ6^(XH1,3'%^6!BZ;JB!J7N(3F?WRSZ&^-S7X&<_S@
M*/@CRSE7U&IN3^BFOUZ8O-2$UQ*C.5BK/(.YET<0]T!X@XV+96@N/L5%(CZ<
M#V&1'1]QUQW_R'MY4V]FY@2J]83\NGDXW!_IH-;6LP5 6-G IBE>PC7#J-?E
M34[D11T=R';Z7G7$AKWPX-'#'_;W'B=':TY56AT;JZ'F@G[QIURX$ALWPA'5
MZB:BQKOI1B>H78A-N!BB^%PXAS TA_N'CY@E^JHS%HLJ3+"V/<#*J"EHZ]5"
M^&;EN(M'<3QL_YBC[Z:M)<K6MN1YA4W?<&0*'UW7%)(W]4MX>X7PA"DY8+RA
M[@!G"LCO=6+6T^8K7'%>-]L:T-%;8VJ9/^M(W^6F2M,^J**!'=6F=P4@O.J%
M84022X-W\"&:A803GQ.B$G9<+.[2^$J3H(/G0".9]I42B$@_'Q[Z^:H\EX]U
MXN8W;(7/C4@[F-0P@@!:6-?]:W3CJ1P"-:<KZ9CL@N09+$OW*TIK;5?R%F7F
MC?!3/O'<XIRQQVC,9  %ZKWD16X.P1P;<WB6VKY!U@MB,H.@:=R%2SKVWN 9
MQ,6'M;LG<2@K-E@;E&:_C)%0@C-V#&;A3VZJ^'E@!:MQ]_WT:V@8$,E2ILC<
M>&Y$,0='WJ8V4 +!=2=.N<8=%<+P6WI#'1W?9'2D&<^=*P 6E0OA5 7=N(,C
MFS/1-<6F+=C?,;1V'1U5 42!^T#]F>3.R7X$>7<,70L-7IFC<)6<M)1-H::
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M9FS7CR<2PN'-W%KT^ GYIT8?DL]Q'G>G%M:;U*B[<BS9%U;)LJ>@P)6RL9A
M\'LU2(OX:!JU):M7%\MP%#1MRO>YIAB98E/K^W:'K[,Y86,T,9,9/V.)3/]2
MD:RQE3WROMQVZ>.#)J+N^/BK)3F74D.'+41?HX-'M=KG53/OUTPUT8XJB&Y-
M) G-B:%T:1P,7A5)=]S;L?%@L\Z0K21KH>PQ="*LJ%RX2(8^8=[\*DLX!W<E
MG+L2SFTMX230 K%D8K'X):FA!ZGC,S)>N69 0<O5,CR;4STX3TS-HDY3:L[.
M,JL@ZU<H8%33[E^H!/"C)Q'_R)%^(VZX\S"*OCL+/F-7[6PXET+3LB1X!G17
M*#5+SPY9;@8>&#29C^<8JM&O?PT3WBZJN>28Q:$%\Y"XR&4BOT5'S.94#@@U
MT'E*.F)\QP[HFYN4!N6YFIJ>RLC@6#X&7X&;3_F$IJ3@_GU9;O%[",NP(LX"
M_>&M<"[7ZYJ7EBG-X"?CG,M9J\K<P? J1+L4R8\1.*B((V?AE02Z9D6( 5=]
MA">+MTYA@SBD'V%XGG1D97:(+R:<*E?/3X&2'=P#IS?))('0N&">+4X9,KL
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MBQ+XJ&R[GHFA9?:1%*.S#-#$3<O0C7BX)5('M.>GC(J"#Y*%@]UN(I P)
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M<TV+U^\K" FU\3>F<V192*</1C>IYQ4F&1L'3TO9]A:U &TLX6X:@(J#0TE
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M\MDL3:B%"H-QKI&0X@LM1\8K$[B$%<V&MN >2VU3IZ?.BG_%X>?O)TQ8P1"
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M(QGBDI0-CX*S14I;%VYG:TXO5$3(5\53(^$!_$/-!?&Z4G]\=6GY-!<*V>H
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MS.1Y&8P%CN(NQ4=-36_J.MX0;QRR-DHEI/,8.YXEX"8+L&B*BPWE"88.AFM
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MM.@RR1Z^@7&!&6 CC#2M/_75*DPX?^XMN;#!30T,%ED(DZ?V(?NRI&9T'5U
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M,3;"1JS*$8M([)MU+$8#2\#'*D!6$;M2+:<_;/U(4I6?>CSO&@H8(H'/@#+
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MA]J)/722803BH.3B[=2R\I9DM ;81%&C*#\G+==P\)WUS8*=AU2X2"G:!>G
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M.&2U&[Q18GH][LAA[)N&51J8C%HS!&PB=;4S*0OISR(U3"^)OFZP?W1R]*;
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M8V]9+CML+T/P"[:0P<Q2>98M06VB,S=+6#$\D'7/'LD%2PP00)3HMGB<KL=
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M5E7^F]QM-RR[050;!W)WX8]2__4 _EJJ&IM#U[&> NBB*I 2!-+U>F?*W5-
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M,%NQ%)S[8% J+3W^2VBRGDRK+IG)(!N=(LS='4ZF/LPBA,EK L.QJ#,K-,N
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MI>Z7NYM6^:-8F8>;+KW+]AIMO^1<\Q)/+,;VB."WB,-8X#.UX]<*=]ZV'$L
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M=N2:'#EU+9"V4!]O4RF=>^N>)_=QJAA3"ME<6.G1BYDVI>@PM_74N1OQCF3
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M4[<4R!W07,<](9<5Y7J0;$U=;H\3/ INB57<E]C\V=A=2D1I?4_AS-%36V/
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MKFOUG8A2^5<(@'G?HF96V(+6M5&B?)U+M/KH,&FIM!OF=A09(L>"=?5X%"[
M6?Q2D#ZR:ES)!))',4)=/CR289"TNEXZ@6*R"/M% >1829G,P[]9K\2J7)B=
MP+)"7+24FLH=3;=4X=#B]Y9YM36Z*E10*#=^L(>JX.?6G[;5>$_7T@VMF$P
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MI[$9KS*.O4EGOQVYMVK4QF@CN<KB.A#U:5AG&WS-&U@ZC&K,5#@=_\V)A>#
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M8@A0,0[_MJ"#9\@9@T=S6CQIU_O8-.\2YRP.13_\G.$7D[&<W\*Z#?N%MHJ
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M?P0'6914/KM9+B'^91D^<AG6U/Y)/>K<D!O[_LC4']O=1MV[[+A(O=/_00T
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M5&%SJ;?)R1?H='*/?7@L392G%H<1W(\=S^_ON2@ E-0^E!Y'&08?^?LI'U=
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MTNU'G]Z$+<.BE[OD"!3\#A_UE8 -,%7P@?H#5>)U7]*;FHZ</K>X+?S(FA-
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M,I7/!>M1ME 2;%G;YOI(WSEO;@0)LE#!F+\J6R7-*2EWUDDX7N3Y*^TI(N3
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M$?7>A##"BSS3PRN:NF*"1/J:@'"299>2C (=[#X1=D9O;^=.$!E@8=TKC*L
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M"8K8=XPD\$% #D*OF/"SG9-V&K>5N@M5;G4;R1$P,^Y(W<%K\LJKE<M>%VA
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MPD\$U$K";<HNHNM(',3"3+%1RI2E958JMO*H(429&GF138$B3RCYMU##83B
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M@3 5C =JU:PT.,W9 \+#5)H(J\3F$SS&%6%=>LQ^1M/<# .]$%,XRP,A#[:
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MR<-)4D;+&VL.=(M7B!S$BXAHJXVYGG!PM0C,(.&=,(T#ST>3@G[3454HG:B
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MQCUT-T!0(D%0[@]Q1!+HWL/::Z_A6<^2D&<E'/J7B67AV :7&W'PWX>\!<%
MUV"#&\0V+V5/R^,]ER8T)S3??3^H75GN<9G#L%.7<A1[)2\RL[+DLG-C2L]
MLG<JF0(8N8.++74497&[]7 0^X'K@ PX,5+#>$R0UJG7=%A=']UFE KCQ_A2
M\RO17:LC#Q*S!A_4,I1&@Q=LN&K,DJ8?6A/:7WA-P3OZ'B'I6B/Y$0)?-?VI
M5>-??3E&HUF)E$>NFH>F3;!EP%T"'X5E@!*%*1KEPAFZ=J>2M0Q?N01>2-J(
M5?0J67(=520%J1AJ0F2JAOJZ>?-V$LU[[\FX6PI1UG8M*)3/15/,@^3H1_'
M8? ":S7X^Z@&,$! I;W*!&1YUL-P3%YX'+->_XVU/;[)-O3XL^T?%!Z_?A(6
MZ&<^<6>!3F0J*FF/10(?(@V@&&%'3!U:>$&[K6?-_W4''09I-@G,N?HS73X9
M-[>O YOW"BMD4%JJ0@H(' 9B\UY)>$-O8W^.#86"G3$/P.6WQ31:,PS"?9,7
M'P50ZQO=[3.F*HWSFY1^ ELEB6NDHJ7EKDO&K6G+J35 [O!JZ>277#.784<F
M^&\N]BA##WHR20M"#8UZ%>P:TIH+\,:!N5VS=REU;W#Y+2/J>-1!QL++1_5Z
M"!<5KN)U+IOUW:D,HB0+0YXEI<IK@B.VQ)6A/NP^>_Z/C4393WZ&#T7)<'>G
M-@J#5I[OIJ-U3_RLI/ :.ZP=;_%VJKVM039@.Y HCA*%EO#$LL=A#&9-L\.;
MKZ $92/)."/!N%"7&QK #J^X(I8$*E11P_ N$4= 4-J8]'+)1D?Q*];0S"PM
MSL=C+%^;<^#F=*C>_?HXN/?1J'7]R-9\-51VS>@+/]@^)?)N E;Q)J+0/E7[
M7N6D(-"S&?)$DFOC$P.M"PI5Z\P$'UKA9->9.GA.7*I'T2CB( 26R/I%:/@)
M/,]VG2'>!":='S16Q$;'NV?F71X;'LQ[I8Z+C?-ZC.;\"?XB(Z3U1@]B[:3!
MFTZ:^^H64X718)QD=B7-;0,'BBU#Y!A:PF$HESE6Q5/Y@/3>]![FU[:LK[IF
M(=)D4#1#''DR&^".)E4MM4!JL&FDM.-#8<!U#;#*6\-.&\9R("0;C(W/%LE
M'/%B72.- >C2G4Q75,%AXT:FLX$9S N][WV;I=(.R/P(;YQ5'A#HF6W,^'6G
M*; E_))J.Z@=F1:W7)[KA_:@=VEILB3?BN5'1>WI7JY?Y.:^LX7L"1+>7;L&
MG&LB&G)2B**DZ0>'D0N]LUGR6V:@:FN-P-R'3<<H] <$^G%@0 HXN7B3VN:U
M]5L#EX_B02N9)AE!"2HC0(D-7*Z<TI=V=%P=?J=-XH;K99X2N>5*6&!)??X&
M%F5%E)?5#;K;U949^'#7&],D^W24!WS-^R-IO\@W[5$K!%Y2V]#O#IU9U'VS
M%HWP&55T:5H]X+?/V+3CR_Z,/C>LW 53>W+!Y(>))3_%%-GYN$^1]2FR?4V1
MW9Z=>>WHU%J:<7O=HLW!K:;RLDU6G^QUGN26&RU0_7HU\J6F%V0MF:A'O]DZ
M%K_[DO.KQ>NL==MT/$9JPUNYLEE^P*Z*[>U(MD]9V3HS?P&'6GHF7[( <AF!
M?1OY@&X3.FZ0#0%[5W;NWT0J"U1QXKA<+-0OJ&UH1B6"!:<P4= _U#E3=F:;
M&X1X-H86JV\($ZUQ,LEOX;>ZT7A6A)B']L1W1@[O0E[S&0WNU_?MW$^G9U-N
MK]FP1KOQJIL>]*?83%*RLUHC*103P+5E4KPEN4*=DAOA5&WHNJ&<1WB< AT@
MD43E$3BPUU#(7J"9E^&M# ;EP'8OSJ7UQH'^V "DWFR>O\2JO$VT2/&H2%1W
M8GX\39AJ)Y^F$H0@<5X3;M89<*!9P&\VRNP7>ZXI7KE;)DG"<JZ'8EM:0TDM
MM&%OU\JH'@\"4'?<Q%OV4&^?=7OS.'DPS<9*T-:[ _VE(/FT/7<($+XAIIY0
MG^B\J#P:E:X-?_0D4R,:QIMGQ?L>KHZO*"Z&%0]H+#95?JN,OEFFWTF9(^MC
M$Y@/%9OZ*;F66(XKFR+0MPTLS#F?[B>]AC86%;E^I4RQ3'Q=R.N"?4&[2BAD
M59:.J(S%U@M%T3$RGY8)E<!2,1(F!J[@P!"]#Y8,-K^D_=ZL*1TWE#ZN)O8*
MLV9ZJZI-N"I+5R'(*\SQ.>UX!8.:2>H CY PG/,ZN*IKV_#8-46"_YO"-^I%
M-!VB(KG!.G?X?Z^0I,*R,3I"6#-02)6-I/B"=_GOX&(;&2M&H% ;4 V:M*G5
M-??'[@]'O")9<5 0K\VTJ$%A<JGHX?CP7#R9.4*NK_RG!M\EU,;;695/36&_
M>S'XSIGDIY-C_D.,M3LPY9_Y*;_@P7D>_U:7%0K8]T/?!$$U3Y -V '#9@9Q
MZI6MV1-MO5V"R!:<TH"]<E1U!$&W<C7(4*+YF];@+F-J=<(&(^G:$)RG+MT-
MJ>.VHJ=A-8^YG>CRAD)@-AS\!:D__W>.@<4W91$9J:S_:X31C'62&H@DK/H"
MRSF*;N$,9-D73M#]T7)ER3]EA/>U8JX-<[V4?C$50=>(DKQ9NS>7E+V?SL07
MO'[YW NO$E0.[G>_^8*6VG8G/H=!1R[1Y,$A$G5NP.)+%*>J?&VRJ70+V+D)
MCQY.Z"66V_Y,77!>^"@NF)9_#MY1%QZ>\O.9.I.3B_-CJ2XU@[]$U>SJX-?H
M$RC\P7/E_>=B=B0JEMRV,1^]1?;(LSE<LXXYEI,BFD,ALZI)<6RY6JD=NY>R
MLV55;SK+OC8,'C-L2, 7K5E'K+1;<@>?:Q/VX%GE4J_$D3H62NN&NRJYH=TJ
MB3"SA) %'HMN&'PG!JB7YW=_+=U7A#R>GHX-Q6*R_76XWY.2I[L]*R-;Y>U/
M+<6>)#*0]B5*M5!(JL*OD69$5S;!/[B)2B]*$S(G<3@#*]:]BQ@QR]U+J_1&
MGYA.B<:S$$(-M6GLMLAR1_#6"KLL@6@>^]MA.PYP!8VM(;7'<<B]PO"DA00'
M,A6$L]A%QB,#]G)PWHBBT0Z>M$)FV3O5SU'=%FPS/@X;U+%>$U@AN4(54W[X
M?PD3-XEE(N!E4HR'/%^OEHX!$ELF>]4+;!V!>B?A^"A_L%M8O320]PZJ)/7[
MI7A81?@4*D =%;>D[RZ_I/L<A-QK8.*)H+Y@U7'T'5\7I3 =X3-"FLM205'*
MC$C6BZ>#J$F"3<]:LBUU&!F_,:\YMLA$E=ZWP\8F0^TIQY\CG:T'W/^2M(]&
MDQ94:T!LYJ6R*,"I>^:ZSS5(;-$+E0O'?,(#AS5GF/&#7U]22:JG%]1,7EY%
MS$^Q]I@'#\:M9K,SR?Q]C^'.2M%?ZOBT%:E0G!J5PUX@A6H%GV2&;=)GV/H,
MV[YFV+R#B==^.5_Y)]COXK QV[+&!"I$K<B5K/$O]PFX*JE#3$/G#;?.P#=2
M+YK\44L:"_+;21+7",JC?/44$=U(R%EDDU4N$8(])[G!018 :\G-M=@7C"$1
MD _DBSA+;()'/\)1(6-_!NN#6<;3J,YF"B!46P1D)DUH\K!.''%P6G$JC<=
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MU^76ASM-KK_DEI^4'6?Y\U)7S>?H>=XV[7QGW1L<FCK3E"X3'7QI4GTWX8S
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M/9#1_F5['(WG<10?'GTPQS/SX7@,NWU^<G+^X>1T=GQ^<7HT/HSCUAX?_LQ
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M6SCWQAL<6+8;(DG#RFFP*7X%&P[>'TP&WQT='1T<GIR>G9]]+S0/B+91Y>:
MNFUV=CPC%NB)ZY645.GP'7Y.K@XA!X-[XWM\;6AN[$IK"VP.JSXK=;_I-'Q[
M,1E-E!AJ.*!@(X*[ZEEE>X-@UUX*91!O,2F.F9UKR$FL_*GXY//1A3YX-*!]
MQ2O>[FL'% $W^,W/;SGK:U^-=[?YA&R I<06*"3)U8]L4 _ VQD>C\\V6 K<
M-]@FU+Z=G([&8TSC\7>X8V=S<> S:]8&ZRP[UX:^-QZ=V*GO*BV+UHQ:NHSO
MX>B):YA(<: TRA#E(S";9: $9/T);&:QBI:ZX[:#-!KLH0-]-#V:'Q_/CS\<
MCT_F'XZGT>F'\[/#BP\79GH61Z='X[/Y82M.<LH@!!._UMOU951%C^F6#DY'
M@__[CD-:\?_W)!,DDSY!TB=(/C=!(J=Y/C\Y.9R>G7TPX\D$3O/A_,/%^=GL
MPWQR/AG'X\E%?-3.3)S]W<(,2@PJUG1OP:7UG(KLDS*?OW[\D-,9AIQ:< @W
M7KIE=<3D6%O+_X4:[?29=ZY7W%O;*VXW5F>R'AOUS9__3UYK)QXXMK'X4UIF
M$(<3C;R)KG%SM%M!1V.\*K_D%(NU*A NGC/P.NXND^*G<1@/O$1#L&W#M#LF
M+<T-\X$)1/XYUU.\HS3/:/ >BUXM:M75O0>]">F+:^>)53$43H(1W_(^'V ?
M5-DWFBT2W44:B2]'E[>Y=,V' ]]8IRYK@[A&":*0DWT##M]!FN=4.^VMFE3Z
M,\$Q%ZCBTQPY,*6)//8A7"4B7!:G,BP60*2B>IMN.<0"$7OZ'1;6ON8/:4"F
M%"M2P4R-Y:(>%\P5H@*CJ#KT'ZRMA!78CO24/Q@80HAAQ((/5P&]86T:F[^%
MM(.MF-RGFW4'1?3V&DR+Q-SLLIZ.FF]+(\ \PUO_<F7Y:^<YK)!C9_/HM&B7
M";PFS76B)>$&'0-6A3V,]*,SZF@LB,-\@?A"(F"9T]8LX>A0;42^U)([[BN@
M'5*X91+&-"KCC7>!]2_4?2RWD2&0'7XE1L=6^F(WF-] #C.S&DJ1U-2D5$-$
M9XBRQCJ8E#'-=)[E*;&F,SG,Y3J<4PE7!K,1PM[(G^9!7""NV1N#\B!0#*Y&
MT.%_N)HH-F;)H,0JX8":+#G):U%+L*V($$:^Y4KZ>H>:1J1I-,U52UOE'"?1
M99:75? 1::-+93Q5CF<,E8@$VE@YTII5]2)WC7Y@3?Y=&QT?U=:HXA$: SCK
MLRLM=XN4WOI@6B=IU;&_._/0V0>U,N_S .#9@!G!?&@[-1*'W_B8Y3?:C0=;
M'&#\.J*HZJ)&?8=H -MOB1><+D9^T"#"#KQ*A4\X7"3YYGLERZ^]733276$F
M,%RI[D!?F Y9@SU)V3)5QKD8@*S$K4ZRHDKY2F@MP(.E:M]2-XXHMG0-2>GO
MRC_>_30!&92X!V-0J=81_Z-"YRVJA_?%" QM##GH7CEJ5+;F%SS"4I-XRTE/
M)'?>XD-8!KQ%I,UG%# 7&6B]F2[X7UZ].\(:&_"F+3XXY #B.A;J?2+A-[\B
MSX\('-#FHN#\C/$8P0X.7KQ[]?Z7M_]XQ6+!5;M: L 3*#G9;T5,BO%PJZ8@
MR/4BF@ZIV!/>>D C7N19/DNIAA!_.<WC%063HO@Z(C0U&7JL%TI$!(,ZX2"_
MOWT6=R)"S/8':GL:*55ATB,.K&Z:1^45!8*XVI6.(+9:$[TG"L5[N^X^CJ!L
MO'\H59:IU)PPZQ!1I*$M"SYE I\1N#;L^F6"" 4<='!M\-6(VR6U O9$XE\:
MRX_A(1::TK* <>D)-?%0BX<+HN#-6I-2UG3?>$U)2F,^(C0([D7NX$YYO.LH
M;>X=?4=62#3^W?9IZ(/<G=E4NMJEUR^?<Q+&'P]G9^EQ.C+86^]16L(9KWVH
M-&&X+(R-=,'"50?V@512@[8WUJ*HWLOUURJTG&GR^.7DMJ;*I(Y-0EX&T+#(
M)E@D"TR<FBQ>YHE26MUQ#EB,[?)=3+ E_:!__-MS#9-GW9L)W[FZB5;==E6X
MJUL>NE=HC21WGGC5:-?<46H(L^TH$M(&LPFM'!Q;\  COU<0 =-8O'E%:(G8
M-+<5?JYJ6;:YJX9_-)!*NT&]C+G3=]8Y3S[3MM6!\PJ\]_ANG760AN"R5?1:
M*H@D6-V0"\&TY:>_^5W+P0S5G :_,;8^6N1'_%=TAA9.8&G)- '+2H)L0N\>
M%T%1UD2U3GV,H(HL%?QAN7L!\_8;EC!1P>'8"18HX1?Y%6[-I*71D+J1JF46
M27S L )ID(5E]DSJP)FB<!YL(X>H ^^5].=;7EI)AU26>U_9@:P<#=!L0/O>
M?,3[MR(^@]^P IHJYEG.V<*R8]^OR/F]QX9_JTLT96_I?\CA#MORC;SFYZ *
M4C$FQI,+WT3!3FYQHZF:Q]ALV0BD[YMZ,KEGX-%5"4HE3ABDJVW>I!K5;GMH
MW.(I3-* 9Z+-1(HG  YVD@]=F(52+W2,BR@IF81.B)B9Z@_T ;6LD:0\TQJ
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M)FR!UHG[19@1T,X*>G.*I7)EHK3B8X!R25Q&LRLP  SR!T?D9)'8WN1%*N1
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MDI]O#AR^<1R\\?..%=T7-<6)"A_[QY]%H;":9-.C_$#L)BFQFHA4$,SA1.:
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M7D(2"<@%UAY$K;2J8WJ96$J:VIU0!B(V.AW,?>H>3,TTYLLXK4Q9K2*FFYJ
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MP*&W9U"2O!V4)&T')47-1AXC7!$U&XEP[K%"9/?4;.1SJ*9ZG:C,SQ53Q_E
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M"["VZJ7:"\5P9@N+V2 ;3#S']\1[[P;9?H*-S-?YDF0T,:X2)V2M6.O6Z@.
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M^I>@+X25O=.[XR_8CJG]>F5>F(<@\ M&_&_LW?< (#YHCH4E] YF6YX'Z?+
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MB7JQM=;4,JDX\4:!365 X81OH_,6ULJFRG23777QM+B6$BC6!BM],,UJR^0
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MLW$5H48 J/%]=E380,.(XFP\TT&S_7,'8&\)#!?%D-MRRKQ3V#Z.5H@<-9'
M#5"1W;3WN!_?S&8D6,1> V:OY OJ&WMYRVC#C,V9X41H$W&8B,.$A<-@#^3M
M/3?_B?R[Q_EW(_84L:>C((-[P^KO!VTB!>B"/LW[09NJH$J0N@TW)86)ZDLM
MB9 H(._G_2#1=FAHA#<7\8G>#][XA\[^N:OT;0;UK_\115D>#*[K/?WN_ E!
M%PQ1C@E.+"6+\K@O6QO<P9#M?&$41N+G)*NP0>>];_DBSN.M,^/R8'A'-IZU
M^QXNV OQ&3*Q?]0EF&&?M@01Q"1C,T-UZF#2-^=^ \9A&Y)@2;PW*-GF;7C
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M$(*BX, J@B\]S!AT&DL 6DJ^(Z4]*FRNF2V52K6JRK:'-K64.]...F=XKS(
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M4 <VI^X:7OS\;J=?;:FX[=B@#HMH+U!K37Z @NL5AI!^S4&X1BNO.0CG4U5
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M1=F[IF3X,737&-8KH_&FV4Z@>+07311,H8)Y)'6[WW':1= M5]0!,#KSUM.
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M_+G+S:8/@HI@W ,6RXCT>A!X\.((P$XU'S$L1>98*P00#>P4B+8.A]1D2"B
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M<$@?5I#?M!4\23\A4Z3>=VEPLH/EGVRSTJ*=KKP'>L8>Z.)S:G_S';;[.X"
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MD,X^@%OX&8Q[$CO:L,@0]/W<MH$V2#R(B [\94]-)Q1 V_ZP]HTAT>==$;;
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MXN-AD@7HSX6-WL8#/8!.7M'/4EP'7HIK=N/]>.\.2R4*7>9%M?8?+Y+,3_*
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MHE[(W>$-IR/\'PP32[5LK&IC40G:-!V,"PIY,#1XG91[DMX,B?BMF+[FRU]
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M]45(G>]9V/A6P/,?)U1.HA[D?%QS6(!TC*+<?2D]/_)R+-M)F=.F3)/]B"K
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MM=%FONQ,>H5HU@XD/8@_AX.WG8MBKY8UY[U&6D*+[& YJ2>FCW%0Q!-O),>
MPT]']GG<?6>E^ ^Y]'POA 9EF(#HEAM4'(^KH13O=^@-<\\/>2N>>IBI+\].
M=!Q%Z\T"4WQ:N W1"IA##PMW<%GA78^=$>1+8E#C5Z]-E?PRQJ:"X>B8'<A$
M$LP2*NFQ0G_W1JW_GBBKR1MP#+M.8=<12QK,AV)HDM9%O \[)FVRZ9HRGL;+
M$H]Y)'4;$@KQ$H"*.@!&1Q2LD*U*;@Y\+.K V(V9</[R%>YX,O".&^-4IL:I
MI=I'%>\#?G+_#0,>I:W#++R.Q-:>$B5IDYEME'XUDN5CJ\[]!(N\^$TRFKCA
MXR$QE4..(I9HRPF>=J"&HSW$J44U"8]O0:E#+\@<J18S*8E7&'0[+]YRVGS=
M+;]N?[%,>Y #48),;)#8FPI&R3:,TO9MOJHP98WJ:JZJYM9>_ 0!==HKPYET
M*RE>%<JY_B1V?]=K?J5RLL@/M&Q#>URUY_%2XD'L&=+]&@N"&!^]B?'[?1M\
M9!/J>/@25>4R<*L75&N<G%5[TG+P.A &R;OZV%F?1>69=\T*,HN/,7[IO,X*
MKZ-4_OFE?FDJS[?DQS.K3L77Z)UD=3-5'E50HY%=56.Y)<1"CX1"=S0G@K%0
MS>F*W%]![L>5+-M6[\5(MLP7YO&'IY(4$V6T!O=8R/ >OQ_A0&AIJXAQ9_06
M!*N4+7 7(W,%OF-\CT/K&TQ5W]LQG),7X*ZA%V>#'>_.,.\<*-!R\1PJ>"LO
M]Z_-\D!*2TY^A4IRO!N=Q" =+GD33\1OHN)1XSYX6X;';8B(#CSH"Q-2?<M5
ML>#[_A@B>YR4FU$S"9[6B9Y RM[H1DPTEU4=OB"O9%4C06MXJ4*.STU,2)TA
M$B7TRB>;I!5V11TR'L!E5]-D3*:[!>Y?0CJ?7\'\.:33O!L)_>)"C<\BI5I1
M%"6GWNN!SIZ^26'DIY(AI1CO(IU@V?X[Z&?D&1>N6A>@(N^=1XHK+X,0A70X
M(8:F"EU(YQV94,0@D4@A)1F/#M H+@]B2DP>I(3A<" HREB6HTIZB)0_:.:(
M[/9#:8R=HAJK3=.2?'??&Q2*[6Q6J4.4=O?)=&6EM(?MBLTO1X-B<Y2-/R0[
MF8&X_V2]_/C:M5MJA<^-GGI#VR[W4*>.GXSO/OF\6#SI\5EJ,8M$QM8L'\VO
MI79F$-U?LZM4%DCKUYHS-8?N<P6Q4"\@&&3'[SZI)I27U\C\+MD6%[6I6C:D
M17X)PROWUNP+J9C9ZN57_/SU994<WD6>Y%8&/[FW3R.7>NC,BTF1[TK]\?VC
M[&1[29B"M?=VK2?J><%1DK-$I=KJ/M0BG5(Q,TCL/UEV=.4NW2_Q[4W+DHW*
MK&>N\A-P+NP^F5@Z[5:AZ%AM,1L5-I'L6!B\P)/N/D\=>-^&V"$M;SNTJ %Y
M1#"" &LO1'QEH6[+U7'VP_'W@Z;LB*G<1LJ)Y4)LD%U.1XO)?MN7\.>^I.U+
M2)I/ZI:&[2/93%/*0R2_)E6:F5:Q6B'<>/(TB-$4*^F@N$KSA69L$&K220=;
M%/B1E-$P#LA/507;$,9$A\ U37PFF-O'4Z^$JJ.28V7;"6V>*"0W3Z,5-NA/
M _F ]".B-S(DY7_^L8ZN<Y8CRJ,"[6FV)4'[#@2=-/$DW00L-^.57#_&@EE3
M%BGEQ_^O&!@^:XOS3^+^\\=)E.)=Z1Y,)@4*>V]?)]*#RLOOI+W%H&N/O+#0
M#_<'_T8@'9*E0D)2X(@F$P:3+WV]QUCFY7YZJVVZ;V6K"?18[^R[*=Q&D\<Z
MV?G2&'WK&WA-!2/)!8G[.[%I?M!450AGOYDBRB!-7NP^*@\QK3@V.G%JZ.>T
M\]JF^/YR2T'QBHA+0(1P&SLZN.2*B',A@K\].KKBBHBK:/J]$'$539>""/XV
M?G0DT!43'\/$1]O%OZ6VGN_4J3!3]2S]F=\2RR<N?'L3*A\$ C:2X,/_]T?\
MCY\%2.(VNM>:_:P#)%+O -BQJ0,]))N<1'+X]_R^[N0-_P2"*]M<(-ND]D!P
M#.44K?O_W1LUX?&'^+/\(8BW_/?F#_#)?=H,CC.0P:^<]<R$(7YWPN!#1>..
M%L8?N)<"<$QZ<-PYYE7F7BJSG14&GZ:I7#!#^9WOUI^?H75\]40WB./+YFA*
M(M5CM$*:L8 HQ*>1]U<?\$LFQ(3/</QV,V&HK_$+3O*54V#>"GYZN7?ZR)@C
MKU%-F04O _EY+G=E]'%^RUL2C1&RS+VG2+J5ZSOUY0Q_H8?RZO2YO/J%(3,T
MC(K&X5%6]NZ0B3/W<\6ZFSY-YS-Y<_<459*Y5H6'S 4RU#)VFH%15PGQ[25$
M/'P^Y^\D(OB B. _742\6//F'3]9U-H)>;X<%ZH34Y+6YQ<1-4LW6\:ZN9 >
MGE;KC-7+FHD$)"+!#.]C$N(;6 <%I",3AEM"5];Q7-55RS:)E_D?H.F?4ZK]
M(^?R,DWH-Q["^YEJ$>,U+/(R 4X+2KWJH"X(:741Y1^4EK*Z4]+IZ%WF_%)O
MKDH=?3IQ4GPS7U#GJ59Z&'E<#^*@& DW4?'8P-^KQ/B-)49\;U#H[RTR?D5-
M>I_($!ZTHAV3^Q7^H9A<SO+ZXW1M?X$MI0L)LY!+1Y29HW9CN>&JJXB=#!89
MH"CMM[7_[DZD-[-A57VD.6.:"<M26_6);W[XU9+\;$ORRP?YGL\9]>5'O209
M^]Y4_7-+Q%Q+,8S<J#J0(O8XTI\W%+,W6P\25(F*)T\TD/PJ%2Z+5<[H@/KR
MLUZ26-A5O>Z;3333]98Q*SP4EOGY,MNL#;_ HZ0JW=4SW[:&TJ;ZVK<>]>0L
M>0\E8UA1BN\/V;B0&>?O9.)3S]OX>#\^4K],6]+NU(V><]^[5?;VVN 0W93J
M;6J!-V7]('53I-@U=-?>B 3R"'RRG83@EMX>/K/OV_@1_[=OR3GE-68YBQOA
M)PU=(YT825TNUF.WE;G>=V_8AW2ZLFISJL61\B>OI2P[(_X=L8(XZX;U<IP3
M^P7_"C5ACH;9W;9NF"\24QMT>"05YM[;R*S6.5Y34>@(=#(JB'0ZC/D['4)Q
M&?EA81K6 C_J0&$:*8=T1T1X96G1-&O7O2;CK,BXU^WZK/=D4\KM;L5KI4O;
MBA*P>:-FW5+H&])[%[.GO>WM3>'K8J'1S%A;]+%'%@L3BYS N%EO+$:FX7M^
M;W60H/[%V[Z'1[(U9:^_@0XQ1-!AVG"W!("GJPP-'4.,?KQ;Y&]A<B5=/#!M
M>.7^)VSF%0MZV@#VP18CM%>'2^/P=^ +=\"2R-^K]ZJUF77+?*^AS9*"7?N%
MON$'JCA-S"$38L=G-WNUMAF 8[!YTQL]BA6QI\BZ]I"?57.6\,PW2[I5AFX_
M-[%4]"86.]HX8+>A),:U!MC4??AB3\-D8M;ZTS"AU>LS)GO@$']M/^%^*\#\
M3.QPK!'^EEW&\K8]K$]&0(V_REHE!(:U,,H[(F!NN2HL!V)E#EUF;L[1BN0P
ML;$A.$%J$P6WZ=\B>O<T1/83+]:']50DTJPHZU_H0_%9U.8V6[@SS * .I3H
MI$*]NXRMYN-90INDK5@QUWNRR;3)I,C?B.F0QHZ,C.@4[(,=':Q#G4^H: GI
M$L&H-$ V(;3!K55-@]O31&2P3V!JPG:('"? X@CZ0^-_\;=%O Q6FR=3_$M4
M<&7\WC[PS25K[GVA(<NB?WTG_6$R1X.'UTTW=[^,SMMJ8VB,-M5T?B*O/V;,
M0H.E!B"<4"'\]BB_J'-GOM,XZ:/$^B(_IP2ID'IM+U]?FJG:HBS4G@.1AMA[
M9T3],IUFO#F.N_*QADS8OCQ!^*G)Q$03+&+H0]6MD/((.B+Z1]D]=89R417O
MI.I,[BVCY<13S(21UGN4_"]7:,GN*WSD$-XKY>WF>-YCZAPK%?@ZAPGP<+,C
MLE2 '3"ER^XK_2VP;63.R8!-3*2&8X8UP>8RT*5[-#V%9 RGS5^6DW?HI?M<
MX M(JD8W<=.1M!@2?J'+Y@GI+WQ6^LHT[*<A/^,?)/WI@>_;FY<4-""^$1(@
M*A-OB,KQ>*N($D&F;H45&^7Q3QA]E;B.OD+7T5>AU/KVZ"O6-BF:BB7CZ41R
MD,(B8A 38J.!G$+) =8XDW(R-1X)RGZ+H\HZ;Z4WLQ:?J+0KCXVIW-L(:RRW
M8KM/EHKQQ%UI:':D>;:L=9[DY:2OP)/)O<9%RX<[9?$Z?Y9R]W(O7Y)[R:@#
M;9/VUGR*]LO9EFE/^ ?K44NUGFK9@@6MF/;6'+[<Y^T7^ZX@%=;FW6/;T?*=
M!CR9WGVR(W?R*;G=;TF%WNML8:;GBV&Y'M:*:5R=51*E=:T]FT\>>3&^3MDJ
MO\9/[NTSN8RV7];)XFN[.Z\V6W)BC.X'$_SDWC[;DE9N\]G$9";&Y'Q-2#C+
MA09K[NWS1<G,-\E%3&L_Z%']Y;7#5_./H8V@NK%6)6/5YPU)?.BK"W46?WK1
M(:MJ;Y\1;?983%3,PFQIIQ/YKFJ5'6&"G]Q[NSB;9FM(E/I\=YJXG[XDUHGD
M)K015%))E8RZG9#;U;7Q<I^4T_67"3RY]_:-:73U2/Q^(8GQA]?DTVMY/4*3
ML)9114M+WDE"J<S/U<[PH78G:>EN9I#<?W*9W\B+.S$KM)>MY52N/&ZT!ZV.
MG]Q[^W.U:V76^,+D"YN^DD;B2S(S6N,G]\X^BLP7;?6U,)PMY:RAI>*Q>*N4
M&:3VWYZ?Y55IJ$E]*9?,WR?*K\M>OUC'3^Z]O=R/HN=B-_7 SU^KZ72\9O5[
M37AR[^W)9C_;+=R+'6F3%<J:D*D-:L/,(/W_L_=>2ZHCVZ+H^XDX_T#,O=>-
M[HB"+0G?O<^,P CO35'%BT)(*1 ("60P]?4W1\H@3'GL+!Y6KUF02)DCA[?[
M;^]P\X91"\^:[#2>S,TI6AY57X9XY=[;IU1T^LS.TE-\[[1!-7*SY*  S]Q^
M.\<DXO0 >JI%F2B^P+B N$&4%C@I(B(Z$98H1MR'ZV :>4YRT>JDW.XW(WDK
M*K4(W>_1T\CJKQ*/S[TL)<^25K:-PD^,<K"Q6GN8K0C9\(AER[U2IO=8D$=9
M?GB(0\RFLTHP68K%N^U^+<LL@M$U>H3&:GO08N;A>+<S#2\FZW"S5V.-1TSU
MRT-T7^HL\VFY*V&5Q&HNB_W'\G-O M0<WET9'=22]"3?[F#]:S"JMF:SN#YM
M'N(0?#7-Y)XS:<2VS70W64C74-Z 9^ZU8!.EIVQ!4S+BI*<$%:O4;ANI0NH0
MW4<I2D5<KQ)EIT_+>FF>RJ@Y+76H 1S*,9722HI95*\V5B?56:VPB@[MU.SM
ME;J4J>7R5GW1E:5HWXJR5C71&![B)?GN2S,]K9I9JCW6QT])YKE8>6H>:BI7
M9YK!W$H85"9E:948&'/6&M66AWA)\GD5Z:]F4I^:OV0&J7%ZF)^D(.UA[T35
M139&M\K4@I6YA69-1KUFA:S<.Y'9+!ET.E.Q)B@K/%%6#"N:\8/\::%'-3;>
M2?8H)K.@V&XAE66KL'+O1&HPWV6[-2$WZ<7FL:%22)JKZL'F=]E^19^7NYT4
MRW"C1S&YRJJ](/ \]^VOC*5\NS/<)_K(,4?3@3X0('C=9?]JO\FS!0SL)JI[
MGHF]]J!;OI>#+A/790=>[HMZT-YTUPZZ:CK7-[MQ:BX6\<-4]-Q^N@('VMOF
MX+#0K\^KYI/271=T<5X8IN?9'#1Z?4C&F0>:WD\2]\S!$5(/7! O:C,3B60>
MQW;Q/UD'COKMF?/[\^9=K]@KG5AW,>A]GYN[O\'ZI'X&AC@:Z*3?"8;_^B(^
M9<14O"GPE2'+3Q[#;+;1X87$)=W_GW0TY(:Q_JJQG#58F2UWZ*XXE1(F8%8D
M\I",OMYZ&C#DE+>T%6"GN?#.(/-/WM+H^;D1%,0\3Z&GP5BFVQ1MY2Y)]9^\
M):Y0X+MS*EJD>O&X]9P9<7S##M?0B>1#DG[5<TX">#,[=J*L0P'[;3;9*6O2
M)QF3LA,D,4>\:?N/," D)).!G@+0J0+_PG2+"5Z86[)O9I[+#6:ZK)&9APMD
MF*0M-,#$D&2\%,:]:)9I>RI=RM\$,C'7P-_H2^CZ;'LC21A5TUU<V^P+GC1"
MBABP9B0-<M,K&F)%)")*?H=,4R'WX'QEQT[Q[@3H@K3=:-J9+H(_Y5?V"[#,
M!LB0-^+?#%Q_&KB37*>:2P8?EHNA0$ZS/UI#WQ6TU7<EL)G%>BX7Z[<E:4XI
M#,6N+F8G/;HSB#"36::\N 3GJ]N1<!)W,HJJW=HVKVN&<9"6>@Q7:KRTK0S5
M+JLO>5-)EJ4G$H6BZ-A#.'Q@8(W;=IQ@Q*%0HG?'G3U)Z\/HCP]!V@Z)DR 4
M1%+M]N6$8CW^X1+O(4D*9(6(*_.8@RR_J?%"VHB3I^&HO@UWD--9-5]_PH&C
M#A'PO;4Y+^^!;3<:;MZ#DYJRESERIK21!Y+YHA(FA!1Y2'KK>YDP6X.RWI@)
M2;"1%P1K:MG;F?%K7<-XYTV$,>QA3.XH&'Q>#%S2:A\&NCI'T_:#2H<GJP;L
MD0*;G'8RCL\T$;)Q'P ,J3XR^'Z=8 9$2V5I[:!ZVZ&C"!/>1,M$=/79)%[7
M;C*7R;F:G?!556/H6HU]'%!,+[^:U%:+^(S_SHROLU@I^6>FDAC3<9;E+66Y
M-"=R6,"[_LTPB0>&V4\[? L?09P:^ T^O@8H8=_NH1CJH=#^@0=\.*)OF+<1
MT]^@G#U1\BCXU\^M>U2'7CQ->AE=7BK&4^HYV/SL'+)KCMQWNJUI,IV7%]WI
M_"E1G:K19O,) JRO1^Z=>3,GC]4'_B(ARXU(4!&\!JO 6#-UF/C?6_'\#?:]
M%ME_A0ECC80H[SPDAV/&KQ/E]$H#_A_ 6X/.+<(3*FA,ZMF@,AQ+7+Q"WY"=
M%Y02\T9P:>6[^=DBV7_.:RA,.&B8>:"B!^:J?B'H?_0X_=C"%I^T?D?=>H-G
MNPF"KFD&B.M2"_#L!W_B("&GH#%39)-8MX(]/DE^<>8Z -N7\9G QEH@DN\+
M% 'J,UK!@,)S.">_D5'U 2RWVFIRF$\JBXE58F<SJ_T2&6E7GW*:S EL>J7D
MVQ/^20^W>_PXVK1@3.A#-!9YB$3>''/V'G^]&OO&-AH<D_3,\V .WR/9D;.A
M%!@/LKDFN17[@U_6Y7X'9;J--&O5*R9=ZD[3W<;P'(-?4IC$IU-@5#L)[@'>
MV3)1Z%RSAK@?,50W?Q\T@F&5E\L)? 8$KH&(^3Y T!O[APQZ<79 ,HU Y74_
ML-.,R"=GG@43B868>U/SJV@O'XK=^_Q?PT4D0Y'[Y(MKN(@[15S-1=SOX1KN
M(1&*,?>+N(*+N'.F:[F(.)EN<+^)R]_$G22NY2*8^P2]:[B(9"A,WR_B>!?Q
MR>9Q[WHV;FO^Q&FX\HV-"SN-0?\C@/"'8<(1YA]19/[1%8]CZ9&_D'BDX5=_
M& :<R&"XFENW\_U3^'S\$+TR!>R.""=3DW\$$-Y342\-A&\I37=]\<]C#9>!
MRK4KD'=<.054?H**^1/5BPM1R]4KGBTTY64H)+"Q =J]0 :8Q2MW]#@WVXB>
M5A/Y-MMPDTB/,)_\KG>=@RC.-ICZ2C6L[Y[?RR2]#1YX2W/(KUY)8IT291L$
M#:A3ON/!<<Y_]4I1!^E3^\A_04G.[E3L^\W_"'VGB%5A635DP8;!(Z]8Z!A*
MSZ5GM_C*\Z"J>+L#39A^V/2<.1K*7_K(1YN 9ZLL?\AHX*\765%<37N2I>9B
MQDS*Z77VI6+T6IW*)8K]'!W-A]1V8=1N&51'X*1%;5E=,*LB5>?*A1*:YEIS
MQ6E.1S_$8_0#%7MK/LN-$\%%9C9=_MC'F,ADY^#>-MEGY84L(C)MR2%\;:@M
M2_EF<,S*1K)6,H3V4X+Z/N%_I#K]!&3OAE =[Z:KOQ/-_1 S$-47<<Z+P>Y<
MC(8K(W8]T&<INU<D%4KN-Y'_8_C \<;!VHK\E9/%)VI /SI1S(?>00,)_XB6
M#G;"0>0>O(_<@T\CM^>U]?EKP6AA//2>+)4>W2XCALTDIK5,LJ5I"]*R-8X9
M13(4C>SWG_]#T/L28HXY/,7SYN2<G1IPY01][+F"7Q!QGQHD>$09YYFDQ!@]
M,'MPN9B6F@FZP'2GA<5SK+]4VZD)=$"FJ5^_XTSX>&.:S^[!]^9/D!KN7[_S
M=BNX6W#+G-P@O47R/&(3Q?<' E]=-T3HOSZFN\/Z*)Z=K"-*K/#<S'%\86AW
M%J<?PE3R(4+M]^6X37R_D.UY<P+XO6+/JR/GKUF5WR?HHQJ9QJ?H^9.&9JS1
MJTN6&5:IMED<1)_,\+C&+NT6_O%0XD^A\&-;E1>D@9U R&W>QZ7,H-M$NK/G
M1'\8YVXPQK2KJ6=(%W/EB+KZI6WM\Q/7JX$GIS&5V]]JM@H8FB*+ 7?:WF5Q
M.O#7W1I@5S/9WK&G0AQ0$^;Y69%=IQB:DOEJHQ\L#%N+V!*:RO[Z'4D\Q&+[
MMOO?=WJZ[=#4^8_]:B#KBMG(W23Y&%/YI%U2U!:#6&K:CDZ8)$<WIZ-"AYTW
M,</!=DDXE$S\N0&P"W";:XR478CO_E ,N(H8T27TUNN+*'T'$-<>)?E,?A]]
MFYZ-8R?S;6D^8:SYB)H%G7]O4/4Y2O_TAEZJ<9/G18:=RE1"0(_TK&M<>6I?
M>-1)U@KE09,-1JHU7A%3B0@'DY2Q]11^@!% \>1^!__;Q/][+.4>2_D>_=Y&
MAMXRW!Z.GC@FV.T5C 4S&+T(M?80TS0Q4.+[PV)NDYS_H,#)=W+O/FIOWT#N
M73S7DM/MTC _"5;Z2;'0EL1>!X01Y-XE0LG3Y=[]\7+H[!&FXV7571-=GCB%
M[B,RZ&I3Z/J/!J.N!I36G<]3%;5G/3>T"(@=2*&CJ8<D=?PLNDO[!1Z1 6-9
MSF0M7OJTIZ\&^^DVY45"=-^0]C;^;T_4.J"1&I91B365%4=9]'* RLJ@4$L/
MN018F;$$9@W1$RJEEZ::'QJCNY>/W5A4[=ML8$??)\E_6=Y$.5[6MY6&#6>H
ME3,1,\RA 9OA^\VG8;J:6W' &;"MBK76MS2&&V<+]VJR$UNTWQOD^Q9FOV;)
M>EB]ZD6BB?B3$J'6,SK&M<=R.=YI8JRV#=EP\EY$]H<%".]%9%=F 1^1^M^U
M?.DLMV8Z3T9F(D^YIU6_7E2,YA*3.UB^X8=(.'[#Y6,^*U<5 V@U0X)I3VQ>
MP'CO>Z#T'BB]]4"IC=\I560=[.YH\-%'XJ?97C\5?AXKG6YOI3VUZ]5HE7U:
M<LE[_/0>/[T9HOXCXZ?O$_4GPZIRL)&+K264ZK;[N9E1'TV%A-[$I'X/J][#
MJJ<.JWX:FU^S4>E-&;78RL2+B4:+74]G=:N:HXQJ=(CQ^1YMO4=;KX)<;\76
M/)_(\EJ)OVN3OHRR$4X+*IG)G(MF)DN%2U8%H.Z/1V/_Q^2QE?)[CPU<"9$>
MGY?OW*8P0J*E(">NM7=I;5,3)N[-X5NP+]LPK*G]60>@U\%[2BMXH7,Q VY:
MK5?BRK@VG/"#WMA<6GKYZ1GC',)7.,.O-W5\GR<!<F>$ DM'2@1X6TP$AN"E
M#XH8I0(2+^N!!>!30)/PZ_&N YI]%GL9_AD6;Y >;>)'@9@+(%7$G^YY  (
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M0X[4>-$/L>1).B3?2?I/(>GK,Z+_/ WDTS1=+65GZ#DG1R9U>6EP82'6?,Q
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M)^H[4;M"]$[5YW/!?XZJ&V.AG$R6$$^A5:/_E!G.^J-H"E-U#*CZK5F[M^E
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M+!U=:::CA:Q9!CX%*<S$I["E*1S$O\5=$&'&@=$< (*W@=$"UB>H_Q")RZ\
M 5V<]@-MX+P&-BQX1\6T::,[;-4"B-IJQ2%= B_1) D<+^YK;-4?<PI@BK)J
M%\C@3T1Y\?M_\7]<7!84#  P@D;_;NO'8<!0UP2B_G,20V9[T"43V1@QCIY
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M6M7>)%;NL!2JK"M"!!JX17[]IJ,/\7#L@8J&CY@X<WX5VI<[Y&;]VO&"6U"
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MR0#0<B>L[:9IE1+6IIXGK"N+ RPIE"OR;WG-CX-9!*"'J1^CKU?G)>+_4E0
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MVAU?NJ*$'P\/2^P , $P 3#W@38I%FP#J*RQN "9M147(+/&TDH!F7O%,6T
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M_=VLMT[D3=G_ALDH^.7_ 5!+ P04    "  A.&-41U%OM[<)  !R"@  &
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M6S/[W8/MPFW!@2[MM.!421$FC)+Y*.[HF?[!##?3^D\69TS_#5!+ P04
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M^T99G?F@)X!8SA/@&][U^)_<\MJ-\LK>?G\"9(T%_42[M_VSVQNV<5W^UT^
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M-TSRLEB/[J^DS3_)B- DM>-'\=^49C_W42Y]D?CAKS3$$CZ\&[3%H"9[GR?
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M-'EJXB<07O_SY;5GTAMFG+"8Q-C>)NIG8LQPH]$6 MYU C9X2[GKQY=>L<H
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M+:J>'LX_ANS#._WY67Q)3E83\;!J0QKMN!0/+>2[M@IF(]%FL,?^HM\T8-.
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MAO\V._^O@A]D:CK05'8LIGZ FYKSG^%Y ]C8^9^/8!I[J_Z\(-S4RP1,_4C
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M<WQ"':E"?()&-3YM?S*6[!]2+^G@^@Y+2LVJ)MYW=!*:IL8L4O?:OJJ+K-<
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MT@!FX$X[3.OSY66!MX(<YN<M0':G!LEB? _I:Y.GG8=+<3($GXL;I#8Y9T/
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M<6WV#'D>?MU_ C8TQ%' 9X_P*[C"?H;P^S TQI8VM/&S6TAB8RQ1L/?12Z.
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MYLGVB[UZJ2"B?$>IO58LW/U4-4Z*25.FGI6@:G<\9]YA_N#G_*BV6?/IQ5Z
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M1(8/7)_%URK-RG_RZ1N^M1!0B:;QC%E3W'#ZNK'$S6V]?#?LO+!(??"$+51
M(=1P>JB0V@WTUY[2,F/<^ME.QU#\CV%W:<NBL=%.]C;T%X/E;)=R9I^2EY$G
M_-F0%@\S)KG]@D/3XJY#\S<>[1^5Q&D#W]LMRF,A&\=1@%2#:X9&Z*>STE]2
M#KAQK[)-Z%1O1M!BREC&+)UIN/PL*L\CM.&K23XR2D#?L?]AU26:"_9X)+&I
M*\<,0F&10X+YP5LZ!3-K_2@)NX@E++&: ;MG^$H-]54CVUGUM9^DK&Y0,$0<
M*Z,S()5C[);N8(XH!BO$(W!JZ-55'H1.;%N&-@G2GGQ.QHR^A"J6I;1I- SK
M3,I:!.<@1N5;J7PB?ZH8I.!PI!_@"E>$I5K\<-Q ?SI$@8[V<\WZ7J(',T6C
MQ5+C'1U98FM3XS[V8")\CLX?$U.)88\B?9Q%\]*+Q"KAVC0)DYG?B^@T)=GO
MEKK<JXFZA[GBOHQ>]0V;0K#=]<Z?YWW_3@Z!U?^1*2+W?\P4(59\GRN79S*V
MN\5W4FX>HNS;DYJ#4^\;/6[5=[SJQ?E:W1H>+5D=2YXV9G_.\'F10>X3HV2B
M>[K(T8:*IO+(,$Y@_.F$E/D4DQWK(N.2O]"Y KWOECCI>OMKY*\17'_H#I7V
M?&W,4=R]U%Y<([B,[LL38AVZ(4O*FQ]52B(+;ZE):-T_PMXD2X;=!D:*""L/
MHIU57X\=(XS+]D8MC>XPEA&_$!":S\'P89ODV-TI;/.?=/Y&6!/ZPY+*#"_7
M9C#\^5$1UJ1Z+UXC^VGQ,^DJMR-9RNCP1S^#@'8HB8!#Q:#"5><B. T9@ZV?
MTW&ST!<%^,(;X?&;**"\GE.+V>(14WAMC.6&O9P@J<O.MB+C^@XE *-6(FP!
M)_S^<,>]8CA,K'%J$,3.O+('_$)Q9K^,<47Q&D"F],NLLBQ!O-$V=LCDL/+1
MAZ=,YV^BDFY3O+"5RDH/R]47A\4 UL$'/+SDFAQH,JGC7T$K3 ,.*KQJ!2"_
MOM,<W>J'58%A:='LIU1R[-"MFTE?)!$ZBOKG2D13SR(K,PNB(4^(8'Z RW8*
MT=L8<3<(?C%M[3$3"C#,DCG@IM-ZD.R5/F@VA'\5VT!U*? 2<KAD\N<!?7TC
M XAJ#=COH]: (Y;O]R8'6+LY4Q96#86ZQ]]"+SFT=(/JB&]6#(I#3B#!('8L
M$@?+H("UEO'K Q+!2?N]R1I2BP/V^X0PP%8'<VRJK9& TX''_B?A!LSHL, !
MH\;J)*W4T=N[G^VGF<_PSGP5O(RN&=>&9?!0@OEU"G2R;E+R7W.G,[I2;V83
M]8SQ*<L9*RLCVF][ 7.SM(ADTT^S#(,[R_%"%4EB GZ5/46V7AVN;VOFKTRM
M=@JXK'5WV.0[R6E=EU><PE# S/GWQ$&,O"QU1OY?4X5XN_3HB?JBPDM!AHCG
MM:(_N.ERSW&#TF]C]8C3>BD9CI5WZ04MRDN,WH_!C>P9SE9]Q:-&/1]"6][;
MF^<VAS^CI=%'O2]KOL(0ZLMV)RN-QAB]_S@<LG[JBIFD;V=%WVUE1LP5'/PN
M,P80_-$@F)>^J.-?CZ/N=7QW\II'A;\<_5H\7$Y%/#BYL3R2:L>:VGE1L1=6
M,:HN=?,'K4&MN;7 &05Q? &&'?JBF'<WJ>W1^-D8R$>63;':D@#.N9+>JI&!
M"I '5HQ?^8\@/<"8VOBNNH@87H0DW-%XS%P/)6D1]C^R!L1FF =O-2X8&%-#
M2GH[%>8TKK6;-Q*Z/WXH9A@2GHRW8:& ',M:3V9 CB<M6>%A^Z19M*M2'&\H
M*W7$]CZ6L5FH#,&<B@B"95*BB5:U0?'4._0KBZ.(F1XK:BJ#H#>G<<%HO?&H
M!8; OC9G=*39RDCD%G.9GR2S('=(4-RV2LK1%M;5);$Q%H,GD_$'O:D!D'*0
M-B)<P^'JDTR(RVG8O%012(X+J_[Z*61!9L(<[$_#^)>GS(-XDDA2%1]9<,9.
M@)[,@C-W^"O/!\8/GB?(!B7/>A1"CQVLIF."K3_*^DL(N^<^NG@S9M,NFAIK
MP4.>@5P=A0Z' DMQ'9X$<NUUVO<X6HXC1%/I40"],HA!U">Y_J8^DG1HC9 *
M0]&E.^!=OH?_2$,^Y/J-=TJT[NN1/ 1;\^M$8ORNO;[H]EF\6*>D8T,3W3UN
MMQ<I17MFWR_OI** N&?0O0EPV-P)S4)<@-S%LQ/^.I6:^#OW_H>QKV/R]/;
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MM;K&8#&='JJ6>*&*;3SDP'43QWU5A75RM#$/[BGMWV2>2<K6)FK.U-:;ORI
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M*G\5Q?GTGQ*ULO9M2M-KGV>XLAFF\GN$SUZOK$(\KQY.-RN4$4KI(P2(DH0
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MW<&'VONW<Q# M"[LZUN)G,\.3>*1.K>BW7KU-IG[>'$AQS7-#%^0*^1(FYC
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MDW;K+,NJ=EQ!FY)OG6:CXAAT\&%(<#,%]ZP;JKDSD,*W6JBQ__,I^ZNH-$&
MZ(#$&0AP1=3\KW/MY.6/S5(X*H3_?'X=K2PK"TVS&><. 5R]'0,%0JVO7\Z>
M]EW*;P, %IP)*LSHCJA2XKG'+E]2*5[W:+2-,44+ES*[!F]'H$;5I8RSP2CB
M\'GC?ARZ(._TTU]_PZM.^#V90TVKO@_6R71B%@B_8'1!5Q9#EJ*3*2@Z+/C<
M4O6^_A-73*I "-1;KWY+9KK)Y6HIX-MD*-S?5QK^LR+[64;CC2_>W^S-_LOZ
M3Z\F)(IQOIK@%HS&BS[JVW# V/QJ>*)[U";.J[&>/7SW0<+\N<MM6:^O*1SV
M#_/G7&(_=E]FPBO+-7I)T?\,N@O:$T/+BK-_B!J-&'K>>#6:UWU+,&A/YF?&
M*GD:(!!JX83<4($DN.M[T('1\6V@\_75CQ;&4LNCO[SD\N'@?_U5SZOK@O;D
M6Y7.D0!MQN8IPF7VZVQWGU?G J_V3+W6E\N::5+1^^K=-7;VM.[+[+^['K9?
M66&UL6\CX]7;?,L,KP[\FR+IZU%>E.=7?ZK J8Y_N\K]:U'F7^7?;"GH%FGJ
M7V!4/;2_?%.PIOMK904E/\^G_Q<$*(OU^2-=IOXO>R@^?]]<H"K[96;C8TI;
M.^UMPA9>)CO*3\HTPE)"67]6FIY7T?XS.31IV9I&NLS#'>E:56&>/1Q%H^:0
MCXE H[NH/*6T?>"B>#I.C3=.NSJX[%IK%E&6@CP^4&93BG;8?5//TEX'$?9J
M5GS%^*!XEX'"^#DF7=AJ1@*-C\1#Y0=\JH-VB7K-#O\J=(HFO<^=SZ50T1$H
MF-OF2/G=%&JL6])*%*_[ P3 X\SHJQ?")JR9X4:VZ*R/C^65-Y"3:'A<3V\<
MNS]>AB'HFXC*9>U,W<K03MHDR=PRVE^_MV1<L[D3W75KGV=##UX2DQ(U#3PN
MCTY/<=[1W&_8++((A7G0JL>7U,57N-E<JJZF=SXZ#S=J53(8M1NAZTSUA2_'
M>:G>9BMD6OMY25">E=*A261B?>H9RY5'D2_XOI&>[RK/<HJU\+G:!;S+W5Q:
M8T4W"<6_C3)7<$3VXRO!'_;]4#Q*>B?R0Z4+1(/E1*9$>6^?73>/1<NZASHG
M:1&S>?I((9(=7 3XR+TX[1= WC32*!:4%,[8(AT+3^I];NSO';\<3_8#]@B.
M40EKCTRC1,"56]'2I;T\:2_AEI?G@7A5>]1HFO7:AFY3P>\G:J_87@5!P7%M
MJST_-<=:2ZC"LA8[PRX7+2A?YX5$TPN<IZVMLZP$ R+;^";O;]OCTO]QIC3L
M#X/35GD3,C(3FUNQCW[(+CWH',:Y2N$YY[AJD3B50#5V&$HOC;_T\!G9,[GT
M^1$4Y@9.PE56(CE!<1@/=SYP*^LVN"JZG<5[B,_67O[E"CIE,.(\[J77.]G7
MLNM:X%IY?H6L=C8]I>/JH)2\'L?4D1MRX'JH73,P812AC/.6H0.Z(G\6RP6<
MIJP1*OX:G1C^OICX'PM3Y/E+!DR3RNK/,)V<0@);)210C&X$5X%U5AFV;6PL
M9[&"VK=O!VZCQ:1U 84'"0-1J"T/+O%?@2\H/1=0>ZF[13+YA^A%,!4H<7D9
M,!S%)&"-C]B#!PAPK6*9-";0D:F?,*!3-8:P)I=4$[1HZ4MJ+NXA0-*.ACS1
M@@5R44A[E=HH.7'=?4HDK_%9KX:'Q^%/QS\*+8G(5=M+O>P&GA50^IX/WKB'
M2W#O9,@_Z&9/%A]:W]9?E]]'7US-I+:7B@YLE9;"59[M@S<;W'*U^+YL? ^U
MQWE&Z)]L[+,Z5I5OG,W_["_/Q7.)<-D\^(DWG;_SJV81#'1F+S&<<!%U\$Y;
MFK65$%5:[8+614HU$>A (1\1+I*595B'9WSAOFXOH]3:4F FSNJ&*.O#L1%%
M C:#=(>GX_ZI[FAGN('Q9$18.&;_9$H/?=-+J2$SD[R<-YG+:>4.GD9R0YR\
M%8ZA&V[*[X)E:SB)=PZ1(QE=Q8/6XQ9V2\OO1/2*J08NX-[:^F*)[9%_N"'-
MGDRI<$?_76BT9LR;6.RI/YNQ;5?O;WCV)X(E/EBQKK-_J'UW$7WD\&&6Y6QB
M)*+]!K"C7RQ]ZMJX.1DRYC\]#+U:R2;HQ_$#_L#O?.YJ9U-LGQDI,G1[N*I;
M2S0>9LV?I@9;]_:G>+@YH<@,P+QY)[<4M^\WURI16*#+&F>%GT1Z')5>1%RF
MBI+Y0H![L 3GX)>12PSP=XQ-UF@5@\D/9CE=B5M?J4.^PZ!QK!PS,VUK1&3Z
MY#)G-A[B+G8\>GWJER3'"25P#J<4:0UAPSWM)1G[0+]2"EG\83,4 7741^5*
MN]_^PNPRL[7MC**?)I?7@O+O29QK=S*0+?#^_&;>2UYE_.BFSIYJXC  OUID
MY:Y^DE:*^F&\YV,LL_/OG""87^($!'W+:?W[NKDW&>""A=;280E9'<,?TQ-=
ME>^#&REQ&);M?3AGJR*LU?,S-FV$.%)<O$IWC /'K7-B01GHJU+8VC(D62IJ
MIP1?\>P5T8[B-&J.54!L04;[24E;$5L!431/O:H/FIH.%K@K-767C.R_F[48
MW\H^A+(<&]751ZX2=$D2!:A!^\+R:K#EJV'^HKUIXGYV)P/G+KZ;J 73J];^
MD(.!NX#]<4%L"'/FY9/FJ"W\':\-VLT@.*<>SW2'(K4:+/2H":I4LK%D[V-(
M<Q%)LWZK):54+D_&FV\CCWR.59V]GS]\\0T(1S\W\U]3?+N6:.[X+L0#3,A)
M+5"B"N/)V#4XMQ;3Z][7&?GM(MLH)B+[HE2/]5FTO*&+W^=M/>\&!("Y@  5
MVBM_W'6G++K@XSYI@:Q$YL+CTAJ%&,N^]6E8P 486E@A7,P><,D.D6".P;<Q
M52[R$:P[9A9PI_3PTCP2]R/BXA.?6@=%_WYC8:L]NLD;I>S#@RB)XR>[;FNO
M&3E#EW]C I*18SE19CFK"^2/1].Z)#Q,?<C8UZNN<%&^5Z[T*'@J>JDM<F9_
M"(QP<-Y?VG6+M<!OJFMW!1L]<O;,GIC&:J #"[' "_52QH?OUI=-.J\46^XY
M._5IS4$T85BSZ"MI$-=7PE$X"R^+:RDO*4>?N?O[] ^5>IW,]O['%@Z%OEN/
MD5&=3^*B\0)4Q<5*.P5M;C"C9F_>)[-%1Z62L>N55SCV*_Z )?MV&.JCW7:.
MU4%;$XF]<;!4W*A9S_E3>N>][5;&)LVQ<).FEP(2U#K45;ZFL-SEX,#A+_D%
M<<D*92E<N%__T=X*-NN$%$Z@ZI3HUC@$F),3O:+6?/N/IPT43FA>F13E?T@O
M_]\40MR,LH-*<W?4FWQV8A8#"UM%#K%U;WKH\W+8REGN5M$N/;JI\A.VTA,;
M9GSE@!,HE 6#*IC!QWQJ&&>X9$UL9Y$0&++ORC&'>OCHH4ZB2 ?:7X+R+9%F
MS^4LXSI96LS)1[NQ6A)M6F\# 2X+@?A=9O"IDYV7'7EH+%U=FHBK]-[]9:KO
M_+HCP69Q-*M'F4PIG?BI'LXJQSGMR7?%; \;)W#!OF;5O?X7M8M%.@-^4H>H
MV>R*<[+<[+M(YZGR+.QEA;S^YU0CE#FD<=;C_"*_X\/91 :=VR*&K!S#OS=(
M4"[ :EZ._#+!LX85]IQIQ:E0Q-%#T9PL&&: >$]$??&SCW\+QJ4@ZRYILSIG
M;57X.#KQZ+&'6'6X+OIC6$2&*VJ)S-B1>-&V4>,I<5!!;CG<><]B.'YR"U'
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M*3 G6G9_2;F9_^6:Z*90)BYD/'6H42MZ#ZOG,P</ <85''S0?+8U1:_/(,"
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MU67GK,I9..2N2>6\!R<-<PH]9D.)W2/J8"CRE><5OF. WKN>K%4[CV^M27"
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ML#=5=X.>LC:UAM-X\F%(>L1MU4UN-=8P?(5-A+<0F'$G2GL36=.ZO D&>IT
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MWG&?/JGA[K5"LBKU'>V.,Z(1MZS0A)JSA6Z8H@/H:<HH7JV*6H.:W[+;3R_
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MN1M<.E^=._+X _.OJ[NS$QF2(O;T%;VKFO]OJW:$N3JH(_O_)@!02P,$%
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M+MHB=[?9OB?^^A!*&9%%E>6,/F'OZ"K<2: $S<#YSI/-*:8+IS4VZ.%G1'3
MXW,U,-R[1,4>-ZQ(;J9M0_LAX7N^8AW)J?L4 FGUD_^ ?G?.3C6.2A-XM-J3
M,"6G1&>C6_^7@^ENRC>JWU5]AR:ROE2Q4!W=1?%1&W;V_'G&T!UO;&"!;'R
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MLV:\-YYM^?N<H>AWI;S,JS/2W:/+)U96-9?85;ZB:"W+PL2Y&5FBD$5"=5G
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M,T&HDW)WJ]O5N6@U)]M2U6X4/92F8N5#PTO&;^I2$K_15T[#C36RJH"C62L
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MJ25)DR*-2NE[!I;TT-21J+JK6975U3MS<DI5]N6,7D6B-5?I2-__?#N,P+!
M,15)K,T_I'C*A>^9LF/OQ<T6^K7*ERM4P?,;8G)NMOH'%"-9$&D#&Q&KPJC&
MO$8YH+#1\V&\2T*ZJ[,^CB07-5.6 )\D)#G;S8=2<*J\QD^5V([:7AN,X=S0
M?\/8IHW5E;D5<@G<0AH1#<OU4T.QEG77_QQ#5[^0]\Z(Y^9 -E70>X!^Q3)1
MF>[Q.PX-E6N(VNK=E6I'SUS5V9F3L?)"[.<UY-?;D2,<R;&Q2?DA(5-\NM@U
M8.9\^!=#E__'<07CP__!V?")__=L>.L+V<RJDH2<QS:N5=7RX>UL2%&TVFH2
M;CZ230IX37@1#05H))$^P@4LX:V(RN[H/!CODB/0Q0ZP(-5G;WD.TD9?G _9
M8[%"7\UY8L#/G:,%ED</F36YD1*$G!EX;S#-\$WHKRIUS>>'_CFD>LNYR6NY
M%<CC0W9BF-;'S/>33T7*X^1,^)S7#:/Y1;XQBZ @"C'DE6A"OT[Y[P8*#P:(
M?/SC-HHTN/]4DGJ3,],(E+WK8]G+?E!#,>\&7:R6YI]4K1#-]>S^_ 4#:$U*
M4/GLBD(5N6([04C5X=_;)PIERH'Z;1\9#E&.PGHG7]L/TU] (LGG4*2[411#
M!0]EJ!\#&S;)XM.F)OG=$S?!5H?A =(.'[[8"#1@F6]<8OB\"0(5*7LPR- \
MPT&R;P8!?CW@H#W7"^NGCR\2M/B7D:?O4%FQ';^X^$7QK?[9Q![/QCOZEB0&
MS<^W.+<*%/%EK[JH@M&9"_^=8:?H>6((),BEN? F!Q=*OK/K'?;;?AXOM.EF
M7JAE;&R)8S/0952IQZQ,34[9_46%0C5/-I\5+1>15[$\L7OV#K$MMN2!G:5)
M0"0EN^Y/;/]5J<^P$62.J@_-/&5U2CFFE/N3D[QQ\YB/B4*G*I5BH*<%GUO0
M<&^D\/-/)4/X82%1Z[B>)?L!8M>[Z/=@KS7VK=:X"3T<'EZ!2?FZH^NI$M1Q
M#)8QK%$#;:^;- QO:Z0Q^$H^>QJL>7A>#4WMEB-;6ZPFRR]11"1B+LA(RE*S
M_]I2_V?F<QO=S7;<3@+VQ!+?$.-D=H"P#GJ93.1\,I>4PUEW2#%$2#:&V'*W
M-D5XQ0Q9RKK%+KCQAAF3[9R]V7BIACK*$QIJL4WW%LHFIV?D(@7DIUBA>Y;\
MBCM=D_.I3>'1O/A@;\%>44_Z^GRT\EKNN\^[@<[]SW0M]7.EH8M3IWDV;>VY
M8XHS:(%%C.(_;T'O32+_3$,I1M'JD]^TS)\UM6G2<K$IM?%46@,0IBT2):D:
M]7+I88!$"VT8H):EYS>"L7=^@/PB9_.$\.%[@S?3U[;.]!"%F<Y55Q21],.#
M$111[5((5+G7VP^YR!FY@V"<HZH\>E^!1PD793T?.^P;]:5J@!@,8'H7]!O.
M<'-0XNYN.NBD(PA4$[]]CW5QU5\,C#_]Q]SAO\T5WPBYYO4&<4U0Q0F_J(C)
M_$(P,P+.H#L[N61BT].[!_QR/-N:4:Z/;E5E5)VW-<82^,7\-_S0.Y2!"J)H
M)X@6A)IV93RO:PIS/=!^AKDTG4KBJT*:RRIC?)BHRH=IPMX'%A?I(0OU@> 8
MA%Z4D\P>LRI0309CSE)8IUZ 5093JNW9?&=<EE>2C'ML]/4P:)X+?/YQQE$T
MT\-"L;V3W]608\ARO;6P7B4?B9V[GV!$L/QW/,FZ<7?F;;NYP8K=>U'M.5D7
M2]HEUY5C30M:"D2"V9P!U_:/#T&$!D;+=_:#_-K/#A;C#_SPY11>J5?<^U=)
MZ$G<P9( ',6E9N6S5[U,=3.'"XP\2*^ECZN0T=:3?R- J^U8^(D%G>]4 A3D
M'Y.?-&  >/JJ$Q5[W8;YFF;4C]0G)C;M,(#A5#F*]N][95SN:5,70:(CK;'1
M7=GH08XB4 (K9^J\0F/HPPKWJX!.:QL4Q$-P$(W0P'PSZH["W'9+.1X^Z7Q@
MO8]N7H!%[0>&A]LJ& #+\"ZY/_GM^#;6!Y]UKRIC/];X])P!8GIOP1%T[I7V
MUL<@#-LE 4<SNB\-#YK<GT?3[V.I>H=17$P>3K5;DG<4/+-^;+>$QSB:8>TJ
M=X1?H:U\\MM6?&2^AWL57KEYW$*@&EAH:)M4E*+[RM-\%["'=_^1Z/NZ3^,
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MK;WWG+__G&NMK8HE7"/MUU&/IK_1]030EAAX-TV<<3J\=IA*/OH\==8Y_PE
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M)Y:CI(;AGW);KWX"'C=]C&<-,4X;KCTC>= B(^/I^KXS=+.^<"MI:ALDAST
M-')A;(0&BKS%5C.(K^-[6(^.J):=?(^N3]2LBO/W,JF3?]85QHGW6*$Q\B$6
M(QI7;5.@Z.H=.TU]V#^?3?W1W@(RRNG8'!-3R5*;R0_7U;.*'GZVR<[D[5@'
M]4N<"!#93XEHE7#-U]^KMYLR&'' W?@IQF@)EQ(G:"GPW9!EYLK>5;FVU8"_
MBRQ;K[MZ,&<1,LJ'M7'29VOCPQIDT?P.3]*6K-]-+W#:)"+IO8)KNF4;5S.[
M7'USZG75MY1"W@(/^N:V9F7S!(;(!II094&&8C]&YP[)^GHK5NID,*T,WMNA
MQ)@?!WKL=P'RWG3O]*2["VG(JX#9E;G_O/;IWQPEQ:L80@HM[0SZ>F\N\%%(
MZXOY)S;$*5"V:&>.(* *.5_K#=OK9#-SDF^Y0\SBTGD.R.Q"FVWWO<55#6!L
MMN1&G/2BK:K+"ISY*UF(B2/S0<4M#;!FUD2:R2VH@FH8'?9DMF,Z>?T2U&KX
M4:3 @*VPBQ0MGO@ <8=8P?O\]HDRW5#&!3W#R2N]#*7S:Q$;_S<"EQO!\:54
MGW$J3 >V4O?KLLA7#'[=U#O?ONKS/6;9_@1<1(8SI[+$.-&=#\ _C0G9S"GJ
M?MDPYQ!9RR'GXL5V,ZJ2V"5RRE2>C<5Q6A%UXA:+;NVC#WU^)I<Z/<UOD-SS
MD_D[7+^VIF7451FP5W4OVG;]"8"371?7<I>L/2CD8](6[8N!CZ.:6DRA8^>E
MWT#2L^85YKS!AGTT:\I$:'>'6"G&)^QV\TU"M(;TUBGKV6T(E*[TW6+-P</8
M&IOPV8'AB103T:-JRM4!:!0&>,]L=3.#_$N [AM8N((K@Q0<Y'&TZ%6[+-#)
M\@HH(2S.7])YE3P! ##'16!0AC]5)^A<2*%]Z,U;M\DBHW+&FU+4L[Z&]\Q>
M/@7#C-/IQ]9.J;-O232;5MT3X(-8K^_QKAR-F"D1@$,8LGIUS*VLLSD/_E:"
M6=J@"/M7N':$\$OP@Y:>G_$>5KATH;AG4M#0O+J"B1!AI6GBK^?)XE'88N#K
M"M7<0/Z*6VTNF!=-VJR P%%"-"A/*PN? #E,?4:W\&*WWX^LLC&9H(3H?S)7
M!L(,>\9_R9]I00&QT-<MN@P($4^ T!"Q1U3#UT^ 3IS?>S\^ ="00?>XK1I/
M@$"8WXXHGX\ ;'9L&$\\ =YH172<(H+.U$'=W5G0#Q4$H/5G3X#-DKK_UAS+
M_R_-,0'^_\J<?QP=C<4NQLQ5@7>.%%<8U1)A^E'KL2JJ?]V@(!82I@5MF_A[
MJ GZ(P?2J_M/<461[3[E"> V*^@)";'O.$AX KP61%$=<Q'#/78H\\-SF7<U
MD.$:0Q?7)9/?R-=@B(;0!DO['Y27FVXBI>Y38+34N5>9>\0R^;O-GY'Q"S?'
MR5SE<Q;VI-E&&E#L"$7:^ZSA^167CE>+\L8V->3^SK68V8Y#<3_F5L[;XY(R
MK*Z>:8QE'*:HM)NJQ1T#R]E%F*88$':)V8Z/*%7#[.5>^2O.ZU24UJ$:O ^J
MT" G5H(GPX8C6B>)>=!NMQ?(]7]_Q'(Y8COD]HGP9U#JVQ94RK&L51-^X@GD
MMD<_@5RJ5K1\[:(V&*!DLRS<K)V<701PBX77:H5-OYBV2Q6B:?Z!CO81^!W=
MKR,4X.R3L=/B_#L+(E-LK7D]'^DM%B^H?V(MYO2H9K4TT%0A4R[31POJ-OD[
M?(M(JM5,EZX>7[N'(>X?0;VS%?/+1]S)1D?POER? (Y69D2O>KWR!NJKK-(N
MF693]X8WDM"\;8!TU>Q85=]3R?LK-D%8CS5J\WT%E2Q$VE5X\C*> 3V9D1%:
ML[OWH_J/Z3P>'?$$6;WDAA?*R<.D:'K%+UQ"Z]F2.Q\ZXZ,0#FXMJELQ"H$H
MD?F-'0U-<%MQ*+XZ\%4.<LR=QJ8B-K$A^;Y8.$.</VCW:!W*R"320VERMT\%
MS1*G2[V4NLF!O0KV3K(?2S)RJEIBPF=](G"/7:=R5 N9#T34%NLV]B GN)S6
M]P$I]DP.',/O^0-?Q\E?[.E2X%56-YRY\L\=.1!STH#9+9CS$UJORQ-E3_O&
MOY:0]M!G:C2:1\R8(!#=*9VDB#S:%FB_5TN*AKM">W>)JV#Z2GVJO(ZTJ"!6
M/6'EI3.M<RG#DCX\G]G%9&JC6XE $LDY>'7?*4?7VD1U++:[?$J\/]\:E]GY
M>RY#]_<H@ B2X/\J?#$ OC<GQ<VZM;00ND2ZHG5KH\<1RTX<:'X7V(D!H[[Z
M.D<=K=!2U:F!0)L*V#SRXUIG0>Y>>#=+-:G8U\H0=>/<72T7%#V*)2!B6_>1
MZM-;/;]6C!8?TWJF3O>'# YAT](UY@#4V?5VK\)/5WJMPQ'O]4UC\*/(?!?:
M=.+LLJFDX:*=:![R8E9GX41@SR.E&$1:&R7*3Y%\U.P KSSC\5,2W3B9PWGL
M@L! FX]2&UOL84<MFYU#J\CU,X*?T?1AIJQ]B.OK6\):%I-OSYEC2;@*5]YS
M:NWMJ?\?K,X_AGFSJ5F7J[T?;^!E3MT21"_E1;^,@+Z^/A^;>,8'!0FS/ $"
M7OWV5@I_RF 8D .<#8&]:W>0TX;'VZS?F^T.W<*82BR3X G0@?=[/U[PE#@9
M,/YW)WY,?^F$Q.C5IB,$ZJ4%A<#<8I^6K13 650&ULGC'YU K/VR/G5<W&TX
M/IR)_25JP?5YB^&!=B^Z.VXV0=#7L7\Y7^\?S_^3$=\5?<^(V6CK^0*(UT@(
M7PUFD<%\IT\;9E-3Q[9QRQ.@'/9WLB/F/ZM7!/1K6&S9>@I4'#E^S+*,<:R]
MM;6+4<:B#LB#(IVH\N:=$5@T1JUXV;(S6HB^A5P^ 6Q7:T$[!+9/ (.EN^=U
M;!"03<?5X!. 0Z^9'=JF9&X(6LCYP,/V\8,>99V7[<TNVL.GVUTRR&RXVNU'
MPNVT+(R ]<"UQK1,YX$Q/;D;M]B;6&BX[-I^G>/]KXY[<HI^RH6BQU:8_)#$
M4YL+H-X+H,S23@9A"+/W[>!KTR_+;,X%4?92DLO?DQ1-NI:227TQ?UP[X?5;
MXZLH\*2 _:D$DR+00C;T?>OP!%14E!S4#KK,GY*/HB-<\[PC;6K#H#DC'8!?
MT,XB(5QAU8B0V%9(8?[I(@I262T=V,JB4/C^"^QECS ZQY*PR<NN\ &C)>3"
M_4[1U1$F*$#D,.ET:'0O<O!^!BH#A,FW15;*GW2VS"(\,QW;7Y^7=E2H<IR)
M]>^^2=/\D7.GHE]6!:0WZ(M(GEC;Z[/5\^H86#!\'2ZN=7J_K  _7DU$MQ2<
M=G93,]UH#K/:%?0$,/&"A3>U!?O\)\"0525,,;F![I48U7MF(NQ9*NXQ>6B/
MSKF/W2L^>C0?"BH -WJXBQOY@^WS@D%MT#%E"O:SO6DCE;6-)P +/?;1.=T0
MG:?EB5MYI!:L]R28.-0'76N5&X"VY;*@W6A/@-PQOY5W&MK#<B*PR'M=;%(\
M)-5>#W$P%*6]#>1!98:<8)[("I^OOEU<J@D0O='7<-U\ E!$"Z)-</4\T"?E
M:IS3#]*0/9[XM*^=<^N#%MEA@3A()Q;V3)7#Q)=1-8BN*)GU>WN+T85D#&&:
M@M):HGF3L.+6[7'=,_1VBI7WH<L?Z7L XEL[-R5.^VLX]*>'J9.-IXM!U EJ
MQ,'VB_K;_B<V82=020H&V*W@ 8NYTPW,8MN?89)L(6,".J$WU:O^&>R?M6.J
M&46#N)"R&4/7_M+K)W<:Z<5CR,^5T=/O=[@_Y>,3 AQ]:EY%MWJ3']?8Z(FS
M%.0)AP^F8!($PG[W1!_R!#BGN_6%=AR+I6K634"B*(1A/V8-NGROX>L-<PS!
M;B://HE26QT4"H^Q(=E81S*,+X[-[]@?!.[:_&%V?;@8 )G-E?-9D;H-$0J@
MQ+/JUQ!L[5Q_)^RXH 8M>#X!IB,<(5U^]K#Q4(8-ST[!U2=8KR'7[!U7RXLA
M_0&B61K3M5<@K$\\#(1>BUVLV-C+E&F/J5=ISNP-4?KX7(<4)N)OD@?X)^P6
M8O=@M@IZL4&[ID",3#]LOT4MSS1-:+[FK521(JB*E_U'-J'\U_LN5/Q]WX5_
M2!#*B._K5(B>K616%=WF2=?,L#"S;B;,[TZ$J&G9:L+ETC@INW1>3K3Y8!#E
M<Z6?.GPMWA.TF[]/SLI93&3]M3FU9185A9Z,CC*6^NM7;N!S205#M3-)_;E2
MGN28 ?7,+F;NE%E3''9X[[>#07IB7L:9(K_@L3[Z>!2*11V.M;I49L#K'MF9
M=[[O]-UZM:=RFP5LM^=)4YX[.79(D$+^L=&-?M8( !7ZM&V"L \4-]<P<#84
M^L]9=]AQ7+$?E(R=SW^V&PK<5<W,5]B !S[Q\&-CP=DP,MLW$:WJW9NB[.Q-
M_&(<2(:>#3#3&G&M/@H29U*<SNQGHJ*GG" _?!-Z)60JI#0MV^\:)[-A8!3N
M1V-J75C9K*#0$CU6;]PR)\W?*:S%2)#95D0--O)2O5Z=6AK](L>ME!9.%1B=
MOHWI7:*LN)D!X(F)W8@LMO,D)IC6UDH6<$P:]TG4W$(SX-+U#%;^.463/>6'
M1QA=7+:_QMVHJ1F="V"G.3 @$[3(<J0>PDBJ=6&3EOV,<QMDZ/P-;*.K<=8Z
M4U91SEK_.75E4>ZG@U 3TBRZV_IET>'QE2*>>GVC[<%!4P5YMH+<2'/X>WT
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M&^)63>4<RG;:D4GC^S&51 [>W*C/Q88O2J!/KGS1LI^1?H8Q,*I%+H8UG%C
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MB7N&N](,"+M"L>BV8/_0G5#>:%]GWQ+MO?@E()E>WJ?<I1T4YV[[ 9#\Y1.
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M4DQ&GA&;"NAI<^KDB!!0E;SQR6+']DW:)=B_*[)L;:BS^G!!:V&)TT\<N#I
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M81=*<]-4^]3*]UR+7!(D^/!>XGF;#X>7584OK;%JRJYOWZ52W!;VVR(U[)7
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M%:%4QP&..VT'E[72;J<IYSQ6;ALZ$E3 :<F)D,-XT2[!7+KK:^QU%04@PAQ
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MY4'JNITH5-'&'A@>D=92H056-KAFB%;3>XFYJKA>59*8E3%-D![T%?&V+&]
M&Z]\J#JB8XM3O@$3W_Z C.KD@A)TET=*5,5;)4[&ZTID2CQ#_9A<"54V&E0!
M0B[!H:)5LJ<X+!TTX&#*[ZG&6,[''%L!@W;-/A49)8D>\RD"@/$9UH!,N:B
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MXLC^$6HL79H!ASMT5G<,4SN8,Q$M1945B.E4I+)&&SUGT%U#,MQB % H@R=
ME/ $&4IG89%Q2SNW9V/)A$N<9S7/E#B-1I1QX+ NYJM-V6U(')-(ADS-8T.Y
MV?IJG$(J&S<T+DJVP.F@ABH0YI4-:/6HI;WBIOO:I8WEW&NJ<LG3ET#P''C[
M?CGC"P\U_D\!_]\&YK]'8/YP&YC?!N:_CC9_/6*_C2)C=9.Z?WB(K\<"=T0S
MN;[.M<-*7.H?IR,>\J5SF,L>;T0F7D,H-JTY@ \X!0NCR1_&\V 7HCHQ_2BH
M3P1#0EU%E3MI.:_M$.E3/&_(]1577]2>PLQ\5E%#IY(@Y'0L12D+S%/ [K&<
M9NJT_,7?$UQOQ_'(!-S^T61T<$%,D\_I$U^["-I18"E2"?CB  O_1B4A*QI
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M(' K&5L$\,T0P+88XJL70WQIY</,Z.BZPH?NT$0+^#')D_C9_P-02P,$%
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M3&R9Y0F!:P/$.H9IOCZ9U>Z&?V40&S(47#(G8PU0US_KYS,<@XMEM]:!N"D
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M0;LUG1K*8C &FA08'; -%(BX BH,8D".-5@";D-@KJ.$Z )_[NK/F6*E$NQ
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M7,/Q7@VD5Q<I]!E&Q.V[EN3@P3WC'QW ]IO[][#GREZ([4O:V0/^.E$01QH
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M_69[=[ELN[*692?N=1#[?LG1_P%02P,$%     @ (3AC5#'7- 6G"   M#(
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M^HL3&1!\S]$8.@%F'M"9Y%'A!OO[]=;N,FJ[MH8E*>Z%#/N&Q]'?4$L#!!0
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M$O.,*BHX9H[3OZJA6J)4&CC.?#ZWYPU;R(D3WCB)FK(#APF1$3M6<>WT6(_
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M .3]_<(I&E>4CS7R#%B@P"H,PF,8-3@I08>I!-2E4'XTONIZ&L,!$I:!?Z"
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MN=R[.-M;F31YL)?D>:4FL8GO/7N*G\"_2L;/GJ;*2!&M9%DI\\.]-Q<_C9_
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MUB"$8<\Q!SO> ,YT36-;S*7_*J9'X4U,G[P5".T@T_N'MDY\L@%&/" 8.*@
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MU_&[+.)[\SS>P(^529-G_P]02P$"% ,4    "  A.&-40R WX/(.   HF
M$0              @ $     96QE=BTR,#(Q,3(S,2YX<V102P$"% ,4
M"  A.&-49G>S;XT*    A@  %0              @ $A#P  96QE=BTR,#(Q
M,3(S,5]C86PN>&UL4$L! A0#%     @ (3AC5 NS[IS,)@  NX4" !4
M         ( !X1D  &5L978M,C R,3$R,S%?9&5F+GAM;%!+ 0(4 Q0    (
M "$X8U2VX@B]A5D  .4-!@ 5              "  >!   !E;&5V+3(P,C$Q
M,C,Q7VQA8BYX;6Q02P$"% ,4    "  A.&-4_FMR/$L^  !\J 0 %0
M        @ &8F@  96QE=BTR,#(Q,3(S,5]P<F4N>&UL4$L! A0#%     @
M(3AC5#P$US \<0, 1[,; !4              ( !%MD  &5L978M,C R,3$R
M,S%X,3!K+FAT;5!+ 0(4 Q0    ( "$X8U1'46^WMPD  '(*   8
M      "  85*! !E;&5V+3(P,C$Q,C,Q>#$P:S P,2YJ<&=02P$"% ,4
M"  A.&-4GN#I7/Y&  #V5   &               @ %R5 0 96QE=BTR,#(Q
M,3(S,7@Q,&LP,#(N:G!G4$L! A0#%     @ (3AC5)OD[8'CA0  *)T  !@
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M9#$N:'1M4$L! A0#%     @ (3AC5%](]\JT P   @T  !@
M ( !M4T& &5L978M,C R,3$R,S%X97@R,V0Q+FAT;5!+ 0(4 Q0    ( "$X
M8U308/O@P @  #(S   8              "  9]1!@!E;&5V+3(P,C$Q,C,Q
M>&5X,S%D,2YH=&U02P$"% ,4    "  A.&-4,=<T!:<(  "T,@  &
M        @ &56@8 96QE=BTR,#(Q,3(S,7AE>#,Q9#(N:'1M4$L! A0#%
M  @ (3AC5%\T@JRB!@  82$  !8              ( !<F,& &5L978M,C R
M,3$R,S%X97@S,BYH=&U02P$"% ,4    "  A.&-44[7L'GT>  #PK0  %P
M            @ %(:@8 96QE=BTR,#(Q,3(S,7AE>#1D,BYH=&U02P4&
/ !( $@#4!   ^H@&

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
